{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 1) Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import datetime as dt\n",
    "import time\n",
    "import re\n",
    "\n",
    "from collections import Counter\n",
    "\n",
    "# Plotting Libs\n",
    "import matplotlib.pyplot as plt \n",
    "import seaborn as sns\n",
    "import matplotlib.ticker as ticker\n",
    "from matplotlib.ticker import MaxNLocator\n",
    "from mpl_toolkits.mplot3d import Axes3D\n",
    "\n",
    "# Statistical libs\n",
    "import scipy\n",
    "from scipy import stats\n",
    "from scipy.stats import norm, skew, chi2_contingency, chi2, chisquare\n",
    "from statsmodels.stats.outliers_influence import variance_inflation_factor\n",
    "import pymannkendall as mk\n",
    "\n",
    "# Model libs \n",
    "import statsmodels.api as sm\n",
    "from ISLP.models import (ModelSpec as MS, summarize)\n",
    "from sklearn.preprocessing import StandardScaler\n",
    "from sklearn.preprocessing import LabelEncoder\n",
    "from sklearn.model_selection import GridSearchCV \n",
    "import sklearn.model_selection as skm\n",
    "\n",
    "from sklearn.discriminant_analysis import (LinearDiscriminantAnalysis as LDA, QuadraticDiscriminantAnalysis as QDA)\n",
    "from sklearn.linear_model import LogisticRegression\n",
    "from sklearn.naive_bayes import GaussianNB\n",
    "from sklearn.neighbors import KNeighborsClassifier\n",
    "from sklearn.naive_bayes import BernoulliNB\n",
    "from sklearn.svm import SVC\n",
    "from sklearn.tree import DecisionTreeClassifier\n",
    "from sklearn.tree import (plot_tree, export_text)\n",
    "from sklearn.ensemble import RandomForestClassifier\n",
    "from sklearn.ensemble import GradientBoostingClassifier \n",
    "from ISLP.bart import BART\n",
    "\n",
    "# Model Selection Libs\n",
    "from sklearn import linear_model\n",
    "from mlxtend.feature_selection import SequentialFeatureSelector\n",
    "\n",
    "# Accuracy Libs\n",
    "from sklearn.model_selection import train_test_split\n",
    "from ISLP.svm import plot as plot_svm\n",
    "from ISLP import confusion_table\n",
    "from ISLP.models import contrast\n",
    "from sklearn.metrics import mean_absolute_error , mean_squared_error\n",
    "from sklearn.metrics import precision_score, recall_score\n",
    "from sklearn.metrics import PrecisionRecallDisplay\n",
    "from sklearn.metrics import accuracy_score , confusion_matrix , classification_report, ConfusionMatrixDisplay\n",
    "from sklearn.metrics import roc_curve, auc, roc_auc_score, RocCurveDisplay"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 2) Preperation df0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_columns', None)\n",
    "df0 = pd.read_pickle(\"df0.pkl\")\n",
    "df = pd.read_pickle(\"df_all.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2304"
      ]
     },
     "execution_count": 117,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df0.shape[0] # Number of rows"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "NCT Number",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Title",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Status",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Brief Summary",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Results",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Conditions",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Interventions",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Primary Outcome Measures",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Secondary Outcome Measures",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Other Outcome Measures",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sponsor",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Collaborators",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sex",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Age",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Phases",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Enrollment",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "Funder Type",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Study Design",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Start Date",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Primary Completion Date",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Completion Date",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "First Posted",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Results First Posted",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Last Update Posted",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Locations",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Enrollment_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Study_Documents",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Document_Counts",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Study_Doc_Bin",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Start_Date_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "First_Posted_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Results_First_Posted_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Last_Update_Posted_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Primary_Completion_Date_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Completion_Date_Year",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Start_Date_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "First_Posted_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Results_First_Posted_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Last_Update_Posted_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Primary_Completion_Date_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Completion_Date_Month",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Completion_Gap",
         "rawType": "Int64",
         "type": "integer"
        },
        {
         "name": "Comp_Prim_Gap",
         "rawType": "Int64",
         "type": "integer"
        },
        {
         "name": "Start_Gap",
         "rawType": "Int64",
         "type": "integer"
        },
        {
         "name": "End_Gap",
         "rawType": "Int64",
         "type": "integer"
        },
        {
         "name": "Start_Date_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "First_Posted_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Results_First_Posted_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Last_Update_Posted_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Primary_Completion_Date_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Completion_Date_Year_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "End_Gap_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Intervention_Type",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Intervention_Counts",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Intervention_Sub",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Placebo",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Standard_Care",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Allocation",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Intervention_Model",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Masking_Detail",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Masking",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Primary_Purpose",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Outcomes",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Outcomes_List",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Outcomes_Counts",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Outcome_Bin",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Capital_Cities",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Capital_Counts",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Capital",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Countries",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Country_Counts",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Continents",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Continent_Counts",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Capital_Counts_Categ",
         "rawType": "category",
         "type": "unknown"
        },
        {
         "name": "Healthy",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "8f67b1a9-7cad-4d34-ae75-6c1bb634a0c6",
       "rows": [
        [
         "0",
         "NCT03099980",
         "Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa",
         "COMPLETED",
         "This is a pilot study in which the the safety and feasibility of secukinumab in HS patients as well as information about the effect size will be determined in order to inform a future larger randomized control trial with an active comparator.",
         "NO",
         "Hidradenitis Suppurativa",
         "BIOLOGICAL: secukinumab",
         "Hidradenitis Suppurativa Clinical Response (HiSCR), percent of patients achieving clinical response, week 24",
         "No Outcome Measure",
         "No Outcome Measure",
         "Tufts Medical Center",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "20.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2016-07",
         "2018-12",
         "2019-01",
         "2017-04",
         null,
         "2019-06",
         "Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, 02111, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2017",
         null,
         "2019",
         "2018",
         "2019",
         "7",
         "4",
         null,
         "6",
         "12",
         "1",
         "30",
         "0",
         "-9",
         "5",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['BIOLOGICAL']",
         "1",
         "secukinumab",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Massachusetts']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "1",
         "NCT02628080",
         "Atovaquone as Tumour HypOxia Modifier",
         "COMPLETED",
         "Solid tumours often have highly disorganised vasculature that results in low oxygenation. This combined with high metabolic rates leads to oxygen demand outstripping supply causing tumour hypoxia. Hypoxia drives multiple cellular processes involved in the hallmarks of cancer. Tumour hypoxia also decreases the effectiveness of anticancer treatments. This is especially true for patients treated with radiotherapy since it has been long recognised that hypoxic tumour cells require 3 times the dose of radiation to cause the same amount of cell death as cells irradiated under normal oxygen conditions.\n\nTo date, the majority of attempts at overcoming tumour hypoxia have focused on increasing oxygen supply. However, such techniques have produced modest benefits at best and subsequently have not been adopted into current clinical practice.\n\nAn interesting alternative approach to tackling tumour hypoxia is to decrease oxygen 'demand' by reducing tumour oxygen consumption. This strategy has been suggested to be more effective in reducing hypoxia than previous methods aimed at increasing oxygen delivery.\n\nPre-clinical data demonstrates that the commonly prescribed anti-protozoal drug atovaquone significantly reduces oxygen consumption in a variety of tumour cell lines in vitro. This reduction in oxygen consumption leads to a profound reduction in tumour hypoxia in animal models. It is anticipated that if these effects on tumour hypoxia could be reproduced in humans, that their tumours could be rendered markedly more sensitive to radiotherapy.\n\nThis window of opportunity trial will assess whether atovaquone significantly reduces tumour hypoxia in adult patients referred for surgery with suspected non-small cell lung cancer. This will be assessed using a combination of functional imaging and circulating markers of hypoxia. If atovaquone is demonstrated to result in a reduction in tumour hypoxia, larger clinical trials will be conducted to determine whether this well-tolerated and inexpensive agent improves radiotherapy efficacy and clinical outcomes.",
         "NO",
         "Carcinoma, Non-Small-Cell Lung",
         "DRUG: Atovaquone",
         "Percentage change in reduction of hypoxia by atovaquone, Average hypoxic volume reduction (%) in 18F-fluoromisonidazole (18F-MISO)/18F-fluoroazomycin arabinoside (18F-FAZA) uptake as detected by hypoxia-PET(positron emission tomography)-CT scans., Day 0 v Day 7-17, and Day 0 post surgery (tumour sample)",
         "Reduction of perfusion by atovaquone, Changes in tumour blood flow measured by perfusion CT, DWI-MRI, DCE-MRI and PET kinetic modelling, Day 0 v Day 7-17|Replacement of hyp-PET-CT imaging with serological markers of hypoxia, Changes in hypoxia-PET-CT derived hypoxic volumes compared with changes in plasma levels of serological markers of hypoxia, Day 0 v Day 7-17|Reproducibility, Comparison of hypoxia-PET-CT, perfusion CT, serological tests, diffusion-weighted imaging (DWI-MRI) and Dynamic contrast-enhanced MRI (DCE-MRI) derived parameters, Day 0 v Day 7-17",
         "Correlation of hypoxia modification with PK (pharmacokinetic) levels of atovaquone (plasma and tumour), HPLC (high pressure liquid chromatography) based measurement of plasma level and tumour level of atovaquone, Day 0 v Day 7-17 for plasma level. Day 0 v Post resection for tumour sample (cohort 1 only)|Correlations between imaging and histology, Comparison of histological hypoxia and vasculature parameters with prior imaging measuring hypoxia, perfusion, and glycolysis, Day 0 v Day 7-17|Correlations between serological hypoxia markers and histology, Comparison of serological hypoxia parameters with immunohistochemistry on pimonidazole staining, Day 0 v Day 7-17|To assess whether atovaquone results in a lower level of hypoxia metagene signature expression, Hypoxia metagene signature expression and Individual tests to measure gene expression/mutation, Day 0 v Day 7-17|Progression-free survival and overall survival, Progression-free survival and overall survival, At 12 and 24 months",
         "University of Oxford",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "46.0",
         "OTHER",
         "Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT",
         "2016-05",
         "2018-10",
         "2018-12",
         "2015-12",
         null,
         "2019-09",
         "Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, United Kingdom",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2015",
         null,
         "2019",
         "2018",
         "2018",
         "5",
         "12",
         null,
         "9",
         "10",
         "12",
         "31",
         "2",
         "5",
         "9",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Atovaquone",
         "No Placebo",
         "No SOC",
         "NON_RANDOMIZED",
         "PARALLEL",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary + Other",
         "['Primary', 'Secondary', 'Other']",
         "3",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United Kingdom']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "2",
         "NCT02370862",
         "Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI",
         "COMPLETED",
         "Bowel care (BC) is a time-consuming and cumbersome activity of daily living for most individuals with SCI. Previous studies have reported that the average time to complete a BC routine is 45 minutes; 10-20% of SCI individuals report BC routines lasting for more than 1 hour. In past studies, the investigators have shown that a medication called neostigmine (NEO) combined with a medication called glycopyrrolate (GLY) can increase bowel activity and thus, promote bowel movement. The investigators have successfully used this medication with traditional and novel methods of colonoscopic preparations, and have shown that it improves the quality of these preparations. In this Phase I, proof of concept pilot study, the investigators propose to study the effectiveness of this medicine when it is delivered through the skin. In order to make delivery more efficient, the investigators will be using a technique called iontophoresis, which uses a mild electric current to drive the drug through the surface of the skin. The instrument includes an electrode containing the active agent (delivers charge) and an oppositely charged electrode (receives charge) which will be placed on the surface of the skin. The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.\n\nIf this delivery method is shown to be effective, it may represent a way to vastly improve the clinical utility of this medication by allowing for needle-free self administration, and expanding the clinical indication to routine, at home bowel care.",
         "NO",
         "Spinal Cord Injury|Neurogenic Bowel",
         "DRUG: Neostigmine and Glycopyrrolate",
         "Biological Responses to Study Drugs (quantified by the presence and strength of biological responses (changes in bowel sounds, heart rate and airway resistance and bowel movement occurrence), We aim to determine the efficacy of transcutaneous (TC) neostigmine (NEO) with glycopyrrolate (GLY) delivered via iontophoresis in promoting bowel movement in persons with chronic SCI. This will be quantified by the presence and strength of biological responses (changes in bowel sounds, heart rate and airway resistance and bowel movement occurrence)., 6 months",
         "Safety of Study Medication (quantified through monitoring of side effects during study visits and through patient self report as measured by the Treatment Satisfaction Questionnaire), We aim to determine the safety and tolerability of TC NEO and GLY in persons with SCI when used to promote bowel movement. This will be quantified through monitoring of side effects during study visits and through patient self report as measured by the Treatment Satisfaction Questionnaire., 6 Months",
         "No Outcome Measure",
         "James J. Peters Veterans Affairs Medical Center",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "28.0",
         "GOV",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2013-02",
         "2016-12",
         "2016-12",
         "2015-02",
         null,
         "2017-03",
         "James J. Peters VA Medical Center, Bronx, New York, 10468, United States",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2013",
         "2015",
         null,
         "2017",
         "2016",
         "2016",
         "2",
         "2",
         null,
         "3",
         "12",
         "12",
         "46",
         "0",
         "-24",
         "3",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Neostigmine and Glycopyrrolate",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'New York']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "3",
         "NCT04112862",
         "Sodium Lactate Infusion in GLUT1DS Patients",
         "COMPLETED",
         "This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.",
         "NO",
         "GLUT1 Deficiency Syndrome|GLUT1DS1|GLUT1DS2|Epilepsy|Lactic Acid Blood Increased|Ketogenic Dieting",
         "OTHER: sodiumlactate",
         "Number of changes in epileptic discharges on EEG during the infusion of lactate., All subjects have frequent epileptic discharges on EEG. We want to objectify the change in epileptic discharges on EEG during and after the infusion of sodium lactate., 1 day",
         "Change in seizure frequency clinical visible by caregivers during and after infusion of sodium lactate., All subjects have frequent seizures, we want to see if these clinically visible seizures reduce during or after infusion with sodium lactate., 1 day|Concentration of lactate in blood during and after sodium lactate infusion, 1 day|Concentration of glucose in blood during and after sodium lactate infusion, 1 day|Concentration of sodium in blood during and after sodium lactate infusion, 1 day|Concentration of potassium in blood during and after sodium lactate infusion, 1 day|Concentration of bicarbonate in blood during and after sodium lactate infusion, 1 day|Concentration of chloride in blood during and after sodium lactate infusion, 1 day|pH in blood during and after sodium lactate infusion, 1 day",
         "No Outcome Measure",
         "Radboud University Medical Center",
         "No collaborators",
         "ALL",
         "['CHILD', 'ADULT']",
         "PHASE0",
         "2.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2022-05",
         "2022-11",
         "2022-11",
         "2019-10",
         null,
         "2022-11",
         "Radboudumc, Nijmegen, Gelderland, 6500GA, Netherlands",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2022",
         "2019",
         null,
         "2022",
         "2022",
         "2022",
         "5",
         "10",
         null,
         "11",
         "11",
         "11",
         "6",
         "0",
         "31",
         "0",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['OTHER']",
         "1",
         "sodiumlactate",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Netherlands']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "4",
         "NCT04067960",
         "Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer",
         "COMPLETED",
         "This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.",
         "NO",
         "Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Biliary Tract Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Malignant Brain Neoplasm|Malignant Genitourinary System Neoplasm|Malignant Solid Neoplasm|Pancreatobiliary Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Pancreatic Cancer|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Pancreatic Cancer|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8",
         "PROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration",
         "Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing, Patient survey responses will be compared across administration time points to look for changes in symptoms, QOL, and perceptions about PGx testing., Baseline up to 3 months post consent",
         "Provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients, Will qualitatively assess provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients via the provider survey. Provider survey responses will be examined to determine the range of perceptions and experiences associated with PGx testing and result reporting for patient tests. Descriptive statistics will be used to report provider survey results., Up to 3 months",
         "No Outcome Measure",
         "Mayo Clinic",
         "No collaborators",
         "ALL",
         "['CHILD', 'ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "197.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING",
         "2019-06",
         "2022-10",
         "2022-10",
         "2019-08",
         null,
         "2024-08",
         "Mayo Clinic in Arizona, Scottsdale, Arizona, 85259, United States",
         "(114.0, 20121212.0]",
         "['No Documents']",
         "0",
         "No",
         "2019",
         "2019",
         null,
         "2024",
         "2022",
         "2022",
         "6",
         "8",
         null,
         "8",
         "10",
         "10",
         "40",
         "0",
         "-2",
         "22",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['GENETIC', 'PROCEDURE', 'OTHER']",
         "3",
         "Biospecimen Collection|Genetic Testing|Quality-of-Life Assessment|Questionnaire Administration",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "SCREENING",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Arizona', 'United States']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "5",
         "NCT01573260",
         "Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.",
         "COMPLETED",
         "Parkinson's disease involves many motor difficulties as well as non-motor ones. Recent research has strongly suggested that exercise is very important for Parkinson's disease. We are interested especially in dance as a form of exercise, because it combines physical movements with balance tasks, social engagement, and mental stimulation. Therefore, we think dance classes may be a very beneficial exercise for Parkinson's disease; the purpose of this study is to see if Argentinean Tango classes might improve motor and non-motor manifestations of Parkinson's disease.",
         "YES",
         "Parkinson's Disease",
         "OTHER: Argentinean Tango classes|OTHER: Simple pamphlet about the exercise in PD",
         "Severity of PD (Unified Parkinson Disease Rating Scale - UPDRS, 2008 Version), This is the standard scale used for grading severity of PD. It starts with a patient self-administered questionnaire covering activities of daily living, motor symptoms, and non-motor domains. It also includes a systematic rated clinical interview assessing cognitive and psychiatric symptoms and motor complications of disease. A Hoehn and Yahr scale (5-point overall disease severity index) is included. Finally, there is a formal examination component (Part III) (performed in the medication 'on' state for this study). Total score for Unified Parkinson Disease Rating Scale is the sum of six subscales, ranging from 0 (best possible outcome) to 60 (worst possible symptoms), 26 weeks",
         "MiniBESTest, Balance will be assessed using a 14-item tool measuring performance of dynamic balance tasks. This test has high interrater and test-retest reliability in PD (intraclass correlation coefficient ≥ .92 and intraclass correlation coefficient ≥.88 respectively). Total score for MiniBESTest is the sum of foursubscales, ranging from 0 (worst possible balance) to 28 (best possible balance). Lower scores indicate greater deficits in balance. Two items have right and left assessment in which the lower score is used within the total score (directions specify which to use). For research, we used of both left and right data, thus calculating data based on 32 (vs 28) points., 26 weeks|Number of Participants With a Fall in the Past 3 Months Using the Falls Questionnaire From the Canadian Longitudinal Study of Aging, Falls will be assessed using an adapted version of the falls questionnaire from the Canadian Longitudinal Study of Aging focusing on the past 3 months. This questionnaire includes 2 questions to assess if the participants felt during the past year and then it assess if this fall happened within the last 3 months. If a participant answered 'yes' to both questions, then the participant screened positive for this outcome. In the results section, we reported the number of participant who answered 'Yes' to both questions., 26 weeks|Freezing of Gait Questionnare (FOG_Q), Freezing of gait will be assessed using the Freezing of Gait Questionnare (FOG_Q), a 6-item tool measuring walking and freezing episodes. Higher scores indicate greater difficulty with walking and freezing. Six items each scored from 0 to 6 were summed to obtain the total score, ranging from 0 (best possible outcome) to 36 (worst possible outcome)., 26 weeks|The Purdue Pegboard, The Purdue Pegboard, a test of dexterity and speed in the hands will be assessed over 1 minute. We calculate the number of pins correctly placed on the board in a minute., 26 weeks|The Montreal Cognitive Assessment, This tool was designed to screen for mild cognitive impairment. This includes visuospatial tests (clock drawing, trail making, cube copying), confrontation naming, attention (digit span, backwards digit span, \"A\" test, sentence repetition), tests of verbal fluency, abstraction, short term memory, and orientation. Recently, it has been used widely in PD, and demonstrates excellent sensitivity for subtle cognitive deficits. Alternate versions (7.1 to 7.3, with a randomly-distributed order) will be administered to prevent training effects. Total score for the MoCA is the sum of eight subscales, ranging from 0 (worst possible outcome) to 30 (best possible symptoms)\", 26 weeks|The Beck Depression Inventory (BDI), The BDI is a self-administered scale of 21 items (scored 0-3) which assesses depression symptoms. The Beck Inventory is one of the most commonly-used scales for depression in PD, and a recent consensus panel of the Movement Disorders Society concluded it was a scale of first choice for assessing depression in PD. Total score for the BDI is the sum of 21 items, ranging from 0 (best possible outcome) to 63 (worst possible symptoms)\", 26 weeks|Apathy Evaluation Scale (AES), This is a 14-item patient-rated scale which measures cognitive, emotional, and behavioural symptoms of apathy. All items are rated on a 0 to 3 Likert Scale. The original 18-item scale has been shortened by four items, and wording simplified and it was reported to have excellent psychometric properties in PD (internal consistency reliability = 0.76, test-retest 1 week r = 0.90). Total score is ranging from 0 (best possible outcome) to 42 (worst possible symptoms)., 26 weeks|The Krupp Fatigue Severity Scale, The fatigue severity scale measures impact of fatigue with a 9-item questionnaire, with a 7-point Likert scale for each question It has been validated, and has been used in PD studies. Total score is ranging from 0 (best possible outcome) to 63 (worst possible fatigue)., 26 weeks|The Parkinson's Disease Questionnaire is a Quality of Life(PDQ-39), The PDQ-39 is a quality of life index for PD. It consists of a 39-item questionnaire that asks about the impact of PD on a person's motor function, gait, mood, cognition, and activities of daily living. Patients are asked to indicate the frequency of each event by selecting one of 5 options: never/occasionally/sometimes/often/always or cannot do at all. Total score is ranging from 0 (best possible outcome) to 156 (worst possible quality of life)., 26 weeks|Adherence to Treatment, Compliance with dance therapy will be conducted by reconfirming the regular assistance to the dance sessions at week 12, to compare how many sessions were attended by the participants. The dance instructors will keep the track of dance classes' assistance., 12 weeks|Clinical Global Impression of Change, Completed by both the examiner and the patient, the scale is a single question\" Since you have enrolled in the study, how has your Parkinson's disease changed?\". It will be scored as very much improved (6), much improved (5), minimally improved (4), no change (3), minimally worse (2), much worse (1), or very much worse(0)., 26 weeks|Exit Questionnaire, An exit questionnaire ranking level of enjoyment and overall satisfaction with their dance/exercise program, scored from 1 (strongly agree) to 5 (strongly disagree), with open questions about willingness continuing practicing tango., 12 weeks|Adverse Events, Adverse events will be queried week 12 through a semi structured interview querying increase in falls, fatigue, pain, cramps or pain, in addition to open-ended questions regarding other potential adverse events. Events will be rated by the patient and investigator as mild, moderate, or serious. All serious adverse events will be reported to the research ethics board, 12 weeks",
         "No Outcome Measure",
         "McGill University Health Centre/Research Institute of the McGill University Health Centre",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "33.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT",
         "2012-04",
         "2013-04",
         "2014-04",
         "2012-04",
         "2016-02",
         "2016-02",
         "Montreal General Hospital, Montreal, Quebec, H3G1A4, Canada",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2012",
         "2016",
         "2016",
         "2013",
         "2014",
         "4",
         "4",
         "2",
         "2",
         "4",
         "4",
         "24",
         "12",
         "0",
         "22",
         "(2010, 2018]",
         "(2004, 2018]",
         "(2010, 2018]",
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['OTHER']",
         "1",
         "Argentinean Tango classes|Simple pamphlet about the exercise in PD",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Canada']",
         "1",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "6",
         "NCT03103594",
         "Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A",
         "COMPLETED",
         "The purpose of this research study is to evaluate the efficacy of intravesical botulinum A toxin and DMSO in women with bladder pain syndrome who have not responded to first-line treatments. Bladder pain syndrome is suprapubic pain with bladder filling as well as frequency, urgency, and nocturia in the absence of urinary tract infection or other pathology. DMSO has been shown to reduce pain in women with bladder pain syndrome as well as increase bladder absorption of various drugs. Botulinum toxin A has also been shown to improve pain in women with bladder pain syndrome when injected into the bladder suburothelium via a cystoscope. The main objective of this study is to assess if DMSO can deliver botulinum toxin to the suburothelium of the bladder to produce the same effect as direct injection of Botulinum toxin and a better effect than DMSO alone.",
         "NO",
         "Bladder Pain Syndrome",
         "DRUG: DMSO|DRUG: Botox",
         "Pain Score, We hypothesize that DMSO can deliver botulinum toxin to the suburothelium of the bladder to produce the same effect as direct injection of botulinum toxin via cystoscopy. The primary endpoint will be a pain score as measured by visual analog scale at 2 months post-instillation compared to pre-instillation pain score. We hypothesize that the effect of DMSO will have dissipated by that point and any improvement in pain will be attributable to the effects of botox., 6 months",
         "No Outcome Measure",
         "No Outcome Measure",
         "University of Pennsylvania",
         "Society for Urodynamics and Female Urology",
         "FEMALE",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "2.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT",
         "2015-08",
         "2016-08",
         "2017-04",
         "2017-04",
         null,
         "2017-06",
         null,
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2015",
         "2017",
         null,
         "2017",
         "2016",
         "2017",
         "8",
         "4",
         null,
         "6",
         "8",
         "4",
         "20",
         "8",
         "-20",
         "2",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "DMSO|Botox",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT']",
         "SINGLE",
         "TREATMENT",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         null,
         "0",
         "Unknown",
         "0",
         "0",
         null,
         "0",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "7",
         "NCT02046694",
         "A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL",
         "COMPLETED",
         "This research is being done to determine if allopurinol can change the metabolism of the oral chemotherapeutic medication 6-mercaptopurine (6-MP) in children with acute lymphoblastic leukemia (ALL). 6-MP is originally started at a standard dose in children with ALL, but the dose is adjusted according to the absolute neutrophil count (ANC). Occasionally, 6-MP doses need to be increased in order to get the ANC into a specific target range. Also, increasing the 6-MP dose can lead to unwanted side effects, such as inflammation of the liver as shown by increases in laboratory values (ALT, aspartate aminotransferase (AST), bilirubin), nausea, and abdominal discomfort. Previous studies in children with inflammatory bowel disease has shown that combining allopurinol with 6-MP can decrease side effects associated with high doses of 6-MP and also increase the efficacy of 6-MP. Allopurinol is approved by the Food and Drug Administration for the treatment of tumor lysis syndrome in ALL. Through this research study, the investigators hope to show that the combination of allopurinol and 6-MP will be safe, tolerable, and effective in children with ALL.",
         "NO",
         "Acute Lymphoblastic Leukemia (ALL)",
         "DRUG: Allopurinol",
         "Absolute neutrophil count, Absolute neutrophil count (ANC) measured 8 weeks after the addition of allopurinol (study week 9)., 8 weeks",
         "Feasibility of the addition of allopurinol to ALL maintenance therapy, Allopurinol compliance rate during ALL maintenance therapy., 8 weeks|Safety of the addition of allopurinol to ALL maintenance therapy, Occurence of grade 4 adverse events that are possibly, probably, or definitely attributable to allopurinol., 8 weeks|Effects of allopurinol on liver function tests, Measurement of ALT, AST, and direct bilirubin before and after adding allopurinol., 8 weeks|Alteration of 6-MP metabolism through the addition of allopurinol, Measurement of 6-thioguanine (6-TGN) and 6-methylmercaptopurine (6-MMP) before and after adding allopurinol., 8 weeks",
         "No Outcome Measure",
         "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
         "No collaborators",
         "ALL",
         "['CHILD', 'ADULT']",
         "PHASE0",
         "34.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2014-01",
         "2020-04",
         "2020-04",
         "2014-01",
         null,
         "2022-06",
         "Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Texas Children's Cancer and Hematology Centers, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2014",
         "2014",
         null,
         "2022",
         "2020",
         "2020",
         "1",
         "1",
         null,
         "6",
         "4",
         "4",
         "75",
         "0",
         "0",
         "26",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "Allopurinol",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Washington']",
         "1",
         "Capital",
         "['United States', 'Maryland', 'Texas', 'Washington']",
         "4",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "8",
         "NCT02764060",
         "The Effect of Tongue Cleaning in Periodontitis Patients",
         "COMPLETED",
         "The aim of this study was to examine in periodontitis patients with visible tongue coating the changes in microbial load (aerobic and anaerobic) of the 14 day use of a tongue scraper versus the use of a regular toothbrush to clean the tongue.",
         "NO",
         "Periodontitis|Tongue Coating",
         "DEVICE: Tongue scraper|DEVICE: Toothbrush",
         "Extension of the tongue coating, Extension of the tongue coating measured according to Miyazaki (1995) and Winkel (2003)., 14 days",
         "Bacterial load measured by culturing methods, Microbiological composition of the tongue coating., 14 days|Bacterial load measured by means of qPCR, Microbiological composition of the tongue coating., 14 days|Bacterial composition of unstimulated saliva (measured with the aid of culturing methods), Microbiological composition of the saliva., 14 days|Bacterial composition of unstimulated saliva (measured with qPCR), Microbiological composition of the saliva., 14 days|Experience of the subject of tongue coating related factors measured using a questionnaire, Experience of the subject of the breath odour, taste perception; and cleanliness of the tongue., 14 days",
         "No Outcome Measure",
         "Universitaire Ziekenhuizen KU Leuven",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "18.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT",
         "2011-01",
         "2015-01",
         "2015-01",
         "2016-05",
         null,
         "2016-05",
         "UZLeuven, Leuven, 3000, Belgium",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2011",
         "2016",
         null,
         "2016",
         "2015",
         "2015",
         "1",
         "5",
         null,
         "5",
         "1",
         "1",
         "48",
         "0",
         "-64",
         "16",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DEVICE']",
         "1",
         "Tongue scraper|Toothbrush",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Belgium']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "9",
         "NCT02729194",
         "Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",
         "COMPLETED",
         "Pazopanib is an orally administered multi-kinase inhibitor targeting VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet derived growth factor) and c-kit, which are critical to growth and proliferation of neoplastic cells. Pazopanib has been FDA approved for advanced renal cell carcinoma (RCC) with a clear cell component. Conventional Pazopanib dosing WITHOUT FOOD is with an initial dose of 800 mg by mouth daily. Investigators hypothesize that administration of pazopanib with low fat meal would be safe and feasible with secondary implications of higher pazopanib levels; potentially translating into greater anti-tumor efficacy in advanced renal cell cancer, with significant cost savings. In the proposed pilot study, investigators seek to test the feasibility and practicality of this approach and gather preliminary data on adverse effects and the safety profile. Investigators hope to ameliorate any potential for greater toxicities with a dynamic dosing design that incorporates adverse events from each cycle into dosing for the next cycle and a structured symptom specific plan.",
         "YES",
         "Carcinoma, Renal Cell",
         "DRUG: Pazopanib|OTHER: Low Fat Diet",
         "Number of Grade 3 or 4 Adverse Events, Number of grade 3 or 4 adverse events associated with pazopanib administered with a low fat meal by CTCAE version 4.0., Through 12 weeks of treatment to 30 days post-treatment|Number of Participants With Dose Reductions, 12 weeks|Duration of Treatment, The median duration of treatment will be reported., 12 weeks|Median Total Dose, Median total dose given., 12 weeks",
         "Percentage of Patients That Respond to Treatment (Overall Response) With Pazopanib Administered Along With a Low Fat Diet, To estimate the overall response proportion to pazopanib administered with a low fat meal by RECIST 1.1 criteria. Overall response is defined as the number patients that experience Partial Response (PR) or Complete Response (CR).\n\nCR is defined as the disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions.\n\nPR is defined as At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions., 12 Weeks after start of study treatment|Number of Participants With Complete Response, Complete response is defined as the disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions., 12 Weeks after start of study treatment|Number of Patients With Partial Response, Partial response is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions., 12 Weeks after start of study treatment",
         "No Outcome Measure",
         "University of Michigan Rogel Cancer Center",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "16.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2016-06",
         "2017-09",
         "2017-09",
         "2016-04",
         "2019-06",
         "2019-06",
         "University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States",
         "(-0.001, 21.0]",
         "['Analysis Plan', 'Protocol']",
         "2",
         "Yes",
         "2016",
         "2016",
         "2019",
         "2019",
         "2017",
         "2017",
         "6",
         "4",
         "6",
         "6",
         "9",
         "9",
         "15",
         "0",
         "2",
         "21",
         "(2010, 2018]",
         "(2004, 2018]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG', 'OTHER']",
         "2",
         "Pazopanib|Low Fat Diet",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Michigan']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "10",
         "NCT02679274",
         "Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents",
         "TERMINATED",
         "Frailty is a recognized cause for disability, hospitalization, and mortality in nursing home residents. Testosterone treatment is among the potentially beneficial treatments in addition to resistance exercise for improving muscle strength and mass in frail adults. The investigators have demonstrated that cycled administration of testosterone improves muscle mass and strength in healthy adults. It is proposed that cycled testosterone administration may be an effective adjuvant therapy for frail older men and women during rehabilitation programs. The hypothesis is that testosterone treatment in addition to standard-of-care (SOC) rehabilitation will result in improved muscle mass and physical function when compared to patients receiving SOC only. Therefore, in a randomized, double-blind, placebo controlled study, the investigators will test the effects of cycled testosterone administration (2 week on treatment, 2 weeks off treatment) on body composition and physical function in male and female nursing home residents undergoing rehabilitative care. Primary outcomes will be assessed before and after 10 weeks of treatment using bioelectric impedance, handgrip dynamometers, short physical performance battery (SPPB), and quality of life (QOL) questionnaires. Data from this pilot project will become the foundation for the development of a larger long-term project solicitation to the NIH aimed at elucidating the efficacy of testosterone treatment on physical function and independence in frail older adults.",
         "YES",
         "Aging",
         "DRUG: Placebo|DRUG: Testosterone",
         "Change in Fat-free Mass as Measured by Bioelectric Impediance Analysis (BIA), Fat-free Mass (kg) calculated from total weight (kg) and percent body fat (%) obtained during bioelectric impedance analysis (BIA)., 0 to 10 Weeks",
         "Change in Handgrip Strength, Measured using a handgrip dynamometer, 0 to 10 Weeks|Change in Knee Extension Strength (Seated), Collected using a manual muscle tester (MMT)., 0 to 10 Weeks|Change in Hip Abduction Strength (Supine), Collected using a manual muscle tester (MMT)., 0 to 10 Weeks|Side by Side Balance as Measured by Short Physical Performance Battery (SPPB) at Baseline, During the Short Physical Performance Battery (SPPB) side by side balance test subjects are asked to stand with their feet together and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., baseline|Side by Side Balance as Measured by Short Physical Performance Battery (SPPB) at 10 Weeks, During the Short Physical Performance Battery (SPPB) side by side balance test subjects are asked to stand with their feet together and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., 10 Weeks|Semi-Tandem Balance as Measured by Short Physical Performance Battery (SPPB) at Baseline, During the Semi-Tandem Balance section of the Short Physical Performance Battery (SPPB) subjects are asked to stand with their feet in a semi-tandem stance (heel of one foot placed to side of the first toe of the other foot) and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., baseline|Semi-Tandem Balance as Measured by Short Physical Performance Battery (SPPB) at 10 Weeks., During the Semi-Tandem Balance section of the Short Physical Performance Battery (SPPB) subjects are asked to stand with their feet in a semi-tandem stance (heel of one foot placed to side of the first toe of the other foot) and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., 10 Weeks|Tandem Balance as Measured by Short Physical Performance Battery (SPPB) at Baseline, During the Tandem Balance section of the Short Physical Performance Battery (SPPB) subjects are asked to stand with their feet in a tandem stance (heel of one foot directly in front of the toes of the other foot) and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., baseline|Tandem Balance as Measured by Short Physical Performance Battery (SPPB) at 10 Weeks, During the Tandem Balance section of the Short Physical Performance Battery (SPPB) subjects are asked to stand with their feet in a tandem stance (heel of one foot directly in front of the toes of the other foot) and balance for a maximum of 10 seconds. If they are unable to perform balance test, they receive a score of 0 seconds, maximum score is 10 seconds. A higher score indicates a better outcome., 10 Weeks|Change in Gait Speed as Measured by Short Physical Performance Battery (SPPB)., During the gait speed section of the Short Physical Performance Battery (SPPB) subjects are timed while walking a predefined 4 meter course. Data is shown as change in speed (meters/second) from baseline (0 weeks) to 10 weeks. A increase in speed indicates a better outcome., 0 to 10 Weeks|Chair Raise as Measured by Short Physical Performance Battery (SPPB) at Baseline, During the chair rise section of the Short Physical Performance Battery (SPPB), subjects are timed while they rise from a seated (chair) to standing position. Subjects perform this task 5 times and data is presented as their faster time., baseline|Chair Raise as Measured by Short Physical Performance Battery (SPPB) at 10 Weeks, During the chair rise section of the Short Physical Performance Battery (SPPB), subjects are timed while they rise from a seated (chair) to standing position. Subjects perform this task 5 times and data is presented as their best time., 10 Weeks",
         "No Outcome Measure",
         "The University of Texas Medical Branch, Galveston",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "3.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",
         "2016-02",
         "2016-09",
         "2016-09",
         "2016-02",
         "2019-02",
         "2019-02",
         "Gulf Health Care Center, Galveston, Texas, 77555, United States|Gulf Health Care Center, Texas City, Texas, 77590, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2016",
         "2019",
         "2019",
         "2016",
         "2016",
         "2",
         "2",
         "2",
         "2",
         "9",
         "9",
         "7",
         "0",
         "0",
         "29",
         "(2010, 2018]",
         "(2004, 2018]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "Placebo|Testosterone",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "SUPPORTIVE_CARE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Texas']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "11",
         "NCT02814474",
         "Effects of Experimental Hyperketonemia on Myocardial Metabolism",
         "COMPLETED",
         "Starvation and metabolic stress increase circulating ketone bodies, potentially providing the heart with an alternative oxidative fuel. Hyperketonemia reduces myocardial fatty acid consumption. It is unclear whether this is due to inhibited peripheral lipolysis or diminished uptake per se.\n\nAim: To test whether infusion of 3-hydroxybutyrate (BHB) inhibits myocardial glucose and fatty acid uptake.\n\nMethods: Randomized, single blinded, cross-over interventional study in 8 healthy volunteers. Myocardial glucose and fatty acid metabolism studied by 11C-palmitate and 18F-FDG PET/CT. Experimental elevation of circulating ketone bodies by infusion of β-hydroxy-β-methylbutyrate.",
         "NO",
         "Healthy Volunteers",
         "OTHER: Na-3-hydroxybutyrate|OTHER: Saline",
         "Myocardial Glucose uptake, Dynamic 18F-FDG PET/CT scan - 50 minutes, After 330 minutes of ketone infusion|Myocardial Fatty Acid Metabolism, Dynamic 11C-palmitate PET/CT scan - 50 minutes, After 210 minutes of ketone infusion|Myocardial Blood Flow, Dynamic 15O-H2O PET/CT scan - 6 minutes, After 180 minutes of ketone infusion",
         "Insulin sensitivity, Glucose infusion rate (GIR) during a 0.3 mIE/kg/min hyperinsulinemic- euglycemic clamp, Time 0-390 of the ketone body infusion",
         "No Outcome Measure",
         "University of Aarhus",
         "Aarhus University Hospital",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "10.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE",
         "2014-10",
         "2016-06",
         "2016-06",
         "2016-06",
         null,
         "2016-07",
         "Department of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, 8000, Denmark|Medical Research Laboratories, Aarhus, 8000, Denmark",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2014",
         "2016",
         null,
         "2016",
         "2016",
         "2016",
         "10",
         "6",
         null,
         "7",
         "6",
         "6",
         "20",
         "0",
         "-20",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['OTHER']",
         "1",
         "Na-3-hydroxybutyrate|Saline",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['PARTICIPANT']",
         "SINGLE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Denmark']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "12",
         "NCT03574220",
         "Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer",
         "TERMINATED",
         "The purpose of this study is to see whether patients who have early stage NSCLC bigger than a certain size might benefit from receiving additional medicinal drug to treat their cancer after the SBRT Surgeons and radiation doctors have understood for some time that the chances of cancer showing up in areas outside the chest are higher for patients with tumors bigger than 3 cm, (about 1 ¼ inches). However, it is not routine to offer chemotherapy or drug treatments after radiation or surgery for lung cancer for patients with early stage lung cancer. This is because giving extra treatment in the form of chemotherapy has not shown to help patients live longer. There has been reluctance to offer additional treatments, especially chemotherapy, to patients with lung cancer who could not have surgery because of their medical issues. Even if these patients were felt to be at a higher risk of their cancer coming back, there is hesitation because the treatments can be difficult to tolerate in frail patients.\n\nRecently, there have been very important advances in the kinds of drug therapy that are used for lung cancer patients. These kinds of drugs are called immunotherapy since they work with the body's immune system to fight the cancer. These drugs have been shown to make patients with advanced, incurable lung cancer, live longer and also to be very safe with very limited side effects. Because of these favorable characteristics, cancer specialists are interested in using these drugs for patients with curable cancer and for patients who may be too fragile for traditional chemotherapy. In this way, patients who get SBRT are already known to be fragile so cancer doctors are interested in now studying this kind of drug in SBRT patients to see if it can make patients with large tumors do better. The idea of the study then is that the patient would receive their standard SBRT and if their tumor is of a certain size that makes the risk of the cancer showing up outside the chest higher than routine, they would be considered for getting the immunotherapy drug.\n\nPembrolizumab is an investigational drug (also known as Keytruda), which has been approved by the FDA for use in certain types of skin cancer (melanoma), and for use in certain types of head and neck cancer. However, it has not been approved for use in other cancers such as newly diagnosed early stage NSCLC. It is FDA approved for advanced NSCLC, that is people who have already had some chemotherapy and their disease has worsened. Pembrolizumab is a monoclonal antibody that binds to the surface of some cells of the immune system and activates them against cancer cells. It is not chemotherapy.",
         "NO",
         "Non Small Cell Lung Cancer",
         "DRUG: Pembrolizumab|RADIATION: Stereotactic body radiotherapy",
         "Percent of patients tolerant to study drug, \\<60% of patients being able to complete the scheduled doses of study drug without experiencing a Grade \\>3 pulmonary toxicity or any Grade \\>4 toxicity. Good tolerability had been defined as \\>90% of patients being able to complete the scheduled doses of study drug without experiencing a Grade \\>3 pulmonary toxicity or any Grade \\>4 toxicity., Up to 12 months",
         "Duration of Distant metastases free survival (DMFS), DMFS is defined as the time from initiation of study drug post-SBRT, until the first documented, confirmed distant-only \\[non local, non-regional nodal\\] progression of disease. DMFS will be measured and reported from the initiation of SBRT., Up to 5 years|Duration of Disease Free Survival, DFS is defined as the time from initiation of study drug post-SBRT that the patient survives without any signs or symptoms of that cancer. DFS will also be measured and reported from the initiation of SBRT., Up to 5 years|Duration of Overall Survival, OS will be measure from the initiation of SBRT until death., Up to 5 years|Duration of Local control, For the purpose of the study, local control will be defined as a complete response, partial response, or stable disease within the planning target volume. The duration of local control will be measured from the time of SBRT initiation., Up to 5 years",
         "No Outcome Measure",
         "Case Comprehensive Cancer Center",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "0.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2019-02",
         "2020-03",
         "2020-03",
         "2018-06",
         null,
         "2020-04",
         null,
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2019",
         "2018",
         null,
         "2020",
         "2020",
         "2020",
         "2",
         "6",
         null,
         "4",
         "3",
         "3",
         "13",
         "0",
         "8",
         "0",
         "(2018, 2024]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG', 'OTHER', 'RADIATION']",
         "3",
         "Pembrolizumab|Stereotactic body radiotherapy",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         null,
         "0",
         "Unknown",
         "0",
         "0",
         null,
         "0",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "13",
         "NCT01587820",
         "Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer",
         "TERMINATED",
         "This is a randomized, open-label investigator initiated pilot/ feasibility study comparing the effectiveness of intra-arterial administration of cisplatin therapy to intravenous administration of cisplatin when each is combined with the radiation therapy found in standard care. Participants will be randomized to either intra-arterial or intravenous cisplatin chemotherapy. This study is designed to determine whether a large scale study is practical in the investigators clinical setting. Approximately 10 subjects will be enrolled over a 2 year period.",
         "NO",
         "Head and Neck Cancer",
         "DRUG: Intra-arterial cisplatin|DRUG: Intravenous cisplatin",
         "number of enrolled subjects, enrollment, 2 years",
         "patient survival, patient survival data including overall survival, disease free survival, and cancer specific survival, 2 years|rate of patient morbidity, rate of local and regional control of cancer, including site of recurrence and organ preservation rate, 2 years",
         "No Outcome Measure",
         "Southern Illinois University",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "1.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT",
         "2012-06",
         "2014-08",
         "2014-08",
         "2012-04",
         null,
         "2014-12",
         "Southern Illinois University School of Medicine, Springfield, Illinois, 62701, United States|Simmons Cancer Institute at SIU School of Medicine, Springfield, Illinois, 62702, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2012",
         null,
         "2014",
         "2014",
         "2014",
         "6",
         "4",
         null,
         "12",
         "8",
         "8",
         "26",
         "0",
         "2",
         "4",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Intra-arterial cisplatin|Intravenous cisplatin",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Illinois']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "14",
         "NCT04642820",
         "Drugs Brain and Behavior (DDP)",
         "COMPLETED",
         "In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.",
         "YES",
         "Stimulant Use",
         "DRUG: Methamphetamine|DRUG: placebo oral tablet",
         "Change in SUbjective Effects as Assessed by Score on \"Feel Drug\", \"Feel High\", \"Like Drug\", and \"Want More\" Sub-scales of Drug Effects Questionnaire (DEQ)., Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: \"Feel Drug\", \"Feel High\", \"Like Drug\", and \"Want More\". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome., Time Frame: Day 1(baseline), 3",
         "No Outcome Measure",
         "No Outcome Measure",
         "University of Chicago",
         "National Institute on Drug Abuse (NIDA)",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "138.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",
         "2020-11",
         "2023-10",
         "2024-06",
         "2020-11",
         "2025-01",
         "2025-01",
         "University of Chicago, Chicago, Illinois, 60637, United States",
         "(114.0, 20121212.0]",
         "['Analysis Plan', 'Protocol']",
         "2",
         "Yes",
         "2020",
         "2020",
         "2025",
         "2025",
         "2023",
         "2024",
         "11",
         "11",
         "1",
         "1",
         "10",
         "6",
         "43",
         "8",
         "0",
         "7",
         "(2018, 2024]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Methamphetamine|placebo oral tablet",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "BASIC_SCIENCE",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Illinois']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "15",
         "NCT03507374",
         "PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis",
         "TERMINATED",
         "This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or placebo.",
         "NO",
         "Stroke|Intracranial Atherosclerosis|Intraplaque Hemorrhage",
         "DRUG: Alirocumab|DRUG: Placebo",
         "Vessel Wall MRI, Our primary outcome measures will be to assess the Vessel Wall MRI on Day 365 and compare it to day 1.The primary endpoint is nominal change in the composite percent atheroma volume (PAV) of the stroke parent artery and additional intra- or extracranial cerebrovasculature arteries with atherosclerosis (≥ 25% stenosis) from baseline to week 52. We will use measure PAV on vessel wall MRI (vwMRI), which evaluates all arteries from the aortic arch to the distal intracranial vasculature in a single scan. The primary endpoint will be analyzed for both: 1) the composite PAV of the stroke parent artery and any additional intra- or extracranial arteries that have at least 25% stenosis, and 2) separately for the PAV of the stroke parent artery. The PAV measurements will be performed using the validated MRI-PlaqueView software. Stenosis of the stroke parent artery and all additional arteries included in the composite PAV will be measured using standard methodology and also be evaluated as, Day 1 and Day 365",
         "Post-Contrast Plaque Enhancement, Secondary endpoint 1 is post-contrast plaque enhancement for intracranial arteries and intraplaque hemorrhage for the carotid artery, which are determined by two experienced neuroradiologist raters. If there is disagreement, then a third rater serves as a tie-breaker. The signal intensity characteristics of both endpoints have been standardized in prior literature., Day 1",
         "Mechanism of Alirocumab's effect, To better understand the mechanism of alirocumab's effect on intra- and extracranial atherosclerosis, we will measure the endpoint of change in cholesterol markers \\[LDL-C, HDL-C, lipoprotein (a), apolipoprotein B, and triglyceride level\\]. The change in cholesterol markers will be correlated with the primary and secondary study endpoints on vwMRI. Cholesterol values will be measured at the baseline and comparison MRIs, which are 52 weeks apart. An additional exploratory outcome that we will measure is the composite endpoint of \"recurrent stroke,\" which encompasses new symptomatic ischemic stroke, transient ischemic attack, or asymptomatic strokes that emerge between the study MRIs., Day 1 and Day 365|Lab Assessment, At both study MRIs, the study coordinator will collect two blood samples. One sample will be tested with an i-STAT for beta hCG and creatinine levels prior to the MRI. The second sample which will be sent to ARUP Laboratories for testing of LDL-C, HDL-C, triglycerides, apolipoprotein B, and lipoprotein (a), biomarkers of cardiovascular disease risk., Baseline visit and Day 365|Clinical Outcomes, b) At both study visits (baseline vwMRI and follow-up vwMRI), a vascular neurologist blinded to treatment arm assignment will assess patients and their medical records for recurrent stroke. The neurologist will also have access to the \"stroke characteristics\" data from the neuroradiologist raters. The endpoint of recurrent stroke is defined both for the stroke parent artery and other arterial distributions in the cerebrovasculature., Baseline and Day 365",
         "University of Utah",
         "Regeneron Pharmaceuticals",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "20.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2018-10",
         "2020-04",
         "2020-04",
         "2018-04",
         null,
         "2020-04",
         "University of Utah, Salt Lake City, Utah, 84132, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2018",
         "2018",
         null,
         "2020",
         "2020",
         "2020",
         "10",
         "4",
         null,
         "4",
         "4",
         "4",
         "18",
         "0",
         "6",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Alirocumab|Placebo",
         "Placebo",
         "SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "TREATMENT",
         "Primary + Secondary + Other",
         "['Primary', 'Secondary', 'Other']",
         "3",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Utah', 'United States']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "16",
         "NCT02885272",
         "FDG PET Imaging in Diagnosing Patients With Glioblastoma",
         "COMPLETED",
         "This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission tomography (PET) imaging works in diagnosing patients with confirmed or suspected glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose glioblastoma.",
         "NO",
         "Brain Glioblastoma",
         "PROCEDURE: Computed Tomography|RADIATION: Fludeoxyglucose F-18|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography",
         "Differences in length-beam ratio, Will be tested via paired t-test after appropriate transformation., Up to 2 years|Quantitative parametric maps based on biophysical principles or pharmacokinetic modeling, Will be derived from magnetic resonance advanced brain tumor imaging., Up to 2 years|Magnetic resonance images of relative blood volume, blood flow, apparent diffusion coefficient and forward volumetric transfer constant, Will be used to derive quantitative parametric maps based on biophysical principles or pharmacokinetic modeling., Up to 2 years|Fluorodeoxyglucose F-18 uptake patterns, Will be correlated with magnetic resonance images., Up to 2 years|Genotypic factors, Will be assessed via two-sample t-tests, for all genes of interest with at least 20% of mutation prevalence., Up to 2 years",
         "No Outcome Measure",
         "No Outcome Measure",
         "M.D. Anderson Cancer Center",
         "National Cancer Institute (NCI)",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "21.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC",
         "2016-10",
         "2022-07",
         "2022-07",
         "2016-08",
         null,
         "2022-07",
         "M D Anderson Cancer Center, Houston, Texas, 77030, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2016",
         null,
         "2022",
         "2022",
         "2022",
         "10",
         "8",
         null,
         "7",
         "7",
         "7",
         "69",
         "0",
         "2",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['PROCEDURE', 'RADIATION']",
         "2",
         "Computed Tomography|Fludeoxyglucose F-18|Magnetic Resonance Imaging|Positron Emission Tomography",
         "No Placebo",
         "SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "DIAGNOSTIC",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Texas']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "17",
         "NCT05408572",
         "Study of SON-1010 (IL12-FHAB) in Healthy Adults",
         "COMPLETED",
         "SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.",
         "NO",
         "Healthy Adult",
         "BIOLOGICAL: SON-1010 (IL12-FHAB)",
         "To evaluate the safety and tolerability of SON-1010 as a single-ascending dose (SAD) in healthy adults., Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29",
         "Serum and urine concentrations of SON-1010 will be determined at various time points, Concentration vs time of SON-1010 will be measured using blood \\& urine samples taken at various time points on study, Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29|Effect of SON-1010 on Serum cytokine levels, Concentration of serum level of IL-2, IL-6, IL-10 will be measured using blood samples taken at various time points on study, Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29|Evaluation of SON-1010 immunogenicity, Evaluate the immunogenicity of SON-1010 by measuring the number of patients developing anti-SON-1010 antibodies, Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29",
         "No Outcome Measure",
         "Sonnet BioTherapeutics",
         "No collaborators",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "32.0",
         "INDUSTRY",
         "Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",
         "2022-07",
         "2023-02",
         "2023-05",
         "2022-06",
         null,
         "2023-09",
         "Nucleus Network Pty Ltd, Melbourne, Victoria, 3004, Australia",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2022",
         "2022",
         null,
         "2023",
         "2023",
         "2023",
         "7",
         "6",
         null,
         "9",
         "2",
         "5",
         "10",
         "3",
         "0",
         "4",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['BIOLOGICAL']",
         "1",
         "SON-1010 (IL12-FHAB)",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "SEQUENTIAL",
         "['PARTICIPANT', 'INVESTIGATOR']",
         "DOUBLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Victoria']",
         "1",
         "Capital",
         "['Australia']",
         "1",
         "['Oceania']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "18",
         "NCT05470972",
         "Relation Between Ethanol Sclerotherapy for Endometrioma Systemic Immune Milieu",
         "COMPLETED",
         "Design: Prospective interventional study. 69 women with OE were evaluated clinically and by transvaginal ultrasonography (TUV). AEST procedure was performed and the collected aspirate and pre-procedural blood samples were collected for estimation of cytokines' levels. At 6-m post-procedure, clinical evaluation and TUV were repeated and serum cytokines' levels were re-estimated.",
         "NO",
         "Endometriosis",
         "DRUG: Ethanol Injection",
         "The effect of AEST procedures on patients' cytokines levels., The effect of AEST on patients serum levels of tumor necrosis factor-α, interleukin-8 and interleukin-10, 6 months",
         "No Outcome Measure",
         "No Outcome Measure",
         "Tanta University",
         "No collaborators",
         "FEMALE",
         "['ADULT']",
         "PHASE0",
         "69.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2020-05",
         "2021-11",
         "2022-05",
         "2022-07",
         null,
         "2022-07",
         "Tanta university, Tanta, El-Gharbyia, 13511, Egypt",
         "(50.0, 114.0]",
         "['No Documents']",
         "0",
         "No",
         "2020",
         "2022",
         null,
         "2022",
         "2021",
         "2022",
         "5",
         "7",
         null,
         "7",
         "11",
         "5",
         "24",
         "6",
         "-26",
         "2",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Ethanol Injection",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['Egypt']",
         "1",
         "['Africa']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "19",
         "NCT05142072",
         "Design and Application of Vitamin D Films for Burn Healing After Cauterizing Surgery",
         "COMPLETED",
         "One of this method's drawbacks is the healing of cauterized cartilage after processing. It was reported that the healing is so slow as no dosage form can reach this place in addition to the scares produced from healing is very irritable to the patient.\n\nFrom this point, the investigators start searching for a solution to this problem and reach the repositioning of Vitamin D3 (calciferol) as an active ingredient for the rapidity and efficacy of burn healing.\n\nThe dosage form of choice that was reported before for intranasal application by the same team of investigators and gave good results. the intranasal films were proved for its convince, simplicity, efficacy, and compliance to patients.",
         "NO",
         "Nasal Obstruction",
         "DRUG: Vitamin D3",
         "Healing of cauterized tissues after surgery procedures, The outcome will be measured by endoscopic scanning pre and after application of the drug in the dosage form (representing the percent of healing) by the ENT surgeon., three week",
         "patients compliance from the new dosage form, The patient compliance will be measured by rating the pain and the development of symptoms before surgery using a questionnaire, three weeks|Assessment of grades of healing by ENT surgeon, Evaluation of (1) bleeding (amount and frequencies), (2) crustation ( amount and nature), and (3) inflammation (size and the redness of the place of surgery), three weeks",
         "No Outcome Measure",
         "Deraya University",
         "No collaborators",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "20.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE",
         "2021-12",
         "2022-01",
         "2022-02",
         "2021-12",
         null,
         "2022-03",
         "Minya university, faculty of medicin, Minya, المنيا, 05673, Egypt",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2021",
         "2021",
         null,
         "2022",
         "2022",
         "2022",
         "12",
         "12",
         null,
         "3",
         "1",
         "2",
         "2",
         "0",
         "0",
         "0",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Vitamin D3",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT']",
         "SINGLE",
         "SUPPORTIVE_CARE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Egypt']",
         "1",
         "['Africa']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "20",
         "NCT02468492",
         "Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation",
         "COMPLETED",
         "The purpose of this study is to evaluate the affect that platelet rich plasma has on the molecular an cellular functioning of the knee joint.",
         "NO",
         "Knee Osteoarthritis",
         "BIOLOGICAL: Platelet Rich Plasma|OTHER: Normal Saline",
         "Biochemical Molecular Outcomes, Evaluate for change in biochemical molecular milieu temporal response after PRP injection or normal saline (control) compared to baseline, as measured by multiplex suspension array technology., Baseline and 10 day follow up",
         "Clinical Outcomes, Evaluation for change in pain level via VAS and WOMAC at baseline and follow up., 1 year|Imaging Outcomes, Evaluation for change in joint space width using knee radiographs at baseline and 6 month follow up., 6 months",
         "No Outcome Measure",
         "Hunter Holmes Mcguire Veteran Affairs Medical Center",
         "Foundation for Physical Medicine and Rehabilitation",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "18.0",
         "GOV",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE",
         "2014-09",
         "2015-11",
         "2015-11",
         "2015-06",
         null,
         "2017-08",
         "Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, 23224, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2014",
         "2015",
         null,
         "2017",
         "2015",
         "2015",
         "9",
         "6",
         null,
         "8",
         "11",
         "11",
         "14",
         "0",
         "-9",
         "21",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['OTHER', 'BIOLOGICAL']",
         "2",
         "Platelet Rich Plasma|Normal Saline",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT']",
         "SINGLE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Virginia']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "21",
         "NCT04077892",
         "Compare the Effect of INS Alone and Added LTRA in Treatment of SAR",
         "COMPLETED",
         "It is not proven unequivocally whether a combination of an intranasal corticosteroids (INS) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the treatment of severe allergic rhinitis (AR) . We performed a randomized, open-label study in 46 seasonal AR subjects receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks. Visual analog scale (VAS) scores, nasal cavity volume (NCV), nasal airway resistance (NAR) and fractional exhaled nitric oxide (FeNO) were assessed before and at end of treatments as the primary treatment outcomes. Similarly, histamine, eosinophil cationic protein (ECP) and cysteinyl-leukotrienes (Cyslts) in nasal secretion and Th1/Th2 cells in nasal mucosa were evaluated as the secondary treatment outcomes.",
         "NO",
         "Allergic Rhinitis",
         "DRUG: budesonide",
         "The change of subjective AR symptoms, The participants were asked by one investigator to fill in a questioner detailing the presence of nasal and eye symptoms (including nasal congestion, rhinorrhea, nasal itching, sneezing and eye itching), and to score each symptom on a 0-10 cm scale; with 0 cm = no symptoms and 10 cm = most severe and bothersome symptom. The same investigator calculated both the individual symptom and the average of the sum of 5 AR symptoms scores, before and at the end of 14 days' treatment. Any subject with a mean score of \\< 4 cm at baseline was excluded from this study., at baseline, 14 days",
         "The change of objective examination: nasal patency, Eccovision acoustic rhinometry was used to measure the nasal cavity volume (NCV) according to standardized recommendations. Measurements of nasal volume were made from the first 2 cm (V2), the first 4 cm (V4), from the first 6 cm (V6), from the segment between 0 and 5 cm (V0-5), and the segment between 0 and 7 cm (V0-7) of the nose. All measurements were performed three times by the same operator, and nasal volumes were calculated as the sum of both nostrils24. In the current study, the change in the nasal cavity volume was measured at 2-5 cm, as this seems to be an important variable for mucosal changes.24 Nasal airway resistance (NAR) was measured by anterior active rhinomanometry in a quiet room at temperature of 25°C and humidity of 70%. NAR was measured at 75 Pa point (R75T)., at baseline, 14 days|The change of Fractional Exhaled NO, A nitric oxide analyser was used to measure exhaled nasal nitric oxide (nNO). Briefly, NO-free air was aspirated through the nasal cavity at a flow rate of 50 ml/s. The subject exhaled against the air-resistance, resulting in an intraoral pressure to close the velum and prevent mixture of oral and nasal gas. Nasal gas from this circuit was continuously routed in part directly into the analyser for determination of nNO, and the level of nNO(ppb) was calculated from a plateau lasting for at least 3s., at baseline, 14 days",
         "No Outcome Measure",
         "Beijing Tongren Hospital",
         "No collaborators",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "46.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2016-06",
         "2016-09",
         "2016-09",
         "2019-09",
         null,
         "2019-09",
         "Beijing Tongren Hospital, Beijing, Beijing, 100730, China",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2019",
         null,
         "2019",
         "2016",
         "2016",
         "6",
         "9",
         null,
         "9",
         "9",
         "9",
         "3",
         "0",
         "-39",
         "36",
         "(2010, 2018]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "budesonide",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'INVESTIGATOR']",
         "TRIPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Beijing']",
         "1",
         "Capital",
         "['China']",
         "1",
         "['Asia']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "22",
         "NCT03032367",
         "TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)",
         "COMPLETED",
         "This is a randomized, open-label, cross-over study comparing the bioequivalence of bedaquiline administered in whole tablet form versus bedaquiline administered in crushed (experimental) form in healthy adult volunteers.",
         "NO",
         "Tuberculosis",
         "DRUG: bedaquiline",
         "Bioequivalence of bedaquiline 4 x 100mg given to healthy adult males and females orally in tablet form compared to crushed form, The bioequivalence evaluation will be based on primary PK parameters affecting the extent of absorption, i.e. the bioavailability., Two single treatment sequences, separated by a 14-day wash-out period",
         "No Outcome Measure",
         "No Outcome Measure",
         "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
         "US National Institute of Allergy and Infectious Diseases|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "24.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER",
         "2016-11",
         "2016-12",
         "2017-01",
         "2017-01",
         null,
         "2017-07",
         "TASK Clinical Research Centre, Bellville, Western Cape, 7530, South Africa",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2017",
         null,
         "2017",
         "2016",
         "2017",
         "11",
         "1",
         null,
         "7",
         "12",
         "1",
         "2",
         "0",
         "-2",
         "6",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "bedaquiline",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['NONE']",
         "NONE",
         "OTHER",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['South Africa']",
         "1",
         "['Africa']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "23",
         "NCT05515692",
         "Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease",
         "TERMINATED",
         "This clinical trial tests the safety and side effects of a single small dose (fraction) of electron beam radiotherapy (e-BRT) at 10 Gy dose in treating patients with refractory (did not respond to other treatments) sclerodermatous chronic graft versus host disease (GVHD). GVHD is the most common complication after bone marrow transplant from a donor and happens as a result of donor immune cells attacking patients cells. Fibroblasts are skin cells that produce collagen and fibers and are the cells mainly involved in development of skin GVHD. Previous research has shown that fibroblasts can become fibrocytes (inactive fibroblast) at the fastest rate after receiving 8 Gy or more radiation. Moreover, regulatory T cells (Tregs) are cells from the immune system that can control GVHD and previous research has shown that radiation can increase the number of Tregs. Therefore, e-BRT at 10 Gy has the potential to improve GVHD by increasing the fibroblast to fibrocyte speed and the number of Tregs.",
         "NO",
         "Hematopoietic and Lymphoid System Neoplasm|Malignant Solid Neoplasm|Refractory Sclerodermatous Graft Versus Host Disease",
         "PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|COMBINATION_PRODUCT: Electron Beam Therapy|PROCEDURE: High Frequency Ultrasound Imaging|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy Treatment Planning and Simulation|PROCEDURE: Skin Biopsy",
         "Incidence of toxicity, Will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. Unacceptable toxicity (UT) is defined as any local toxicity at the level of the treatment portal that is greater or equal to Grade 3 per National Cancer Institute (NCI) CTCAE version 5.0. The observation window of UT is from receiving study treatment until day 28 or observation of UT, whichever comes first. Patients who receive study treatment and complete UT evaluation will be evaluable for UT. Patients who are inevaluable for UT will be replaced. Toxicity information recorded in each patient will include the type, severity, and the probable association with electron beam radiotherapy (eBRT). Tables will be constructed to summarize the observed incidence by severity and type of toxicity, and dose levels. All patients who receive eBRT will be included as part of an 'as treated' analysis, in toxicities/complications., From study initiation of study treatment to day 28",
         "Incidence of disease specific response, Disease-specific response criteria including, but not limited to: complete response (CR) and partial response (PR) according to the core clinician-assessed and patient-reported chronic graft versus host disease (GVHD)-specific measures recommended by National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. The 2014 Response Criteria Working Group Report and modified Rodnan skin score, and 20 MHz ultrasound (US). The cumulative incidence of relapse/progression will be calculated as competing risks., Up to day 168|Incidence of disease specific response, Disease-specific response criteria including, but not limited to: complete response (CR) and partial response (PR) according to the core clinician-assessed and patient-reported chronic graft versus host disease (GVHD)-specific measures recommended by National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. The 2014 Response Criteria Working Group Report and modified Rodnan skin score, and 20 MHz ultrasound (US). The cumulative incidence of non-relapse mortality will be calculated as competing risks., Up to day 168",
         "No Outcome Measure",
         "City of Hope Medical Center",
         "National Cancer Institute (NCI)",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "0.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2024-06",
         "2024-09",
         "2024-09",
         "2022-08",
         null,
         "2024-07",
         null,
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2024",
         "2022",
         null,
         "2024",
         "2024",
         "2024",
         "6",
         "8",
         null,
         "7",
         "9",
         "9",
         "3",
         "0",
         "22",
         "-2",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['OTHER', 'PROCEDURE', 'RADIATION', 'COMBINATION_PRODUCT']",
         "4",
         "Biospecimen Collection|Computed Tomography|Electron Beam Therapy|High Frequency Ultrasound Imaging|Questionnaire Administration|Radiation Therapy Treatment Planning and Simulation|Skin Biopsy",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         null,
         "0",
         "Unknown",
         "0",
         "0",
         null,
         "0",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "24",
         "NCT03648892",
         "Brain Dopamine Function in Human Obesity",
         "COMPLETED",
         "Background:\n\nDopamine is a natural chemical in the brain that may influence eating behavior and physical activity. Researchers want to measure the brain s dopamine activity and understand how it differs in people with obesity.\n\nObjective:\n\nTo better understand how brain function, particularly dopamine activity, relates to body weight and eating behavior.\n\nIndividuals may be able to participate if they:\n\nHave a BMI of at least 18.5 kg/m2\n\nAre weight-stable and generally healthy\n\nAre between ages 18-45 years\n\nHave normal blood pressure\n\nAre not using illegal drugs (based on urine drug screen)\n\nAre not following a special diet\n\nDo not have metal implants\n\nDesign:\n\nParticipants will be screened with:\n\n* Medical history\n* Physical exam\n* Questionnaires and an interview to see if it is safe to have a PET/MRI scan\n* Fasting blood and urine tests\n* Participants will eat a special diet given to them for the 5 days before their inpatient visit.\n\nParticipants will have a 5-day inpatient visit. Some days include blood and urine tests. Each day includes surveys and tests to measure habits and likes/dis-likes. A sample schedule may be:\n\nDay 1: Participants will wear a monitor that uses a needle below the skin to measure glucose. Their body fat will be measured with low-dose x-rays\n\nDay 2: Participants will have a PET scan. They will lie on a table that slides in and out of a donut-shaped scanner. They will be injected with a small amount of a radioactive substance and wear a cap on their head.\n\nDay 3: Participants will have an MRI. They will lie on a table that slides in and out of a scanner.\n\nDay 4: Participants will have another PET scan. This time, they will drink a milk shake during a break from the scanner. Then, they will go back inside the scanner for the end of their scan.\n\nDay 5: Participants will wear a hood for up to 40 minutes to measure their breathing. They will also drink special water and collect samples of their urine to measure the rate they burn energy.\n\nFor 12 months after the visit, participants will track their weight and physical activity daily using a special scale and activity monitor. A few times over the year, the study team will send participants special activity monitors to use for 7 days at a time.\n\nParticipants will have an in-person 1-day follow-up visit. This includes most tests except for PET scanning....",
         "YES",
         "Obesity|Healthy Volunteers|Overweight",
         "DRUG: [c11] raclopride|DRUG: [18F]fallypride",
         "Correlation Between Striatal D2 Receptor Binding Potential (D2BP) as Measured by [18F]Fallypride and [11C]Raclopride Time-activity Curves, Correlations between striatal D2BP via \\[18F\\]Fallypride and striatal D2BP via \\[11C\\]Raclopride is obtained.\n\nPearson's correlation coefficient is used with a possible range between -1 to 1 indicating strong association in the same direction as correlation is closer to 1, strong association in opposite direction as correlation is closer to -1, and no association as correlation is closer to 0., assessed at Days 2-5|Relationship Between Striatal D2BP and BMI is Quadratic or Linear, Coefficient estimate of the quadratic term of BMI in quadratic regression is obtained and Coefficient estimate of the linear term of BMI in simple linear regression is obtained., assessed at Days 2-5|Change in Striatal Dopamine D2BP After a Palatable Meal, To determine the effect of palatable meal consumption on striatal D2BP using \\[11C\\]Raclopride, assessed at Days 2-5|Correlation Between Change in Striatal Dopamine D2BP After a Palatable Meal and BMI, To determine association between change in striatal dopamine D2BP after a palatable meal consumption and BMI. Binding potential estimates will be estimated within subjects using \\[11C\\]Raclopride, assessed at Days 2-5",
         "Associations Between Behavioral Performance on Food Go/No Go Computer Task and Striatal D2BP, Exploratory analyses of correlations between behavioral performance on Food Go/No Go computer task measured by No Go accuracy as commission errors and striatal D2BP via \\[18F\\]Fallypride and via \\[11C\\]Raclopride.\n\nPearson's correlation coefficient is used with a possible range between -1 to 1 indicating strong association in the same direction as correlation is closer to 1, strong association in opposite direction as correlation is closer to -1, and no association as correlation is closer to 0., assessed at Days 2-5|Associations Between ad Libitum Meal Consumption and Striatal D2 Receptor (D2R), Exploratory analyses of correlations between eating behavior measured by ad libitum food intake at a single meal and striatal D2R via \\[18F\\]Fallypride and via \\[11C\\]Raclopride, assessed at Days 2-5|Associations Between Brain Metabolite GABA Via MRS and Striatal D2BP Via [18F]Fallypride, Exploratory analyses of correlations between brain metabolite GABA via magnetic resonance spectroscopy (MRS) and striatal D2BP via \\[18F\\]Fallypride.\n\nPearson's correlation coefficient is used with a possible range between -1 to 1 indicating strong association in the same direction as correlation is closer to 1, strong association in opposite direction as correlation is closer to -1, and no association as correlation is closer to 0., assessed at Days 2-5",
         "No Outcome Measure",
         "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "61.0",
         "GOV",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE",
         "2018-09",
         "2022-03",
         "2023-02",
         "2018-08",
         "2023-05",
         "2023-07",
         "National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States",
         "(50.0, 114.0]",
         "['Analysis Plan', 'Protocol']",
         "2",
         "Yes",
         "2018",
         "2018",
         "2023",
         "2023",
         "2022",
         "2023",
         "9",
         "8",
         "5",
         "7",
         "3",
         "2",
         "53",
         "11",
         "0",
         "5",
         "(2010, 2018]",
         "(2004, 2018]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "[c11] raclopride|[18F]fallypride",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Maryland']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "25",
         "NCT05467774",
         "Operant H-reflex Down-conditioning of Rectus Femoris in Post-stroke Stiff Knee Gait",
         "COMPLETED",
         "The investigators performed a feasibility trial of operant conditioning of spinal reflex excitability on five healthy individuals and two post-stroke individuals. The investigators found that operant conditioning of rectus femoris reflex excitability was feasible in all participants.",
         "YES",
         "Training",
         "BEHAVIORAL: Operant RF H-reflex conditioning",
         "Percentage Change From Baseline in RF H-reflex Magnitude, H-reflex magnitude of rectus femoris. Lower values are considered better. The H-reflex is the amplitude of the monosynaptic spinal reflex, elicitied by electrical stimulation of the femoral nerve, normalized by the preceding M-wave. The M-wave is the amplitude of the muscle activity response to surface electrical stimulation of the femoral nerve. All muscle activity measured at the individual's rectus femoris of the stimulated limb. A value of 100% would mean no change in reflex magnitude, whereas a change of -20%, for instance, would mean a 20% drop in reflex magnitude over the 3 month training period., 3 months",
         "Percentage Change From Baseline in VM H-reflex Magnitude, H-reflex magnitude of vastus medialis. Lower values are considered better. The H-reflex is the amplitude of the monosynaptic spinal reflex, elicitied by electrical stimulation of the femoral nerve, normalized by the preceding M-wave. The M-wave is the amplitude of the muscle activity response to surface electrical stimulation of the femoral nerve. All muscle activity measured at the individual's vastus medialis of the stimulated limb. A value of 100% would mean no change in reflex magnitude, whereas a change of -20%, for instance, would mean a 20% drop in reflex magnitude over the 3 month training period., 3 months",
         "No Outcome Measure",
         "University of Texas at Austin",
         "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "7.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2018-07",
         "2020-02",
         "2020-02",
         "2022-07",
         "2024-07",
         "2024-07",
         "University of Texas at Austin, Austin, Texas, 78712, United States",
         "(-0.001, 21.0]",
         "['Analysis Plan', 'Consent Form', 'Protocol']",
         "3",
         "Yes",
         "2018",
         "2022",
         "2024",
         "2024",
         "2020",
         "2020",
         "7",
         "7",
         "7",
         "7",
         "2",
         "2",
         "19",
         "0",
         "-48",
         "53",
         "(2010, 2018]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['BEHAVIORAL']",
         "1",
         "Operant RF H-reflex conditioning",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Texas']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "26",
         "NCT03027674",
         "Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud",
         "COMPLETED",
         "Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).\n\nMethods: A randomized, double-blind, placebo-controlled pilot study took place in 10 patients with secondary RP. Topical 10% nifedipine on one hand and 5% sildenafil on the other hand were applied. The thumbs didn't receive any cream and served as a control group. The primary outcome was the improvement of blood flow and vessel diameter of the digital arteries measured by high frequency color Doppler ultrasound before and 1 hour after treatment.",
         "NO",
         "Raynaud Phenomenon Due to Trauma|Raynaud Disease|System; Sclerosis|Lupus Erythematosus, Systemic|Dermatomyositis|Ultrasound Therapy; Complications",
         "DRUG: 10% nifedipine cream|DRUG: 5% sildenafil cream",
         "Improvement of blood flow in the digital arteries (peak systolic velocity ) of the dorsal arterial arch of the proximal nail fold of the index, middle and thumb fingers of both hands, The peak systolic velocity peak is measured with Doppler sonography in centimeters/second, Outcome measure will be assessed the same day of the study and the data will be presented after the data is analyzed (12 weeks)",
         "Improvement of the diameter (mm) of the dorsal arterial arch of the proximal nail fold of the of the index, middle and thumb fingers of both hands., The diameter is measured with Doppler sonography in millimeters, Outcome measure will be assessed the same day of the study and the data will be presented after the data is analyzed (12 weeks)",
         "No Outcome Measure",
         "Pontificia Universidad Catolica de Chile",
         "No collaborators",
         "ALL",
         "['CHILD', 'ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "10.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2016-08",
         "2016-08",
         "2016-08",
         "2017-01",
         null,
         "2017-01",
         "Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile., Santiago, RM, 7820436, Chile",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2017",
         null,
         "2017",
         "2016",
         "2016",
         "8",
         "1",
         null,
         "1",
         "8",
         "8",
         "0",
         "0",
         "-5",
         "5",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "10% nifedipine cream|5% sildenafil cream",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'INVESTIGATOR']",
         "TRIPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Santiago']",
         "1",
         "Capital",
         "['Chile']",
         "1",
         "['South America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "27",
         "NCT04742374",
         "Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
         "COMPLETED",
         "CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described. Treatments include corticotherapy, IVIg and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques - single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.",
         "NO",
         "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",
         "BIOLOGICAL: Blood sampling",
         "Cycle 1, Group A : TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Time 0|Cycle 1, Group A : TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 1, Group A : TH1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7 -10|Cycle 1, Group A : TH17 cells BEFORE first single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH17 peripheral lymphocyte cells will be measured in %., Day 0, Time 0|Cycle 1, Group A : TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 1, Group A : TH17 cells 7 - 10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 1, Group A : T-reg cells BEFORE first single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 1, Group A : T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 1, Group A : T-reg cells 7 - 10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7 - 10|Cycle 1, Group B : TH1 cells BEFORE first double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 1, Group B : TH1 cells AFTER the first double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 1, Group B : TH1 cells 7-10 days AFTER the first double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 1, Group B : TH17 cells BEFORE the first double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day0, Hour 0|Cycle 1, Group B : TH17 cells AFTER the first double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 1, Group B : T17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 7-10|Cycle 1, Group B : T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 1, Group B : T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 1, Group B : T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 7 - 10|Cycle 2, Group A: TH1 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH1 cells will be measured in %., Day 0, Hour 0|Cycle 2, Group A: TH1 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 cells will be measured in %., Day 0, Hour 3|Cycle 2, Group A: TH1 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 cells will be measured in %., Day 7 - 10|Cycle 2, Group A: TH17 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 2, Group A: TH17 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 2, Group A: TH17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 7-10|Cycle 2, Group A: T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 2, Group A: T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 2, Group A: T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 7-10|Cycle 2, Group B: TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 cells will be measured in %., Day 0, Hour 0|Cycle 2, Group B: TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 cells will be measured in %., Day 0, Hour 3|Cycle 2, Group B: TH1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 cells will be measured in %., Day 7-10|Cycle 2, Group B: T17 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T17 cells will be measured in %., Day 0, Hour 0|Cycle 2, Group B: TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T17 cells will be measured in %., Day 0, Hour 3|Cycle 2, Group B: TH17 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 7-10|Cycle 2, Group B: T-reg cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 2, Group B: T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 2, Group B: T-reg cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7-10|Cycle 3, Group A: TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 1, Hour 1|Cycle 3, Group A: TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 1, Hour 3|Cycle 3, Group A: T1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 3, Group A: TH17 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH17 cells will be measured in %., Day 1, Hour 1|Cycle 3, Group A: TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 1, Hour 3|Cycle 3, Group A: TH17 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 7 - 10|Cycle 3, Group A: T-reg cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 3, Group A: T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 3, Group A: T-reg cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7-10|Cycle 3, Group B: TH1 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 3, Group B: TH1 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 3, Group B: TH1 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7-10|Cycle 3, Group B: TH17 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 3, Group B: TH17 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 3, Group B: TH17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 7-10|Cycle 3, Group B: T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 3, Group B: T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 3, Group B: T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 7-10|Cycle 4, Group A: T1 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 4, Group A: T1 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 4, Group A: TH1 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 4, Group A: TH17 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 4, Group A: TH17 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 4, Group A: TH17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 4, Group A: T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 4, Group A: T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 4, Group A: T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg peripheral lymphocyte cells will be measured in %., Day 7 - 10|Cycle 4, Group B : TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 4, Group B : TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 4, Group B : TH1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7 -10|Cycle 4, Group B : TH17 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 4, Group B : TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 4, Group B : T17 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T1 peripheral lymphocyte cells will be measured in %., Day 7 -10|Cycle 4, Group B : T-reg cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 4, Group B : T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 4, Group B : T-reg cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7 - 10|Cycle 5, Group A : TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 5, Group A : TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 5, Group A : TH1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 cells will be measured in %., Day 7 - 10|Cycle 5, Group A : TH17 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 5, Group A : TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 5, Group A : TH17 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 7 - 10|Cycle 5, Group A : T-reg cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 5, Group A : T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 5, Group A : T-reg cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7 - 10|Cycle 5, Group B : TH1 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 0|Cycle 5, Group B : TH1 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0, Hour 3|Cycle 5, Group B : TH1 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7-10|Cycle 5, Group B : TH17 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 0|Cycle 5, Group B : TH17 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0, Hour 3|Cycle 5, Group B : TH17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 7-10|Cycle 5, Group B : T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 0|Cycle 5, Group B : T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0, Hour 3|Cycle 5, Group B : T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 7-10|Cycle 6, Group A : TH1 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0 Hour 0|Cycle 6, Group A : TH1 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0 Hour 3|Cycle 6, Group A : TH1 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7-10|Cycle 6, Group A : TH17 cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0 Hour 0|Cycle 6, Group A : TH17 cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 0 Hour 3|Cycle 6, Group A : TH17 cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and the number of TH17 cells will be measured in %., Day 7-10|Cycle 6, Group A : T-reg cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0 Hour 0|Cycle 6, Group A : T-reg cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 0 Hour 3|Cycle 6, Group A : T-reg cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and the number of T-reg cells will be measured in %., Day 7-10|Cycle 6, Group B : TH1 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0 Hour 0|Cycle 6, Group B : TH1 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 0 Hour 3|Cycle 6, Group B : TH1 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH1 peripheral lymphocyte cells will be measured in %., Day 7-10|Cycle 6, Group B : TH17 cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of TH17 cells will be measured in %., Day 0 Hour 0|Cycle 6, Group B : TH17 cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 0 Hour 3|Cycle 6, Group B : TH17 cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of TH17 cells will be measured in %., Day 7-10|Cycle 6, Group B : T-reg cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and the number of T-reg cells will be measured in %., Day 0 Hour 0|Cycle 6, Group B : T-reg cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 0 Hour 3|Cycle 6, Group B : T-reg cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and the number of T-reg cells will be measured in %., Day 7-10",
         "Cycle 1, Group A : T4 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : T4-DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : T8 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : CD45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : CD45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : CD45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group A : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : T4-DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : CR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group A : T4 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : T4-DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group A : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B: CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 1, Group B:T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B:T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B:T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B:T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 1, Group B: T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 1, Group B: CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube 7-10 days AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group A : T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 0|Cycle 2, Group A : T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) a,d measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group A : T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group A : CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7 - 10|Cycle 2, Group B : T4 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : T4 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : T8 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : CD45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : CD45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : CD45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 2, Group B : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : T4 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : CCR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 2, Group B : T4 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : T4 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 2, Group B : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured a percentage., Day 7-10|Cycle 2, Group B : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : T4 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : T4 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : T8 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : CC45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : CC45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : CC45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group A : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : T4 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : CCR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group A : T4 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : T4 lymphocytes 7 -10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group A : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 3, Group B : T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 3, Group B : T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 3, Group B : CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group A : T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group A : T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group A : CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : T4 lymphocytes BEFORE plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : T4 DR+ lymphocytes BEFORE plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : T8 lymphocytes BEFORE plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : CD45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : CD45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : CD45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 0|Cycle 4, Group B : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : T4 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : CCR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0 Hour 3|Cycle 4, Group B : T4 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : T4 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 4, Group B : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : T4 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : T4 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : T8 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : CD45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : CD45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : CD45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group A : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : T4 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : CCR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group A : T4 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : T4 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group A : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 5, Group B : T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 5, Group B : T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 5, Group B : CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : T4 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : T4 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : T8 lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : T8 DR+ lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : B lymphocytes BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : CD45RA+CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : CD45RA-CCR7+ cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : CD45RA-CCR7- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : CCR6-CXCR3- cells BEFORE double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube BEFORE double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 0|Cycle 6, Group A : T4 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : T4 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : T8 lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : T8 DR+ lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : B lymphocytes AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : CD45RA+CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : CD45RA-CCR7+ cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : CD45RA-CCR7- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : CCR6-CXCR3- cells AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, Hour 3|Cycle 6, Group A : T4 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : T4 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : T8 lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : T8 DR+ lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : B lymphocytes 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : CD45RA+CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : CD45RA-CCR7+ cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : CD45RA-CCR7- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group A : CCR6-CXCR3- cells 7-10 days AFTER double filtration plasmapheresis, 5 mL of blood will be collected in an EDTA tube AFTER double filtration plasmapheresis and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : T4 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : T4 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : T8 lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : T8 DR+ lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : B lymphocytes BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : CD45RA+CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : CD45RA-CCR7+ cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : CD45RA-CCR7- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : CCR6-CXCR3- cells BEFORE single plasma exchange, 5 mL of blood will be collected in an EDTA tube BEFORE single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H0|Cycle 6, Group B : T4 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : T4 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : T8 lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : T8 DR+ lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : B lymphocytes AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : CD45RA+CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : CD45RA-CCR7+ cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : CD45RA-CCR7- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : CCR6-CXCR3- cells AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 0, H3|Cycle 6, Group B : T4 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : T4 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : T8 lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : T8 DR+ lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : B lymphocytes 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : CD45RA+CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : CD45RA-CCR7+ cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : CD45RA-CCR7- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10|Cycle 6, Group B : CCR6-CXCR3- cells 7-10 days AFTER single plasma exchange, 5 mL of blood will be collected in an EDTA tube AFTER single plasma exchange and cell counts will be made by flow cytometry after marking with specific fluorescent antibodies (Luminex) and measured as a percentage., Day 7-10",
         "Group A, Cycle 1 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 1 (each cycle lasts 3 hours)|Group B, Cycle 1 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 1 (each cycle lasts 3 hours)|Group A, Cycle 2 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 2 (each cycle lasts 3 hours)|Group B, Cycle 2 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 2 (each cycle lasts 3 hours)|Group A, Cycle 3 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 3 (each cycle lasts 3 hours)|Group B, Cycle 3 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 3 (each cycle lasts 3 hours)|Group A, Cycle 4 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 4 (each cycle lasts 3 hours)|Group B, Cycle 4 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 4 (each cycle lasts 3 hours)|Group A, Cycle 5 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 5 (each cycle lasts 3 hours)|Group B, Cycle 5 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 5 (each cycle lasts 3 hours)|Group A, Cycle 6 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 6 (each cycle lasts 3 hours)|Group B, Cycle 6 : Link between variations in lymphocyte sub-populations and the clinical evolution ., All the above primary and secondary outcome measures will be compared with clinical information in the patient file in order to determine a link between these variations at the end of each treatment cycle., Day 7-10 after the end of Cycle 6 (each cycle lasts 3 hours)|Group A, Cycle 1 : Cost of single plasma exchange to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 1 (each cycle lasts 3 hours)|Group B, Cycle 1 : Cost of double filtration plasmapheresis to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 1 (each cycle lasts 3 hours)|Group A, Cycle 2 : Cost of double filtration plasmapheresis to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 2 (each cycle lasts 3 hours)|Group B, Cycle 2 : Cost of single plasma exchange to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 2 (each cycle lasts 3 hours)|Group A, Cycle 3 : Cost of single plasma exchange to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 3 (each cycle lasts 3 hours)|Group B, Cycle 3 : Cost of double filtration plasmapheresis to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 3 (each cycle lasts 3 hours)|Group A, Cycle 4 : Cost of double filtration plasmapheresis to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 4 (each cycle lasts 3 hours)|Group B, Cycle 4 : Cost of single plasma exchange to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 4 (each cycle lasts 3 hours)|Group A, Cycle 5 : Cost of single plasma exchange to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 5 (each cycle lasts 3 hours)|Group B, Cycle 5 : Cost of double filtration to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 5 (each cycle lasts 3 hours)|Group A, Cycle 6 : Cost of double filtration to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 6 (each cycle lasts 3 hours)|Group B, Cycle 6 : Cost of double filtration to the health institution., The cost of each cycle will be recorded in Euros in the electronic clinical research file and the average amount will be calculated from this information at the end of 6 cycles., Day 7-10 after the end of Cycle 6 (each cycle lasts 3 hours)|Constitution of a biological resource centre using the blood samples taken in view of future research, especially immunological phenotyping., After all the above analyses, the unused aliquots from the samples taken (bottom of tubes) will be conserved and indexed., Day 0, Hour 0|Constitution of a biological resource centre using the blood samples taken in view of future research, especially immunological phenotyping., After all the above analyses, the unused aliquots from the samples taken (bottom of tubes) will be conserved and indexed., Day 0, Hour 3|Constitution of a biological resource centre using the blood samples taken in view of future research, especially immunological phenotyping., After all the above analyses, the unused aliquots from the samples taken (bottom of tubes) will be conserved and indexed., Day 7-10|Compare lymphocyte phenotype between patients with PIDC and control subjects., Significant difference in Th1/Th2 ratio between PIDC patients and control subjects., Day 0",
         "Centre Hospitalier Universitaire de Nīmes",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "8.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT",
         "2021-02",
         "2022-02",
         "2022-02",
         "2021-02",
         null,
         "2023-09",
         "Olivier MORANNE, Nîmes, France",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2021",
         "2021",
         null,
         "2023",
         "2022",
         "2022",
         "2",
         "2",
         null,
         "9",
         "2",
         "2",
         "12",
         "0",
         "0",
         "19",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['BIOLOGICAL']",
         "1",
         "Blood sampling",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['PARTICIPANT']",
         "SINGLE",
         "TREATMENT",
         "Primary + Secondary + Other",
         "['Primary', 'Secondary', 'Other']",
         "3",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['France']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "28",
         "NCT06432374",
         "Written Exposure Therapy for Nurses",
         "COMPLETED",
         "Nurses often experience elevated levels of stress, overwork, and trauma in the workplace, leading to posttraumatic stress disorder (PTSD), depression, burnout, and even nurse turnover. While effective therapies for PTSD exist, barriers to treatment arise from nursing culture, such as workplace stigma about mental health problems, fear that psychological status may impact performance evaluations, and demands of shiftwork. There is a pressing need for scalable evidence-based interventions tailored to nursing culture to effectively address PTSD and related mental health issues. The study aimed to assess the feasibility, safety, and acceptability of a tailored evidence-based treatment, Written Exposure Therapy (WET), for nurses experiencing work-related traumatic stress.\n\nThis single-arm open pilot study with pre- and post-intervention assessments, included participants from two nursing schools' alumni. Eligibility criteria included nurses screening positive for work-related trauma with a report of at least two PTSD symptoms. Participants engaged in a self-administered, asynchronous, five-week online writing session, facilitated by WET-trained nurses. Outcomes measures (PTSD, depression, anxiety, burnout, and intention to quit) were assessed at baseline, post-intervention, and 5-weeks follow-up.",
         "NO",
         "Posttraumatic Stress Disorder|Depressive Symptoms|Burn Out|Anxiety|Work Related Stress",
         "BEHAVIORAL: WET",
         "Posttraumatic stress disorder, The PTSD Checklist for DSM-5 was used to assess symptoms of posttraumatic stress disorder in the past month. The total score ranges from 0-80, with higher scores indicating more severe PTSD symptoms., Baseline, immediately post-intervention, and 5 weeks follow-up",
         "Depression, The Patient Health Questionnaire-8 was used to assess the frequency of depressed mood in the past two weeks. The total score ranges from 0-24, with higher scores indicating more severe depression symptoms., Baseline, immediately post-intervention, and 5 weeks follow-up|Anxiety, The Generalized Anxiety Disorder-7 was used to assess the frequency of anxiety symptoms in the past two weeks. The total score ranges from 0-21, with higher scores indicating more severe anxiety symptoms., Baseline, immediately post-intervention, and 5 weeks follow-up|Professional Quality of Life, The Professional Quality of Life was used to assess compassion satisfaction, burnout, and secondary traumatic stress. Each subscale score ranges from 10-50, with higher scores indicating higher levels of compassion satisfaction, more burnout symptoms, and more secondary traumatic stress., Baseline, immediately post-intervention, and 5 weeks follow-up|Intention to Quit, Intention to quit the job or leave the nursing profession were asked using two questions - \"How often have you thought about quitting your job in the past month?\", \"How often have you thought about leaving the nursing profession in the past month?\". The five responses are \"never,\" \"rarely,\" \"sometimes,\" \"very often\", and \"always.\" The scores for both intention to quit the job and intention to leave the nursing profession range from 1-5, with higher scores indicating greater intention to quit the job or leave the nursing profession., Baseline, immediately post-intervention, and 5 weeks follow-up",
         "No Outcome Measure",
         "University of Texas at Austin",
         "University of Michigan",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "10.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2022-02",
         "2023-03",
         "2023-09",
         "2024-05",
         null,
         "2024-05",
         "University of Michigan, Ann Arbor, Michigan, 48104, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2022",
         "2024",
         null,
         "2024",
         "2023",
         "2023",
         "2",
         "5",
         null,
         "5",
         "3",
         "9",
         "19",
         "6",
         "-27",
         "8",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['BEHAVIORAL']",
         "1",
         "WET",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Michigan']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "29",
         "NCT02214862",
         "2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism",
         "COMPLETED",
         "The PET tracer \\[F18\\]-FDDNP has a specific affinity for lesions containing tau protein.\n\nThe study consists of two phases:\n\n* In the first (cross-sectional) phase it will be assessed the uptake of \\[18F\\]-FDDNP in 10 cases with progressive supranuclear palsy (PSP, a tauopathy) en 10 with multi-system atrophy (MSA, a non-tauopathy), along with 20 individuals with Unclassifiable Parkinsonism, as previously defined in a European cohort study.\n* In the second (longitudinal) phase it will be prospectively followed the 20 unclassifiable patients (at 6, 12 and 18 months) by means of validated scales and accepted diagnostic criteria in order to try to correlate their eventual clinical diagnosis with baseline PET findings. On this basis, we endeavour to estimate the ability of this technique to detect in vivo underlying tau pathology in subjects initially unclassifiable on clinical grounds.\n\nWe hypothesized that:\n\n1. Patients with clinically definite PSP will present an increased uptake in basal ganglia, brainstem and cerebellum.\n2. Patients with clinically defined MSA will not present specific uptake.\n3. Part of unclassifiable patients with parkinsonism will present a pattern of uptake similar to patients with clinically defined PSP and this part along the clinical follow-up will be meet clinical criteria for diagnose of PSP",
         "NO",
         "Progressive Supranuclear Palsy|Multi-System Atrophy|Parkinsonism",
         "DRUG: [F18]-FDDNP",
         "To assess the Relative Volume of Distribution of [18F]-FDDNP in individuals with unclassifiable parkinsonism, and to try to correlate their eventual clinical diagnosis with baseline PET findings., 18 months",
         "to assess the uptake of [18F]-FDDNP in cases clinically defined of progressive supranuclear palsy and multi-system atrophy, Baseline assessment|To assess the ability to detect in vivo underlying tau pathology in unclassifiable parkinsonism by means of PET -[18F]-FDDNP., 18 months",
         "No Outcome Measure",
         "Fundacion Clinic per a la Recerca Biomédica",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "40.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",
         "2013-03",
         "2015-12",
         "2016-02",
         "2014-08",
         null,
         "2016-02",
         "Hospital Clinic, Barcelona, 08036, Spain",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2013",
         "2014",
         null,
         "2016",
         "2015",
         "2016",
         "3",
         "8",
         null,
         "2",
         "12",
         "2",
         "35",
         "2",
         "-17",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "[F18]-FDDNP",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         null,
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Spain']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "30",
         "NCT01633762",
         "Eradication of Gut Microbiota",
         "COMPLETED",
         "The aim of the study is to assess the effect of eradication of gut microbiota on 1) glucose metabolism including postprandial plasma responses of the incretin hormones GIP and GLP-1, insulin, C-peptide and glucagon, 2) metabolomic profiles and resting energy expenditure (REE) 3) appetite, satiety, food intake, gastric emptying and gall bladder emptying, 4) levels of markers of bone formation and resorption as well as serotonin, 5) markers of systemic inflammation, and 6) on the (prospective) composition of bacteria in faeces, blood and saliva. Thus, the overall objective is to provide detailed knowledge on the physiological role of gut microbiota combined with bioinformatic analyses of the functional implications of changes in bacteria composition on the level of both species and phylum.",
         "NO",
         "Diabetes|Obesity|Osteoporosis|Inflammation",
         "DRUG: meropenem, gentamicin, vancomycin (together)",
         "changes in postprandial GLP-1 secretion, plasma level of GLP-1 at baseline and during a 4 hour-meal test, 0, 4 and 42 days after antibiotic eradication of gut bacteria",
         "changes in postprandial insulin/c-peptide secretion, plasma level of insulin/C-peptide at baseline and during a 4 hour-meal test, 0, 4 and 42 days after antibiotic eradication of gut bacteria|changes in postprandial glucose levels, plasma level of glucose at baseline and during a 4 hour-meal test, 0, 4 and 42 days after antibiotic eradication of gut bacteria|changes in postprandial GLP-2, glucagon, PYY, oxyntomodulin, gastrin, CCK, GIP, leptin, adiponectin and ghrelin secretion, plasma levels of GLP-2, glucagon, PYY, oxyntomodulin, gastrin, CCK, GIP, leptin, adiponectin and ghrelin at baseline and during a 4 hour-meal test, 0, 4 and 42 days after antibiotic eradication of gut bacteria|changes in markers of bone formation and resorption, fasting plasma levels of osteocalcin, P1NP, CTX, 1CTP, sklerostin and serotonin, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|gut microbiome composition, faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|changes in markers of systemic inflammation, plasma levels of high sensitive CRP, LPBP, TNF-alfa, IL-6 and PAI, 0, 4, 42 and 180 days after antibiotic eradication of gut bacteria|changes in glycated hemoglobin (HbA1c), plasma level of glycated hemoblobin, 42 days after antibiotic eradication of gut bacteria|changes in body weight, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|changes in basal metabolic rate and respiratory quotient, indirect calorimetry measurements (210 minutes postprandial), 0, 4 and 42 days after antibiotic eradication of gut bacteria|changes in gastric emptying, 1,5 grams of paracetamol will be added to a standardized meal, plasma paracetamol will be measured at baseline and succeeding 4 hours postprandial, 0, 4 and 42 days after antibiotic eradication of gut bacteria|changes in gall bladder emptying, ultrasonic determination of gall bladder dimensions at baseline and during a 4 hour-meal test (expressed as gall bladder ejection fraction), 0, 4 and 42 days after antibiotic eradication of gut bacteria|appetite, satiety and food intake, the impact of eradication on alimentary processes and appetite regulation will be measured using questionnaires and food intake measures, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|changes in ketone metabolism, measurement of fasting plasma beta-hydroxybutyrate level, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|changes in bile acid deconjugation, measurement of feces bile acid (conjugated and deconjugated) concentration to study the effect of gut microbiome presence on bile acid deconjugation, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|changes in plasma lipid levels, fasting plasma levels of triglyceride, VLDL, LDL, HDL, total cholesterol, in addition: measurements of free fatty acids during a 4 hour meal 0, 4 and 42 days after eradication (not on day 8 and 180), 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|microbiome in blood, urine and saliva, measurements on bacteria or bacterial components in blood, urine and saliva to study the effects of gut eradication on blood, urine and saliva microbiome, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria|adverse effects of the used antibiotics, standardized questionaries regarding gastointestinal function are filled out at each study visit (0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period., up to 180 days after antibiotic eradication of gut bacteria|changes in metabolomic profile, plasma and urine samples for metabolomic analysis, 0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria",
         "No Outcome Measure",
         "University Hospital, Gentofte, Copenhagen",
         "University of Copenhagen|Steno Diabetes Center Copenhagen|Department of clinical microbiology, Rigshospitalet, Copenhagen",
         "MALE",
         "['ADULT']",
         "PHASE0",
         "12.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE",
         "2012-04",
         "2013-04",
         "2013-04",
         "2012-07",
         null,
         "2015-12",
         "Gentofte University Hospital, Hellerup, 2900, Denmark",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2012",
         null,
         "2015",
         "2013",
         "2013",
         "4",
         "7",
         null,
         "12",
         "4",
         "4",
         "12",
         "0",
         "-3",
         "32",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "meropenem, gentamicin, vancomycin (together)",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Denmark']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "31",
         "NCT01733680",
         "Amiloride Hydrochloride as an Effective Treatment for ADHD",
         "TERMINATED",
         "The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inhibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.",
         "YES",
         "ADHD",
         "DRUG: amiloride|BEHAVIORAL: Behavioral",
         "Improvement in CGI, CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, 8 weeks",
         "AISRS, Adult ADHD Investigator Rating Scale, An 18 item clinician administered questionnaire to evaluate ADHD in adults. Responses to questions were 0-None, 1-Mild, 2-Moderate, 3-Severe. A decrease of 30% in the total score would be considered improvement. Total score range is 0-54. A lower score indicates improvement in symptoms. A score of 24 or more indicates symptomatic ADHD., 8 weeks|The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A), BRIEF-A is a 75 item self report questionnaire that measures behavior and executive function. For each item the subject is asked \"during the past month, how often has each of the following behaviors been a problem?:\" The choices are N (never), S (sometimes), O (Often). Total score for the Global Executive Composite used. Raw data were transformed into t-scores, which are standardized scores that indicate the number of standard deviations away from the mean. A T-score of 50 is equal to the mean. Values less than 65 indicate executive function is not a problem and values greater than 65 indicate executive function is often a problem., 8 weeks",
         "No Outcome Measure",
         "State University of New York - Upstate Medical University",
         "No collaborators",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "3.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",
         "2012-09",
         "2015-09",
         "2015-09",
         "2012-11",
         "2018-07",
         "2018-07",
         "SUNY Upstate Medical University, Syracuse, New York, 13210, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2012",
         "2018",
         "2018",
         "2015",
         "2015",
         "9",
         "11",
         "7",
         "7",
         "9",
         "9",
         "36",
         "0",
         "-2",
         "34",
         "(2010, 2018]",
         "(2004, 2018]",
         "(2010, 2018]",
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG', 'BEHAVIORAL']",
         "2",
         "amiloride|Behavioral",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "TRIPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'New York']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "32",
         "NCT02439580",
         "Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells",
         "COMPLETED",
         "Annona muricata L., include the leaves, is found to contain biologically active Annonaceous acetogenins and plant polyphenols that are important components of human diet and a number of them are considered to have chemopreventive and therapeutic properties against cancer.\n\nTo confirm previous findings in in vitro, animal study and traditionally use, a human, ex vivo and in vitro studies were conducted to evaluate the effects of consecutive ingestion of A. muricata leaves extract for eight weeks.",
         "NO",
         "Colorectal Cancer",
         "DIETARY_SUPPLEMENT: Annona muricata extract|DIETARY_SUPPLEMENT: Placebo",
         "Nutritional Status, eight weeks",
         "Cytotoxicity, Cytotoxicity against colorectal cancer cell lines that were treated with serum of participants, is assessed by MTT assay, two days",
         "No Outcome Measure",
         "Indonesia University",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "30.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",
         "2013-10",
         "2014-06",
         "2014-10",
         "2015-05",
         null,
         "2015-05",
         null,
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2013",
         "2015",
         null,
         "2015",
         "2014",
         "2014",
         "10",
         "5",
         null,
         "5",
         "6",
         "10",
         "12",
         "4",
         "-19",
         "7",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DIETARY_SUPPLEMENT']",
         "1",
         "Annona muricata extract|Placebo",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'INVESTIGATOR']",
         "TRIPLE",
         "SUPPORTIVE_CARE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         null,
         "0",
         "Unknown",
         "0",
         "0",
         null,
         "0",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "33",
         "NCT04635072",
         "Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis",
         "COMPLETED",
         "This clinical trial serves to look at the effectiveness of SWRB for the treatment of mild to moderate Atopic Dermatitis in patients below the age of 18. Atopic Dermatitis (AD) is a common condition seen in dermatology, paediatric and primary care clinics in Malaysia. AD poses a significant biopsychosocial burden among sufferers and their families. Current management patterns of AD sufferers in South-east Asia mainly involve use of topical moisturizers and topical corticosteroids.\n\nRice bran and products derived from it have been studied regarding their anti-oxidant, nutritional, cholesterol lowering and health promoting properties. However, there are very few studies that have focused on the benefits of SWRB when used topically.\n\nSWRB is cost-effective and easily available, while being an under-utilised product. The investigators wanted to study its effectiveness in controlling the signs and symptoms of Atopic Dermatitis when used as a cleanser and topical paste (emollient) as very little is known on this subject.\n\nThe investigators wish to study participants below 18 years of age with mild and moderate Atopic Dermatitis.\n\nThe participants will be followed up for four to six (4 - 6) weeks and the clinical features tabulated. This study does not involve any enteral or parenteral administration of SWRB.\n\nNeither does it involve any invasive procedures.",
         "NO",
         "Dermatitis, Atopic",
         "DRUG: Stabilised Whole Rice Bran",
         "SCORAD index change, Used to assess the effectiveness of treatment, done before treatment. http://scorad.corti.li/, 0 weeks|SCORAD index change, Used to assess the effectiveness of treatment, done during treatment. http://scorad.corti.li/, 2 weeks|SCORAD index change, Used to assess the effectiveness of treatment, done after treatment. http://scorad.corti.li/, 4 weeks",
         "No Outcome Measure",
         "No Outcome Measure",
         "RCSI & UCD Malaysia Campus",
         "No collaborators",
         "ALL",
         "['CHILD', 'ADULT']",
         "PHASE0",
         "75.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2020-09",
         "2021-04",
         "2021-09",
         "2020-11",
         null,
         "2023-03",
         "Loh Guan Lye Specialist Centre 238, Jalan Macalister 10400 George Town Pulau Pinang, George Town, Penang, 10400, Malaysia",
         "(50.0, 114.0]",
         "['Consent Form', 'Protocol']",
         "2",
         "Yes",
         "2020",
         "2020",
         null,
         "2023",
         "2021",
         "2021",
         "9",
         "11",
         null,
         "3",
         "4",
         "9",
         "12",
         "5",
         "-2",
         "18",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "Stabilised Whole Rice Bran",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['George Town']",
         "1",
         "Capital",
         "['Malaysia']",
         "1",
         "['Asia']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "34",
         "NCT03146572",
         "Primary Care and Parenting",
         "COMPLETED",
         "The objective of this study to evaluate potential impact of a brief, low-cost primary care-based intervention of parenting self-efficacy, knowledge, and behavior.",
         "NO",
         "Parenting|Knowledge, Attitudes, Practice|Development, Child",
         "BEHAVIORAL: Sit Down and Play|OTHER: Handout",
         "Change in Parental Knowledge, Change in parental knowledge regarding importance of talking with children, Enrollment and 7 months post-enrollment|Change in participation in cognitively stimulating activities, Change in participation in cognitively stimulating activities such as reading and play as measured by the StimQ, Enrollment and 7 months post-enrollment|Change in parenting self-efficacy, Change in perceived self-efficacy in parenting activity as measured by The Tool to Measure Parenting Self Efficacy, Enrollment and 7 months post-enrollment",
         "No Outcome Measure",
         "No Outcome Measure",
         "University of Illinois at Chicago",
         "Society of Developmental and Behavioral Pediatrics",
         "ALL",
         "['CHILD']",
         "PHASE0",
         "61.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",
         "2017-04",
         "2018-02",
         "2018-04",
         "2017-05",
         null,
         "2020-02",
         "University of Illinois at Chicago, Chicago, Illinois, 60612, United States",
         "(50.0, 114.0]",
         "['No Documents']",
         "0",
         "No",
         "2017",
         "2017",
         null,
         "2020",
         "2018",
         "2018",
         "4",
         "5",
         null,
         "2",
         "2",
         "4",
         "12",
         "2",
         "-1",
         "22",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['OTHER', 'BEHAVIORAL']",
         "2",
         "Sit Down and Play|Handout",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['OUTCOMES_ASSESSOR', 'CARE_PROVIDER']",
         "DOUBLE",
         "PREVENTION",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Illinois']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "35",
         "NCT02887768",
         "Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study",
         "COMPLETED",
         "Epicardial Infarct Repair with CorMatrix-Extracellular Matrix (ECM) is an open-label, non-randomized, feasibility pilot study. Following ischemic injury the ECM of the heart adversely remodels leading to cardiac fibrosis, left ventricular (LV) dilatation and subsequent heart failure. Preclinical evidence demonstrates that epicardial infarct repair with CorMatrix-ECM restores the damaged ECM, prevents LV dilatation and improves myocardial performance. This study will interrogate epicardial infarct repair in patients undergoing coronary artery bypass grafting (CABG) surgery within 6 weeks following acute myocardial infarction as an adjunct to surgical revascularization. Patients will be evaluated for markers of cardiac function and left ventricular remodelling using cardiac magnetic resonance imaging (MRI). Adverse events will be monitored to ensure safety.",
         "NO",
         "Acute Coronary Syndrome|Heart Failure",
         "DEVICE: Epicardial Infarct Repair with CorMatrix-ECM|PROCEDURE: Coronary Artery Bypass Grafting Surgery",
         "The number of patients in which the study intervention is successfully completed, Feasibility will be accessed through qualitative evaluation by the performing surgeon. Successful application of CorMatrix-ECM to the infarcted myocardium at the time of coronary artery bypass grafting surgery will be deemed as successful completion of the study intervention., 6 weeks",
         "The number of patients in which the target myocardium can be successfully identified at the time of surgery, The infarct area will be identified by CMR using a standard late gadolinium enhancement protocol and the feasibility of correlating the CMR images with the surgical anatomy will be qualitatively evaluated by the performing surgeon., 6 weeks|The number of patients in which regional myocardial function and tissue characteristics are successfully measured by CMR, The feasibility of evaluating both regional function and tissue characteristics will be confirmed by successful measurement of left ventricular volume, ejection fraction, regional wall motion, myocardial edema, myocardial fibrosis, myocardial tissue viability and myocardial strain using cardiac magnetic resonance (CMR)., 6 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 months",
         "No Outcome Measure",
         "University of Calgary",
         "CorMatrix Cardiovascular, Inc.",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "8.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2016-01",
         "2017-07",
         "2017-10",
         "2016-09",
         null,
         "2017-10",
         "University of Calgary, Calgary, Alberta, T2N 2T9, Canada",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2016",
         "2016",
         null,
         "2017",
         "2017",
         "2017",
         "1",
         "9",
         null,
         "10",
         "7",
         "10",
         "21",
         "3",
         "-8",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['PROCEDURE', 'DEVICE']",
         "2",
         "Epicardial Infarct Repair with CorMatrix-ECM|Coronary Artery Bypass Grafting Surgery",
         "No Placebo",
         "No SOC",
         "NON_RANDOMIZED",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Canada']",
         "1",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "36",
         "NCT02772068",
         "Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a",
         "COMPLETED",
         "Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart failure cases and is particularly common in the elderly. The disease has no current treatment options. Symptoms typically occur during exertion or exercise and is likely the result of increased cardiac and pulmonary congestion as a result of impaired diastolic function. Istaroxime is a novel activator of SERCA2a, an important regulator of calcium uptake within the myocyte. We will test the hypothesis that Istaroxime will improve diastolic function during exercise in HFpEF patients which in turn will reduce cardiac and pulmonary congestion.",
         "NO",
         "Heart Failure, Congestive",
         "DRUG: Istaroxime|OTHER: Exercise",
         "Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with Istaroxime, Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with Istaroxime, Immediate; 90 minutes after infusion",
         "Change in cardiac relaxation time (isovolumic relaxation time) during exercise with Istaroxime, Change in cardiac relaxation time (isovolumic relaxation time) during exercise, 90 minutes",
         "No Outcome Measure",
         "Benjamin Levine",
         "National Institute on Aging (NIA)",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "26.0",
         "OTHER",
         "Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE",
         "2015-09",
         "2018-12",
         "2018-12",
         "2016-05",
         null,
         "2022-06",
         "The Institute for Exercise and Environmental Medicine, Dallas, Texas, 75231, United States",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2015",
         "2016",
         null,
         "2022",
         "2018",
         "2018",
         "9",
         "5",
         null,
         "6",
         "12",
         "12",
         "39",
         "0",
         "-8",
         "42",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG', 'OTHER']",
         "2",
         "Istaroxime|Exercise",
         "Placebo",
         "No SOC",
         "NON_RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT']",
         "SINGLE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Texas']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "37",
         "NCT01446068",
         "Comparison of Postprandial Inflammation in Lean and Obese Subjects",
         "COMPLETED",
         "The purpose of this study is to quantify the systemic inflammatory and metabolic response of lean subjects and obese subjects to the ingestion of three caloric doses of a high-fat meal.",
         "NO",
         "Nutritional Intervention|Nutritional and Metabolic Diseases|Obesity",
         "DIETARY_SUPPLEMENT: High-fat meal",
         "Interleukin-6 (serum), A statistically-significant increase in serum Interleukin-6 is expected at 4h compared to 0h, 4h vs 0h",
         "Glucose (serum), 0h, 1h, 2h, 4h, 6h|Triglyceride (serum), 0h, 1h, 2h, 4h, 6h|Insulin (serum), 0h, 1h, 2h, 4h, 6h|high sensitivity C-Reactive Protein, 0h, 1h, 2h, 4h, 6h|HDL-cholesterol, 0h, 1h, 2h, 4h, 6h|Total cholesterol, 0h, 1h, 2h, 4h, 6h|Total cholesterol / HDL cholesterol, 0h, 1h, 2h, 4h, 6h|Interleukin-6 (serum), 0h, 1h, 2h, 4h, 6h|Glucagon-like-protein-1 (serum), 0h, 1h 2h, 4h, 6h|Endotoxin (serum), 0h, 1h, 2h, 4h, 6h",
         "No Outcome Measure",
         "Agroscope Liebefeld-Posieux Research Station ALP",
         "Insel Gruppe AG, University Hospital Bern",
         "MALE",
         "['ADULT']",
         "PHASE0",
         "36.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE",
         "2011-03",
         "2012-06",
         "2013-01",
         "2011-10",
         null,
         "2013-06",
         "Agroscope Liebefeld-Posieux ALP Research Station, Berne, 3003, Switzerland|University Hospital Inselspital, Berne, Berne, 3010, Switzerland",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2011",
         "2011",
         null,
         "2013",
         "2012",
         "2013",
         "3",
         "10",
         null,
         "6",
         "6",
         "1",
         "22",
         "7",
         "-7",
         "5",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DIETARY_SUPPLEMENT']",
         "1",
         "High-fat meal",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['NONE']",
         "NONE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Bern']",
         "1",
         "Capital",
         "['Switzerland']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "38",
         "NCT03143920",
         "Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder",
         "TERMINATED",
         "Pilot study to determine feasibility for treating patients with two chronic inflammatory conditions of the urinary bladder: chronic interstitial cystitis and recurrent urinary tract infections using a standardized hyperbaric oxygen treatment plan. Presently there are no good treatments for these conditions and hyperbaric oxygen may be a safe and readily accessible therapy as it has proven successful an another type of chronic inflammatory condition of the urinary bladder known as \"radiation cystitis\". The study will determine if patients will consider this an acceptable treatment for their conditions and that it is well tolerated.",
         "NO",
         "Chronic Interstitial Cystitis|Painful Bladder Syndrome|Recurrent Urinary Tract Infection",
         "COMBINATION_PRODUCT: Hyperbaric Oxygen Therapy-",
         "HBOT acceptance, The primary outcome will be the number of patients that enroll in the study relative to the number offered enrollment and reported as a percentage of total patients offered enrollment., Three year study period. Determination is made for this endpoint at time of initiation of HBOT|HBOT adherence, The number of individuals completing the prescribed 40 treatment sessions and reported as a percentage of the number of individuals who initially enrolled in the study., Three year study period. Determination is made for this endpoint on the date of final HBOT session.",
         "Pre and post treatment symptom survey for the chronic interstitial cystitis study group., The global response assessment (GRA)will be obtained and comparison between the pre and post treatment scores will be performed. The GRA measures overall improvement with therapy. It is now used as the primary end point in clinical trials of therapies for CIC/PBS. The assessment asks: \"As compared to when you started the study \\[treatment\\], how would you rate your interstitial cystitis symptoms now?\" The seven point scale is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved. Responders will be defined as those individuals with scores falling in the moderately and markedly improved categories. The number of responders will be reported as a percentage of total number of individuals completing 40 HBOT sessions., Three year study period. Determination is made for this endpoint on the date prior to first HBOT and final HBOT session and then by telephone followup at 1, 6, and 12 months following the last HBOT session.|Post treatment incidence of recurrent urinary tract infection., The number of patients who develop recurrent urinary tract infections relative to the total number of patients receiving HBOT and reported as a percentage., Three year study period. Determination of this endpoint will be made for each individual patient at one year after final HBOT session.|Pre and post treatment symptom survey fro the chronic interstitial cystitis study group. The patient's overall rating of improvement of symptoms (PORIS) will be used., The PORIS has three questions that address the overall change in CIC/PBS, pain, and urgency after treatment as worse, no better (0% improvement), slightly improved (25%), moderately improved (50%), greatly improved (75%), or symptoms gone (100% improvement). Responders will be defined as those individuals with scores falling into the moderately or greatly improved or no symptoms categories. The number of responders will be reported as a percentage of total number of individuals completing 40 HBOT sessions., Three year study period. Determination is made for this endpoint on the date prior to first HBOT and final HBOT session and then by telephone followup at 1, 6, and 12 months following the last HBOT session.|Time of occurrence of recurrent urinary tract infection., The time in days at which a recurrent urinary tract infection is occurs will be recorded from the date following final HBOT session and reported as a mean with standard deviation., Three year study period. Determination of this endpoint will be made for each individual patient at one year after final HBOT session.",
         "No Outcome Measure",
         "University of California, San Diego",
         "No collaborators",
         "FEMALE",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "11.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2017-11",
         "2022-07",
         "2022-07",
         "2017-05",
         null,
         "2022-07",
         "UCSD Hillcrest Hosptial, San Diego, California, 92103, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2017",
         "2017",
         null,
         "2022",
         "2022",
         "2022",
         "11",
         "5",
         null,
         "7",
         "7",
         "7",
         "56",
         "0",
         "6",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['COMBINATION_PRODUCT']",
         "1",
         "Hyperbaric Oxygen Therapy-",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['California', 'United States']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "39",
         "NCT01867320",
         "Raltegravir for HAM/TSP",
         "COMPLETED",
         "Background:\n\n- Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infection of the spinal cord. The infection is caused by a virus that has been known to cause cancers like leukemia and lymphoma. It causes a weakening of the legs. Researchers want to see if raltegravir, a drug for treating human immunodeficiency virus (HIV), can be used to treat HAM/TSP. They will see if the drug can reduce the amount of virus in the blood of people with HAM/TSP.\n\nObjectives:\n\n- To see if raltegravir can reduce the viral load of people with HAM/TSP.\n\nEligibility:\n\n- Individuals at least 18 years of age who have HAM/TSP.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. Blood samples will be collected. Imaging studies will be performed. A lumbar puncture will also be taken.\n* Participants will take the study drug twice a day for 6 months. They will note each dose in a study diary, as well as any side effects.\n* At the 6-month visit, participants will stop taking the study drug. They will have a physical exam and blood samples, as well as other tests.\n* Participants will have two further exams 9 months and 15 months after starting the study drug. They will have a physical exam and blood samples, as well as other tests.",
         "NO",
         "HTLV-I Infection",
         "DRUG: Raltegravir",
         "HTLV-1 Proviral load, which will be measured by quantitative PCR, The primary outcome measure is HTLV-1 proviral load in the peripheral blood mononuclear cells (PBMCs) measured by Taqman at month 6 compared to pretreatment value., month 6 compared to pretreatment value",
         "Safety and tolerability of Raltegravir, Safety and tolerability will be assessed at each patient visit by full interim history, physical exam and clinical bloodwork. Neurologic safety will be specifically assessed by Standardized neurologic examination and scoring relevant to HAM/TSP, each patient visit",
         "No Outcome Measure",
         "National Institute of Neurological Disorders and Stroke (NINDS)",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "19.0",
         "GOV",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT",
         "2013-09",
         "2018-09",
         "2018-09",
         "2013-06",
         null,
         "2023-03",
         "National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2013",
         "2013",
         null,
         "2023",
         "2018",
         "2018",
         "9",
         "6",
         null,
         "3",
         "9",
         "9",
         "60",
         "0",
         "3",
         "54",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "Raltegravir",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Maryland']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "40",
         "NCT05871320",
         "Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms",
         "COMPLETED",
         "The main goal of the study is to expand cancer preclinical research results on the usefulness of SSTR2-Antagonist \\[99mTc\\]Tc-TECANT1 in clinical practice. Detection of NEN and monitoring of response to therapy is still challenging due to their cellular heterogeneity. Initial preclinical studies suggest that NEN imaging with the use of SSTR2-Antagonist may be advantageous in comparison to the widely used SSTR2-Agonists.\n\nRecently, novel radiopharmaceuticals, based on SSTR2-Antagonists, were shown to provide superior SSTR2 visualisation than currently used agonists. The need for molecular imaging of NEN is expected to grow significantly in the near future due to their increasing incidence and prevalence. Although a persistent trend to shift the molecular imaging of NEN from conventional SPECT/CT gamma cameras to PET/CT has been observed in the last decade, labelling the compound with Tc-99m offers significant advantages by its extremely wide availability, low cost and low radiation exposure to patients. Effective and accessible molecular imaging methods as an integral part of personalised patient management are needed to optimise selection and follow-up of available therapeutic modalities. The Tc-99m-labeled SSTR2-Antagonist \\[99mTc\\]Tc-TECANT1 is expected to be an effective, widely available compound for quantitative assessment of SSTR2 NEN status, allowing a personalised therapeutic approach.",
         "NO",
         "Neuroendocrine Tumors",
         "DRUG: [99mTc]Tc-TECANT1",
         "Safety and Tolerability assessment - incidence of Treatment-Emergent Adverse Events of iv administration of TECANT1 radiolabeled with 740±10% MBq of 99mTc, The number of patients with treatment-related adverse events as assessed by CTCAE v.5.0 (time frame: 2 weeks after administration)CTCAE v.5.0 (time frame: 2 weeks after administration), 14 days|Dosimetry assessment - effective dose absorbed in critical organs, Effective dose counted based on absorbed dose (energy deposited per unit mass) adjusted for radiation type and relative organ sensitivity measured in sievert (Sv), 2 days|Assessment of ionization radiation related to injection of TECANT1, Assessment of effective absorbed dose per injected activity \\[mSv/MBq\\] for critical organs (bone marrow, kidneys, bladder wall) and neoplastic lesions, 2days|Analysis of human pharmacokinetics of TECANT1, 1. Calculation of biological half-life of Tc-99m -SSTR2-Antagonist \\[99mTc\\]Tc-TECANT1 in blood (min) (based on time-activity curves)\n2. Assessment of the biological half-life of Tc-99m-SSTR2-Antagonist \\[99mTc\\]Tc-TECANT1 (min) in normal organs, tumour lesions (based on time-activity curves), 2 days",
         "Evaluation of [99mTc]Tc-TECANT01 uptake in tumour lesions., Diagnostic accuracy assessed as the number of neoplastic lesions detected with \\[99mTc\\]Tc-TECANT1 in comparison to the number of lesions detected with (\\[68Ga\\]Ga-DOTA-TATE PET/CT), 14 days",
         "No Outcome Measure",
         "Jagiellonian University",
         "Medical University Innsbruck|NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom|University of Ljubljana|University Medical Centre Ljubljana",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "10.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC",
         "2022-12",
         "2023-06",
         "2023-06",
         "2023-05",
         null,
         "2023-09",
         "Innsbruck Medical University Department of Nuclear Medicine, Innsbruck, Austria|Department of Endocrinology, Jagiellonian University Medical College, Kraków, 30-688, Poland|University Medical Centre Ljubljana Department of Nuclear Medicine, Ljubljana, Slovenia",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2022",
         "2023",
         null,
         "2023",
         "2023",
         "2023",
         "12",
         "5",
         null,
         "9",
         "6",
         "6",
         "6",
         "0",
         "-5",
         "3",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "[99mTc]Tc-TECANT1",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "DIAGNOSTIC",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Ljubljana']",
         "1",
         "Capital",
         "['Austria', 'Poland', 'Slovenia']",
         "3",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "41",
         "NCT06738420",
         "Medical Nutrition Formulations Enriched with Postbiotics for the Management of Gastrointestinal Disorders",
         "COMPLETED",
         "Efficacy and tolerability of ABB i5 prebiotic and ABB C22 postbiotics for the management of constipation and gastrointestinal well-being: a pilot trial",
         "NO",
         "Diarrhoea of Diverse Aetiology Requiring Oral Rehydration Therapy|Diarrhoea and Gastrointestinal Symptoms Secondary to Enteral Nutrition",
         "DIETARY_SUPPLEMENT: ABB S3|DIETARY_SUPPLEMENT: ABB C22|DIETARY_SUPPLEMENT: Placebo|DIETARY_SUPPLEMENT: Placebo",
         "Faecal calprotectin, reduction in faecal calprotectin levels (mg/g), from baseline to day 14 of supplementation|faecal lactoferrin, reduction in the number of participants with a positive \"faecal lactoferrin\" result (%), from baseline to day 14 of supplementation|Blood IgAs, levels of serum IgAs (mg/dL), from baseline to day 14 of supplementation",
         "Gastrointestinal symptoms, assessment of number of diarrhea, vomits and regurgitation events, from baseline to day 14 of supplementation|faecal consisitency, assessed through Bristol scale (1-7 score), from baseline to day 14 of supplementation",
         "No Outcome Measure",
         "AB Biotek",
         "Colisée Barcelona Isabel Roig|Grupo Colisée",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "100.0",
         "INDUSTRY",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2023-01",
         "2024-03",
         "2024-04",
         "2024-12",
         null,
         "2024-12",
         "Isabel Roig, Barcelona, 0803', Spain",
         "(50.0, 114.0]",
         "['No Documents']",
         "0",
         "No",
         "2023",
         "2024",
         null,
         "2024",
         "2024",
         "2024",
         "1",
         "12",
         null,
         "12",
         "3",
         "4",
         "15",
         "0",
         "-23",
         "8",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DIETARY_SUPPLEMENT']",
         "1",
         "ABB S3|ABB C22|Placebo|Placebo",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Spain']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "42",
         "NCT01441531",
         "Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension",
         "TERMINATED",
         "The purpose of the study is to find out if taking a dose of gabapentin 600 mg by mouth (po) before surgery will help prevent the development of tourniquet pain and hypertension while the tourniquet is inflated during orif of tibia fracture.",
         "NO",
         "Tourniquet-induced Pain|Tourniquet-induced Hypertension",
         "DRUG: gabapentin 600 mg po|DRUG: Placebo pill given one hour before surgery",
         "Incidence of tourniquet-induced hypertension, Primary outcome is incidence of tourniquet-induced hypertension, which is defined as an increase of systolic or diastolic blood pressure \\> 30% from baseline. This will be looked at during the time of tourniquet inflation (from inflation to deflation) during the actual surgical procedure. Usual maximum inflation time is 120 minutes., During the tourniquet inflation time period",
         "Postoperative pain, Postoperative pain scores for 24 hours after surgery, 24 hours|Narcotic use, Total use of morphine, vicodin during 24 hours after surgery, 24 hours",
         "No Outcome Measure",
         "Baylor College of Medicine",
         "No collaborators",
         "ALL",
         "['ADULT']",
         "PHASE0",
         "0.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2012-01",
         "2014-06",
         "2014-06",
         "2011-09",
         null,
         "2015-03",
         "Ben Taub General Hospital, Houston, Texas, 77030, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2011",
         null,
         "2015",
         "2014",
         "2014",
         "1",
         "9",
         null,
         "3",
         "6",
         "6",
         "29",
         "0",
         "4",
         "9",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "gabapentin 600 mg po|Placebo pill given one hour before surgery",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Texas']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "43",
         "NCT01245660",
         "A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy",
         "TERMINATED",
         "Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.",
         "NO",
         "Bladder Carcinoma|Infiltrative Bladder Carcinoma|Cystectomy",
         "DRUG: LAPATINIB",
         "Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib., The primary objective of the study is to evaluate the effect at a molecular level, of 3 weeks of neoadjuvant lapatinib, in locally advanced muscle-invasive transitional cell carcinoma of the bladder. A comparison of tissue from the original biopsy and cystectomy after lapatinib will allow this to occur. This effect will be evaluated by studying proliferation and apoptotic markers as well as the phosphorylation of proteins which are components of the egf signalling pathway., At surgery (day 21-27)",
         "Lapatinib biological response on key molecules of the egf pathway (EGFR, ERBB2, AKT ERK as well as their phosphorylation status.), Because the availability of large scale data, the correlation between lapatinib biological response and the molecular alteration of other molecules beside those involved in the egf pathway will be explored. i.e. key molecules of the pathway will also be studied at the protein level (EGFR, ERBB2, AKT ERK) as well as their phosphorylation status., At screening (day -10 before inclusion) , surgery (day 21-27) and Follow up visit surgery (day 42-62)|Histological response, To evaluate the histological response to lapatinib at the time of surgery, At surgery (day 21-27)",
         "No Outcome Measure",
         "University Hospital, Bordeaux",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "3.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",
         "2011-01",
         "2011-10",
         "2011-10",
         "2010-11",
         null,
         "2013-01",
         "CHU Bordeaux - Hôpital Saint André - Department of Medical Oncology, Bordeaux, 33075, France",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2011",
         "2010",
         null,
         "2013",
         "2011",
         "2011",
         "1",
         "11",
         null,
         "1",
         "10",
         "10",
         "9",
         "0",
         "2",
         "15",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "LAPATINIB",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         null,
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['France']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "44",
         "NCT06539260",
         "Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease",
         "COMPLETED",
         "The aim of this study is to detect the expression levels of vitamin D, Treg, and Th17 in the peripheral blood of patients with Parkinson\\&amp;#39;s disease (PD), investigate the impact of Treg/Th17 imbalance on PD patients, and explore the effects of vitamin D intervention on Treg/Th17 imbalance and clinical outcomes. Furthermore, this study aims to delve into the potential mechanisms of vitamin D deficiency and Treg/Th17 imbalance in the pathogenesis of Parkinson\\&amp;#39;s disease, ultimately providing new theoretical evidence for the research, prevention, and treatment of PD.",
         "NO",
         "Neurology|Immunology",
         "DRUG: Vitamin D|DRUG: Placebo",
         "Th17, Detect the level of Th17 in peripheral blood., Evaluation at the time of enrollment and intervention after three months.|Treg, Detect the level of Treg in peripheral blood., Evaluation at the time of enrollment and intervention after three months.|Vitamin D, Detect the level of Vitamin D in peripheral blood., Evaluation at the time of enrollment and intervention after three months",
         "UPDRS, Each item in the UPDRS (Unified Parkinson's Disease Rating Scale) is scored on a scale of 0 to 4, with 0 indicating normal and 4 indicating the most severe symptoms. The UPDRS can be divided into four subscales: the first subscale is used to assess the degree of mental activity, behavior, and emotional disorders in Parkinson's disease patients; the second subscale evaluates the patients' ability to perform activities of daily living; the third subscale, known as UPDRS-III, is the focus of the UPDRS scoring and assesses the motor function of PD patients, using 18 sub-items and a total of 132 points to describe the main motor symptoms of Parkinson's disease; the fourth subscale is used to evaluate treatment-related complications that occur during the course of PD treatment., Evaluation at the time of enrollment and intervention after three months|Berg balance scale, This scale consists of 14 items, each scored from 0 to 4. The sum of these items gives a total score ranging from 0 to 56, with higher scores indicating better balance., Evaluation at the time of enrollment and intervention after three months.|MMSE, This scale consists of 11 items, covering inquiries about orientation such as time and place, as well as assessments of memory, calculation ability, attention, recall ability, language skills, and visuospatial abilities. The language test further includes sub-tests for repetition ability, naming ability, command comprehension, reading ability, and writing ability. The total score for the MMSE is 30, and the entire test takes about 8-10 minutes to complete. A higher score indicates better cognitive function., Evaluation at the time of enrollment and intervention after three months|MoCA, It is an assessment tool used for rapid screening of cognitive dysfunction. It covers eight cognitive domains: visuospatial skills, executive function, memory, language, attention and concentration, calculation, abstract thinking, and orientation. The total score is 30, with a score of ≥26 considered normal., Evaluation at the time of enrollment and intervention after three months|SDS, This scale is an effective clinical tool for measuring subjective feelings of depression. It is a self-rating scale consisting of 20 items, each rated on a 4-point scale., Evaluation at the time of enrollment and intervention after three months|SAS, This scale is a self-rating scale consisting of 20 items, each rated on a 4-point scale, used to assess the subjective feelings of patients with anxiety., Evaluation at the time of enrollment and intervention after three months.",
         "No Outcome Measure",
         "Suzhou Municipal Hospital of Anhui Province",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "30.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
         "2023-01",
         "2024-07",
         "2024-07",
         "2024-08",
         null,
         "2024-08",
         "Suzhou Hospital of Anhui Medical University, Suzhou, Anhui, 234000, China",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2023",
         "2024",
         null,
         "2024",
         "2024",
         "2024",
         "1",
         "8",
         null,
         "8",
         "7",
         "7",
         "18",
         "0",
         "-19",
         "0",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Vitamin D|Placebo",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['China']",
         "1",
         "['Asia']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "45",
         "NCT05935280",
         "Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8",
         "COMPLETED",
         "Animal studies suggest that the transient receptor potential ion channels TRPM8 and TRPA1 are cold sensors and that sodium channels Nav1.8 and Nav1.7 are essential for detecting pain induced by cold temperatures. This study aims to validate these findings in humans.",
         "NO",
         "Pain",
         "OTHER: Room temperature|OTHER: Cold temperature|DRUG: Lidocain|DRUG: PF-05105679|DRUG: A967079|DRUG: PF-05089771|DRUG: PF-06305591",
         "AUC Pain3°C, The primary outcome variable is the area under the curve (AUC) of pain ratings over a limited duration of the infusion period, i.e. from 120-150 seconds (last 30 seconds of the cold stimulus)., Through study completion, on average 90 minutes.",
         "AUC Pain, The secondary outcome variable is the area under the curve (AUC) of pain ratings over the full duration of the infusion period (full 150 seconds of the cold stimulus)., Through study completion, on average 90 minutes.",
         "No Outcome Measure",
         "Medical University of Vienna",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "36.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",
         "2023-07",
         "2023-09",
         "2023-09",
         "2023-07",
         null,
         "2024-03",
         "Medical University of Vienna, Vienna, 1090, Austria",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2023",
         "2023",
         null,
         "2024",
         "2023",
         "2023",
         "7",
         "7",
         null,
         "3",
         "9",
         "9",
         "2",
         "0",
         "0",
         "6",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG', 'OTHER']",
         "2",
         "Room temperature|Cold temperature|Lidocain|PF-05105679|A967079|PF-05089771|PF-06305591",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "SINGLE_GROUP",
         "['PARTICIPANT', 'OUTCOMES_ASSESSOR', 'CARE_PROVIDER', 'INVESTIGATOR']",
         "QUADRUPLE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Vienna']",
         "1",
         "Capital",
         "['Austria']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ],
        [
         "46",
         "NCT04264962",
         "Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter",
         "COMPLETED",
         "Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.",
         "NO",
         "Hepatocellular Carcinoma",
         "DRUG: Yang Yin Fu Zheng Jie Du therapy|OTHER: Routine medical care",
         "Recurrance rate, 1 year",
         "Objective response rate, 1 year|quality of life (QOL) questionnaire, 1 year",
         "No Outcome Measure",
         "Beijing Ditan Hospital",
         "Xiyuan Hospital of China Academy of Chinese Medical Sciences",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "300.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT",
         "2017-01",
         "2021-02",
         "2021-02",
         "2020-02",
         null,
         "2021-10",
         "Zhiyun Yang, Beijing, Beijing, 100015, China",
         "(114.0, 20121212.0]",
         "['No Documents']",
         "0",
         "No",
         "2017",
         "2020",
         null,
         "2021",
         "2021",
         "2021",
         "1",
         "2",
         null,
         "10",
         "2",
         "2",
         "49",
         "0",
         "-37",
         "8",
         "(2010, 2018]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG', 'OTHER']",
         "2",
         "Yang Yin Fu Zheng Jie Du therapy|Routine medical care",
         "No Placebo",
         "No SOC",
         "RANDOMIZED",
         "PARALLEL",
         "['NONE']",
         "NONE",
         "TREATMENT",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['Beijing']",
         "1",
         "Capital",
         "['China']",
         "1",
         "['Asia']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "47",
         "NCT02384473",
         "Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma",
         "COMPLETED",
         "This pilot clinical trial studies real-time contrast-enhanced ultrasonography and shear wave elastography in predicting treatment response in patients with soft tissue sarcomas. Ultrasonography and elastography are diagnostic imaging tests that use sound waves to make pictures of the body without using radiation (x-rays). Real-time contrast-enhanced ultrasonography and shear wave elastography may help measure a patient's response to treatment given before surgery in patients with soft tissue sarcoma.",
         "NO",
         "Adult Soft Tissue Sarcoma|Bone Sarcoma|Retroperitoneal Sarcoma",
         "PROCEDURE: Real-Time CEUS|PROCEDURE: SWE|DRUG: Definity Suspension for Injection|DEVICE: Philips Shear Wave Elastography",
         "Inter-reader agreement for sequential contrast-enhanced ultra sound for evaluating treatment response as determined by kappa coefficient, Kappa coefficient will be used. Reviewer 1 will first rate the treatment response followed by reviewer 2. Reviewer 2 will be blinded to the rating of reviewer 1., Up to 9 weeks",
         "No Outcome Measure",
         "No Outcome Measure",
         "University of Southern California",
         "National Cancer Institute (NCI)",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "25.0",
         "OTHER",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC",
         "2014-12",
         "2024-01",
         "2024-01",
         "2015-03",
         null,
         "2024-01",
         "USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States",
         "(21.0, 50.0]",
         "['No Documents']",
         "0",
         "No",
         "2014",
         "2015",
         null,
         "2024",
         "2024",
         "2024",
         "12",
         "3",
         null,
         "1",
         "1",
         "1",
         "109",
         "0",
         "-3",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(-108.001, 9.0]",
         "['DRUG', 'PROCEDURE', 'DEVICE']",
         "3",
         "Real-Time CEUS|SWE|Definity Suspension for Injection|Philips Shear Wave Elastography",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "DIAGNOSTIC",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['California', 'United States']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "48",
         "NCT05908773",
         "A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors",
         "COMPLETED",
         "This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases.\n\nThe study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists of 3 parts: a screening period, dosing period, and follow-up period. The estimated total duration of the study is approximately 46 days.\n\nApproximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single site.",
         "NO",
         "Advanced Solid Tumor",
         "DRUG: TTX-MC138-NODAGA-Cu64",
         "Injected Dose, Measure the percent injected dose per cubic centimeter (%ID/cc) tissue of TTX-MC138-NODAGA-Cu64 in radiographically confirmed metastatic lesions in subjects with advanced solid tumors using PET-MRI., Throughout study completion for 12 subjects, average 12 months",
         "No Outcome Measure",
         "No Outcome Measure",
         "TransCode Therapeutics",
         "No collaborators",
         "ALL",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "1.0",
         "INDUSTRY",
         "Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER",
         "2023-04",
         "2023-08",
         "2023-09",
         "2023-06",
         null,
         "2025-01",
         "Massachusetts General Hospital, Boston, Massachusetts, 02114, United States",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2023",
         "2023",
         null,
         "2025",
         "2023",
         "2023",
         "4",
         "6",
         null,
         "1",
         "8",
         "9",
         "5",
         "0",
         "-2",
         "16",
         "(2018, 2024]",
         "(2018, 2025]",
         null,
         "(2018, 2025]",
         "(2018, 2024]",
         "(2018, 2024]",
         "(9.0, 166.0]",
         "['DRUG']",
         "1",
         "TTX-MC138-NODAGA-Cu64",
         "No Placebo",
         "No SOC",
         "NOT_APPLICABLE",
         "SINGLE_GROUP",
         "['NONE']",
         "NONE",
         "OTHER",
         "No Outcome Measures",
         "['No Outcome Measures']",
         "0",
         "No",
         "['No Capital']",
         "0",
         "No Capital",
         "['United States', 'Massachusetts']",
         "2",
         "['North America']",
         "1",
         "(-0.001, 1.0]",
         "Condition"
        ],
        [
         "49",
         "NCT01595373",
         "Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue",
         "COMPLETED",
         "The metabolic effects of ghrelin is investigated by microdialysis technique. Subjects are healthy young men. End points are interstitial concentrations of glucose, lactate, and glycerol.",
         "NO",
         "Healthy",
         "DRUG: Acyl ghrelin|DRUG: Placebo (Ringer acetate)",
         "Interstitial concentrations of glycerol, Interstitial concentrations of glycerol at t=120 minutes",
         "Interstitial concentrations of lactate, Interstitial concentrations of lactate at t=120 minutes|Interstitial concentrations of glucose, Interstitial concentrations of glucose at t=120 minutes",
         "No Outcome Measure",
         "Esben Thyssen Vestergaard",
         "No collaborators",
         "MALE",
         "['ADULT', 'OLDER_ADULT']",
         "PHASE0",
         "10.0",
         "OTHER",
         "Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE",
         "2012-06",
         "2012-09",
         "2013-01",
         "2012-05",
         null,
         "2013-01",
         "Aarhus University Hospital, Aarhus, 8000, Denmark",
         "(-0.001, 21.0]",
         "['No Documents']",
         "0",
         "No",
         "2012",
         "2012",
         null,
         "2013",
         "2012",
         "2013",
         "6",
         "5",
         null,
         "1",
         "9",
         "1",
         "7",
         "4",
         "0",
         "0",
         "(2010, 2018]",
         "(2004, 2018]",
         null,
         "(2009, 2018]",
         "(2010, 2018]",
         "(2010, 2018]",
         "(-108.001, 9.0]",
         "['DRUG']",
         "1",
         "Acyl ghrelin|Placebo (Ringer acetate)",
         "Placebo",
         "No SOC",
         "RANDOMIZED",
         "CROSSOVER",
         "['PARTICIPANT']",
         "SINGLE",
         "BASIC_SCIENCE",
         "Primary + Secondary",
         "['Primary', 'Secondary']",
         "2",
         "Yes",
         "['No Capital']",
         "0",
         "No Capital",
         "['Denmark']",
         "1",
         "['Europe']",
         "1",
         "(-0.001, 1.0]",
         "Healthy"
        ]
       ],
       "shape": {
        "columns": 75,
        "rows": 2304
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome Measures</th>\n",
       "      <th>Secondary Outcome Measures</th>\n",
       "      <th>Other Outcome Measures</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Sex</th>\n",
       "      <th>Age</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Funder Type</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Enrollment_Categ</th>\n",
       "      <th>Study_Documents</th>\n",
       "      <th>Document_Counts</th>\n",
       "      <th>Study_Doc_Bin</th>\n",
       "      <th>Start_Date_Year</th>\n",
       "      <th>First_Posted_Year</th>\n",
       "      <th>Results_First_Posted_Year</th>\n",
       "      <th>Last_Update_Posted_Year</th>\n",
       "      <th>Primary_Completion_Date_Year</th>\n",
       "      <th>Completion_Date_Year</th>\n",
       "      <th>Start_Date_Month</th>\n",
       "      <th>First_Posted_Month</th>\n",
       "      <th>Results_First_Posted_Month</th>\n",
       "      <th>Last_Update_Posted_Month</th>\n",
       "      <th>Primary_Completion_Date_Month</th>\n",
       "      <th>Completion_Date_Month</th>\n",
       "      <th>Completion_Gap</th>\n",
       "      <th>Comp_Prim_Gap</th>\n",
       "      <th>Start_Gap</th>\n",
       "      <th>End_Gap</th>\n",
       "      <th>Start_Date_Year_Categ</th>\n",
       "      <th>First_Posted_Year_Categ</th>\n",
       "      <th>Results_First_Posted_Year_Categ</th>\n",
       "      <th>Last_Update_Posted_Year_Categ</th>\n",
       "      <th>Primary_Completion_Date_Year_Categ</th>\n",
       "      <th>Completion_Date_Year_Categ</th>\n",
       "      <th>End_Gap_Categ</th>\n",
       "      <th>Intervention_Type</th>\n",
       "      <th>Intervention_Counts</th>\n",
       "      <th>Intervention_Sub</th>\n",
       "      <th>Placebo</th>\n",
       "      <th>Standard_Care</th>\n",
       "      <th>Allocation</th>\n",
       "      <th>Intervention_Model</th>\n",
       "      <th>Masking_Detail</th>\n",
       "      <th>Masking</th>\n",
       "      <th>Primary_Purpose</th>\n",
       "      <th>Outcomes</th>\n",
       "      <th>Outcomes_List</th>\n",
       "      <th>Outcomes_Counts</th>\n",
       "      <th>Outcome_Bin</th>\n",
       "      <th>Capital_Cities</th>\n",
       "      <th>Capital_Counts</th>\n",
       "      <th>Capital</th>\n",
       "      <th>Countries</th>\n",
       "      <th>Country_Counts</th>\n",
       "      <th>Continents</th>\n",
       "      <th>Continent_Counts</th>\n",
       "      <th>Capital_Counts_Categ</th>\n",
       "      <th>Healthy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03099980</td>\n",
       "      <td>Exploratory Trial Evaluating Cosentyx (Secukin...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This is a pilot study in which the the safety ...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Hidradenitis Suppurativa</td>\n",
       "      <td>BIOLOGICAL: secukinumab</td>\n",
       "      <td>Hidradenitis Suppurativa Clinical Response (Hi...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>Tufts Medical Center</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>2016-07</td>\n",
       "      <td>2018-12</td>\n",
       "      <td>2019-01</td>\n",
       "      <td>2017-04</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2019-06</td>\n",
       "      <td>Tufts Medical Center, Department of Dermatolog...</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2016</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019</td>\n",
       "      <td>2018</td>\n",
       "      <td>2019</td>\n",
       "      <td>7</td>\n",
       "      <td>4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6</td>\n",
       "      <td>12</td>\n",
       "      <td>1</td>\n",
       "      <td>30</td>\n",
       "      <td>0</td>\n",
       "      <td>-9</td>\n",
       "      <td>5</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2004, 2018]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[BIOLOGICAL]</td>\n",
       "      <td>1</td>\n",
       "      <td>secukinumab</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>No Outcome Measures</td>\n",
       "      <td>[No Outcome Measures]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[United States, Massachusetts]</td>\n",
       "      <td>2</td>\n",
       "      <td>[North America]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT02628080</td>\n",
       "      <td>Atovaquone as Tumour HypOxia Modifier</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Solid tumours often have highly disorganised v...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>DRUG: Atovaquone</td>\n",
       "      <td>Percentage change in reduction of hypoxia by a...</td>\n",
       "      <td>Reduction of perfusion by atovaquone, Changes ...</td>\n",
       "      <td>Correlation of hypoxia modification with PK (p...</td>\n",
       "      <td>University of Oxford</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>46.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>2016-05</td>\n",
       "      <td>2018-10</td>\n",
       "      <td>2018-12</td>\n",
       "      <td>2015-12</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2019-09</td>\n",
       "      <td>Churchill Hospital, Oxford, Oxfordshire, OX3 7...</td>\n",
       "      <td>(21.0, 50.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2016</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019</td>\n",
       "      <td>2018</td>\n",
       "      <td>2018</td>\n",
       "      <td>5</td>\n",
       "      <td>12</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9</td>\n",
       "      <td>10</td>\n",
       "      <td>12</td>\n",
       "      <td>31</td>\n",
       "      <td>2</td>\n",
       "      <td>5</td>\n",
       "      <td>9</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2004, 2018]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[DRUG]</td>\n",
       "      <td>1</td>\n",
       "      <td>Atovaquone</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary + Other</td>\n",
       "      <td>[Primary, Secondary, Other]</td>\n",
       "      <td>3</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[United Kingdom]</td>\n",
       "      <td>1</td>\n",
       "      <td>[Europe]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02370862</td>\n",
       "      <td>Transdermal Administration of a Prokinetic Age...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Bowel care (BC) is a time-consuming and cumber...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Spinal Cord Injury|Neurogenic Bowel</td>\n",
       "      <td>DRUG: Neostigmine and Glycopyrrolate</td>\n",
       "      <td>Biological Responses to Study Drugs (quantifie...</td>\n",
       "      <td>Safety of Study Medication (quantified through...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>James J. Peters Veterans Affairs Medical Center</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>28.0</td>\n",
       "      <td>GOV</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>2013-02</td>\n",
       "      <td>2016-12</td>\n",
       "      <td>2016-12</td>\n",
       "      <td>2015-02</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2017-03</td>\n",
       "      <td>James J. Peters VA Medical Center, Bronx, New ...</td>\n",
       "      <td>(21.0, 50.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2013</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>2016</td>\n",
       "      <td>2016</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "      <td>12</td>\n",
       "      <td>12</td>\n",
       "      <td>46</td>\n",
       "      <td>0</td>\n",
       "      <td>-24</td>\n",
       "      <td>3</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2004, 2018]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2009, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[DRUG]</td>\n",
       "      <td>1</td>\n",
       "      <td>Neostigmine and Glycopyrrolate</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>NOT_APPLICABLE</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[United States, New York]</td>\n",
       "      <td>2</td>\n",
       "      <td>[North America]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04112862</td>\n",
       "      <td>Sodium Lactate Infusion in GLUT1DS Patients</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This study investigates the effect of lactate ...</td>\n",
       "      <td>NO</td>\n",
       "      <td>GLUT1 Deficiency Syndrome|GLUT1DS1|GLUT1DS2|Ep...</td>\n",
       "      <td>OTHER: sodiumlactate</td>\n",
       "      <td>Number of changes in epileptic discharges on E...</td>\n",
       "      <td>Change in seizure frequency clinical visible b...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>Radboud University Medical Center</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[CHILD, ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>2022-05</td>\n",
       "      <td>2022-11</td>\n",
       "      <td>2022-11</td>\n",
       "      <td>2019-10</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2022-11</td>\n",
       "      <td>Radboudumc, Nijmegen, Gelderland, 6500GA, Neth...</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2022</td>\n",
       "      <td>2019</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2022</td>\n",
       "      <td>2022</td>\n",
       "      <td>2022</td>\n",
       "      <td>5</td>\n",
       "      <td>10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11</td>\n",
       "      <td>11</td>\n",
       "      <td>11</td>\n",
       "      <td>6</td>\n",
       "      <td>0</td>\n",
       "      <td>31</td>\n",
       "      <td>0</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[OTHER]</td>\n",
       "      <td>1</td>\n",
       "      <td>sodiumlactate</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>NOT_APPLICABLE</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[Netherlands]</td>\n",
       "      <td>1</td>\n",
       "      <td>[Europe]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04067960</td>\n",
       "      <td>Pharmacogenomics Testing in the Optimal Use of...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This early phase I trial studies how well a ge...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Anatomic Stage III Breast Cancer AJCC v8|Anato...</td>\n",
       "      <td>PROCEDURE: Biospecimen Collection|OTHER: Genet...</td>\n",
       "      <td>Changes in symptoms, quality of life (QOL), an...</td>\n",
       "      <td>Provider opinions surrounding the clinical uti...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[CHILD, ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>197.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>2019-06</td>\n",
       "      <td>2022-10</td>\n",
       "      <td>2022-10</td>\n",
       "      <td>2019-08</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2024-08</td>\n",
       "      <td>Mayo Clinic in Arizona, Scottsdale, Arizona, 8...</td>\n",
       "      <td>(114.0, 20121212.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2019</td>\n",
       "      <td>2019</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024</td>\n",
       "      <td>2022</td>\n",
       "      <td>2022</td>\n",
       "      <td>6</td>\n",
       "      <td>8</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8</td>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "      <td>40</td>\n",
       "      <td>0</td>\n",
       "      <td>-2</td>\n",
       "      <td>22</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(9.0, 166.0]</td>\n",
       "      <td>[GENETIC, PROCEDURE, OTHER]</td>\n",
       "      <td>3</td>\n",
       "      <td>Biospecimen Collection|Genetic Testing|Quality...</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>NOT_APPLICABLE</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>SCREENING</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[Arizona, United States]</td>\n",
       "      <td>2</td>\n",
       "      <td>[North America]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Healthy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2299</th>\n",
       "      <td>NCT02373254</td>\n",
       "      <td>NSAIDS Versus Opioids in Acute SER II Ankle Fr...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This study is being conducted to evaluate whet...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Ankle Fracture</td>\n",
       "      <td>DRUG: Ibuprofen|DRUG: Acetaminophen/hydrocodone</td>\n",
       "      <td>fracture healing as measured by radiographic e...</td>\n",
       "      <td>pain level improvement as measured by VAS scor...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>University of California, Davis</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>2015-01</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>2015-02</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2017-07</td>\n",
       "      <td>University of California Davis, Sacramento, Ca...</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2015</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>2015</td>\n",
       "      <td>2015</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7</td>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "      <td>9</td>\n",
       "      <td>0</td>\n",
       "      <td>-1</td>\n",
       "      <td>21</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2004, 2018]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2009, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(9.0, 166.0]</td>\n",
       "      <td>[DRUG]</td>\n",
       "      <td>1</td>\n",
       "      <td>Ibuprofen|Acetaminophen/hydrocodone</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>[OUTCOMES_ASSESSOR]</td>\n",
       "      <td>SINGLE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[California, United States]</td>\n",
       "      <td>2</td>\n",
       "      <td>[North America]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2300</th>\n",
       "      <td>NCT06566833</td>\n",
       "      <td>Effectiveness of Different Remineralizing Stra...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>the primary aim of the study is remineralizati...</td>\n",
       "      <td>NO</td>\n",
       "      <td>White Spot Lesion</td>\n",
       "      <td>DRUG: self assmbling peptide p11-4 combined wi...</td>\n",
       "      <td>Assessing the remineralization of early cariou...</td>\n",
       "      <td>comparing the change in esthetic appearance of...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>Alexandria University</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[CHILD]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>66.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>2023-08</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>2024-08</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2025-01</td>\n",
       "      <td>Karin Dowidar, Alexandria, Professor, Egypt</td>\n",
       "      <td>(50.0, 114.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2023</td>\n",
       "      <td>2024</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025</td>\n",
       "      <td>2024</td>\n",
       "      <td>2024</td>\n",
       "      <td>8</td>\n",
       "      <td>8</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1</td>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "      <td>14</td>\n",
       "      <td>0</td>\n",
       "      <td>-12</td>\n",
       "      <td>3</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[DRUG]</td>\n",
       "      <td>1</td>\n",
       "      <td>self assmbling peptide p11-4 combined with 0.0...</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>[PARTICIPANT, OUTCOMES_ASSESSOR]</td>\n",
       "      <td>DOUBLE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[Egypt]</td>\n",
       "      <td>1</td>\n",
       "      <td>[Africa]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Healthy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2301</th>\n",
       "      <td>NCT01335854</td>\n",
       "      <td>Promoting Continuous Positive Airway Pressure ...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The proposed research will evaluate new approa...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Obstructive Sleep Apnea</td>\n",
       "      <td>BEHAVIORAL: Web-based Access to CPAP Data|BEHA...</td>\n",
       "      <td>Average daily hours of CPAP., Average daily ho...</td>\n",
       "      <td>The percentage of days that the CPAP apparatus...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>University of Pennsylvania</td>\n",
       "      <td>National Institute on Aging (NIA)</td>\n",
       "      <td>ALL</td>\n",
       "      <td>[ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>135.0</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>2011-09</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>2011-04</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2014-05</td>\n",
       "      <td>Hospital of the University of Pennsylvania, Ph...</td>\n",
       "      <td>(114.0, 20121212.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2011</td>\n",
       "      <td>2011</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2014</td>\n",
       "      <td>2013</td>\n",
       "      <td>2013</td>\n",
       "      <td>9</td>\n",
       "      <td>4</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5</td>\n",
       "      <td>8</td>\n",
       "      <td>8</td>\n",
       "      <td>23</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>9</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2004, 2018]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2009, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[BEHAVIORAL]</td>\n",
       "      <td>1</td>\n",
       "      <td>Web-based Access to CPAP Data|Web-based Access...</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>[PARTICIPANT]</td>\n",
       "      <td>SINGLE</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[United States, Pennsylvania]</td>\n",
       "      <td>2</td>\n",
       "      <td>[North America]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2302</th>\n",
       "      <td>NCT04789954</td>\n",
       "      <td>Study on the Dose-response Relationship of Pha...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Randomized, double-blind, single-dose, 5 ways ...</td>\n",
       "      <td>NO</td>\n",
       "      <td>Hemophilia A With Inhibitor|Hemophilia B With ...</td>\n",
       "      <td>BIOLOGICAL: Eptacog alfa, activated</td>\n",
       "      <td>Lag time of the thrombin generation curve, Tim...</td>\n",
       "      <td>Endogenous Thrombin Potential (PD parameter), ...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>AryoGen Pharmed Co.</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>MALE</td>\n",
       "      <td>[CHILD, ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>14.0</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>2020-12</td>\n",
       "      <td>2021-08</td>\n",
       "      <td>2022-07</td>\n",
       "      <td>2021-03</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2022-09</td>\n",
       "      <td>Comprehensive Hemophilia Care Center, Teheran,...</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>[No Documents]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>2020</td>\n",
       "      <td>2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2022</td>\n",
       "      <td>2021</td>\n",
       "      <td>2022</td>\n",
       "      <td>12</td>\n",
       "      <td>3</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9</td>\n",
       "      <td>8</td>\n",
       "      <td>7</td>\n",
       "      <td>19</td>\n",
       "      <td>11</td>\n",
       "      <td>-3</td>\n",
       "      <td>2</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>[BIOLOGICAL]</td>\n",
       "      <td>1</td>\n",
       "      <td>Eptacog alfa, activated</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>CROSSOVER</td>\n",
       "      <td>[PARTICIPANT, OUTCOMES_ASSESSOR, CARE_PROVIDER...</td>\n",
       "      <td>QUADRUPLE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary + Secondary</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[Iran]</td>\n",
       "      <td>1</td>\n",
       "      <td>[Asia]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2303</th>\n",
       "      <td>NCT05737433</td>\n",
       "      <td>Single Dose ADME Study of [14C]-Rencofilstat i...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This is a single-center, single-period, single...</td>\n",
       "      <td>YES</td>\n",
       "      <td>NASH With Fibrosis</td>\n",
       "      <td>DRUG: [14C]-rencofilstat 225mg</td>\n",
       "      <td>To Determine the Mass Balance Recovery After a...</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>No Outcome Measure</td>\n",
       "      <td>Hepion Pharmaceuticals, Inc.</td>\n",
       "      <td>No collaborators</td>\n",
       "      <td>MALE</td>\n",
       "      <td>[ADULT, OLDER_ADULT]</td>\n",
       "      <td>PHASE0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>2023-03</td>\n",
       "      <td>2023-05</td>\n",
       "      <td>2023-08</td>\n",
       "      <td>2023-02</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>Quotient Sciences, Nottingham, United Kingdom</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>[Analysis Plan, Protocol]</td>\n",
       "      <td>2</td>\n",
       "      <td>Yes</td>\n",
       "      <td>2023</td>\n",
       "      <td>2023</td>\n",
       "      <td>2024</td>\n",
       "      <td>2024</td>\n",
       "      <td>2023</td>\n",
       "      <td>2023</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "      <td>5</td>\n",
       "      <td>8</td>\n",
       "      <td>5</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>14</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018.0, 2025.0]</td>\n",
       "      <td>(2018, 2025]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(9.0, 166.0]</td>\n",
       "      <td>[DRUG]</td>\n",
       "      <td>1</td>\n",
       "      <td>[14C]-rencofilstat 225mg</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>[NONE]</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>No Outcome Measures</td>\n",
       "      <td>[No Outcome Measures]</td>\n",
       "      <td>0</td>\n",
       "      <td>No</td>\n",
       "      <td>[No Capital]</td>\n",
       "      <td>0</td>\n",
       "      <td>No Capital</td>\n",
       "      <td>[United Kingdom]</td>\n",
       "      <td>1</td>\n",
       "      <td>[Europe]</td>\n",
       "      <td>1</td>\n",
       "      <td>(-0.001, 1.0]</td>\n",
       "      <td>Healthy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2304 rows × 75 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       NCT Number                                        Study Title  \\\n",
       "0     NCT03099980  Exploratory Trial Evaluating Cosentyx (Secukin...   \n",
       "1     NCT02628080              Atovaquone as Tumour HypOxia Modifier   \n",
       "2     NCT02370862  Transdermal Administration of a Prokinetic Age...   \n",
       "3     NCT04112862        Sodium Lactate Infusion in GLUT1DS Patients   \n",
       "4     NCT04067960  Pharmacogenomics Testing in the Optimal Use of...   \n",
       "...           ...                                                ...   \n",
       "2299  NCT02373254  NSAIDS Versus Opioids in Acute SER II Ankle Fr...   \n",
       "2300  NCT06566833  Effectiveness of Different Remineralizing Stra...   \n",
       "2301  NCT01335854  Promoting Continuous Positive Airway Pressure ...   \n",
       "2302  NCT04789954  Study on the Dose-response Relationship of Pha...   \n",
       "2303  NCT05737433  Single Dose ADME Study of [14C]-Rencofilstat i...   \n",
       "\n",
       "     Study Status                                      Brief Summary  \\\n",
       "0       COMPLETED  This is a pilot study in which the the safety ...   \n",
       "1       COMPLETED  Solid tumours often have highly disorganised v...   \n",
       "2       COMPLETED  Bowel care (BC) is a time-consuming and cumber...   \n",
       "3       COMPLETED  This study investigates the effect of lactate ...   \n",
       "4       COMPLETED  This early phase I trial studies how well a ge...   \n",
       "...           ...                                                ...   \n",
       "2299    COMPLETED  This study is being conducted to evaluate whet...   \n",
       "2300    COMPLETED  the primary aim of the study is remineralizati...   \n",
       "2301    COMPLETED  The proposed research will evaluate new approa...   \n",
       "2302    COMPLETED  Randomized, double-blind, single-dose, 5 ways ...   \n",
       "2303    COMPLETED  This is a single-center, single-period, single...   \n",
       "\n",
       "     Study Results                                         Conditions  \\\n",
       "0               NO                           Hidradenitis Suppurativa   \n",
       "1               NO                     Carcinoma, Non-Small-Cell Lung   \n",
       "2               NO                Spinal Cord Injury|Neurogenic Bowel   \n",
       "3               NO  GLUT1 Deficiency Syndrome|GLUT1DS1|GLUT1DS2|Ep...   \n",
       "4               NO  Anatomic Stage III Breast Cancer AJCC v8|Anato...   \n",
       "...            ...                                                ...   \n",
       "2299            NO                                     Ankle Fracture   \n",
       "2300            NO                                  White Spot Lesion   \n",
       "2301            NO                            Obstructive Sleep Apnea   \n",
       "2302            NO  Hemophilia A With Inhibitor|Hemophilia B With ...   \n",
       "2303           YES                                 NASH With Fibrosis   \n",
       "\n",
       "                                          Interventions  \\\n",
       "0                               BIOLOGICAL: secukinumab   \n",
       "1                                      DRUG: Atovaquone   \n",
       "2                  DRUG: Neostigmine and Glycopyrrolate   \n",
       "3                                  OTHER: sodiumlactate   \n",
       "4     PROCEDURE: Biospecimen Collection|OTHER: Genet...   \n",
       "...                                                 ...   \n",
       "2299    DRUG: Ibuprofen|DRUG: Acetaminophen/hydrocodone   \n",
       "2300  DRUG: self assmbling peptide p11-4 combined wi...   \n",
       "2301  BEHAVIORAL: Web-based Access to CPAP Data|BEHA...   \n",
       "2302                BIOLOGICAL: Eptacog alfa, activated   \n",
       "2303                     DRUG: [14C]-rencofilstat 225mg   \n",
       "\n",
       "                               Primary Outcome Measures  \\\n",
       "0     Hidradenitis Suppurativa Clinical Response (Hi...   \n",
       "1     Percentage change in reduction of hypoxia by a...   \n",
       "2     Biological Responses to Study Drugs (quantifie...   \n",
       "3     Number of changes in epileptic discharges on E...   \n",
       "4     Changes in symptoms, quality of life (QOL), an...   \n",
       "...                                                 ...   \n",
       "2299  fracture healing as measured by radiographic e...   \n",
       "2300  Assessing the remineralization of early cariou...   \n",
       "2301  Average daily hours of CPAP., Average daily ho...   \n",
       "2302  Lag time of the thrombin generation curve, Tim...   \n",
       "2303  To Determine the Mass Balance Recovery After a...   \n",
       "\n",
       "                             Secondary Outcome Measures  \\\n",
       "0                                    No Outcome Measure   \n",
       "1     Reduction of perfusion by atovaquone, Changes ...   \n",
       "2     Safety of Study Medication (quantified through...   \n",
       "3     Change in seizure frequency clinical visible b...   \n",
       "4     Provider opinions surrounding the clinical uti...   \n",
       "...                                                 ...   \n",
       "2299  pain level improvement as measured by VAS scor...   \n",
       "2300  comparing the change in esthetic appearance of...   \n",
       "2301  The percentage of days that the CPAP apparatus...   \n",
       "2302  Endogenous Thrombin Potential (PD parameter), ...   \n",
       "2303                                 No Outcome Measure   \n",
       "\n",
       "                                 Other Outcome Measures  \\\n",
       "0                                    No Outcome Measure   \n",
       "1     Correlation of hypoxia modification with PK (p...   \n",
       "2                                    No Outcome Measure   \n",
       "3                                    No Outcome Measure   \n",
       "4                                    No Outcome Measure   \n",
       "...                                                 ...   \n",
       "2299                                 No Outcome Measure   \n",
       "2300                                 No Outcome Measure   \n",
       "2301                                 No Outcome Measure   \n",
       "2302                                 No Outcome Measure   \n",
       "2303                                 No Outcome Measure   \n",
       "\n",
       "                                              Sponsor  \\\n",
       "0                                Tufts Medical Center   \n",
       "1                                University of Oxford   \n",
       "2     James J. Peters Veterans Affairs Medical Center   \n",
       "3                   Radboud University Medical Center   \n",
       "4                                         Mayo Clinic   \n",
       "...                                               ...   \n",
       "2299                  University of California, Davis   \n",
       "2300                            Alexandria University   \n",
       "2301                       University of Pennsylvania   \n",
       "2302                              AryoGen Pharmed Co.   \n",
       "2303                     Hepion Pharmaceuticals, Inc.   \n",
       "\n",
       "                          Collaborators   Sex                          Age  \\\n",
       "0                      No collaborators   ALL         [ADULT, OLDER_ADULT]   \n",
       "1                      No collaborators   ALL         [ADULT, OLDER_ADULT]   \n",
       "2                      No collaborators   ALL         [ADULT, OLDER_ADULT]   \n",
       "3                      No collaborators   ALL               [CHILD, ADULT]   \n",
       "4                      No collaborators   ALL  [CHILD, ADULT, OLDER_ADULT]   \n",
       "...                                 ...   ...                          ...   \n",
       "2299                   No collaborators   ALL                      [ADULT]   \n",
       "2300                   No collaborators   ALL                      [CHILD]   \n",
       "2301  National Institute on Aging (NIA)   ALL         [ADULT, OLDER_ADULT]   \n",
       "2302                   No collaborators  MALE  [CHILD, ADULT, OLDER_ADULT]   \n",
       "2303                   No collaborators  MALE         [ADULT, OLDER_ADULT]   \n",
       "\n",
       "      Phases  Enrollment Funder Type  \\\n",
       "0     PHASE0        20.0       OTHER   \n",
       "1     PHASE0        46.0       OTHER   \n",
       "2     PHASE0        28.0         GOV   \n",
       "3     PHASE0         2.0       OTHER   \n",
       "4     PHASE0       197.0       OTHER   \n",
       "...      ...         ...         ...   \n",
       "2299  PHASE0         1.0       OTHER   \n",
       "2300  PHASE0        66.0       OTHER   \n",
       "2301  PHASE0       135.0       OTHER   \n",
       "2302  PHASE0        14.0    INDUSTRY   \n",
       "2303  PHASE0         6.0    INDUSTRY   \n",
       "\n",
       "                                           Study Design Start Date  \\\n",
       "0     Allocation: NA|Intervention Model: SINGLE_GROU...    2016-07   \n",
       "1     Allocation: NON_RANDOMIZED|Intervention Model:...    2016-05   \n",
       "2     Allocation: NA|Intervention Model: SINGLE_GROU...    2013-02   \n",
       "3     Allocation: NA|Intervention Model: SINGLE_GROU...    2022-05   \n",
       "4     Allocation: NA|Intervention Model: SINGLE_GROU...    2019-06   \n",
       "...                                                 ...        ...   \n",
       "2299  Allocation: RANDOMIZED|Intervention Model: PAR...    2015-01   \n",
       "2300  Allocation: RANDOMIZED|Intervention Model: PAR...    2023-08   \n",
       "2301  Allocation: RANDOMIZED|Intervention Model: PAR...    2011-09   \n",
       "2302  Allocation: RANDOMIZED|Intervention Model: CRO...    2020-12   \n",
       "2303  Allocation: NA|Intervention Model: SINGLE_GROU...    2023-03   \n",
       "\n",
       "     Primary Completion Date Completion Date First Posted  \\\n",
       "0                    2018-12         2019-01      2017-04   \n",
       "1                    2018-10         2018-12      2015-12   \n",
       "2                    2016-12         2016-12      2015-02   \n",
       "3                    2022-11         2022-11      2019-10   \n",
       "4                    2022-10         2022-10      2019-08   \n",
       "...                      ...             ...          ...   \n",
       "2299                 2015-10         2015-10      2015-02   \n",
       "2300                 2024-10         2024-10      2024-08   \n",
       "2301                 2013-08         2013-08      2011-04   \n",
       "2302                 2021-08         2022-07      2021-03   \n",
       "2303                 2023-05         2023-08      2023-02   \n",
       "\n",
       "     Results First Posted Last Update Posted  \\\n",
       "0                     NaT            2019-06   \n",
       "1                     NaT            2019-09   \n",
       "2                     NaT            2017-03   \n",
       "3                     NaT            2022-11   \n",
       "4                     NaT            2024-08   \n",
       "...                   ...                ...   \n",
       "2299                  NaT            2017-07   \n",
       "2300                  NaT            2025-01   \n",
       "2301                  NaT            2014-05   \n",
       "2302                  NaT            2022-09   \n",
       "2303              2024-10            2024-10   \n",
       "\n",
       "                                              Locations     Enrollment_Categ  \\\n",
       "0     Tufts Medical Center, Department of Dermatolog...       (-0.001, 21.0]   \n",
       "1     Churchill Hospital, Oxford, Oxfordshire, OX3 7...         (21.0, 50.0]   \n",
       "2     James J. Peters VA Medical Center, Bronx, New ...         (21.0, 50.0]   \n",
       "3     Radboudumc, Nijmegen, Gelderland, 6500GA, Neth...       (-0.001, 21.0]   \n",
       "4     Mayo Clinic in Arizona, Scottsdale, Arizona, 8...  (114.0, 20121212.0]   \n",
       "...                                                 ...                  ...   \n",
       "2299  University of California Davis, Sacramento, Ca...       (-0.001, 21.0]   \n",
       "2300        Karin Dowidar, Alexandria, Professor, Egypt        (50.0, 114.0]   \n",
       "2301  Hospital of the University of Pennsylvania, Ph...  (114.0, 20121212.0]   \n",
       "2302  Comprehensive Hemophilia Care Center, Teheran,...       (-0.001, 21.0]   \n",
       "2303      Quotient Sciences, Nottingham, United Kingdom       (-0.001, 21.0]   \n",
       "\n",
       "                Study_Documents Document_Counts Study_Doc_Bin Start_Date_Year  \\\n",
       "0                [No Documents]               0            No            2016   \n",
       "1                [No Documents]               0            No            2016   \n",
       "2                [No Documents]               0            No            2013   \n",
       "3                [No Documents]               0            No            2022   \n",
       "4                [No Documents]               0            No            2019   \n",
       "...                         ...             ...           ...             ...   \n",
       "2299             [No Documents]               0            No            2015   \n",
       "2300             [No Documents]               0            No            2023   \n",
       "2301             [No Documents]               0            No            2011   \n",
       "2302             [No Documents]               0            No            2020   \n",
       "2303  [Analysis Plan, Protocol]               2           Yes            2023   \n",
       "\n",
       "     First_Posted_Year Results_First_Posted_Year Last_Update_Posted_Year  \\\n",
       "0                 2017                       NaN                    2019   \n",
       "1                 2015                       NaN                    2019   \n",
       "2                 2015                       NaN                    2017   \n",
       "3                 2019                       NaN                    2022   \n",
       "4                 2019                       NaN                    2024   \n",
       "...                ...                       ...                     ...   \n",
       "2299              2015                       NaN                    2017   \n",
       "2300              2024                       NaN                    2025   \n",
       "2301              2011                       NaN                    2014   \n",
       "2302              2021                       NaN                    2022   \n",
       "2303              2023                      2024                    2024   \n",
       "\n",
       "     Primary_Completion_Date_Year Completion_Date_Year Start_Date_Month  \\\n",
       "0                            2018                 2019                7   \n",
       "1                            2018                 2018                5   \n",
       "2                            2016                 2016                2   \n",
       "3                            2022                 2022                5   \n",
       "4                            2022                 2022                6   \n",
       "...                           ...                  ...              ...   \n",
       "2299                         2015                 2015                1   \n",
       "2300                         2024                 2024                8   \n",
       "2301                         2013                 2013                9   \n",
       "2302                         2021                 2022               12   \n",
       "2303                         2023                 2023                3   \n",
       "\n",
       "     First_Posted_Month Results_First_Posted_Month Last_Update_Posted_Month  \\\n",
       "0                     4                        NaN                        6   \n",
       "1                    12                        NaN                        9   \n",
       "2                     2                        NaN                        3   \n",
       "3                    10                        NaN                       11   \n",
       "4                     8                        NaN                        8   \n",
       "...                 ...                        ...                      ...   \n",
       "2299                  2                        NaN                        7   \n",
       "2300                  8                        NaN                        1   \n",
       "2301                  4                        NaN                        5   \n",
       "2302                  3                        NaN                        9   \n",
       "2303                  2                         10                       10   \n",
       "\n",
       "     Primary_Completion_Date_Month Completion_Date_Month  Completion_Gap  \\\n",
       "0                               12                     1              30   \n",
       "1                               10                    12              31   \n",
       "2                               12                    12              46   \n",
       "3                               11                    11               6   \n",
       "4                               10                    10              40   \n",
       "...                            ...                   ...             ...   \n",
       "2299                            10                    10               9   \n",
       "2300                            10                    10              14   \n",
       "2301                             8                     8              23   \n",
       "2302                             8                     7              19   \n",
       "2303                             5                     8               5   \n",
       "\n",
       "      Comp_Prim_Gap  Start_Gap  End_Gap Start_Date_Year_Categ  \\\n",
       "0                 0         -9        5          (2010, 2018]   \n",
       "1                 2          5        9          (2010, 2018]   \n",
       "2                 0        -24        3          (2010, 2018]   \n",
       "3                 0         31        0          (2018, 2024]   \n",
       "4                 0         -2       22          (2018, 2024]   \n",
       "...             ...        ...      ...                   ...   \n",
       "2299              0         -1       21          (2010, 2018]   \n",
       "2300              0        -12        3          (2018, 2024]   \n",
       "2301              0          5        9          (2010, 2018]   \n",
       "2302             11         -3        2          (2018, 2024]   \n",
       "2303              3          0       14          (2018, 2024]   \n",
       "\n",
       "     First_Posted_Year_Categ Results_First_Posted_Year_Categ  \\\n",
       "0               (2004, 2018]                             NaN   \n",
       "1               (2004, 2018]                             NaN   \n",
       "2               (2004, 2018]                             NaN   \n",
       "3               (2018, 2025]                             NaN   \n",
       "4               (2018, 2025]                             NaN   \n",
       "...                      ...                             ...   \n",
       "2299            (2004, 2018]                             NaN   \n",
       "2300            (2018, 2025]                             NaN   \n",
       "2301            (2004, 2018]                             NaN   \n",
       "2302            (2018, 2025]                             NaN   \n",
       "2303            (2018, 2025]                (2018.0, 2025.0]   \n",
       "\n",
       "     Last_Update_Posted_Year_Categ Primary_Completion_Date_Year_Categ  \\\n",
       "0                     (2018, 2025]                       (2010, 2018]   \n",
       "1                     (2018, 2025]                       (2010, 2018]   \n",
       "2                     (2009, 2018]                       (2010, 2018]   \n",
       "3                     (2018, 2025]                       (2018, 2024]   \n",
       "4                     (2018, 2025]                       (2018, 2024]   \n",
       "...                            ...                                ...   \n",
       "2299                  (2009, 2018]                       (2010, 2018]   \n",
       "2300                  (2018, 2025]                       (2018, 2024]   \n",
       "2301                  (2009, 2018]                       (2010, 2018]   \n",
       "2302                  (2018, 2025]                       (2018, 2024]   \n",
       "2303                  (2018, 2025]                       (2018, 2024]   \n",
       "\n",
       "     Completion_Date_Year_Categ    End_Gap_Categ            Intervention_Type  \\\n",
       "0                  (2018, 2024]  (-108.001, 9.0]                 [BIOLOGICAL]   \n",
       "1                  (2010, 2018]  (-108.001, 9.0]                       [DRUG]   \n",
       "2                  (2010, 2018]  (-108.001, 9.0]                       [DRUG]   \n",
       "3                  (2018, 2024]  (-108.001, 9.0]                      [OTHER]   \n",
       "4                  (2018, 2024]     (9.0, 166.0]  [GENETIC, PROCEDURE, OTHER]   \n",
       "...                         ...              ...                          ...   \n",
       "2299               (2010, 2018]     (9.0, 166.0]                       [DRUG]   \n",
       "2300               (2018, 2024]  (-108.001, 9.0]                       [DRUG]   \n",
       "2301               (2010, 2018]  (-108.001, 9.0]                 [BEHAVIORAL]   \n",
       "2302               (2018, 2024]  (-108.001, 9.0]                 [BIOLOGICAL]   \n",
       "2303               (2018, 2024]     (9.0, 166.0]                       [DRUG]   \n",
       "\n",
       "      Intervention_Counts                                   Intervention_Sub  \\\n",
       "0                       1                                        secukinumab   \n",
       "1                       1                                         Atovaquone   \n",
       "2                       1                     Neostigmine and Glycopyrrolate   \n",
       "3                       1                                      sodiumlactate   \n",
       "4                       3  Biospecimen Collection|Genetic Testing|Quality...   \n",
       "...                   ...                                                ...   \n",
       "2299                    1                Ibuprofen|Acetaminophen/hydrocodone   \n",
       "2300                    1  self assmbling peptide p11-4 combined with 0.0...   \n",
       "2301                    1  Web-based Access to CPAP Data|Web-based Access...   \n",
       "2302                    1                            Eptacog alfa, activated   \n",
       "2303                    1                           [14C]-rencofilstat 225mg   \n",
       "\n",
       "         Placebo Standard_Care      Allocation Intervention_Model  \\\n",
       "0     No Placebo        No SOC      RANDOMIZED       SINGLE_GROUP   \n",
       "1     No Placebo        No SOC  NON_RANDOMIZED           PARALLEL   \n",
       "2     No Placebo        No SOC  NOT_APPLICABLE       SINGLE_GROUP   \n",
       "3     No Placebo        No SOC  NOT_APPLICABLE       SINGLE_GROUP   \n",
       "4     No Placebo        No SOC  NOT_APPLICABLE       SINGLE_GROUP   \n",
       "...          ...           ...             ...                ...   \n",
       "2299  No Placebo        No SOC      RANDOMIZED           PARALLEL   \n",
       "2300  No Placebo        No SOC      RANDOMIZED           PARALLEL   \n",
       "2301  No Placebo        No SOC      RANDOMIZED           PARALLEL   \n",
       "2302  No Placebo        No SOC      RANDOMIZED          CROSSOVER   \n",
       "2303  No Placebo        No SOC  NON_RANDOMIZED       SINGLE_GROUP   \n",
       "\n",
       "                                         Masking_Detail    Masking  \\\n",
       "0                                                [NONE]       NONE   \n",
       "1                                                [NONE]       NONE   \n",
       "2                                                [NONE]       NONE   \n",
       "3                                                [NONE]       NONE   \n",
       "4                                                [NONE]       NONE   \n",
       "...                                                 ...        ...   \n",
       "2299                                [OUTCOMES_ASSESSOR]     SINGLE   \n",
       "2300                   [PARTICIPANT, OUTCOMES_ASSESSOR]     DOUBLE   \n",
       "2301                                      [PARTICIPANT]     SINGLE   \n",
       "2302  [PARTICIPANT, OUTCOMES_ASSESSOR, CARE_PROVIDER...  QUADRUPLE   \n",
       "2303                                             [NONE]       NONE   \n",
       "\n",
       "               Primary_Purpose                     Outcomes  \\\n",
       "0                    TREATMENT          No Outcome Measures   \n",
       "1                    TREATMENT  Primary + Secondary + Other   \n",
       "2                    TREATMENT          Primary + Secondary   \n",
       "3                    TREATMENT          Primary + Secondary   \n",
       "4                    SCREENING          Primary + Secondary   \n",
       "...                        ...                          ...   \n",
       "2299                 TREATMENT          Primary + Secondary   \n",
       "2300                 TREATMENT          Primary + Secondary   \n",
       "2301  HEALTH_SERVICES_RESEARCH          Primary + Secondary   \n",
       "2302                 TREATMENT          Primary + Secondary   \n",
       "2303                 TREATMENT          No Outcome Measures   \n",
       "\n",
       "                    Outcomes_List Outcomes_Counts Outcome_Bin Capital_Cities  \\\n",
       "0           [No Outcome Measures]               0          No   [No Capital]   \n",
       "1     [Primary, Secondary, Other]               3         Yes   [No Capital]   \n",
       "2            [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "3            [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "4            [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "...                           ...             ...         ...            ...   \n",
       "2299         [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "2300         [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "2301         [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "2302         [Primary, Secondary]               2         Yes   [No Capital]   \n",
       "2303        [No Outcome Measures]               0          No   [No Capital]   \n",
       "\n",
       "      Capital_Counts     Capital                       Countries  \\\n",
       "0                  0  No Capital  [United States, Massachusetts]   \n",
       "1                  0  No Capital                [United Kingdom]   \n",
       "2                  0  No Capital       [United States, New York]   \n",
       "3                  0  No Capital                   [Netherlands]   \n",
       "4                  0  No Capital        [Arizona, United States]   \n",
       "...              ...         ...                             ...   \n",
       "2299               0  No Capital     [California, United States]   \n",
       "2300               0  No Capital                         [Egypt]   \n",
       "2301               0  No Capital   [United States, Pennsylvania]   \n",
       "2302               0  No Capital                          [Iran]   \n",
       "2303               0  No Capital                [United Kingdom]   \n",
       "\n",
       "      Country_Counts       Continents  Continent_Counts Capital_Counts_Categ  \\\n",
       "0                  2  [North America]                 1        (-0.001, 1.0]   \n",
       "1                  1         [Europe]                 1        (-0.001, 1.0]   \n",
       "2                  2  [North America]                 1        (-0.001, 1.0]   \n",
       "3                  1         [Europe]                 1        (-0.001, 1.0]   \n",
       "4                  2  [North America]                 1        (-0.001, 1.0]   \n",
       "...              ...              ...               ...                  ...   \n",
       "2299               2  [North America]                 1        (-0.001, 1.0]   \n",
       "2300               1         [Africa]                 1        (-0.001, 1.0]   \n",
       "2301               2  [North America]                 1        (-0.001, 1.0]   \n",
       "2302               1           [Asia]                 1        (-0.001, 1.0]   \n",
       "2303               1         [Europe]                 1        (-0.001, 1.0]   \n",
       "\n",
       "        Healthy  \n",
       "0     Condition  \n",
       "1     Condition  \n",
       "2     Condition  \n",
       "3     Condition  \n",
       "4       Healthy  \n",
       "...         ...  \n",
       "2299  Condition  \n",
       "2300    Healthy  \n",
       "2301  Condition  \n",
       "2302  Condition  \n",
       "2303    Healthy  \n",
       "\n",
       "[2304 rows x 75 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Drop Columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [],
   "source": [
    "def drop_fun(dfi, cols):\n",
    "    for col in cols:\n",
    "      dfi = dfi.drop([col] , axis=1)  \n",
    "    \n",
    "    return dfi"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [],
   "source": [
    "cols = [\n",
    "       'NCT Number', 'Study Title', 'Brief Summary', 'Conditions',\n",
    "       'Study Results', 'Enrollment', 'Study Design', \n",
    "       'Start Date', 'Primary Completion Date', 'Completion Date', 'First Posted',\n",
    "       'Results First Posted', 'Last Update Posted', \n",
    "       'Locations', 'Interventions', 'Intervention_Sub', \n",
    "       'Study_Documents', 'Document_Counts', 'Study_Doc_Bin', \n",
    "       'Start_Date_Year', 'First_Posted_Year', 'Results_First_Posted_Year',\n",
    "       'Last_Update_Posted_Year', 'Primary_Completion_Date_Year', 'Completion_Date_Year', \n",
    "       'First_Posted_Year_Categ', 'Results_First_Posted_Year_Categ', 'Last_Update_Posted_Year_Categ', 'Primary_Completion_Date_Year_Categ', \n",
    "       'Start_Date_Month', 'First_Posted_Month',\n",
    "       'Results_First_Posted_Month', 'Last_Update_Posted_Month',\n",
    "       'Primary_Completion_Date_Month', 'Completion_Date_Month',\n",
    "       'Comp_Prim_Gap', 'Start_Gap', 'End_Gap',\n",
    "       'Primary Outcome Measures', 'Secondary Outcome Measures', 'Other Outcome Measures',\n",
    "       'Sponsor', 'Collaborators',\n",
    "       'Outcomes', 'Outcomes_Counts', 'Capital_Cities', 'Outcome_Bin',\n",
    "       'Capital_Counts', 'Capital', 'Countries', \n",
    "       'Capital_Counts_Categ', \"Phases\", \"Masking_Detail\" # Drop \"Phases\", as we have only a specific Phase per dfi.\n",
    "       ]\n",
    "\n",
    "df0 = drop_fun(df0, cols)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Study Status', 'Sex', 'Age', 'Funder Type', 'Enrollment_Categ',\n",
       "       'Study_Doc_Categ', 'Completion_Gap', 'Start_Date_Year_Categ',\n",
       "       'Completion_Date_Year_Categ', 'End_Gap_Categ', 'Intervention_Type',\n",
       "       'Intervention_Counts', 'Placebo', 'Standard_Care', 'Allocation',\n",
       "       'Intervention_Model', 'Masking', 'Primary_Purpose',\n",
       "       'Outcomes_List', 'Country_Counts', 'Continents',\n",
       "       'Continent_Counts', 'Healthy'], dtype=object)"
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df0.columns.values # Check the columns of df0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Dummy Variables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [],
   "source": [
    "def explode(cols, dfi, i, t):   \n",
    "    for col in cols: \n",
    "        dfi = dfi.explode(col)\n",
    "        dfi[col] = pd.Categorical(dfi[col], ordered = t)\n",
    "        dfi = dfi.reset_index(drop=True)\n",
    "    return dfi\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "dummy_cols = ['Sex', 'Age', 'Funder Type', 'Enrollment_Categ',\n",
    "       'Study_Doc_Categ', 'Start_Date_Year_Categ',\n",
    "       'Completion_Date_Year_Categ', 'End_Gap_Categ', 'Intervention_Type',\n",
    "       'Intervention_Counts', 'Placebo', 'Standard_Care', 'Allocation',\n",
    "       'Intervention_Model', 'Masking', 'Primary_Purpose',\n",
    "       'Outcomes_List', 'Continents',\n",
    "       'Continent_Counts', 'Healthy']\n",
    "\n",
    "df0 = explode(dummy_cols, df0, 0, True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Sex</th>\n",
       "      <th>Age</th>\n",
       "      <th>Funder Type</th>\n",
       "      <th>Enrollment_Categ</th>\n",
       "      <th>Study_Doc_Categ</th>\n",
       "      <th>Completion_Gap</th>\n",
       "      <th>Start_Date_Year_Categ</th>\n",
       "      <th>Completion_Date_Year_Categ</th>\n",
       "      <th>End_Gap_Categ</th>\n",
       "      <th>Intervention_Type</th>\n",
       "      <th>Intervention_Counts</th>\n",
       "      <th>Placebo</th>\n",
       "      <th>Standard_Care</th>\n",
       "      <th>Allocation</th>\n",
       "      <th>Intervention_Model</th>\n",
       "      <th>Masking</th>\n",
       "      <th>Primary_Purpose</th>\n",
       "      <th>Outcomes_List</th>\n",
       "      <th>Country_Counts</th>\n",
       "      <th>Continents</th>\n",
       "      <th>Continent_Counts</th>\n",
       "      <th>Healthy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>ALL</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>No Documents</td>\n",
       "      <td>30</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>BIOLOGICAL</td>\n",
       "      <td>1</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>No Outcome Measures</td>\n",
       "      <td>2</td>\n",
       "      <td>North America</td>\n",
       "      <td>1</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>ALL</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>(-0.001, 21.0]</td>\n",
       "      <td>No Documents</td>\n",
       "      <td>30</td>\n",
       "      <td>(2010, 2018]</td>\n",
       "      <td>(2018, 2024]</td>\n",
       "      <td>(-108.001, 9.0]</td>\n",
       "      <td>BIOLOGICAL</td>\n",
       "      <td>1</td>\n",
       "      <td>No Placebo</td>\n",
       "      <td>No SOC</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>NONE</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>No Outcome Measures</td>\n",
       "      <td>2</td>\n",
       "      <td>North America</td>\n",
       "      <td>1</td>\n",
       "      <td>Condition</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Study Status  Sex          Age Funder Type Enrollment_Categ Study_Doc_Categ  \\\n",
       "0    COMPLETED  ALL        ADULT       OTHER   (-0.001, 21.0]    No Documents   \n",
       "1    COMPLETED  ALL  OLDER_ADULT       OTHER   (-0.001, 21.0]    No Documents   \n",
       "\n",
       "   Completion_Gap Start_Date_Year_Categ Completion_Date_Year_Categ  \\\n",
       "0              30          (2010, 2018]               (2018, 2024]   \n",
       "1              30          (2010, 2018]               (2018, 2024]   \n",
       "\n",
       "     End_Gap_Categ Intervention_Type Intervention_Counts     Placebo  \\\n",
       "0  (-108.001, 9.0]        BIOLOGICAL                   1  No Placebo   \n",
       "1  (-108.001, 9.0]        BIOLOGICAL                   1  No Placebo   \n",
       "\n",
       "  Standard_Care  Allocation Intervention_Model Masking Primary_Purpose  \\\n",
       "0        No SOC  RANDOMIZED       SINGLE_GROUP    NONE       TREATMENT   \n",
       "1        No SOC  RANDOMIZED       SINGLE_GROUP    NONE       TREATMENT   \n",
       "\n",
       "         Outcomes_List  Country_Counts     Continents Continent_Counts  \\\n",
       "0  No Outcome Measures               2  North America                1   \n",
       "1  No Outcome Measures               2  North America                1   \n",
       "\n",
       "     Healthy  \n",
       "0  Condition  \n",
       "1  Condition  "
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def unused(cols , dfi, i):\n",
    "    for col in cols:\n",
    "        dfi[col] = dfi[col].cat.remove_unused_categories()\n",
    "    return dfi\n",
    "\n",
    "df0 = unused(dummy_cols, df0, 0)\n",
    "df0.head(2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "def dummies(cols, dfi):\n",
    "    for col in cols:\n",
    "            dfi = pd.get_dummies(data=dfi, columns=[col], drop_first = True, dtype=int, prefix_sep=' - ')\n",
    "    return dfi\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [],
   "source": [
    "df0 = dummies(dummy_cols, df0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Study Status', 'Completion_Gap', 'Country_Counts', 'Sex - FEMALE',\n",
       "       'Sex - MALE', 'Age - CHILD', 'Age - OLDER_ADULT',\n",
       "       'Funder Type - INDUSTRY', 'Funder Type - OTHER',\n",
       "       'Enrollment_Categ - (21.0, 50.0]',\n",
       "       'Enrollment_Categ - (50.0, 114.0]',\n",
       "       'Enrollment_Categ - (114.0, 20121212.0]',\n",
       "       'Study_Doc_Categ - Analysis Plan + Consent Form + Protocol',\n",
       "       'Study_Doc_Categ - Analysis Plan + Protocol',\n",
       "       'Study_Doc_Categ - Consent Form',\n",
       "       'Study_Doc_Categ - Consent Form + Protocol',\n",
       "       'Study_Doc_Categ - No Documents', 'Study_Doc_Categ - Protocol',\n",
       "       'Start_Date_Year_Categ - (2018, 2024]',\n",
       "       'Completion_Date_Year_Categ - (2018, 2024]',\n",
       "       'End_Gap_Categ - (9.0, 166.0]', 'Intervention_Type - BIOLOGICAL',\n",
       "       'Intervention_Type - COMBINATION_PRODUCT',\n",
       "       'Intervention_Type - DEVICE',\n",
       "       'Intervention_Type - DIAGNOSTIC_TEST',\n",
       "       'Intervention_Type - DIETARY_SUPPLEMENT',\n",
       "       'Intervention_Type - DRUG', 'Intervention_Type - GENETIC',\n",
       "       'Intervention_Type - OTHER', 'Intervention_Type - PROCEDURE',\n",
       "       'Intervention_Type - RADIATION', 'Intervention_Counts - 2',\n",
       "       'Intervention_Counts - 3', 'Intervention_Counts - 4',\n",
       "       'Placebo - Placebo', 'Standard_Care - SOC',\n",
       "       'Allocation - NOT_APPLICABLE', 'Allocation - RANDOMIZED',\n",
       "       'Intervention_Model - FACTORIAL', 'Intervention_Model - PARALLEL',\n",
       "       'Intervention_Model - SEQUENTIAL',\n",
       "       'Intervention_Model - SINGLE_GROUP', 'Masking - NONE',\n",
       "       'Masking - QUADRUPLE', 'Masking - SINGLE', 'Masking - TRIPLE',\n",
       "       'Primary_Purpose - DEVICE_FEASIBILITY',\n",
       "       'Primary_Purpose - DIAGNOSTIC',\n",
       "       'Primary_Purpose - HEALTH_SERVICES_RESEARCH',\n",
       "       'Primary_Purpose - OTHER', 'Primary_Purpose - PREVENTION',\n",
       "       'Primary_Purpose - SCREENING', 'Primary_Purpose - SUPPORTIVE_CARE',\n",
       "       'Primary_Purpose - TREATMENT', 'Outcomes_List - Other',\n",
       "       'Outcomes_List - Primary', 'Outcomes_List - Secondary',\n",
       "       'Continents - Asia', 'Continents - Europe',\n",
       "       'Continents - North America', 'Continents - Oceania',\n",
       "       'Continents - South America', 'Continent_Counts - 1',\n",
       "       'Continent_Counts - 2', 'Continent_Counts - 3',\n",
       "       'Healthy - Healthy'], dtype=object)"
      ]
     },
     "execution_count": 126,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df0.columns.values # Check the columns of df0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Train-Test Split, Scale Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "def train_test(cont_cols, dfi):\n",
    "    X = dfi.drop(\"Study Status\", axis = 1)\n",
    "    y = dfi[\"Study Status\"]\n",
    "    # Train-Test Set\n",
    "    X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.3, random_state=42)\n",
    "    # Scale Continuous X\n",
    "    scaler = StandardScaler()\n",
    "    X_train[cont_cols] = scaler.fit_transform(X_train[cont_cols])\n",
    "    X_test[cont_cols] = scaler.transform(X_test[cont_cols])\n",
    "\n",
    "    return X_train, X_test, y_train, y_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Study_Doc_Categ</th>\n",
       "      <th>Completion_Gap</th>\n",
       "      <th>Country_Counts</th>\n",
       "      <th>Sex - FEMALE</th>\n",
       "      <th>Sex - MALE</th>\n",
       "      <th>Age - CHILD</th>\n",
       "      <th>Age - OLDER_ADULT</th>\n",
       "      <th>Funder Type - INDUSTRY</th>\n",
       "      <th>Funder Type - OTHER</th>\n",
       "      <th>Enrollment_Categ - (21.0, 50.0]</th>\n",
       "      <th>Enrollment_Categ - (50.0, 114.0]</th>\n",
       "      <th>Enrollment_Categ - (114.0, 20121212.0]</th>\n",
       "      <th>Start_Date_Year_Categ - (2018, 2024]</th>\n",
       "      <th>Completion_Date_Year_Categ - (2018, 2024]</th>\n",
       "      <th>End_Gap_Categ - (9.0, 166.0]</th>\n",
       "      <th>Intervention_Type - BIOLOGICAL</th>\n",
       "      <th>Intervention_Type - COMBINATION_PRODUCT</th>\n",
       "      <th>Intervention_Type - DEVICE</th>\n",
       "      <th>Intervention_Type - DIAGNOSTIC_TEST</th>\n",
       "      <th>Intervention_Type - DIETARY_SUPPLEMENT</th>\n",
       "      <th>Intervention_Type - DRUG</th>\n",
       "      <th>Intervention_Type - GENETIC</th>\n",
       "      <th>Intervention_Type - OTHER</th>\n",
       "      <th>Intervention_Type - PROCEDURE</th>\n",
       "      <th>Intervention_Type - RADIATION</th>\n",
       "      <th>Intervention_Counts - 2</th>\n",
       "      <th>Intervention_Counts - 3</th>\n",
       "      <th>Intervention_Counts - 4</th>\n",
       "      <th>Placebo - Placebo</th>\n",
       "      <th>Standard_Care - SOC</th>\n",
       "      <th>Allocation - NOT_APPLICABLE</th>\n",
       "      <th>Allocation - RANDOMIZED</th>\n",
       "      <th>Intervention_Model - FACTORIAL</th>\n",
       "      <th>Intervention_Model - PARALLEL</th>\n",
       "      <th>Intervention_Model - SEQUENTIAL</th>\n",
       "      <th>Intervention_Model - SINGLE_GROUP</th>\n",
       "      <th>Masking - NONE</th>\n",
       "      <th>Masking - QUADRUPLE</th>\n",
       "      <th>Masking - SINGLE</th>\n",
       "      <th>Masking - TRIPLE</th>\n",
       "      <th>Primary_Purpose - DEVICE_FEASIBILITY</th>\n",
       "      <th>Primary_Purpose - DIAGNOSTIC</th>\n",
       "      <th>Primary_Purpose - HEALTH_SERVICES_RESEARCH</th>\n",
       "      <th>Primary_Purpose - OTHER</th>\n",
       "      <th>Primary_Purpose - PREVENTION</th>\n",
       "      <th>Primary_Purpose - SCREENING</th>\n",
       "      <th>Primary_Purpose - SUPPORTIVE_CARE</th>\n",
       "      <th>Primary_Purpose - TREATMENT</th>\n",
       "      <th>Outcomes_List - Other</th>\n",
       "      <th>Outcomes_List - Primary</th>\n",
       "      <th>Outcomes_List - Secondary</th>\n",
       "      <th>Continents - Asia</th>\n",
       "      <th>Continents - Europe</th>\n",
       "      <th>Continents - North America</th>\n",
       "      <th>Continents - Oceania</th>\n",
       "      <th>Continents - South America</th>\n",
       "      <th>Continent_Counts - 1</th>\n",
       "      <th>Continent_Counts - 2</th>\n",
       "      <th>Continent_Counts - 3</th>\n",
       "      <th>Healthy - Healthy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1108</th>\n",
       "      <td>No Documents</td>\n",
       "      <td>-0.167775</td>\n",
       "      <td>-0.683665</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4003</th>\n",
       "      <td>No Documents</td>\n",
       "      <td>0.822044</td>\n",
       "      <td>-0.347368</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Study_Doc_Categ  Completion_Gap  Country_Counts  Sex - FEMALE  \\\n",
       "1108    No Documents       -0.167775       -0.683665             0   \n",
       "4003    No Documents        0.822044       -0.347368             0   \n",
       "\n",
       "      Sex - MALE  Age - CHILD  Age - OLDER_ADULT  Funder Type - INDUSTRY  \\\n",
       "1108           0            1                  0                       0   \n",
       "4003           0            0                  0                       0   \n",
       "\n",
       "      Funder Type - OTHER  Enrollment_Categ - (21.0, 50.0]  \\\n",
       "1108                    1                                1   \n",
       "4003                    1                                0   \n",
       "\n",
       "      Enrollment_Categ - (50.0, 114.0]  \\\n",
       "1108                                 0   \n",
       "4003                                 1   \n",
       "\n",
       "      Enrollment_Categ - (114.0, 20121212.0]  \\\n",
       "1108                                       0   \n",
       "4003                                       0   \n",
       "\n",
       "      Start_Date_Year_Categ - (2018, 2024]  \\\n",
       "1108                                     0   \n",
       "4003                                     1   \n",
       "\n",
       "      Completion_Date_Year_Categ - (2018, 2024]  End_Gap_Categ - (9.0, 166.0]  \\\n",
       "1108                                          0                             1   \n",
       "4003                                          1                             0   \n",
       "\n",
       "      Intervention_Type - BIOLOGICAL  Intervention_Type - COMBINATION_PRODUCT  \\\n",
       "1108                               0                                        0   \n",
       "4003                               0                                        0   \n",
       "\n",
       "      Intervention_Type - DEVICE  Intervention_Type - DIAGNOSTIC_TEST  \\\n",
       "1108                           0                                    0   \n",
       "4003                           0                                    0   \n",
       "\n",
       "      Intervention_Type - DIETARY_SUPPLEMENT  Intervention_Type - DRUG  \\\n",
       "1108                                       0                         1   \n",
       "4003                                       0                         1   \n",
       "\n",
       "      Intervention_Type - GENETIC  Intervention_Type - OTHER  \\\n",
       "1108                            0                          0   \n",
       "4003                            0                          0   \n",
       "\n",
       "      Intervention_Type - PROCEDURE  Intervention_Type - RADIATION  \\\n",
       "1108                              0                              0   \n",
       "4003                              0                              0   \n",
       "\n",
       "      Intervention_Counts - 2  Intervention_Counts - 3  \\\n",
       "1108                        0                        0   \n",
       "4003                        0                        0   \n",
       "\n",
       "      Intervention_Counts - 4  Placebo - Placebo  Standard_Care - SOC  \\\n",
       "1108                        0                  0                    0   \n",
       "4003                        0                  1                    0   \n",
       "\n",
       "      Allocation - NOT_APPLICABLE  Allocation - RANDOMIZED  \\\n",
       "1108                            0                        1   \n",
       "4003                            0                        1   \n",
       "\n",
       "      Intervention_Model - FACTORIAL  Intervention_Model - PARALLEL  \\\n",
       "1108                               0                              1   \n",
       "4003                               0                              1   \n",
       "\n",
       "      Intervention_Model - SEQUENTIAL  Intervention_Model - SINGLE_GROUP  \\\n",
       "1108                                0                                  0   \n",
       "4003                                0                                  0   \n",
       "\n",
       "      Masking - NONE  Masking - QUADRUPLE  Masking - SINGLE  Masking - TRIPLE  \\\n",
       "1108               0                    0                 1                 0   \n",
       "4003               0                    0                 0                 0   \n",
       "\n",
       "      Primary_Purpose - DEVICE_FEASIBILITY  Primary_Purpose - DIAGNOSTIC  \\\n",
       "1108                                     0                             0   \n",
       "4003                                     0                             0   \n",
       "\n",
       "      Primary_Purpose - HEALTH_SERVICES_RESEARCH  Primary_Purpose - OTHER  \\\n",
       "1108                                           0                        0   \n",
       "4003                                           0                        0   \n",
       "\n",
       "      Primary_Purpose - PREVENTION  Primary_Purpose - SCREENING  \\\n",
       "1108                             0                            0   \n",
       "4003                             0                            0   \n",
       "\n",
       "      Primary_Purpose - SUPPORTIVE_CARE  Primary_Purpose - TREATMENT  \\\n",
       "1108                                  0                            1   \n",
       "4003                                  0                            1   \n",
       "\n",
       "      Outcomes_List - Other  Outcomes_List - Primary  \\\n",
       "1108                      1                        0   \n",
       "4003                      0                        1   \n",
       "\n",
       "      Outcomes_List - Secondary  Continents - Asia  Continents - Europe  \\\n",
       "1108                          0                  0                    0   \n",
       "4003                          0                  0                    0   \n",
       "\n",
       "      Continents - North America  Continents - Oceania  \\\n",
       "1108                           0                     0   \n",
       "4003                           0                     0   \n",
       "\n",
       "      Continents - South America  Continent_Counts - 1  Continent_Counts - 2  \\\n",
       "1108                           0                     0                     0   \n",
       "4003                           0                     1                     0   \n",
       "\n",
       "      Continent_Counts - 3  Healthy - Healthy  \n",
       "1108                     0                  0  \n",
       "4003                     0                  0  "
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cont_cols = ['Completion_Gap','Country_Counts'] # Continuous columns\n",
    "X_train0, X_test0, y_train0, y_test0 = train_test(cont_cols , df0)\n",
    "X_train0.head(2)  # if needed re-reset_index because train_test split changed it again"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(9938, 61)"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df0.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Collinearity Check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "ufunc 'isfinite' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe''",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[78], line 3\u001b[0m\n\u001b[0;32m      1\u001b[0m pd\u001b[38;5;241m.\u001b[39mset_option(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mdisplay.max_rows\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;241m100\u001b[39m)\n\u001b[0;32m      2\u001b[0m vif_data \u001b[38;5;241m=\u001b[39m pd\u001b[38;5;241m.\u001b[39mDataFrame({\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mFeature\u001b[39m\u001b[38;5;124m\"\u001b[39m: X_train0\u001b[38;5;241m.\u001b[39mcolumns})\n\u001b[1;32m----> 3\u001b[0m vif_data[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mVIF\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m [\u001b[43mvariance_inflation_factor\u001b[49m\u001b[43m(\u001b[49m\u001b[43mX_train0\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mvalues\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mi\u001b[49m\u001b[43m)\u001b[49m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(X_train0\u001b[38;5;241m.\u001b[39mshape[\u001b[38;5;241m1\u001b[39m])]\n\u001b[0;32m      4\u001b[0m vif_data[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mVIF\u001b[39m\u001b[38;5;124m\"\u001b[39m]\n\u001b[0;32m      5\u001b[0m vif_data\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\stats\\outliers_influence.py:196\u001b[0m, in \u001b[0;36mvariance_inflation_factor\u001b[1;34m(exog, exog_idx)\u001b[0m\n\u001b[0;32m    194\u001b[0m mask \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39marange(k_vars) \u001b[38;5;241m!=\u001b[39m exog_idx\n\u001b[0;32m    195\u001b[0m x_noti \u001b[38;5;241m=\u001b[39m exog[:, mask]\n\u001b[1;32m--> 196\u001b[0m r_squared_i \u001b[38;5;241m=\u001b[39m \u001b[43mOLS\u001b[49m\u001b[43m(\u001b[49m\u001b[43mx_i\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mx_noti\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241m.\u001b[39mfit()\u001b[38;5;241m.\u001b[39mrsquared\n\u001b[0;32m    197\u001b[0m vif \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m1.\u001b[39m \u001b[38;5;241m/\u001b[39m (\u001b[38;5;241m1.\u001b[39m \u001b[38;5;241m-\u001b[39m r_squared_i)\n\u001b[0;32m    198\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m vif\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\regression\\linear_model.py:924\u001b[0m, in \u001b[0;36mOLS.__init__\u001b[1;34m(self, endog, exog, missing, hasconst, **kwargs)\u001b[0m\n\u001b[0;32m    921\u001b[0m     msg \u001b[38;5;241m=\u001b[39m (\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mWeights are not supported in OLS and will be ignored\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    922\u001b[0m            \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAn exception will be raised in the next version.\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m    923\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(msg, ValueWarning)\n\u001b[1;32m--> 924\u001b[0m \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__init__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmissing\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmissing\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    925\u001b[0m \u001b[43m                          \u001b[49m\u001b[43mhasconst\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhasconst\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    926\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mweights\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_init_keys:\n\u001b[0;32m    927\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_init_keys\u001b[38;5;241m.\u001b[39mremove(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mweights\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\regression\\linear_model.py:749\u001b[0m, in \u001b[0;36mWLS.__init__\u001b[1;34m(self, endog, exog, weights, missing, hasconst, **kwargs)\u001b[0m\n\u001b[0;32m    747\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m    748\u001b[0m     weights \u001b[38;5;241m=\u001b[39m weights\u001b[38;5;241m.\u001b[39msqueeze()\n\u001b[1;32m--> 749\u001b[0m \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__init__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmissing\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmissing\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    750\u001b[0m \u001b[43m                          \u001b[49m\u001b[43mweights\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mweights\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mhasconst\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhasconst\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    751\u001b[0m nobs \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mexog\u001b[38;5;241m.\u001b[39mshape[\u001b[38;5;241m0\u001b[39m]\n\u001b[0;32m    752\u001b[0m weights \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mweights\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\regression\\linear_model.py:203\u001b[0m, in \u001b[0;36mRegressionModel.__init__\u001b[1;34m(self, endog, exog, **kwargs)\u001b[0m\n\u001b[0;32m    202\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m__init__\u001b[39m(\u001b[38;5;28mself\u001b[39m, endog, exog, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m--> 203\u001b[0m     \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__init__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    204\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mpinv_wexog: Float64Array \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m    205\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_data_attr\u001b[38;5;241m.\u001b[39mextend([\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mpinv_wexog\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mwendog\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mwexog\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mweights\u001b[39m\u001b[38;5;124m'\u001b[39m])\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\model.py:270\u001b[0m, in \u001b[0;36mLikelihoodModel.__init__\u001b[1;34m(self, endog, exog, **kwargs)\u001b[0m\n\u001b[0;32m    269\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m__init__\u001b[39m(\u001b[38;5;28mself\u001b[39m, endog, exog\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m--> 270\u001b[0m     \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__init__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    271\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39minitialize()\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\model.py:95\u001b[0m, in \u001b[0;36mModel.__init__\u001b[1;34m(self, endog, exog, **kwargs)\u001b[0m\n\u001b[0;32m     93\u001b[0m missing \u001b[38;5;241m=\u001b[39m kwargs\u001b[38;5;241m.\u001b[39mpop(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mmissing\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mnone\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m     94\u001b[0m hasconst \u001b[38;5;241m=\u001b[39m kwargs\u001b[38;5;241m.\u001b[39mpop(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhasconst\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[1;32m---> 95\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mdata \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_handle_data\u001b[49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmissing\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mhasconst\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     96\u001b[0m \u001b[43m                              \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     97\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mk_constant \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mdata\u001b[38;5;241m.\u001b[39mk_constant\n\u001b[0;32m     98\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mexog \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mdata\u001b[38;5;241m.\u001b[39mexog\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\model.py:135\u001b[0m, in \u001b[0;36mModel._handle_data\u001b[1;34m(self, endog, exog, missing, hasconst, **kwargs)\u001b[0m\n\u001b[0;32m    134\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_handle_data\u001b[39m(\u001b[38;5;28mself\u001b[39m, endog, exog, missing, hasconst, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m--> 135\u001b[0m     data \u001b[38;5;241m=\u001b[39m \u001b[43mhandle_data\u001b[49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmissing\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mhasconst\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    136\u001b[0m     \u001b[38;5;66;03m# kwargs arrays could have changed, easier to just attach here\u001b[39;00m\n\u001b[0;32m    137\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m key \u001b[38;5;129;01min\u001b[39;00m kwargs:\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\data.py:675\u001b[0m, in \u001b[0;36mhandle_data\u001b[1;34m(endog, exog, missing, hasconst, **kwargs)\u001b[0m\n\u001b[0;32m    672\u001b[0m     exog \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(exog)\n\u001b[0;32m    674\u001b[0m klass \u001b[38;5;241m=\u001b[39m handle_data_class_factory(endog, exog)\n\u001b[1;32m--> 675\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mklass\u001b[49m\u001b[43m(\u001b[49m\u001b[43mendog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mexog\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mexog\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmissing\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmissing\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mhasconst\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhasconst\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    676\u001b[0m \u001b[43m             \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\data.py:88\u001b[0m, in \u001b[0;36mModelData.__init__\u001b[1;34m(self, endog, exog, missing, hasconst, **kwargs)\u001b[0m\n\u001b[0;32m     86\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mconst_idx \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m     87\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mk_constant \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m---> 88\u001b[0m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_handle_constant\u001b[49m\u001b[43m(\u001b[49m\u001b[43mhasconst\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     89\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_check_integrity()\n\u001b[0;32m     90\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_cache \u001b[38;5;241m=\u001b[39m {}\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\statsmodels\\base\\data.py:133\u001b[0m, in \u001b[0;36mModelData._handle_constant\u001b[1;34m(self, hasconst)\u001b[0m\n\u001b[0;32m    131\u001b[0m check_implicit \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mFalse\u001b[39;00m\n\u001b[0;32m    132\u001b[0m exog_max \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39mmax(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mexog, axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m0\u001b[39m)\n\u001b[1;32m--> 133\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[43mnp\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43misfinite\u001b[49m\u001b[43m(\u001b[49m\u001b[43mexog_max\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241m.\u001b[39mall():\n\u001b[0;32m    134\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m MissingDataError(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mexog contains inf or nans\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m    135\u001b[0m exog_min \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39mmin(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mexog, axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m0\u001b[39m)\n",
      "\u001b[1;31mTypeError\u001b[0m: ufunc 'isfinite' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe''"
     ]
    }
   ],
   "source": [
    "pd.set_option('display.max_rows', 100)\n",
    "vif_data = pd.DataFrame({\"Feature\": X_train0.columns})\n",
    "vif_data[\"VIF\"] = [variance_inflation_factor(X_train0.values, i) for i in range(X_train0.shape[1])]\n",
    "vif_data[\"VIF\"]\n",
    "vif_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Performance Metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def accuracy(dfi, i, model, X_test, y_test, y_pred, title):\n",
    "    print(f\"Model : Phase {i} - {title}\")\n",
    "    \n",
    "    print(\"\\na).\\nAccuracy Score : (True P + True N) / N total :\")\n",
    "    print(f\"{accuracy_score(y_test, y_pred) * 100:.2f}%\")\n",
    "\n",
    "    print(\"\\nb).\\nClassification Report :\")\n",
    "    print(classification_report(y_test, y_pred))\n",
    "\n",
    "    print(\"\\nc).\\nPlots :\")\n",
    "    fig , ax = plt.subplots(figsize=(20, 5), nrows = 1, ncols = 2)\n",
    "    ConfusionMatrixDisplay.from_predictions(y_test , y_pred, ax = ax[0]);\n",
    "    RocCurveDisplay.from_estimator(model, X_test , y_test, pos_label=\"COMPLETED\", ax = ax[1], name = f'{title}');\n",
    "    print(roc_auc_score(y_test, y_pred))\n",
    "    plt.suptitle(f\"Phase {i} - {title}\", fontsize = 11, fontweight = 'bold')\n",
    "\n",
    "    ax[0].set_title(\"1. Confusion Matrix\", fontsize = 10, fontweight = 'bold')\n",
    "    ax[0].set_xlabel(\"Predicted Label\", fontsize = 10, fontweight = 'bold')\n",
    "    ax[0].set_ylabel(\"True Label\", fontsize = 10, fontweight = 'bold')\n",
    "    #ax[0].set_xticklabels([\"Terminated\", \"Completed\"], fontsize = 10, fontweight = 'bold')\n",
    "    #ax[0].set_yticklabels([\"Terminated\", \"Completed\"], fontsize = 10, fontweight = 'bold')\n",
    "\n",
    "    ax[1].set_title(\"2. ROC Curve\" , fontsize = 10, fontweight = 'bold')\n",
    "    ax[1].set_xlabel(\"True Positive Rate (Completed)\", fontsize = 10, fontweight = 'bold')\n",
    "    ax[1].set_ylabel(\"False Positive Rate (Completed)\", fontsize = 10, fontweight = 'bold')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 3) Models"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## A) Classic Classification"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1. Logistic Regression"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Small C (e.g. 0.001) --> Strong regularization   --> More bias, smaller coefficients (simpler model)\n",
    "Large C (e.g. 1000)  --> Weak regularization     --> Model fits more to data (can overfit)\n",
    "C = 1 (default)      --> Moderate regularization --> Balanced by default"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "\nAll the 50 fits failed.\nIt is very likely that your model is misconfigured.\nYou can try to debug the error by setting error_score='raise'.\n\nBelow are more details about the failures:\n--------------------------------------------------------------------------------\n50 fits failed with the following error:\nTraceback (most recent call last):\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_validation.py\", line 888, in _fit_and_score\n    estimator.fit(X_train, y_train, **fit_params)\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\base.py\", line 1473, in wrapper\n    return fit_method(estimator, *args, **kwargs)\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\linear_model\\_logistic.py\", line 1223, in fit\n    X, y = self._validate_data(\n           ^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\base.py\", line 650, in _validate_data\n    X, y = check_X_y(X, y, **check_params)\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\validation.py\", line 1301, in check_X_y\n    X = check_array(\n        ^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\validation.py\", line 1012, in check_array\n    array = _asarray_with_order(array, order=order, dtype=dtype, xp=xp)\n            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\_array_api.py\", line 751, in _asarray_with_order\n    array = numpy.asarray(array, order=order, dtype=dtype)\n            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\pandas\\core\\generic.py\", line 2150, in __array__\n    arr = np.asarray(values, dtype=dtype)\n          ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\nValueError: could not convert string to float: 'No Documents'\n",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[45], line 11\u001b[0m\n\u001b[0;32m      8\u001b[0m log_model \u001b[38;5;241m=\u001b[39m GridSearchCV(log , param_grid \u001b[38;5;241m=\u001b[39m param_grid)\n\u001b[0;32m     10\u001b[0m \u001b[38;5;66;03m# Final Model\u001b[39;00m\n\u001b[1;32m---> 11\u001b[0m log_model \u001b[38;5;241m=\u001b[39m \u001b[43mlog_model\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfit\u001b[49m\u001b[43m(\u001b[49m\u001b[43mX_train0\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43my_train0\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     12\u001b[0m display(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mBest Parameter C = 1/λ : \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mlog_model\u001b[38;5;241m.\u001b[39mbest_params_\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m     14\u001b[0m \u001b[38;5;66;03m# y_pred\u001b[39;00m\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\base.py:1473\u001b[0m, in \u001b[0;36m_fit_context.<locals>.decorator.<locals>.wrapper\u001b[1;34m(estimator, *args, **kwargs)\u001b[0m\n\u001b[0;32m   1466\u001b[0m     estimator\u001b[38;5;241m.\u001b[39m_validate_params()\n\u001b[0;32m   1468\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m config_context(\n\u001b[0;32m   1469\u001b[0m     skip_parameter_validation\u001b[38;5;241m=\u001b[39m(\n\u001b[0;32m   1470\u001b[0m         prefer_skip_nested_validation \u001b[38;5;129;01mor\u001b[39;00m global_skip_validation\n\u001b[0;32m   1471\u001b[0m     )\n\u001b[0;32m   1472\u001b[0m ):\n\u001b[1;32m-> 1473\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfit_method\u001b[49m\u001b[43m(\u001b[49m\u001b[43mestimator\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_search.py:1018\u001b[0m, in \u001b[0;36mBaseSearchCV.fit\u001b[1;34m(self, X, y, **params)\u001b[0m\n\u001b[0;32m   1012\u001b[0m     results \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_format_results(\n\u001b[0;32m   1013\u001b[0m         all_candidate_params, n_splits, all_out, all_more_results\n\u001b[0;32m   1014\u001b[0m     )\n\u001b[0;32m   1016\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m results\n\u001b[1;32m-> 1018\u001b[0m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_run_search\u001b[49m\u001b[43m(\u001b[49m\u001b[43mevaluate_candidates\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   1020\u001b[0m \u001b[38;5;66;03m# multimetric is determined here because in the case of a callable\u001b[39;00m\n\u001b[0;32m   1021\u001b[0m \u001b[38;5;66;03m# self.scoring the return type is only known after calling\u001b[39;00m\n\u001b[0;32m   1022\u001b[0m first_test_score \u001b[38;5;241m=\u001b[39m all_out[\u001b[38;5;241m0\u001b[39m][\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtest_scores\u001b[39m\u001b[38;5;124m\"\u001b[39m]\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_search.py:1572\u001b[0m, in \u001b[0;36mGridSearchCV._run_search\u001b[1;34m(self, evaluate_candidates)\u001b[0m\n\u001b[0;32m   1570\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_run_search\u001b[39m(\u001b[38;5;28mself\u001b[39m, evaluate_candidates):\n\u001b[0;32m   1571\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Search all candidates in param_grid\"\"\"\u001b[39;00m\n\u001b[1;32m-> 1572\u001b[0m     \u001b[43mevaluate_candidates\u001b[49m\u001b[43m(\u001b[49m\u001b[43mParameterGrid\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mparam_grid\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_search.py:995\u001b[0m, in \u001b[0;36mBaseSearchCV.fit.<locals>.evaluate_candidates\u001b[1;34m(candidate_params, cv, more_results)\u001b[0m\n\u001b[0;32m    988\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(out) \u001b[38;5;241m!=\u001b[39m n_candidates \u001b[38;5;241m*\u001b[39m n_splits:\n\u001b[0;32m    989\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[0;32m    990\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcv.split and cv.get_n_splits returned \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    991\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124minconsistent results. Expected \u001b[39m\u001b[38;5;132;01m{}\u001b[39;00m\u001b[38;5;124m \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    992\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124msplits, got \u001b[39m\u001b[38;5;132;01m{}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;241m.\u001b[39mformat(n_splits, \u001b[38;5;28mlen\u001b[39m(out) \u001b[38;5;241m/\u001b[39m\u001b[38;5;241m/\u001b[39m n_candidates)\n\u001b[0;32m    993\u001b[0m     )\n\u001b[1;32m--> 995\u001b[0m \u001b[43m_warn_or_raise_about_fit_failures\u001b[49m\u001b[43m(\u001b[49m\u001b[43mout\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43merror_score\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    997\u001b[0m \u001b[38;5;66;03m# For callable self.scoring, the return type is only know after\u001b[39;00m\n\u001b[0;32m    998\u001b[0m \u001b[38;5;66;03m# calling. If the return type is a dictionary, the error scores\u001b[39;00m\n\u001b[0;32m    999\u001b[0m \u001b[38;5;66;03m# can now be inserted with the correct key. The type checking\u001b[39;00m\n\u001b[0;32m   1000\u001b[0m \u001b[38;5;66;03m# of out will be done in `_insert_error_scores`.\u001b[39;00m\n\u001b[0;32m   1001\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mcallable\u001b[39m(\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mscoring):\n",
      "File \u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_validation.py:529\u001b[0m, in \u001b[0;36m_warn_or_raise_about_fit_failures\u001b[1;34m(results, error_score)\u001b[0m\n\u001b[0;32m    522\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m num_failed_fits \u001b[38;5;241m==\u001b[39m num_fits:\n\u001b[0;32m    523\u001b[0m     all_fits_failed_message \u001b[38;5;241m=\u001b[39m (\n\u001b[0;32m    524\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124mAll the \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mnum_fits\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m fits failed.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    525\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mIt is very likely that your model is misconfigured.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    526\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mYou can try to debug the error by setting error_score=\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mraise\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    527\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mBelow are more details about the failures:\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;132;01m{\u001b[39;00mfit_errors_summary\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    528\u001b[0m     )\n\u001b[1;32m--> 529\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(all_fits_failed_message)\n\u001b[0;32m    531\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m    532\u001b[0m     some_fits_failed_message \u001b[38;5;241m=\u001b[39m (\n\u001b[0;32m    533\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;132;01m{\u001b[39;00mnum_failed_fits\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m fits failed out of a total of \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mnum_fits\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    534\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mThe score on these train-test partitions for these parameters\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    538\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mBelow are more details about the failures:\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;132;01m{\u001b[39;00mfit_errors_summary\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    539\u001b[0m     )\n",
      "\u001b[1;31mValueError\u001b[0m: \nAll the 50 fits failed.\nIt is very likely that your model is misconfigured.\nYou can try to debug the error by setting error_score='raise'.\n\nBelow are more details about the failures:\n--------------------------------------------------------------------------------\n50 fits failed with the following error:\nTraceback (most recent call last):\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\model_selection\\_validation.py\", line 888, in _fit_and_score\n    estimator.fit(X_train, y_train, **fit_params)\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\base.py\", line 1473, in wrapper\n    return fit_method(estimator, *args, **kwargs)\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\linear_model\\_logistic.py\", line 1223, in fit\n    X, y = self._validate_data(\n           ^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\base.py\", line 650, in _validate_data\n    X, y = check_X_y(X, y, **check_params)\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\validation.py\", line 1301, in check_X_y\n    X = check_array(\n        ^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\validation.py\", line 1012, in check_array\n    array = _asarray_with_order(array, order=order, dtype=dtype, xp=xp)\n            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\sklearn\\utils\\_array_api.py\", line 751, in _asarray_with_order\n    array = numpy.asarray(array, order=order, dtype=dtype)\n            ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n  File \"C:\\Users\\Eugenia\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.12_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python312\\site-packages\\pandas\\core\\generic.py\", line 2150, in __array__\n    arr = np.asarray(values, dtype=dtype)\n          ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\nValueError: could not convert string to float: 'No Documents'\n"
     ]
    }
   ],
   "source": [
    "# Model\n",
    "log = LogisticRegression(max_iter = 2000 , solver = 'saga', random_state = 42)  \n",
    "\n",
    "# Hyperparameters CV\n",
    "penalty = [\"l1\",\"l2\"]\n",
    "C = [0.1, 1, 10, 100, 1000] # C = 1/λ = Positive float. Default = 1.0 Inverse of regularization strength. Like in SVM, smaller values --> stronger regularization --> smaller coefs.\n",
    "param_grid = {\"penalty\" : penalty, \"C\" : C}\n",
    "log_model = GridSearchCV(log , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "log_model = log_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter C = 1/λ : {log_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_log_l1 = log_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, log_model, X_test0, y_test0, y_pred_log_l1, \"Ridge Logistic Regression (L1)\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2. Elastic Net Logistic Regression"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter l1_ratio : {'l1_ratio': 0.2}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Elastic Net Logistic Regression (L1 + L2)\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "83.19%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.90      0.79      0.84      3118\n",
      "  TERMINATED       0.76      0.89      0.82      2338\n",
      "\n",
      "    accuracy                           0.83      5456\n",
      "   macro avg       0.83      0.84      0.83      5456\n",
      "weighted avg       0.84      0.83      0.83      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "log_el = LogisticRegression(max_iter = 2000, random_state = 42, penalty = 'elasticnet', solver = \"saga\")   \n",
    "\n",
    "# Hyperparameters CV\n",
    "l1_ratio = np.linspace(0.1, 1, 10, endpoint = True) # l1_ratio = ratio between l1 and l2. l1_ratio = 1 = l1 / l1_ratio = 0 = l2 / 0 < l1_ratio < 1 = elastic net\n",
    "param_grid = {\"l1_ratio\" : l1_ratio} \n",
    "log_el_model = GridSearchCV(log_el , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "log_l2_model = log_el_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter l1_ratio : {log_el_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_log_el = log_el_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, log_el_model, X_test0, y_test0, y_pred_log_el, \"Elastic Net Logistic Regression (L1 + L2)\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. LDA - Linear Discriminant Analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Linear Discriminant Analysis (LDA)\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "83.39%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.93      0.77      0.84      3118\n",
      "  TERMINATED       0.75      0.92      0.83      2338\n",
      "\n",
      "    accuracy                           0.83      5456\n",
      "   macro avg       0.84      0.84      0.83      5456\n",
      "weighted avg       0.85      0.83      0.83      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABU0AAAHyCAYAAADfte/mAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8g+/7EAAAACXBIWXMAAA9hAAAPYQGoP6dpAADj6UlEQVR4nOzdd1gUV9sG8HtoS5Hee7GAYm+IxoIxYoklltiVoDEmGqPmjS1GsURNTGzR6JtYSN5oNE1ji8ZgN9hjYgULRVQQRHrfne8PPiasFFl2YVe5f9c1lzNnzpx9ZkFgnj1FEEVRBBEREREREREREREBAPS0HQARERERERERERGRLmHSlIiIiIiIiIiIiKgUJk2JiIiIiIiIiIiISmHSlIiIiIiIiIiIiKgUJk2JiIiIiIiIiIiISmHSlIiIiIiIiIiIiKgUJk2JiIiIiIiIiIiISmHSlIiIiIiIiIiIiKgUJk2JiIiIiIiIiIiISmHSlIiIqA4JCQmBIAhKm0wmg5+fH8LCwpCXl1du3efN/fv3ERISAkdHRxgbG6NJkyZYtWoVFAqFRl8nNjZWeo+6detWYb3n+b0srfT3jb6+PszNzVG/fn0MGjQI+/btK1M/LCxMqh8bG1ursXp5eT3z66ILbaorNjYWYWFhCAsLw+XLl1W69tSpU0pf09mzZ9dMkOUoec2QkJAaab8mvlbTpk2DIAgYMmSIVFb6ezw8PPyZ8ZT83zEzM4OXlxf69u2Lbdu2QS6XV3jthAkTlL5ON2/eLFPniy++gCAIaN26NURRVOs+iYiIqBiTpkRERHVcQUEBoqKisHDhQgwYMEDb4ajt0aNH6NixI7755hs8evQI+fn5uHHjBmbMmIHJkydrO7wXhkKhQFZWFu7evYtdu3ahX79+GDlyJIqKirQdWp0SGxuLhQsXYuHChSonTXfs2KF0vHPnTg1G9mKJi4vDhg0bAACzZs1Sqy2FQoGcnBzExcXhwIEDGD16NHr27ImMjIwydQsLC/HLL78olT39dQOA8ePHw9bWFn/99Rd++OEHteIjIiKiYkyaEhER1VFHjx6FQqHApUuX4ODgAAD4/fffcfToUS1Hpp6wsDDEx8cDADZv3oxHjx7h1VdfBQBs3LgR586dq/WYwsPDIYqizvcAE0VRqbdxRTw9PSGKItLT0/Hrr7/Cx8cHAPD9999j7ty5Ur2wsDDpvr28vGoqbCW5ubkAipOJoiji2LFjGmu7JtrUFrlcjp9++kmpLDY2FmfOnNFSRJql6a/V+vXrUVBQgKZNm6Jdu3ZqtSWKIrKzsxEREYFWrVoBAI4cOYIJEyaUqfv777/jyZMnSmXlJbdNTU0xdOhQAMDq1avVio+IiIiKMWlKRERUhwmCgFatWmH48OFS2YULF8rUu337Nvr27QszMzP4+PiUeSj/7rvvEBQUBBcXF8hkMpiamqJFixZYuXKl0rDT7OxsvP/++6hfvz5MTExgZWWFZs2aYcKECVKyCwASExPxzjvvwMvLC0ZGRrC3t8eIESNw+/btSu9HoVBg+/btAABfX1+EhobC3t5eKZG3bds2ld4jTShveH7pYb0nT57E4MGDUa9ePbi5uWHu3LllhutevHgRgwYNgr29PYyMjODt7Y3//Oc/yMrKkuqkpaVh1KhRaNy4MaysrGBoaAgnJycMGTIE165dU2qv9PDlnTt3okmTJjAyMsLBgwerfF8WFhbo378/9uzZA319fQDA2rVrkZKSUuYeS4bnV/V74NGjR3jvvffQoEEDyGQy2NjYoEuXLlLSOzw8XGr7p59+wujRo2FlZYWOHTuWub8S3bp1gyAI8PLywh9//IFmzZrBxMQEQUFBuHv3LuLi4tC7d2+YmZnB19e3TI++Z7V58uRJdOjQASYmJvDz8ytz/cqVK9GxY0c4OjrCyMgI5ubmCAgIwNatW5XqVfV7IyQkBEFBQdJ1b7zxRpWnQzh27BiSkpIAAGPHjpXKn4752LFjUpsbN27E+++/D0dHR1hbW+P111/H48ePpbp3797F0KFD0aBBA1hYWMDIyAju7u4ICQnBvXv3Ko2nc+fOEAQBHh4eStNo/PLLL0pfZwD4448/EBQUBHt7e8hkMri6uqJXr17YvXu3dF15X6uLFy/i1VdfhZOTE2QyGZycnBAUFIRNmzZVGptCocA333wDAEpD89VhamqK7t2749ChQ7CwsAAA/Pjjj7hy5YpSvZKvhyAIGD16NADg5s2b5fYqLontzJkziIqK0kicREREdZpIREREdca4ceNEACIA8ejRo1L5u+++K5V/+umnZeo6ODhI+yXboUOHym336e3DDz+U6k2aNKnCesnJyaIoiuL9+/dFV1fXcutYW1uLUVFRFd7frVu3pLoDBgyQylNTU6Xyl156SUPvpijGxMRI7Xbt2rXCeqXfnxILFiyQyiwtLcvc63//+1+p7u+//y4aGRmV+560adNGzM3NLRPP05uNjY2YlJQktenp6SkCEK2srERBEKR6u3btqvA+Sup4enqWOde7d2/p/M6dO8vcY0xMjCiKVf8ecHd3L7fO1q1bRVEUxa1btyrdW8l+ixYtlO6v9Nela9euIgDRzMxMNDY2Vmq3adOmYv369ZXK9PT0xBs3bpR5z8pr08TEpMzX6OnrS+qWt3399dcqf29U9v+u5P2uyIQJE6S6N27cEBs2bCgCEF1cXES5XC7VO3r0aKWxjBgxoty6T28+Pj5iXl5eme+lcePGiaIoit9//71UdvDgQaneiBEjpK9xfn6+GBsbW+ZrV7JNnjy5wq9VVlaWaGtrW+51ffv2rfS9+vvvv6W6pX/uPf21KvneLE9JPKV/BpR4++23pXOffPKJVJ6bmyuam5uLAMSAgADx9OnTUr1Zs2aVaSczM1PU09MTAYjr1q2r9J6IiIjo2djTlIiIqI67fPmyUu+yNm3alKnTtm1bJCUl4bfffpPKfvzxR2k/JCQEly5dQmpqKgoLCxEbG4vWrVsDKB7WKv7/sPRTp04BAIYOHYqsrCw8efIE586dw/z58yGTyQAA8+fPx/3792FpaYnjx48jLy8Ply5dgo2NDZ48eYIPP/ywwntJTk6W9kt6bz29/+jRo6q9MbWoYcOGiIuLw6VLl2BsbAxA+f195513UFBQgNatW+PWrVvIy8vD//73PwDFvec2b94MALC2tsbPP/+Me/fuIS8vD1lZWfj6668BAKmpqVIv3NLS0tIwfvx4PHr0CA8fPkRgYGC17qFRo0bSfmW9HKv6PVDSM3H48OGIj4/HkydPsHv3btSvX79Mm3p6ejhy5Aiys7Px/fffPzPW7OxsTJs2Denp6dKQ5qtXr6KgoAC3b9/Grl27ABT3MPz555+rdP+5ubkYO3YsUlNT8d///rfc62fOnImrV68iLS0NBQUFuHHjBtzd3QEA69atK7fdyr43wsPDlabT2Lp1a5WmQyg9T2ajRo3g5+eH/v37AwAePHiAEydOlHudnp4eTp06hcTERDRt2hQA8PPPP0s9Q+vXr4/9+/fj4cOHyM/PR1paGhYsWACguBdq6Z8fTxs8eDCcnJwAAFu2bAEA5OfnSwuMjRgxAkZGRrhw4YI0hcT58+eRn5+PuLg4bN++HS+99FKF7d+8eVPqFfvzzz+joKAACQkJ+PXXX9GvX78KrwOAS5cuSfv+/v6V1q2Oiv7vHDhwAJmZmQCAAQMGoEOHDtJUKuUN0a9Xrx68vb0BFP9cICIiIvUwaUpERFRHBQUFScPzS5KNQUFBSsN9S6xYsQIODg7o1auX9NBeMm8oADg5OWHp0qVo0qQJjI2N4eXlJSUa0tLSpESlp6cnAOD06dNYsmQJ9u3bBzMzMyxcuBDm5uYAihMFAJCeno6uXbvC2NgYrVu3RmpqKoDiuf9UVZK0BaCTK9gvXLgQHh4eaNWqFZo3bw7g3/c3Ojpampbg0qVLaNiwIYyNjTFmzBjp+pL3xNLSErGxsejfvz9sbW1Rr149vPnmm1K98obsWllZ4YsvvoC9vT2cnJzg6OhYrXsoPaS6svdYle8BS0tLbNmyBe7u7rCyssKAAQPQuXPnMm2+//77CAoKgqmpKRo3bvzMWA0NDTF//nxYWFgofb+HhISgfv366NOnj1RW+vu8Mvr6+vj8889hbW2t9LUpfb2NjQ1mzpyJBg0awNjYGI0bN5aSwxUNp67se6O6Dh8+LP1/GjhwIAAoLQJX3kJDQPEq7p06dYKjo6P0HhUUFEjD/B0dHREZGYnu3bvD0tISVlZWWLhwoXR9ZUPGDQ0Npe/VX3/9FampqTh06JCUNAwJCQHw7/cPACxduhTr16/HzZs38eqrrypNM/I0V1dXaQqJ9evXY9WqVbh8+TI6deqEt956q8LrAOUPWmxtbSutWx0V/d8p/XUYOHAg9PT0pPmZK5p/1s7ODgCkrwkRERFVH5OmREREdZyRkREaNmyIuXPnYt++feUmvBo2bCjtl/R2y8/PBwBkZGSgZ8+e+Omnn5CYmFhmLk7g38V5PvvsMzRr1gwPHjzA8uXLMWbMGPj7+6N9+/ZIS0sDoNxbtDwlyZ7y2NvbS/vp6enSfkni5ek6Tys9f2PJFh4eXmk8mlDZ+/us9wP49z1ZtWoV3n//ffz111/Izs4uU6/0nKElGjVqJL2mOqKjo6X9yno5qvI94OnpCRMTk2e+dosWLVSK1cHBQWq3dPseHh4Aiv9PlCj5OjyLo6Oj1KO59PtZcn1cXByCg4Nx4MABpKSkKCXKAFS4AFdl3xvVVToZ5+fnh6tXr8LCwgL16tUDUNwTs6ioqEqxlI7ngw8+wJIlS3Djxo1y76e877/S3nrrLRgYGCA/Px/fffedNIepv78/2rZtC6C41/uHH34IExMT7Nq1CzNmzEBwcDAcHR0rnZvUyckJa9euhaWlJY4cOYJZs2ZJ85uWTuxqQ3n/d7Kzs7F//34AgLOzM+RyOa5evarU07W85PbT31dERERUfUyaEhER1VFHjx6FKIrIz89HdHQ0Pv74Y5iampZb19DQUNp/Oql65swZqbfcmDFjkJaWBlEUMXjw4DLt+Pn54Z9//sGdO3ewd+9ehIWFQV9fH+fPn8f69esB/JvU9PX1lYYal94qSwr4+PjAysoKgHKvtps3b0r7JdMG6JLK3t/SSd633nqr3PekpKdpybBtY2NjnD17FkVFRWUWlnlaVZKSz3Lt2jX88ccf0mt37969wrqqfA/ExcVVmExU5x4MDAxUKq+Kyr6GAHDo0CFkZGQAAGbPno3s7GyIoljudBiqtKtqz+n8/Hz8+uuv0nFoaCiaNWuGli1bSouKpaSkSF9PVWIp+f5zcnLCjRs3oFAosHfv3irH5urqKvV4/eqrr6Rrx40bp1RvyZIlSElJwenTpxEeHo7AwEDk5uZi6tSp5SZ7S7zzzjtITk7GuXPnsG3bNvTt2xdFRUVYuHAhEhISKryupHc9AKWFrzQhOTlZadqM3r17AwD27NmDnJwcAMDDhw/RrFkzNGvWDO+//75U98cffyzz87Akvur2GCciIqJ/MWlKREREaind683ExARGRkY4fPiwNMS6tE8//RS7du2CgYEBevbsiaFDh0o91kp6F5YkDaKiohAWFoYnT54gJycHkZGRmDx5Mj755JMKY9HT08OIESOk67du3Yrk5GQsXbpUqjNq1KgKr+/WrVuZhGTJsOBnSU1NxcGDB5W2kpXe1dGoUSNpHs9vvvkGu3btQk5ODlJTU7Fv3z70799fmoOy5GshCALMzc2RlpaGsLAwtWOoSGZmJvbu3Yv+/ftLPYzfe++9SocwV+V7oG/fvgCKewtPmDABCQkJyMjIwL59+yqcb1PXlf5/YmZmBkEQsG3bNqX5MqvD2tpa2r9+/Xq5Pb1LO3DggJS8rUxFQ/QrU3KP+vr6MDc3x/379yv9/1qeyZMnAyhOxKelpUFfX19aNR4Arly5gsWLFyM6Ohr+/v4YMmQIWrZsCaC4J2vpXuWlJSUlYfbs2bh06RJ8fHwwePBgdOzYEUDx9B0pKSkVxlT6g5arV69WWO/KlStlfgbcv3+/3Lq5ubk4evQoevXqJcU8bNgwaa7Yqrz/T88/m5WVJc2J+qxkPBERET0bk6ZERESklk6dOsHGxgZAce8wU1NTBAcHw9nZuUzdAwcOYNCgQfD09IRMJoO/v780jDw4OBgAsGjRIri6ugIons/RxsYGZmZm6NixI7788stn9jwMCwuThlmHhobCwcFBWkxm0qRJaN++vWZu/ClXrlxB7969lbaZM2dqpO0NGzbA0NAQeXl5GDRoEMzMzGBra4t+/fph79690pytJQva5ObmokmTJrCzs8Ply5c1EkNpcXFxEAQBFhYW6N+/P+7evQsAGDlyJJYsWVLptVX9HihZIGnbtm1wd3eHpaUl+vXrJ73W8yY4OFga9v/RRx/B1NQU48ePh4uLi1rtNmjQQEqcrlixAgYGBnBzc6uwfulk3PHjx5U+ICgsLJR6+e7evVvlaQBKvv/u378PNzc3uLu74+HDhyq1ERQUhCZNmkjHPXv2VPpZ8vjxY8yfPx+tWrWClZUV6tWrhw0bNgAAAgIClJLIpeXm5uKTTz5Bhw4dYGdnB2NjY2lROXd3d6XXfFrTpk2lnpuRkZEV1lu5cmWZnwGHDx8uU08QBJiamqJ79+5S0vzll1/GV199BaD4w4KDBw8CKO49//QHObt375baKv31PHPmjNTztEePHhXGSURERFXDpCkRERGpxcbGBnv37kW7du1gbGyMhg0b4n//+1+5C/aEhISgZ8+ecHFxgZGREWxsbBAYGIgdO3ZIPUxdXV1x4cIFvPPOO/D09IShoSHs7OzQtm1bzJs3D2PHjq00HgcHB/z5558YO3Ys7O3tYWRkhMaNG2PlypXS8O/nzSuvvILIyEgMGjQI9vb2MDQ0hKurK7p37441a9ZIPeHmzJmDadOmwcHBAfXq1cOQIUOqtJp8dQiCADMzM/j4+GDQoEHYt28ftm3b9swh7lX5HnB2dsaFCxcwdepU+Pj4wMjICFZWVujcuXOlyS1d1qhRI/z4449o0qQJZDIZmjdvjj179qBBgwZqtWtqaor//e9/8Pf3V5qLtTzZ2dnSBwienp5l/o8aGBhg6NChAIoTd5Wtdl+e1atXY+zYsbCxsYG1tTUmTpyItWvXqtQGALz99tvS/tM9vRs0aICJEyfC398flpaWkMlk8PLywsSJE5WSiU+ztbXF1KlT0apVK1hbW0v/h0aOHIk//vij0vdOT09PmiKgZJ5VdQiCABMTE3h6eqJPnz7Yvn07Dh06JM2Ju2vXLhQUFAAov2d87969peRw6flnS2ILDAyEr6+v2nESERHVdYJYejlZIiIiIiIiLZo3bx4+/vhj2NnZISEhATKZTNshIS4uDo0aNUJBQQHOnj1bYz3WqysnJwfu7u5ITU3Fzp078frrr2s7JCIioucee5oSEREREZHWzZkzB56envj4448BANOnT9eJhClQ3DO3pAfsp59+quVoytq8eTNSU1PRqlUrqbcwERERqYc9TYmIiIiISOtCQkLwzTffwNbWFqNGjcLKlSuhr6+v7bCIiIiojmLSlIiIiIiIiIiIiKgUDs8nIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyIiIiIiIiIiIqJSmDQlIiIiIiIiIiIiKoVJUyLSWbdv30aPHj1gYWEBQRDQrVs3jbUdGxsLQRAgCAKOHTumsXafN+Hh4dL7QERERERERETFmDQlegGdOHECffr0gb29vZQQ27hxo1ptpqWlISwsDC1btkS9evVQr149+Pv7Y8aMGUhOTtZQ5Mref/99REREoLCwEO3atUOTJk001rZMJkNAQAACAgJgYWGhsXafpeTrIQgCpk6dqnTuwIEDSucPHjyoUtshISEqJ5ft7e2l94GIiIiIqK77/PPP0a1bNzg7O0Mmk8HT0xPjxo3D3bt3q9Wel5eX0t/4hoaGcHd3R2hoKFJSUsrUP3PmDIYMGQJnZ2cYGRnBzs4OvXv3xm+//VZu+5cuXcLo0aPh4eEBmUwGR0dHdOvWDZs2bXpmbLdu3cJbb72F+vXrw9jYGLa2tujQoQOWL19erXsletEIoiiK2g6CiDRr9erV+OCDD+Dj44Po6GgAwIYNGzBp0qRqtRcbG4tu3bohLi4OAGBjYwMXFxfcvXsXOTk5OHr0qEZ7gZZo0KAB7ty5g9mzZ2PZsmUab18bSvfotLCwwP3791GvXj0AQO/evZUSpb/99ht69epV5bZDQkLwzTffoGvXrlXqPVtQUAAjI6OqB09ERERE9ILz8vJCfHw8fH19kZ+fj5iYGACAk5MToqKiVO5w4eXlhbi4OJibm6NJkyZ4+PAh4uPjAQB9+/bFvn37pLrh4eGYMGEC5HI5jIyM0KBBA8TGxiInJwcAsGjRInz00UdS/U2bNmHSpEmQy+UQBAHe3t4Aip/f3N3dERsbW2FcBw4cwNChQ6W23dzcYGZmhjt37qCoqAiaSBXxeYOed+xpSvQCGjNmDDIyMnDo0CGNtDd69GgpYbpmzRqkpKTgypUryMzMxJ49e+Dk5CTV3bp1K9q0aQMTExOYmZmhU6dO+PXXX6XzpYfFh4eH49VXX4WpqSm8vb2xefNmpTp37twBACxfvhyCICAkJATHjh2Tri/9R0DpNgEgKysLb7/9Ntzd3SGTyWBvb49OnTrhm2++KRNH6QTjqVOnEBwcDEtLS8hkMjRu3BgrVqyAXC6X6pR8Wjxr1ixMmTIFtra2cHBwwHvvvYeioqIqvaeGhobIyMiQ4rl16xYOHToEQ0PDMnUTEhLQp08fuLu7w8TEBCYmJmjatClWr14t/THj5eUltXX8+HGleyv9nv34449o3749jIyMsH379jLD8y9evAgjIyMIgiC199dff8HQ0BCCIGDLli1Vuj8iIiIioufRm2++idjYWNy4cQN3797FtGnTAACJiYmIiIiodrutW7fGmTNnEBcXh86dOwMo/ru9xIMHD/D2229DLpejQYMGuH37Nq5du4aEhAR06NABADB//nxcvHgRAHDz5k0pYerp6Ym//voLd+7cwZ07d5CSkoK5c+dWGEtKSgpGjBiBnJwcWFtb4+jRo7h37x5u3ryJ9PR0rF27Vqr79HMWAHTr1k16PgOUn602bdqEl19+GcbGxpg/fz6srKwgCALWrFkjXX/nzp0yo+sePHiA0NBQuLi4wMjICD4+Pli8eHGVn6+IagKTpkQvIFtbW5iYmGikrWvXruH06dMAgP79+2Pq1KlSgk1PTw/9+vWDn58fAGDJkiUIDQ3FpUuX4ODgAAsLC/z5558YOHAgvvvuuzJtT5w4EdeuXYOhoSFiY2MxceJE3Lx5Uxo6X/KppKurKwICAlC/fv0qxz1//nxs3LgRycnJ8Pf3h7m5Oc6ePYujR49WeM2xY8cQFBSE33//Hfr6+vD09MTNmzcxc+bMcnvprlq1Ct9//z1MTEyQnJyMtWvXYuvWrVWK77XXXoOenh7WrVsHURSlf4cMGVKmbkpKijQcp3HjxrCwsMC1a9cwffp0fPnllwCAVq1awc7ODgBgbm5e4dQDo0ePRkJCAry9vcudx7RNmzZYsGABAGDGjBlISEhAaGgoioqK8NprryE0NLRK90dERERE9Dz68MMP4eHhIR2XJDiB4im+NKn06/z444/Iy8sDAMybNw/u7u4AAGtra6VRdyXPVZs3b5Y6dqxatQotWrSQ6lhbW2PixIkVvu7OnTuRkZEBAPjoo4+URg2ampri3XffrfY9TZ48GX///Tfq168PMzMzDBs2DACwY8cOpdcHABcXF7zyyit4/PgxOnTogK1btyIrKwuNGzfGvXv3MH/+/Ervg6imMWlKRJW6fv26tN+lS5cK62VnZ2Pp0qUAihOCMTExiI2NRfv27QEU/+J/2oABA3D37l2cPHkSAKBQKHDs2DE4OzvjzJkzcHZ2BgBMmDABZ86cURqK8iy3bt0CUPxHwKVLl3D37l08evQI06dPr/CaBQsWoKioCJ6enrh79y6io6Px3nvvASj+o+TpeYzc3Nxw9+5d3L59Gy4uLgBQ5U+fvb290bdvX9y8eRO7du1CeHg4rK2tMXr06HLrxsTE4N69e7h06RIePnwofS1K/vjYtWsX+vbtC+DfT7HPnDmD1q1bK7U1ZMgQJCQkICoqqtzXAoDZs2ejY8eOSE1NRdu2bXH58mU4Ozvj66+/rtK9ERERERG9CORyOb766isAgI+PD15++eVqt3Xp0iV06NABXl5eOHnyJNzc3KS2ASAqKkrab9mypdK1pY9L6lX1Oa086lz7LIGBgUhISMC1a9cwd+5cjBs3DgCkXrbAv0nT0aNHQ19fH+vWrcO9e/fg6OiIO3fu4O+//8ZPP/0EoHjKgtu3b2s0RqKqYtKUiCpVei6bylZYv3btGnJzcwEAw4cPh56eHmQyGQYPHgwAiIuLK7Ng1KhRoyAIgtICT0lJSRqJu1+/fgCKk6aenp4IDg7GF198AUdHxwqvOX/+PACgT58+sLKyAgCMHDkSQPH7UDIUpkT//v1haWkJY2Njaf4gVeIv+QT3jTfeQEZGBkJDQ2FqalqmnoGBAT799FN4enrC0NAQ+vr6OHHiBIDiYSyqePfdd6GnV/yjX19fv9w6+vr6+N///gczMzPpfrZs2QJbW1uVXouIiIiI6HmVnZ2N1157DYcOHYKTkxP27t2rVk/TzMxMnD17Vkoctm3bFq1atSq37tPPXSV/v5dW1ee08qhz7bNMmjQJxsbGAIqfKzp27IiGDRsCKE6W3rx5E//88w8ASMP7z507B6D4WcrBwQGCIGDgwIFSrGfPntVojERVxaQpEVXK399f2i/pEaopJYlJAwMDqexZE46X/qVeMhwlPT29TL2JEyfi+PHjmDFjBvz8/HDx4kWEhYWhR48eGoi8WEn8wL/3oMqE6T169ICfnx8yMjKgp6eHyZMnl1tv2rRp2LBhA+Lj4+Ht7Y2AgABpKH7puVarorKkcWlJSUnS8CAA/HSXiIiIiOqMxMREdO3aFXv37kWjRo1w+vRppY4e1dG1a1cUFhZK6wbs3r0bc+bMkc77+vpK+3/99ZfStaWPS+qp85xWnWtLP3eU9/xVorznjbFjxwIoTpqW9DJt164dGjdurFSv9DRjpbfyOpYQ1QYmTYnqsJdffhl+fn5Kv6yf5u/vj44dOwIo/sW+fv166Zwoivjpp59w48YN+Pv7S/Oo7ty5EwqFAvn5+fjll18AAJ6enrC3t1c7ZgcHB2k/OjoaQPH8P087d+4c/P398dlnn+HQoUPSqpTXrl3D48ePy227Xbt2AIpXkkxLSwMAfP/99wCKk7Vt2rRRO/7SBEHAlClTABSvnFnSW/VpZ86cAQD07NkT0dHROHbsGFxdXcvUK/ljIjs7u9LXfJasrCyMGTMGcrlcGgo0c+ZMpSFDREREREQvomvXrqFDhw64ePEiOnfujMjISPj4+JSpV5VnqacZGBhg7NixGDRoEABg48aNuH//PoDiabRKerIuWbIECQkJAIC0tDTMnj1baqNkiq3Q0FBp5Nj06dNx5coVqU5qairWrVtXYRzDhg2T1j5YtGiRNIoNKH6W+Oyzz6TjkuevkmevmzdvKr3W08p73hgzZgwEQcClS5ewceNGAP/2MgX+fQ4zMDDAjh07pKnGDh8+jHfeeQevvfZaha9HVJOYNCV6Af3yyy9o0KCB0oTe8+fPR4MGDTBq1Cip7M6dO4iKisLDhw8rbW/btm3w9PQEAGm1+ObNm8PS0hJDhw5FUlISzMzMpBUaf/nlF3h7e8PLy0saSrFkyRKN3FvDhg2lCdNHjhyJoKCgcntorl27Fk5OTvD29kabNm0QHBwMoHhRKRsbm3LbXrhwIQwMDBAXFwcfHx80atQIq1evBgCMHz++3D+W1DVp0iQkJydLn7iWp3nz5gCA33//Hb6+vnB3d8e9e/fK1CtZkOvChQto1qwZOnToIE2ZoIpp06bhzp07qF+/Pk6dOoXevXsjNzcXo0eP5uqVRERERPRCGzRokDSEPjMzE3369EGHDh3QoUMHbNq0SapX1Wep8pQkWgsKCqQEpaurKzZs2AA9PT3cvn0b9evXR9OmTeHq6ip1oli4cKHUkaNx48bYuHEj9PX1ERMTg5YtW6JBgwZo2LAhHB0dlRKfT7Ozs8P27dthamqK1NRUdO3aFR4eHmjSpAlsbGzwwQcfSHVL5nH9/PPPERQUhMDAQJVG1wHFHWhKnk0TExMhk8kwfPhw6fzkyZPh6uqKJ0+ewNfXFy1btkT9+vVha2srzYlKpA1MmhK9gDIyMnDnzh3plz0AJCcn486dO9Inmarw8vLC5cuXMX/+fDRv3hx5eXm4c+cOnJ2d8d5770nDO+bNm4fNmzejdevWePToEdLT0xEYGIjdu3dXuOiQqgwMDLBz5060atUKeXl5SE1Nxa5du8rU69u3Lzp37ozc3FxcuXIFxsbG6NevHw4cOFBhb8tu3brh6NGjeOWVVyCXyxEbGws/Pz988skn0ieimqavrw87Ozupl255Vq5ciQEDBqBevXrIzMzEBx98IM3ZWlpoaCgGDx4MS0tLXL16FWfPnlV5+P6vv/6KzZs3QxAEbNmyBWZmZvj6669hZWWFCxcuYNGiRSrfIxERERHR8yI/P1/av3z5Ms6ePSttJb0/1dW2bVspGfnVV18hJSUFQPFaB6dOncKgQYNgbW2NqKgoGBsbIzg4GPv378f8+fOV2pkwYQLOnj2LkSNHwsXFBfHx8Xjy5AkCAgLw4YcfVhpD37598ddff+HNN9+Et7c3kpKS8PDhQzRr1kxa4Bcofhbp27cvTExMcOfOHcydOxcvvfSSyvdcOvnZr18/pY4s9vb2OHPmDN544w3Y2tpK62V07twZq1atUvm1iDRFEFX9iICIiIiIiIiIiIjoBcaepkRERERERERERESlMGlKREREREREREREVAqTpkRERERERERERESlMGlKREREREREREREVAqTpkRERERERERERESlMGlKREREREREREREVIqBtgMg7VIoFHjw4AHMzc0hCIK2wyEiolokiiIyMzPh4uICPT3tf46al5eHgoICjbRlZGQEY2NjjbRFRETqOXHiBFasWIGLFy/i4cOH2LVrFwYOHFjpNceOHcOMGTNw7do1uLu7Y968eQgJCanya/I5h4io7tLUcw6TpnXcgwcP4O7uru0wiIhIi+7duwc3NzetxpCXlwdvz3pIfCTXSHtOTk6IiYlh4pSISAdkZ2ejRYsWCA0NxaBBg55ZPyYmBn379sWkSZOwbds2REREYMKECXB2dkZwcHCVXpPPOUREpO5zjiCKoqjBeOg5k56eDisrK8Rd8oJFPe33MiLShj7vjtN2CERaUVSUh/MRy5CWlgZLS0utxpKRkQFLS0vEXPSEhbl6v48yMhXwbhOH9PR0WFhYaChCIiLSBEEQntnTdNasWdi/fz+uXr0qlQ0fPhxpaWk4ePBglV6n5Dnn3r17/F1ARFTHZGRkwN3dXe3nHPY0reNKhqpY1NNT+yGV6HllYMieaFS36dKwRQtz/j4iIqrrIiMj0aNHD6Wy4OBgTJs2rcJr8vPzkZ+fLx1nZmYCACwsLJg0JSJ6AYmiiG1n4xH3OFsqc7cxxdhAL+lY3eccJk2JiIhIZ8hFBeRqjoGRiwrNBENERFqRmJgIR0dHpTJHR0dkZGQgNzcXJiYmZa5ZtmwZFi5cWFshEhFRLckpKMLJWykolCuw8/w9eNma4cStZMQ9zilTt52XtVLSVF1MmhIREZHOUECEAuplTdW9noiInj9z5szBjBkzpOOSoZlERFSzVJ31UyEC/ySkIb9IgbvJ2bj1qHhkQGxKNo5GJcPL1lTqIZqUkYecAuU1D07eSinT5ltdfAAAbtZlP1RTB5OmREREREREpDOcnJyQlJSkVJaUlAQLC4tye5kCgEwmg0wmq43wiIheSDkFRXiQlgcAeJSRh0KFiMIiBe6mZKGezBBAcbLzbko20nMKcTclC4XqDhErR2w5PUgBwMRQH83cLHEuJhVTghogu6AIHjamGNrWHfVkNZPeZNKUiIiIdIYCCqg7uF79FoiISJsCAwNx4MABpbLDhw8jMDBQSxEREdW+9NxCpGYXIDopExXNzJlbKEfc4xyYG1ec3otOyoLMQA8GeuW3Evs4B3/cSCr3XE3ztjNDTEo23G1M0NLdGmZG+vCyM0MbT2upjlwhwtfRHNZmRrUeH5OmREREpDPkogi5ikN8ymuDiIh0R1ZWFm7fvi0dx8TE4PLly7CxsYGHhwfmzJmD+/fv49tvvwUATJo0CevWrcPMmTMRGhqKI0eO4IcffsD+/fu1dQtERLUiPacQ+648wIe7rmotBksTQyhEEZl5RWjibIHsgiIUFCnQ1NUSogjEp2bD284Mzd2s0MLNClamhnC2VG1xZRMjfZga6X5KUvcjJCIiIiIioufWhQsXEBQUJB2XzD06btw4hIeH4+HDh4iPj5fOe3t7Y//+/Zg+fTrWrFkDNzc3bNq0CcHBwbUeOxFRbZArRDxIy0X3z4+VO+S9ibMFjA31yr02PbcQhvp6aOhoXmH7sSnZaO9tAwP98nubFhaJ6FjfFp0b2UFmoF+9m3gBMWlKREREOoMLQRERvXi6detW6UIh4eHh5V7z119/1WBURETaI4oi8goVSHiSg1dWnSi3zviXvDG7tx8M9ARpYSSqXUyaEhERkc5QQIScSVMiIiIiegEVyhW4/yQXvdacQF5hxfPw31zcC8aG7PGpbUyaEhERERERERFRnSWKIqKTspCVXwQAyCuU40FaLmSlEpe3kjKhJwi4ej8duYVy5BXKkZpdgPTcQtibyyptPzopC4IAVNTpPsjXHl+NbQtD/fKH4JN2MGlKREREOoPD84mIiIiopsWmZOOjX6/izqMsFMgVSMkqUKu9JzmFz6zzdMJ0cGs3fPxaU/Yo1WFMmhIREZHOkIsi5JXMe1fVNoiIiIiISiQ8ycHcXVfxT0IaCooUyCmQV1jX09YUAPAwPQ8O5jJ42JhK56KTstCxvi0K5Qo4WhjD09YUBnoCXKxMYGJUefLTxFAftmYyOFsZs0fpc4JJUyIiIiIiIiIieq6JooiIG49w/WEG7iRn4UR0MlysTHDtQUal173TrT5eamAHH/t6cLI0rqVo6XnApCkRERHpDMX/b+q2QURERER1R0GRAo3m/VamvLxh8wv7+8PGzAiB9W1hV6/yuUipbmPSlIiIiHSGHCLkas5Jqu71RERERKT7Hmfl49vIOKyJuFXmnKWJIbzszNDB2waB9W1hbmyAVu7W0NMTtBApPa+YNCUiIiIiIiIiIp2UWyBHxM0kfPtnHM7FpsLGzAip2eUv3ORoIcPZuT1qOUJ6UTFpSkRERDpDLhZv6rZBRERERLrp9qMs5BQUAQAK5SK+PHobV+6nw9RIH6ZGymmqvCI57iZnK5WVlzD9akwbBHjbwtLUsOYCpzqHSVMiIiLSGZzTlIiIiOjFkpFXiF8uJiC7QI4Vh6LUaqtHYwd0amCH9t42MJcZwsPW9NkXEVUTk6ZERERERERERKRxoihiy6kYrP6j7LyjLv+/Un2RQoSDhQz9W7igvn09GOjrKdVTiCKauVpy0SaqdUyaEhERkc5QQIAc6k3Qr1DzeiIiIiJSX16hHC9/fhz303KlsuHt3GFpaoi3u9aHlamRFqMjejYmTYmIiEhnKMTiTd02iIiIiEg75AoRfdeexM3ETKXy/45pg2B/Jy1FRaQ6vWdXISIiInpxLVu2DO3atYO5uTkcHBwwcOBAREX9O99Wamoq3n33Xfj6+sLExAQeHh6YOnUq0tPTldoRBKHMtmPHDqU6x44dQ+vWrSGTydCgQQOEh4fXxi0SERER1ZrzsalKCdMgX3vc/rg3E6b03GFPUyIiItIZcg0Mz1f1+uPHj2Py5Mlo164dioqKMHfuXPTs2RPXr1+HmZkZHjx4gAcPHuCzzz5DkyZNEBcXh0mTJuHBgwf46aeflNraunUrevXqJR1bWVlJ+zExMejbty8mTZqEbdu2ISIiAhMmTICzszOCg4PVumciIiIiXTFj52Vp/9zcl+FgYay9YIjUwKQpERER6QxtJE0PHjyodBweHg4HBwdcvHgRXbp0QdOmTfHzzz9L5+vXr4+PP/4Yo0ePRlFREQwM/v1zysrKCk5O5fei2LhxI7y9vfH5558DABo3boxTp05h1apVTJoSERHRC8PCxBAP0vMAgAlTeq5xeD4RERG9kDIyMpS2/Pz8Kl1XMuzexsam0joWFhZKCVMAmDx5Muzs7NC+fXts2bIFovjvBKuRkZHo0aOHUv3g4GBERkZW9ZaIiIiIdFZqdgEepudKQ/M/fq2pliMiUg97mhIREZHOUIgCFKJ6PU1Lrnd3d1cqX7BgAcLCwiq/VqHAtGnT0KlTJzRtWv4f+ikpKVi8eDEmTpyoVL5o0SJ0794dpqam+P333/HOO+8gKysLU6dOBQAkJibC0dFR6RpHR0dkZGQgNzcXJiYmqtwmERERkdak5xbi2z9jceJWMmQG+jh1O6VMnW6+DlqIjEhzmDQlIiIinaHJ4fn37t2DhYWFVC6TyZ557eTJk3H16lWcOnWq3PMZGRno27cvmjRpUiYB+9FHH0n7rVq1QnZ2NlasWCElTYmIiIieV3/fS0No+Hm4WptAZqCH87FPKq3/sp8DXK34gTA935g0JSIioheShYWFUtL0WaZMmYJ9+/bhxIkTcHNzK3M+MzMTvXr1grm5OXbt2gVDQ8NK2wsICMDixYuRn58PmUwGJycnJCUlKdVJSkqChYUFe5kSERGRzoh/nIOU7Hws+PUaBAFQiCKu3s8AADzOLlCqa2Koj2k9GsLRwhguViZo52UNQVDvA3AiXcGkKREREekMOfQgV3PKdbmK9UVRxLvvvotdu3bh2LFj8Pb2LlMnIyMDwcHBkMlk2LNnD4yNn72oweXLl2FtbS31cA0MDMSBAweU6hw+fBiBgYEqRkxERERUufTcQuQX/vtX0ePsApy6lYKrD9JhYVz2g9/opEyIInAuNrXSdrs0ssfrbd2gLwjwc7aAt52ZxmMn0hVMmhIREZHOEDUwp6mo4vWTJ0/G9u3b8euvv8Lc3ByJiYkAAEtLS5iYmCAjIwM9e/ZETk4OvvvuO2lhKQCwt7eHvr4+9u7di6SkJHTo0AHGxsY4fPgwli5div/85z/S60yaNAnr1q3DzJkzERoaiiNHjuCHH37A/v371bpfIiIiqnsy8grxx/UkzPjhb7jbmEC/VO/O2Mc5GnkNWzMjNHGxwBudvAAAjZ0t4GzJ0TFUdzBpSkRERHXahg0bAADdunVTKt+6dStCQkJw6dIlnD17FgDQoEEDpToxMTHw8vKCoaEh1q9fj+nTp0MURTRo0AArV67Em2++KdX19vbG/v37MX36dKxZswZubm7YtGkTgoODa/YGiYiI6Ll0Kf4JMnILkZyZj4NXE5GRV1juXKL3UnMrbEOv1GfJChFwtTJBa0/rcnuIPskugI+9GezNZejR2BHGhvoauQ+i5xWTpkRERKQzNLkQVFWJoljp+W7duj2zTq9evdCrV69nvla3bt3w119/qRQfERER1R2nbqVg9OazKl3zels3vN7WXanMTGYAPydzzi9KpAYmTYmIiEhnyEU9yEU15zStPL9JREREpFUZeYXY+/cDxKfm4L/H78LMqLhHZ3ZB+TOzN3W1QGZeEZq5WqKpqyV8nczR0KEe3KxNazNsojqHSVMiIiIiIiIiohoiiiIycotwIS4V47+5UOZ8ecnSVh5WmN3LD+29bdhblEhLmDQlIiIinaGAAAXU62mqALuaEhERkXbkFBQBAFKzC3A0KhmnbiXj0LWkCut3amCLnk2cEOTrAAAQBMDN2oSJUiIdwKQpERER6QxtzGlKREREVF1/XE/CN5GxOHkrpcrXTHjJG/NebVKDURGRJjBpSkRERERERERUilwhIjkzH0kZeSiUK3Dqdgoy84pw6FoirEwNcfV+RpXaMdAT4GNvhjl9Gku9SYno+cCkKREREekMzSwExeH5REREpLrs/CJ8fy4ed1Oysf1sfIX1Ep7klikL9LFFY2cLjGjvDjdrUwgCYGyoX5PhElENY9KUiIiIdEbxnKbqDa9X93oiIiKqG/5JSMP52CcQRRFL9t+otK6rlQky8woRWN8WcoWIbr4OaOxsDidLE7hYGnMOUqIXEJOmRERERERERPRCS88pRFxqNgAgp0CO4V+dqbS+j70Z3n/FF32bO9dGeESkg5g0JSIiIp2hgB7kUG94vgIcnk9ERET/SsrIQ8DSiArP6wnAK00c4edkgTc6ecHK1KgWoyMiXcWkKREREekMzmlKRERE1ZXwJAe/XUnEqdspOB6dDCcLY2TkFSKnQC7VcbE0BgBkF8jR3M0S/xsfoK1wiUjHMWlKRERERERERM8tuUJEaPh5HI9OVipPzMhTOh7c2g2fv96iNkMjoucYk6ZERESkMxTQg4LD84mIiKgSOQVFiE7KwuOsfKw8HI1rDzKUzvs5maORozmcrYzRy98JeoKAxs4WMDJQ728MIqpbmDQlIiIinSEXBchF9VafVfd6IiIi0k2h4edx5OajSuv8MaMLGjiY11JERPQiY9KUiIiIiIiIiHTWL5cSMOOHv8s9Z21qiNYe1vigly/8nCxqOTIiepExaUpEREQ6Qw49yNUcni/n8HwiIqIXhtfs/WXK1o5ohT5NnWCgz+H2RFRzmDQlIiIinaEQ9aAQ1ZzTVGTSlIiI6Hm28vcorD1yu0z5+Je8Mae3H5OlRFQrmDQlIiIiIiIiIq0SRRFzd13B9+fulXs+ZlkfCALnLSei2sOkKREREekMDs8nIiKqm7znHChT9k63+nizsw+szYy0EBER1XVMmhIREZHOUACQi+r1IlFoJhQiIiKqYQqFiKikTHy8/4ZS+crXW6BfCxcYchg+EWkRk6ZEREREREREVOPScwqRX1Q8JuS/x+9iy+mYMnWuLgxGPRlTFUSkffxJRERERDpDAT0o1Byer+71REREVD1FcgUu30tDfGoOPtp9FfWMDZCdL0dWftEzrzU3NsCq11syYUpEOoM/jYiIiEhnyEU9yEU15zRV83oiIiJ6tvTcQiSm52Hoxj+RkVcEIwM9FBQpT5KTXSAv91o9AVD8/xTkywc1w9C27tDX4yJPRKRbmDQlIiIiIiIiokolPMnB5lMx2Ho6ttzzTydMAcDN2gTvdm8AN2tT1JMZwMvWDJamhjUcKRGRZjBpSkRERDpDAQEKqLsQFHuqEBERaUpaTgEGrj+N2Mc55Z430BNQpBCxelhLeNmZwdvODJYmTIwS0fOPSVMiIiLSGRyeT0REpH2nbqVg0b5raOFmhR8vJpQ5/3pbN4wN9IK/iwUEgR9WEtGLiUlTIiIiIiIiIkLCkxys/D0av/x1HwAQnZSldP7kzCC425hqIzQiolrHpCkRERHpDDn0IIeaPU3VvJ6IiKiuEUURH/z0D356qlepq5UJRnfwhI2ZIQa2coXMQF9LERIR1T4mTYmIiEhnKEQBClHNOU3VvJ6IiKguyM4vQsTNR/j6xF0kZeThUWa+dM7VygRfjGyF1h7WWoyQiEi7mDQlIiIiIiIiqiMeZeShy4qjyCssu9o9AGwc3Ro9GjvCQJ8jN4iobmPSlIiIiHSGQgPD8xUcnk9ERFTG3eQsdP/8eLnn7M1lGNzaDQNbucDPyaKWIyMi0k1MmhIREZHOUIh6UIhqJk3VvJ6IiOhFIFeIiLiRhEK5iMnbL5U5H+hji2WDmsHLzkwL0RER6T4mTYmIiIiIiIheILeSMvHKqhPlnuvXwgXLBzWDmYzpACKiyrArBhEREekMOQSNbKpYtmwZ2rVrB3Nzczg4OGDgwIGIiopSqpOXl4fJkyfD1tYW9erVw+DBg5GUlKRUJz4+Hn379oWpqSkcHBzwwQcfoKioSKnOsWPH0Lp1a8hkMjRo0ADh4eHVep+IiIgqMm/3lTIJ0+ZulgCAmGV98MWIVkyYEhFVAZOmREREpDNKhueru6ni+PHjmDx5Ms6cOYPDhw+jsLAQPXv2RHZ2tlRn+vTp2Lt3L3788UccP34cDx48wKBBg6Tzcrkcffv2RUFBAf7880988803CA8Px/z586U6MTEx6Nu3L4KCgnD58mVMmzYNEyZMwKFDh9R/44iIiAB882csvjsTLx2PaO+B2OV9sWfKS4hd3heCoNoHi0REdRk/XiIiIqI67eDBg0rH4eHhcHBwwMWLF9GlSxekp6dj8+bN2L59O7p37w4A2Lp1Kxo3bowzZ86gQ4cO+P3333H9+nX88ccfcHR0RMuWLbF48WLMmjULYWFhMDIywsaNG+Ht7Y3PP/8cANC4cWOcOnUKq1atQnBwcK3fNxERvVjyCuVYsOeadPzjpEC087LRYkRERM839jQlIiIinSGHJoboqyc9PR0AYGNT/KB58eJFFBYWokePHlIdPz8/eHh4IDIyEgAQGRmJZs2awdHRUaoTHByMjIwMXLt2TapTuo2SOiVtEBHpipSUFGzcuBGjRo1CQEAA/Pz80L59e4waNQobN25ESkqKtkOkcvh99O+HgJ8Oac6EKRGRmtjTlIiIiHRGdYbXl9cGAGRkZCiVy2QyyGSyyq9VKDBt2jR06tQJTZs2BQAkJibCyMgIVlZWSnUdHR2RmJgo1SmdMC05X3KusjoZGRnIzc2FiYmJCndJRKR50dHRCAsLw88//4yioiKIoqh0/sKFC9ixYwfee+89DB06FPPnz0ejRo20FC2VNvHbC0rHr7d111IkREQvDiZNiYiI6IXk7q78wLhgwQKEhYVVes3kyZNx9epVnDp1qgYjIyLSTf7+/pDL5dDX10dAQADat28PT09PWFhYICMjA3FxcTh37hzOnz+P7du344cffkBBQYG2w67zsvOL8Pv1fxcnjFnWR4vREBG9OJg0JSIiIp0hF/UgV7Onacn19+7dg4WFhVT+rF6mU6ZMwb59+3DixAm4ublJ5U5OTigoKEBaWppSb9OkpCQ4OTlJdc6dO6fUXlJSknSu5N+SstJ1LCws2MuUiHSCu7s7ZsyYgWHDhsHe3r7CesnJyfj++++xZs2aWoyOyjPoy9O4FJ8mHR+c1pmLPRERaQjnNCUiIiKdIUKAQs1NRPHDooWFhdJWUdJUFEVMmTIFu3btwpEjR+Dt7a10vk2bNjA0NERERIRUFhUVhfj4eAQGBgIAAgMDceXKFTx69Eiqc/jwYVhYWKBJkyZSndJtlNQpaYOISNtu376NKVOmVJowBQB7e3tMnToVt27dqqXI6Gl3k7PgNXu/UsK0c0M7+DlZVHwRERGphD1NiYiIqE6bPHkytm/fjl9//RXm5ubSHKSWlpYwMTGBpaUlxo8fjxkzZsDGxgYWFhZ49913ERgYiA4dOgAAevbsiSZNmmDMmDH49NNPkZiYiHnz5mHy5MlSsnbSpElYt24dZs6cidDQUBw5cgQ//PAD9u/fr7V7JyIqTU9PtT41qtYnzbiSkI5+65Snkbm6MBhmRvpaioiI6MXEpCkRERHpDE0Oz6+qDRs2AAC6deumVL5161aEhIQAAFatWgU9PT0MHjwY+fn5CA4OxpdffinV1dfXx759+/D2228jMDAQZmZmGDduHBYtWiTV8fb2xv79+zF9+nSsWbMGbm5u2LRpE4KDg6t3o0REGhYaGlqleoIgYPPmzSq3v379eqxYsQKJiYlo0aIFvvjiC7Rv377C+qtXr8aGDRsQHx8POzs7DBkyBMuWLYOxsbHKr/28y8ovwrmYxwgNV17w6a0uPpjTp7GWoiIierExaUpEREQ6QyEKUIjqzcWm6vVPrw5dHmNjY6xfvx7r16+vsI6npycOHDhQaTvdunXDX3/9pVJ8RES1JTw8/JnzYYqiWK2k6c6dOzFjxgxs3LgRAQEBWL16NYKDgxEVFQUHB4cy9bdv347Zs2djy5Yt6NixI6KjoxESEgJBELBy5UqVXvt5JVeIOHDlId79vvzfG4sH+GNMoFftBkVEVIcwaUpERERERETw8PBQSpomJiYiPz8fNjY2AIDU1FQYGhrC1dVV5bZXrlyJN998E2+88QYAYOPGjdi/fz+2bNmC2bNnl6n/559/olOnThg5ciQAwMvLCyNGjMDZs2erc2vPlcBlEXiYnldpnXNzX4aDRd3rcUtEVJs4CQ0RERHpDDn0NLIREZHqYmNjERMTg5iYGKxatQr6+vr4448/kJKSgpSUFEREREBfXx9Lly5Vqd2CggJcvHgRPXr0kMr09PTQo0cPREZGlntNx44dcfHiRZw7dw4AcPfuXRw4cAB9+vQpt35+fj4yMjKUtufNqVsp8Jq9v9yEaRNnC9z6uDdil/dF7PK+TJgSEdUC9jQlIiIinaGN4flERFTWrFmz4OXlhe7du0tlQUFB8PHxwUcffYThw4dXua2UlBTI5XI4OjoqlTs6OuLmzZvlXjNy5EikpKTgpZdegiiKKCoqwqRJkzB37txy6y9btgwLFy6scky65mF6LkZvVu5Fe2pWEOzqyWBsyAWeiIi0gV0xiIiIiIiISEl8fDyioqLw9ddf4/Hjx3j8+DE2bdqEmzdvIiEhocZf/9ixY1i6dCm+/PJLXLp0Cb/88gv279+PxYsXl1t/zpw5SE9Pl7Z79+7VeIyaFLjsiLQ/oKULYpb1gZu1KROmRERaxJ6mREREpDMU0INCzc901b2eiIiAzp07448//sCkSZMwadIkqVwURXTu3Fmltuzs7KCvr4+kpCSl8qSkJDg5OZV7zUcffYQxY8ZgwoQJAIBmzZohOzsbEydOxIcffgg9PeWf9TKZDDKZTKW4dMHevx8oLfRUT2aANcNbaTEiIiIqwacKIiIi0hlyUdDIRkRE6tm0aRNat24NURSVtlatWmHTpk0qtWVkZIQ2bdogIiJCKlMoFIiIiEBgYGC51+Tk5JRJjOrrF/e6FEVRxbvRXaUTpgBw5D9dtRQJERE9jT1NiYiIiIiISImHhwcuXLiAI0eO4Nq1awAAf39/pTlOVTFjxgyMGzcObdu2Rfv27bF69WpkZ2fjjTfeAACMHTsWrq6uWLZsGQCgX79+WLlyJVq1aoWAgADcvn0bH330Efr16yclT593a/64Je3P6uWHt7vV12I0RET0NCZNiYiISGdwISgiIt3SvXt3NG7cGEVFRXB3d692O8OGDUNycjLmz5+PxMREtGzZEgcPHpQWh4qPj1fqWTpv3jwIgoB58+bh/v37sLe3R79+/fDxxx+rfU+6YtUf0dL+pK4+WoyEiIjKw+H5REREpDNEUQ8KNTdR5J83RESa8N1338HT0xNubm4YNmwY9u7di+7du+PAgQPVam/KlCmIi4tDfn4+zp49i4CAAOncsWPHEB4eLh0bGBhgwYIFuH37NnJzcxEfH4/169fDyspKzbvSvofpufCavV86XjO8JQSBH/gREeka9jQlIiIiIiIiJT///DPGjh2rVNa6dWscP34cDg4O6NOnj5Yie37FPc5G1xXHypT3beZc+8EQEdEzsSsGERER6Qw5BI1sRESknqVLl0IQBEybNk0qc3V1hYuLC86fP6+9wJ5TC/deKzdhen1RMAz0+VhORKSL+NOZiIiIdIZC/Hde0+pv2r4LIqLn3/Xr1+Hr64uVK1cqldvb2+PBgwdaiur5FP84B1tPx0rHrzRxRMyyPohd3hemRhz8SUSkq/gTmoiIiIiIiJQYGxsjIyMDCoVCKsvPz0dMTAxMTU21GNnzp8uKo9L+j5MC0c7LRovREBFRVTFpSqSmHV844PQBK9y7LYORsQJN2uZg/IcP4N4gv0xdUQTmjfbBhaMWWLA5Bh17p0vnHiUY4os5bvj7tDmMzeR4ZegThM59AP3//1/62TQPHP6h7B9YHo1y8fWxqBq7PyJV7Vi2A052WWXKdx1tjDXbO+HVzjfRI+A2Gno8hplJIV6dOgZZuTKluqP7/IUOze6hgftjFMn18ep7Y8u0Ry+mksWc1G2DiIjUExgYiEOHDklzlyYkJKBHjx7IyMhA7969tRzd8yE7vwj+Cw5Jx72bOjFhSkT0HGHSlEhN/0TWQ7+QFDRqmQN5ERC+3BlzR9TH18dvwthUoVR319f2KG9hTLkc+GisD6zti7Bqzy2kPjLAiqme0DcUETrnIQDg7UUJCJ3771AoeZGAt1/xRZdX08s2SKRFb308APp6/46P9nZ9gs9n/IbjF7wBAMZGRTh31R3nrrpj4uDy50QzMFDg2EVvXLvrgL4vRddK3KQbFBCgUHNOUnWvJyIiYMGCBYiIiMDhw4chCALu37+PhIQEGBoa4qOPPtJ2eM+FlYeV/4bZMLqNliIhIqLq0LmuGImJiXj33Xfh4+MDmUwGd3d39OvXDxEREVKdP//8E3369IG1tTWMjY3RrFkzrFy5EnK5XKktQRAgCALOnDmjVJ6fnw9bW1sIgoBjx46VqS8IAiwtLdGpUyccOXJEOh8SEoKBAwdWGLuXl5dSGyXb8uXLERYWVu650lvJa5R3rlevXuW+jomJCby8vPD6668rxUq1Z+n2u+g5LBVevnmo75+H91fH49F9I9z6x0Sp3p2rJvj5v/aYsTK+TBuXjpsjPtoYs9bFoX7TXLTrnomxMx9ib7gdCguKvzfMLBSwcSiStlt/myIrTR89hz+ulfskqqr0LBOkZphKW2DzeNx/ZIHL0cUrw/4U0RTbD7bA9bv2FbYRvqcNfvqjGWLuszcGERGRNgQEBODIkSPo0qULTExMYGJigq5du+KPP/5AQECAtsPTaaIo4r/H72DzqRipLGZZHy1GRERE1aFTSdPY2Fi0adMGR44cwYoVK3DlyhUcPHgQQUFBmDx5MgBg165d6Nq1K9zc3HD06FHcvHkT7733HpYsWYLhw4dDFJVXf3B3d8fWrVuVynbt2oV69eqVG8PWrVvx8OFDnD59GnZ2dnj11Vdx9+7dKt/DokWL8PDhQ6Xt3XffxX/+8x+lMjc3tzJ1S/Tq1atMG99//325rxMVFYVvv/0WVlZW6NGjBz7++OMqx0o1IztDHwBgbvVvEj8vR8DyyZ6Y/HECbByKylxz/YIZvPzyYG3/77m23TKRk6mPuCjjcl/n4Pc2aNU5E45uhRq+AyLNMdCX45WA2zhwuhHA3n9UBXJR0MhGRETq69SpE44ePYqsrCxkZWXh6NGj6Ny5s7bD0mlyhYhVh6Ox7LebUtnWN9pJnWSIiOj5oVPD89955x0IgoBz587BzMxMKvf390doaCiys7Px5ptvon///vjqq6+k8xMmTICjoyP69++PH374AcOGDZPOjRs3DmvXrsXq1athYlLc82/Lli0YN24cFi9eXCYGKysrODk5wcnJCRs2bICrqysOHz6Mt956q0r3YG5uDicnp3LPlU7U6uvrV1hXJpNV2EZ5r+Ph4YEuXbrA2dkZ8+fPx5AhQ+Dr61uleEmzFApg4wJX+LfLgpdfnlT+3zBXNGmbjY69Msq97kmyAaztlZOfVnaF0rmnPU40wPmjFpi9Pk6D0RNp3kut4lDPtAAHTzfUdij0nOCcpkREukFfXx8dOnTA6dOnlcpDQ0Nx7do1nD17VkuR6bY1Ebew9sht6Xjqyw0R5OugxYiIiKi6dOapIjU1FQcPHsTkyZOVEqYlrKys8Pvvv+Px48f4z3/+U+Z8v3790KhRozI9Mtu0aQMvLy/8/PPPAID4+HicOHECY8aMeWZMJUnWgoKC6txSrXvvvfcgiiJ+/fXXCuvk5+cjIyNDaSPNWTfXDXE3TTBnw7/JzMhDFrh82hyTFt3X2Osc/tEG9Szk6NiL85mSbuvzUhTOXnXD4/SyP9eJiIhId4miWGYUHwBcvXoVFy5c0EJEz4evT/w7SnHDqNaY8UojLUZDRETq0Jmeprdv34YoivDz86uwTnR08UTajRs3Lve8n5+fVKe00NBQbNmyBaNHj0Z4eDj69OkDe/uK59IDgJycHMybNw/6+vro2rVrle9j1qxZmDdvnlLZb7/9ptIwln379pWZPmDu3LmYO3dupdfZ2NjAwcEBsbGxFdZZtmwZFi5cWOVYqOrWzXXF2cMW+HzXbdi7/Ntr9PJpczyMNcIgv2ZK9Re/6YWmAdlY8fNtWNsXIeov5aRSWoohACgN2QcAUQQO7bDFy0NSYWhU9g9ZIl3haJOJNo0fYP6XPbQdCj1HFBCgUHN4PReCIiKqvkWLFkn7CQkJSsfZ2dn4559/YGxc/vRRBOQWFk/RNauXH3o3c9ZyNEREpA6dSZqW9ymmJuoCwOjRozF79mzcvXsX4eHhWLt2bYV1R4wYAX19feTm5sLe3h6bN29G8+bNq/xaH3zwAUJCQpTKXF1dVYo3KCgIGzZsUCqzsanaYiiiKFY6X86cOXMwY8YM6TgjIwPu7u4qxUfKRBFY/6Er/jxoiRU/3YaTh3LP5GFTktB7pPJiTW9198NbYffRoWdxT98mbbOxY60j0lIMYGVXnCS9dMIcpuZyeDTKU7r2n8h6eBAjQ68RqTV4V0Tq690pGmkZxjhzhT9jqOpECGonPUUmTYmIqq1kAVsAuH//fpkOF6IoIjAwUBuhPRfqyQyQlV+EFu6W2g6FiIjUpDNJ04YNG0IQBNy8ebPCOo0aFQ9tuHHjBjp27Fjm/I0bN9CkSZMy5ba2tnj11Vcxfvx45OXloXfv3sjMzCz3NVatWoUePXrA0tLymb1Ry2NnZ4cGDRqofF1pZmZm1Wrj8ePHSE5Ohre3d4V1ZDIZZDKZOuHRU9bNdcPRXdYI23oXJvUUSH1U/N/KzFwOmYkorXb/NAfXQinB2rprJjwa5eHTdz0wft4DPEk2RPgnTugXkgIjmfKHBIe+t4Ff62ylOVOJdI0giOjV6RYORTaEXKE8E4yNRQ5sLHPh6lD8oYG32xPk5hki6bEZMnOKe6442GTBwiwfDjZZ0NMT0cC9+IOH+48skJtvWLs3Q0REVId4eHhAEATEx8fDyMhIaa0FU1NT+Pn5YcmSJVqMULeVfGznYmmi1TiIiEh9OpM0tbGxQXBwMNavX4+pU6eWmdc0LS0NPXv2hI2NDT7//PMySdM9e/bg1q1b5S7uBBQP0e/Tpw9mzZoFfX39CuNwcnJSO+mpLWvWrIGenh4GDhyo7VDqlH3f2AEAPhisvNDN+6vi0XNY1XqD6usDi769iy9mu2N6v0YwNlWgx9BUjPvgoVK97Aw9nNpvhUmLEzQTPFENadP4Ppxss3DgdNlF6fp3vYGQ/n9Jx1/M3AcAWL61Cw7+WfzhWOiAi+jV8ZZUZ9P8XQCAaSv64HK0S02GTlqmEDUwPF/N64mI6rKSqb709PTQqlUr/Pnnn9oNiIiISEt0JmkKAOvXr0enTp3Qvn17LFq0CM2bN0dRUREOHz6MDRs24MaNG/jvf/+L4cOHY+LEiZgyZQosLCwQERGBDz74AEOGDMHrr79ebtu9evVCcnIyLCws1IoxPT0dly9fViqztbWVhrhnZmYiMTFR6bypqalKr5ufn1+mDQMDA9jZ2UnHJa9TWFiImJgYfPfdd9i0aROWLVv23CZ9n1eHHlzWyDWOboVY8t3dspVLMbNQYM/df1R+PaLaduG6G7q9OaHcc+F72yB8b5tKr1++tSuWb636fNL04lCIelCI6q1Tqe71REQExMTEKI1QKyoqgoGBTj0+6py0nAJk5pcdYUZERM8nnXqq8PHxwaVLlxAUFIT3338fTZs2xSuvvIKIiAhpjs8hQ4bg6NGjiI+PR+fOneHr64tVq1bhww8/xI4dOyqcz1MQBNjZ2cHIyEitGI8dO4ZWrVopbaXn+Zk/fz6cnZ2VtpkzZ6r0GgcPHizTxksvvaRUp+R1GjRogDFjxiA9PR0RERGYNWuWWvdHRERERETk6emJqKgodO3aFcbGxujatSsiIiIQGhrK3qcVuHo/Q9p3suRiWUREzzud+6jQ2dkZ69atw7p16yqs07lzZxw8ePCZbVW2YJSVlVWZ889aYCo8PBzh4eEVnq9s1fqq1n3Wa6j6OkRERM8TDs8nItINx44dQ8+ePVFUVNxzUhRFeHh4SM8q5a0xUdddjHsCAPCxN4OxYcVTwhER0fNBp3qaEhERUd2mgKCRjYiI1DN//nzI5XK89tprUlnDhg3h6OiI06dPazEy3bXqj2gAwN3kbC1HQkREmsCkKRERERERESm5cOECvL298fPPPyuVOzs74/79+1qKSnfJFf+OWlw8wF+LkRARkabo3PB8IiIiqrs4PJ+ISDcYGBiUmb5MoVDg/v370Nfn0PPSpu+8jF1//ZtI7t7YUYvREBGRpjBpSkRERDqDSVMiIt3QqlUrnDp1Cm+++SYAIDk5GSNGjEBycjK6deum3eC0QKEQcTYmFY8y83A8OhlWJsULDCtEUSlhKjPQgwsXgSIieiEwaUpERERERERKZs+ejVdffRVbtmyBIAi4e/cu7t69C0EQ8MEHH2g7vFrnv+AQcgvlldY5NSsILpYmEAR+eEdE9CJg0pSIiIh0BnuaEhHpht69e2P79u2YPXs24uLiAACenp5YunQpevfureXoaldugVwpYdrU1QJG+nro4GMLAFCIQCsPK7hZm2orRCIiqgFMmhIREREREVEZw4YNw7Bhw5CSkgIAsLOz03JE2vHTxXvSfsyyPuxJSkRUR+hpOwAiIiKiEiU9TdXdVHXixAn069cPLi4uEAQBu3fvVjovCEK524oVK6Q6Xl5eZc4vX75cqZ1//vkHnTt3hrGxMdzd3fHpp59W630iIqoJ8fHx5W45OTnIyclRKqtLPj5wQ9pnwpSIqO5gT1MiIiLSGSIABdR7IBWfXaWM7OxstGjRAqGhoRg0aFCZ8w8fPlQ6/u233zB+/HgMHjxYqXzRokXSoikAYG5uLu1nZGSgZ8+e6NGjBzZu3IgrV64gNDQUVlZWmDhxYjWiJiLSLG9v7yrVEwQBRUVFNRyN7mjuaoVzsakY2NJF26EQEVEtYtKUiIiI6rzevXtXOkefk5OT0vGvv/6KoKAg+Pj4KJWbm5uXqVti27ZtKCgowJYtW2BkZAR/f39cvnwZK1euZNKUiHSCKFbnY6cXmyiKyC8qns802L/8n+9ERPRiYtKUiIiIdIYmF4LKyMhQKpfJZJDJZGq1DQBJSUnYv38/vvnmmzLnli9fjsWLF8PDwwMjR47E9OnTYWBQ/OdWZGQkunTpAiMjI6l+cHAwPvnkEzx58gTW1tZqx0ZEpI6jR49qOwSdkZ5biBYLf1cqY0qZiKhuYdKUiIiIdIYmk6bu7u5K5QsWLEBYWJhabQPAN998A3Nz8zLD+KdOnYrWrVvDxsYGf/75J+bMmYOHDx9i5cqVAIDExMQyQ18dHR2lc0yaEpG2de3aVdsh6ARRFMskTAGgqYulFqIhIiJtYdKUiIiIXkj37t2DhYWFdKyJXqYAsGXLFowaNQrGxsZK5TNmzJD2mzdvDiMjI7z11ltYtmyZxl6biKg27du3D0uXLsXVq1cBAM2aNcPs2bPRr18/LUdWsz45GKV0vH1CANp728BAn+soExHVJUyaEhERkc7QZE9TCwsLpaSpJpw8eRJRUVHYuXPnM+sGBASgqKgIsbGx8PX1hZOTE5KSkpTqlBxXNA8qEZG2fPnll3j33XcB/DvXaWRkJAYOHIi1a9di8uTJ2gyvRm08fkfaj13eV4uREBGRNvGjMiIiItIZJUlTdbeasnnzZrRp0wYtWrR4Zt3Lly9DT08PDg4OAIDAwECcOHEChYWFUp3Dhw/D19eXQ/OJSOcsW7YMoiiiQYMGmD59OqZPn45GjRpBFEUsX75c2+HVmM8O/dvLdFSAhxYjISIibWNPUyIiIqrzsrKycPv2bek4JiYGly9fho2NDTw8ih+aMzIy8OOPP+Lzzz8vc31kZCTOnj2LoKAgmJubIzIyEtOnT8fo0aOlhOjIkSOxcOFCjB8/HrNmzcLVq1exZs0arFq1qnZukohIBY8fP4a9vT0uXboEMzMzAMCiRYvg4+ODJ0+eaDm6mnMzMVPaXzSgqRYjISIibWPSlIiIiHSGKAoQ1ewpWp3rL1y4gKCgIOm4ZH7ScePGITw8HACwY8cOiKKIESNGlLleJpNhx44dCAsLQ35+Pry9vTF9+nSleU4tLS3x+++/Y/LkyWjTpg3s7Owwf/58TJw4UeV4iYhqWlBQEKKioqSEKQCYmZmhXr16CAwM1GJkNeuPG8XTpkwJagB9vZobuUBERLqPSVMiIiLSGQoIUEDNOU2rcX23bt2kOfsqMnHixAoTnK1bt8aZM2ee+TrNmzfHyZMnVY6PiKi2DR8+HBMnTsSYMWMwbNgwAMAPP/yA5ORkDB8+HCdOnJDqdunSRVthapyVqSHScgpR38Hs2ZWJiOiFxqQpERERERERKRk3bhwEQcD27duxfft2pXOjRo2S9gVBQFFRUW2HV+OauVppOwQiItIyJk2JiIhIZ2hiIaeaXAiKiKgueVYPfCIiohcZk6ZERESkM7Q1pykRESmLiYnRdghERERaxaQpERERERERKfH09NR2CERERFrFpCkRERHpDA7PJyLSHYcPH8bRo0eRlJSkNFRfEARs3rxZi5ERERHVPCZNiYiISGdweD4RkW4ICwvD4sWLy5SLovhCJ03Tcgq1HQIREekIJk2JiIiIiIhIyVdffQVRFOHp6QlPT08Iwov/gdT1BxnSvrWpoRYjISIiXcCkKREREekMUQPD89nTlIhIfUVFRahfvz5u3bql7VBqzdbT/y5+ZVtPpsVIiIhIF+hpOwAiIiKiEiIAUVRz0/ZNEBG9AKZOnYqHDx/izJkz2g6lVuQVyvHjxQQAgL+LhZajISIiXcCepkRERERERKRkxowZ+P7779GpUydYW1vDwuLfRKIgCLhz544Wo9O8g1cTpf2JXXy0GAkREekKJk2JiIhIZyggQIB6w+sVal5PRETAW2+9hZs3b0IURaSmpiI1NVU69yLOb/rT//cyBYABLV21GAkREekKJk2JiIhIZ4iioPacpJzTlIhIfbt27QIAdOrUCV5eXjAweLEfHU/dTgEA+DqaazkSIiLSFS/2bz4iIiIiIiJSmYuLCwwMDHDy5Elth1IrDPUFFMpFTH25obZDISIiHcGFoIiIiEhnKERBIxsREaln7dq1uH//Pnbs2IGsrCxth1OjFAoRhfLiZQSdrYy1HA0REekK9jQlIiIinSGKxZu6bRARkXr69u0LABg1alSZc4IgoKioqLZDqjFFin9/cXjbmmkxEiIi0iVMmhIREREREZESsY5+AqWvz9EKRERUjElTIiIi0hlcCIqISDcsWLBA2yEQERFpFZOmREREpDOYNCUi0g11KWkqV9TNXrVERFQ5Jk2JiIiIiIiojMePH2PdunW4cOECAKBdu3aYPHkybG1ttRyZZt1J/nehKxNDfS1GQkREuoRJUyIiItIZClGAoGZPUQV7mhIRqe3evXvo2LEjHjx4IJUdOHAAmzZtwp9//gk3NzctRqdZP19KkPYN9fW0GAkREekS/kYgIiIinSGKmtmIiEg9c+fOxf379yEIAvz8/ODn5wdBEHD//n18+OGH2g5PYwrlCmw9HavtMIiISAcxaUpERERERERKDh8+DBMTE5w/fx7Xrl3DtWvXcO7cOchkMhw6dEjb4WlM5J3H0v7aEa20GAkREekaJk2JiIhIZxT3FBXU3LR9F0REz7/U1FT4+PigVat/E4mtW7eGj48Pnjx5osXINCunQC7t92vurMVIiIhI1zBpSkRERDpD/YRp8UZEROpxcnJCdHQ09u7dK5Xt2bMH0dHRcHJy0mJkNaOtpzUEgb8/iIjoX0yaEhERERERkZJ+/fqhsLAQAwcOhLm5OczNzfHaa69BLpejf//+2g6PiIioxjFpSkRERDpD1NBGRETqWbJkCfz9/SGKIrKzs5GdnQ1RFOHv74/FixdrOzwiIqIaZ6DtAIiIiIhKaGJ4PYfnExGpz9raGhcuXMD333+P8+fPAwDatWuHESNGQCaTaTk6IiKimsekKREREREREZUhk8kQEhKCkJAQbYdCRERU6zg8n4iIiHQHx+cTEWnV5s2b4ePjg02bNpU5t379evj4+GDLli1aiKxmyBX8pUFEROVj0pSIiIh0x/8Pz1dnA4fnExFV23fffYd79+5h6NChZc6NHDkSCQkJCA8Pr1bb69evh5eXF4yNjREQEIBz585VWj8tLQ2TJ0+Gs7MzZDIZGjVqhAMHDlTrtSvy5bHbAIACuUKj7RIR0fOPw/OJiIiIiIgIAHDjxg14eXnB0tKyzDlra2t4eXnh5s2bKre7c+dOzJgxAxs3bkRAQABWr16N4OBgREVFwcHBoUz9goICvPLKK3BwcMBPP/0EV1dXxMXFwcrKqjq3VaFrDzIAAHceZWm0XSIiev4xaUpEREQ6QxSLN3XbICKi6klLS4O5uXmF50VRREZGhsrtrly5Em+++SbeeOMNAMDGjRuxf/9+bNmyBbNnzy5Tf8uWLUhNTcWff/4JQ0NDAICXl5fKr/ssMgM95BcpsHRQM423TUREz7cqJU0XLVpU5Qbnz59f7WCIiIiobpOG2KvZhqpOnDiBFStW4OLFi3j48CF27dqFgQMHSudDQkLwzTffKF0THByMgwcPSsepqal49913sXfvXujp6WHw4MFYs2YN6tWrJ9X5559/MHnyZJw/fx729vZ49913MXPmTNVvkoiohjg6OiImJgZXr15F06ZNlc5dvXoVMTExcHV1VanNgoICXLx4EXPmzJHK9PT00KNHD0RGRpZ7zZ49exAYGIjJkyfj119/hb29PUaOHIlZs2ZBX1+/TP38/Hzk5+dLx1VN7OYXFQ/Lb+NprcotERFRHVClpGlYWBgEoWoPIEyaEhER0fMmOzsbLVq0QGhoKAYNGlRunV69emHr1q3SsUwmUzo/atQoPHz4EIcPH0ZhYSHeeOMNTJw4Edu3bwdQ/ADfs2dP9OjRAxs3bsSVK1cQGhoKKysrTJw4seZujohIBZ07d8b27dvRv39/rF69Gp07d4YgCDh58iSmT58OURTRpUsXldpMSUmBXC6Ho6OjUrmjo2OFQ/3v3r2LI0eOYNSoUThw4ABu376Nd955B4WFhViwYEGZ+suWLcPChQtViispI0/atzAxVOlaIiJ68VUpaerh4VHlpCkRERFRtWliIadqXN+7d2/07t270joymQxOTk7lnrtx4wYOHjyI8+fPo23btgCAL774An369MFnn30GFxcXbNu2DQUFBdiyZQuMjIzg7++Py5cvY+XKlUyaEpHOeP/997Fz507ExcXhtddeUzoniiIMDAwwY8aMGo9DoVDAwcEBX331FfT19dGmTRvcv38fK1asKDdpOmfOHKW4MjIy4O7uXulrFJZa/MnCmElTIiJSVqWkaWxsbA2HQURERKTbc5oeO3YMDg4OsLa2Rvfu3bFkyRLY2toCACIjI2FlZSUlTAGgR48e0NPTw9mzZ/Haa68hMjISXbp0gZGRkVQnODgYn3zyCZ48eQJraw4NJSLta9WqFTZs2IC3334bcrlc6Zy+vj42bNiAVq1aqdSmnZ0d9PX1kZSUpFSelJRU4YdRzs7OMDQ0VBqK37hxYyQmJqKgoEDpZylQ/MHW0yMAqsrYUK9a1xER0Yut2gtBZWdn459//oG+vj7at2+vyZiIiIiI1Pb0fHbqPFD36tULgwYNgre3N+7cuYO5c+eid+/eiIyMhL6+PhITE8us/mxgYAAbGxskJiYCABITE+Ht7a1Up2SoamJiIpOmRKQzJkyYgM6dO2Pz5s24fv06RFGEv78/QkND4efnp3J7RkZGaNOmDSIiIqT5ohUKBSIiIjBlypRyr+nUqRO2b98OhUIBPb3ipGZ0dDScnZ3LJEyJiIhqQrWSpkuWLMHy5cuRm5uLgIAATJs2DbNnz8aSJUswcuRITcdIREREdYX4/5u6bQBlhmUuWLAAYWFh1Wpy+PDh0n6zZs3QvHlz1K9fH8eOHcPLL79c3UiJiHSWr68vPv30U421N2PGDIwbNw5t27ZF+/btsXr1amRnZ+ONN94AAIwdOxaurq5YtmwZAODtt9/GunXr8N577+Hdd9/FrVu3sHTpUkydOlVjMWXmFWmsLSIievGonDTduHFjmcWeXn75Zdy7dw87duxg0pSIiIiqTRQFiGrOaVpy/b1792BhYSGVV7eXaXl8fHxgZ2eH27dv4+WXX4aTkxMePXqkVKeoqAipqanS0FMnJ6dyh6aWnCMi0ra7d+/Cx8enyvVjYmLK9KCvyLBhw5CcnIz58+cjMTERLVu2xMGDB6Ue9/Hx8VKPUqD4g69Dhw5h+vTpaN68OVxdXfHee+9h1qxZqt1UJR6m5wIA8goVz6hJRER1kcqTt6xduxZ6enpYvXq1VGZrawtXV1f8/fffmoyNiIiIqNosLCyUNk0mTRMSEvD48WM4OzsDAAIDA5GWloaLFy9KdY4cOQKFQoGAgACpzokTJ1BYWCjVOXz4MHx9fTk0n4h0gq+vL4YMGYJdu3YhLy+v3DoFBQXYs2cPhg4dCl9fX5XanzJlCuLi4pCfn4+zZ89KPx+B4nmjw8PDleoHBgbizJkzyMvLk6ZGKT3HqboK5cVDE3zszTTWJhERvThU7ml6584d+Pv7Y+rUqZg2bZpUbmNjg+vXr2syNiIiIqqLamghp8pkZWXh9u3b0nFMTAwuX74MGxsb2NjYYOHChRg8eDCcnJxw584dzJw5Ew0aNEBwcDCA4sVJevXqhTfffBMbN25EYWEhpkyZguHDh8PFxQUAMHLkSCxcuBDjx4/HrFmzcPXqVaxZswarVq2q/RsmIiqHq6srfvnlF+zatQsGBgZo0qQJvLy8YG5ujqysLMTFxeHatWsoLCyEKIrw9PTUdsjVplCIeOt/xR90GepxISgiIipL5aSppaUlHjx4oPTJY1paGqKjo2FpaanR4IiIiKhu0eTwfFVcuHABQUFB0vGMGTMAAOPGjcOGDRvwzz//4JtvvkFaWhpcXFzQs2dPLF68WKn36rZt2zBlyhS8/PLL0NPTw+DBg7F27VrpvKWlJX7//XdMnjwZbdq0gZ2dHebPn4+JEyeqcbdERJpz69YtbN68GV9++SWuXr2Kv//+u9zRhM2aNcM777yD0NBQLUSpGX8npEn7zlbG2guEiIh0lspJ065du+KXX36RhlLcuXMH7du3R25uLl599VWNB0hERERU07p16wZRrLiL66FDh57Zho2NDbZv315pnebNm+PkyZMqx0dEVBsMDQ0xadIkTJo0CdevX8epU6dw69YtpKenw8LCAg0bNkTnzp3RpEkTbYeqttxCubS/fmRrLUZCRES6SuWk6ZIlS3D48GFcuXIFgiAgJSUFycnJsLS0rPaKtEREREQAiofmqzs8XwvD+4mIXjRNmjR5IZKjz9LQoR7MZCo/FhMRUR2g8uQtvr6+uHDhAsaNG4fGjRujcePGGDduHM6ePQs/P7+aiJGIiIjqDEFDGxERUcWK5PyEjYiIKletj9QaNGiArVu3ajoWIiIiIiIioho3dss5AIC8kqlZiIiobqvWMoF///03Ro4ciWbNmqFZs2YYNWoULl++rOHQiIiIqM4RNbQRERFVICnj30WNHc25CBQREZVP5Z6mP//8M4YPHw6FQiEtmHD9+nX88MMP2LFjBwYPHqzxIImIiKiO4JymRERUw365dF/aDw9tp8VIiIhIl6nc03T27NmQy+WwtLTEa6+9htdeew1WVlaQy+WYM2dOTcRIREREREREpBH7/nkAADA21IPMQF/L0RARka5SuadpQkICLC0tcePGDTg6OgIAHj16BF9fXyQkJGg8QCIiIqpDRKF4U7cNIiLSiKNHj+LMmTOwtrbGyJEjkZaWBkdHR8hkMm2HVm2p2QUAgFebu2g5EiIi0mUqJ00DAgKQlJQkJUwBwMHBAU5OTnByctJocERERFS3iGLxpm4bRESkntzcXPTv3x9HjhwBUPwc6ODggKFDh2Lp0qWYNWuWliOsnoIiBR6mF89p2sHHVsvREBGRLqvS8Pz4+HhpmzNnDhISEjBv3jxcvXoVV69exUcffYT79+9zeD4REREREdELYN68eYiIiIAoitJaFn379oWRkRH279+v5eiqb/+VB9J+dz8HLUZCRES6rko9Tb29vcuULVu2DMuWLZOORVFEnz59UFRUpLnoiIiIqG7hQlBERDrhhx9+gImJCSIjI9GyZUsAgEwmg6enJ6Kjo7UbnBr0hH+ncLExM9JiJEREpOuqlDQVqzjOrar1iIiIiMrFOU2JiHTCo0eP0KRJEzRv3lyp3NDQEGlpadoJSoNeamCn7RCIiEjHVSlpevTo0ZqOg4iIiIiIiHSEs7MzoqOjcefOHans8uXLuHHjBjw8PLQYGRERUe2oUtK0a9euNR0HEREREQSxeFO3DSIiUs+AAQPwxRdfoGnTphAEAX/99Rfat28PURQxYMAAbYdHRERU46qUNH3ao0ePsH//fjx48AByuVzp3Pz58zUSGBEREdVBnNOUiEgnLF68GCdOnMDff/8NAMjPzwcANG/eHAsXLtRmaERERLVC5aTp+fPn8corryAzM7Pc80yaEhERERERPd8sLCxw7tw5fP/99zh37hwAoF27dhgxYgSMjLiAEhERvfhUTpp+9NFHyMjIKPecIHDhBSIiIlIDF4IiItIJ3377Lezt7TF27FiMHTtWKo+NjUVOTg6aNGmixeiIiIhqnp6qF5w7dw7Gxsa4desWAKBDhw6IjIyEo6Oj9AkkERERUbWIGtqIiEgtISEhWLx4cZnyESNGoHnz5lqIiIiIqHapnDTNysqCn58f6tevD0EQUFRUhICAADg4OOCdd96piRiJiIiIiIhIB6SmpkIU+ekUERG9+FQenm9paYm8vDwAgJWVFa5du4adO3fi9u3b/OVJRERE6uFCUEREWuXj4yPt//XXX0rHOTk5SE5Ohq2trTZCIyIiqlUqJ029vb1x7do15OXloXXr1oiIiMDIkSMBgPPaEBERkXqYNCUi0qrY2FgAxetV5OfnS8elDRo0qHaDIiIi0gKVk6bTpk3D+fPncf/+fSxduhQ9e/ZEeno6zMzM8Nlnn9VEjERERERERFQLFixYAABYuHAh3NzcMH78eOmcqakp/Pz88Oqrr2orPCIiolqjctJ05MiRUs/S+vXrIyEhAVFRUfDx8YGVlZWm4yMiIqK6RBSKN3XbICKiailJmh49ehT+/v7SMRERUV2jctL0aWZmZmjevDlef/11CIKAn3/+WRNxERERUR0kiMWbum0QEZF6jh07pu0QiIiItErtpCkAyOVy7N69G4LAnh1ERERERETPu6KiInz44YfYsWMHHjx4AIVCIZ0TBAFFRUVajI6IiKjmaSRpSkRERKQRXAiKiEgnLF68GCtWrNB2GERERFqjp+0AiIiIiIiISLd8//33EAQBo0ePBgC4ubmhT58+sLGxwbx587QcHRERUc2rck/T+Pj4Cs/l5+drJBgiIiIiIiLSvvj4eLi5ueHbb7/Fd999Bzc3N+zZsweenp7Iy8vTdnhEREQ1rspJUy8vL85ZSkRERDVKgAYWgtJIJEREdZuBgQHs7OwAAEZGRkhKSoKenh4MDQ2xZcsWfPLJJ1qOkIiIqGapNKepKHKSsBfVa42awUAw1HYYRFox49Y2bYdApBU5mXJEHtJ2FE8RheJN3TaIiEgtDg4OSExMBAB4enri9u3baNy4MWJjY2Ftba3l6IiIiGpelZOmCxYsqMk4iIiIiIiISEc0b94ce/bswc2bNzF48GAsX74cUVFRAIABAwZoOToiIqKax6QpERER6Q7x/zd12yAiIrXs2LED+fn5MDMzw5IlS2BmZoazZ8+iefPmmDt3rrbDIyIiqnEqDc8nIiIiqlFMmhIR6QRjY2MYGxtLxx9++KG0n5qaClNTU22ERUREVGv0tB0AERERERER6b6HDx/i/fffh5eXl7ZDISIiqnFMmhIREZHOEETNbKo6ceIE+vXrBxcXFwiCgN27d0vnCgsLMWvWLDRr1gxmZmZwcXHB2LFj8eDBA6U2vLy8IAiC0rZ8+XKlOv/88w86d+4MY2NjuLu749NPP63O20REVGMeP36M/v37w9LSEs2bN8eZM2eQl5eH6dOnw8fHB6tXr0Z2dra2wyQiIqpxHJ5PREREukNLw/Ozs7PRokULhIaGYtCgQUrncnJycOnSJXz00Udo0aIFnjx5gvfeew/9+/fHhQsXlOouWrQIb775pnRsbm4u7WdkZKBnz57o0aMHNm7ciCtXriA0NBRWVlaYOHGi6kETEdWAmTNnYt++fQCAq1evYtiwYWjbti12794NUSz+AdujRw9thkhERFQrmDQlIiKiOq93797o3bt3uecsLS1x+PBhpbJ169ahffv2iI+Ph4eHh1Rubm4OJyenctvZtm0bCgoKsGXLFhgZGcHf3x+XL1/GypUrmTQlIp1x+PBhCIKAl156CQBw8uRJJCQkQBRFDBo0CHPmzEGbNm20HCUREVHNq9bw/Pz8fGzduhVvvfUWFixYgPj4eJw4cQKpqamajo+IiIjqElFDG4p7dpbe8vPzNRZmeno6BEGAlZWVUvny5ctha2uLVq1aYcWKFSgqKpLORUZGokuXLjAyMpLKgoODERUVhSdPnmgsNiIidSQmJsLDwwPHjx/H8ePH4enpCQD45ptv8NNPPzFhSkREdYbKSdPHjx+jbdu2mDBhAjZt2oTDhw/jxo0bCAoKwtq1a2siRiIiIqojNDmnqbu7OywtLaVt2bJlGokxLy8Ps2bNwogRI2BhYSGVT506FTt27MDRo0fx1ltvYenSpZg5c6Z0PjExEY6OjkptlRwnJiZqJDYiInUVFRXB2dlZOi7pPT9q1ChthURERKQVKg/PnzlzJq5duwYTExPk5uYCKJ7TxtTUFL/99hvCwsI0HSMRERGRyu7du6eU1JTJZGq3WVhYiNdffx2iKGLDhg1K52bMmCHtN2/eHEZGRnjrrbewbNkyjbw2EVFtuX79Orp37y7tA8rzmAqCgIiICK3ERkREVFtUTpru27cPlpaWuHHjBlxcXAAA+vr68PT0xN27dzUeIBEREdUholC8qdsGAAsLC6WkqbpKEqZxcXE4cuTIM9sOCAhAUVERYmNj4evrCycnJyQlJSnVKTmuaB5UIiJtyMzMxPHjx5XKSo5FUYQgqPlzmoiI6DmgctI0LS0NTZo0KfPHvVwuR2ZmpsYCIyIiojqo1JykarWhYSUJ01u3buHo0aOwtbV95jWXL1+Gnp4eHBwcAACBgYH48MMPUVhYCENDQwDFC674+vrC2tpa80ETEVWDh4cHk6JERESoRtLU09MT165dw6lTp6SyvXv3IioqCo0aNdJocERERES1ISsrC7dv35aOY2JicPnyZdjY2MDZ2RlDhgzBpUuXsG/fPsjlcmkOUhsbGxgZGSEyMhJnz55FUFAQzM3NERkZienTp2P06NFSQnTkyJFYuHAhxo8fj1mzZuHq1atYs2YNVq1apZV7JiIqT2xsrLZDICIi0gkqJ01HjBiBxYsXo2vXrhAEAWfPnsXAgQMhCAJGjBhREzESERFRHVF6ISd12lDVhQsXEBQUJB2XzE86btw4hIWFYc+ePQCAli1bKl139OhRdOvWDTKZDDt27EBYWBjy8/Ph7e2N6dOnK81zamlpid9//x2TJ09GmzZtYGdnh/nz52PixImqB0xERERERDVK5aTphx9+iAsXLuC3335TKg8ODsacOXM0FhgRERHVQVoant+tWzeIYsUXVnYOAFq3bo0zZ84883WaN2+OkydPqhwfERERERHVLpWTpkZGRti/fz9OnDiBc+fOAQDatWuHrl27ajw4IiIiIiIiIiIiotqmctK0RJcuXdClSxdNxkJERER1nQaG59fEQlBERPRiuP4gQ9shEBHRc0LlpGn37t0rPCcIAiIiItQKiIiIiOowLQ3PJyKiusFAXwAA3H6UpeVIiIhI16mcND127BgEQVCa26vkWBAEjQZHRERERERE2pOdnY1//vkH+vr6aN++vbbDUZve/z+zBvs7ajkSIiLSdSonTceOHauUHE1PT8exY8eQmZmJ4cOHazQ4IiIiqmPY05SISGcsWbIEy5cvR25uLgICAjBt2jTMnj0bS5YswciRI7UdnlrY4YeIiJ5F5aRpeHh4mbKUlBQ0b94cbm5umoiJiIiI6ihBA3Oaqj0nKhERYePGjZg/f75S2csvv4x79+5hx44dz33SlIiI6Fn0NNGInZ0dGjRoUG5ClYiIiIiIiJ4va9euhZ6eHlavXi2V2drawtXVFX///bf2AiMiIqolKvc0XbRokdKxXC5HdHQ0Tp06BWtra40FRkRERERERNpx584d+Pv7Y+rUqZg2bZpUbmNjg+vXr2svMCIiolqictI0LCyswvlfXn31VbUDIiIiojqMc5oSEekES0tLPHjwAHl5eVJZWloaoqOjYWlpqcXIiIiIaofKSVMPDw+lpKkgCHBwcMDLL7+MOXPmaDQ4IiIiIiIiqn1du3bFL7/8goCAAADFPU/bt2+P3NxcdpYhIqI6QeWkaWxsbA2EQURERMSFoIiIdMWSJUtw+PBhXLlyBYIgICUlBcnJybC0tERYWJi2wyMiIqpxKi0EVVhYiPr166N169YQRT6REBERUQ0Q1dyIiEhtvr6+OH/+PMaNG4fGjRujcePGGDduHM6ePQs/Pz9th0dERFTjVOppamhoiMzMTNSrV6/CeU2JiIiIiIjo+RYdHY1GjRph69at2g6FiIhIK1TqaQoAISEhiIqKwtWrV2siHiIiIqrL1O1lyt6mREQa0bhxY3Tq1AlfffUV0tPTtR0OERFRrVN5TtPExEQAQLt27RAUFARHR0ep16kgCNi8ebNmIyQiIqI6g3OaEhHpBlEUERkZiTNnzmDatGkYMGAAxo0bh+DgYI46JCKiOkHlpOl3330HQRAgiiIOHjwo/cIURZFJUyIiIiIiohfAH3/8gZ07d+KXX37B48ePsXPnTvzwww9wcnLCmDFjsHz5cm2HSEREVKOqnDRdtGgR3Nzc0LVr15qMh4iIiOoyTQyvZ09TIiK1de/eHd27d8eXX34pJVB3796Nhw8fYsWKFUyaEhHRC6/KSdOwsDB06NABf/75Z03GQ0RERHUYh+cTEemWwsJCZGZmIjMzE/n5+doOh4iIqNaovBAUERERERERvdj27t2LUaNGwcHBAcOGDcMvv/yC3Nxc+Pj4YMGCBdVqc/369fDy8oKxsTECAgJw7ty5Kl23Y8cOCIKAgQMHVut1iYiIqkOlOU3z8/MRHx9faR0PDw+1AiIiIqI6jMPziYh0woABA6S1LCwsLDB06FCMGzcOL730UrXa27lzJ2bMmIGNGzciICAAq1evRnBwMKKiouDg4FDhdbGxsfjPf/6Dzp07V/dWlGw8fkcj7RAR0YtPpaTp5cuX4e3tXeF5QRBQVFSkdlBERERURzFpSkSkEwRBwCuvvIJx48bhtddeg7GxsVrtrVy5Em+++SbeeOMNAMDGjRuxf/9+bNmyBbNnzy73GrlcjlGjRmHhwoU4efIk0tLS1IoBAKxNjfAoMx93U7LVbouIiF5sKiVNAUAU+SRCRERERET0Irt37x5cXFw00lZBQQEuXryIOXPmSGV6enro0aMHIiMjK7xu0aJFcHBwwPjx43Hy5MlKXyM/P19pztWMjIxy61mYGOJRZj7e7FxxZyAiIiJAxaSpq6srxo8fX1OxEBERUR3HhaCIiLTn22+/hb29PXr37o0//vij0rpjx46tcrspKSmQy+VwdHRUKnd0dMTNmzfLvebUqVPYvHkzLl++XKXXWLZsGRYuXFjlmAz1ubwHERFVTqWkqZubW7Un/SYiIiJ6Jg7PJyLSmpCQEAQGBqJ3794ICQmBIAjl1hMEQaWkqaoyMzMxZswYfP3117Czs6vSNXPmzMGMGTOk44yMDLi7u5epVyhXaCxOIiJ6sak8PJ+IiIiIiIheTKWnY6toajZVp2yzs7ODvr4+kpKSlMqTkpLg5ORUpv6dO3cQGxuLfv36SWUKRXGy08DAAFFRUahfv77SNTKZDDKZ7JmxxD3O+f97UOkWiIioDqpy0tTDwwPOzs41GQsRERHVdexpSkSkNSWJyaf31WVkZIQ2bdogIiICAwcOlNqPiIjAlClTytT38/PDlStXlMrmzZuHzMxMrFmzptwepKpysVJvYSsiInrxVTlpGhsbW4NhEBEREXFOUyIiXbFo0SK4u7tLq92XiIyMxJMnT9CnTx+V2psxYwbGjRuHtm3bon379li9ejWys7Ol9seOHQtXV1csW7YMxsbGaNq0qdL1VlZWAFCmvLrMZBx0SUREleNvCiIiIiIiIlISFhaGDh06lEmazpgxA+fOnYNcLlepvWHDhiE5ORnz589HYmIiWrZsiYMHD0qLQ8XHx0NPj4szERGR7mDSlIiIiHQHh+cTEems3NxcPHz4sNrXT5kypdzh+ABw7NixSq8NDw+v9usSERFVB5OmREREpDM4PJ+ISLv09fUBAIIg4OzZs9JxaSW9Q4mIiF5kTJoSERERERERAED8/2XlBUGQ9p82ceLE2gyJiIhIK5g0JSIiIt3B4flERFq1detWAMAbb7yB+vXrY968edI5U1NT+Pn5oVmzZtoKj4iIqNZwpm0iIiLSHaKGNhWdOHEC/fr1g4uLCwRBwO7du5XDEkXMnz8fzs7OMDExQY8ePXDr1i2lOqmpqRg1ahQsLCxgZWWF8ePHIysrS6nOP//8g86dO8PY2Bju7u749NNPVQ+WiKgGjRs3DuPGjcPYsWOl/ZJt6NChTJgSEVGdwaQpERER1XnZ2dlo0aIF1q9fX+75Tz/9FGvXrsXGjRtx9uxZmJmZITg4GHl5eVKdUaNG4dq1azh8+DD27duHEydOKA1hzcjIQM+ePeHp6YmLFy9ixYoVCAsLw1dffVXj90dEVBXx8fFISkoCACxatAhjx45FfHx8uRsREdGLjsPziYiISGcI/7+p24aqevfujd69e5d7ThRFrF69GvPmzcOAAQMAAN9++y0cHR2xe/duDB8+HDdu3MDBgwdx/vx5tG3bFgDwxRdfoE+fPvjss8/g4uKCbdu2oaCgAFu2bIGRkRH8/f1x+fJlrFy5kvMDEpFO8PLyQmBgIE6fPg1vb+8K6wmCgKKiolqMjIiIqPaxpykRERHpDi0Nz69MTEwMEhMT0aNHD6nM0tISAQEBiIyMBABERkbCyspKSpgCQI8ePaCnp4ezZ89Kdbp06QIjIyOpTnBwMKKiovDkyRPNBk1EVE0liz+JoljpRkRE9KJjT1MiIiJ6IWVkZCgdy2QyyGQyldtJTEwEADg6OiqVOzo6SucSExPh4OCgdN7AwAA2NjZKdZ7uuVXSZmJiIqytrVWOjYhIk44ePQoLCwtpn4iIqC5j0pSIiIh0hiAWb+q2AQDu7u5K5QsWLEBYWJh6jRMRvcC6du1a7j4REVFdxOH5REREpDs0ODz/3r17SE9Pl7Y5c+ZUKyQnJycAkBZHKZGUlCSdc3JywqNHj5TOFxUVITU1ValOeW2Ufg0iIl1x8OBBLFq0CNHR0cjMzES/fv1gaWmJLl26ICEhQdvhERER1TgmTYmIiOiFZGFhobRVZ2g+AHh7e8PJyQkRERFSWUZGBs6ePYvAwEAAQGBgINLS0nDx4kWpzpEjR6BQKBAQECDVOXHiBAoLC6U6hw8fhq+vL4fmE5HOWbFiBRYtWgRLS0v897//xf79+5GZ+X/t3XlYVNX/B/D3sAz7vqMIoiDIprkgmqmJoiLlkmsKbpVrpmFqqRhWmt/cKr9a7pZrpmZ+y1QCTUXNhVIxFBVRBMQNBJT1/P7gx42RddhmxPfree7zOOeee+7n3hmcez9zzrmPcfz4ccyaNUvV4REREdU5Jk2JiIhIvajgIVCZmZmIiYlBTEwMgKKHP8XExCAxMREymQzvvfcePvnkE+zbtw8XLlxAcHAw7O3t0a9fPwCAu7s7evXqhbfeegunT5/G8ePHMXnyZAwdOhT29vYAgOHDh0Mul2Ps2LG4dOkSduzYgRUrVmD69OnVC5qIqA7FxsaicePGsLGxwZEjR2BsbIxt27ZBV1cXUVFRqg6PiIiozjFpSkRERGqjeE7Tmi7KOnPmDFq3bo3WrVsDAKZPn47WrVtj3rx5AIAPPvgAU6ZMwdtvv4127dohMzMTBw4cgK6urtTGli1b4Obmhu7du6NPnz54+eWX8e2330rrTUxMcPDgQdy4cQNt2rTB+++/j3nz5uHtt9+u2UkjIqoDDx8+hJWVFQDgn3/+Qdu2bTFkyBC4u7vj3r17Ko6OiIio7vFBUERERPTC69q1K4QoP9sqk8kQHh6O8PDwcuuYm5tj69atFe7H29sbf/zxR7XjJCKqL+bm5rhy5Qq2bduGhIQEBAYGAgDS09Nhamqq2uCIiIjqAXuaEhERkfqoxQdBERFR9XXr1g2PHz/GiBEjUFhYiICAAGRlZeHWrVtwcXFRdXhERER1jj1NiYiISG1Ud3j9s20QEVHNLF26FE+ePEF8fDyCgoLQu3dvHD9+HO3atcPQoUNVHR4REVGdY9KUiIiIiIiIFNjY2GD37t0KZZ06deIUI0RE9MJg0pSIiIjUR20Mr2dPUyKiWnH//n18/fXXOHPmDACgXbt2mDRpEiwsLFQcGRERUd1j0pSIiIjUBofnExGph1u3bqFjx464c+eOVPbLL79g7dq1OHHiBBo3bqzC6IiIiOoeHwRFRERERERECj788EMkJSVBJpPBzc0Nbm5ukMlkSEpKwkcffaTq8IiIiOock6ZERESkPkQtLUREVCOHDh2Cnp4e/vzzT1y6dAmXLl3C6dOnoaOjg99++03V4REREdU5Jk2JiIhIfTBpSkSkFh48eABnZ2e0bt1aKnvppZfg7OyMhw8fqjAyIiKi+sGkKRERERERESmwtbXFlStX8PPPP0tl+/btw5UrV2Bra6vCyIiIiOoHk6ZERESkNoofBFXThYiIaiYoKAh5eXno168fjIyMYGRkhP79+6OgoACvvfaaqsMjIiKqc0yaEhERkfrg8HwiIrXwySefwMPDA0IIZGVlISsrC0IIeHh4YMGCBaoOj4iIqM5pqToAIiIiIiIiUi9mZmY4c+YMtm7dijNnzgAA2rVrh2HDhkFHR0fF0REREdU9Jk2JiIhIbciEgEzUrKtoTbcnIiIgPT0dADB69GiMHj1axdEQERHVPw7PJyIiIvXB4flERCqVnZ2Nfv36wdzcHObm5ujfvz+ePHmi6rCIiIjqHZOmREREREREBABYtmwZ9u3bByEEhBDYt28fli1bpuqwiIiI6h2TpkRERKQ2ZKJ2FiIiqp5t27ZBJpPB19cXvr6+EEJg27Ztqg6LiIio3nFOUyIiIlIftTG8nklTIqJqS0xMhJ2dHU6cOIHCwkI0adIEN2/eVHVYRERE9Y49TYmIiIiIiAgAkJmZiSZNmkAmk0FTUxNNmjRBVlaWqsMiIiKqd+xpSkRERGqjNobXc3g+EVHNpKWlYfPmzdK/AeC7776DEP/+BxscHKyS2IiIiOoLk6ZERESkPjg8n4hI5a5fv47Ro0crlI0aNUr6t0wmY9KUiIgaPCZNiYiIiIiISFKyRykREdGLiklTIiIiUhscnk9EpFqRkZGqDoGIiEgtMGlKRERE6oPD84mIVKpLly6qDoGIiEgtaKg6ACIiIiIiIiIiIiJ1wp6mREREpFY4vJ6IiIiIiFSNSVMiIiJSH0IULTVtg4iIiIiIqAY4PJ+IiIiIiIiIiIioBPY0JSIiIrUhEzUfns/h/UREREREVFPsaUpERETqQ9TSQkRENRYXF4eQkBC0aNECQUFBOHnyJMLDw3Hx4kVVh0ZERFTn2NOUiIiIiIiIFPz111/o3LkzsrKyIISAhYUFdHV1MX/+fNy9exdff/21qkMkIiKqU+xpSkRERGpDVlg7CxER1cysWbOQmZmJNm3aSGWtWrWCubk5IiMjVRgZERFR/WDSlIiIiNQHh+cTEamF48ePo1GjRoiOjlYod3BwwK1bt1QUFRERUf3h8HyiWubpm4lBE9Pg4pUNC9t8zB/jhOgDJtJ6U8s8jP0oGW26PIaBSQEunjTEyjmNcOeGjlRn8a54+HTMUmj3f5st8OWsxvV2HERVcXa1Ga4fNMLD63Jo6RTC9qWn8JuRBjPnPKnOpe0muPKzEdIu6SAvSxPjzsZDx7jsroAFOTL88IYD7v+ji8E/3YRVyxwAwMPr2jgyzwYP4uXIfawBA+t8uAQ9Rrsp96GpXS+HSkRE9EIpKCiAoaEhNDU1FcrT0tJQWMgu/URE1PCprKepTCarcJk/fz4SEhLKXX/y5EkAwMaNG6UyDQ0N2NnZYciQIUhMTFTYX9euXSGTybBo0aJSsQQGBkr7LFn/vffeK7X99u3bFbZdvnw5nJycSrX55MkTmJubw9LSEjk5OaViLW9JSEjA/Pnzy1zn5uZWKh6ZTAYdHR00atQIQUFB2L17t7JvBdUyXf1CXL+ki68/LCvBKRC2PgF2jrmYP7opJvV0ReptbSzacQ06egUKNX/53hxDfVpKy9pP7OrnAIiUcOe0PjzffISBPyTitY23UZgH7BvdGHnZMqlO/hMZmryShTYTHlTa3onFljCwKShVrqEFtOiXgdc23Mbwgwl4eU4aYnea4PSXFrV6PKR6MlE7izKcnJzK/N6dNGkSAMXv3OJl/PjxCm0kJiYiMDAQ+vr6sLa2xowZM5Cfn19bp4WIqN61bNkSV65cwSeffAIAyMjIQGhoKO7cuQNPT08VR0dERFT3VNbTNDk5Wfr3jh07MG/ePMTFxUllhoaGuHfvHgDg8OHD8PDwUNjewuLfG2VjY2PExcVBCIEbN25g4sSJGDRoEE6dOqWwjYODAzZu3IhZs2ZJZUlJSYiIiICdXeUJKV1dXcyZMwcDBw6EtnbFXZt+/PFHeHh4QAiBvXv3YsiQIRgyZAh69eol1RkwYAA8PT0RHh4ulVlZWQEAPDw8cPjwYYU2tbQU36633noL4eHhyM/Px+3bt7Fnzx4MHToUo0aNwrffflvp8VDdOBNpjDORxmWua+Sci5Zts/F21xa4eUUXAPDVrMbY/lcsuvV/hANb//1c5zzRwMM0dqEj9Ra0PknhdffPU7G+QzOkXdSFffsnAACf0Y8AAEmn9Cps6+YRfdw6po9eXycj8YiBwjqTJnkwafJv71XjRvlIOvUYyWcqbpOeQ0IULTVtQwl//vknCgr+TdZfvHgRPXr0wKBBg6Sy4u/cYvr6+tK/CwoKEBgYCFtbW5w4cQLJyckIDg6GtrY2PvvssxocCBGR6kydOhXBwcEICwuDTCbD5cuXcfnyZchkMkyePFnV4REREdU5lSVNbW1tpX+bmJhAJpMplAGQkqYWFhal1pVUcls7OzuMHTsW7777LjIyMmBs/G/yqm/fvti5cyeOHz+OTp06AQA2bdqEnj17luqZWpZhw4Zh3759WLNmDSZOnFhh3XXr1mHEiBEQQmDdunUYMmQI9PT0oKf37w2+XC6Hvr5+mcempaVV4TEDUNi2cePG6NChA9zc3DBmzBgMHjwY/v7+lR4T1S9tedFQptycf3vhCSFDXq4MHu2yFJKm3QY8xKsDH+LhXW2cPGSMrcttkPOE0xCTesvJLPqM6piW7i1akex7moj8yAZ9Vt2Bll7lQ/4e3dRG4lF9OPfMrFacRCUV/2BZbNGiRWjWrBm6dOkilZX3fQ0ABw8eRGxsLA4fPgwbGxu0atUKCxYswMyZMzF//nzI5fI6jZ+IqC6MGDECd+7cQXh4OLKzswEAenp6mDt3LkaMGKHi6IiIiOpeg8vA3L17F3v27IGmpmap+XfkcjnefPNNbNiwQSrbuHEjxowZU6W2jY2N8dFHHyE8PBxZWVnl1rt27Rqio6MxePBgDB48GH/88Qdu3rxZvQNSUkhICMzMzModpp+Tk4OMjAyFherPrXhdpN7WxpjZyTA0yYeWdiEGT7oLK/s8mNv824suco8ZFk9ugg/eaIbtX1mj+8CH+OCryhP7RKokCoFjn1jBrs0TWLjmVn07AUTMtIXnsHRYe+VUWPfHwQ5Y7dEcW/ybwq7tE/i+d7+mYZOaqc3h+c9+3xVPl1OR3NxcfP/99xgzZgxksn9/4NqyZQssLS3h6emJ2bNnSwkEAIiOjoaXlxdsbGyksoCAAGRkZODSpUu1d3KIiOrZBx98gLS0NJw+fRqnT5/GvXv3FEbtERERNWTPRdK0Y8eOMDQ0VFhKSk9Ph6GhIQwMDGBjY4PIyEhMmjQJBgYGpdoaM2YMdu7ciaysLBw9ehTp6eno27dvlWOZOHEidHV1sXTp0nLrrF+/Hr1794aZmRnMzc0REBCgkKitigsXLpQ65mfnTyuLhoYGXF1dkZCQUOb6hQsXwsTERFocHByUiotqpiBfhvCxTmjULAc/Xr6EfdcuwKdjJk5HGEEU/ntz/usWC5w9YoyEf/QQuccM/5nqgJf7pMPOsfIbfiJVOTLfGg+u6qDnsuTKK5fw92ZT5GVp4KXxlc952nNFMgbvTUSPpcm4GWWA82vNqhsuqStRSwuKpuUp+Z23cOHCSne/d+9ePHr0CKNGjZLKhg8fju+//x6RkZGYPXs2vvvuO4VeVikpKQoJUwDS65SUFKVPARGROtHT00Pbtm0hhMDq1atLTSFGRETUUKlseL4yduzYAXd393LXGxkZ4dy5c8jLy8Ovv/6KLVu24NNPPy2zro+PD1xcXLBr1y5ERkZi5MiRpeYKrYiOjg7Cw8MxZcoUTJgwodT6goICbNq0CStWrJDKRowYgdDQUMybNw8aGlXLU7do0QL79u1TKCs51UBFhBAKvWNKmj17NqZPny69zsjIYOK0nsVf0MfEHi2gb1QAbW2B9AdaWLH/Kq78Xf7cjP+cK5o7z94pB8k3deorVKIqO/qxNW5GGqD/1lswtFPu4TdJJ/WRcl4Xqz1cFMp/GNAErq9lwH9xqlRm9P9tm7vkQhQCUXNs0GrsQ2goDiwgAgDcunVL4btTR6fy/z/XrVuH3r17w97eXip7++23pX97eXnBzs4O3bt3x7Vr19CsWbPaDZqISE0EBwdjy5YtOHLkCIQQePXVV1FYWDSFzpo1a6o8Wo+IiOh59VwkTR0cHNC8efNy12toaEjr3d3dce3aNUyYMAHfffddmfXHjBmDlStXIjY2FqdPn1Y6nhEjRuCLL77AJ598AicnJ4V1v/32G5KSkjBkyBCF8oKCAkRERKBHjx5V2odcLq/wmMtTUFCAq1evol27dmWu19HRqdJNI9W97MdFWR77pjlw8cnGpv+UP4dtM8+nAIAHd/lgKFIvQgB/hFvj+iFD9Pv+FowdlH9aeOe5d+E77d8flLJStfDzmMYIWJ4MG5+n5e+7ECjMl0EUAmDStMEoOby+Jm0ART82VvUHRwC4efMmDh8+XO4UN8V8fX0BAPHx8WjWrBlsbW1LXU+kphYl+yubn5yISF2dOXMGhoaG6NSpEyZMmICCggK4ubnhn3/+wddff82kKRERNXjPxfB8Zc2aNQs7duzAuXPnylw/fPhwXLhwAZ6enmjZsqXS7WtoaGDhwoVYtWpVqWHw69atw9ChQxETE6OwDB06FOvWravO4Shl06ZNePjwIQYOHFjn+6Ky6eoXwNnjCZw9ip4cbuuQC2ePJ7BqVDTHY+e+j+DtlwnbJjnwC0jHwu3XEH3ABOeOGAEA7BxzMPy9VDT3yoZN41x06JmOGSsS8Xe0AW5c5pPCSb0cnW+NuJ+M0GNJMrQNCpGVpomsNE3kP/23t3tWmibSYnWQfrMo6X8/TgdpsTp4+qjoK8jIPh8WrrnSYtq06G/FuEme1Gs17icjXP3FEA/i5UhP1MbVXwxxcokVmvd5DE3+ltCwCFE7SzVs2LAB1tbWCAwMrLBeTEwMgKKHTwKAn58fLly4gLt370p1Dh06BGNj42pdZxARqYPbt2/DyckJMpkMMTExaNmyJWJjY9G0aVNcu3ZN1eERERHVueeip+n9+/dLzQlmamoKXV3dMus7ODigf//+mDdvHvbv319qvZmZGZKTk6GtXf077cDAQPj6+uKbb76R5i1LS0vDzz//jH379sHT01OhfnBwMPr3748HDx7A3Ny80vbz8/NLHbNMJlOYMy07OxspKSnIz8/H7du3sWfPHixbtgwTJkxAt27dqn1sVDOuPk/wnx//vZAc//EdAMDBHWZYMq0JzG3y8M78OzC1zMeDu1o4/IMZti7/933Nz5OhdefH6D8uDbr6hUi7o41jv5hg23KbUvsiUrWLW00BAHtHKE7z8eqiFLgPLHrQ3KVtpvjzKwtp3Z7hDqXqVEZDS+D8t+Z4lCCHEICRfR68RjyEz+hHNT8IIgCFhYXYsGEDQkJCFKbtuXbtGrZu3Yo+ffrAwsICf//9N6ZNm4ZXXnkF3t7eAICePXuiZcuWGDlyJBYvXoyUlBTMmTMHkyZN4ugOInquFT9A78qVKwgICABQ1Iu/uDc9ERFRQ/ZcJE39/f1LlW3btg1Dhw4td5tp06bBz88Pp0+fRvv27UutNzU1rXFcn3/+OTp27Ci93rx5MwwMDNC9e/dSdbt37w49PT18//33ePfddytt+9KlS1IPlmI6Ojp4+vTfoapr1qzBmjVrIJfLYWFhgTZt2mDHjh3o379/DY6KaurvaEME2PuUu/6ndVb4aZ1VuevT7sgxY6DyUzMQqcKkq1cqrdP+3fto/27Vn3Jv3Di/VLsugZlwCcxUOj56/tTm8HxlHD58GImJiaWGm8rlchw+fBjLly9HVlYWHBwcMHDgQMyZM0eqo6mpif3792PChAnw8/ODgYEBQkJCEB4eXrMDISJSoWbNmuHvv/+Gu7s70tPT0aZNGwDAnTt3FOZ9JiIiaqhkQlRzDBs1CBkZGTAxMUFXvA4tGce40oupKok/ooYo+3EB3mx9Cenp6UrN/VkXir+P/HqFQ0u77JEkVZWf9xTRB+apxXERET2vNm/ejNGjR0MIAXNzc1y6dAl3796Fj48Phg0bhi1btqg6xAoVf688+13gNOt/AIAzc/xhacjRAEREDVF53wHKei56mhIREREREVH9CQ4ORqtWrRAfH49OnTrBxsYGhYWFOHToEJydnVUdHhERUZ1j0pSIiIjUhqqG5xMRUWne3t7S/M1A0QPwnp1CjIiIqKFi0pSIiIjUR6EoWmraBhERKe3VV1+tUj2ZTIaIiIg6joaIiEi1mDQlIiIiIiIiREVFQSaTobLHXshksnqKiIiISHWYNCUiIiL1If5/qWkbRESktODgYCZEiYiI/h+TpkRERERERISNGzeqOgQiIiK1oaHqAIiIiIiKyfDvw6Cqvaj6IIiIGpDc3FwkJSUhMTFRYamOlStXwsnJCbq6uvD19cXp06fLrbtmzRp07twZZmZmMDMzg7+/f4X1iYiIahuTpkRERKQ+hKidhYiIauTx48cYMmQIjIyM0KRJEzRt2lRanJ2dlW5vx44dmD59OsLCwnDu3Dn4+PggICAAd+/eLbN+VFQUhg0bhsjISERHR8PBwQE9e/ZEUlJSTQ+NiIioSpg0JSIiIiIiIgVz5szBDz/8gLy8PAghSi3KWrp0Kd566y2MHj0aLVu2xOrVq6Gvr4/169eXWX/Lli2YOHEiWrVqBTc3N6xduxaFhYWIiIio6aERERFVCZOmREREpDZqPDT//xciIqqZn376CTKZDB999BEAoFmzZhg/fjzMzc3x9ddfK9VWbm4uzp49C39/f6lMQ0MD/v7+iI6OrlIb2dnZyMvLg7m5eZnrc3JykJGRobAQERHVBJOmREREpD5ELS1ERFQjycnJcHZ2xoIFCwAAlpaW+O9//wsTExOcO3dOqbbu3buHgoIC2NjYKJTb2NggJSWlSm3MnDkT9vb2ConXkhYuXAgTExNpcXBwUCpGIiKiZzFpSkRERERERAp0dHRgZGQEANDV1cXt27eRl5eHnJwc/PDDD/Uay6JFi7B9+3bs2bMHurq6ZdaZPXs20tPTpeXWrVv1GiMRETU8WqoOgIiIiKiYTAjIavggp5puT0REgK2tLW7fvg2gaGh+bGwsrKyskJGRASsrK6XasrS0hKamJlJTUxXKU1NTYWtrW+G2X3zxBRYtWoTDhw/D29u73Ho6OjrQ0dFRKi4iIqKKsKcpERERqY/CWlqIiKhG/Pz8kJeXhwsXLmDUqFEQQkjzhAYHByvVllwuR5s2bRQe4lT8UCc/P79yt1u8eDEWLFiAAwcOoG3bttU7kBJy8gtq3AYREb042NOUiIiIiIiIFGzatEn6t5eXF+zs7HDy5El4e3tj7NixSrc3ffp0hISEoG3btmjfvj2WL1+OrKwsjB49GkBRIrZRo0ZYuHAhAODzzz/HvHnzsHXrVjg5OUlznxoaGsLQ0LBax3TrQbb0b1M97Wq1QURELw4mTYmIiEhtcHg+EZFq7du3D+bm5nj55ZcVyocPH47hw4dXu90hQ4YgLS0N8+bNQ0pKClq1aoUDBw5ID4dKTEyEhsa/AyFXrVqF3NxcvPHGGwrthIWFYf78+dWOAwCMdLWgpclBl0REVDEmTYmIiEh9iP9fatoGERFVS79+/eDn54fjx48DADQ1NdGhQwfpdU1MnjwZkydPLnNdVFSUwuuEhIQa7688mhqyOmubiIgaDv68RkRERERERBJRose+EELhNRER0YuCPU2JiIhIfQhRtNS0DSIiIiIiohpg0pSIiIjUhkwULTVtg4iIiIiIqCaYNCUiIiIiIiLJ+fPn4ezsXO5rmUyGa9euqSI0IiKiesOkKREREakPDs8nIlK53NxchQcx5eTkKLyWyZ7PByklpz9VdQhERPQcYdKUiIiI1IassGipaRtERFQ9r7zyynObFK1M5tN8AMCj7DwVR0JERM8DJk2JiIiIiIgIABAVFaXqEOpMcS64raOZagMhIqLnApOmREREpD44PJ+IiOpYA+1IS0REtYxJUyIiIlIf4v+XmrZBRERERERUAxqqDoCIiIiIiIiIiIhInbCnKREREakNmRCQ1XB4fU23JyIiIiIiYtKUiIiI1AfnNCUiojoScysdAL8miIioajg8n4iIiIiIiBo8Qx1NAMDNB9kqjoSIiJ4H7GlKRERE6kMAKKyFNoiIiMrh726t6hCIiOg5wKQpERERqQ3OaUpEREREROqAw/OJiIjohTZ//nzIZDKFxc3NTVr/9OlTTJo0CRYWFjA0NMTAgQORmpqq0EZiYiICAwOhr68Pa2trzJgxA/n5+fV9KEREVIH8Qv6oRkREVceepkRERKQ+BGrhQVDKb+Lh4YHDhw9Lr7W0/r1EmjZtGv73v//hhx9+gImJCSZPnowBAwbg+PHjAICCggIEBgbC1tYWJ06cQHJyMoKDg6GtrY3PPvusZsdCRES15siVNABAfgGTp0REVDkmTYmIiEh9CFELSVPlt9fS0oKtrW2p8vT0dKxbtw5bt27Fq6++CgDYsGED3N3dcfLkSXTo0AEHDx5EbGwsDh8+DBsbG7Rq1QoLFizAzJkzMX/+fMjl8podDxER1Yom5vo4n/gIeQU1nTybiIheBByeT0RERC+8q1evwt7eHs7OznjzzTeRmJgIADh79izy8vLg7+8v1XVzc0OTJk0QHR0NAIiOjoaXlxdsbGykOgEBAcjIyMClS5fq90CIiKhSno1MVB0CERE9B9jTlIiIiNRHIQBZLbQBICMjQ6FYR0cHOjo6par7+vpi48aNaNGiBZKTk/Hxxx+jc+fOuHjxIlJSUiCXy2FqaqqwjY2NDVJSUgAAKSkpCgnT4vXF64iIiIiI6PnDpCkRERGpDZkQkNVweH7x9g4ODgrlYWFhmD9/fqn6vXv3lv7t7e0NX19fODo6YufOndDT06tRLERERERE9Hxi0pSIiIgapFu3bsHY2Fh6XVYv07KYmprC1dUV8fHx6NGjB3Jzc/Ho0SOF3qapqanSHKi2trY4ffq0QhupqanSOiIiIiIiev5wTlMiIiJSH8UPgqrpAsDY2FhhqWrSNDMzE9euXYOdnR3atGkDbW1tRERESOvj4uKQmJgIPz8/AICfnx8uXLiAu3fvSnUOHToEY2NjtGzZshZPDhERERER1Rf2NCUiIiL1USLpWaM2lBAaGoqgoCA4Ojrizp07CAsLg6amJoYNGwYTExOMHTsW06dPh7m5OYyNjTFlyhT4+fmhQ4cOAICePXuiZcuWGDlyJBYvXoyUlBTMmTMHkyZNqnKiloiIiIiI1AuTpkRERPRCu337NoYNG4b79+/DysoKL7/8Mk6ePAkrKysAwLJly6ChoYGBAwciJycHAQEB+O9//yttr6mpif3792PChAnw8/ODgYEBQkJCEB4erqpDIiIiIiKiGmLSlIiIiNSHCnqabt++vcL1urq6WLlyJVauXFluHUdHR/zyyy9K7ZeIiIiIiNQXk6ZERESkPgoByGqhDSIiIiIiohrgg6CIiIiIiIiIiIiISmBPUyIiIlIbMiEgq+Hw/JpuT0RERERExKQpERERqQ8VzGlKRERERET0LA7PJyIiIiIiIiIiIiqBPU2JiIhIfRQKQFbDnqKF7GlKREREREQ1w6QpERERqQ8OzyciIiIiIjXA4flEREREREREREREJbCnKREREamRWuhpCvY0JSIiIiKimmHSlIiIiNQHh+cTEREREZEa4PB8IiIiIiIiavDOJDxUdQhERPQcYU9TIiIiUh+FAjUeXl/InqZERFSajnZRn6HMnHwVR0JERM8DJk2JiIhIfYjCoqWmbRARET1DT1sTAODVyETFkRAR0fOAw/OJiIiIiIjohaGlydtgIiKqHHuaEhERkfrgg6CIiEhJBQUFyMvLUyjLzc2Fo6MjcnNz8fTpUwCApZ4MjYw0ISvIk8qIiOj5pKmpCS0tLchksjrbB5OmREREpD44pykRESkhMzMTt2/fhnjmB7PCwkKsXr0aqampSEtLAwCM8TZAboE+jPIe4MaNdFWES0REtUhfXx92dnaQy+V10j6TpkRERERERPTcKSgowO3bt6Gvrw8rKyuF3kYFBQV48uQJnJycoKlZNJep7F4WcvIL0NhMDwY62qoKm4iIakgIgdzcXKSlpeHGjRtwcXGBhkbtT73CpCkRERGpDw7PJyKiKsrLy4MQAlZWVtDT01NYV1BQAADQ1dWVkqaa2nmQoQByHV3o6jJpSkT0PNPT04O2tjZu3ryJ3Nxc6Orq1vo+mDQlIiIi9SFQC0nTWomEiIieE3U5nx0REamvuuhdqtB+nbZORERERERERERE9Jxh0pSIiIjUR/Hw/JouREREzymZTIa9e/eqOowa27hxI0xNTet0H7VxrkaNGoV+/frVSjzPOycnJyxfvrxW2qqN8zp37ly8/fbbtRKPsnJzc+Hk5IQzZ85Uqb4qY22IYmNj0bhxY2RlZak0DiZNiYiISH0UFtbOQkREpKYqSyYlJyejd+/e9ReQkmQymbQYGBjAxcUFo0aNwtmzZxXqDRkyBFeuXKnTWGrjXK1YsQIbN26snYCUoGxSMTo6GpqamggMDKy7oGpRTc9rSkoKVqxYgY8++kgqq+ycOTk5SZ9NPT09ODk5YfDgwfj999/LrP/kyROYm5vD0tISOTk5CuvkcjlCQ0Mxc+bMasVarKL3LSoqCjKZDI8ePSrzWJ5NYEdGRqJPnz6wsLCAvr4+WrZsiffffx9JSUmVxlhdT58+xaRJk2BhYQFDQ0MMHDgQqampFW6TmpqKUaNGwd7eHvr6+ujVqxeuXr2qVLstW7ZEhw4dsHTp0jo5rqpi0pSIiIiIiIhITdja2kJHR0elMQghkJ+fX+76DRs2IDk5GZcuXcLKlSuRmZkJX19fbN68Waqjp6cHa2vrOokvNzcXQO2cKxMTkzrvEVsb1q1bhylTpuDo0aO4c+eOqsOpVE3P69q1a9GxY0c4OjoqtV14eDiSk5MRFxeHzZs3w9TUFP7+/vj0009L1f3xxx/h4eEBNze3Mnssv/nmmzh27BguXbpU7Vhr63375ptv4O/vD1tbW/z444+IjY3F6tWrkZ6ejiVLllS73cpMmzYNP//8M3744QccOXIEd+7cwYABA8qtL4RAv379cP36dfz00084f/48HB0d4e/vr9BrtCrtjh49GqtWrarw/6K6xqQpERERqQ8OzyciohdcySHnCQkJkMlk2L17N7p16wZ9fX34+PggOjpaYZtjx46hc+fO0NPTg4ODA959912FBMV3332Htm3bwsjICLa2thg+fDju3r0rrS/u8fbrr7+iTZs20NHRwbFjx8qN0dTUFLa2tnByckLPnj2xa9cuvPnmm5g8eTIePnwIoPTw/L/++gvdunWDkZERjI2N0aZNG4Whz8ePH0fXrl2hr68PMzMzBAQESG117doVkydPxnvvvQdLS0sEBASUe6527twpnYt27drhypUr+PPPP9G2bVsYGhqid+/eSEtLk/b7bO/Frl274t1338UHH3wAc3Nz2NraYv78+QrHv3TpUnh5ecHAwAAODg6YOHEiMjMzpfXFx/7bb7/B3d0dhoaG6NWrF5KTkwEA8+fPx6ZNm/DTTz9JPSOjoqLKPd+ZmZnYsWMHJkyYgMDAwFI9OIvfv4iICLRt2xb6+vro2LEj4uLipDrXrl3D66+/DhsbGxgaGqJdu3Y4fPhwufscM2YM+vbtq1CWl5cHa2trrFu3DgCwa9cueHl5QU9PDxYWFgqJsWfPa0V1y7J9+3YEBQWVu748xZ/xJk2a4JVXXsG3336LuXPnYt68eQrnAyhKaI4YMQIjRoyQjqkkMzMzdOrUCdu3b69wn+XFWtn7VlW3b9/Gu+++i3fffRfr169H165d4eTkhFdeeQVr167FvHnzqtVuZdLT07Fu3TosXboUr776Ktq0aYMNGzbgxIkTOHnyZJnbXL16FSdPnsSqVavQrl07tGjRAqtWrcKTJ0+wbds2pdrt0aMHHjx4gCNHjtTJ8VUFk6ZERESkPpg0JSKiahJCIDs3X1qe5iu+fpJXgKd5BQpltbWIOv7u+eijjxAaGoqYmBi4urpi2LBhUu+ra9euoVevXhg4cCD+/vtv7NixA8eOHcPkyZOl7fPy8rBgwQL89ddf2Lt3LxISEjBq1KhS+5k1axYWLVqEy5cvw9vbW6kYp02bhsePH+PQoUNlrn/zzTfRuHFj/Pnnnzh79ixmzZoFbW1tAEBMTAy6d++Oli1bIjo6GseOHUNQUBAKCgqk7Tdt2gS5XI7jx49j9erV5cYRFhaGOXPm4Ny5c9DS0sLw4cPxwQcfYMWKFfjjjz8QHx9faZJp06ZNMDAwwKlTp7B48WKEh4crHJeGhga+/PJLXLp0CZs2bcLvv/+ODz74QKGN7OxsfPHFF/juu+9w9OhRJCYmIjQ0FAAQGhqKwYMHS4nU5ORkdOzYsdx4du7cCTc3N7Ro0QIjRozA+vXry/zMffTRR1iyZAnOnDkDLS0tjBkzRlqXmZmJPn36ICIiAufPn0evXr0QFBSExMTEMvc5btw4HDhwQEr0AsD+/fuRnZ2NIUOGIDk5GcOGDcOYMWNw+fJlREVFYcCAAWXGpUxdAHjw4AFiY2PRtm3bcs+JMqZOnQohBH766Sep7Nq1a4iOjsbgwYMxePBg/PHHH7h582apbdu3b48//vij3LYrirWq71tlfvjhB+Tm5pb6jBWrqEdv7969YWhoWO7i4eFR7rZnz55FXl4e/P39pTI3Nzc0adKk1A83xYqnOdDV1ZXKNDQ0FH6IqWq7crkcrVq1qvD81zUtle2ZiIiIiIiIqJY8yStAy3m/KRbuLb8nXW2KDQ+Avrzubq9DQ0OlORE//vhjeHh4ID4+Hm5ubli4cCHefPNNvPfeewAAFxcXfPnll+jSpQtWrVoFXV1dheSZs7MzvvzyS7Rr1w6ZmZkwNDSU1oWHh6NHjx7VitHNzQ1AUY/PsiQmJmLGjBlSPRcXF2nd4sWL0bZtW/z3v/+Vyp5N5ri4uGDx4sWVxhEaGir1RJ06dSqGDRuGiIgIdOrUCQAwduzYSnv8eXt7IywsTNrv119/jYiICOncFJ9roGjuyU8++QTjx49XiD8vLw+rV69Gs2bNAACTJ09GeHg4AMDQ0BB6enrIycmBra1tpcdU3CMSAHr16oX09HQcOXIEXbt2Vaj36aefokuXLgCKEuCBgYF4+vQpdHV14ePjAx8fH6nuggULsGfPHuzbt08hwV6sY8eOaNGiBb777jspWbdhwwYMGjQIhoaGuHLlCvLz8zFgwABpWLqXl1eZ8ScnJ1e5LlD0WRFCwN7evtJzUxXm5uawtrZW+GyuX78evXv3hpmZGQAgICAAGzZsKNWr2N7evsxkalVirer7VpmrV6/C2NgYdnZ2Sm0HFE0d8OTJk3LXF/9wUZaUlBTI5fJSSVkbGxukpKSUuU1x8nP27Nn45ptvYGBggGXLluH27dtSAl6Zdis7/3WNPU2JiIhIfRSK2lmIiIgakJK9PosTJ8XD6//66y9s3LhRofdYQEAACgsLcePGDQBFPbuCgoLQpEkTGBkZSYm1Z3sZ1qRnX3EPOplMVub66dOnY9y4cfD398eiRYtw7do1aV1xT9OKtGnTpkpxlDxXNjY2ABQTdDY2NgpTE1TWBlB0zktuc/jwYXTv3h2NGjWCkZERRo4cifv37yM7O1uqo6+vLyVMy2qjquLi4nD69GkMGzYMAKClpYUhQ4aUOZy8os9JZmYmQkND4e7uDlNTUxgaGuLy5cvl9jQFinqbbtiwAUDRw31+/fVXKQHv4+OD7t27w8vLC4MGDcKaNWuk6RSepUxdAFKSr2RvxZoSQkifzYKCAmzatElKaALAiBEjsHHjRhQ+80BRPT09hfe1qrEq874pE7uyGjVqhObNm5e7KDtnbGW0tbWxe/duXLlyBebm5tDX10dkZCR69+4NDQ3lU5CVnf+6xp6mREREpDaEKIQQhZVXrKQNIiJ68ehpayI2vKiHYUFBAf7662/4+HhDU1MTABB/NxNP8wrgaKEPI93ye1dVd991qWRvsOLkSXFyJzMzE++88w7efffdUts1adIEWVlZCAgIQEBAALZs2QIrKyskJiYiICBAeqBSMQMDg2rHePnyZQBA06ZNy1w/f/58DB8+HP/73//w66+/IiwsDNu3b0f//v2hp6dXaftVja2sc/Vs2bOJsYraeHabhIQE9O3bFxMmTMCnn34Kc3NzHDt2DGPHjkVubi709fXLbaM6Q7PXrVuH/Px8hZ6MQgjo6Ojg66+/homJSZlxP/s5CQ0NxaFDh/DFF1+gefPm0NPTwxtvvFHqM1BScHAwZs2ahejoaJw4cQJNmzZF586dAQCampo4dOgQTpw4gYMHD+Krr77CRx99hFOnTpX6DChTFwAsLS0BAA8fPoSVlZWyp6yU+/fvIy0tTdrXb7/9hqSkJAwZMkShXkFBgUKPYqBo+H1FMZQXa1XeN2NjYwBFc3w+2+vy0aNH0nvr6uqK9PR0JCcnK93btHfv3hUOb3d0dCz3QVe2trbIzc3Fo0ePFOJLTU2tsId0mzZtEBMTg/T0dOTm5sLKygq+vr7SjzLKtPvgwQOFHx/qG3uaEhERERER0XNPJpNBX64lLbpaiq/1tDWhq62pUFZbS3V7gdWGl156CbGxsWX2IpPL5fjnn39w//59LFq0CJ07d4abm1u1ejxWZvny5TA2NlaYp/BZrq6umDZtGg4ePIgBAwZIvRi9vb0RERFR6zHVhbNnz6KwsBBLlixBhw4d4OrqWq2nosvlcoU5W8uSn5+PzZs3Y8mSJYiJiZGWv/76C/b29tKDdari+PHjGDVqFPr37w8vLy/Y2tqWO5VCMQsLC/Tr1w8bNmzAxo0bMXr0aIX1MpkMnTp1wscff4zz589DLpdjz549ZbalTN1mzZrB2NgYsbGxVT6+iqxYsQIaGhrSg6nWrVuHoUOHKpzTmJgYDB06tFRP0IsXL6J169bltl1WrFV931xcXKChoYGzZ88qtHn9+nWkp6fD1dUVAPDGG29ALpeXOz3Fo0ePyo1v7dq1pY6z5PLLL7+Uu22bNm2gra2t8LcZFxeHxMRE+Pn5lbtdMRMTE1hZWeHq1as4c+YMXn/9daXbrez81zX2NCUiIiL1IWpheD0fBEVERGouPT0dMTExCmUWFhZwcHBQuq2ZM2eiQ4cOmDx5MsaNGwcDAwPExsbi0KFD+Prrr9GkSRPI5XJ89dVXGD9+PC5evIgFCxbUKP5Hjx4hJSUFOTk5uHLlCr755hvs3bsXmzdvLvOhNE+ePMGMGTPwxhtvoGnTprh9+zb+/PNPDBw4EAAwe/ZseHl5YeLEiRg/fjzkcjkiIyMxaNAgqSefumjevDny8vLw1VdfISgoqNIHU5XHyckJv/32G+Li4mBhYQETE5NSvVP379+Phw8fYuzYsQo9SgFg4MCBWLduHcaPH1+l/bm4uGD37t0ICgqCTCbD3LlzK+1xCxQN0e/bty8KCgoQEhIilZ86dQoRERHo2bMnrK2tcerUKaSlpcHd3b1UG8rUBYoeHOTv749jx45Jic5ilf3tPH78GCkpKcjLy8ONGzfw/fffY+3atVi4cCGaN2+OtLQ0/Pzzz9i3bx88PT0V2gkODkb//v3x4MEDmJubAwD++OOPCv9eyoq1qu+bkZERxo0bh/fffx9aWlrw8vLCrVu3pL/p4oeDOTg4YNmyZZg8eTIyMjIQHBwMJycn3L59G5s3b4ahoSGWLFlSZnyNGjUqN/bKmJiYYOzYsZg+fTrMzc1hbGyMKVOmwM/PDx06dJDqFc+t3L9/fwBFD66ysrJCkyZNcOHCBUydOhX9+vVDz549lWo3ISEBSUlJFf4QU9fY05SIiIjUhxC1sxAREamxqKgotG7dWmH5+OOPq9WWt7c3jhw5gitXrqBz585o3bo15s2bJw0LtrKywsaNG/HDDz+gZcuWWLRoEb744osaxT969GjY2dnBzc0NEyZMgKGhIU6fPo3hw4eXWV9TUxP3799HcHAwXF1dMXjwYPTu3Vs6ZldXVxw8eBB//fUX2rdvDz8/P/z000/Q0lK/fl4+Pj5YunQpPv/8c3h6emLLli1YuHCh0u289dZbaNGiBdq2bQsrKyscP368VJ1169bB39+/VOINKEq+nTlzBn///XeV9rd06VKYmZmhY8eOCAoKQkBAAF566aVKt/P394ednR0CAgIUhpobGxvj6NGj6NOnD1xdXTFnzhwsWbIEvXv3LtWGMnWLjRs3Dtu3by+V2K3sb2fevHmws7ND8+bNMXLkSKSnpyMiIgIzZ84EAGzevBkGBgZlzqHbvXt36Onp4fvvvwcAREdHIz09HW+88UaF5+jZWJV531asWIGQkBDMnDkTHh4eGDVqFLy9vfHzzz8r9GCfOHEiDh48iKSkJPTv3x9ubm4YN24cjI2NERoaWmF8NbFs2TL07dsXAwcOxCuvvAJbW1vs3r1boU5cXBzS09Ol18nJyRg5ciTc3Nzw7rvvYuTIkaV6RVel3W3btqFnz561Pu+qMmSiOpNqUIORkZEBExMTdMXr0JLV7rw+RM+LSVevqDoEIpXIflyAN1tfQnp6ujSnkqoUfx91NxkJLZm8Rm3li1xEpH+nFsdFRER15+nTp7hx4waaNm1a6iEsBQUFOH/+PFq3bi3NaXo19TGe5BWgqaVBrc9pStRQZWZmolGjRtiwYQMGDBhQb/sVQsDX1xfTpk2THqZU34YMGQIfHx98+OGHFdZTh1gbmtzcXLi4uGDr1q3o1KlTufXK+x4ovreo6f0Ae5oSERGR+igsrJ2FiIjoGU/yKp4/koj+VVhYiLt372LBggUwNTXFa6+9Vq/7l8lk+Pbbb5Gfn1+v+y2Wm5sLLy8vTJs2rdK6qo61IUpMTMSHH35YYcK0PjBpSkREROpDBcPzFy5ciHbt2sHIyAjW1tbo168f4uLiFOp07doVMplMYXl2DrHExEQEBgZCX18f1tbWmDFjBi+eiYiI6LmUmJgIGxsbbN26FevXr1fJVAmtWrXCyJEj632/QNGDuubMmQM9Pb0q1VdlrA1R8+bN8c4776g6DD4IioiIiF5sR44cwaRJk9CuXTvk5+fjww8/RM+ePREbGwsDAwOp3ltvvYXw8HDptb6+vvTvgoICBAYGwtbWFidOnEBycjKCg4Ohra2Nzz77rF6Ph4iIyqYhk6FQCOhose8QUWWcnJzA2RzpRcekKREREakNUVgIIavZ8HohlNv+wIEDCq83btwIa2trnD17Fq+88opUrq+vD1tb2zLbOHjwIGJjY3H48GHY2NigVatWWLBgAWbOnIn58+dDLq/ZPK1ERFSbZJVXISKiFx5/YiMiIiL1UYvD8zMyMhSWnJycKoVQ/PRPc3NzhfItW7bA0tISnp6emD17NrKzs6V10dHR8PLygo2NjVQWEBCAjIwMXLp0qaZnhYiIiIiI6hl7mhIREVGD5ODgoPA6LCwM8+fPr3CbwsJCvPfee+jUqRM8PT2l8uHDh8PR0RH29vb4+++/MXPmTMTFxWH37t0AgJSUFIWEKQDpdUpKSi0cDRERlacqQ4iFECjkUGMiogalrqeQYNKUiIiI1EehAGQ1vPj5/4unW7duwdjYWCrW0dGpdNNJkybh4sWLOHbsmEL522+/Lf3by8sLdnZ26N69O65du4ZmzZrVLF4iIqoWTU1NAEVPua7sYS1ZuQXSvzU4Op+IqEEoHvmlra1dJ+0zaUpERETqQwgANZvTtDhpamxsrJA0rczkyZOxf/9+HD16FI0bN66wrq+vLwAgPj4ezZo1g62tLU6fPq1QJzU1FQDKnQeViOhFs3LlSvznP/9BSkoKfHx88NVXX6F9+/bl1v/hhx8wd+5cJCQkwMXFBZ9//jn69OkjrdfS0oK+vj7S0tKgra0NDY1/Z58rKChKkj59+hSampp4+jQPIj8XAJCfl4v8vDo6SCIiqnNCCGRnZ+Pu3bswNTWVfkSrbUyaEhER0QtNCIEpU6Zgz549iIqKQtOmTSvdJiYmBgBgZ2cHAPDz88Onn36Ku3fvwtraGgBw6NAhGBsbo2XLlnUWOxHR82LHjh2YPn06Vq9eDV9fXyxfvhwBAQGIi4uT/t8s6cSJExg2bBgWLlyIvn37YuvWrejXrx/OnTsnTZ8ik8lgZ2eHGzdu4ObNmwrbFxYW4t69e0hISICGhgae5hXgXmYu5Foy3Hhyv16OmYiI6papqWmddlCQibqeAIDUWkZGBkxMTNAVr0NLVjfdmYnU3aSrV1QdApFKZD8uwJutLyE9PV2pHpl1ofj7qJvWGzX+PsoXeYjM31Xl45o4cSK2bt2Kn376CS1atJDKTUxMoKenh2vXrmHr1q3o06cPLCws8Pfff2PatGlo3Lgxjhw5AqCoR1OrVq1gb2+PxYsXIyUlBSNHjsS4cePw2Wef1eh4iIgaAl9fX7Rr1w5ff/01gKKkpoODA6ZMmYJZs2aVqj9kyBBkZWVh//79UlmHDh3QqlUrrF69WqFuYWEhcnNzFcoyMzPRtm1bnDlzBoaGhvhwzwWcun4frjZGWDWiTR0cIRER1Sdtbe1ye5gW31vU9D6HPU2JiIhIfYhC1Hx4vnLbr1q1CgDQtWtXhfINGzZg1KhRkMvlOHz4MJYvX46srCw4ODhg4MCBmDNnjlRXU1MT+/fvx4QJE+Dn5wcDAwOEhIQgPDy8ZsdCRNQA5Obm4uzZs5g9e7ZUpqGhAX9/f0RHR5e5TXR0NKZPn65QFhAQgL1795aqq6GhAZlMhpycHKns6dOnuHnzJuRyOXR1dXHjYS6SHhfAQD8furq6tXNgRETUoDFpSkRERC+0ygbdODg4SD1KK+Lo6IhffvmltsIiImow7t27h4KCAtjY2CiU29jY4J9//ilzm5SUlDLrp6SklFl/4cKF+Pjjj8uNQVNW9PSn0J4tyq1DRERUEpOmREREpDZEoYCQ1WzmIM48RET04pk9e7ZCz9SMjAw4ODhIr3dN6KiKsIiI6DnGpCkRERGpDxUMzyciorplaWkJTU1NpKamKpSnpqaW+wAPW1tbperr6OhAR0endgImIiICk6YvvOLeOPnIA9gxh15Q2Y8LVB0CkUpkZxZ99tWpZ2ZtfB/lI692giEiolohl8vRpk0bREREoF+/fgCKHt4UERGByZMnl7mNn58fIiIi8N5770llhw4dgp+fX5X2WfzdlpGRUaPYiYjo+VP8f39N73OYNH3BPX78GABwDJyDjV5cUa1VHQGRaj1+/BgmJiYqjUEul8PW1hbHUmrn+8jW1hZyubxW2iIiopqbPn06QkJC0LZtW7Rv3156uN7o0aMBAMHBwWjUqBEWLlwIAJg6dSq6dOmCJUuWIDAwENu3b8eZM2fw7bffVml/xfc5JYfoExHRi6Wm9zlMmr7g7O3tcevWLRgZGUH2/5OjU/0pnmvp1q1bMDY2VnU4RPWOfwOqJYTA48ePYW9vr+pQip5sfOMGcnNza6W94qclExGRehgyZAjS0tIwb948pKSkoFWrVjhw4ID0sKfExERoaGhI9Tt27IitW7dizpw5+PDDD+Hi4oK9e/fC09OzSvt79j6H1xzK4fmqOp4r5fB8VR3PlXJKni8jI6Nauc+RCXUak0f0gsnIyICJiQnS09P5nyC9kPg3QERERPWB1xzK4fmqOp4r5fB8VR3PlXLq4nxpVF6FiIiIiIiIiIiI6MXBpCkRERERERERERFRCUyaEqmQjo4OwsLCoKOjo+pQiFSCfwNERERUH3jNoRyer6rjuVIOz1fV8Vwppy7OF+c0JSIiIiIiIiIiIiqBPU2JiIiIiIiIiIiISmDSlIiIiIiIiIiIiKgEJk2JiIiIiIiIiIiISmDSlIiIiIiIiIiIiKgEJk2pwUtJScGUKVPg7OwMHR0dODg4ICgoCBEREVKdEydOoE+fPjAzM4Ouri68vLywdOlSFBQUKLQlk8kgk8lw8uRJhfKcnBxYWFhAJpMhKiqqVH2ZTAYTExN06tQJv//+u7R+1KhR6NevX7mxOzk5KbRRvCxatAjz588vc13JpXgfZa3r1atXmfvR09ODk5MTBg8erBArPR8q+0zMnz8fCQkJ5a4v/mxv3LhRKtPQ0ICdnR2GDBmCxMREhf117dpV+kw+KzAwUNpnyfrvvfdeqe23b9+usO3y5cvh5ORUqs0nT57A3NwclpaWyMnJKRVreUtCQkK5fzNubm6l4pHJZNDR0UGjRo0QFBSE3bt3K/tWEBERUT1buXIlnJycoKurC19fX5w+fbrC+j/88APc3Nyk6/9ffvmlniJVD8qcrzVr1qBz584wMzODmZkZ/P39Kz2/DYmyn61i27dvh0wmq/CeryFS9nw9evQIkyZNgp2dHXR0dODq6vrC/D0qe66WL1+OFi1aQE9PDw4ODpg2bRqePn1aT9GqztGjRxEUFAR7e3vIZDLs3bu30m2ioqLw0ksvQUdHB82bN8fGjRuV3i+TptSgJSQkoE2bNvj999/xn//8BxcuXMCBAwfQrVs3TJo0CQCwZ88edOnSBY0bN0ZkZCT++ecfTJ06FZ988gmGDh0KIYRCmw4ODtiwYYNC2Z49e2BoaFhmDBs2bEBycjKOHz8OS0tL9O3bF9evX6/yMYSHhyM5OVlhmTJlCkJDQxXKGjduXKpusV69epVqY9u2bWXuJy4uDps3b4apqSn8/f3x6aefVjlWUr2S7/Hy5cthbGysUBYaGirVPXz4cKnPRZs2baT1xdsmJSXhxx9/RFxcHAYNGlRqnw4ODqW+gJKSkhAREQE7O7tKY9bV1cWcOXOQl5dXad0ff/wRHh4ecHNzk74ohwwZonAMfn5+eOuttxTKHBwcAAAeHh6ljvnYsWMK+yje9tq1a/jxxx/RsmVLDB06FG+//Xal8REREZFq7NixA9OnT0dYWBjOnTsHHx8fBAQE4O7du2XWP3HiBIYNG4axY8fi/Pnz6NevH/r164eLFy/Wc+Sqoez5ioqKwrBhwxAZGYno6Gg4ODigZ8+eSEpKqufI65+y56pYQkICQkND0blz53qKVD0oe75yc3PRo0cPJCQkYNeuXYiLi8OaNWvQqFGjeo68/il7rrZu3YpZs2YhLCwMly9fxrp167Bjxw58+OGH9Rx5/cvKyoKPjw9WrlxZpfo3btxAYGAgunXrhpiYGLz33nsYN24cfvvtN+V2LIgasN69e4tGjRqJzMzMUusePnwoMjMzhYWFhRgwYECp9fv27RMAxPbt26UyAGLOnDnC2NhYZGdnS+U9evQQc+fOFQBEZGSkQv09e/ZIr5OSkgQAsXr1aiGEECEhIeL1118vN35HR0exbNmyKh1reXUr20dF286bN09oaGiIf/75p0oxkHrZsGGDMDExKVV+48YNAUCcP39eqW2//PJLAUCkp6dLZV26dBETJkwQFhYW4tixY1L5p59+KoKCgoSPj48ICwtTqD916lSF16NHjxYWFhZi5cqVUvmyZcuEo6Njqbi6du0qVq9eLVatWiV69OhRZuzP7qNYWFiY8PHxKfeYK9p2/fr1AoA4dOhQhdsTERGRarRv315MmjRJel1QUCDs7e3FwoULy6w/ePBgERgYqFDm6+sr3nnnnTqNU10oe76elZ+fL4yMjMSmTZvqKkS1UZ1zlZ+fLzp27CjWrl1bpfuxhkTZ87Vq1Srh7OwscnNz6ytEtaHsuZo0aZJ49dVXFcqmT58uOnXqVKdxqptn8yxl+eCDD4SHh4dC2ZAhQ0RAQIBS+2JPU2qwHjx4gAMHDmDSpEkwMDAotd7U1BQHDx7E/fv3FXrfFQsKCoKrq2upHplt2rSBk5MTfvzxRwBAYmIijh49ipEjR1Yak56eHoCiX9OeB1OnToUQAj/99JOqQyEVu3v3Lvbs2QNNTU1oamoqrJPL5XjzzTcVemBv3LgRY8aMqVLbxsbG+OijjxAeHo6srKxy6127dg3R0dEYPHgwBg8ejD/++AM3b96s3gEpKSQkBGZmZhymT0REpIZyc3Nx9uxZ+Pv7S2UaGhrw9/dHdHR0mdtER0cr1AeAgICAcus3JNU5X8/Kzs5GXl4ezM3N6ypMtVDdcxUeHg5ra2uMHTu2PsJUG9U5X/v27YOfnx8mTZoEGxsbeHp64rPPPis1VV5DU51z1bFjR5w9e1Yawn/9+nX88ssv6NOnT73E/Dyprf/jmTSlBis+Ph5CCIX5Cp915coVAIC7u3uZ693c3KQ6JY0ZMwbr168HUJQc6tOnD6ysrCqMJzs7G3PmzIGmpia6dOlS1cPAzJkzYWhoqLD88ccfVd4eAPbv31+qjc8++6zS7czNzWFtbY2EhASl9kfPh44dO5b6XJSUnp4OQ0NDGBgYwMbGBpGRkeX+CDFmzBjs3LkTWVlZOHr0KNLT09G3b98qxzJx4kTo6upi6dKl5dZZv349evfuDTMzM5ibmyMgIKDUVBmVuXDhQqljHj9+fKXbaWhowNXVlX8LREREaujevXsoKCiAjY2NQrmNjQ1SUlLK3CYlJUWp+g1Jdc7Xs2bOnAl7e/tSSYmGpjrn6tixY1i3bh3WrFlTHyGqleqcr+vXr2PXrl0oKCjAL7/8grlz52LJkiX45JNP6iNklanOuRo+fDjCw8Px8ssvQ1tbG82aNUPXrl1fiOH5yirv//iMjAw8efKkyu1o1XZgROpCPDMXaW3VBYARI0Zg1qxZuH79OjZu3Igvv/yy3LrDhg2DpqYmnjx5AisrK6xbtw7e3t5V3teMGTMwatQohTJl53fp1q0bVq1apVBW1V+FhRDSQ6WoYdmxY0e5PxgAgJGREc6dO4e8vDz8+uuv2LJlS7lz3Pr4+MDFxQW7du1CZGQkRo4cCS2tqn/F6OjoIDw8HFOmTMGECRNKrS8oKMCmTZuwYsUKqWzEiBEIDQ3FvHnzoKFRtd8AW7RogX379imUGRsbV2lb/i0QERERAYsWLcL27dsRFRUFXV1dVYejVh4/foyRI0dizZo1sLS0VHU4z4XCwkJYW1vj22+/haamJtq0aYOkpCT85z//QVhYmKrDUytRUVH47LPP8N///he+vr6Ij4/H1KlTsWDBAsydO1fV4TVITJpSg+Xi4gKZTIZ//vmn3Dqurq4AgMuXL6Njx46l1l++fBktW7YsVW5hYYG+ffti7NixePr0KXr37o3Hjx+XuY9ly5bB398fJiYmlfZGLYulpSWaN2+u9HYlGRgYVKuN+/fvIy0tDU2bNq3R/kk9OTg4VPi50NDQkNa7u7vj2rVrmDBhAr777rsy648ZMwYrV65EbGxstZ6mOmLECHzxxRf45JNP4OTkpLDut99+Q1JSEoYMGaJQXlBQgIiICPTo0aNK+5DL5dX6WygoKMDVq1fRrl07pbclIiKiumVpaQlNTU2kpqYqlKempsLW1rbMbWxtbZWq35BU53wV++KLL7Bo0SIcPnxYqY4gzytlz9W1a9eQkJCAoKAgqaywsBAAoKWlhbi4ODRr1qxug1ah6ny27OzsoK2trTAFmLu7O1JSUpCbmwu5XF6nMatKdc7V3LlzMXLkSIwbNw4A4OXlhaysLLz99tv46KOPqtyR5EVQ3v/xxsbG0rSJVcEzSg1W8fDdlStXljlP4qNHj9CzZ0+Ym5tjyZIlpdbv27cPV69exbBhw8psf8yYMYiKikJwcHCpOR5LsrW1RfPmzauVMFW1FStWQENDA/369VN1KKQGZs2ahR07duDcuXNlrh8+fDguXLgAT0/PMn9sqIyGhgYWLlyIVatWlRoGv27dOgwdOhQxMTEKy9ChQ7Fu3brqHI5SNm3ahIcPH2LgwIF1vi8iIiJSjlwuR5s2bRARESGVFRYWIiIiAn5+fmVu4+fnp1AfAA4dOlRu/YakOucLABYvXowFCxbgwIEDaNu2bX2EqnLKnis3NzdcuHBB4Xr1tddek57g7eDgUJ/h17vqfLY6deqE+Ph4KbkMFE2jZ2dn12ATpkD1zlV2dnapxGhxLkLZ0bMNXW39H8+eptSgrVy5Ep06dUL79u0RHh4Ob29v5Ofn49ChQ1i1ahUuX76Mb775BkOHDsXbb7+NyZMnw9jYGBEREZgxYwbeeOMNDB48uMy2e/XqhbS0tCoP7S1Peno6YmJiFMosLCykL9THjx+XmtNEX19fqf3m5OSUakNLS0thyEjxfvLy8nDjxg18//33WLt2LRYuXFjjnq6knu7fv1/qc2FqalruMCsHBwf0798f8+bNw/79+0utNzMzQ3JyMrS1tasdU2BgIHx9ffHNN99Ic9CkpaXh559/xr59++Dp6alQPzg4GP3798eDBw+qNOVEfn5+qWOWyWQK891kZ2cjJSUF+fn5uH37Nvbs2YNly5ZhwoQJ6NatW7WPjYiIiOrO9OnTERISgrZt26J9+/ZYvnw5srKyMHr0aABF1wyNGjXCwoULARQ98LRLly5YsmQJAgMDsX37dpw5cwbffvutKg+j3ih7vj7//HPMmzcPW7duhZOTk3Q9Vda8+A2NMudKV1e31PWqqakpAJQqb6iU/WxNmDABX3/9NaZOnYopU6bg6tWr+Oyzz/Duu++q8jDqhbLnKigoCEuXLkXr1q2l4flz585FUFBQhR25GoLMzEzEx8dLr2/cuIGYmBiYm5ujSZMmmD17NpKSkrB582YAwPjx4/H111/jgw8+wJgxY/D7779j586d+N///qfcjgVRA3fnzh0xadIk4ejoKORyuWjUqJF47bXXRGRkpFTn6NGjIiAgQBgbGwu5XC48PDzEF198IfLz8xXaAiD27NlT5n4ePnwoACi0W1F9IYQICQkRAEotY8eOFUII4ejoWOb6d955p1Rbjo6OYtmyZVXeR4sWLRS2LS6Xy+WiSZMmYvDgweL3338vN3ZSfxs2bBAmJialym/cuFHmZwKA2LZtW4XbRkdHCwDi1KlTQgghunTpIqZOnVpuDD4+PiIsLEx6/Wz9srY/ceKEACAcHR2FEEJ88cUXwtTUVOTm5pZqPycnR5iamooVK1ZU2KYQQoSFhZV5zDo6OgrblvxbsLOzE3379hW7d+8u9xiJiIhIPXz11VeiSZMmQi6Xi/bt24uTJ09K67p06SJCQkIU6u/cuVO4urpK1///+9//6jli1VLmfJV3X1LyOq8hU/azVVJISIh4/fXX6z5INaLs+Tpx4oTw9fUVOjo6wtnZWXz66ael7sUbKmXOVV5enpg/f75o1qyZ0NXVFQ4ODmLixIni4cOH9R94PYuMjCzz/6Di8xMSEiK6dOlSaptWrVoJuVwunJ2dxYYNG5Ter0wI9uElIiIiIiIiIiIiKsY5TYmIiIiIiIiIiIhKYNKUiIiIiIiIiIiIqAQmTYmIiIiIiIiIiIhKYNKUiIiIiIiIiIiIqAQmTYmIiIiIiIiIiIhKYNKUiIiIiIiIiIiIqAQmTYmIiIiIiIiIiIhKYNKUiNRGQkICZDIZZDIZNm7cCADYuHGjVKZKUVFRUhxRUVH1ur+EhIQat+fk5ASZTIb58+fXuC0iIiIiooZk/vz5kMlkcHJyqrRubV+nNySXL1+GpqYmnJ2dUVBQoOpwqkWZz0JdK+v+OD4+HpqammjatClyc3NVG+ALgElTIlLQtWtX6T9mmUwGTU1NNGrUCEFBQThx4kS9x2NlZQVfX1/4+vpWeRtVXsgUf8nyIoqIiIiI1FXxD+oVLar8sb3kNXXxYmlpCT8/P3z//fe1vr/GjRvD19cXrVu3lspGjRoFmUyGrl27KtQ1NjaW7k90dHRqPZZnlUycFS96enpwd3fH/PnzUVhYqHSbxfd8o0aNqtVYP/74YxQWFmLq1KnQ1NRUWLd792706tULVlZW0NHRQZMmTTBgwIB66ZBSH0q+T3V5TM2bN0e/fv2QkJCA9evX19l+qIiWqgMgIvUkl8vRunVr5OTk4OLFi9i/fz8OHDiA48ePo3379mVuk5ubC7lcXqtxBAYGIjAwsFbbJCIiIiJ6kbVu3Rq2trYAgNu3byMpKQkA0KpVKykR2Lhx41Lb1cX1fmVatWoFLS0tXLlyBSdPnsTJkydx9+5dTJ8+vdb2MW7cOIwbN65KdV966SWcPHmy1vatjEaNGsHe3h7Xrl3DP//8g48//hiGhoYIDQ1VSTwlpaam4scff4SmpiaGDRsmlQshMGbMGKmnpFwuR/PmzfHgwQPs2bMHxsbGpRLTVLHhw4dj9+7dWLVqFcaPH6/qcBo09jQlojLZ2dnh5MmTOH/+PPbu3QsAyM/Px9atWwEo/vK6ePFiNG7cGLq6utL233//Pdq1awd9fX0YGRmhV69eiImJUdhHZGQkPD09oauri5dffhmxsbGl4ihveP6OHTvQsWNHGBoaQl9fHz4+Pjh06BDmz5+Pbt26SfWaNm2q8CtqYWEhVqxYIe3XzMwMgwYNwo0bNxTa37lzJ5ydnaGnp4c+ffpIF5K1YcuWLWjfvj0sLS2hra0NMzMzBAQE4PTp02XW/+eff9C1a1fo6uqiefPm2LVrV6n1gwYNgpWVFeRyOdzd3bFq1apai5eIiIiIGpY9e/ZICciSycKS5d9//z1kMhlGjhyJGTNmwNraGi1atABQ9tRPZfXMzMnJQVhYGFxcXCCXy2FtbY0xY8bg3r17SsX6559/Ij4+Hvr6+gCAzZs3S+svXryIAQMGwMLCAnK5HM7Ozpg9ezaePHki1Tl58iS6d+8OCwsL6OrqwsnJCf369cO1a9cAlB6S7eTkhE2bNgEAjhw5otCD8NlRbdu3b4dMJoO2tjbu378v7XPu3LmQyWRo1KiRNFT9119/RZcuXWBkZAQ9PT107twZkZGRVT4X48aNw+nTp3Hjxg0YGBhI8RWLiYlB9+7dYWdnBx0dHRgYGKBdu3YKvXNlMpm0zaZNm0qNkqvuvcWuXbuQn5+P9u3bw9raWipfu3atlDDt0aMHkpKScOnSJSQnJyM+Ph59+/aV6lblvSzuJdu1a1d8/vnnsLa2hqWlJRYuXIiMjAyMHDkShoaGcHFxke5jAcX7yqioKLRu3Rq6urrw9vZWOIdlqewecuPGjWjatKlUv1u3bqX+Fmrr/hgAevfuDU1NTfz999/l1qFaIoiISujSpYsAIBwdHaWy/fv3CwACgJg6daoQQoiQkBABQMjlcqGhoSHc3d2FhYWFEEKIzz//XKrv6uoq7O3tBQBhYGAgYmNjhRBCJCcnCwMDAwFA6OvrCzc3N+k1ALFhwwYhhBAbNmyQyop98cUXUpmxsbHw9PQU+vr6YtmyZWLNmjXC3d1dWt+qVSvh6+srwsPDhRBCTJgwQVrn4eEhLCwsBABha2srUlNThRBCnD9/XmhoaAgAwsTERDRr1kwhtsjIyHLPX1hYmFTvxo0bZdaZOnWq0NXVFa6ursLHx0fo6OgIAMLIyEgkJycLIYSIjIyU2jEwMBCurq7C2NhYABAaGhri3LlzQgghrly5IkxMTAQAYW5uLjw9PYVMJhMAxMcffyzt09HRUQAQYWFhVfocEBEREdGLobzr1+L7ArlcLrS1tYWnp6fw9vYWQpR9bVl8f9ClSxeprE+fPgKA0NTUFN7e3tL1bMuWLUV2drZSMd29e1fo6+sLAMLHx0cIIURsbKwwNDQUAIShoaFwd3eXroV79OghhBCioKBAuua3sbERrVq1ElZWVgrX9cX7K74H6tevn7C0tJSu0X19fYWvr684e/aswnX6jRs3xJMnT6Tr8dWrV0vH4OLiIgCImTNnCiGE2L59uxSbo6OjaNq0qXRufv/993LPxY0bN6T9FZ/v9PR06f5k4sSJUt09e/YIDQ0N4ejoKFq3bi3MzMykbffv3y+EEMLX11cYGRkJAMLS0lI6tjt37lT53qIsQ4cOFQDEu+++q1Detm1bAUDo6OhI9zplqcp7KcS/n0sdHR1hbGwsmjRpIh2ju7u7sLKyEjY2NtJ91L1794QQiveV+vr6wt3dXejp6Un1kpKSyvwsCFH5PeT+/ftFq1atFOLw9fUVEyZMEELU7v1xMW9v71KfOap9TJoSkYKSF0e+vr6iVatWQktLSwAQWlpa4uTJk0KIfy+KAIhffvlFCCFEfn6+yMrKki5mir9Y8/LypC/LESNGCCGEmDNnjnSRcPHiRYWyipKmWVlZ0peHn5+fSE9PF0II8fjxY3H16lUhhCh1IVPs+vXr0hfvpk2bpO0aN24sAIg5c+YIIYQYMWKElDBNSUkRQggxcuTIWkuaXrlyRWRlZUmvr169Km2zdu3aUscwa9YsIUTRF6mpqakAIIYMGSKEEGLUqFECgPD09JTaXL58uQAg9PT0REZGhhCCSVMiIiIiKltVkqYxMTFCiKLrfSGqljSNioqS2j1y5IgQQog7d+5Iiari697KYmrVqpVo166dlHAFIJYsWSKEECI4OFhKsiUmJgohhFi2bJlU7/fffxf37t2TXt++fVvax8WLF6VOE2UlyspKAgtR9r3GW2+9JQCIbt26CSGEOHfunFSnOCnm5OQkAIgxY8aIwsJCUVhYKPr37y8AiJdffrncc1EyadqoUSPRrl07YW5uLt0PlUxEJicnS/cvQgjx5MkT0bx5c4X7MCH+fW9DQkIU9lXVe4uytGnTRgAQS5cuVSgvvjf09PQsd1shqvZeloxdW1tb3LhxQ2RmZgq5XC4ACCsrK/Hw4UMRHx8vbffrr78KIRTvK4sTjRcvXpTudYuT289+Fqp6D1nyfSp5v1jb98fFgoKCBAARGhpa4XmlmuHwfCIqU25uLk6dOoW///4bVlZWCAwMxJEjR0o9kKlFixbo3bs3AEBTUxOXLl1CdnY2ACAsLEwaqnLmzBkAkOb/uXTpkrS9h4cHAGDw4MGVxnXp0iVkZWUBACZNmgRjY2MAgKGhIZo3b17htmfOnIEQAgAQEhICmUwGIyMj3L59u8zYOnXqBBsbGwDAoEGDKo2tqh4+fIjXX38d5ubm0NDQgIuLi7Tuzp07peoXzwlka2srTT1w4cIFAJCG9F+8eBEGBgaQyWR47733AABPnjzB33//XWtxExEREdGLp1u3bvDx8QGAUg/3qUjJqae6dOkCmUwGe3t7aah1VecFjYmJwZ9//gktLS106NABmzdvluYz/fPPPwEAnTt3hoODA4Ci+R6LnTlzBhYWFvDz8wNQ9BAdLy8vDBs2DOfPn4elpWWVj6ciISEhAIqGyqekpGDHjh0AgPbt28Pd3R1paWnS8Pf169dDQ0MDGhoa2LNnDwDg1KlTVdpPUlIS/vzzTzx48ABaWlro1auXNDctUDT0/v3334e9vT20tLSgp6eH+Ph4AGXfZzyrJvcW6enpAAAjIyOF8uL7r2enW3tWVd7Lkjw9PeHk5AQDAwNYWVkBAF5++WWYmprC2dlZqpeamlpqX8X3Vx4eHvDy8gLw7/3Vs6p6D1meuro/Lr4PLj7vVDf4ICgiKpOjo2OVnv5enFQsi7u7u/SfeTELC4uahlYrSk5yX8zR0bHO95uZmYmAgAA8evQIurq6aN26NbS1taULpeL5jpRlaWmJZs2alSpX5sKWiIiIiOhZZV3vFyfASl67VpS8ebbjBQCFZF9Fbty4Ic01Wl0RERHYunUrjh8/jtjYWOzatQvbt29HcnIyZsyYUaO2gaLOFs2bN0d8fDx27tyJnTt3Avg3mVqSs7OzlOQrqSoP2QoLC8OMGTMQGhqK1atXIywsDF5eXujfvz8AYMSIETh8+DBkMhlatmwJQ0NDxMbG4vHjx0rdZ1Tn3qL4vi8zM1Oh3MPDA2fOnMGVK1eQmppa4f2jMkreZ2ppaSmUlUzQFic8a0NN7yFr8/44IyMDAEq1R7WLSVMiqpFnfzH08PCAnp4enjx5gl69emHJkiVSnfPnz0u/LHt4eGDPnj2Ii4vD5cuX4e7uXuoBR2Xx8PCAgYEBsrKysGrVKrz22mswMjJCVlYWkpOT0bx5c2mCeABSr1QAaNOmDWQyGYQQGDVqFKZOnQqg6Iv02LFjMDExkfZx/vx5HD9+HHfv3oW1tXWVYntWTk4Onj59Kr3W1NREXFwcHj16BKDoV+Zhw4bh5MmT0q/fZdmxYwe8vb1x9+5dREVFAYD0i2i7du0QGxsLExMT/PLLLzA3NwcA3Lt3DxEREejQoYPScRMRERERFSurh6C1tTUSEhJw5coVAEXXnsXXqcXatWsn/Xv27Nl4/fXXARQ9XPbw4cNwc3OrcWzt2rXD5cuX8ccff+D27dto3Lix9OBaAGjbti2EEDhx4gRGjRqFsWPHAgDGjx+Pb775BkePHi03aVp8T1HyfqIiwcHBmDdvHhYuXIiUlBTo6OhIPRqtrKzg6OiImzdv4qWXXsK2bdukRN+VK1dw8+bNShOmxQwMDLBs2TLs27cPd+7cwbx589CvXz/IZDKp1+Jbb72Fb775Bg8ePICnpyceP35cpWOryb2Fi4sLzp07h5s3byqUv/322zhz5gxycnIQEhKCLVu2SInCuLg4xMTEYMiQIVV6L2vLjh078NZbb+Hy5ctSD9Pi+6tnVfUesrx70Lq6Py4+zyVHLVLt4/B8IqpV+vr6mDt3LgBg2bJlaNy4MVq1agULCwu89NJLOHjwIABg4sSJ0NfXR0FBAdq2bQt3d3csXry4Su1//PHHAIDjx4/DwcEB3t7esLGxwf79+wEAzZo1g7a2NgDA398fHTp0wK5du+Ds7Iy33noLAPDee+/B2dkZ3t7eMDU1xSuvvIJz584BAKZPnw6ZTIb09HS4urrCxcVFGmKjDDc3N+jp6UnLoEGD4OzsLD3pcuzYsfD29ka/fv0qbGfFihVwc3ODq6srHj58CA0NDXzwwQcAii5AjY2Nce3aNTg4OKB169ZwdHSEra0tZs6cqXTMRERERESV6d69OwBg586d6Ny5M7y8vKSeb8W6du2KgIAAAEC/fv3g5uYGDw8PmJqaonfv3lUa1VaZWbNmwdDQEJmZmXB3d0fLli2lofs9evRAt27dUFBQAH9/f5iZmUnDsdesWQMA8Pb2Lrft4qTumTNn4OXlhQ4dOig8xf1ZI0eOhEwmQ0pKCgAgKCgIZmZm0vrPPvsMQNFT5u3t7dG6dWvY2tqiRYsW2LJli1LHrauri2nTpgEoGkq/b98+heNZu3YtPDw80KxZM4VOHM8e2+7du/HSSy+hV69eAGp2b9G5c2cApYfRjxs3DqNGjQIA/Pbbb7C3t4enpycaNWoENzc3/PrrrwCq9l7WltDQUHh4eKBt27bIz8+Hvr4+pkyZUmbdqt5DWllZScngkSNHwtfXF1999VWd3B9nZ2dLw/mLzzvVDSZNiajWzZ49G5s2bUK7du3w8OFDxMfHw9raGuPHj8eAAQMAAHZ2dti3bx9atmyJ/Px8GBkZVfli4f3338e2bdvg5+eHvLw8xMfHw9nZGS1btgRQNMThyy+/hIODA1JTU3Hq1Cnp4mXVqlVYtmwZvLy8cOfOHdy8eRNOTk6YPn06unbtCgBo3bo1tm7dCicnJzx9+hSOjo5YtWpVrZwbMzMz/PDDD2jZsiUKCwshl8vx888/V7jNrl27YGNjg6dPn8LZ2Rnbtm3DSy+9BKBozpvo6GgMGjQI+vr6uHTpEgoLC9GrVy8sWLCgVmImIiIiIipp9uzZGDFiBExNTXHlyhUEBwdj6NChpert3bsX8+bNg4uLC65fv46UlBS4u7tjzpw58PT0rHEc7u7uiI6ORv/+/SGXy3H16lU4OTlh1qxZ+OmnnwAUjfYaP348mjZtiqSkJMTHx8PJyQmhoaGYN29euW2PGTMGAwcOhImJCS5evIhTp05VOMTdyckJXbp0kV4XJwqLDR8+HPv370eXLl3w5MkTxMXFwcjICMHBwRg3bpzSx/7OO+/A1NQUAPDpp58CADZu3Ihu3bpBV1cX2dnZWL58eZmJ4dDQUPj7+0NfXx/nz5+XEp01ubd44403oKWlhZMnT+LevXtSuUwmw4YNG7Br1y707NkTRkZGUg/l1157TZrCoCrvZW359ddfoauri/z8fHh6euLnn39Go0aNyq1flXtImUyGNWvWoHnz5sjIyMDp06el3qC1fX/866+/oqCgAN7e3tI9MNUNmajNCR6IiIiIiIiIiOiFM3ToUOzYsQNffvlluT03VWXjxo0YPXo0gNqd51QVBgwYgD179mD16tV45513VB1Og8aepkREREREREREVCNhYWHQ0NDA8uXLq/2AW6pYfHw8fvrpJzg5OWHMmDGqDqfB44OgiIiIiIiIiIioRtzd3ZksrWPNmzfnOa5HHJ5PREREREREREREVAKH5xMRERERERERERGVwKQpERERERERERERUQlMmhIRERERERERERGVwKQpERERERERERERUQlMmhIRERERERERERGVwKQpERERERERERERUQlMmhIRERERERERERGVwKQpERERERERERERUQlMmhIRERERERERERGV8H+AqHsCkel49wAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "lda = LDA(store_covariance = True, solver = 'lsqr')\n",
    "\n",
    "# Hyperparameters CV --> Always Chooses the lowest (e.g 0.001). Thus, do not use cv for computational efficacy./ # Use solver = lsqr if cv needed.\n",
    "#shrinkage = np.linspace(0.001, 1, 10) \n",
    "#param_grid = {\"shrinkage\" : shrinkage} \n",
    "#lda_model = GridSearchCV(lda_model , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "#display(f'Best Parameter shrinkage : {lda_model.best_params_}')\n",
    "\n",
    "# Final model\n",
    "lda_model = lda.fit(X_train0, y_train0)\n",
    "\n",
    "# y_pred\n",
    "y_pred_lda = lda_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, lda_model, X_test0, y_test0, y_pred_lda, \"Linear Discriminant Analysis (LDA)\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4. QDA - Quantratic Discriminant Analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Quantric Discriminant Analysis (QDA)\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "87.68%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.93      0.85      0.89      3118\n",
      "  TERMINATED       0.82      0.91      0.86      2338\n",
      "\n",
      "    accuracy                           0.88      5456\n",
      "   macro avg       0.87      0.88      0.88      5456\n",
      "weighted avg       0.88      0.88      0.88      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABU0AAAHyCAYAAADfte/mAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8g+/7EAAAACXBIWXMAAA9hAAAPYQGoP6dpAADh4ElEQVR4nOzdeVxU9f7H8fewLwqIyiIggru45q65lWlqlq1q5pKZ11Jvar9KzdzyZquZZVqZWrfMuqXdUq9mplm5b+W+orihuCCoLMKc3x/EiQlUYMAZ5fV8PM7Dme/5nu/5nJlBOJ/5LhbDMAwBAAAAAAAAACRJLo4OAAAAAAAAAACcCUlTAAAAAAAAAMiBpCkAAAAAAAAA5EDSFAAAAAAAAAByIGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQA0lTAABuYv369ZPFYrHZPD09VaNGDY0fP16pqal51r3ZHD9+XP369VNwcLC8vLxUq1Ytvf3227JarcVyvjNnzmj06NGqXbu2fH195evrq5iYGL3wwgs6ffp0sZzTHnPnztX48eM1derUAh23atUq8zMxd+5cu+No27at2Z6Li4t8fHwUHh6u9u3ba8aMGUpJSSnW8xdEcfw8OOvP2Pjx4zV+/Hh9++23BTouJSVFfn5+5jU1a9aseALMQ/ZnqVKlSsXSfnG8V99++60sFovCwsKUnp5usy8uLk5Dhw5VtWrV5O3trdKlS+u2227Tv/71LyUnJ9vUzflzYbFY5O7urjJlyqh27doaOHCgfv/996vGkN/3rFGjRrJYLAX+PwMAgJKEpCkAALeY9PR07d27VxMmTNB9993n6HDsdvr0abVo0UKffPKJTp8+rbS0NO3evVsjRozQ4MGDi/x8u3btUv369TV58mTt3LlTly9f1uXLl7Vr1y69/vrrqlevnrZv317k57XH3LlzNWHCBKdKgBiGoZSUFB0/flwrVqzQ008/rebNm+vEiROODq3EmTBhgiZMmFDgpOnixYttEnrr16/X4cOHiza4W4TVatWLL74oSRo2bJg8PDzMfatXr1bdunX13nvvaf/+/UpNTdXFixe1detWjRkzRo0bN9axY8eu2nZGRoYSExO1c+dOffTRR2rYsKGmTZuWZ938vmfPP/+8JOmVV17RxYsXC3PJAADc8kiaAgBwi1i5cqWsVqu2bNmioKAgSdIPP/yglStXOjgy+4wfP15xcXGSpI8//linT5/WPffcI0maOXOmNmzYUGTnysjI0AMPPKDjx49LykosnD17VmfPntVzzz0nSYqPj9cDDzygK1euFNl5HSElJUVt27aVYRgyDEP9+vUr0vZjY2OVmpqqdevW6c4775Qk/f7773rggQdkGIYkFev5ryY9PV1Wq1Vz5841z11UiqNNR/ryyy9zlc2fP98BkRS9on6vli5dql27dsnV1VV9+/Y1y8+dO6eHHnpIFy5ckMVi0ZQpU5ScnKwTJ06od+/ekqS9e/fqsccey7Pdvn37ymq16uTJk3r33Xfl4+OjzMxMDRs2TIsXL85VP7/vWbdu3eTv76+EhAR9/vnnhb1sAABuaSRNAQC4hVgsFjVo0EA9evQwyzZt2pSr3oEDB9SlSxf5+voqOjo6Vw/Fzz77TO3atVOFChXk6ekpHx8f1atXT1OmTFFmZqZZ79KlS3r22WdVuXJleXt7KyAgQHXq1NGAAQNshmLHx8fr6aefVqVKleTh4aHy5curZ8+eOnDgwDWvx2q1at68eZKk6tWrq3///ipfvrxGjx5t1inKG/4FCxZo7969kqSmTZvqtddeU2BgoAIDA/X666+radOmkrJev2+++UbS1YeYjx8/3izP7ul16NAhPfzww6pSpYr8/Pzk4eGhiIgI9evXT0ePHrWJJfvYfv366cMPP1TVqlXl6+urFi1aaNu2bZKkw4cPy2Kx6Oeff5YkHTlyxOY4yXaY84oVK9SwYUN5enrqgw8+uGrsV65c0VtvvaUGDRrI19dXpUqVUr169Qo8hN7T01NNmzbV4sWLFRkZKSmr59uiRYuu+dq9//77ql+/vvz8/OTr66vKlSvrkUce0c6dO/MdY/ZrY7FY9NJLL2ns2LEKCwuTl5eXkpKS8hyenfM9W7lypTp06CAfHx/FxMRo2bJlSklJ0eDBgxUQEKCwsDCNHj3a5ufhem3+8ssvevDBB1WqVCmFh4fnOn7p0qXq2LGjwsPD5e3tLS8vL9WoUUMvvfSSzc9Tztdt5syZevbZZxUcHKwyZcrokUce0dmzZyVlJQZzxvLJJ5/kezqEixcvmkm5Dh06KCQkRFLeCbj8fFaz9e/fX3Xr1lVgYKDc3d1Vrlw5de7cWb/99ts143nppZfM8+zfv98sT0hIkJubmywWi4YMGSIp6+ezR48eCgsLk6enp8qXL68WLVpo8uTJ5nF5vVenT5/Wk08+qcjISHl5eals2bJq2LChhg8ffs3YJGnOnDmSpFatWplfWknSrFmzlJCQIEl65JFHNHz4cJUqVUqhoaGaPXu2wsLCJEk///yz1q1bl2fbFotFISEhGjJkiKZMmSIpqyf32LFjbeoV5D3z8PBQ165dJemGT40BAMBNwwAAADetvn37GpIMScbKlSvN8qFDh5rlr7/+eq66QUFB5uPsbdmyZXm2+/ftxRdfNOsNGjToqvUSEhIMwzCM48ePG2FhYXnWKVOmjLF3796rXt/+/fvNuvfdd59Zfu7cObP89ttvL6JX0zCefPJJs91p06bl2j9t2jRz/8CBAw3DMIyVK1eaZXPmzDHrjhs3ziyPjY3NVffvW3R0tJGammoen13u7++fq25kZKSRnp5uxMbGXrW9vn37GoZhGG3atDEkGT4+Poanp6e5/+23384z9oyMDKNDhw7XbPNqss+V85qzvfbaa+a+p5566qqv3fz58696Tf/5z3/yHWPO1yYwMNCmzvnz520+43m9Z2XLlrU5xtvb27jrrrtyne+DDz4wj79em3m9lzmPz1n371uvXr3Mejlft7za7Nmzp2EYhjFnzpyrtpfzs5qXzz77zKw7Y8YMm5+N3bt329TNz2f173X/vnl6ehrbt2/P9VmKjIw0DMMwjh49ari6uhqSjJEjR5r1PvjgA7ONjRs3GoZhGDVq1MjzHDExMdd8r+6+++48j/P19b3ma2W1Ws3P2KhRo2z25fzMfPfdd7mOHTFihLn/lVdeMQzD9v39+89cRkaGUapUKXN/fHx8od4zwzCM999/35BkuLq6GhcuXLjmNQIAUBLR0xQAgFvMtm3bbHoWNWzYMFedRo0a6dSpU/rf//5nlv3nP/8xH/fr109btmzRuXPndOXKFR0+fFi33XabJGn69OnmkNZff/1VkvTwww/r4sWLOn/+vDZs2KCxY8fK09NTkjR27FgdP35c/v7++vnnn5WamqotW7YoMDBQ58+fN+cBzEt2Dy1J8vPzy/NxUS7MlLO3Z14L0GT3lpR0zTkIr6Zy5cpavHixTp48qbS0NCUmJmrcuHGSsnqh5nw/sl24cEEfffSREhMTzd6jR44c0YYNG1SpUiUZhqE2bdqY8Rl/Djn+e++xy5cvq3379jp69KjOnj2rBx98MM8Yv/jiC/3www+SpHr16mnLli26ePGi1q5dq/bt2xf4mrNVq1bNfHyteTGzP1PR0dE6efKkLl++rN27d2vatGnm61/QGM+fP6+ZM2cqKSlJu3fvlq+v73XjrV+/vhISEsxe2CkpKVqxYoWWLl2qw4cPq3Tp0pJsf26up2rVqjpy5Ii2bNkiLy+vXMd36dJFa9asUUJCgq5cuaKTJ0+qc+fOkqR58+bp3Llzudp0cXHRr7/+qvj4eNWuXVuS9M0338hqtapfv342w8/79u2b7+kQsod5WywW3Xvvvbr33nvNfVcbon+tz2q2zz//XLGxsbp8+bJSUlLMz3xaWppmzZp11XjCw8PNOZo//fRTs4fu119/LUmqXbu2GjVqpLNnz2rPnj2SpClTpigtLU3x8fH64Ycf1KdPn2tec/Znb/jw4UpJSVFCQoJWr1593Z6mR44cMd+bmJgYm31F/X+Kq6urKleubHPubAV9z+rUqSNJyszMzNUjGAAAMDwfAIBbRrt27czh+dnJxnbt2qldu3a56r7xxhsKCgrS3XffbQ4lzZ43VJJCQkL0yiuvqFatWvLy8lKlSpW0ZcsWSVJiYqKZqMy+4f/tt980adIkLVq0SL6+vpowYYKZVFqyZImkrIRKmzZt5OXlpdtuu81MMvz0008FvtaciSBHrVTu6upa4GOCg4O1du1a3XHHHfL391dAQIAmTJhg7s+eGiCnxo0ba8CAAfL399cjjzxilud8v/LDYrHoo48+Unh4uAIDAxUREZFnvez3S8oaJp89/L1Zs2ZXnXcxP6xWq00sV5P9mTp+/LgmTpyoTz/9VImJiXrqqafUuHHjQsXYoUMH/eMf/1Dp0qVVo0YNubu7XzfekSNHqly5curQoYNZ1rJlS3Xs2FGRkZFmgrIg78OECRNUsWJFNWjQQHXr1s11fFhYmD766CPddttt8vHxUWhoqHmthmHYDEvPNmDAALVs2VLBwcFmgjU9PV2nTp3Kd1x/l5iYqGXLlknK+vxVqFBB7du3N5PNec2bmV33ep/VjIwM9ezZU8HBwfLx8VGnTp3MfXl9/nPKXvjtxIkT+t///qdz586ZczZnzyMaEBBgfqkyb948vf7661qzZo1q165tLn50NdmfvSVLlmjy5Mn66aefFBYWppdffvmax+X84qZs2bLXrHst+f0/Ja+fpcK8Z+XKlTMf2/N5AQDgVkXSFACAW4yHh4eqVq2q0aNHa9GiRXkmqKpWrWo+zu7xlpaWJklKSkpShw4d9PXXXys+Pt5mzsVs2fMrvvnmm6pTp45OnDihV199Vb1791ZMTIyaNGmixMRESba9RfOSV++5bOXLlzcfX7hwwXycc3XonHX+Lufcj/mZyzE8PNx8/Pc5RiXbXl1XSzpmy+t1e+655zRp0iTt3r1bqampufbnnLcyW17vlfTX+5Vf5cuXV2ho6HXr5Xy/atasWaBzXMu+ffvMx3n1uMv29NNPq2vXrkpPT9eMGTM0aNAgNW/eXJGRkeb8vAWNsV69egWONztGb29vs6xixYrm4+zV0QvyPlzr585qteqee+7RnDlzdPTo0TwXGivOz0dOCxYsUHp6uqSsnuo7duzQgQMHzF7re/bsybNn4vViWbhwofr27at169YpOTk51yJMeV1fTnfccYf5fs+ePVvffvutMjIy5OrqaibLXV1dNWfOHAUHB2vTpk166aWX9MADDygsLExPPvnkNdv/4IMPFBUVpb1792rixInq3r27KleurHvuuafQC78V5f8pUlbSOTY21nyenegtzHuWM/kKAAByI2kKAMAtYuXKlTIMQ2lpadq3b5/+9a9/ycfHJ8+6OXva/T2pum7dOvPmvnfv3kpMTJRhGHkO565Ro4b++OMPHTx4UN9//73Gjx8vV1dXbdy4UdOnT5f0V1KzevXq5tDgnNu1btyjo6MVEBAgybYXWvbwW0nmtAFF4Y477jAf59UzK3tRKilrKLUkcxoCSTaJ0JyJjWzZQ7FDQkK0e/duWa1Wff/999eM6Vrv1fXKc8qZ/LuWnEnonK+zPdLS0jRz5kzzeXaPyLz4+Pjou+++0+nTp/Xjjz/q3XffVYUKFXTixAmNGjWqUDHm99pzcnNzy1dZQVzrvTxw4IC2bt0qSWrfvr1OnTolwzD07LPPFrrNwsr52Z8xY4bq1KmjOnXqaPXq1WZ5XsO9rxdLzqkIvv/+e6Wnp9t8AZIfTz/9tCRp0aJF+uCDDyRJHTt2NBc9kqQHHnhAJ06c0LZt2/TVV1+pd+/eMgxDs2bNuuaCUy1bttShQ4e0e/duLViwQMOGDZMkLV68WF999dVVj8u58FP2IlzZrvV/SkZGRq7pGa5n1qxZunjxoqSsaVayz12Y9yxnrMHBwdc9NwAAJQ1JUwAAYCNnDzVvb295eHho+fLlNkOis73++utauHCh3Nzc1KFDBz388MNmD7Ps3oDZw2/37t2r8ePH6/z587p8+bLWrl2rwYMH67XXXrtqLC4uLurZs6d5/Jw5c5SQkKBXXnnFrNOrV6+rHt+2bdtcSdprzeX44IMPmvMFrl69WuPGjVNiYqLOnz+vUaNGmatb161bV3fffbck295hy5Ytk2EY2rZtmxYuXJir/ezX1tXVVaVLl9bx48evef35VaZMGUnSmTNnFB8fb1dbORM3gwcP1u+//67Lly9r48aN+ve//12gttLT07Vhwwbdc889Zo+6Zs2aXTNp+vXXX+uDDz7Q+fPn1aJFCz3yyCPmCuPZn6mijNFZ5Py58/T0lLe3tzZt2lQk15P9+Thw4MB1e3MmJCTka8qMqw3Rv5ac11i6dGmlpqZq9OjRBWqjT58+KlWqlK5cuWLOlfr3n+mhQ4fql19+UWhoqO677z6bKRau1fP9xRdf1LJly+Tn56d77rlH999/f76Oi4yMVGBgoCRpx44dNvuefPJJ8/X//PPPNWPGDF26dEnx8fEaMGCA+QXVPffco1q1auXZvmEYOn36tKZPn24m0S0WiyZOnGjGVpj3bPv27ZKy/j+qX7/+dY8HAKCkIWkKAABstGzZ0kwAfPjhh/Lx8VHHjh3zHNq9ZMkSPfDAA4qMjJSnp6diYmJ06dIlSVm9vyRp4sSJZtJrwoQJCgwMlK+vr1q0aKH3338/z2HqOY0fP94cFt2/f38FBQVp0aJFkqRBgwapSZMmRXPhyhpyvWDBArPX2sSJE1WmTBkFBgbq1VdflZQ1RHvhwoVyccn6Myo8PFzNmjWTJH377bfy8/NTgwYN8my/a9eukrLm6wwPD1dERIROnjxpd9zZc31eunRJoaGhslgs11xU51p69OhhJpm2bt2q+vXry9fXV02aNNGKFSvy3U5UVJQ8PT3VtGlT/fjjj5KyFlf65ptvrtkjcseOHRo0aJCqVasmHx8fBQcHa+PGjZJkJqqLKkZnUqNGDVWpUkVSVs9GPz8/NW7c2Jwb2B7Zn4/ffvtNPj4+slgsOnDgQJ51v/76a2VkZEjK+nn9+5cO3bp1k5S1mFf2lwj5lf35l7K+0PDz88vzy5hr8fPzU+/evc3nZcqUsVnwSJLee+89tW3bVsHBwfL09DTr+/v7mz+refn888919913KywsTB4eHuYCa+7u7jY9Rv/OYrGY+9euXWuzr1y5cvrPf/6j0qVLKzMzU08//bRKlSql0NBQffLJJ5KyvoTJfvx3n3zyiVxcXBQcHKwhQ4bo8uXLcnV11TvvvGN+IVXY92zNmjWSsj4fORfXAwAAWUiaAgAAG4GBgfr+++/VuHFjeXl5qWrVqvr3v/+tVq1a5arbr18/dejQQRUqVJCHh4cCAwPVvHlzzZ8/37yhDwsL06ZNm/T0008rMjJS7u7uKleunBo1aqQxY8Zcd0XroKAgrVmzRn369FH58uXl4eGhmjVrasqUKeYUAEWpbt26+v333zVy5EjFxMTYTHEQHR2t7du3Kzo62uaYL774Qh06dFCpUqXk5+enl156Kc8Vt6dOnao+ffooMDBQZcqU0cCBAzVt2jS7Yx46dKh69+5ts7BLYbm6umrRokV64403VL9+fXl7e8vHx0d16tRR27Zt892OxWKRl5eXwsLCdOedd2rGjBlau3atKlSocM3j2rdvr0ceeURRUVHy8fFRqVKlVKtWLU2cOFGTJk0q0hidibu7u7777ju1a9dOvr6+ioiI0FtvvWXX4lvZpk2bprZt2+YrAZuzN2Je53700UfNx3kN0b+Wvn37atKkSQoPD5e3t7fuuusu/fDDDwVqQ/priL6UlUDPOUWGJL3wwgtq2rSpypUrJ3d3d4WEhOjee+/Vjz/+aDOM/++GDh2qNm3aKDg4WO7u7ipfvrzuvPNOLV682Fy462r69+8vSfr1119zLap055136o8//tDgwYNVtWpVm/leW7RooY0bN5pfVOXF1dVV/v7+iomJ0cCBA7V161YNHTrU3F+Y9ywtLc388unxxx+/5rUBAFBSWYy/z8AOAAAAG8uXL1eXLl105coVjR8/XuPGjXN0SECJ9eOPP+quu+6SJG3atMlc7MiRrFar6tSpo127dum1117T888/f836c+fO1eOPPy6LxaLZs2dfc9qQ4vDll1+qR48eKl++vA4dOqRSpUrd0PMDAHAzoKcpAADAddx1112aO3euLBaLxo8fr/fff9/RIQElzsKFC1W1alWzF/tdd93lFAlTKWv+5X/961+SpHfeecdcyf5q+vXrp8mTJ8swDA0YMEDffffdjQjT9MYbb0jKmseVhCkAAHmjpykAAAAAp5fdO9PX11dt27bVxx9/zKrvAACg2JA0BQAAAAAAAIAcGJ4PAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQA0lTAAAAAAAAAMiBpCkAAAAAAAAA5EDSFAAAAAAAAAByIGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQA0lTAAAAAAAAAMiBpCkAAAAAAAAA5EDSFIDTOnDggNq3by8/Pz9ZLBa1bdu2yNo+fPiwLBaLLBaLVq1aVWTt3mzmzp1rvg4AAAAAACALSVPgFrR69Wp17txZ5cuXNxNiM2fOtKvNxMREjR8/XvXr11epUqVUqlQpxcTEaMSIEUpISCiiyG09++yzWrFiha5cuaLGjRurVq1aRda2p6enmjZtqqZNm8rPz6/I2r2e7PfDYrHon//8p82+JUuW2OxfunRpgdru169fgZPL5cuXN18HAAAAoKR766231LZtW4WGhsrT01ORkZHq27evDh06VKj2KlWqZPM3vru7uyIiItS/f3+dOXMmV/1169bpoYceUmhoqDw8PFSuXDl16tRJ//vf//Jsf8uWLXrsscdUsWJFeXp6Kjg4WG3bttWsWbOuG9v+/fv1j3/8Q5UrV5aXl5fKli2rZs2a6dVXXy3UtQK3GothGIajgwBQtKZOnarnnntO0dHR2rdvnyRpxowZGjRoUKHaO3z4sNq2basjR45IkgIDA1WhQgUdOnRIly9f1sqVK4u0F2i2KlWq6ODBgxo5cqQmT55c5O07Qs4enX5+fjp+/LhKlSolSerUqZNNovR///uf7r777ny33a9fP33yySdq06ZNvnrPpqeny8PDI//BAwAAALe4SpUqKS4uTtWrV1daWppiY2MlSSEhIdq7d2+BO1xUqlRJR44cUenSpVWrVi2dPHlScXFxkqQuXbpo0aJFZt25c+dqwIAByszMlIeHh6pUqaLDhw/r8uXLkqSJEyfqpZdeMuvPmjVLgwYNUmZmpiwWi6KioiRl3b9FRETo8OHDV41ryZIlevjhh822w8PD5evrq4MHDyojI0NFkSrifgM3O3qaAreg3r17KykpScuWLSuS9h577DEzYfrOO+/ozJkz2r59u5KTk/Xdd98pJCTErDtnzhw1bNhQ3t7e8vX1VcuWLfXf//7X3J9zWPzcuXN1zz33yMfHR1FRUfr4449t6hw8eFCS9Oqrr8pisahfv35atWqVeXzOPwJytilJFy9e1FNPPaWIiAh5enqqfPnyatmypT755JNcceRMMP7666/q2LGj/P395enpqZo1a+qNN95QZmamWSf72+IXXnhBQ4YMUdmyZRUUFKRnnnlGGRkZ+XpN3d3dlZSUZMazf/9+LVu2TO7u7rnqHjt2TJ07d1ZERIS8vb3l7e2t2rVra+rUqeYfM5UqVTLb+vnnn22uLedr9p///EdNmjSRh4eH5s2bl2t4/ubNm+Xh4SGLxWK2t3XrVrm7u8tisWj27Nn5uj4AAADgZvTkk0/q8OHD2r17tw4dOqRhw4ZJkuLj47VixYpCt3vbbbdp3bp1OnLkiFq1aiUp6+/2bCdOnNBTTz2lzMxMValSRQcOHNDOnTt17NgxNWvWTJI0duxYbd68WZK0Z88eM2EaGRmprVu36uDBgzp48KDOnDmj0aNHXzWWM2fOqGfPnrp8+bLKlCmjlStX6ujRo9qzZ48uXLigadOmmXX/fp8lSW3btjXvzyTbe6tZs2bpzjvvlJeXl8aOHauAgABZLBa988475vEHDx7MNbruxIkT6t+/vypUqCAPDw9FR0fr5Zdfzvf9FVAcSJoCt6CyZcvK29u7SNrauXOnfvvtN0nSvffeq3/+859mgs3FxUVdu3ZVjRo1JEmTJk1S//79tWXLFgUFBcnPz09r1qxRt27d9Nlnn+Vqe+DAgdq5c6fc3d11+PBhDRw4UHv27DGHzmd/KxkWFqamTZuqcuXK+Y577NixmjlzphISEhQTE6PSpUtr/fr1Wrly5VWPWbVqldq1a6cffvhBrq6uioyM1J49e/T888/n2Uv37bff1hdffCFvb28lJCRo2rRpmjNnTr7iu//+++Xi4qL33ntPhmGY/z700EO56p45c8YcjlOzZk35+flp586dGj58uN5//31JUoMGDVSuXDlJUunSpa869cBjjz2mY8eOKSoqKs95TBs2bKhx48ZJkkaMGKFjx46pf//+ysjI0P3336/+/fvn6/oAAACAm9GLL76oihUrms+zE5xS1hRfRSnnef7zn/8oNTVVkjRmzBhFRERIksqUKWMz6i77vurjjz82O3a8/fbbqlevnlmnTJkyGjhw4FXP++WXXyopKUmS9NJLL9mMGvTx8dHQoUMLfU2DBw/W77//rsqVK8vX11fdu3eXJM2fP9/m/JJUoUIF3XXXXTp79qyaNWumOXPm6OLFi6pZs6aOHj2qsWPHXvM6gOJG0hTANe3atct83Lp166vWu3Tpkl555RVJWQnB2NhYHT58WE2aNJGU9Yv/7+677z4dOnRIv/zyiyTJarVq1apVCg0N1bp16xQaGipJGjBggNatW2czFOV69u/fLynrj4AtW7bo0KFDOn36tIYPH37VY8aNG6eMjAxFRkbq0KFD2rdvn5555hlJWX+U/H0eo/DwcB06dEgHDhxQhQoVJCnf3z5HRUWpS5cu2rNnjxYuXKi5c+eqTJkyeuyxx/KsGxsbq6NHj2rLli06efKk+V5k//GxcOFCdenSRdJf32KvW7dOt912m01bDz30kI4dO6a9e/fmeS5JGjlypFq0aKFz586pUaNG2rZtm0JDQ/XRRx/l69oAAACAW0FmZqY+/PBDSVJ0dLTuvPPOQre1ZcsWNWvWTJUqVdIvv/yi8PBws21J2rt3r/m4fv36NsfmfJ5dL7/3aXmx59jrad68uY4dO6adO3dq9OjR6tu3rySZvWylv5Kmjz32mFxdXfXee+/p6NGjCg4O1sGDB/X777/r66+/lpQ1ZcGBAweKNEYgv0iaArimnHPZXGuF9Z07dyolJUWS1KNHD7m4uMjT01MPPvigJOnIkSO5Fozq1auXLBaLzQJPp06dKpK4u3btKikraRoZGamOHTvq3XffVXBw8FWP2bhxoySpc+fOCggIkCQ9+uijkrJeh+yhMNnuvfde+fv7y8vLy5w/qCDxZ3+D+/jjjyspKUn9+/eXj49Prnpubm56/fXXFRkZKXd3d7m6umr16tWSsoaxFMTQoUPl4pL1X7+rq2uedVxdXfXvf/9bvr6+5vXMnj1bZcuWLdC5AAAAgJvVpUuXdP/992vZsmUKCQnR999/b1dP0+TkZK1fv95MHDZq1EgNGjTIs+7f77uy/37PKb/3aXmx59jrGTRokLy8vCRl3Ve0aNFCVatWlZSVLN2zZ4/++OMPSTKH92/YsEFS1r1UUFCQLBaLunXrZsa6fv36Io0RyC+SpgCuKSYmxnyc3SO0qGQnJt3c3Myy6004nvOXevZwlAsXLuSqN3DgQP38888aMWKEatSooc2bN2v8+PFq3759EUSeJTt+6a9rKMiE6e3bt1eNGjWUlJQkFxcXDR48OM96w4YN04wZMxQXF6eoqCg1bdrUHIqfc67V/LhW0jinU6dOmcODJPHtLgAAAEqM+Ph4tWnTRt9//72qVaum3377zaajR2G0adNGV65cMdcN+PbbbzVq1Chzf/Xq1c3HW7dutTk25/PsevbcpxXm2Jz3HXndf2XL636jT58+krKSptm9TBs3bqyaNWva1Ms5zVjOLa+OJcCNQNIUKMHuvPNO1ahRw+aX9d/FxMSoRYsWkrJ+sU+fPt3cZxiGvv76a+3evVsxMTHmPKpffvmlrFar0tLStGDBAklSZGSkypcvb3fMQUFB5uN9+/ZJypr/5+82bNigmJgYvfnmm1q2bJm5KuXOnTt19uzZPNtu3LixpKyVJBMTEyVJX3zxhaSsZG3Dhg3tjj8ni8WiIUOGSMpaOTO7t+rfrVu3TpLUoUMH7du3T6tWrVJYWFiuetl/TFy6dOma57yeixcvqnfv3srMzDSHAj3//PM2Q4YAAACAW9HOnTvVrFkzbd68Wa1atdLatWsVHR2dq15+7qX+zs3NTX369NEDDzwgSZo5c6aOHz8uKWsareyerJMmTdKxY8ckSYmJiRo5cqTZRvYUW/379zdHjg0fPlzbt28365w7d07vvffeVePo3r27ufbBxIkTzVFsUta9xJtvvmk+z77/yr732rNnj825/i6v+43evXvLYrFoy5YtmjlzpqS/eplKf92Hubm5af78+eZUY8uXL9fTTz+t+++//6rnA4oTSVPgFrRgwQJVqVLFZkLvsWPHqkqVKurVq5dZdvDgQe3du1cnT568Znuff/65IiMjJclcLb5u3bry9/fXww8/rFOnTsnX19dcoXHBggWKiopSpUqVzKEUkyZNKpJrq1q1qjlh+qOPPqp27drl2UNz2rRpCgkJUVRUlBo2bKiOHTtKylpUKjAwMM+2J0yYIDc3Nx05ckTR0dGqVq2apk6dKkl64okn8vxjyV6DBg1SQkKC+Y1rXurWrStJ+uGHH1S9enVFRETo6NGjueplL8i1adMm1alTR82aNTOnTCiIYcOG6eDBg6pcubJ+/fVXderUSSkpKXrsscdYvRIAAAC3tAceeMAcQp+cnKzOnTurWbNmatasmWbNmmXWy++9VF6yE63p6elmgjIsLEwzZsyQi4uLDhw4oMqVK6t27doKCwszO1FMmDDB7MhRs2ZNzZw5U66uroqNjVX9+vVVpUoVVa1aVcHBwTaJz78rV66c5s2bJx8fH507d05t2rRRxYoVVatWLQUGBuq5554z62bP4/rWW2+pXbt2at68eYFG10lZHWiy703j4+Pl6empHj16mPsHDx6ssLAwnT9/XtWrV1f9+vVVuXJllS1b1pwTFXAEkqbALSgpKUkHDx40f9lLUkJCgg4ePGh+k1kQlSpV0rZt2zR27FjVrVtXqampOnjwoEJDQ/XMM8+YwzvGjBmjjz/+WLfddptOnz6tCxcuqHnz5vr222+vuuhQQbm5uenLL79UgwYNlJqaqnPnzmnhwoW56nXp0kWtWrVSSkqKtm/fLi8vL3Xt2lVLliy5am/Ltm3bauXKlbrrrruUmZmpw4cPq0aNGnrttdfMb0SLmqurq8qVK2f20s3LlClTdN9996lUqVJKTk7Wc889Z87ZmlP//v314IMPyt/fXzt27ND69esLPHz/v//9rz7++GNZLBbNnj1bvr6++uijjxQQEKBNmzZp4sSJBb5GAAAA4GaRlpZmPt62bZvWr19vbtm9P+3VqFEjMxn54Ycf6syZM5Ky1jr49ddf9cADD6hMmTLau3evvLy81LFjRy1evFhjx461aWfAgAFav369Hn30UVWoUEFxcXE6f/68mjZtqhdffPGaMXTp0kVbt27Vk08+qaioKJ06dUonT55UnTp1zAV+pax7kS5dusjb21sHDx7U6NGjdfvttxf4mnMmP7t27WrTkaV8+fJat26dHn/8cZUtW9ZcL6NVq1Z6++23C3wuoKhYjIJ+RQAAAAAAAAAAtzB6mgIAAAAAAABADiRNAQAAAAAAACAHkqYAAAAAAAAAkANJUwAAAAAAAADIgaQpAAAAAAAAAORA0hQAAAAAAAAAcnBzdABwLKvVqhMnTqh06dKyWCyODgcAcAMZhqHk5GRVqFBBLi6O/x41NTVV6enpRdKWh4eHvLy8iqQtAIB9Vq9erTfeeEObN2/WyZMntXDhQnXr1u2ax6xatUojRozQzp07FRERoTFjxqhfv375Pif3OQBQchXVfQ5J0xLuxIkTioiIcHQYAAAHOnr0qMLDwx0aQ2pqqqIiSyn+dGaRtBcSEqLY2FgSpwDgBC5duqR69eqpf//+euCBB65bPzY2Vl26dNGgQYP0+eefa8WKFRowYIBCQ0PVsWPHfJ2T+xwAgL33ORbDMIwijAc3mQsXLiggIEBHtlSSXynH9zICHOHhjl0cHQLgEBnWdK068oESExPl7+/v0FiSkpLk7++v2M2R8itt3++jpGSrohoe0YULF+Tn51dEEQIAioLFYrluT9MXXnhBixcv1o4dO8yyHj16KDExUUuXLs3XebLvc44ePcrvAgAoYZKSkhQREWH3fQ49TUu47KEqfqVc7L5JBW5Wbi6ejg4BcChnGrboV5rfRwBQ0q1du1bt27e3KevYsaOGDRt21WPS0tKUlpZmPk9OTpYk+fn5kTQFgCJktRraf/qiMq1F0wdz/+lkbY1LlLur/fckEYE+6tO8kvnc3vsckqYAAMBpZBpWZdr591emYS2aYAAADhEfH6/g4GCbsuDgYCUlJSklJUXe3t65jpk8ebImTJhwo0IEgFtS6pVMJaVc0Za48/ppz2ntOpmk4NK2012t2HPaQdFdX+NKZWySpvYiaQoAAJyGVYassi9rau/xAICbz6hRozRixAjzefbQTADA9e0/laypP+7X4u0nc+3boaSrHle+dNGM2kxITtODt4WrXCkPu9oJL5P7SzV7kDQFAAAAADiNkJAQnTp1yqbs1KlT8vPzy7OXqSR5enrK05MplwAgv/afStZzX/+hbUcTr1onLMBbnWqHqGpwKZvyEH9vta5azqmm+SoOJE0BAIDTsMoqewfX298CAMCRmjdvriVLltiULV++XM2bN3dQRABwazmemKK73l6dq9zXw1WL/9lKlcr5OiAq50PSFAAAOI1Mw1CmYd/wenuPBwAUrYsXL+rAgQPm89jYWG3btk2BgYGqWLGiRo0apePHj+vTTz+VJA0aNEjvvfeenn/+efXv318//fSTvvrqKy1evNhRlwAADnH2YpqOnLusUxdSte1Yosr4XH34eqbV0LQV+9WiclmzB+iltAytjz0nTzcXubv+tdjqxbQM87G3u6vefLieutQNLb4LuUmRNAUAAAAAFJtNmzapXbt25vPsuUf79u2ruXPn6uTJk4qLizP3R0VFafHixRo+fLjeeecdhYeHa9asWerYseMNjx3AzeXC5St6/+cD8nF306Yj5xTi5yVHjSBfd+icKgR4ydXFot8OnFVYgHeBVog/fPZyoc67cm9CrrK0DKvSMnKPxuoYE6wPejcq1HlKApKmAADAabAQFADcetq2bSvjGqMA5s6dm+cxW7duLcaoADir1CuZ2nT4vDKsVh04fVHeHq7adSJJGw+fk5+Xu1lv05HzCvT1kKfbXz0oT15IdUTIVxV37q/E5/HEFLvbC/X3Ussq5a66PyPTqiPnLqtnk4o5ygwF+LgrpoKfTd2g0l7y9nC1O6ZbGUlTAADgNKwylEnSFAAAoEQxDEMXUq5IkupPXJ7v485dSr/qvl5NK+pEYooaRwXaHV9hnbuYrjrh/pKk9AyrossXbK7QcqU8FVmW+UUdhaQpAAAAAAAAbrjZv8Zq4qJdV91fK9RPh85cVJtq5ZWUkqEOMcEK9fc292dYrYoM9LUZgu/v7a6IQJ/iDBslBElTAADgNBieDwAAcHPLtNr+LbbzxAVtjUuUT46h4BdSrmjS4t3XbOfQK53l4uKgCUkBkTQFAABOJNMwlHmNee/y2wYAAADsk3olUxfTMrT9+AVZrYZ2HE/SV5uOKsTfK8/6GZlW/X7sQqHONeKuahrQKkqeblmJVVeSpXACJE0BAAAAAAAgSYo7e1mt31h51f2FXdCotKebGlUqYz5Py7CqZqifRtxVTb6epKfgfPhUAgAAp2H9c7O3DQAAABTcK0t268PVh3KVh/h5qbSXm85fTlfHmBC1rlY+z+MNw1Cwn5eiyv21eJG7qwtJUdyU+NQCAACnkSlDmXbOSWrv8QAAALcSq/Wv6Y9Sr2RqS1yi3FwsOnL2slxdsnp8frPluH4/mmhzXP2IAH0+oKm83F0ZLo8SiaQpAAAAAADALcAwDG0/fkGnktJ05mKaXv3fHl1IuVLgdhYNvV21w/yLIULg5kHSFAAAOI1MI2uztw0AAIBbSUp6ptYcPKOtcYk6nZwqd1cXubu6SJJ+2nNacecuy9/bPd8JUm93V1UM9NHeU8m6o0aQLqdn6OzFdD1xe5Q61w2Vn5d7cV4OcFMgaQoAAJwGc5oCAICS6nJ6hhIv/5X0XHforCYu2iU/L3fFnbt83eP/njCtGlRKx86nyNvDVR/2bqiqQaUlSb6ernL7M+EK4OpImgIAAAAAABSTrHlEz8tqlQ6cTpa3h6sk6atNx+TqYtGG2HPXPD5nIlWSgkp7KryMtxpGlpGHm4sMQzp7MV2tqpVTjRA/+Xu7q3xpz2K7HqCkIGkKAACchlUWZcq+hQasBTx+8uTJWrBggfbs2SNvb2+1aNFCr732mqpXr27Wadu2rX7++Web4/7xj39o5syZ5vO4uDg99dRTWrlypUqVKqW+fftq8uTJcnP768+tVatWacSIEdq5c6ciIiI0ZswY9evXr3AXCgAAnNbRc5e188QFfbD6kLbGJRboWA+3P3uBGlJ6plU9Gkfo3voVVL6Up6oGly76YAHkiaQpAABwGlYja7O3jYL4+eefNXjwYDVu3FgZGRkaPXq0OnTooF27dsnX19es9+STT2rixInmcx8fH/NxZmamunTpopCQEK1Zs0YnT55Unz595O7urldeeUWSFBsbqy5dumjQoEH6/PPPtWLFCg0YMEChoaHq2LGjfRcNAAAcbuPhcxo2f5uOJ6ZctU714NKKPXNJrauVkySlXMnUo00iFeDjrhohpVW2FD1EAWdB0hQAAJRoS5cutXk+d+5cBQUFafPmzWrdurVZ7uPjo5CQkDzb+OGHH7Rr1y79+OOPCg4OVv369fXyyy/rhRde0Pjx4+Xh4aGZM2cqKipKb731liSpZs2a+vXXX/X222+TNAUA4CZzIeWKLqZlSJKSUq5oa1yiRi/cnquem4tFwX5eeuOhumpRpdyNDhOAHUiaAgAAp5FZBMPzs49PSkqyKff09JSn5/V7b1y4cEGSFBgYaFP++eef67PPPlNISIi6du2ql156yextunbtWtWpU0fBwcFm/Y4dO+qpp57Szp071aBBA61du1bt27e3abNjx44aNmxYga8RAAA4xlcbj+r5b/64Zp3OdUL0xO1RahBRRi4u9v1dA8BxSJoCAACnUZRJ04iICJvycePGafz48dc81mq1atiwYWrZsqVq165tlj/66KOKjIxUhQoV9Mcff+iFF17Q3r17tWDBAklSfHy8TcJUkvk8Pj7+mnWSkpKUkpIib2/vgl8sAAC4IdYcOKN3VuzX+r8t2uT55/yjaRlWVSrro2faV9X9DcIdESKAIkbSFAAA3JKOHj0qPz8/83l+epkOHjxYO3bs0K+//mpTPnDgQPNxnTp1FBoaqjvvvFMHDx5U5cqViy5oAABQrE4lperkhdRr1jEMQ0fOXpa7q4sWbz+hJdvjc9V5tGlF/atbbVks9CQFblUkTQEAgNOwGhZZDftuPrKP9/Pzs0maXs+QIUO0aNEirV69WuHh1+4h0rRpU0nSgQMHVLlyZYWEhGjDhg02dU6dOiVJ5jyoISEhZlnOOn5+fvQyBQCgiKVeydQfxy7IahhKTs3Qd7+f0Pe/n7C73Xrh/prxWENVCOB3N3CrI2kKAACcRlEOz88vwzA0dOhQLVy4UKtWrVJUVNR1j9m2bZskKTQ0VJLUvHlz/etf/9Lp06cVFBQkSVq+fLn8/PxUq1Yts86SJUts2lm+fLmaN29eoHgBAMDVZWRa9e22E/q///x+zXrhZa6d9LySadWppDQ1jQrU+thzerdnA3WtV6EoQwXg5EiaAgCAEm3w4MGaN2+e/vvf/6p06dLmHKT+/v7y9vbWwYMHNW/ePHXu3Flly5bVH3/8oeHDh6t169aqW7euJKlDhw6qVauWevfurddff13x8fEaM2aMBg8ebE4LMGjQIL333nt6/vnn1b9/f/3000/66quvtHjxYoddOwAAN4OU9EwdTLioY+dT9Pd1lb7adFQ/7j4tf293XUi5kutYDzcXRZTx1uX0TEWW9VH9iDIa1r6qvNxdb1D0AG5WJE0BAIDTyJSLMuViZxsFM2PGDElS27ZtbcrnzJmjfv36ycPDQz/++KOmTp2qS5cuKSIiQg8++KDGjBlj1nV1ddWiRYv01FNPqXnz5vL19VXfvn01ceJEs05UVJQWL16s4cOH65133lF4eLhmzZqljh07FvZSAQC46a3el6Dlu05ddf+/1x3JVzt5JUyfubOqht9VrdCxASjZSJoCAACnYRTBnKZGAY83DOOa+yMiIvTzzz9ft53IyMhcw+//rm3bttq6dWuB4gMA4FZzOjlVS3fEa+x/dxboOB8PV11Oz1SDigE25YcSLunFzjVVLyJALhYpxN9LPh5ucv17t1QAKACSpgAAAAAA4IZ4c9levbfyQK7yga2jrzpk3svdRf9oXZkkKIAbiqQpAABwGo5YCAoAABS/faeS1eHt1TZlAT7uKlfKU18ObKaypTwdFBkA5I2kKQAAcBqZhosyDTvnNL32aHsAAHCDJCSnacryvfpiw9Fc+74c2ExNo8s6ICoAyB+SpgAAAAAAoEh8temonv/6j6vuD/bz1NJnWquMr8cNjAoACo6kKQAAcBpWWWSVfT1NraKrKQAAjrBgy7GrJkznPdlUzaPLymJhGh0ANweSpgAAwGkwpykAADent5fv0zsr9pvPx3Wtpe6NI+TjQdoBwM2J/70AAAAAAECBWa2G3v5xn9796YBN+czHbtPdtUMdFBUAFA2SpgAAwGkUzUJQDM8HAKC4fbXxqJ7/JvdQ/BXPtlHl8qUcEBEAFC2SpgAAwGlkzWlq3/B6e48HAADX9tK3O/TvdUdsyiY/UEc9GkcwZymAWwZJUwAAAAAAcF2GYej7P07aJEz/0SZaL3SsIRcXkqUAbi0kTQEAgNOwykWZsm94vlUMzwcAoKhZrYaiRy+xKZvzeGO1qx7koIgAoHiRNAUAAE6DOU0BAHAul9Mz9OayfZr9W6xN+ZsP1yNhCuCWRtIUAAAAAADYuJiWoUtpGWr12kqlZ1pt9h1+tYuDogKAG4ekKQAAcBpWucjK8HwAAG64ZTvjdeTsJc357bBOXkjNs85zHaurf8uoGxwZADgGSVMAAOA0Mg2LMg37FpKw93gAAG51yalXtPtksn47cEYr9pzSjuNJ16x/X/0KeqdHgxsUHQA4B5KmAAAAAADcQqxWQ6v3J+g/m45p4+FzKuXppoTkNCWnZVz32PsbhMnNxaJBbSsrvIy3JMnTzbW4QwYAp0PSFAAAOI1MuSjTzuH5mQzPBwCUYDuOX9A97/5qU3Y6OS3PuhGB3jp6LkUdY4LVuU6o7qsfdiNCBICbAklTAADgNKyGi6yGnXOaGiRNAQAlz4gvt2nB1uN57mtbvbw6xoTIy91FMRX8FejroQBvd7m52vc7FwBuZSRNAQAAAAC4CR1MuKjBn2/RnvjkXPtaVS2nT/s3kcXCXN8AUBgkTQEAgNNgeD4AAPnT8tWfdDwxJVf5L8+3U4UAb7m6kCwFAHuQNAUAAE7DKinTsO8mz1o0oQAA4HCGYeh4Yor+tz1eFouUnmnVnpPJ+u73Ezb1qgeX1gudqqtd9SB6lgJAESFpCgAAAACAk7iSadV7Px3QOyv256v+npfvlpc7q9sDQFEjaQoAAJyGVS6y2jk8397jAQBwhF0nkrTrZJL+7z+/X7VOh1rBshqGMqyGWlQuqydbRdOzFACKCUlTAADgNDINF2Uads5paufxAADcKIZhaPrKA3rzh3157v/nHVU0oHW0/Lzcb3BkAACSpgAAAAAA3GBHz13WhO936cfdp2zK21Qrr7KlPPTag3Xl7soXgQDgKCRNAQCA07DKIqvsXQiKYYoAAOe1ZPtJPf35llzlt1cpp9ceqquwAG8HRAUA+DuSpgAAwGkwPB8AcKtKSE5T43/9mKu8VqifZjx2myLL+jogKgDA1ZA0BQAAAACgmP09Yfr6Q3X1SKMIB0UDALgekqYAAMBpZMpFmbKzp6mdxwMAUNSSU6/YPN83qZM83Ph9BQDOjKQpAABwGlbDIqth55ymdh4PAEBR++PYBfPx/n91YoEnALgJ8D81AAAAAADFaH3sOfMxCVMAuDnQ0xQAADgNaxEMz7fynTAAwIkcTLioaSv2S5JKe3ILDgA3C/7HBgAATsNquMhq2Jk0tfN4AACKitVq6M63fjafN69c1oHRAAAKgrsKAAAAAACKQZ3xy8zHLhZpWs8GDowGAFAQ9DQFAABOI1MWZcq+hZzsPR4AAHucTkrVqn0Jev7rP2zKD77SWRYLv6MA4GZB0hQAADgNhucDAG5mZy6mqckrK3KV/zbyDhKmAHCTIWkKAAAAAEARmLnqoPk4xM9Ld9cO0dh7asnFhYQpANxsSJoCAACnkSn7h9dnFk0oAFBinTlzRl9//bV++eUXHThwQBcuXJCfn5+qVq2qVq1a6aGHHlK5cuUcHaZT+mbLMfPx2lH0LgWAmxlJUwAA4DQYng8AjrNv3z6NHz9e33zzjTIyMmQYhs3+TZs2af78+XrmmWf08MMPa+zYsapWrZqDonUOhmHo92MXdDIxRU99vsUs790skoQpANzkSJoCAAAAABQTE6PMzEy5urqqadOmatKkiSIjI+Xn56ekpCQdOXJEGzZs0MaNGzVv3jx99dVXSk9Pd3TYDnM5PUNdpv2q2DOXcu3r3TzSAREBAIoSSVMAAOA0Mg0XZdrZU9Te4wGgpIqIiNCIESPUvXt3lS9f/qr1EhIS9MUXX+idd965gdE5l2+3HtewL7fZlEWV81UpTzd981QLebjxuwgAbnYkTQEAgNMwZJHVzjlNDTuPB4CS6sCBA3JxuX6yr3z58vrnP/+pIUOG3IConNPfE6a/PN9OEYE+jgkGAFAsSJoCAAAAAPKVMLWn/s3OajW0ZMdJDZm31Swb2amGBrWp7MCoAADFhaQpAABwGgzPBwDH6d+/f77qWSwWffzxxwVuf/r06XrjjTcUHx+vevXq6d1331WTJk2uWn/q1KmaMWOG4uLiVK5cOT300EOaPHmyvLy8Cnxuex04naz2U1bnKv9H6+gbHgsA4MYgaQoAAJyG1bDIatg3vN7e4wGgpJo7d+51V3w3DKNQSdMvv/xSI0aM0MyZM9W0aVNNnTpVHTt21N69exUUFJSr/rx58zRy5EjNnj1bLVq00L59+9SvXz9ZLBZNmTKlQOcuCv/bHm/z/Inbo/TSPbVueBwAgBuHpCkAAAAAQBUrVrRJmsbHxystLU2BgYGSpHPnzsnd3V1hYWEFbnvKlCl68skn9fjjj0uSZs6cqcWLF2v27NkaOXJkrvpr1qxRy5Yt9eijj0qSKlWqpJ49e2r9+vWFuTS7HTufIklqWaWsPh/QzCExAABuLMavAQAAp5EplyLZAAAFd/jwYcXGxio2NlZvv/22XF1d9eOPP+rMmTM6c+aMVqxYIVdXV73yyisFajc9PV2bN29W+/btzTIXFxe1b99ea9euzfOYFi1aaPPmzdqwYYMk6dChQ1qyZIk6d+6cZ/20tDQlJSXZbEXp/OV0SZKHK79jAKCk4H98AADgNLKH59u7AQDs88ILL6hSpUq64447zLJ27dopOjpaL730UoHaOnPmjDIzMxUcHGxTHhwcrPj4+DyPefTRRzVx4kTdfvvtcnd3V+XKldW2bVuNHj06z/qTJ0+Wv7+/uUVERBQoxmu5kHJFP+w6JUmqHuJXZO0CAJwbSVMAAAAAgI24uDjt3btXH330kc6ePauzZ89q1qxZ2rNnj44dO1bs51+1apVeeeUVvf/++9qyZYsWLFigxYsX6+WXX86z/qhRo3ThwgVzO3r0aJHEYRiG6k34wXwe6n/jF6ECADgGc5oCAACnYZWLrHZ+p2vv8QAAqVWrVvrxxx81aNAgDRo0yCw3DEOtWrUqUFvlypWTq6urTp06ZVN+6tQphYSE5HnMSy+9pN69e2vAgAGSpDp16ujSpUsaOHCgXnzxRbm42P5f7+npKU9PzwLFlR8r9562eX5P3dAiPwcAwDlxVwEAAJxGpmEpkg0AYJ9Zs2bptttuk2EYNluDBg00a9asArXl4eGhhg0basWKFWaZ1WrVihUr1Lx58zyPuXz5cq7EqKurq6SsxO2NkJFpVf+5m8zneyfdrbKlij4xCwBwTvQ0BQAAAADYqFixojZt2qSffvpJO3fulCTFxMTYzHFaECNGjFDfvn3VqFEjNWnSRFOnTtWlS5f0+OOPS5L69OmjsLAwTZ48WZLUtWtXTZkyRQ0aNFDTpk114MABvfTSS+ratauZPC1uO0/8tZjU0DuqyNPtxpwXAOAcSJoCAACnURQLObEQFAAUnTvuuEM1a9ZURkaGXYsrde/eXQkJCRo7dqzi4+NVv359LV261FwcKi4uzqZn6ZgxY2SxWDRmzBgdP35c5cuXV9euXfWvf/3L7mvKr8SUK+bjZztUv2HnBQA4B4bnAwAAp2EYLrLauRkGf94AQFH47LPPFBkZqfDwcHXv3l3ff/+97rjjDi1ZsqRQ7Q0ZMkRHjhxRWlqa1q9fr6ZNm5r7Vq1apblz55rP3dzcNG7cOB04cEApKSmKi4vT9OnTFRAQYOdV5d+x85dv2LkAAM6HnqYAAAAAABvffPON+vTpY1N222236eeff1ZQUJA6d+7soMhuHDeXrJELNUJKOzgSAIAj0BUDAAA4jUxZimQDANjnlVdekcVi0bBhw8yysLAwVahQQRs3bnRcYDfQukPnJEnlWPwJAEokkqYAAMBpWI2/5jUt/OboqwCAm9+uXbtUvXp1TZkyxaa8fPnyOnHihIOiurEWbj0uSUpKvXKdmgCAWxFJUwAAAACADS8vLyUlJclqtZplaWlpio2NlY+PjwMjuzEOJVw0H99br4IDIwEAOApzmgJ2mv9ukH5bEqCjBzzl4WVVrUaX9cSLJxRRJc2m3q5NPpr7Wqj2bPGRq6sUHZOiV+YdlKf3X12i1v/op8/fDlbsbm95eFpVp9kljZ8Ta+4/fcxd744K1++/lZaXb6buevi8+o8+IVd+kuGkHn5sn/oN2q1vv4rWR9PqSJImv/ur6jY4a1NvybeVNP3NeubzqjXOq9+gXapSPVGSRXt3BWjOjBjFHvC/gdHDEbIXc7K3DQCAfZo3b65ly5aZc5ceO3ZM7du3V1JSkjp16uTg6IpffFKq+XhAq2gHRgIAcBRSLYCd/lhbSl37nVG1+peVmSHNfTVUo3tW1kc/75GXT9Y387s2+ejFXpXVY8gpPT3puFxdDR3a5S1Ljvv6Xxb7a+pzEXp85EnVb3lRmZnS4T3e5v7MTOmlPtEqUz5Db3+3X+dOu+mNf0bK1d1Q/1Enb/RlA9dVtcZ53X3vER064Jdr39LvIvXZrBrm89RUV/Oxl3eGJr61Vut/DdH7b9WVq5uhXv336OW31qrvAx2UmUlC7FZmlUVWO+cktfd4AIA0btw4rVixQsuXL5fFYtHx48d17Ngxubu766WXXnJ0eMVu8OdbJEmlPLllBoCSyunuPOPj4zV06FBFR0fL09NTERER6tq1q1asWGHWWbNmjTp37qwyZcrIy8tLderU0ZQpU5SZmWnTlsVikcVi0bp162zK09LSVLZsWVksFq1atSpXfYvFIn9/f7Vs2VI//fSTub9fv37q1q3bVWOvVKmSTRvZ26uvvqrx48fnuS/nln2OvPbdfffdeZ7H29tblSpV0iOPPGITK26cV+YdUofu51Speqoqx6Tq2alxOn3cQ/v/+Cvh+cH4MHV7IkHdh55WpeqpiqiSpjb3JsrDM6uXaWaGNHNsmJ4cc0L39Dmr8MppiqyWVSfblp9LK26fl15474gq105R4zuS1ef5k/p+bjldSSdBAOfi5Z2h58Zt1ruv19PFZPdc+1NTXXX+nJe5pVz+q054xWT5+V/RZx/X1PGjpRUX66d5c2qoTNk0BYVcvpGXAQBAidW0aVP99NNPat26tby9veXt7a02bdroxx9/VNOmTR0dXrEr5ZWVLK0SVMrBkQAAHMWpkqaHDx9Ww4YN9dNPP+mNN97Q9u3btXTpUrVr106DBw+WJC1cuFBt2rRReHi4Vq5cqT179uiZZ57RpEmT1KNHDxmG7eoPERERmjNnjk3ZwoULVapU3r/85syZo5MnT+q3335TuXLldM899+jQoUP5voaJEyfq5MmTNtvQoUP1f//3fzZl4eHhuepmu/vuu3O18cUXX+R5nr179+rTTz9VQECA2rdvr3/961/5jhXF41JSVo+50gFZSfzEM27as8VXAWUzNKxrVXWvG6P/e6CKdqz3NY/Zv91HZ056yOIiPX1XNfWsH6MXe0Xr8B4vs86uTb6qVCNVZcpnmGWN2ibrcrKrjuz9qx7gDJ4a8Yc2rgnWtk1Bee5vd9cxzVv0P03/9Cf1/ccueXr+9bk+HldKFxI91OGeI3Jzs8rDI1Md7jmiuNhSOhV/68+hVtJlGpYi2QAA9mvZsqVWrlypixcv6uLFi1q5cqVatWrl6LBuCG/3rL/pR9xVzcGRAAAcxanGGjz99NOyWCzasGGDfH3/SijFxMSof//+unTpkp588knde++9+vDDD839AwYMUHBwsO6991599dVX6t69u7mvb9++mjZtmqZOnSpv76yef7Nnz1bfvn318ssv54ohICBAISEhCgkJ0YwZMxQWFqbly5frH//4R76uoXTp0goJCclzX85Eraur61Xrenp6XrWNvM5TsWJFtW7dWqGhoRo7dqweeughVa9ePV/xomhZrdLMcWGKaXxRlWpkzYN08oiHJOnfU0L05EsnVDkmRT9+XUYju1fWBz/tUVh0uuL/rPPZWyEaOP64QiLS9fXMID33YBV9/Otu+ZXJ1PkEN5Upb7tyZ0C5rOfnE5zqRxklXOs7j6lKtUQNe7JNnvt/Xh6u0/E+OnvGS1GVL+jxp3YpvOJF/evFJpKklBR3jRraUmMmb1CPvnslSSeOldJLI5rLytD8Wx5zmgKAc3B1dVWzZs3022+/2ZT3799fO3fu1Pr16x0U2Y2RkJy1PoGbC1/EAUBJ5TR3FefOndPSpUs1ePBgm4RptoCAAP3www86e/as/u///i/X/q5du6patWq5emQ2bNhQlSpV0jfffCNJiouL0+rVq9W7d+/rxpSdZE1PTy/MJd1wzzzzjAzD0H//+9+r1klLS1NSUpLNhqLz3uhwHdnjrVEzjphl2QuOdn7srDr2OKcqdVI0aMIJhVdO07L5ZW3q9HzmlFp1uaCqdVP07NtxslikXxYF3OCrAAqvXFCKBj6zQ29MbKgr6a551ln6XSVt2RCkI4f8tGp5hN6adJtatDmpkAqXJEkeHpl6ZtRW7doeqGf/0VrPPd1KRw6V1vg31snDIzPPNgEAQNEyDCPXKD5J2rFjhzZt2uSAiG6s85ezOidYc78EAIASwmm6px04cECGYahGjRpXrbNv3z5JUs2aNfPcX6NGDbNOTv3799fs2bP12GOPae7cuercubPKly9/zXguX76sMWPGyNXVVW3a5N1bKi8vvPCCxowZY1P2v//9r0DDWBYtWpRr+oDRo0dr9OjR1zwuMDBQQUFBOnz48FXrTJ48WRMmTMh3LMi/90aHaf1yP7218IDKV/irR2jZ4Kxhx5HVUm3qR1RJ1enjWfM4Bv5Zp2LVv+p4eBoKiUwz65Qpn6G9W22/UEg889c+wBlUqZ6oMoFpmvbxz2aZq5uh2vXOqusDsep2R1dZrbY9NvbuKiNJqhB+SfEnfNX2rmMKCknRs/9oLePPYdZvTGikL/+3RM1andTqFeE37oJww1llkdXO4fUsBAUAhTdx4kTz8bFjx2yeX7p0SX/88Ye8vG79qaFcLFkJ00rlmBoIAEoqp0ma5vUtZlHUlaTHHntMI0eO1KFDhzR37lxNmzbtqnV79uwpV1dXpaSkqHz58vr4449Vt27dfJ/rueeeU79+/WzKwsLCChRvu3btNGPGDJuywMDAfB1rGIa5qFReRo0apREjRpjPk5KSFBERUaD4YMswpOkvhmnNUn+98fUBhVS07ZkcHJGusiHpOnbQ06b8+CFPNbojWZJUte5luXtadeygp2o3zeptl3FFOnXUQ8HhWQnYWo0uaf60YCWecVNAuawk6ZbVpeVTOlMV/5aQBRzl903l9HTvdjZlw0Zv1bEjpfT151VzJUwlKbrqBUnSubNZPyOeXpkyrFk/W9msRtZzi9OMj0BxMWSxO+lpkDQFgELLXsBWko4fP56rw4VhGGrevLkjQruhsnuYerjxxwcAlFROkzStWrWqLBaL9uzZc9U61aplTcK9e/dutWjRItf+3bt3q1atWrnKy5Ytq3vuuUdPPPGEUlNT1alTJyUnJ+d5jrffflvt27eXv7//dXuj5qVcuXKqUqVKgY/LydfXt1BtnD17VgkJCYqKirpqHU9PT3l6el51PwruvdHhWrmwjMbPOSTvUladO531Y+VbOlOe3oYsFumhpxL07zdDFF0rRdExKfrxP4E6etBLYz46/Gddq7r0Pqt/vxWi8hWuKCg8XV/PyFpAp9U9iZKk29okq2K1VL0+tKKeGHNC5xPcNfe1EHXtd0YenowbgnNISXHXkVh3m7LUVFclJXnoSKyfQipcUtu7jmnTumAlXfBQVOULevKfO7R9a1kdPugvSdq6sbz6P71TTz/7h77/OloWF0MP99qvzEyL/thSzhGXBQBAiVGxYkVZLBbFxcXJw8PDZq0FHx8f1ahRQ5MmTXJghMUvLYPpgAAATjSnaWBgoDp27Kjp06fr0qVLufYnJiaqQ4cOCgwM1FtvvZVr/3fffaf9+/erZ8+eebbfv39/rVq1Sn369JGra97z7ElSSEiIqlSpUqiEqaO98847cnFxUbdu3RwdSomy6JNyupTkqucerKqe9Wub28/flTHrPPBkgnoMOaWZ48L0VPvq2vpLaU3+4qAqVPqrV+qTLx1Xm3sT9fo/K+qfnavp1DEPvfafgyodkPVHm6urNPHTQ3JxlYZ3rabXh0Sq/UPn1fe5kzf8moHCyshwUf1GCXp5yhp98PkKPTFkp35bVUETXmhq1jkWV1oTXmiqSpWT9ObM1Xp9+q8KLJeqsf/XXOfP3vrDAUs6q2Epkq0gJk+erMaNG6t06dIKCgpSt27dtHfvXps6qampGjx4sMqWLatSpUrpwQcf1KlTp2zqxMXFqUuXLvLx8VFQUJCee+45ZWTYTp+yatUq3XbbbfL09FSVKlU0d+7cQr1OAFBcDh8+rNjYWBmGoQYNGig2Ntbcdu7cqW+++eaq06XdKn7Zd8Z8XNaXDicAUFI5TU9TSZo+fbpatmypJk2aaOLEiapbt64yMjK0fPlyzZgxQ7t379YHH3ygHj16aODAgRoyZIj8/Py0YsUKPffcc3rooYf0yCOP5Nn23XffrYSEBPn5+dkV44ULF7Rt2zabsrJly5pD3JOTkxUfH2+z38fHp0DnTUtLy9WGm5ubypX7q4dV9nmuXLmi2NhYffbZZ5o1a5YmT55sd09XFMyyE9vyVa/70NPqPvT0Vfe7uUsDx53QwHEnrlonOPyKJn12qKAhAg41aujt5uMzp701Msfzq9m2KUjbNgUVZ1hwUlbDRVbDvu90C3r8zz//rMGDB6tx48bKyMjQ6NGj1aFDB+3atctcnHL48OFavHix/vOf/8jf319DhgzRAw88YK4qnZmZqS5duigkJERr1qzRyZMn1adPH7m7u+uVV16RJMXGxqpLly4aNGiQPv/8c61YsUIDBgxQaGioOnbsaNc1A0BRi42NtRmhlpGRITc3p7p9LDaZOeYIcnVhyhcAKKmcpqepJEVHR2vLli1q166dnn32WdWuXVt33XWXVqxYYc7x+dBDD2nlypWKi4tTq1atVL16db399tt68cUXNX/+/KvO52mxWFSuXDl5eHjYFeOqVavUoEEDmy3nPD9jx45VaGiozfb8888X6BxLly7N1cbtt9smGbLPU6VKFfXu3VsXLlzQihUr9MILL9h1fQAAlDRLly5Vv379FBMTo3r16mnu3LmKi4vT5s2bJWV9Yfrxxx9rypQpuuOOO9SwYUPNmTNHa9as0bp16yRJP/zwg3bt2qXPPvtM9evXV6dOnfTyyy9r+vTpSk/PGlUwc+ZMRUVF6a233lLNmjU1ZMgQPfTQQ3r77bcddu0AcDWRkZHau3ev2rRpIy8vL7Vp00YrVqxQ//79tWbNGkeHd0PcVjHA0SEAABzI6b4qDA0N1Xvvvaf33nvvqnVatWqlpUuXXretay0YFRAQkGv/9RaYmjt37jWH0V1r1fr81r3eOQp6HgAAbiaFGV6fVxv2uHAha3Gy7EUYN2/erCtXrqh9+/ZmnRo1aqhixYpau3atmjVrprVr16pOnToKDg4263Ts2FFPPfWUdu7cqQYNGmjt2rU2bWTXGTZsmF3xAkBxWLVqlTp06GBOM2IYhipWrGjeq+S1xsSt4ui5y44OAQDgBJyqpykAACjZrLIUySZJSUlJNltaWtr1z2+1atiwYWrZsqVq164tSYqPj5eHh4cCAgJs6gYHB5vT6cTHx9skTLP3Z++7Vp2kpCSlpKQU/MUCgGI0duxYZWZm6v777zfLqlatquDgYHNqkltRSnqmJi3eLUk6nsj/zQBQkpE0BQAAt6SIiAj5+/ub2+TJk697zODBg7Vjxw7Nnz//BkQIAM5r06ZNioqK0jfffGNTHhoaquPHjzsoquI38+eD5uNGkYEOjAQA4GhONzwfAACUXEU5PP/o0aM2CzHmXNAkL0OGDNGiRYu0evVqhYeHm+UhISFKT09XYmKiTW/TU6dOKSQkxKyzYcMGm/ZOnTpl7sv+N7ssZx0/Pz95e3sX8CoBoHi5ubnlmr7MarXq+PHjcnV1dVBUxa+011+3yNN73ebASAAAjkZPUwAA4DSyk6b2bpLk5+dns10taWoYhoYMGaKFCxfqp59+UlRUlM3+hg0byt3dXStWrDDL9u7dq7i4ODVv3lyS1Lx5c23fvl2nT5826yxfvlx+fn6qVauWWSdnG9l1stsAAGfSoEEDHT58WE8++aQkKSEhQT179lRCQoIaNmzo4OiKz5XMrERxt/oVHBwJAMDRSJoCAIASbfDgwfrss880b948lS5dWvHx8YqPjzfnGfX399cTTzyhESNGaOXKldq8ebMef/xxNW/eXM2aNZMkdejQQbVq1VLv3r31+++/a9myZRozZowGDx5sJmsHDRqkQ4cO6fnnn9eePXv0/vvv66uvvtLw4cMddu0AcDUjR46UJM2ePVsWi0WHDh3S119/LYvFoueee87B0RWPpNQrem3pHkl/JU8BACUXSVMAAOA0irKnaX7NmDFDFy5cUNu2bRUaGmpuX375pVnn7bff1j333KMHH3xQrVu3VkhIiBYsWGDud3V11aJFi+Tq6qrmzZvrscceU58+fTRx4kSzTlRUlBYvXqzly5erXr16euuttzRr1ix17NjR/hcOAIpYp06dNG/ePFWsWFGGYcgwDFWsWFGfffaZOnXq5OjwisX3v58wH1cLLu3ASAAAzoA5TQEAQIn29zn78uLl5aXp06dr+vTpV60TGRmpJUuWXLOdtm3bauvWrQWOEQAcoXv37urevbvOnDkjSSpXrpyDIypeu04kmY+faV/VgZEAAJwBSVMAAOA0inIhKABAwcTFxeV7f8WKFYs7nBtu+a6sxfpiKvhdpyYAoCQgaQoAAJyGIckq+5KezEIHAIXz94XwrsZisSgjI6OYo7nx/LzddTo5TfUiAhwdCgDACZA0BQAAAADka7qSW9mB0xclSQ1ImgIARNIUAAA4EYbnA4DjrFy50tEhOMyFlCvm44hAHwdGAgBwFiRNAQCA0yBpCgCO06ZNG0eH4DDz1v81X2uNkNIOjAQA4CxcHB0AAAAAAMD5LFq0SC1atJCfn5/8/PzUsmVLff/9944Oq1i8tnSP+TjAx8OBkQAAnAU9TQEAgNOgpykAOIf3339fQ4cOlfTXXKdr165Vt27dNG3aNA0ePNiR4RWJw2cu6aGZa3TmYrpZ1qBigOMCAgA4FXqaAgAAp5GdNLV3AwDYZ/LkyTIMQ1WqVNHw4cM1fPhwVatWTYZh6NVXX3V0eEWiz+wNNglTSZrbr4mDogEAOBt6mgIAAAAAbJw9e1bly5fXli1b5OvrK0maOHGioqOjdf78eQdHVzTKlvJQ3LnLkqT/Dm6pehEBjg0IAOBU6GkKAACchmFYimQDANinXbt2Kl26tJkwlSRfX1+VKlVK7du3d2BkRcNqNbQ1LlGSNPOxhiRMAQC50NMUAAA4DassssrOOU3tPB4AIPXo0UMDBw5U79691b17d0nSV199pYSEBPXo0UOrV68267Zu3dpRYRba3lPJ5uPqIaUdGAkAwFmRNAUAAAAA2Ojbt68sFovmzZunefPm2ezr1auX+dhisSgjI+NGh2e385f/mss0qpzvNWoCAEoqkqYAAMBpFMVCTiwEBQBFwzAMR4dQbGLPXJIkVQ0q5eBIAADOiqQpAABwGkUxJylzmgKA/WJjYx0dQrHKtGYlhPefvujgSAAAzoqkKQAAAADARmRkpKNDKFYp6ZmSpE61QxwcCQDAWZE0BQAAToPh+QDgPJYvX66VK1fq1KlTNkP1LRaLPv74YwdGZr/lu05JklKvZDo4EgCAsyJpCgAAnAbD8wHAOYwfP14vv/xyrnLDMG6JpOm5S1kLQaVnWh0cCQDAWZE0BQAAAADY+PDDD2UYhiIjIxUZGSmL5db5QurkhRQd+nMhqDbVyjs4GgCAsyJpCgAAnIZRBMPz6WkKAPbLyMhQ5cqVtX//fkeHUuR+2X/GfNw0qqwDIwEAODMXRwcAAACQzZBkGHZujr4IALgF/POf/9TJkye1bt06R4dS9P78RVE1qJTqRQQ4NBQAgPOipykAAAAAwMaIESP0xRdfqGXLlipTpoz8/PzMfRaLRQcPHnRgdEWjYqCPo0MAADgxkqYAAMBpWGWRRfYNr7faeTwAQPrHP/6hPXv2yDAMnTt3TufOnTP33UrzmwIAcDUkTQEAgNMwDIvdc5IypykA2G/hwoWSpJYtW6pSpUpyc+PWEQBQsvCbDwAAAABgo0KFCnJzc9Mvv/zi6FAAAHAIFoICAABOw2pYimQDANhn2rRpOn78uObPn6+LFy86OhwAAG44epoCAACnYRhZm71tAADs06VLF0lSr169cu2zWCzKyMi40SEBAHBDkTQFAAAAANgw+AYKAFDCkTQFAABOg4WgAMA5jBs3ztEhAADgUCRNAQCA0yBpCgDOgaQpAKCkI2kKAAAAAMjl7Nmzeu+997Rp0yZJUuPGjTV48GCVLVvWwZEBAFD8SJoCAACnYTUsstjZU9RKT1MAsNvRo0fVokULnThxwixbsmSJZs2apTVr1ig8PNyB0QEAUPxcHB0AAABANsMomg0AYJ/Ro0fr+PHjslgsqlGjhmrUqCGLxaLjx4/rxRdfdHR4AAAUO5KmAAAAAAAby5cvl7e3tzZu3KidO3dq586d2rBhgzw9PbVs2TJHhwcAQLEjaQoAAJxGVk9Ri52bo68CAG5+586dU3R0tBo0aGCW3XbbbYqOjtb58+cdGBkAADcGSVMAAOA07E+YZm0AAPuEhIRo3759+v77782y7777Tvv27VNISIgDIwMA4MYgaQoAAAAAsNG1a1dduXJF3bp1U+nSpVW6dGndf//9yszM1L333uvo8AAAKHYkTQEAgNMwimgDANhn0qRJiomJkWEYunTpki5duiTDMBQTE6OXX37Z0eEBAFDs3BwdAAAAQLaiGF7P8HwAsF+ZMmW0adMmffHFF9q4caMkqXHjxurZs6c8PT0dHB0AAMWPpCkAAAAAIBdPT0/169dP/fr1c3QoAADccAzPBwAAzoPx+QDgUB9//LGio6M1a9asXPumT5+u6OhozZ492wGRAQBwY5E0BQAAzuPP4fn2bGJ4PgAU2meffaajR4/q4YcfzrXv0Ucf1bFjxzR37txCtT19+nRVqlRJXl5eatq0qTZs2HDN+omJiRo8eLBCQ0Pl6empatWqacmSJYU6NwAABcXwfAAAAACAJGn37t2qVKmS/P39c+0rU6aMKlWqpD179hS43S+//FIjRozQzJkz1bRpU02dOlUdO3bU3r17FRQUlKt+enq67rrrLgUFBenrr79WWFiYjhw5ooCAgMJcFgAABUbSFAAAOA3DyNrsbQMAUDiJiYkqXbr0VfcbhqGkpKQCtztlyhQ9+eSTevzxxyVJM2fO1OLFizV79myNHDkyV/3Zs2fr3LlzWrNmjdzd3SVJlSpVKvB5AQAorHwlTSdOnJjvBseOHVvoYAAAQMlmDrG3sw0AQOEEBwcrNjZWO3bsUO3atW327dixQ7GxsQoLCytQm+np6dq8ebNGjRpllrm4uKh9+/Zau3Ztnsd89913at68uQYPHqz//ve/Kl++vB599FG98MILcnV1zVU/LS1NaWlp5vPCJHYBAMgpX0nT8ePHy2LJ3w0ISVMAAAAAuDm1atVK8+bN07333qupU6eqVatWslgs+uWXXzR8+HAZhqHWrVsXqM0zZ84oMzNTwcHBNuXBwcFXHep/6NAh/fTTT+rVq5eWLFmiAwcO6Omnn9aVK1c0bty4XPUnT56sCRMmFCguAACuJV9J04oVK+Y7aQoAAFBoRbGQEz1NAaDQnn32WX355Zc6cuSI7r//fpt9hmHIzc1NI0aMKPY4rFargoKC9OGHH8rV1VUNGzbU8ePH9cYbb+SZNB01apRNXElJSYqIiCj2OAEAt658JU0PHz5czGEAAAAwpykAOFqDBg00Y8YMPfXUU8rMzLTZ5+rqqhkzZqhBgwYFarNcuXJydXXVqVOnbMpPnTqlkJCQPI8JDQ2Vu7u7zVD8mjVrKj4+Xunp6fLw8LCp7+npKU9Pz3zFM/a7HQWKHwBQMhV6IahLly7pjz/+kKurq5o0aVKUMQEAAAAAHGTAgAFq1aqVPv74Y+3atUuGYSgmJkb9+/dXjRo1Ctyeh4eHGjZsqBUrVqhbt26SsnqSrlixQkOGDMnzmJYtW2revHmyWq1ycXGRJO3bt0+hoaG5EqYFlXrFKkk6eSHVrnYAALc2l8IcNGnSJAUHB+v222/XsGHD9NVXXyk6Olrz5s0r6vgAAEBJYhTRBgCwS/Xq1fX6669r0aJFWrx4sV5//fVCJUyzjRgxQh999JE++eQT7d69W0899ZQuXbqkxx9/XJLUp08fm4WinnrqKZ07d07PPPOM9u3bp8WLF+uVV17R4MGD7bquuLOXzcdvd69vV1sAgFtbgXuazpw5M9diT3feeaeOHj2q+fPn69FHHy2y4AAAQMliGBYZds5Jau/xAFBSHTp0SNHR0fmuHxsbq6ioqHzV7d69uxISEjR27FjFx8erfv36Wrp0qbk4VFxcnNmjVJIiIiK0bNkyDR8+XHXr1lVYWJieeeYZvfDCCwW7qL85ev6vpGn1kNJ2tQUAuLUVOGk6bdo0ubi4aMqUKRo2bJgkqWzZsgoLC9Pvv/9e1PEBAAAAAG6A6tWr67777lOvXr3UqVMneXl55aqTnp6upUuX6t///rf++9//Kj09Pd/tDxky5KrD8VetWpWrrHnz5lq3bl2+288PhuQDAPKrwEnTgwcPKiYmRv/85z/NpKkkBQYGateuXUUZGwAAKIkYXg8ADhEWFqYFCxZo4cKFcnNzU61atVSpUiWVLl1aFy9e1JEjR7Rz505duXJFhmEoMjLS0SEXmLtr1miEmAp+Do4EAODsCpw09ff314kTJ5Sa+tc3dImJidq3b5/8/f2LNDgAAFCyMDwfABxn//79+vjjj/X+++9rx44d+v333/McTVinTh09/fTT6t+/vwOiLBplfOxbTAoAcOsrcNK0TZs2WrBggZo2bSopq+dpkyZNlJKSonvuuafIAwQAAAAAFD93d3cNGjRIgwYN0q5du/Trr79q//79unDhgvz8/FS1alW1atVKtWrVcnSoAAAUuwInTSdNmqTly5dr+/btslgsOnPmjBISEuTv76/x48cXQ4gAAKDEMGT/8HyG9wOA3WrVqkVyFABQorlcv4qt6tWra9OmTerbt69q1qypmjVrqm/fvlq/fr1q1KhRHDECAIASw1JEGwAAAAAUXoF7mkpSlSpVNGfOnKKOBQAAAAAAAAAcrsA9TSXp999/16OPPqo6deqoTp066tWrl7Zt21bEoQEAgBLHKKINAAAAAOxQ4J6m33zzjXr06CGr1SrDyLor2bVrl7766ivNnz9fDz74YJEHCQAASgjmNAUAAADgBArc03TkyJHKzMyUv7+/7r//ft1///0KCAhQZmamRo0aVRwxAgAAAAAAAMANU+CepseOHZO/v792796t4OBgSdLp06dVvXp1HTt2rMgDBAAAJYhhydrsbQMAUCRWrlypdevWqUyZMnr00UeVmJio4OBgeXp6Ojo0AACKVYGTpk2bNtWpU6fMhKkkBQUFKSQkRCEhIUUaHAAAKFkMI2uztw0AgH1SUlJ077336qeffpKUdR8YFBSkhx9+WK+88opeeOEFB0cIAEDxytfw/Li4OHMbNWqUjh07pjFjxmjHjh3asWOHXnrpJR0/fpzh+QAAAABwCxgzZoxWrFghwzDMtSy6dOkiDw8PLV682MHRAQBQ/PLV0zQqKipX2eTJkzV58mTzuWEY6ty5szIyMoouOgAAULKwEBQAOIWvvvpK3t7eWrt2rerXry9J8vT0VGRkpPbt2+fY4AAAuAHylTQ18jnOLb/1AAAA8sScpgDgFE6fPq1atWqpbt26NuXu7u5KTEx0TFAAANxA+Uqarly5srjjAAAAAAA4idDQUO3bt08HDx40y7Zt26bdu3erYsWKDowMAIAbI19J0zZt2hR3HAAAALIYWZu9bQAA7HPffffp3XffVe3atWWxWLR161Y1adJEhmHovvvuc3R4AAAUu3wlTf/u9OnTWrx4sU6cOKHMzEybfWPHji2SwAAAQAnEnKYA4BRefvllrV69Wr///rskKS0tTZJUt25dTZgwwZGhAQBwQxQ4abpx40bdddddSk5OznM/SVMAAHCzWb16td544w1t3rxZJ0+e1MKFC9WtWzdzf79+/fTJJ5/YHNOxY0ctXbrUfH7u3DkNHTpU33//vVxcXPTggw/qnXfeUalSpcw6f/zxhwYPHqyNGzeqfPnyGjp0qJ5//vlivz4AKCg/Pz9t2LBBX3zxhTZs2CBJaty4sXr27CkPDw8HRwcAQPErcNL0pZdeUlJSUp77LBYWXgAAAHZw0EJQly5dUr169dS/f3898MADeda5++67NWfOHPO5p6enzf5evXrp5MmTWr58ua5cuaLHH39cAwcO1Lx58yRJSUlJ6tChg9q3b6+ZM2dq+/bt6t+/vwICAjRw4MACxwwAxenTTz9V+fLl1adPH/Xp08csP3z4sC5fvqxatWo5MDoAAIpfgZOmGzZskJeXl7Zv366qVauqWbNmevvtt9WtWzctWrSoOGIEAAAlhYOG53fq1EmdOnW6Zh1PT0+FhITkuW/37t1aunSpNm7cqEaNGkmS3n33XXXu3FlvvvmmKlSooM8//1zp6emaPXu2PDw8FBMTo23btmnKlCkkTQE4nX79+qlZs2a5/m/s2bOnNm7cqIyMDAdFZp9MK3O4AADyx6WgB1y8eFE1atRQ5cqVZbFYlJGRoaZNmyooKEhPP/10ccQIAABQYElJSTZb9nx8hbVq1SoFBQWpevXqeuqpp3T27Flz39q1axUQEGAmTCWpffv2cnFx0fr16806rVu3thnW2rFjR+3du1fnz5+3KzYAuFHOnTsnw7h5E497T2VNMxdextvBkQAAnF2Be5r6+/srNTVVkhQQEKCdO3fqyy+/1IEDB27qX54AAMAJFGFP04iICJvicePGafz48YVq8u6779YDDzygqKgoHTx4UKNHj1anTp20du1aubq6Kj4+XkFBQTbHuLm5KTAwUPHx8ZKk+Ph4RUVF2dQJDg4295UpU6ZQsQFAUYqOjjYfb9261eb55cuXlZCQoLJlyzoitCKx+XDWl1SNKwU6OBIAgLMrcNI0KipKO3fuVGpqqm677TatWLFCjz76qCQxrw0AALBPESZNjx49Kj8/P7P473OQFkSPHj3Mx3Xq1FHdunVVuXJlrVq1SnfeeWeh2wUAZ3P48GFJWetVpKWlmc9zutrczzeDc5fTJdHTFABwfQVOmg4bNkwbN27U8ePH9corr6hDhw66cOGCfH199eabbxZHjAAAAAXm5+dnkzQtStHR0SpXrpwOHDigO++8UyEhITp9+rRNnYyMDJ07d86cBzUkJESnTp2yqZP9/GpzpQLAjTZu3DhJ0oQJExQeHq4nnnjC3Ofj46MaNWronnvucVR4drP+OaepqwuLGAMArq3ASdNHH33U7FlauXJlHTt2THv37lV0dLQCAgKKOj4AAFCSGJaszd42itmxY8d09uxZhYaGSpKaN2+uxMREbd68WQ0bNpQk/fTTT7JarWratKlZ58UXX9SVK1fk7u4uSVq+fLmqV6/O0HwATiM7abpy5UrFxMSYz28V2etAWSwkTQEA11bgpOnf+fr6qm7dunrkkUdksVj0zTffFEVcAACgBLIYWZu9bRTUxYsXdeDAAfN5bGystm3bpsDAQAUGBmrChAl68MEHFRISooMHD+r5559XlSpV1LFjR0lSzZo1dffdd+vJJ5/UzJkzdeXKFQ0ZMkQ9evRQhQoVJGV98TxhwgQ98cQTeuGFF7Rjxw698847evvtt+27YAAoBqtWrXJ0CMUik56mAIB8sjtpKkmZmZn69ttv+bYOAADclDZt2qR27dqZz0eMGCFJ6tu3r2bMmKE//vhDn3zyiRITE1WhQgV16NBBL7/8ss08qZ9//rmGDBmiO++8Uy4uLnrwwQc1bdo0c7+/v79++OEHDR48WA0bNlS5cuU0duxYDRw48MZdKADkU0ZGhl588UXNnz9fJ06ckNVqNfdZLBZlZGQ4MLrCy168mJwpAOB6iiRpCgAAUCSKcCGogmjbtq15I52XZcuWXbeNwMBAzZs375p16tatq19++aXA8QHAjfbyyy/rjTfecHQYRS7TTJqSNQUAXJuLowMAAAAAADiXL774QhaLRY899pgkKTw8XJ07d1ZgYKDGjBnj4OgKL3tOU5KmAIDryXdP07i4uKvuS0tLK5JgAAAAAACOFxcXp/DwcH366af67LPPFB4eru+++06RkZFKTU11dHiFZmVOUwBAPuU7aVqpUiXmLAUAAMXKoiJYCKpIIgGAks3NzU3lypWTJHl4eOjUqVNycXGRu7u7Zs+erddee83BERaOlTlNAQD5VKA5Ta811xdubvdXqyM3i7ujwwAcoubmY44OAXCI9ItX9GNrR0fxN4Yla7O3DQCAXYKCghQfHy9JioyM1IEDB1SzZk0dPnxYZcqUcXB0hZf5Z09TF7KmAIDryHfSdNy4ccUZBwAAAADASdStW1ffffed9uzZowcffFCvvvqq9u7dK0m67777HBxd4RnMaQoAyCeSpgAAwHkYf272tgEAsMv8+fOVlpYmX19fTZo0Sb6+vlq/fr3q1q2r0aNHOzq8Qsv8M2vqStIUAHAdBRqeDwAAUKxImgKAU/Dy8pKXl5f5/MUXXzQfnzt3Tj4+Po4Iy27Zc5qSMwUAXI+LowMAAAAAADi/kydP6tlnn1WlSpUcHUqhWa1Z/7oypykA4DpImgIAAKdhMYpmAwAUztmzZ3XvvffK399fdevW1bp165Samqrhw4crOjpaU6dO1aVLlxwdZqFl9zRlTlMAwPUwPB8AADgPhucDgEM9//zzWrRokSRpx44d6t69uxo1aqRvv/1Wxp8Jx/bt2zsyRLtkz2nqQvchAMB1kDQFAAAAAEiSli9fLovFottvv12S9Msvv+jYsWMyDEMPPPCARo0apYYNGzo4ysIxDEN/5kzpaQoAuK5CJU3T0tI0b948rVu3TiEhIXriiSd0+PBh1a5dW4GBgUUdIwAAKCnoaQoADhUfH6+KFSvq559/liRFRUUpLi5On3zyiXr37u3g6OxjzfH7wZWkKQDgOgo8KOHs2bNq1KiRBgwYoFmzZmn58uXavXu32rVrp2nTphVHjAAAoIRgTlMAcKyMjAyFhoaaz0NCQiRJvXr1clRIRSZ7PlOJnqYAgOsrcE/T559/Xjt37pS3t7dSUlIkZc1p4+Pjo//9738aP358UccIAAAAALhBdu3apTvuuMN8LNnOY2qxWLRixQqHxGaPzBxdTZnTFABwPQVOmi5atEj+/v7avXu3KlSoIElydXVVZGSkDh06VOQBAgCAEsSwZG32tgEAKLTk5GRzeH627OeGYchyk/bSzNHRlJ6mAIDrKnDSNDExUbVq1TKHaWTLzMxUcnJykQUGAABKIOY0BQCHqlix4k2bFL2ezBxZU1eXW/MaAQBFp8BJ08jISO3cuVO//vqrWfb9999r7969qlatWpEGBwAAAAC4cQ4fPuzoEIpNzjlNb9G8MACgCBV4JpeePXsqIyNDbdq0kcVi0fr169WtWzdZLBb17NmzOGIEAAAlBAtBAQCKizXHnKauZE0BANdR4KTpiy++qE6dOskwDJutQ4cOGjVqVHHECAAASgqjiDYAAP4mR86U4fkAgOsq8PB8Dw8PLV68WKtXr9aGDRskSY0bN1abNm2KPDgAAAAAAIpCZo6s6a06bysAoOgUOGmarXXr1mrdunVRxgIAAEq6ohheT09TAEAejD/nNKWXKQAgPwqcNL3jjjuuus9isWjFihV2BQQAAEqwohheT9IUAJCHzD+TpuRMAQD5UeCk6apVq2SxWMxv6SSZzxniAAAAAAC3jkuXLumPP/6Qq6urmjRp4uhw7JI9Ot+F+1YAQD4UOGnap08fm+TohQsXtGrVKiUnJ6tHjx5FGhwAAChh6GkKAE5j0qRJevXVV5WSkqKmTZtq2LBhGjlypCZNmqRHH33U0eEVmNWa3dOUpCkA4PoKnDSdO3durrIzZ86obt26Cg8PL4qYAABACWUpgjlN7Z4TFQCgmTNnauzYsTZld955p44ePar58+ffnElT5jQFABSAS1E0Uq5cOVWpUiXPhCoAAAAA4OYybdo0ubi4aOrUqWZZ2bJlFRYWpt9//91xgdkh88+epnQ0BQDkR4F7mk6cONHmeWZmpvbt26dff/1VZcqUKbLAAAAAAACOcfDgQcXExOif//ynhg0bZpYHBgZq165djgvMDtlzmtLTFACQHwVOmo4fP/6qCz7dc889dgcEAABKMOY0BQCn4O/vrxMnTig1NdUsS0xM1L59++Tv7+/AyAove3g+c5oCAPKjwEnTihUr2iRNLRaLgoKCdOedd2rUqFFFGhwAAAAA4MZr06aNFixYoKZNm0rK6nnapEkTpaSk3LSdZUiaAgAKosBJ08OHDxdDGAAAACwEBQDOYtKkSVq+fLm2b98ui8WiM2fOKCEhQf7+/ho/fryjwyuU7DlNGZ0PAMiPAi0EdeXKFVWuXFm33XabDIM7EgAAUAwMOzcAgN2qV6+ujRs3qm/fvqpZs6Zq1qypvn37av369apRo4ajwysUqzXrX+Y0BQDkR4F6mrq7uys5OVmlSpW66rymAAAAAICb2759+1StWjXNmTPH0aEUGYbnAwAKokA9TSWpX79+2rt3r3bs2FEc8QAAgJLM3l6m9DYFgCJRs2ZNtWzZUh9++KEuXLjg6HCKRGZ20rTAd8EAgJKowHOaxsfHS5IaN26sdu3aKTg42Ox1arFY9PHHHxdthAAAoMRgTlMAcA6GYWjt2rVat26dhg0bpvvuu099+/ZVx44db9pRhwY9TQEABVDgpOlnn30mi8UiwzC0dOlS8xemYRgkTQEAAADgFvDjjz/qyy+/1IIFC3T27Fl9+eWX+uqrrxQSEqLevXvr1VdfdXSIBZaZPacpSVMAQD7kO2k6ceJEhYeHq02bNsUZDwAAKMmKYng9PU0BwG533HGH7rjjDr3//vtmAvXbb7/VyZMn9cYbb9yUSdPsOU3JmQIA8iPfSdPx48erWbNmWrNmTXHGAwAASjCG5wOAc7ly5YqSk5OVnJystLQ0R4djF6s16xeEqwtZUwDA9TEFNgAAAADAxvfff69evXopKChI3bt314IFC5SSkqLo6GiNGzeuUG1Onz5dlSpVkpeXl5o2baoNGzbk67j58+fLYrGoW7duhTpvtj9zpsxpCgDIlwLNaZqWlqa4uLhr1qlYsaJdAQEAgBKM4fkA4BTuu+8+cy0LPz8/Pfzww+rbt69uv/32QrX35ZdfasSIEZo5c6aaNm2qqVOnqmPHjtq7d6+CgoKuetzhw4f1f//3f2rVqlVhL8WUyUJQAIACKFDSdNu2bYqKirrqfovFooyMDLuDAgAAJRRJUwBwChaLRXfddZf69u2r+++/X15eXna1N2XKFD355JN6/PHHJUkzZ87U4sWLNXv2bI0cOTLPYzIzM9WrVy9NmDBBv/zyixITE+2KIXtOUxfGWwIA8qFASVNJMgzuRAAAAADgVnb06FFVqFChSNpKT0/X5s2bNWrUKLPMxcVF7du319q1a6963MSJExUUFKQnnnhCv/zyyzXPkZaWZjPnalJSUq465pym9DQFAORDgZKmYWFheuKJJ4orFgAAUMKxEBQAOM6nn36q8uXLq1OnTvrxxx+vWbdPnz75bvfMmTPKzMxUcHCwTXlwcLD27NmT5zG//vqrPv74Y23bti1f55g8ebImTJhwzTrZc5paSJoCAPKhQEnT8PDwQk/6DQAAcF0MzwcAh+nXr5+aN2+uTp06qV+/fldNLloslgIlTQsqOTlZvXv31kcffaRy5crl65hRo0ZpxIgR5vOkpCRFRETY1MnM7mnqQtIUAHB9BR6eDwAAAAC4NeWcju1qU7MVdMq2cuXKydXVVadOnbIpP3XqlEJCQnLVP3jwoA4fPqyuXbuaZVarVZLk5uamvXv3qnLlyjbHeHp6ytPT85pxGOZCUAUKHwBQQuU7aVqxYkWFhoYWZywAAKCko6cpADhMdmLy74/t5eHhoYYNG2rFihXq1q2b2f6KFSs0ZMiQXPVr1Kih7du325SNGTNGycnJeuedd3L1IM2vTDNpStYUAHB9+U6aHj58uBjDAAAAYE5TAHAWEydOVEREhLnafba1a9fq/Pnz6ty5c4HaGzFihPr27atGjRqpSZMmmjp1qi5dumS236dPH4WFhWny5Mny8vJS7dq1bY4PCAiQpFzlBZE9pylJUwBAfjA8HwAAAABgY/z48WrWrFmupOmIESO0YcMGZWZmFqi97t27KyEhQWPHjlV8fLzq16+vpUuXmotDxcXFycXFpcjiz4uVOU0BAAVA0hQAADgPhucDgNNKSUnRyZMnC338kCFD8hyOL0mrVq265rFz584t9HmzWf8cnk9HUwBAfpA0BQAAToPh+QDgWK6urpIki8Wi9evXm89zyu4derPJpKcpAKAASJoCAAAAACT9tcK8xWIxH//dwIEDb2RIRcZgTlMAQAGQNAUAAM6D4fkA4FBz5syRJD3++OOqXLmyxowZY+7z8fFRjRo1VKdOHUeFZ5fMP7OmJE0BAPlB0hQAADgPkqYA4FB9+/aVJK1cuVJVqlQxn98KrGbS1MGBAABuCiRNAQAAAACKi4uTp6engoODNXHiRLMsLxUrVryRoRUJK3OaAgAKgKQpAABwGpY/N3vbAAAUXKVKldS8eXP99ttvioqKumo9i8WijIyMGxhZ0bAypykAoABImgIAAOfB8HwAcKjsxZ+utgjUzSzzz6ypCz1NAQD5QNIUAAAAAKCVK1fKz8/PfHyrYU5TAEBBkDQFAABOw2Jkbfa2AQAouDZt2uT5+FaRnTR1ZXg+ACAfXBwdAAAAgMkoog0AYJelS5dq4sSJ2rdvn5KTk9W1a1f5+/urdevWOnbsmKPDK5TsOU0tJE0BAPlA0hQAAAAAYOONN97QxIkT5e/vrw8++ECLFy9WcnKyfvvtN40cOdLR4RVK9pymrtwFAwDygV8XAADAudDLFAAcbteuXQoPD1dwcLB+/vln+fn56YsvvpCXl5dWrVrl6PAKxTDnNKWnKQDg+kiaAgAAp5E9p6m9GwDAPufPn1f58uUlSXv27FGjRo3UvXt31axZU2fOnHFwdIWTac3614WVoAAA+UDSFAAAAABgIzAwUPv27dMXX3yhw4cPq3bt2pKkCxcuKCAgwLHBFZLV7Gnq4EAAADcFkqYAAMB5sBAUADiFdu3aKTk5WY899pisVqs6duyoS5cu6ejRo6pataqjwyuU7KSpK8PzAQD54OboAAAAALIVxfB6hucDgP2mTJmilJQUHThwQF27dlWnTp3022+/qXHjxurRo4ejwyuU7KSphaQpACAfSJoCAAAAAGwEBwdrwYIFNmUtW7bUL7/84qCI7Jc9p6kr4/MBAPlA0hQAADiPohheT09TACgSZ8+e1XvvvadNmzZJkho3bqzBgwerbNmyDo6scAzmNAUAFABJUwAA4DQYng8AzuHo0aNq0aKFTpw4YZYtWbJEs2bN0po1axQeHu7A6Aon0/pn0pSsKQAgH1gICgAAAABgY/To0Tp+/LgsFotq1KihGjVqyGKx6Pjx43rxxRcdHV6h/JkzlQtzmgIA8oGkKQAAcB5GEW0FtHr1anXt2lUVKlSQxWLRt99+axuWYWjs2LEKDQ2Vt7e32rdvr/3799vUOXfunHr16iU/Pz8FBAToiSee0MWLF23q/PHHH2rVqpW8vLwUERGh119/veDBAsANsHz5cnl7e2vjxo3auXOndu7cqQ0bNsjT01PLli1zdHiFkr0QlCtJUwBAPpA0BQAAzsNBSdNLly6pXr16mj59ep77X3/9dU2bNk0zZ87U+vXr5evrq44dOyo1NdWs06tXL+3cuVPLly/XokWLtHr1ag0cONDcn5SUpA4dOigyMlKbN2/WG2+8ofHjx+vDDz8seMAAUMzOnTun6OhoNWjQwCy77bbbFB0drfPnzzswssKzMqcpAKAAmNMUAACUeJ06dVKnTp3y3GcYhqZOnaoxY8bovvvukyR9+umnCg4O1rfffqsePXpo9+7dWrp0qTZu3KhGjRpJkt5991117txZb775pipUqKDPP/9c6enpmj17tjw8PBQTE6Nt27ZpypQpNslVAHAGISEh2rdvn77//nt17dpVkvTdd99p3759Cg0NdXB0hcOcpgCAgqCnKQAAcBrZC0HZu0lZPTtzbmlpaYWKKTY2VvHx8Wrfvr1Z5u/vr6ZNm2rt2rWSpLVr1yogIMBMmEpS+/bt5eLiovXr15t1WrduLQ8PD7NOx44dtXfv3pu21xaAW1fXrl115coVdevWTaVLl1bp0qV1//33KzMzU/fee6+jwysU5jQFABQESVMAAOA8inB4fkREhPz9/c1t8uTJhQopPj5ekhQcHGxTHhwcbO6Lj49XUFCQzX43NzcFBgba1MmrjZznAABnMWnSJMXExMgwDF26dEmXLl2S8f/t3XlYVNX/B/D3zMAMIPsiiyKIiCCImAuimZoaLlHa4pa7aa5phlupIGUuuaepmYqViqZZZuk3Rc1yydx+rrmCJgLuIDvMnN8fNDfGYZlhEaT363nuU3Puued+7p3Bufcz55wrBPz9/fHRRx9Vdnilovkna6pgT1MiIjIAh+cTERFRtfT333/D2tpaeq1SqSoxGiKiZ4udnR2OHz+OjRs34vjx4wCA5s2bo0+fPs/sv6faOU3Z0ZSIiAzBpCkRERFVGTIhIBOleJLTE20AgLW1tU7StLRcXFwAAMnJyTrz+CUnJyMoKEiqc+fOHZ3t8vLy8ODBA2l7FxcXJCcn69TRvtbWISKqKlJSUgAAgwcPxuDBgys5mvKh/uf7QcGsKRERGYDD84mIiKjqKMfh+eWlbt26cHFxQWxsrFSWmpqKP/74AyEhIQCAkJAQPHr0CCdOnJDq7Nu3DxqNBsHBwVKdgwcPIjc3V6qzZ88eNGjQAHZ2duUbNBFRKWVkZKB79+6wt7eHvb09evTogczMzMoOq1xof5PjnKZERGQIJk2JiIjoPy8tLQ2nT5/G6dOnAeQ//On06dO4efMmZDIZxo8fj48//hg7duzA2bNnMWDAALi5uaF79+4AAD8/P3Tu3BnDhg3DsWPHcOjQIYwZMwa9e/eGm5sbAKBv375QKpUYOnQozp8/j82bN2PJkiWYMGFCJR01EZG+RYsWYceOHRBCQAiBHTt2YNGiRZUdVrlQ/zOnqZxzmhIRkQGYNCUiIqIqQybKZzHW8ePH0aRJEzRp0gQAMGHCBDRp0gQzZswAAEyaNAljx47F8OHD0bx5c6SlpWH37t0wMzOT2tiwYQN8fX3RoUMHdO3aFc8//zy++OILab2NjQ1++eUXxMXFoWnTpnj//fcxY8YMDB8+vGwnjYioHG3atAkymQzBwcEIDg6GEAKbNm2q7LDKhXZOU+ZMiYjIEJzTlIiIiKqO8hheX4rt27VrB1HMXKoymQxRUVGIiooqso69vT02btxY7H4CAwPx22+/GR8gEdFTcvPmTbi6uuLw4cPQaDSoU6cObty4UdlhlQtt0lTBrCkRERmAPU2JiIiIiIgIQP50JXXq1IFMJoNCoUCdOnWQnp5e2WGVC40m/78yzmlKREQGYE9TIiIiqjJKO7z+yTaIiKj07t69i6+++kr6fwD4+uuvdXrkDxgwoFJiKwu1tqcpk6ZERGQAJk2JiIio6qik4flERPSv69evY/DgwTplgwYNkv5fJpM9k0lTwTlNiYjICEyaEhERERERkaS4OZ6fZWrNP0lTZk2JiMgATJoSERFRlcHh+URElWv//v2VHUKF+SdnCjmH5xMRkQGYNCUiIqKqg8PziYgqVdu2bSs7hAqj0c5pyschExGRAfh1QURERERERNWeRprTlD1NiYioZOxpSkRERFUKh9cTEVFFkOY0ZdKUiIgMwKQpERERVR1C5C9lbYOIiOgJnNOUiIiMweH5REREREREVO1pNJzTlIiIDMeepkRERFRlyETZh+dzeD8RERVGO6epjD1NiYjIAPyNjYiIiKoOUU4LERGV2aVLlzBw4EA0aNAAYWFhOHr0KKKionDu3LnKDq1U1P98PyiYNCUiIgOwpykRERERERHp+L//+z+0adMG6enpEELAwcEBZmZmiIyMxJ07d7Bs2bLKDtFo4p+epnJ2HSIiIgPw64KIiIiqDJmmfBYiIiqbKVOmIC0tDU2bNpXKgoKCYG9vj/3791diZKWn/mdOUz4IioiIDMGkKREREVUdHJ5PRFQlHDp0CLVq1cKRI0d0yt3d3fH3339XUlRl80/OlElTIiIyCIfnE5WzXmOS0bprCty9s5GTJceF4xZYM8sVt66ZSXW6vHUf7Xs8hHejTNSw0uA13wCkpyoKbc9UqcGSn66gnn8WRnbywfXz5k/rUIhKdG+tBo/3a5ATD8hUgHmgDDXflUPl+e/NyMPvNEjdrUHWX4AmHfA5oIDC6t/1ObcF7n2pQcafAnn3ARNHwKarDI5D5ZCZ6t/U5PwtENdXDciBBr/ya4yIiKgiqNVqWFpaQqHQvUa9e/cuNJpns0u/5p+sqULOpCkREZWs0nqaymSyYpfIyEjEx8cXuf7o0aMAgOjoaKlMLpfD1dUVvXr1ws2bN3X2165dO8hkMsyZM0cvlm7dukn7LFh//PjxetvHxMTobLt48WJ4enrqtZmZmQl7e3s4OjoiOztbL9ailvj4eERGRha6ztfXVy8emUwGlUqFWrVqISwsDN99952xbwWVs8CQdPwY7YjxL9fH1N5eUJgIfLLpOlTmaqmOmbkGxw9YIeazmiW2N3RaIu4nmVZkyESllnFSwO5NOTyjFajzuQIiD7g5Wg1N5r9d/UQWUCNEDofBhX/l5MQLQAO4fCCH1xYFnN+X4+E2gTvL9G/IRK5AwgdqmDfhzU51JRPlsxARUdk0bNgQly9fxscffwwASE1NRXh4OG7fvo2AgIBKjq50NP/MacqOpkREZIhKS5omJiZKy+LFi2Ftba1TFh4eLtXdu3evzrrExESduXW02yYkJGDbtm24dOkS3nzzTb19uru7Izo6WqcsISEBsbGxcHV1LTFmMzMzTJs2Dbm5uSXW3bZtG/z9/eHr64vvv/8eANCrVy+dYwgJCcGwYcN0ytzd3QEA/v7+esf8+++/6+xDu+21a9ewbds2NGzYEL1798bw4cNLjI8qzodveWHPFnvcuGyG6xfMsWB8HTjXzkX9wEypzvYvnbBlmTP+OlGj2LaatU9F07aPsTrKraLDJiqVOssUsH1FDlU9Gcx8ZHCbKUdeEpB18d869n3lcBwsh3mjwtuwbCWHW6QCliFyKGvLYNVWDof+cjzer5/5urtCA6WnDNYdebdTbQlRPgsREZXJuHHjIIRAREQEZDIZLl68iEWLFkEmk2HMmDGVHV6pqP/5flAwa0pERAaotHGNLi4u0v/b2NhAJpPplAHAvXv3AAAODg566woquK2rqyuGDh2Kd999F6mpqbC2tpbqvfzyy9iyZQsOHTqE1q1bAwDWr1+Pl156Sa9namH69OmDHTt2YPXq1Rg1alSxddesWYN+/fpBCIE1a9agV69eMDc3h7n5v0OrlUolLCwsCj02ExOTYo8ZgM62tWvXRsuWLeHr64shQ4agZ8+e6NixY4nHRBWvhnV+D9PHjwoffl8UW8dcjP/0FmYO8UR2JqcfpmeDJi3/v3Lr4uuVRJ0moHiijfRjGqTuFai7UYHH+5gUIyIiqkj9+vXD7du3ERUVhYyMDACAubk5pk+fjn79+lVydKWj/U1NzuH5RERkgGqXiblz5w62b98OhUKhN/+OUqnEW2+9hXXr1kll0dHRGDJkiEFtW1tb48MPP0RUVBTS09OLrHft2jUcOXIEPXv2RM+ePfHbb7/hxo0bpTsgIw0cOBB2dnZFDtPPzs5GamqqzkIVRyYTGDEzAeeOWeDGJWPmIhUIX/w3fvraAVfOWFRYfETlSWgEkudrYN4YMPMu/c1Izt8CD2MEbF/79ysq75HA7UgN3CIVUFjyRqc64/B8IqKqY9KkSbh79y6OHTuGY8eO4d69e5gyZUplh1Vq6n/mNOWDoIiIyBDPRNK0VatWsLS01FkKSklJgaWlJWrUqAFnZ2fs378fo0ePRo0a+kOfhwwZgi1btiA9PR0HDx5ESkoKXn75ZYNjGTVqFMzMzLBw4cIi66xduxZdunSBnZ0d7O3tERoaqpOoNcTZs2f1jnnEiBElbieXy+Hj44P4+PhC18+ePRs2NjbSop0OgCrGmE8S4OGbhdkjPYza7tWh92BuqcZmA+Y8JaoqkuZokH1NoNZs43pVF5R7R+DmGDWsOspgVyBpmvSxBjadZbB4jjc51Z4op4WIiMqFubk5mjVrBiEEVq5cib1791Z2SKWmndOUHU2JiMgQz8Rjhzdv3gw/P78i11tZWeHkyZPIzc3Frl27sGHDBsyaNavQuo0bN0b9+vWxdetW7N+/H/3794eJieGnQaVSISoqCmPHjsXIkSP11qvVaqxfvx5LliyRyvr164fw8HDMmDEDcrlheeoGDRpgx44dOmUFpxoojhACsiJ+PZ06dSomTJggvU5NTWXitIKMnnULwZ1S8X6PeriXqDRq26DWafBrmoGd8Wd0ypftuox939lh/vg65RkqUZklzVUj7XcBj9UKmDqX7k4k967AzXfUsGgsg+s03X8r0/8UeHwQuP9NXn6BAKABLrbIg+uHcti++kz8BkhERPTMGDBgADZs2IBff/0VQgi8+OKL0GjyH9K4evVqg0frVSWaf3qaKpg1JSIiAzwTSVN3d3d4e3sXuV4ul0vr/fz8cO3aNYwcORJff/11ofWHDBmC5cuX48KFCzh27JjR8fTr1w/z58/Hxx9/DE9PT511//vf/5CQkIBevXrplKvVasTGxqJTp04G7UOpVBZ7zEVRq9W4cuUKmjdvXuh6lUoFlUpldLtkDIHRsxLQqnMKJr7hjeS/jT/fn0+vhei5/85p6+CSh9mbruOTER746xSH61PVIYRA8jwNHu8X8PhCAWWtUiZM7+QnTM38ZHCNkEP2xM2MZ7QCQv3v67RfBe6v18BjrQKm7JBdrZTH8HoOzyciKrvjx4/D0tISrVu3xsiRI6FWq+Hr64u//voLy5YtezaTpto5TTk8n4iIDFAtu+ZMmTIFmzdvxsmTJwtd37dvX5w9exYBAQFo2LCh0e3L5XLMnj0bK1as0BsGv2bNGvTu3RunT5/WWXr37o01a9aU5nCMsn79ejx8+BCvv/56he+LCjfmkwS8+NpDzBntgcw0OeyccmHnlAulmUaqY+eUCy//TLjVzQYA1PXNhJd/Jqxs83vR3U1Q4sYlc2lJuJafeL19Q2V0r1WiipQ0R4OUnwXcZikgtwDy7gnk3RPQZP2btcq7J5B1SSDn7/zX2VeBrEsC6pT8Orl3BG4MV8PERYaa4+VQP/y3HS1VXRnMvP9dTJwAyPLnTlVY88anWhGifBYiIiqTW7duwdPTEzKZDKdPn0bDhg1x4cIF1K1bF9euXavs8EpFLQ3P57UDERGV7JnoaXr//n0kJSXplNna2sLMzKzQ+u7u7ujRowdmzJiBnTt36q23s7NDYmIiTE1NSx1Tt27dEBwcjFWrVsHZ2RkAcPfuXfz444/YsWMHAgICdOoPGDAAPXr0wIMHD2Bvb19i+3l5eXrHLJPJpH0BQEZGBpKSkpCXl4dbt25h+/btWLRoEUaOHIn27duX+tiobMIG3QcAzP9O92Jy/nh37NmS/953G3Af/d9PltYt+P6aXh2iZ8Gjrfk3HzeHq3XKXSPksH0l/4bk4TYN7n3xbxLrxttqnTrpRwVy/wZy/xa42kW3Hb8Tz8TXFBERUbWUnZ3/A//ly5cRGhoKIH/KsOTk5OI2q7KENmlaLbsOERFReXsm7kY7duyoV7Zp0yb07t27yG3ee+89hISE4NixY2jRooXeeltb2zLHNXfuXLRq1Up6/dVXX6FGjRro0KGDXt0OHTrA3Nwc33zzDd59990S2z5//jxcXV11ylQqFbKysqTXq1evxurVq6FUKuHg4ICmTZti8+bN6NGjRxmOisoq1K1xiXW+WeCCbxa4lFhPK/mW0qB2iZ42Q5KaTu8o4PRO0ettX5HD9hXj7l5Ksw09Gzg8n4ioaqhXrx7OnDkDPz8/pKSkoGnTpgCA27dvw83NrZKjKx21dk5T9jQlIiIDyITgGLb/stTUVNjY2KAdXoWJrPQ9b4meZezNSP9VOWm5WPXCNqSkpBj8sMGKov0+CukcBRPTwkeSGCovNwtHds+oEsdFRPSs+uqrrzB48GAIIWBvb4/z58/jzp07aNy4Mfr06YMNGzZUdojF0n6vFPwuaDzzF6Rk5mLvhLbwrmlZyRESEVFFKew7oDSYKSAiIiIiIiIdAwYMQFBQEK5evYrWrVvD2dkZGo0Ge/bsgZeXV2WHVyoabU9TOXuaEhFRyZg0JSIioiqDw/OJiKqOwMBABAYGSq9dXV31phB7lvz7IKhKDoSIiJ4JTJoSERFR1aER+UtZ2yAiIqO9+OKLBtWTyWSIjY2t4GjKn0ZKmjJrSkREJWPSlIiIiIiIiHDgwAHIZDKU9NgL2TOadNRo8v8rZ1dTIiIyAJOmREREVHWIf5aytkFEREYbMGDAM5sQNYS2p6miGh8jERGVHyZNiYiIiIiICNHR0ZUdQoXinKZERGQMeWUHQERERKQlw78Pgyr1UtkHQURUjeTk5CAhIQE3b97UWUpj+fLl8PT0hJmZGYKDg3Hs2LEi665evRpt2rSBnZ0d7Ozs0LFjx2Lrl0QIAe2sAxyeT0REhmDSlIiIiKoOIcpnISKiMnn8+DF69eoFKysr1KlTB3Xr1pUWLy8vo9vbvHkzJkyYgIiICJw8eRKNGzdGaGgo7ty5U2j9AwcOoE+fPti/fz+OHDkCd3d3vPTSS0hISCjV8RR8RiAfBEVERIZg0pSIiIiIiIh0TJs2Dd9++y1yc3P/6aWpuxhr4cKFGDZsGAYPHoyGDRti5cqVsLCwwNq1awutv2HDBowaNQpBQUHw9fXFl19+CY1Gg9jY2FIdj6ZAzJzTlIiIDMGkKREREVUZZR6a/89CRERl88MPP0Amk+HDDz8EANSrVw8jRoyAvb09li1bZlRbOTk5OHHiBDp27CiVyeVydOzYEUeOHDGojYyMDOTm5sLe3r7Q9dnZ2UhNTdVZClIX6Goq410wEREZgF8XREREVHWIclqIiKhMEhMT4eXlhY8++ggA4OjoiM8//xw2NjY4efKkUW3du3cParUazs7OOuXOzs5ISkoyqI3JkyfDzc1NJ/Fa0OzZs2FjYyMt7u7uOusLdo5lT1MiIjIEk6ZERERERESkQ6VSwcrKCgBgZmaGW7duITc3F9nZ2fj222+faixz5sxBTEwMtm/fDjMzs0LrTJ06FSkpKdLy999/66xXF8iack5TIiIyhEllB0BERESkJRMCsjI+yKms2xMREeDi4oJbt24ByB+af+HCBTg5OSE1NRVOTk5GteXo6AiFQoHk5GSd8uTkZLi4uBS77fz58zFnzhzs3bsXgYGBRdZTqVRQqVRFri84p6mcXYeIiMgA/LogIiKiqkNTTgsREZVJSEgIcnNzcfbsWQwaNAhCCGme0AEDBhjVllKpRNOmTXUe4qR9qFNISEiR282bNw8fffQRdu/ejWbNmpXuQKT9sacpEREZhz1NiYiIiIiISMf69eul/2/UqBFcXV1x9OhRBAYGYujQoUa3N2HCBAwcOBDNmjVDixYtsHjxYqSnp2Pw4MEA8hOxtWrVwuzZswEAc+fOxYwZM7Bx40Z4enpKc59aWlrC0tLS6P1rOKcpEREZiUlTIiIiqjI4PJ+IqHLt2LED9vb2eP7553XK+/bti759+5a63V69euHu3buYMWMGkpKSEBQUhN27d0sPh7p58ybkBcbNr1ixAjk5OXjjjTd02omIiEBkZKTR+1cXyJoyZ0pERIZg0pSIiIiqDvHPUtY2iIioVLp3746QkBAcOnQIAKBQKNCyZUvpdVmMGTMGY8aMKXTdgQMHdF7Hx8eXeX8FiX9+UJPLABmzpkREZADOaUpEREREREQSUaDHvhBC5/WzSi0lTZkwJSIiw7CnKREREVUdQuQvZW2DiIioAO3ofLmcSVMiIjIMk6ZERERUZchE/lLWNoiIiArSaP4dnk9ERGQIJk2JiIiIiIhIcurUKXh5eRX5WiaT4dq1a5URWqlp/hmFoODwfCIiMhCTpkRERFR1cHg+EVGly8nJ0XkQU3Z2ts7rZ/FBSmoN5zQlIiLjMGlKREREVYZMk7+UtQ0iIiqdF1544ZlMipaEc5oSEZGxmDQlIiIiIiIiAMCBAwcqO4QKoR2ez5wpEREZiklTIiIiqjo4PJ+IiCqANKcps6ZERGQgJk2JiIio6hD/LGVtg4iIqADtnKbVceoBIiKqGPLKDoCIiIiIiIioImkHISiYNCUiIgOxpykRERFVGTIhICvj8Pqybk9ERNWPtqcpR+cTEZGhmDQlIiKiqoNzmhIRUQWQHgTFrCkRERmIw/OJiIiIiIioWpOSphyeT0REBmJPUyIiIqo6BABNObRBRERUgEY7pyl7mhIRkYGYNCUiIqIqg3OaEhFRRdDOacqOpkREZCgOzyciIiIiIqJqTTs8X8GsKRERGYg9TYmIiKjqECiHB0GVSyRERFSNaP6Z+oVzmhIRkaGYNCUiIqKqQ4hySJoya0pERLqkB0FxTlMiIjIQh+cTERERERFRtabWJk2ZMyUiIgOxpykRERFVHRoAZb2h1ZRHIEREVJ0I7ZymzJoSEZGBmDQlIiKiKkMmBGRlHF5f1u2JiKj6Uf/zg5qMc5oSEZGBODyfiIiIiIiIqjXtnKYK5kyJiMhA7GlKREREVQcfBEVERBVAo9HOacqsKRERGYY9TYmIiKjq0CZNy7oYITIyEjKZTGfx9fWV1mdlZWH06NFwcHCApaUlXn/9dSQnJ+u0cfPmTXTr1g0WFhaoWbMmJk6ciLy8vHI5JUREVHb/5Ewh55ymRERkIPY0JSIiov88f39/7N27V3ptYvLvJdJ7772Hn376Cd9++y1sbGwwZswYvPbaazh06BAAQK1Wo1u3bnBxccHhw4eRmJiIAQMGwNTUFJ988slTPxYiItKnFtqeppUcCBERPTOYNCUiIqKqo5KG55uYmMDFxUWvPCUlBWvWrMHGjRvx4osvAgDWrVsHPz8/HD16FC1btsQvv/yCCxcuYO/evXB2dkZQUBA++ugjTJ48GZGRkVAqlWU7HiIiKjOhndOUWVMiIjIQh+cTERFR1aEpp8VIV65cgZubG7y8vPDWW2/h5s2bAIATJ04gNzcXHTt2lOr6+vqiTp06OHLkCADgyJEjaNSoEZydnaU6oaGhSE1Nxfnz540PhoiIyp2ac5oSEZGR2NOUiIiIqqXU1FSd1yqVCiqVSq9ecHAwoqOj0aBBAyQmJmLmzJlo06YNzp07h6SkJCiVStja2ups4+zsjKSkJABAUlKSTsJUu167joiIKp80pymTpkREZCAmTYmIiKjKkAkBWRmH52u3d3d31ymPiIhAZGSkXv0uXbpI/x8YGIjg4GB4eHhgy5YtMDc3L1MsRERUNWg0nNOUiIiMw6QpERERVR3lOKfp33//DWtra6m4sF6mhbG1tYWPjw+uXr2KTp06IScnB48ePdLpbZqcnCzNgeri4oJjx47ptJGcnCytIyKiyqfhnKZERGQkzmlKRERE1ZK1tbXOYmjSNC0tDdeuXYOrqyuaNm0KU1NTxMbGSusvXbqEmzdvIiQkBAAQEhKCs2fP4s6dO1KdPXv2wNraGg0bNizfgyIiolJR/5M0lXF4PhERGYg9TYmIiKjq0AhAVsaephrjtg8PD0dYWBg8PDxw+/ZtREREQKFQoE+fPrCxscHQoUMxYcIE2Nvbw9raGmPHjkVISAhatmwJAHjppZfQsGFD9O/fH/PmzUNSUhKmTZuG0aNHG5yoJSKiiqX9alAwaUpERAZi0pSIiIiqjnIcnm+oW7duoU+fPrh//z6cnJzw/PPP4+jRo3BycgIALFq0CHK5HK+//jqys7MRGhqKzz//XNpeoVBg586dGDlyJEJCQlCjRg0MHDgQUVFRZTsOIiIqN9KcphxrSUREBmLSlIiIiP7TYmJiil1vZmaG5cuXY/ny5UXW8fDwwM8//1zeoRERUTnRzmkqZ09TIiIyEJOmREREVIWUQ09TlHV7IiKqbtQaJk2JiMg4TJoSERFR1VEJw/OJiKj60341KORMmhIRkWE4owsRERERERFVa+p/sqbsaEpERIZiT1MiIiKqOjQCZR5er2FPUyIi0qWd01TBrCkRERmISVMiIiKqOoQmfylrG0RERAVoOKcpEREZicPziYiIiIiIqFrTDkKQc05TIiIyEHuaEhERUdXBB0EREVV7Qgjk5eVBrVZX2D5ycnLg4eGBnJwcZGVlQYk81LJSwNpUICsrq8L2S0RET4dCoYCJiQlkFTiCgElTIiIiqjo4pykRUbWWk5ODxMREZGRkVOh+NBoNVq5cieTkZNy9exdN7HJRr31NWKoE4uLiKnTfRET0dFhYWMDV1RVKpbJC2mfSlIiIiIiIiCqcRqNBXFwcFAoF3NzcoFQqK6yHkFqtRmZmJjw9PaFQKHD3cRbM0nNgZ6FETWuzCtknERE9HUII5OTk4O7du4iLi0P9+vUhl5f/DKRMmhIREVHVweH5RETVVk5ODjQaDdzd3WFhYVGh+9IO/TczM8sfwpktIMsGTJQqmJkxaUpE9KwzNzeHqakpbty4gZycnAr5t51JUyIiIqo6BMohaVoukRARUQWpiN5ARET031PR3yf8tiIiIiIiIqLq7Z8f1CrweSFERFTNMGlKREREVYd2eH5ZFyIiogL+y98MkZGRCAoKeir78vT0xOLFiyus/fI4lvj4eMhkMpw+fbpcYnqWRUdHw9bWtlzaKo/zev/+fdSsWRPx8fHlElNZ7N69G0FBQdBoNCXWzcnJgbe3Nw4fPvwUIvtvmDJlCsaOHVvZYTBpSkRERFWIRlM+CxERUSFK29H077//xpAhQ6QHWHl4eGDcuHG4f/9+ucZnqHbt2mH8+PEG1Q0PD0dsbGyp9xUZGQmZTAaZTAYTExM4OjrihRdewOLFi5Gdna1T988//8Tw4cNLva+SlPVYAMDd3R2JiYkICAgop6gMU5qkYmhoKBQKBf7888+KC6yclMd5nTVrFl599VV4enrqlK9fvx7NmzeHhYUFrKys0LZtW+zcuVOnzoEDB6TPqVwuh42NDZo0aYJJkyYhMTGx0P1t2rQJCoUCo0eP1lvXuXNnmJqaYsOGDSXGvXLlStStWxetWrXSW/fOO+9AoVDg22+/1Vs3aNAgdO/eXa9ceyyPHj2SynJycjBv3jw0btwYFhYWcHR0ROvWrbFu3Trk5uaWGGNpnTlzBm3atIGZmRnc3d0xb968EreJjY1Fq1atYGVlBRcXF0yePBl5eXmF1r169SqsrKz0kvfh4eFYv349rl+/Xh6HUWpMmhIREREREVG19m9PU+PTptevX0ezZs1w5coVbNq0CVevXsXKlSsRGxuLkJAQPHjwoDxDLTdCCOTl5cHS0hIODg5lasvf3x+JiYm4efMm9u/fjzfffBOzZ89Gq1at8PjxY6mek5NThTzkqzyPRaFQwMXFBSYmVfsRLzdv3sThw4cxZswYrF27trLDKVFZz2tGRgbWrFmDoUOH6pSHh4fjnXfeQa9evXDmzBkcO3YMzz//PF599VUsW7ZMr51Lly7h9u3b+PPPPzF58mTs3bsXAQEBOHv2rF7dNWvWYNKkSdi0aROysrL01g8aNAhLly4tNm4hBJYtW6YXt/aYYmJiMGnSpDK9hzk5OQgNDcWcOXMwfPhwHD58GMeOHcPo0aPx2Wef4fz586Vuuzipqal46aWX4OHhgRMnTuDTTz9FZGQkvvjiiyK3+b//+z907doVnTt3xqlTp7B582bs2LEDU6ZM0aubm5uLPn36oE2bNnrrHB0dERoaihUrVpTrMRmLSVMiIiKqOjg8n4iIKsI/3w2lmdN09OjRUCqV+OWXX9C2bVvUqVMHXbp0wd69e5GQkIAPP/xQqiuTyfD999/rbG9ra4vo6Gjp9eTJk+Hj4wMLCwt4eXlh+vTpOj3FtEPQv/76a3h6esLGxga9e/eWkpODBg3Cr7/+iiVLlkg96+Lj46Xeabt27ULTpk2hUqnw+++/Fzqkfe3atfD394dKpYKrqyvGjBlT7DkwMTGBi4sL3Nzc0KhRI4wdOxa//vorzp07h7lz50r1Cg7PF0IgMjISderUgUqlgpubG959912pbnZ2NiZPngx3d3eoVCp4e3tjzZo1AGDwsWh76n3yySdwdnaGra0toqKikJeXh4kTJ8Le3h61a9fGunXrpG2e7PGp3VdsbCyaNWsGCwsLtGrVCpcuXZK2uXbtGl599VU4OzvD0tISzZs3x969e3XOkaenJz755BMMGTIEVlZWqFOnjk5yqW7dugCAJk2aQCaToV27dsWe83Xr1uHll1/GyJEjsWnTJmRmZuqsb9euHd59911MmjQJ9vb2cHFxQWRkpE6dhQsXolGjRqhRowbc3d0xatQopKWlFbq/+Ph4yOVyHD9+XKd88eLF8PDwgEajwcOHD/HWW2/ByckJ5ubmqF+/vnRunzyvxdUtzM8//wyVSoWWLVtKZUePHsWCBQvw6aefIjw8HN7e3vDz88OsWbMwfvx4TJgwAX///bdOOzVr1oSLiwt8fHzQu3dvHDp0CE5OThg5cqROvbi4OBw+fBhTpkyBj48PvvvuO72YwsLCcPz4cVy7dq3IuE+cOIFr166hW7dueuu+/fZbNGzYEFOmTMHBgwf1YjXU4sWLcfDgQcTGxmL06NEICgqCl5cX+vbtiz/++AP169cvVbsl2bBhA3JycqR/L3r37o13330XCxcuLHKbzZs3IzAwEDNmzIC3tzfatm2LefPmYfny5To/sADAtGnT4Ovri549exbaVlhYGGJiYsr1mIzFpCkRERFVHUyaEhH9pwghkJGTVyFLVl7BttXIylUjM0eNjJw8CAO/Kx48eID//e9/GDVqFMzNzXXWubi44K233sLmzZsNbg8ArKysEB0djQsXLmDJkiVYvXo1Fi1apFPn2rVr+P7777Fz507s3LkTv/76K+bMmQMAWLJkCUJCQjBs2DAkJiYiMTER7u7u0rZTpkzBnDlzcPHiRQQGBurtf8WKFRg9ejSGDx+Os2fPYseOHfD29jY4fi1fX1906dKl0GQTAGzbtg2LFi3CqlWrcOXKFXz//fdo1KiRtH7AgAHYtGkTli5diosXL2LVqlWwtLTUaaOkYwGAffv24fbt2zh48CAWLlyIiIgIvPzyy7Czs8Mff/yBESNG4J133sGtW7eKPZ4PP/wQCxYswPHjx2FiYoIhQ4ZI69LS0tC1a1fExsbi1KlT6Ny5M8LCwnDz5k2dNhYsWIBmzZrh1KlTGDVqFEaOHCklX48dOwYA2Lt3LxITE4s8b0D+38W6devQr18/+Pr6wtvbG1u3btWrt379etSoUQN//PEH5s2bh6ioKOzZs0daL5fLsXTpUpw/fx7r16/Hvn37MGnSpEL36enpiY4dO+olNtetW4dBgwZBLpdj+vTpuHDhAnbt2oWLFy9ixYoVcHR0LLQ9Y+oCwG+//YamTZvqlG3atAmWlpZ455139Oq///77yM3NxbZt24psEwDMzc0xYsQIHDp0CHfu3NE5rm7dusHGxgb9+vWTEvYF1alTB87Ozvjtt9+KjdvHxwdWVlZ669asWYN+/frBxsYGXbp00fnxxBgbNmxAx44d0aRJE711pqamqFGjRqHb3bx5E5aWlsUun3zySZH7PXLkCF544QUolUqpLDQ0FJcuXcLDhw8L3SY7OxtmZmY6Zebm5sjKysKJEyeksn379uHbb7/F8uXLi9x/ixYtcOvWrUqd47Zq90cnIiIiIiKiaiszV42GM/5XcTv4fm+hxReiQmGhLPl2+MqVKxBCwM/Pr9D1fn5+ePjwIe7evYuaNWsaFNK0adOk//f09ER4eLg0hFdLo9EgOjpaSsT0798fsbGxmDVrFmxsbKBUKmFhYQEXFxe99qOiotCpU6ci9//xxx/j/fffx7hx46Sy5s2bGxT7k3x9ffHLL78Uuu7mzZtwcXFBx44dYWpqijp16qBFixYAgMuXL2PLli3Ys2cPOnbsCADw8vIy+lgAwN7eHkuXLoVcLkeDBg0wb948ZGRk4IMPPgAATJ06FXPmzMHvv/+O3r17F9nOrFmz0LZtWwD5ydpu3bohKysLZmZmaNy4MRo3bizV/eijj7B9+3bs2LFDp5du165dMWrUKAD5PYoXLVqE/fv3o0GDBnBycgIAODg4FPq+FbR3715kZGQgNDQUAKSkXv/+/XXqBQYGIiIiAgBQv359LFu2DLGxsdI5KzjvraenJz7++GOMGDECn3/+eaH7ffvttzFixAgsXLgQKpUKJ0+exNmzZ/HDDz8AyH9PmzRpgmbNmkltFsWYugBw48YNuLm56ZRdvnwZ9erV00naabm5ucHa2hqXL18utl0g/3MK5PeGrVmzpvT39dlnnwEAevfujffffx9xcXFSj+CC+7lx44ZRcQP5/3YcPXpUSo7369cPEyZMwLRp0yAzssv7lStXSuyZXBg3N7cS59C1t7cvcl1SUpLe+XB2dpbW2dnZ6W0TGhqKxYsXY9OmTejZsyeSkpIQFRUFANLcsvfv38egQYPwzTffwNrautj4gfxzXNLnp6KwpykRERFVHRpRPgsREVE5KqknaWFJnaJs3rwZrVu3houLCywtLTFt2jS9Houenp46PddcXV11eskVR5ukKsydO3dw+/ZtdOjQweB4iyOEKDIB9OabbyIzMxNeXl4YNmwYtm/fLj0M5vTp01AoFFKSsijFHYuWv78/5PJ/UxvOzs46PVoVCgUcHBxKPH8Fe7K6uroCgLRNWloawsPD4efnB1tbW1haWuLixYt671vBNmQyGVxcXAx+3wpau3YtevXqJc0P2qdPHxw6dEhvmPiTvW+f/Jzs3bsXHTp0QK1atWBlZYX+/fvj/v37yMjIKHS/3bt3h0KhwPbt2wEA0dHRaN++vZSwGjlyJGJiYhAUFIRJkyYV+7R4Y+oCQGZmpl4PRaB8/vaEND1H/md1z549SE9PR9euXQHkz5/ZqVOnQucdNTc3L/J8FRf32rVrERoaKvWu7dq1K1JSUrBv374S4y0qfmOZmJjA29u72KW4pGlpvPTSS/j0008xYsQIqFQq+Pj4SOdZ+3c6bNgw9O3bFy+88EKxbWl79xd3/isae5oSERFRlSGEBkJoytwGERE9G8xNFbgQFVru7arVavzf/51B48aBUCgUuPUgE48yc+BsbQYnKxXMTRUGtePt7Q2ZTIaLFy+iR48eeusvXrwIJycn6cnPMplML8FRcL7SI0eO4K233sLMmTMRGhoKGxsbxMTEYMGCBTrbmJqa6ryWyWTQaAz7fitqqC4AvSkGyurixYt6PdG03N3dcenSJezduxd79uzBqFGj8Omnn+LXX381OI7ijkWrsHNVmvNXcBttck27TXh4OPbs2YP58+fD29sb5ubmeOONN5CTk1NiLIa+b1oPHjzA9u3bkZubq/MQHLVajbVr12LWrFkG7S8+Pl6aE3XWrFmwt7fH77//jqFDhyInJ6fQB3YplUoMGDAA69atw2uvvYaNGzdiyZIl0vouXbrgxo0b+Pnnn7Fnzx506NABo0ePxvz58/XaMqYukJ+4fHLId/369fH7778jJydHLzl6+/ZtpKamwsfHp6hTKbl48SKAf3u7rlmzBg8ePND5HGo0Gpw5cwYzZ87UScI/ePBA6iVcVNxPPmRKrVZj/fr1SEpK0nkwlvY91P5oYW1tXWgv1kePHkGhUEiffx8fH/z1118lHueTbt68iYYNGxZb54MPPpB6ZT/JxcUFycnJOmXa18X1lp4wYQLee+89JCYmws7ODvHx8Zg6darUm3zfvn3YsWOH9FkQQkCj0cDExARffPGFNDWG9iF7xZ3/isakKREREREREVUKmUxm0DB5Y6nVMpiZ5LetUChgrlQgK08BC6XCqP05ODigU6dO+Pzzz/Hee+/pJFmSkpKwYcMGjB49WipzcnKShqAC+cNqC/aSOnz4MDw8PHQeHlXc0N+iKJVKqNVqo7ezsrKCp6cnYmNj0b59e6O3L+ivv/7C7t27MXXq1CLrmJubIywsDGFhYRg9ejR8fX1x9uxZNGrUCBqNBr/++qs0PL8qO3ToEAYNGiQlztPS0oyeZ1Gb9CvpfduwYQNq166t90CxX375BQsWLEBUVBQUipKT/idOnIBGo8GCBQukJOCWLVtK3O7tt99GQEAAPv/8c+Tl5eG1117TWe/k5ISBAwdi4MCBaNOmDSZOnFhkItSYuk2aNME333yjU9anTx989tlnWLVqFcaOHauzbv78+TAzM0OvXr2KPZ7MzEx88cUXeOGFF+Dk5IT79+/jhx9+QExMDPz9/aV6arUazz//PH755Rd07twZAJCVlYVr164VOpdowbhXrFih0+v6559/xuPHj3Hq1Cmd9+rcuXMYPHgwHj16BFtbWzRo0AAxMTHIzs6GSqWS6p08eRJ169aVkuJ9+/bFBx98gFOnTunFkpubi5ycnEJ/YCjr8PyQkBB8+OGHyM3NlWLZs2cPGjRoUOjQ/IJkMpk0vH7Tpk1wd3fHc889ByD/x6OCfwc//PAD5s6di8OHD6NWrVpS+blz52BqaqrzPj1tTJoSERFR1SHKYXg9HwRFRERP+Pebwbi5BAFg2bJlaNWqFUJDQ/Hxxx+jbt26OH/+PCZOnAgfHx/MmDFDqvviiy9i2bJlCAkJgVqtxuTJk3V6A9avXx83b95ETEwMmjdvjp9++kkaCm0MT09P/PHHH4iPj4elpaVRQ2wjIyMxYsQI1KxZE126dMHjx49x6NAhvaRUQXl5eUhKSoJGo8H9+/dx4MABfPzxxwgKCsLEiRML3SY6OhpqtRrBwcGwsLDAN998A3Nzc3h4eMDBwQEDBw7EkCFDsHTpUjRu3Bg3btzAnTt3inySdmWqX78+vvvuO4SFhUEmk2H69OlG9yCtWbMmzM3NsXv3btSuXRtmZmawsbHRq7dmzRq88cYbCAgI0Cl3d3fH1KlTsXv37kKf1P4kb29v5Obm4rPPPkNYWBgOHTqElStXlridn58fWrZsicmTJ2PIkCE6PxTMmDEDTZs2hb+/P7Kzs7Fz584i5/s1pi6QPxfm1KlT8fDhQykhFxISgnHjxmHixInIyclB9+7dkZubi2+++QZLly5FdHQ0HBwcdNq5c+cOsrKy8PjxY5w4cQLz5s3DvXv3pLlFv/76azg4OKBnz556U0t07doVa9askZKmR48ehUqlQkhISJFxt2/fHmlpaTh//rz0nq1ZswbdunXTmQcXABo2bIj33ntP+rHlrbfeQlRUFAYMGIBJkybBxsYGBw8exOLFizFv3jxpu/Hjx+Onn35Chw4d8NFHH+H555+HlZUVjh8/jrlz52LNmjUICgrSi007PL+0+vbti5kzZ2Lo0KGYPHkyzp07hyVLlug8uG779u2YOnWqTk/YTz/9FJ07d4ZcLsd3332HOXPmYMuWLVIC+cnPwfHjxyGXy/U+87/99hvatGlT7j3kjcE5TYmIiKjqEKJ8FiIiooK0cxqWYtP69evjzz//hJeXF3r27AkPDw906dIFPj4+OHTokM4T3xcsWAB3d3e0adMGffv2RXh4uM4w6FdeeQXvvfcexowZg6CgIBw+fBjTp083Oqbw8HAoFAo0bNgQTk5OenNrFmfgwIFYvHgxPv/8c/j7++Pll1/GlStXit3m/PnzcHV1RZ06ddCuXTts2bIFU6dOxW+//ab3xHstW1tbrF69Gq1bt0ZgYCD27t2LH3/8UUpyrVixAm+88QZGjRoFX19fDBs2DOnp6YafhKdo4cKFsLOzQ6tWrRAWFobQ0FCp15yhTExMsHTpUqxatQpubm549dVX9eqcOHEC//d//4fXX39db52NjQ06dOhQ6FPeC9O4cWMsXLgQc+fORUBAADZs2IDZs2cbtK12CL92mLSWUqnE1KlTERgYiBdeeAEKhQIxMTGFtmFMXQBo1KgRnnvuOb3esNrP6qZNmxAQEAA/Pz98+umn2LdvH/r166fXToMGDeDm5oamTZtizpw56NixI86dOycNU1+7di169OhR6Fy8r7/+Onbs2IF79+4ByO8h+dZbbxU6lYGWg4MDevTogQ0bNgDIH77+008/FfoeyuVy9OjRQ3oPbW1t8dtvvyE3NxevvPIKgoKCsHTpUixcuBDvvPOOtJ1KpcKePXswadIkrFq1Ci1btkTz5s2xdOlSvPvuu3rJxvJiY2ODX375BXFxcWjatCnef/99zJgxA8OHD5fqpKSk4NKlSzrb7dq1C23atEGzZs3w008/4YcffkD37t2N3n9MTAyGDRtW1sMoE5ko7YyyVC2kpqbCxsYG7fAqTGSmJW9AVA35nWCne/pvyknLxaoXtiElJaXYJ1c+Ddrvow42/WEiM/xhGoXJEzmITfm6ShwXERH9KysrS3o6dWEPTilParVaGsqqUChw4346UjJz4WZrDkdLVckNlCAiIgILFy7Enj170LJly3KImKjq+Oijj/Dtt9/izJkzT3W/P/30EyZOnIhz587pzCtaUHx8PNq2bYuQkBBs2LDBoKkKSuPevXto0KABjh8/XuS8vVpnzpxBp06dcO3atSJ/RCDj7Nq1C++//z7OnDmjMy/sk4r6XtHeW5T1foA9TYmIiKjq0GjKZyEiIipEaXqaFmbmzJlYunQpjh49avQwbaKqKi0tDefOncOyZcuKna6honTr1g3Dhw9HQkJCkXU8PT1x4MAB+Pr6ljhfZ1nEx8fj888/LzFhCgCBgYGYO3cu4uLiKiye/5r09HSsW7eu2ITp08DuVURERFR1CIGCM8+Vvg0iIqJ/VcRXw+DBg8u/UaJKNGbMGGzatAndu3fXG5r/tIwfP77EOnXr1kVkZGSFxtGsWTM0a9bM4PqDBg2quGD+g954443KDgEAk6ZERERERET0X1FeXU2JqqHo6GhER0dXdhhEVQaTpkRERFRlCI0GQla2YY5CcJgkEREVTsasKRERGYhJUyIiIqo6ODyfiIgqAL8ZiIjIWHwQFBERERERET01ohJ+3NLuk/1MiYiqj4r+PmFPUyIiIqo6NAKQsacpEVF1ZGpqCgDIyMiAubl55QTBrCkRUbWRkZEB4N/vl/LGpCkRERFVHUIAKOOcpEyaEhFVSStXrsT169fRtWtX1KxZE25ubqhRo0aR9R89eoQ7d+4gNzcXSqUSLi4usLKyMmhfarUaAJCVlQWFQoG83GyIPDVys+XIknPuayKiZ5kQAhkZGbhz5w5sbW2hUCgqZD9MmhIREREREVGF2rx5MyZMmICVK1fC0dER9+/fx+3bt1GrVq1Cb3azs7ORlJQEW1tbWFhYIC0tDSdOnICrqyuUSmWJ+9NoNLh37x7i4+Mhl8tx93E2svM0UKcoYa6smJtrIiJ6umxtbeHi4lJh7TNpSkRERFWG0AiIMg7Pr4y58oiIqHgLFy7EsGHDMHjwYABAbm4uWrVqhf79+2P48OF69d977z1kZmZi5cqVUlmvXr3g6+uLmTNnlri/tLQ0dOvWDcePH4elpSUWbTqF87dTEBHWEC/UrVl+B0ZERJXC1NS0wnqYajFpSkRERFWH0KDsw/M57JKIqCrJycnBiRMnMHXqVKnM1NQUDRs2RGxsLN599129bX766SdMmDABZmZmUllQUBC+//57zJ07V69+dnY2srOzpddZWVm4ceMGlEolzMzMcC9Tg4THamjkSp02iYiIiiKv7ACIiIiIiIio+rp37x7UajWcnZ11yp2dnZGUlFToNklJSUbVnz17NmxsbKTF3d1dZ71MJoNMBijkfBIUEREZhj1NiYiIqMrg8HwiIiqNqVOnYsKECdLr1NRUncTptpGtKiMsIiJ6hjFpSkRERFUHh+cTEVU7jo6OUCgUSE5O1ilPTk4u8gEeLi4uRtVXqVRQqVTlEzARERGYNP3P0/bGyUMuwI459B+Vk8YPP/035aTnAqhaPTPL4/soD7nlEwwREZULpVKJpk2bIjY2Ft27dweQ/3T72NhYjBkzptBtQkJCEBsbi/Hjx0tle/bsQUhIiEH71H63paamlil2IiJ69mj/7S/rfQ6Tpv9xjx8/BgD8jp8rORKiynPghcqOgKhyPX78GDY2NpUag1KphIuLC35PKp/vIxcXFyiVynJpi4iIym7ChAkYOHAgmjVrhhYtWmDx4sVIT0/H4MGDAQADBgxArVq1MHv2bADAuHHj0LZtWyxYsADdunVDTEwMjh8/ji+++MKg/Wnvc56c25SIiP47ynqfw6Tpf5ybmxv+/vtvWFlZQSbjpOhPm3aupb///hvW1taVHQ7RU8e/gcolhMDjx4/h5uZW2aHAzMwMcXFxyMnJKZf2tE9LJiKiqqFXr164e/cuZsyYgaSkJAQFBWH37t3Sw55u3rwJufzf5xS3atUKGzduxLRp0/DBBx+gfv36+P777xEQEGDQ/p68z+E1h3F4vgzHc2Ucni/D8VwZp+D5srKyKpf7HJmoSmPyiP5jUlNTYWNjg5SUFP4jSP9J/BsgIiKip4HXHMbh+TIcz5VxeL4Mx3NlnIo4X/KSqxARERERERERERH9dzBpSkRERERERERERFQAk6ZElUilUiEiIgIqlaqyQyGqFPwbICIioqeB1xzG4fkyHM+VcXi+DMdzZZyKOF+c05SIiIiIiIiIiIioAPY0JSIiIiIiIiIiIiqASVMiIiIiIiIiIiKiApg0JSIiIiIiIiIiIiqASVMiIiIiIiIiIiKiApg0pWovKSkJY8eOhZeXF1QqFdzd3REWFobY2FipzuHDh9G1a1fY2dnBzMwMjRo1wsKFC6FWq3XakslkkMlkOHr0qE55dnY2HBwcIJPJcODAAb36MpkMNjY2aN26Nfbt2yetHzRoELp3715k7J6enjptaJc5c+YgMjKy0HUFF+0+ClvXuXPnQvdjbm4OT09P9OzZUydWejaU9JmIjIxEfHx8keu1n+3o6GipTC6Xw9XVFb169cLNmzd19teuXTvpM/mkbt26SfssWH/8+PF628fExOhsu3jxYnh6euq1mZmZCXt7ezg6OiI7O1sv1qKW+Pj4Iv9mfH199eKRyWRQqVSoVasWwsLC8N133xn7VhAREdFTtnz5cnh6esLMzAzBwcE4duxYsfW//fZb+Pr6Stf/P//881OKtGow5nytXr0abdq0gZ2dHezs7NCxY8cSz291YuxnSysmJgYymazYe77qyNjz9ejRI4wePRqurq5QqVTw8fH5z/w9GnuuFi9ejAYNGsDc3Bzu7u547733kJWV9ZSirTwHDx5EWFgY3NzcIJPJ8P3335e4zYEDB/Dcc89BpVLB29sb0dHRRu+XSVOq1uLj49G0aVPs27cPn376Kc6ePYvdu3ejffv2GD16NABg+/btaNu2LWrXro39+/fjr7/+wrhx4/Dxxx+jd+/eEELotOnu7o5169bplG3fvh2WlpaFxrBu3TokJibi0KFDcHR0xMsvv4zr168bfAxRUVFITEzUWcaOHYvw8HCdstq1a+vV1ercubNeG5s2bSp0P5cuXcJXX30FW1tbdOzYEbNmzTI4Vqp8Bd/jxYsXw9raWqcsPDxcqrt37169z0XTpk2l9dptExISsG3bNly6dAlvvvmm3j7d3d31voASEhIQGxsLV1fXEmM2MzPDtGnTkJubW2Ldbdu2wd/fH76+vtIXZa9evXSOISQkBMOGDdMpc3d3BwD4+/vrHfPvv/+usw/ttteuXcO2bdvQsGFD9O7dG8OHDy8xPiIiIqocmzdvxoQJExAREYGTJ0+icePGCA0NxZ07dwqtf/jwYfTp0wdDhw7FqVOn0L17d3Tv3h3nzp17ypFXDmPP14EDB9CnTx/s378fR44cgbu7O1566SUkJCQ85cifPmPPlVZ8fDzCw8PRpk2bpxRp1WDs+crJyUGnTp0QHx+PrVu34tKlS1i9ejVq1ar1lCN/+ow9Vxs3bsSUKVMQERGBixcvYs2aNdi8eTM++OCDpxz505eeno7GjRtj+fLlBtWPi4tDt27d0L59e5w+fRrjx4/H22+/jf/973/G7VgQVWNdunQRtWrVEmlpaXrrHj58KNLS0oSDg4N47bXX9Nbv2LFDABAxMTFSGQAxbdo0YW1tLTIyMqTyTp06ienTpwsAYv/+/Tr1t2/fLr1OSEgQAMTKlSuFEEIMHDhQvPrqq0XG7+HhIRYtWmTQsRZVt6R9FLftjBkzhFwuF3/99ZdBMVDVsm7dOmFjY6NXHhcXJwCIU6dOGbXt0qVLBQCRkpIilbVt21aMHDlSODg4iN9//10qnzVrlggLCxONGzcWEREROvXHjRun83rw4MHCwcFBLF++XCpftGiR8PDw0IurXbt2YuXKlWLFihWiU6dOhcb+5D60IiIiROPGjYs85uK2Xbt2rQAg9uzZU+z2REREVDlatGghRo8eLb1Wq9XCzc1NzJ49u9D6PXv2FN26ddMpCw4OFu+8806FxllVGHu+npSXlyesrKzE+vXrKyrEKqM05yovL0+0atVKfPnllwbdj1Unxp6vFStWCC8vL5GTk/O0QqwyjD1Xo0ePFi+++KJO2YQJE0Tr1q0rNM6q5sk8S2EmTZok/P39dcp69eolQkNDjdoXe5pStfXgwQPs3r0bo0ePRo0aNfTW29ra4pdffsH9+/d1et9phYWFwcfHR69HZtOmTeHp6Ylt27YBAG7evImDBw+if//+JcZkbm4OIP/XtGfBuHHjIITADz/8UNmhUCW7c+cOtm/fDoVCAYVCobNOqVTirbfe0umBHR0djSFDhhjUtrW1NT788ENERUUhPT29yHrXrl3DkSNH0LNnT/Ts2RO//fYbbty4UboDMtLAgQNhZ2fHYfpERERVUE5ODk6cOIGOHTtKZXK5HB07dsSRI0cK3ebIkSM69QEgNDS0yPrVSWnO15MyMjKQm5sLe3v7igqzSijtuYqKikLNmjUxdOjQpxFmlVGa87Vjxw6EhIRg9OjRcHZ2RkBAAD755BO9qfKqm9Kcq1atWuHEiRPSEP7r16/j559/RteuXZ9KzM+S8vo3nklTqrauXr0KIYTOfIVPunz5MgDAz8+v0PW+vr5SnYKGDBmCtWvXAshPDnXt2hVOTk7FxpORkYFp06ZBoVCgbdu2hh4GJk+eDEtLS53lt99+M3h7ANi5c6deG5988kmJ29nb26NmzZqIj483an/0bGjVqpXe56KglJQUWFpaokaNGnB2dsb+/fuL/BFiyJAh2LJlC9LT03Hw4EGkpKTg5ZdfNjiWUaNGwczMDAsXLiyyztq1a9GlSxfY2dnB3t4eoaGhelNllOTs2bN6xzxixIgSt5PL5fDx8eHfAhERURV07949qNVqODs765Q7OzsjKSmp0G2SkpKMql+dlOZ8PWny5Mlwc3PTS0pUN6U5V7///jvWrFmD1atXP40Qq5TSnK/r169j69atUKvV+PnnnzF9+nQsWLAAH3/88dMIudKU5lz17dsXUVFReP7552Fqaop69eqhXbt2/4nh+cYq6t/41NRUZGZmGtyOSXkHRlRViCfmIi2vugDQr18/TJkyBdevX0d0dDSWLl1aZN0+ffpAoVAgMzMTTk5OWLNmDQIDAw3e18SJEzFo0CCdMmPnd2nfvj1WrFihU2bor8JCCOmhUlS9bN68ucgfDADAysoKJ0+eRG5uLnbt2oUNGzYUOcdt48aNUb9+fWzduhX79+9H//79YWJi+FeMSqVCVFQUxo4di5EjR+qtV6vVWL9+PZYsWSKV9evXD+Hh4ZgxYwbkcsN+A2zQoAF27NihU2ZtbW3QtvxbICIiIgLmzJmDmJgYHDhwAGZmZpUdTpXy+PFj9O/fH6tXr4ajo2Nlh/NM0Gg0qFmzJr744gsoFAo0bdoUCQkJ+PTTTxEREVHZ4VUpBw4cwCeffILPP/8cwcHBuHr1KsaNG4ePPvoI06dPr+zwqiUmTanaql+/PmQyGf76668i6/j4+AAALl68iFatWumtv3jxIho2bKhX7uDggJdffhlDhw5FVlYWunTpgsePHxe6j0WLFqFjx46wsbEpsTdqYRwdHeHt7W30dgXVqFGjVG3cv38fd+/eRd26dcu0f6qa3N3di/1cyOVyab2fnx+uXbuGkSNH4uuvvy60/pAhQ7B8+XJcuHChVE9T7devH+bPn4+PP/4Ynp6eOuv+97//ISEhAb169dIpV6vViI2NRadOnQzah1KpLNXfglqtxpUrV9C8eXOjtyUiIqKK5ejoCIVCgeTkZJ3y5ORkuLi4FLqNi4uLUfWrk9KcL6358+djzpw52Lt3r1EdQZ5Vxp6ra9euIT4+HmFhYVKZRqMBAJiYmODSpUuoV69exQZdiUrz2XJ1dYWpqanOFGB+fn5ISkpCTk4OlEplhcZcWUpzrqZPn47+/fvj7bffBgA0atQI6enpGD58OD788EODO5L8FxT1b7y1tbU0baIheEap2tIO312+fHmh8yQ+evQIL730Euzt7bFgwQK99Tt27MCVK1fQp0+fQtsfMmQIDhw4gAEDBujN8ViQi4sLvL29S5UwrWxLliyBXC5H9+7dKzsUqgKmTJmCzZs34+TJk4Wu79u3L86ePYuAgIBCf2woiVwux+zZs7FixQq9YfBr1qxB7969cfr0aZ2ld+/eWLNmTWkOxyjr16/Hw4cP8frrr1f4voiIiMg4SqUSTZs2RWxsrFSm0WgQGxuLkJCQQrcJCQnRqQ8Ae/bsKbJ+dVKa8wUA8+bNw0cffYTdu3ejWbNmTyPUSmfsufL19cXZs2d1rldfeeUV6Qne7u7uTzP8p640n63WrVvj6tWrUnIZyJ9Gz9XVtdomTIHSnauMjAy9xKg2F2Hs6Nnqrrz+jWdPU6rWli9fjtatW6NFixaIiopCYGAg8vLysGfPHqxYsQIXL17EqlWr0Lt3bwwfPhxjxoyBtbU1YmNjMXHiRLzxxhvo2bNnoW137twZd+/eNXhob1FSUlJw+vRpnTIHBwfpC/Xx48d6c5pYWFgYtd/s7Gy9NkxMTHSGjGj3k5ubi7i4OHzzzTf48ssvMXv27DL3dKWq6f79+3qfC1tb2yKHWbm7u6NHjx6YMWMGdu7cqbfezs4OiYmJMDU1LXVM3bp1Q3BwMFatWiXNQXP37l38+OOP2LFjBwICAnTqDxgwAD169MCDBw8MmnIiLy9P75hlMpnOfDcZGRlISkpCXl4ebt26he3bt2PRokUYOXIk2rdvX+pjIyIiooozYcIEDBw4EM2aNUOLFi2wePFipKenY/DgwQDyrxlq1aqF2bNnA8h/4Gnbtm2xYMECdOvWDTExMTh+/Di++OKLyjyMp8bY8zV37lzMmDEDGzduhKenp3Q9Vdi8+NWNMefKzMxM73rV1tYWAPTKqytjP1sjR47EsmXLMG7cOIwdOxZXrlzBJ598gnfffbcyD+OpMPZchYWFYeHChWjSpIk0PH/69OkICwsrtiNXdZCWloarV69Kr+Pi4nD69GnY29ujTp06mDp1KhISEvDVV18BAEaMGIFly5Zh0qRJGDJkCPbt24ctW7bgp59+Mm7Hgqiau337thg9erTw8PAQSqVS1KpVS7zyyiti//79Up2DBw+K0NBQYW1tLZRKpfD39xfz588XeXl5Om0BENu3by90Pw8fPhQAdNotrr4QQgwcOFAA0FuGDh0qhBDCw8Oj0PXvvPOOXlseHh5i0aJFBu+jQYMGOttqy5VKpahTp47o2bOn2LdvX5GxU9W3bt06YWNjo1ceFxdX6GcCgNi0aVOx2x45ckQAEH/88YcQQoi2bduKcePGFRlD48aNRUREhPT6yfqFbX/48GEBQHh4eAghhJg/f76wtbUVOTk5eu1nZ2cLW1tbsWTJkmLbFEKIiIiIQo9ZpVLpbFvwb8HV1VW8/PLL4rvvvivyGImIiKhq+Oyzz0SdOnWEUqkULVq0EEePHpXWtW3bVgwcOFCn/pYtW4SPj490/f/TTz895YgrlzHnq6j7koLXedWZsZ+tggYOHCheffXVig+yCjH2fB0+fFgEBwcLlUolvLy8xKxZs/TuxasrY85Vbm6uiIyMFPXq1RNmZmbC3d1djBo1Sjx8+PDpB/6U7d+/v9B/g7TnZ+DAgaJt27Z62wQFBQmlUim8vLzEunXrjN6vTAj24SUiIiIiIiIiIiLS4pymRERERERERERERAUwaUpERERERERERERUAJOmRERERERERERERAUwaUpERERERERERERUAJOmRERERERERERERAUwaUpERERERERERERUAJOmRERERERERERERAUwaUpEVUZ8fDxkMhlkMhmio6MBANHR0VJZZTpw4IAUx4EDB57q/uLj48vcnqenJ2QyGSIjI8vcFhERERFRdRIZGQmZTAZPT88S65b3dXp1cvHiRSgUCnh5eUGtVld2OKVizGehohV2f3z16lUoFArUrVsXOTk5lRvgfwCTpkSko127dtI/zDKZDAqFArVq1UJYWBgOHz781ONxcnJCcHAwgoODDd6mMi9ktF+yvIgiIiIioqpK+4N6cUtl/the8Jpauzg6OiIkJATffPNNue+vdu3aCA4ORpMmTaSyQYMGQSaToV27djp1ra2tpfsTlUpV7rE8qWDiTLuYm5vDz88PkZGR0Gg0RrepvecbNGhQucY6c+ZMaDQajBs3DgqFQmfdd999h86dO8PJyQkqlQp16tTBa6+99lQ6pDwNBd+nijwmb29vdO/eHfHx8Vi7dm2F7YfymVR2AERUNSmVSjRp0gTZ2dk4d+4cdu7cid27d+PQoUNo0aJFodvk5ORAqVSWaxzdunVDt27dyrVNIiIiIqL/siZNmsDFxQUAcOvWLSQkJAAAgoKCpERg7dq19bariOv9kgQFBcHExASXL1/G0aNHcfToUdy5cwcTJkwot328/fbbePvttw2q+9xzz+Ho0aPltm9j1KpVC25ubrh27Rr++usvzJw5E5aWlggPD6+UeApKTk7Gtm3boFAo0KdPH6lcCIEhQ4ZIPSWVSiW8vb3x4MEDbN++HdbW1nqJaSpe37598d1332HFihUYMWJEZYdTrbGnKREVytXVFUePHsWpU6fw/fffAwDy8vKwceNGALq/vM6bNw+1a9eGmZmZtP0333yD5s2bw8LCAlZWVujcuTNOnz6ts4/9+/cjICAAZmZmeP7553HhwgW9OIoanr9582a0atUKlpaWsLCwQOPGjbFnzx5ERkaiffv2Ur26devq/Iqq0WiwZMkSab92dnZ48803ERcXp9P+li1b4OXlBXNzc3Tt2lW6kCwPGzZsQIsWLeDo6AhTU1PY2dkhNDQUx44dK7T+X3/9hXbt2sHMzAze3t7YunWr3vo333wTTk5OUCqV8PPzw4oVK8otXiIiIiKqXrZv3y4lIAsmCwuWf/PNN5DJZOjfvz8mTpyImjVrokGDBgAKn/qpsJ6Z2dnZiIiIQP369aFUKlGzZk0MGTIE9+7dMyrWP//8E1evXoWFhQUA4KuvvpLWnzt3Dq+99hocHBygVCrh5eWFqVOnIjMzU6pz9OhRdOjQAQ4ODjAzM4Onpye6d++Oa9euAdAfku3p6Yn169cDAH799VedHoRPjmqLiYmBTCaDqakp7t+/L+1z+vTpkMlkqFWrljRUfdeuXWjbti2srKxgbm6ONm3aYP/+/Qafi7fffhvHjh1DXFwcatSoIcWndfr0aXTo0AGurq5QqVSoUaMGmjdvrtM7VyaTSdusX79eb5Rcae8ttm7diry8PLRo0QI1a9aUyr/88kspYdqpUyckJCTg/PnzSExMxNWrV/Hyyy9LdQ15L7W9ZNu1a4e5c+eiZs2acHR0xOzZs5Gamor+/fvD0tIS9evXl+5jAd37ygMHDqBJkyYwMzNDYGCgzjksTEn3kNHR0ahbt65Uv3379np/C+V1fwwAXbp0gUKhwJkzZ4qsQ+VEEBEV0LZtWwFAeHh4SGU7d+4UAAQAMW7cOCGEEAMHDhQAhFKpFHK5XPj5+QkHBwchhBBz586V6vv4+Ag3NzcBQNSoUUNcuHBBCCFEYmKiqFGjhgAgLCwshK+vr/QagFi3bp0QQoh169ZJZVrz58+XyqytrUVAQICwsLAQixYtEqtXrxZ+fn7S+qCgIBEcHCyioqKEEEKMHDlSWufv7y8cHBwEAOHi4iKSk5OFEEKcOnVKyOVyAUDY2NiIevXq6cS2f//+Is9fRESEVC8uLq7QOuPGjRNmZmbCx8dHNG7cWKhUKgFAWFlZicTERCGEEPv375faqVGjhvDx8RHW1tYCgJDL5eLkyZNCCCEuX74sbGxsBABhb28vAgIChEwmEwDEzJkzpX16eHgIACIiIsKgzwERERER/TcUdf2qvS9QKpXC1NRUBAQEiMDAQCFE4deW2vuDtm3bSmVdu3YVAIRCoRCBgYHS9WzDhg1FRkaGUTHduXNHWFhYCACicePGQgghLly4ICwtLQUAYWlpKfz8/KRr4U6dOgkhhFCr1dI1v7OzswgKChJOTk461/Xa/Wnvgbp37y4cHR2la/Tg4GARHBwsTpw4oXOdHhcXJzIzM6Xr8ZUrV0rHUL9+fQFATJ48WQghRExMjBSbh4eHqFu3rnRu9u3bV+S5iIuLk/anPd8pKSnS/cmoUaOkutu3bxdyuVx4eHiIJk2aCDs7O2nbnTt3CiGECA4OFlZWVgKAcHR0lI7t9u3bBt9bFKZ3794CgHj33Xd1yps1ayYACJVKJd3rFMaQ91KIfz+XKpVKWFtbizp16kjH6OfnJ5ycnISzs7N0H3Xv3j0hhO59pYWFhfDz8xPm5uZSvYSEhEI/C0KUfA+5c+dOERQUpBNHcHCwGDlypBCifO+PtQIDA/U+c1T+mDQlIh0FL46Cg4NFUFCQMDExEQCEiYmJOHr0qBDi34siAOLnn38WQgiRl5cn0tPTpYsZ7Rdrbm6u9GXZr18/IYQQ06ZNky4Szp07p1NWXNI0PT1d+vIICQkRKSkpQgghHj9+LK5cuSKEEHoXMlrXr1+XvnjXr18vbVe7dm0BQEybNk0IIUS/fv2khGlSUpIQQoj+/fuXW9L08uXLIj09XXp95coVaZsvv/xS7ximTJkihMj/IrW1tRUARK9evYQQQgwaNEgAEAEBAVKbixcvFgCEubm5SE1NFUIwaUpEREREhTMkaXr69GkhRP71vhCGJU0PHDggtfvrr78KIYS4ffu2lKjSXveWFFNQUJBo3ry5lHAFIBYsWCCEEGLAgAFSku3mzZtCCCEWLVok1du3b5+4d++e9PrWrVvSPs6dOyd1migsUVZYEliIwu81hg0bJgCI9u3bCyGEOHnypFRHmxTz9PQUAMSQIUOERqMRGo1G9OjRQwAQzz//fJHnomDStFatWqJ58+bC3t5euh8qmIhMTEyU7l+EECIzM1N4e3vr3IcJ8e97O3DgQJ19GXpvUZimTZsKAGLhwoU65dp7w4CAgCK3FcKw97Jg7KampiIuLk6kpaUJpVIpAAgnJyfx8OFDcfXqVWm7Xbt2CSF07yu1icZz585J97ra5PaTnwVD7yELvk8F7xfL+/5YKywsTAAQ4eHhxZ5XKhsOzyeiQuXk5OCPP/7AmTNn4OTkhG7duuHXX3/VeyBTgwYN0KVLFwCAQqHA+fPnkZGRAQCIiIiQhqocP34cAKT5f86fPy9t7+/vDwDo2bNniXGdP38e6enpAIDRo0fD2toaAGBpaQlvb+9itz1+/DiEEACAgQMHQiaTwcrKCrdu3So0ttatW8PZ2RkA8Oabb5YYm6EePnyIV199Ffb29pDL5ahfv7607vbt23r1tXMCubi4SFMPnD17FgCkIf3nzp1DjRo1IJPJMH78eABAZmYmzpw5U25xExEREdF/T/v27dG4cWMA0Hu4T3EKTj3Vtm1byGQyuLm5SUOtDZ0X9PTp0/jzzz9hYmKCli1b4quvvpLmM/3zzz8BAG3atIG7uzuA/PketY4fPw4HBweEhIQAyH+ITqNGjdCnTx+cOnUKjo6OBh9PcQYOHAggf6h8UlISNm/eDABo0aIF/Pz8cPfuXWn4+9q1ayGXyyGXy7F9+3YAwB9//GHQfhISEvDnn3/iwYMHMDExQefOnaW5aYH8offvv/8+3NzcYGJiAnNzc1y9ehVA4fcZTyrLvUVKSgoAwMrKSqdce//15HRrTzLkvSwoICAAnp6eqFGjBpycnAAAzz//PGxtbeHl5SXVS05O1tuX9v7K398fjRo1AvDv/dWTDL2HLEpF3R9r74O1550qBh8ERUSF8vDwMOjp79qkYmH8/Pykf8y1HBwcyhpauSg4yb2Wh4dHhe83LS0NoaGhePToEczMzNCkSROYmppKF0ra+Y6M5ejoiHr16umVG3NhS0RERET0pMKu97UJsILXrsUlb57seAFAJ9lXnLi4OGmu0dKKjY3Fxo0bcejQIVy4cAFbt25FTEwMEhMTMXHixDK1DeR3tvD29sbVq1exZcsWbNmyBcC/ydSCvLy8pCRfQYY8ZCsiIgITJ05EeHg4Vq5ciYiICDRq1Ag9evQAAPTr1w979+6FTCZDw4YNYWlpiQsXLuDx48dG3WeU5t5Ce9+XlpamU+7v74/jx4/j8uXLSE5OLvb+0RgF7zNNTEx0ygomaLUJz/JQ1nvI8rw/Tk1NBQC99qh8MWlKRGXy5C+G/v7+MDc3R2ZmJjp37owFCxZIdU6dOiX9suzv74/t27fj0qVLuHjxIvz8/PQecFQYf39/1KhRA+np6VixYgVeeeUVWFlZIT09HYmJifD29pYmiAcg9UoFgKZNm0Imk0EIgUGDBmHcuHEA8r9If//9d9jY2Ej7OHXqFA4dOoQ7d+6gZs2aBsX2pOzsbGRlZUmvFQoFLl26hEePHgHI/5W5T58+OHr0qPTrd2E2b96MwMBA3LlzBwcOHAAA6RfR5s2b48KFC7CxscHPP/8Me3t7AMC9e/cQGxuLli1bGh03EREREZFWYT0Ea9asifj4eFy+fBlA/rWn9jpVq3nz5tL/T506Fa+++iqA/IfL7t27F76+vmWOrXnz5rh48SJ+++033Lp1C7Vr15YeXAsAzZo1gxAChw8fxqBBgzB06FAAwIgRI7Bq1SocPHiwyKSp9p6i4P1EcQYMGIAZM2Zg9uzZSEpKgkqlkno0Ojk5wcPDAzdu3MBzzz2HTZs2SYm+y5cv48aNGyUmTLVq1KiBRYsWYceOHbh9+zZmzJiB7t27QyaTSb0Whw0bhlWrVuHBgwcICAjA48ePDTq2stxb1K9fHydPnsSNGzd0yocPH47jx48jOzsbAwcOxIYNG6RE4aVLl3D69Gn06tXLoPeyvGzevBnDhg3DxYsXpR6m2vurJxl6D1nUPWhF3R9rz3PBUYtU/jg8n4jKlYWFBaZPnw4AWLRoEWrXro2goCA4ODjgueeewy+//AIAGDVqFCwsLKBWq9GsWTP4+flh3rx5BrU/c+ZMAMChQ4fg7u6OwMBAODs7Y+fOnQCAevXqwdTUFADQsWNHtGzZElu3boWXlxeGDRsGABg/fjy8vLwQGBgIW1tbvPDCCzh58iQAYMKECZDJZEhJSYGPjw/q168vDbExhq+vL8zNzaXlzTffhJeXl/Sky6FDhyIwMBDdu3cvtp0lS5bA19cXPj4+ePjwIeRyOSZNmgQg/wLU2toa165dg7u7O5o0aQIPDw+4uLhg8uTJRsdMRERERFSSDh06AAC2bNmCNm3aoFGjRlLPN6127dohNDQUANC9e3f4+vrC398ftra26NKli0Gj2koyZcoUWFpaIi0tDX5+fmjYsKE0dL9Tp05o37491Go1OnbsCDs7O2k49urVqwEAgYGBRbatTeoeP34cjRo1QsuWLXWe4v6k/v37QyaTISkpCQAQFhYGOzs7af0nn3wCIP8p825ubmjSpAlcXFzQoEEDbNiwwajjNjMzw3vvvQcgfyj9jh07dI7nyy+/hL+/P+rVq6fTiePJY/vuu+/w3HPPoXPnzgDKdm/Rpk0bAPrD6N9++20MGjQIAPC///0Pbm5uCAgIQK1ateDr64tdu3YBMOy9LC/h4eHw9/dHs2bNkJeXBwsLC4wdO7bQuobeQzo5OUnJ4P79+yM4OBifffZZhdwfZ2RkSMP5teedKgaTpkRU7qZOnYr169ejefPmePjwIa5evYqaNWtixIgReO211wAArq6u2LFjBxo2bIi8vDxYWVkZfLHw/vvvY9OmTQgJCUFubi6uXr0KLy8vNGzYEED+EIelS5fC3d0dycnJ+OOPP6SLlxUrVmDRokVo1KgRbt++jRs3bsDT0xMTJkxAu3btAABNmjTBxo0b4enpiaysLHh4eGDFihXlcm7s7Ozw7bffomHDhtBoNFAqlfjxxx+L3Wbr1q1wdnZGVlYWvLy8sGnTJjz33HMA8ue8OXLkCN58801YWFjg/Pnz0Gg06Ny5Mz766KNyiZmIiIiIqKCpU6eiX79+sLW1xeXLlzFgwAD07t1br97333+PGTNmoH79+rh+/TqSkpLg5+eHadOmISAgoMxx+Pn54ciRI+jRoweUSiWuXLkCT09PTJkyBT/88AOA/NFeI0aMQN26dZGQkICrV6/C09MT4eHhmDFjRpFtDxkyBK+//jpsbGxw7tw5/PHHH8UOcff09ETbtm2l19pEoVbfvn2xc+dOtG3bFpmZmbh06RKsrKwwYMAAvP3220Yf+zvvvANbW1sAwKxZswAA0dHRaN++PczMzJCRkYHFixcXmhgODw9Hx44dYWFhgVOnTkmJzrLcW7zxxhswMTHB0aNHce/ePalcJpNh3bp12Lp1K1566SVYWVlJPZRfeeUVaQoDQ97L8rJr1y6YmZkhLy8PAQEB+PHHH1GrVq0i6xtyDymTybB69Wp4e3sjNTUVx44dk3qDlvf98a5du6BWqxEYGCjdA1PFkInynOCBiIiIiIiIiIj+c3r37o3Nmzdj6dKlRfbcrCzR0dEYPHgwgPKd57QyvPbaa9i+fTtWrlyJd955p7LDqdbY05SIiIiIiIiIiMokIiICcrkcixcvLvUDbql4V69exQ8//ABPT08MGTKkssOp9vggKCIiIiIiIiIiKhM/Pz8mSyuYt7c3z/FTxOH5RERERERERERERAVweD4RERERERERERFRAUyaEhERERERERERERXApCkRERERERERERFRAUyaEhERERERERERERXApCkRERERERERERFRAUyaEhERERERERERERXApCkRERERERERERFRAUyaEhERERERERERERXApCkRERERERERERFRAf8PEKhLtq1474wAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "qda = QDA(store_covariance =True)\n",
    "qda_model = qda.fit(X_train0, y_train0)\n",
    "\n",
    "# y_pred\n",
    "y_pred_qda = qda_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, qda_model, X_test0, y_test0, y_pred_qda, \"Quantric Discriminant Analysis (QDA)\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 5. Naive Bayes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Naive Bayes Classifier\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "71.44%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.89      0.57      0.70      3118\n",
      "  TERMINATED       0.61      0.91      0.73      2338\n",
      "\n",
      "    accuracy                           0.71      5456\n",
      "   macro avg       0.75      0.74      0.71      5456\n",
      "weighted avg       0.77      0.71      0.71      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "nb = BernoulliNB()  \n",
    "nb_model = nb.fit(X_train0, y_train0)\n",
    "\n",
    "# y_pred\n",
    "y_pred_nb = nb_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, nb_model, X_test0, y_test0, y_pred_nb, \"Naive Bayes Classifier\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## B) ML Classification"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1. KNN - K Nearest Neighbors"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter n_neighbors : {'n_neighbors': 1}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - K-Nearest Neighbors Classifier (KNN)\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "99.29%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.99      0.99      0.99      3118\n",
      "  TERMINATED       0.99      0.99      0.99      2338\n",
      "\n",
      "    accuracy                           0.99      5456\n",
      "   macro avg       0.99      0.99      0.99      5456\n",
      "weighted avg       0.99      0.99      0.99      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABU0AAAHyCAYAAADfte/mAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8g+/7EAAAACXBIWXMAAA9hAAAPYQGoP6dpAADdgUlEQVR4nOzdd3wU1frH8e8mkAYkIUAKLQlFCE2KlIA0RSIgiqIXpYOKKKiI10IRQhH8WQBRhKuA6FXA7kVAEBBsdBQVpEgJoYUeQg0kO78/wg5Z0nazi7vA5/16zSvZmTNnnlkCYZ49zzkWwzAMAQAAAAAAAAAkST6eDgAAAAAAAAAAvAlJUwAAAAAAAADIhqQpAAAAAAAAAGRD0hQAAAAAAAAAsiFpCgAAAAAAAADZkDQFAAAAAAAAgGxImgIAAAAAAABANiRNAQAAAAAAACAbkqYAAAAAAAAAkA1JUwAArgO9e/eWxWKx2/z9/VW9enUlJibq/Pnzuba91uzfv1+9e/dWRESEAgICVKNGDU2cOFFWq9Wt10lKSjLfo1atWtkdGzhwoHnszjvv1IULF3LtY9asWWa7okWLavfu3eaxrVu3msd69+7t1tg9adasWUpMTNSkSZMcbn+13qPsfa9YscLp8xMTE83zk5KS8m17Lf6d2rJli/r166cqVaooMDBQpUqVUoMGDTR69GgdPXpUknPvwdWU18/BuHHjVKlSJfn5+ZnHV6xYYbafNWvWPxbjgQMHFBQUJB8fH/355585Yo+JibFr/9prr5nH6tWrp9TUVLvYLRaLfvrpJ7P9+fPnc/03KfufUcmSJZWWlmYeW7RokXksMTHR3N+5c2dZLBYNGjTI3W8DAADXFZKmAABcpy5cuKBt27Zp1KhRuueeezwdjssOHz6spk2b6oMPPtDhw4eVnp6uLVu2aPDgwRowYMA/EsOQIUM0ZcoUSdKtt96qL7/8Un5+fgWel5GRof/7v/+72uF53KxZszRq1CiHk6bZ3SjvkTf48MMPVbduXb333nvauXOnzp8/r+PHj+vXX3/VyJEj9fPPP3s6xAItWLBAw4YN0+7du3Xx4kVPh6PRo0fr3LlzateunWrXrp1v22nTpun555+XJFWrVk3fffedQkNDc7R7+eWXnYohNTVV77zzToHtXnjhBTOO5ORkp64BAMCNhKQpAADXmeXLl8tqterXX39VeHi4JOm7777T8uXLPRyZaxITE80H/BkzZujw4cO66667JGU9/K9du/aqXn/cuHF65ZVXJEn169fX/PnzFRQU5PD5s2bN0v79+69WeE7JzMzMc4SsJ7nzPerdu7cMw5BhGDlGC1/Lzp0759L569at08MPP6wLFy7I19dXr776qg4fPqxz585p1apV6t69u9eNmLX9OWYfObpx40bz+x9++ME83qpVK7O9O0dx5/e+Hz9+3Iytb9+++fbz8ccf64knnpAkRUdHa+nSpSpTpkyubRcvXqz169c7FefEiRN19uzZfNs0atRIcXFxSk9P19SpU53qHwCAGwlJUwAArkO2ks8HH3zQ3Jfbw/eOHTvUoUMHFStWTJUqVcoxQvCjjz5S69atVbZsWfn7+ysoKEg333yzJkyYoMzMTLPdmTNn9Oyzz6py5coKDAxUaGioateurUceecQu2ZCSkqInnnhCMTEx8vPzU5kyZfTQQw9px44d+d6P1WrV7NmzJWWNzOrbt6/KlCmjoUOHmm0+/vhjp94jZ7z99tsaNmyYJCkuLk6LFy9WSEiIw+f7+voqPT1dr7/+eoFtly1bpoSEBJUsWVL+/v6qVq2axo4dazeabteuXXrggQdUpUoVBQcHy8/PTxUqVFDv3r21d+9eu/6ylzZPnjzZLGf+66+/JEl///23evbsqbJly8rPz0/lypVTv379dOjQIbt+3nnnHdWtW1fBwcEqVqyYKleurH/961/avHmzOZ3BDz/8IEnas2eP06X17n6P8irP//3339W8eXMFBgaqatWq+vDDDwssrz906JC6du2q4OBglS9fXkOHDrX7+c9u+/btatu2rYKCglSuXDmNHTtWhmHYtVm8eLHatGmj0NBQM/6XXnrJ7u9K9vg///xzde/eXaGhoWratKkkaenSpWrdurXKlCkjf39/lStXTnfeeae+/vrrfN+7l19+WRkZGZKkf//733ruuedUpkwZBQQEqEmTJvrvf/9rfhiRG2d+9j799FM1btxYYWFhCggIUMWKFXXPPffYlZ070ubKn6WYmBgNHz7cPN6yZUuzHD+v8vwLFy5o/PjxqlWrlgIDA1WiRAnddtttWrZsmV3MrVq1Msvply1bpgYNGsjf31//+c9/8nxP5syZo/T0dAUGBqp9+/Z5tvv666/NZH5kZKSWLl2q8uXL59rW19dXknOjTX19fXX48GG99957Bbbt3LmzJOmDDz7I8fMJAAAuMQAAwDWvV69ehiRDkrF8+XJz/5NPPmnuf/XVV3O0DQ8PN7+3bYsXL8613yu3YcOGme369++fZ7sjR44YhmEY+/fvN8qVK5drm5IlSxrbtm3L8/7+/vtvs+0999xj7j9+/Li5/9Zbb3XTu2kYu3fvNvsNCQkxLBaLIcmIjY019u3b51Af77//vtnHQw89ZEgygoKCjCNHjhhbtmwxj/Xq1cvuHNu1rtw6dOhgWK1WwzAMY/ny5Xm+35UqVTLOnz9v9mnbHxYWZtfut99+M/744w8jODg4136io6ONw4cPG4ZhGHPnzs3zep999pnd+3Xllv3+/sn3KHvftr8Tx44dM0qVKpXjvLJly5rf24wcOTLfvyf/+c9/zLbZ/55ERUXlaDty5Eiz7XvvvZdn/M2aNTPS09NzxJ/9z+7mm282kpKSjICAgFz7GDBgQJ7vd0ZGhhEUFGS2PXjwYJ5tr3wPdu/e7dTP3sqVK/O8z9dee83hNoZx+WfY9nMQHR2d6znvv/++XXzvv/++ed9t2rTJ9RyLxWLMnTvXvFbLli3Nn0N/f3+z3cSJE/N8n+69915DkhEfH5/jmO38wMBAs7+wsDDjzz//zNE2e+wPPPCAUaRIEcNisRibNm0yzp07Zx5r2bJlrn9Gtr9D5cuXN9LT041vv/02159BwzCMhQsXmsc2bdqU570BAHAjY6QpAADXqY0bN2ru3Lnm6wYNGuRoc8stt+jQoUP69ttvzX2fffaZ+X3v3r3166+/6vjx47p48aKSkpJUv359SdKUKVPMEUq2ORAfeOABnT59WidOnNDatWs1YsQI+fv7S5JGjBih/fv3KyQkRD/88IPOnz+vX3/9VWFhYTpx4oQ5kjM3R44cMb8PDg7O9fvDhw879sY46eTJkzIMQ0WLFtXixYtVrlw5p/to0aKFmjdvrrNnz2rChAm5tjl9+rQGDRokwzDUrl077d27V2fPntW4ceMkZc3huHDhQklS5cqVtWDBAh08eFDp6elKTU3VyJEjJWWNBMz+52lz/PhxjRgxQidOnNDu3btVqVIlPfPMM0pLS1N0dLR+++03nT9/XsuWLVORIkW0Z88evfrqq5Iu//lWqlRJBw8e1NmzZ7VlyxZNnjxZ0dHRiomJkWEYatmypaSssmMjl5Lqf/I9ys3EiRN17NgxSdKTTz6p1NRUffbZZzp48GC+sVWsWFF79uzRr7/+qoCAAEn2f0+ya9asmY4ePaq1a9eqdOnSkqRXX31VqampOnXqlJ599lkZhqEyZcpozZo1OnbsmB544AFJ0i+//KIPPvggR58+Pj76/vvvdebMGc2ZM0fr1683F3dbt26d0tPTtWfPHs2ePVu33nprnvdx9OhRs3Q7JCREkZGR+d53bhz92Vu5cqUMw1CJEiXMeVN37Nih6dOnm3N+OtImN0lJSeY1JWn37t35luPPmTNHS5culZQ1YvrMmTPat2+f4uPjZRiGBg0alGPk8NmzZ9WmTRvt3btXx44dM0dm5ubXX3+VJNWsWTPPNufOnVN6erok6YsvvlCtWrXybCtl/V176KGHZBiGw6NNu3btqtjYWO3bt6/Av3fZ398NGzY41D8AADcakqYAAFxnWrdubZbn25KNrVu3VuvWrXO0fe211xQeHq4777zTnP80+8IgkZGRGjdunGrUqKGAgADFxMSYCYLU1FQzURkdHS0pK+kzduxYzZ8/X8WKFdOoUaNUokQJSTKTWSdPnlTLli0VEBCg+vXr6/jx45Kk77//3ul7tSVtJV31eRgvXrzo0kJFtqTwlClTlJqamuP4ypUrdfLkSUnSt99+qwoVKigoKMhuCgLbexQREaFVq1bptttuU0hIiEJDQzVq1Ciz3bZt23L0X716dY0aNUqhoaGKiYlRkSJFzLL1PXv2qF69egoICNDtt99ulm/brmf7892/f79Gjx6tDz/8UKmpqXr88cfVsGHDQr8nV3Lne5SblStXSspKQr788ssKCQnR/fffr2bNmuUb16hRo1SxYkXVq1dPderUkaQ8F9AZP368SpUqpYYNG5pJvHPnzmnNmjVauXKlubp5r1691KhRI4WFhZlJXylrxfMrPfvss2rdurWCgoIUFxdn/nlIWXPtTpkyRVu3btVdd91lNyXHldzxd8TRnz1bjKdPn9bo0aP13nvvad++ferWrZsSEhIcbuMO2RPpTzzxhIoVK6by5ctr1apVkrKmDbFNV2FjsVj03nvvqXz58goLC1OFChXy7N/272CpUqUciuf//u//HJpTeMiQIfLx8dGnn35a4BQmklSkSBFzkaf/+7//y3MKCUlmQl9Sjqk4AABAFpKmAABcp/z8/FS1alUNHTpU8+fPzzVhUrVqVfN72wg622iotLQ0tW3bVp9//rlSUlJyfQC3zcH4+uuvq3bt2jpw4IBeeeUV9ejRQzVr1lSjRo3M5Ff20aK5sSVPc5N9oRRb0kySTp06lWubK2Wf5zC3+Q7zU7VqVXNE3owZM/Tss88Wqt+EhATdcsstSktL01tvvZXjeEHvj3T5PXruuec0duxYbdmyxRxxmF1ui9bYkn02J06cyDepkv16TzzxhDp27KgLFy5o6tSp6t+/v+Lj4xUdHe30QjX5ced7lJsDBw5IyhplaUvmS8pzXkmb/P6eXCl7ci17v0ePHtXRo0dzbZf9+9zu8eabb7Z7fcstt2jYsGEKDAzUV199pcGDByshIUERERGaPn16nvdRqlQpc/GykydPFipZ5ujP3n333ae+ffvK19dXH3zwgZ588km1atVKUVFRWrBggcNt3KEwPzdlypRRVFSU22IoXbq0qlevLikrMd69e3dZrdZ8z4mLi9N9992nzMxMjR8/3qHr9OnTR+XKldOuXbvMeaBzU9C1AQAASVMAAK47y5cvl2EYSk9P1/bt2/Xyyy/nucp70aJFze+vTKquXr3aXNilR48eSk1NlWEYuZapVq9eXX/88Yd27typb775RomJifL19dW6des0ZcoUSZeTmtWqVTNLt7Nv+T3EV6pUSaGhoZLsR1Fu3brV/N42bYC7lS1bVt99951KliwpSZowYYLGjBlTqL5sIyk/+eSTHMeyJ33Hjx+f63s0c+ZMSZdLwyMjI7VlyxZZrVZ98803+V47MDDQ7nVYWJi52ExCQkKu19u1a5ckKSgoSPPmzdPhw4e1dOlSvfXWWypbtqwOHDigIUOGmH26YySju96j3JQtW1ZSVsLwzJkz5v4rFzC6Un5/T66Uva99+/aZ35cuXdpudF/2Y9nPyd7G5so/O0kaO3asjh49ql9++UWzZs1SfHy8zp07p6eeesocKXwlX19f3XHHHebrN998M9d2+SXTHf3Z8/Hx0YwZM3T06FGtWLFC7777ruLi4pSamqpBgwY53MYdsv/cHDx4MNd/e2xTS9jk9p7nxTZK3zb1Q26KFSumJUuWmKNrP/vsMz322GMF9m0bRZ3b34fc+Pn56d///neB52SPNSIiwqG+AQC40ZA0BQAAuco+ki4wMFB+fn5asmRJrnNGvvrqq/rqq69UpEgRtW3bVg888IA5Is82yqtdu3aSspKeiYmJOnHihM6ePatVq1ZpwIAB+Za++/j46KGHHjLPf//993XkyBG7suZu3brleX6rVq1yJEocXdVdypr/b+HChSpevLikrPlZ3377baf7veeee1SrVq1ck1JNmzZVSEiIpKzE7PLly5Wenq7Dhw/r008/VYsWLbRnzx5Jl/9sfH19VaJECe3fv9/pqQMCAwPNRNF3332nd999V6dOndKpU6f0/fffq0ePHvr4448lSZ9//rn+85//6MSJE2ratKn+9a9/mXO7Zh/FZ0ssHz16VCkpKU7FY+Ou9yg3tvk+rVarRo0apbS0NH3++edm2b47DBs2TMePH9f69evNUceBgYFq0qSJmjZtao5w/eCDD7R+/XqdOHHCbiX4O++8s8Br/PnnnxozZoy2b9+umjVr6v7771fdunUlZY30zD4CO7f4ihQpIilreo433nhDx44d0/nz57V69Wp1795d8+fPz/N8R3/2li9frgkTJmj//v1q0KCBHnjgAXPEru1nxpE27mD7t0eSHnvsMe3Zs0cXLlzQli1bNG7cOPPflsKyfWCzadOmfNuVL19eS5cuNUeuT58+3Uxw5qVevXpq3759gaPCs+vXr5/KlCmT7zl//vmn+X1u810DAACSpgAAIA/NmjVTWFiYJOndd99VUFCQEhISci1ZXbhwoe677z5FR0fL399fNWvWNEfy2eYmHD16tJloGzVqlMLCwlSsWDE1bdpU77zzTq6lvtklJiaqYsWKkqS+ffsqPDzcTO70799fjRo1cs+N56FJkyb6+uuvzYWtnnrqKf33v/91qg+LxWI3/2Z2xYsX18SJE2WxWHTkyBHddtttCggIUEREhLp06aKffvrJbNuxY0dJWXOMli9fXhUqVChwMaPcTJw4UcHBwTIMQ4899piCg4MVHBys22+/XR999JE5YnHTpk3q37+/brrpJgUFBSkiIkLr1q2TZJ/ks81veubMGUVFRcliseRbLp4bd71HuXn66afNeSdfe+01hYSE6IEHHnDrSLuffvrJnNPUVo7//PPPm1MCvP7665Ky5sFs2LChwsLCzBGBTZo0cSiZf+zYMY0YMUL16tVTaGioihcvrqlTp0qSGjdubCavc9OwYUPNmDFDRYsWVUZGhv7973+rdOnSCgwMVHx8vD7++GO7uYKv5OjP3p49e/Tss8+qZs2aKlGihEqWLKl58+ZJuvwz40gbd+jatatuv/12SdK8efMUExMjf39/1ahRQ8OGDSt0gt/G1vfGjRtznRojuypVqtiNXH/jjTc0duzYfM/JnlR3RFBQkJ555pl829g+KChbtqxq1KjhVP8AANwoSJoCAIBchYWF6ZtvvlHDhg0VEBCgqlWr6r///a+aN2+eo23v3r3Vtm1blS1bVn5+fgoLC1N8fLzmzp1rjvIqV66c1q9fryeeeELR0dEqWrSoSpcurVtuuUXDhw9Xz549840nPDxcK1euVM+ePVWmTBn5+fkpLi5OEyZMMKcAuNpuv/12zZ07V76+vjIMQ3379tXXX3/tVB//+te/7ObIzK5Pnz5asmSJEhISVLJkSfn5+alixYpq37693nvvPbO8fNKkSerZs6fCwsJUsmRJ9evXT5MnT3b6furUqaP169erR48eKlu2rIoUKaKIiAg1bdpU48aNMxNXbdq00b/+9S/FxsYqKChIxYsXV40aNTR69Gi7hM+TTz6pHj165Fpi7gx3vEe5CQsL07Jly9SsWTP5+/urUqVKmjFjhm655RbzuKtWrFihO+64Q4GBgYqKitKYMWPsVnrv16+fFixYoNatWys4OFhFixY15x5etmyZ/Pz8CrxGlSpV1K9fP9WsWVMhISHy9/dXTEyM+vXr59DPY8+ePbVx40Y98sgjio2Nlb+/v0qWLKn69esrMTHRHJGbG0d/9ho2bKiePXuqatWqKl68uAIDA1WlShX9+9//1nvvvedwG3fw9fXVwoULNX78eNWqVUsBAQEqUaKE4uLi9Nhjjzm8On1eunbtqoCAAJ0/f96huVivHLn+0ksv6e23386zfXx8fK4L+eVnwIAB5pQmufniiy8kZS1IdrUX0QMA4FplMfL7KBkAAAC4jixbtkxNmjRRsWLFJEnff/+92rdvr/T0dHXu3Fmff/65hyPEtah///76z3/+o3bt2uU6hYk3WbNmjZo0aSJ/f39t377dHMEPAADskTQFAADADaN69erasWOHwsPDdf78eZ04cUJS1nysq1atUrVq1TwcIa5FBw4cUJUqVXTu3Dn98ccfql27tqdDylPnzp315ZdfatCgQZo4caKnwwEAwGuRNAUAAMANY+TIkfr888+VnJys9PR0lS9fXnfccYeGDh1qrmwOAAAAkDQFAAAAAAAAgGxYCAoAAAAAAAAAsiFpCgAAAAAAAADZkDQFAAAAAAAAgGxImgIAAAAAAABANiRNAQAAAAAAACAbkqYAAAAAAAAAkA1JUwAAAAAAAADIhqQpAAAAAAAAAGRD0hQAAAAAAAAAsiFpCgAAAAAAAADZkDQFAAAAAAAAgGxImgIAAAAAAABANiRNAQAAAAAAACAbkqYAAAAAAAAAkA1JUwAAAAAAAADIhqQpAK+1Y8cOtWnTRsHBwbJYLGrVqpXb+k5KSpLFYpHFYtGKFSvc1u+1ZtasWeb7AAAAAAAAspA0Ba5DP/74o9q3b68yZcqYCbFp06a51GdqaqoSExNVt25dFS9eXMWLF1fNmjU1ePBgHTlyxE2R23v22We1bNkyXbx4UQ0bNlSNGjXc1re/v78aN26sxo0bKzg42G39FsT252GxWPTUU0/ZHVu4cKHd8UWLFjnVd+/evZ1OLpcpU8Z8HwAAAIAb3RtvvKFWrVopKipK/v7+io6OVq9evbRr165C9RcTE2P3f/yiRYuqQoUK6tu3r44ePZqj/erVq3X//fcrKipKfn5+Kl26tNq1a6dvv/021/5//fVXde/eXRUrVpS/v78iIiLUqlUrTZ8+vcDY/v77bz322GOqXLmyAgICVKpUKTVp0kSvvPJKoe4VuN5YDMMwPB0EAPeaNGmSnnvuOVWqVEnbt2+XJE2dOlX9+/cvVH9JSUlq1aqV9uzZI0kKCwtT2bJltWvXLp09e1bLly936yhQmypVqmjnzp168cUXNX78eLf37wnZR3QGBwdr//79Kl68uCSpXbt2donSb7/9VnfeeafDfffu3VsffPCBWrZs6dDo2QsXLsjPz8/x4AEAAIDrXExMjJKTk1WtWjWlp6dr9+7dkqTIyEht27bN6QEXMTEx2rNnj0qUKKEaNWro4MGDSk5OliR16NBB8+fPN9vOmjVLjzzyiDIzM+Xn56cqVaooKSlJZ8+elSSNHj1aL730ktl++vTp6t+/vzIzM2WxWBQbGysp6/mtQoUKSkpKyjOuhQsX6oEHHjD7Ll++vIoVK6adO3cqIyND7kgV8byBax0jTYHrUI8ePZSWlqbFixe7pb/u3bubCdM333xTR48e1Z9//qlTp05p3rx5ioyMNNu+//77atCggQIDA1WsWDE1a9ZM//vf/8zj2cviZ82apbvuuktBQUGKjY3VjBkz7Nrs3LlTkvTKK6/IYrGod+/eWrFihXl+9v8EZO9Tkk6fPq3HH39cFSpUkL+/v8qUKaNmzZrpgw8+yBFH9gTjzz//rISEBIWEhMjf319xcXF67bXXlJmZabaxfVr8wgsvaODAgSpVqpTCw8P19NNPKyMjw6H3tGjRokpLSzPj+fvvv7V48WIVLVo0R9t9+/apffv2qlChggIDAxUYGKhatWpp0qRJ5n9mYmJizL5++OEHu3vL/p599tlnatSokfz8/DR79uwc5fkbNmyQn5+fLBaL2d9vv/2mokWLymKxaObMmQ7dHwAAAHAtevTRR5WUlKQtW7Zo165dGjRokCQpJSVFy5YtK3S/9evX1+rVq7Vnzx41b95cUtb/220OHDigxx9/XJmZmapSpYp27NihzZs3a9++fWrSpIkkacSIEdqwYYMkaevWrWbCNDo6Wr/99pt27typnTt36ujRoxo6dGiesRw9elQPPfSQzp49q5IlS2r58uXau3evtm7dqpMnT2ry5Mlm2yufsySpVatW5vOZZP9sNX36dN1+++0KCAjQiBEjFBoaKovFojfffNM8f+fOnTmq6w4cOKC+ffuqbNmy8vPzU6VKlTRmzBiHn6+Aq4GkKXAdKlWqlAIDA93S1+bNm/XLL79Iku6++2499dRTZoLNx8dHHTt2VPXq1SVJY8eOVd++ffXrr78qPDxcwcHBWrlypTp16qSPPvooR9/9+vXT5s2bVbRoUSUlJalfv37aunWrWTpv+1SyXLlyaty4sSpXruxw3CNGjNC0adN05MgR1axZUyVKlNCaNWu0fPnyPM9ZsWKFWrdure+++06+vr6Kjo7W1q1b9fzzz+c6SnfixImaM2eOAgMDdeTIEU2ePFnvv/++Q/Hde++98vHx0dtvvy3DMMyv999/f462R48eNctx4uLiFBwcrM2bN+uZZ57RO++8I0mqV6+eSpcuLUkqUaJEnlMPdO/eXfv27VNsbGyu85g2aNBAI0eOlCQNHjxY+/btU9++fZWRkaF7771Xffv2dej+AAAAgGvRsGHDVLFiRfO1LcEpZU3x5U7Zr/PZZ5/p/PnzkqThw4erQoUKkqSSJUvaVd3ZnqtmzJhhDuyYOHGibr75ZrNNyZIl1a9fvzyv+8knnygtLU2S9NJLL9lVDQYFBenJJ58s9D0NGDBAv//+uypXrqxixYqpS5cukqS5c+faXV+SypYtqzvuuEPHjh1TkyZN9P777+v06dOKi4vT3r17NWLEiHzvA7jaSJoCyNdff/1lft+iRYs82505c0bjxo2TlJUQ3L17t5KSktSoUSNJWb/4r3TPPfdo165d+umnnyRJVqtVK1asUFRUlFavXq2oqChJ0iOPPKLVq1fblaIU5O+//5aU9Z+AX3/9Vbt27dLhw4f1zDPP5HnOyJEjlZGRoejoaO3atUvbt2/X008/LSnrPyVXzmNUvnx57dq1Szt27FDZsmUlyeFPn2NjY9WhQwdt3bpVX331lWbNmqWSJUuqe/fuubbdvXu39u7dq19//VUHDx40/yxs//n46quv1KFDB0mXP8VevXq16tevb9fX/fffr3379mnbtm25XkuSXnzxRTVt2lTHjx/XLbfcoo0bNyoqKkrvvfeeQ/cGAAAAXA8yMzP17rvvSpIqVaqk22+/vdB9/frrr2rSpIliYmL0008/qXz58mbfkrRt2zbz+7p169qdm/21rZ2jz2m5ceXcgsTHx2vfvn3avHmzhg4dql69ekmSOcpWupw07d69u3x9ffX2229r7969ioiI0M6dO/X777/r888/l5Q1ZcGOHTvcGiPgKJKmAPKVfS6b/FZY37x5s86dOydJevDBB+Xj4yN/f3917txZkrRnz54cC0Z169ZNFovFboGnQ4cOuSXujh07SspKmkZHRyshIUFvvfWWIiIi8jxn3bp1kqT27dsrNDRUktS1a1dJWe+DrRTG5u6771ZISIgCAgLM+YOcid/2CW6fPn2Ulpamvn37KigoKEe7IkWK6NVXX1V0dLSKFi0qX19f/fjjj5Kyylic8eSTT8rHJ+uffl9f31zb+Pr66r///a+KFStm3s/MmTNVqlQpp64FAAAAXKvOnDmje++9V4sXL1ZkZKS++eYbl0aanjp1SmvWrDETh7fccovq1auXa9srn7ts/3/PztHntNy4cm5B+vfvr4CAAElZzxVNmzZV1apVJWUlS7du3ao//vhDkszy/rVr10rKepYKDw+XxWJRp06dzFjXrFnj1hgBR5E0BZCvmjVrmt/bRoS6iy0xWaRIEXNfQROOZ/+lbitHOXnyZI52/fr10w8//KDBgwerevXq2rBhgxITE9WmTRs3RJ7FFr90+R6cmTC9TZs2ql69utLS0uTj46MBAwbk2m7QoEGaOnWqkpOTFRsbq8aNG5ul+NnnWnVEfknj7A4dOmSWB0ni010AAADcMFJSUtSyZUt98803uummm/TLL7/YDfQojJYtW+rixYvmugFff/21hgwZYh6vVq2a+f1vv/1md27217Z2rjynFebc7M8duT1/2eT2vNGzZ09JWUlT2yjThg0bKi4uzq5d9mnGsm+5DSwB/gkkTYEb2O23367q1avb/bK+Us2aNdW0aVNJWb/Yp0yZYh4zDEOff/65tmzZopo1a5rzqH7yySeyWq1KT0/Xl19+KUmKjo5WmTJlXI45PDzc/H779u2Ssub/udLatWtVs2ZNvf7661q8eLG5KuXmzZt17NixXPtu2LChpKyVJFNTUyVJc+bMkZSVrG3QoIHL8WdnsVg0cOBASVkrZ9pGq15p9erVkqS2bdtq+/btWrFihcqVK5ejne0/E2fOnMn3mgU5ffq0evTooczMTLMU6Pnnn7crGQIAAACuR5s3b1aTJk20YcMGNW/eXKtWrVKlSpVytHPkWepKRYoUUc+ePXXfffdJkqZNm6b9+/dLyppGyzaSdezYsdq3b58kKTU1VS+++KLZh22Krb59+5qVY88884z+/PNPs83x48f19ttv5xlHly5dzLUPRo8ebVaxSVnPEq+//rr52vb8ZXv22rp1q921rpTb80aPHj1ksVj066+/atq0aZIujzKVLj+HFSlSRHPnzjWnGluyZImeeOIJ3XvvvXleD7iaSJoC16Evv/xSVapUsZvQe8SIEapSpYq6detm7tu5c6e2bdumgwcP5tvfxx9/rOjoaEkyV4uvU6eOQkJC9MADD+jQoUMqVqyYuULjl19+qdjYWMXExJilFGPHjnXLvVWtWtWcML1r165q3bp1riM0J0+erMjISMXGxqpBgwZKSEiQlLWoVFhYWK59jxo1SkWKFNGePXtUqVIl3XTTTZo0aZIk6eGHH871P0uu6t+/v44cOWJ+4pqbOnXqSJK+++47VatWTRUqVNDevXtztLMtyLV+/XrVrl1bTZo0MadMcMagQYO0c+dOVa5cWT///LPatWunc+fOqXv37qxeCQAAgOvafffdZ5bQnzp1Su3bt1eTJk3UpEkTTZ8+3Wzn6LNUbmyJ1gsXLpgJynLlymnq1Kny8fHRjh07VLlyZdWqVUvlypUzB1GMGjXKHMgRFxenadOmydfXV7t371bdunVVpUoVVa1aVREREXaJzyuVLl1as2fPVlBQkI4fP66WLVuqYsWKqlGjhsLCwvTcc8+ZbW3zuL7xxhtq3bq14uPjnaquk7IG0NieTVNSUuTv768HH3zQPD5gwACVK1dOJ06cULVq1VS3bl1VrlxZpUqVMudEBTyBpClwHUpLS9POnTvNX/aSdOTIEe3cudP8JNMZMTEx2rhxo0aMGKE6dero/Pnz2rlzp6KiovT000+b5R3Dhw/XjBkzVL9+fR0+fFgnT55UfHy8vv766zwXHXJWkSJF9Mknn6hevXo6f/68jh8/rq+++ipHuw4dOqh58+Y6d+6c/vzzTwUEBKhjx45auHBhnqMtW7VqpeXLl+uOO+5QZmamkpKSVL16df3f//2f+Ymou/n6+qp06dLmKN3cTJgwQffcc4+KFy+uU6dO6bnnnjPnbM2ub9++6ty5s0JCQrRp0yatWbPG6fL9//3vf5oxY4YsFotmzpypYsWK6b333lNoaKjWr1+v0aNHO32PAAAAwLUiPT3d/H7jxo1as2aNudlGf7rqlltuMZOR7777ro4ePSopa62Dn3/+Wffdd59Kliypbdu2KSAgQAkJCVqwYIFGjBhh188jjzyiNWvWqGvXripbtqySk5N14sQJNW7cWMOGDcs3hg4dOui3337To48+qtjYWB06dEgHDx5U7dq1zQV+paxnkQ4dOigwMFA7d+7U0KFDdeuttzp9z9mTnx07drQbyFKmTBmtXr1affr0UalSpcz1Mpo3b66JEyc6fS3AXSyGsx8RAAAAAAAAAMB1jJGmAAAAAAAAAJANSVMAAAAAAAAAyIakKQAAAAAAAABkQ9IUAAAAAAAAALIhaQoAAAAAAAAA2ZA0BQAAAAAAAIBsing6AHiW1WrVgQMHVKJECVksFk+HAwD4BxmGoVOnTqls2bLy8fH856jnz5/XhQsX3NKXn5+fAgIC3NIXAMA1P/74o1577TVt2LBBBw8e1FdffaVOnTrle86KFSs0ePBgbd68WRUqVNDw4cPVu3dvh6/Jcw4A3Ljc9ZxD0vQGd+DAAVWoUMHTYQAAPGjv3r0qX768R2M4f/68YqOLK+Vwplv6i4yM1O7du0mcAoAXOHPmjG6++Wb17dtX9913X4Htd+/erQ4dOqh///76+OOPtWzZMj3yyCOKiopSQkKCQ9fkOQcA4OpzjsUwDMON8eAac/LkSYWGhmrPrzEKLu75UUaAJ9x7U21PhwB4RIYu6mctVGpqqkJCQjwaS1pamkJCQrR7Q7SCS7j2+yjtlFWxDfbo5MmTCg4OdlOEAAB3sFgsBY40feGFF7RgwQJt2rTJ3Pfggw8qNTVVixYtcug6tuecvXv38rsAAG4waWlpqlChgsvPOYw0vcHZSlWCi/u4/JAKXKuKWIp6OgTAMy59bOpNZYvBJfh9BAA3ulWrVqlNmzZ2+xISEjRo0KA8z0lPT1d6err5+tSpU5Kk4OBgkqYAvIJhGLIaktUwZFz6Ktm/thqSbG2yHbOda+jSV3O/7bys9obZ16W21tyvY2SLxzDsr2O7rt11LvV1OaYrrmNkv3bO69ja5txn//VyX9nittrfu654L6xZJ8pqGKoYFqQe8THme+7qcw5JUwAA4DUyDasyXayByTSs7gkGAOARKSkpioiIsNsXERGhtLQ0nTt3ToGBgTnOGT9+vEaNGvVPhYhriJEt+WNLtOSa2LHaJ2GuTCDZJ5YKSGpZL18n36RW9sTUldexxW6XqHItqWVLNuWdtLNPVOWftMsWi9X+vc0rwWe9Iqb8E2y5XCe3BJs1+/3Zv9eO3bOtr9z+nPO5Z8Mw36MC7/lSG1x9jWLC7JKmriJpCgAAvIZVhqxy7X+Vrp4PALj2DBkyRIMHDzZf20ozc2MYhjbtT9Op9IsuJbUkW+LkcsLlyhFidqOizKSK7fucCaQrR6LlvK59osqhpFb2BFSOpNaVCbZcrpPnPec+Ki7HSDBrbvecM9nk0D1nj+WK+8prhB5wrbNYJIskH4tFPpde+FgkiyxZXy0WWSxZx82vyr4/t332X2392/bJdj2fy9eR5dL18orFx/7cK2PJijXbNS8d87HY38fl+7K1vXwfud6zJB+frK/lw4Lc+t6TNAUAAAAAeI3IyEgdOnTIbt+hQ4cUHByc6yhTSfL395e/v79D/X+0eo9e+t9ml+PE9c+WnPG5IsFjnwy6nLApMBmUPcmTra0tGZRrMstsn3v/V7bNntS6sn9bAiz7/twSbGbbXK4ju/tStsSZ/T0r+3UvtbVcSrRlv07+92x/bv73nMt1JAfvOVtM+d2zT87rZE8gWuyun8d1bH375JOovOLnDp5D0hQAAHgNq6xytbje9R4AAJ4UHx+vhQsX2u1bsmSJ4uPj3dL/nmNnJUklg4oqvESAfeIlj0RH9gRPziTP5aSWrR8pW9Ik18RS7skmh2Oxtb3iOjkTPnkkbK5MsPkUdM+5jPy64joF37MtmZZzdFj2BFFu73WB18nWV67XyfHe5nMdXU58AbixkTQFAABeI9MwlOliLZ2r5wMA3Ov06dPasWOH+Xr37t3auHGjwsLCVLFiRQ0ZMkT79+/Xhx9+KEnq37+/3n77bT3//PPq27evvv/+e3366adasGCBW+KxXvo18VCjinr+zupu6RMAcP1heVoAAHBDmzp1qurUqWOusBwfH69vv/3WPH7+/HkNGDBApUqVUvHixdW5c+ccZaPJycnq0KGDgoKCFB4erueee04ZGRl2bVasWKH69evL399fVapU0axZs/6J2wMAj1u/fr3q1aunevXqSZIGDx6sevXqacSIEZKkgwcPKjk52WwfGxurBQsWaMmSJbr55pv1xhtvaPr06UpISHBLPLa5OX0YSQgAyAcjTQEAgNfwxEJQ5cuX1yuvvKKqVavKMAx98MEHuueee/Tbb7+pZs2aeuaZZ7RgwQJ99tlnCgkJ0cCBA3Xffffpl19+kSRlZmaqQ4cOioyM1MqVK3Xw4EH17NlTRYsW1bhx4yRljarq0KGD+vfvr48//ljLli3TI488oqioKLclAQDAW7Vq1UpGPlUAuX2I1KpVK/32229XJZ7LSdOr0j0A4DpB0hQAAHgNqwxl/sNJ044dO9q9fvnllzV16lStXr1a5cuX14wZMzR79mzddtttkqT3339fcXFxWr16tZo0aaLvvvtOf/31l5YuXaqIiAjVrVtXY8aM0QsvvKDExET5+flp2rRpio2N1RtvvCFJiouL088//6yJEyeSNAWAf5gtacqclQCA/FCeDwAArktpaWl2W3p6eoHnZGZmau7cuTpz5ozi4+O1YcMGXbx4UW3atDHbVK9eXRUrVtSqVaskSatWrVLt2rUVERFhtklISFBaWpo2b95stsneh62NrQ8AwD/HNqepL0NNAQD5IGkKAAC8hq0839VNkipUqKCQkBBzGz9+fJ7X/fPPP1W8eHH5+/urf//++uqrr1SjRg2lpKTIz89PoaGhdu0jIiKUkpIiSUpJSbFLmNqO247l1yYtLU3nzp1z6T0DADjHoDwfAOAAyvMBAIDXyDQMZeYz752jfUjS3r17FRwcbO739/fP85xq1app48aNOnnypD7//HP16tVLP/zwg0txAAC8U6aV8nwAQMFImgIAgOtScHCwXdI0P35+fqpSpYokqUGDBlq3bp3efPNNdenSRRcuXFBqaqrdaNNDhw4pMjJSkhQZGam1a9fa9Xfo0CHzmO2rbV/2NsHBwQoMDCzU/QEACsdWnu9D0hQAkA/K8wEAgNewumlzOQ6rVenp6WrQoIGKFi2qZcuWmce2bdum5ORkxcfHS5Li4+P1559/6vDhw2abJUuWKDg4WDVq1DDbZO/D1sbWBwDgn2NbCMqXp2EAQD4YaQoAALxGpgxlysXyfCfPHzJkiNq1a6eKFSvq1KlTmj17tlasWKHFixcrJCREDz/8sAYPHqywsDAFBwfrySefVHx8vJo0aSJJatu2rWrUqKEePXro1VdfVUpKioYPH64BAwaYUwL0799fb7/9tp5//nn17dtX33//vT799FMtWLDApXsFADjPYKQpAMABJE0BAMAN7fDhw+rZs6cOHjyokJAQ1alTR4sXL9Ydd9whSZo4caJ8fHzUuXNnpaenKyEhQe+88455vq+vr+bPn6/HH39c8fHxKlasmHr16qXRo0ebbWJjY7VgwQI988wzevPNN1W+fHlNnz5dCQkJ//j9AsCNzjbSlDlNAQD5IWkKAAC8RqaRtbnahzNmzJiR7/GAgABNmTJFU6ZMybNNdHS0Fi5cmG8/rVq10m+//eZccAAAt7MtBOVDzhQAkA+SpgAAwGu4Y05Sd8xpCgC4flGeDwBwBFNfAwAAAABuGLbyfB+GmgIA8sFIUwAA4DWssihTrj3EWl08HwBwfTOTpvy6AADkg6QpAADwGlYja3O1DwAA8mKlPB8A4ADK8wEAAAAANwwrC0EBABzASFMAAOA1Mt1Qnu/q+QCA65utPN/CSFMAQD5ImgIAAK9B0hQAcLXZyvN9SZoCAPJBeT4AAAAA4IZhLgTF0zAAIB+MNAUAAF7DalhkNVwb+ePq+QCA65vBQlAAAAeQNAUAAF6D8nwAwNWWaWVOUwBAwShIAAAAAADcMMzyfHKmAIB8MNIUAAB4jUz5KNPFz3Qz3RQLAOD6ZLAQFADAASRNAQCA1zDcMKepwZymAIB82EaaUp4PAMgP5fkAAAAAgBsG5fkAAEcw0hQAAHgNFoICAFxtmZfK830YaQoAyAdJUwAA4DUyDR9lGi7OaWq4KRgAwHXJsI00pe4SAJAPfk0AAAAAAG4Yl8vzGWkKAMgbI00BAIDXsMoiq4uf6VrFUFMAQN6s1qyvJE0BAPkhaQoAALwGc5oCAK42RpoCABxBeT4AAAAA4IZxOWnq4UAAAF6NkaYAAMBruGchKMrzAQB5s176NWFhpCkAIB8kTQEAgNfImtPUtYdYV88HAFzfbCNNfRlqCgDIB+X5AAAAAIAbhq0ggZwpACA/jDQFAABewyofZbr4ma5VlOcDAPKWeak+n/J8AEB+SJoCAACvwZymAICrjYWgAACOoDwfAAAAAHDDuFyeT9YUAJA3RpoCAACvYZWPrJTnAwCuIhaCAgA4gqQpAADwGpmGRZmGaw+xrp4PALi+2ZKmDDQFAOSH8nwAAAAAwA0j05r1lfJ8AEB+GGkKAAC8RqZ8lOniZ7qZlOcDAPJhmAtBkTQFAOSNpCkAAPAaVsNHVsPFOU0NkqYAgLxZzaSphwMBAHg1yvMBAAAAADcM66XP1nzImgIA8sFIUwAA4DUozwcAXG1WyvMBAA4gaQoAALyGVVKm4dpDrNU9oQAArlNWK+X5AICCUZ4PAAAAALhhmOX5jDQFAOSDkaYAAMBrWOUjq4uf6bp6PgDg+mYrzydnCgDID0lTAADgNTINH2UaLs5p6uL5AIDr26WcqXypzwcA5IOnCgAAAADADYOFoAAAjmCkKQAA8BpWWWSVqwtB8RAMAMhbJuX5AAAHkDQFAABeg/J8AMDVZBiGWZ7PSFMAQH54qgAAAAAA3BBsCVOJpCkAIH+MNAUAAF4jUz7KdPEzXVfPBwBcv6zZsqa+JE0BAPkgaQoAALyG1bDIarg4p6mL5wMArl/WbCNNLXzGBgDIB78mAAAAAAA3hOwjTSnPBwDkh5GmAADAa1jdUJ5v5TNhAEAe7JOmHgwEAOD1SJoCAACvYTV8ZDVcTJq6eD4A4PplZSEoAICDeKoAAAAAANwQKM8HADiKkaYAAMBrZMqiTLn2EOvq+QCA65dhvfw95fkAgPyQNAUAAF6D8nwAwNWUyUhTAICDeKoAAAAAANwQspfnkzMFAOSHkaYAAMBrZMr18vpM94QCADeso0eP6vPPP9dPP/2kHTt26OTJkwoODlbVqlXVvHlz3X///SpdurSnwywUW9LUxyJZyJoCAPLBSFMAAOA1bOX5rm7OGD9+vBo2bKgSJUooPDxcnTp10rZt2+zatGrVShaLxW7r37+/XZvk5GR16NBBQUFBCg8P13PPPaeMjAy7NitWrFD9+vXl7++vKlWqaNasWYV6nwDgati+fbu6du2qcuXKacCAAZozZ47WrVun7du3a/369ZozZ44GDBigcuXKqXv37tq+fbunQ3aabaAppfkAgIIw0hQAANzQfvjhBw0YMEANGzZURkaGhg4dqrZt2+qvv/5SsWLFzHaPPvqoRo8ebb4OCgoyv8/MzFSHDh0UGRmplStX6uDBg+rZs6eKFi2qcePGSZJ2796tDh06qH///vr444+1bNkyPfLII4qKilJCQsI/d8MAkIeaNWsqMzNTvr6+aty4sRo1aqTo6GgFBwcrLS1Ne/bs0dq1a7Vu3TrNnj1bn376qS5cuODpsJ1yeaQpSVMAQP5ImgIAAK+Rafgo08WFnJw9f9GiRXavZ82apfDwcG3YsEEtWrQw9wcFBSkyMjLXPr777jv99ddfWrp0qSIiIlS3bl2NGTNGL7zwghITE+Xn56dp06YpNjZWb7zxhiQpLi5OP//8syZOnEjSFIBXqFChggYPHqwuXbqoTJkyebY7cuSI5syZozfffPMfjM49Mq1ZSVNypgCAglCeDwAAvIYhi6wuboaLc6KePHlSkhQWFma3/+OPP1bp0qVVq1YtDRkyRGfPnjWPrVq1SrVr11ZERIS5LyEhQWlpadq8ebPZpk2bNnZ9JiQkaNWqVS7FCwDusmPHDg0cODDfhKkklSlTRk899ZT+/vvvfygy96E8HwDgKEaaAgCA61JaWprda39/f/n7++d7jtVq1aBBg9SsWTPVqlXL3N+1a1dFR0erbNmy+uOPP/TCCy9o27Zt+vLLLyVJKSkpdglTSebrlJSUfNukpaXp3LlzCgwMLNyNAoCb+Pg4N6bG2fbewFae7+tD0hQAkD+SpgAAwGu4szy/QoUKdvtHjhypxMTEfM8dMGCANm3apJ9//tluf79+/czva9euraioKN1+++3auXOnKleu7FK8AOAt+vbt61A7i8WiGTNmON3/lClT9NprryklJUU333yz3nrrLTVq1CjP9pMmTdLUqVOVnJys0qVL6/7779f48eMVEBDg9LVtLlXnU54PACgQSVMAAOA1rIZFVsO1J1nb+Xv37lVwcLC5v6BRpgMHDtT8+fP1448/qnz58vm2bdy4saSsUtbKlSsrMjJSa9eutWtz6NAhSTLnQY2MjDT3ZW8THBzMKFMAXmHWrFmyFJBNNAyjUEnTTz75RIMHD9a0adPUuHFjTZo0SQkJCdq2bZvCw8NztJ89e7ZefPFFzZw5U02bNtX27dvVu3dvWSwWTZgwwalrZ8dCUAAAR1179RQAAAAOCA4OttvySpoahqGBAwfqq6++0vfff6/Y2NgC+964caMkKSoqSpIUHx+vP//8U4cPHzbbLFmyRMHBwapRo4bZZtmyZXb9LFmyRPHx8YW5PQBwu4oVK9ptfn5+MgxDJUuWVMmSJWUYhooWLaro6Gin+54wYYIeffRR9enTRzVq1NC0adMUFBSkmTNn5tp+5cqVatasmbp27aqYmBi1bdtWDz30UI4PqJxltdqSpi51AwC4AZA0BQAAXiNTPm7ZnDFgwAB99NFHmj17tkqUKKGUlBSlpKTo3LlzkqSdO3dqzJgx2rBhg5KSkjRv3jz17NlTLVq0UJ06dSRJbdu2VY0aNdSjRw/9/vvvWrx4sYYPH64BAwaYydr+/ftr165dev7557V161a98847+vTTT/XMM8+4900EgEJKSkrS7t27tXv3bk2cOFG+vr5aunSpjh49qqNHj2rZsmXy9fXVuHHjnOr3woUL2rBhg91ieD4+PmrTpk2ei+E1bdpUGzZsMJOku3bt0sKFC9W+fftc26enpystLc1uy42VhaAAAA4iaQoAALyGrTzf1c0ZU6dO1cmTJ9WqVStFRUWZ2yeffCJJ8vPz09KlS9W2bVtVr15dzz77rDp37qxvvvnG7MPX11fz58+Xr6+v4uPj1b17d/Xs2VOjR48228TGxmrBggVasmSJbr75Zr3xxhuaPn26EhIS3PPmAYAbvfDCC4qJidFtt91m7mvdurUqVaqkl156yam+jh49qszMzFwXw7Mtlnelrl27avTo0br11ltVtGhRVa5cWa1atdLQoUNzbT9+/HiFhISY25XzWtuY5fkMNQUAFIA5TQEAwA3NuPQAnZcKFSrohx9+KLCf6OhoLVy4MN82rVq10m+//eZUfADgCcnJycrIyNB7772n++67T5L01VdfaevWrSpatOhVv/6KFSs0btw4vfPOO2rcuLF27Nihp59+WmPGjMk1aTtkyBANHjzYfJ2WlpZr4vTynKZXL3YAwPWBpCkAAPAaVvnI6mIhjKvnAwCk5s2ba+nSperfv7/69+9v7jcMQ82bN3eqr9KlS8vX1zfXxfBsi+Vd6aWXXlKPHj30yCOPSJJq166tM2fOqF+/fho2bJh8fOz/rff39y9wwb+s+LO+Up4PACgITxUAAMBrZBoWt2wAANdMnz5d9evXl2EYdlu9evU0ffp0p/ry8/NTgwYN7BbDs1qtWrZsWZ6L4Z09ezZHYtTX11dSwRUC+ck0F4LidwUAIH+MNAUAAAAA2KlYsaLWr1+v77//Xps3b5Yk1axZ026OU2cMHjxYvXr10i233KJGjRpp0qRJOnPmjPr06SNJ6tmzp8qVK6fx48dLkjp27KgJEyaoXr16Znn+Sy+9pI4dO5rJ08KwleeTMwUAFISkKQAA8BqFWcgptz4AAO5x2223KS4uThkZGXkuruSILl266MiRIxoxYoRSUlJUt25dLVq0yFwcKjk52W5k6fDhw2WxWDR8+HDt379fZcqUUceOHfXyyy+7dD+XBprKl0lNAQAFoDwfAAB4DcPwkdXFzTD47w0AuMNHH32k6OholS9fXl26dNE333yj2267rcBF7/IycOBA7dmzR+np6VqzZo0aN25sHluxYoVmzZplvi5SpIhGjhypHTt26Ny5c0pOTtaUKVMUGhrq0j0ZBuX5AADHMNIUAAAAAGDniy++UM+ePe321a9fXz/88IPCw8PVvn17D0XmGttIU3KmAICCMBQDAAB4jUxZ3LIBAFwzbtw4WSwWDRo0yNxXrlw5lS1bVuvWrfNcYC5iISgAgKNImgIAAK9hNS7Pa1r4zdN3AQDXvr/++kvVqlXThAkT7PaXKVNGBw4c8FBUrrtcnu/hQAAAXo+kKQAAAADATkBAgNLS0mS1Ws196enp2r17t4KCgjwYmWtsH6wx0hQAUBDmNAVc9M0HpbTgw9I6tNdPkhRd7by6PZOihredkiRdOG/Ru6PKasW8krqYblGDVqf05Ph9Klkmw+zjt5+K64NXo5S0NUABQVa1eeC4+rx4UL7Z/ob+MC9UcydHaP8uf4WUytDdfY7ogSeO/KP3ChRGrcan9cATR1S19lmVisxQYt8YrVoUYh4PLX1RDw87qAYtT6lYSKY2rS6uKcPL6cBufw9GDU+xLebkah8AANfEx8dr8eLF5tyl+/btU5s2bZSWlqZ27dp5OLrCs7IQFADAQTxVAC4qE3VRfYce0NuLtumtb7fr5manlNgnVknbAiRJ0xLLafWSEA3/T5Je/3KHjh8qqtEPx5jn79wcoJd6VNItrdM05bttGjotSau/C9GMl8uabdZ9X0L/NzBaHXoe1X+Wb9XA8fv05Xvh+t/M0v/07QJOCwiyatfmAL09tHwuRw2NnJmkqOgLSuwTqwFtb9KhfUX1yic75R+Y+Y/HCs+zyuKWDQDgmpEjR6pIkSJasmSJLBaL9u/fr19++UVFihTRSy+95OnwCs1MmvIkDAAogNf9qkhJSdGTTz6pSpUqyd/fXxUqVFDHjh21bNkys83KlSvVvn17lSxZUgEBAapdu7YmTJigzEz7B2yLxSKLxaLVq1fb7U9PT1epUqVksVi0YsWKHO0tFotCQkLUrFkzff/99+bx3r17q1OnTnnGHhMTY9eHbXvllVeUmJiY67Hsm+0auR278847c71OYGCgYmJi9K9//csuVvxzmrRNU6PbT6lcpQsqXzldfV5MUUAxq7ZuCNKZNB8tnhOmxxL3q+6tp1W1zjkNnpCsv9YX15YNWWVNP8wrqdi48+o++JDKxV5QnfgzemT4AX3zQWmdPZ31V3Tp52FqeudJ3dXzmKKiL6hxmzQ9OPCQPp0SLoO5++Dl1i8P1gevRmllttGlNuUqXVCNW87qrRfLa/vvQdq3M0BvvVhe/gGGWt+b+s8HCwAAJEmNGzfW999/rxYtWigwMFCBgYFq2bKlli5dqsaNG3s6vEJjpCkAwFFelTRNSkpSgwYN9P333+u1117Tn3/+qUWLFql169YaMGCAJOmrr75Sy5YtVb58eS1fvlxbt27V008/rbFjx+rBBx80J/a2qVChgt5//327fV999ZWKFy+eawzvv/++Dh48qF9++UWlS5fWXXfdpV27djl8D6NHj9bBgwfttieffFL//ve/7faVL18+R1ubO++8M0cfc+bMyfU627Zt04cffqjQ0FC1adNGL7/8ssOxwv0yM6UVX4cq/ayP4m45o7//CFLGRR/Va37abFOxarrCy13Qlg3FJEkXL1hU1N9q149fgFUXzvvo7z+CzDZ+ubQ5etBPh/b5XeW7Aq6eon5ZP9cX0i8/uBiGRRcvWFSz4RlPhQUPyjQsbtkAAK5r1qyZli9frtOnT+v06dNavny5mjdv7umwXGKbotVC0hQAUACvmtP0iSeekMVi0dq1a1WsWDFzf82aNdW3b1+dOXNGjz76qO6++269++675vFHHnlEERERuvvuu/Xpp5+qS5cu5rFevXpp8uTJmjRpkgIDAyVJM2fOVK9evTRmzJgcMYSGhioyMlKRkZGaOnWqypUrpyVLluixxx5z6B5KlCihyMjIXI9lT9T6+vrm2dbf3z/PPnK7TsWKFdWiRQtFRUVpxIgRuv/++1WtWjWH4oV77N4SoEEdq+pCuo8Ci1k1YsZuRd+Urp2bAlXUz6riIfajoEPLXNTxw1l//W5peUpfv1dGy78KVYu7U3XicFF9PDHrz/b4oUttWp3StJFldce/iuvmZqd1YLe/vvhPuNkmssKFf/BuAffZuyNAh/YVVd8hB/XmC+V1/qyP7ut3VGXKXlRYxEVPhwcPYE5TAPAOvr6+atKkiX755Re7/X379tXmzZu1Zs0aD0XmGttIU19ypgCAAnjNU8Xx48e1aNEiDRgwwC5hahMaGqrvvvtOx44d07///e8cxzt27Kibbropx4jMBg0aKCYmRl988YUkKTk5WT/++KN69OhRYEy2JOuFC9dGQurpp5+WYRj63//+l2eb9PR0paWl2W1wXfnK6XpnyTZNXrBdd/U8qtefjtae7Y4tYtOg1Sk98tIBTX6xgu6KuVl9b62uRrdl/blYLv0NbdftmO7uc1QjelVSh+ib9XTHqmp1zwlJzMeEa1tmhkWjH45Rucrp+mLLZs3b+adubnpaa5eVkGHlaQYAAE8xDCNHFZ8kbdq0SevXr/dARO5hvXRLlOcDAAriNSNNd+zYIcMwVL169TzbbN++XZIUFxeX6/Hq1aubbbLr27evZs6cqe7du2vWrFlq3769ypQpk288Z8+e1fDhw+Xr66uWLVs6fB8vvPCChg8fbrfv22+/daqMZf78+TmmDxg6dKiGDh2a73lhYWEKDw9XUlJSnm3Gjx+vUaNGORwLHFPUz1C52KzketU657RtY5C+nl5GLe9O1cULPjp90tdutGnqkaIKC88wX3d+7Iju63dExw8VUfGQTB3a56eZ48sqKjpdkmSxSI8MP6g+Qw7qxOGiCimVoY0/Z/2MRF5qA1yrdvwZpCfuqKagEpkqWtTQyeNF9Ob8v7X9j0BPhwYPsMoiq4vl9SwEBQCFN3r0aPP7ffv22b0+c+aM/vjjDwUEBHgiNLcwmNMUAOAgr0ma5vYppjvaSlL37t314osvateuXZo1a5YmT56cZ9uHHnpIvr6+OnfunMqUKaMZM2aoTp06Dl/rueeeU+/eve32lStXzql4W7duralTp9rtCwsLc+hcwzDynZ9nyJAhGjx4sPk6LS1NFSpUcCo+FMwwpIsXfFS1zlkVKWrVbz8XV/MOJyVJe3f46/B+P8U1sJ+v0WKRSkVmJVKXf1VSZcpeUJXa5+za+PpKpaOySpaXf11ScQ3OKLQUK4zj+nD2lK8kqWxsuqrefFYfvJb/NCW4PhmyuJz0NEiaAkCh2RawlaT9+/fnGHBhGIbi4+M9EZpbZF56liRnCgAoiNckTatWrSqLxaKtW7fm2eamm26SJG3ZskVNmzbNcXzLli2qUaNGjv2lSpXSXXfdpYcffljnz59Xu3btdOrUqVyvMXHiRLVp00YhISEFjkbNTenSpVWlShWnz8uuWLFiherj2LFjOnLkiGJjY/Ns4+/vL39/x8rG4ZiZ46LU8LY0lSl3UedO+2j5VyX1x8rienn2ThULtirhoeN6N7GcSoRmqliJTE0ZVl5xDc4orsFZs4/P3imjW1qfksVH+mVhiD6dEq5h0/bINyuHpJPHfPXTglDViT+ti+k++u6TMP00P1SvfbHDQ3cNOC4gKFNlYy9PcxJZ4YIq1TynU6m+OrLfT83vStXJY0V0eH9RxcadV//R+7VqUYh+/aGEB6MGAODGVLFiRVksFiUnJ8vPz89urYWgoCBVr15dY8eO9WCErqE8HwDgKK9JmoaFhSkhIUFTpkzRU089lWNe09TUVLVt21ZhYWF64403ciRN582bp7///jvXxZ2krBL99u3b64UXXpCvLROVi8jISJeTnp7y5ptvysfHR506dfJ0KDeU1KNF9NpT0Tp+uIiCSmQqNu68Xp69Uw1anpYk9U/cLx+LoTGPxuhiukW3tDqlgeP32fWxbnmw5kyO1MULFlWqcU6J7+9Ww9vsE/tLPwvTe6PLyjCkuAZn9drnO1S93lkB3u6mm8/ptS92mq/7jzogSfruk5J645mKCou4qMcSDyi0dIaOHy6ipZ+V1OxJEZ4KFx5mNdxQnu/i+QBwI7NN9eXj46N69epp5cqVng3IzWxVi74+/K4AAOTPa5KmkjRlyhQ1a9ZMjRo10ujRo1WnTh1lZGRoyZIlmjp1qrZs2aL//Oc/evDBB9WvXz8NHDhQwcHBWrZsmZ577jndf//9+te//pVr33feeaeOHDmi4OBgl2I8efKkNm7caLevVKlSZon7qVOnlJKSYnc8KCjIqeump6fn6KNIkSIqXbq0+dp2nYsXL2r37t366KOPNH36dI0fP/6aTfpeqwZP2Jvvcb8AQwPH79fA8fvzbPPqZzvzPCZJIaUyNembvwsVH+Bpf6wqroSyN+d5/H8zyuh/M5wf2Y/rk9XwkdVwbYU7V88HAEi7d++2q1DLyMhQkSJe9fhYKFbK8wEADvKqp4pKlSrp119/VevWrfXss8+qVq1auuOOO7Rs2TJzjs/7779fy5cvV3Jyspo3b65q1app4sSJGjZsmObOnZvnfJ4Wi0WlS5eWn5+fSzGuWLFC9erVs9uyz/MzYsQIRUVF2W3PP/+8U9dYtGhRjj5uvfVWuza261SpUkU9evTQyZMntWzZMr3wwgsu3R8AAAAAREdHa9u2bWrZsqUCAgLUsmVLLVu2TH379r2mR59mWrO+Up4PACiI131UGBUVpbfffltvv/12nm2aN2+uRYsWFdhXfgtGhYaG5jhe0AJTs2bN0qxZs/I8nt+q9Y62Legazl4HAIBrCeX5AOAdVqxYobZt2yojI2uhUsMwVLFiRfNZJbc1Jq4FtpGmVOcDAAriVSNNAQDAjc0qi1s2AIBrRowYoczMTN17773mvqpVqyoiIkK//PKLByNzjWEmTfldAQDIH0lTAAAAAICd9evXKzY2Vl988YXd/qioKO3fn/dc/d7Oeqm40IehpgCAAnhdeT4AALhxUZ4PAN6hSJEiOaYvs1qt2r9/v3x9fT0UlesozwcAOIqRpgAAwGvYkqaubgAA19SrV09JSUl69NFHJUlHjhzRQw89pCNHjqhBgwYejq7wrFbK8wEAjiFpCgAAAACw8+KLL0qSZs6cKYvFol27dunzzz+XxWLRc8895+HoCs8szydpCgAoAElTAADgNRhpCgDeoV27dpo9e7YqVqwowzBkGIYqVqyojz76SO3atfN0eIVmludTnw8AKABzmgIAAAAAcujSpYu6dOmio0ePSpJKly7t4Yhcd3mkqWfjAAB4P5KmAADAa7AQFAB4TnJyssPHK1aseLXDuSoMgzlNAQCOIWkKAAC8hiHJKtceZI2CmwAAchEbG+tQO4vFooyMjKsczdWReWmoKTlTAEBBSJoCAAAAAMxRmNczFoICADiKpCkAAPAalOcDgOcsX77c0yFcdbaFoHxJmgIACkDSFAAAeA2SpgDgOS1btvR0CFedOaepj4cDAQB4PX5VAAAAAABymD9/vpo2barg4GAFBwerWbNm+uabbzwdlkts5fkWRpoCAApA0hQAAHgN20hTVzcAgGveeecd3XPPPVqzZo1Onz6t06dPa9WqVerUqZOmTJni6fAKzbYQlA+/KgAABSBpCgAAvAZJUwDwDuPHj5dhGKpSpYqeeeYZPfPMM7rppptkGIZeeeUVT4dXaGZ5PiNNAQAFYE5TAAAAAICdY8eOqUyZMvr1119VrFgxSdLo0aNVqVIlnThxwsPRFZ6tPJ+kKQCgIIw0BQAAXsMwLG7ZAACuad26tUqUKGEmTCWpWLFiKl68uNq0aePByFxjZaQpAMBBjDQFAABewyqLrHLtQdbV8wEA0oMPPqh+/fqpR48e6tKliyTp008/1ZEjR/Tggw/qxx9/NNu2aNHCU2E67fJIU8/GAQDwfiRNAQAAAAB2evXqJYvFotmzZ2v27Nl2x7p162Z+b7FYlJGR8U+HV2jmSFOypgCAApA0BQAAXsMdCzmxEBQAuIdt0aTrifXSUFOq8wEABSFpCgAAvIY75iRlTlMAcN3u3bs9HcJVYSvP9yVrCgAoAElTAAAAAICd6OhoT4dwVbAQFADAUSRNAQCA16A8HwC8x5IlS7R8+XIdOnTIrlTfYrFoxowZHoys8AwzaerhQAAAXo+kKQAA8BqU5wOAd0hMTNSYMWNy7DcM45pOmmYatjlN+V0BAMgfSVMAAAAAgJ13331XhmEoOjpa0dHR102S0TanKeX5AICCkDQFAABew3BDeT4jTQHAdRkZGapcubL+/vtvT4fiVrbyfF8fDwcCAPB6/KoAAABew5BkGC5unr4JALgOPPXUUzp48KBWr17t6VDcymrN+nq9jJwFAFw9jDQFAAAAANgZPHiw5syZo2bNmqlkyZIKDg42j1ksFu3cudOD0RWe1VwIiqQpACB/JE0BAIDXsMoii1x7kLW6eD4AQHrssce0detWGYah48eP6/jx4+axa3mUZqaZNPVwIAAAr0fSFAAAeA3DsLg8JylzmgKA67766itJUrNmzRQTE6MiRa6PR0eDhaAAAA5iTlMAAHBDGz9+vBo2bKgSJUooPDxcnTp10rZt2+zanD9/XgMGDFCpUqVUvHhxde7cWYcOHbJrk5ycrA4dOigoKEjh4eF67rnnlJGRYddmxYoVql+/vvz9/VWlShXNmjXrat8eABRK2bJlVa1aNf3000/673//q/fff99uu1aZ5fkMNQUAFICkKQAA8BpWw+KWzRk//PCDBgwYoNWrV2vJkiW6ePGi2rZtqzNnzphtnnnmGX3zzTf67LPP9MMPP+jAgQO67777zOOZmZnq0KGDLly4oJUrV+qDDz7QrFmzNGLECLPN7t271aFDB7Vu3VobN27UoEGD9Mgjj2jx4sWuv3EA4GaTJ0/W/v37NXfuXJ0+fdrT4biN1Rxp6tk4AADe7/qosQAAANcFw7hcOulKH85YtGiR3etZs2YpPDxcGzZsUIsWLXTy5EnNmDFDs2fP1m233SZJev/99xUXF6fVq1erSZMm+u677/TXX39p6dKlioiIUN26dTVmzBi98MILSkxMlJ+fn6ZNm6bY2Fi98cYbkqS4uDj9/PPPmjhxohISEly7aQBwsw4dOkiSunXrluOYxWLJMZL+WsFCUAAARzHSFAAAXJfS0tLstvT0dIfOO3nypCQpLCxMkrRhwwZdvHhRbdq0MdtUr15dFStW1KpVqyRJq1atUu3atRUREWG2SUhIUFpamjZv3my2yd6HrY2tDwDwJoZh5Ltdq6xWFoICADiGkaYAAMBruHMhqAoVKtjtHzlypBITE/M912q1atCgQWrWrJlq1aolSUpJSZGfn59CQ0Pt2kZERCglJcVskz1hajtuO5Zfm7S0NJ07d06BgYGO3yQAXGUjR470dAhXhW2kqYWRpgCAApA0BQAAXsOdSdO9e/cqODjY3O/v71/guQMGDNCmTZv0888/uxQDAFzrrt+kadZXX4aaAgAKQNIUAABcl4KDg+2SpgUZOHCg5s+frx9//FHly5c390dGRurChQtKTU21G2166NAhRUZGmm3Wrl1r19+hQ4fMY7avtn3Z2wQHBzPKFIBXOnbsmN5++22tX79ektSwYUMNGDBApUqV8nBkhWcYlOcDABxD0hQAAHgNq2GRxcWRplYnzzcMQ08++aS++uorrVixQrGxsXbHGzRooKJFi2rZsmXq3LmzJGnbtm1KTk5WfHy8JCk+Pl4vv/yyDh8+rPDwcEnSkiVLFBwcrBo1aphtFi5caNf3kiVLzD4AwJvs3btXTZs21YEDB8x9Cxcu1PTp07Vy5Uq7D5euJbaRppTnAwAKwkJQAADAaxiGezZnDBgwQB999JFmz56tEiVKKCUlRSkpKTp37pwkKSQkRA8//LAGDx6s5cuXa8OGDerTp4/i4+PVpEkTSVLbtm1Vo0YN9ejRQ7///rsWL16s4cOHa8CAAea0AP3799euXbv0/PPPa+vWrXrnnXf06aef6plnnnHrewgA7jB06FDt379fFotF1atXV/Xq1WWxWLR//34NGzbM0+EVWqa5EBRJUwBA/kiaAgCAG9rUqVN18uRJtWrVSlFRUeb2ySefmG0mTpyou+66S507d1aLFi0UGRmpL7/80jzu6+ur+fPny9fXV/Hx8erevbt69uyp0aNHm21iY2O1YMECLVmyRDfffLPeeOMNTZ8+XQkJCf/o/QKAI5YsWaLAwECtW7dOmzdv1ubNm7V27Vr5+/tr8eLFng6v0KyU5wMAHER5PgAA8BpZI0VdXQjK2fYFnxAQEKApU6ZoypQpebaJjo7OUX5/pVatWum3335zLkAA8IDjx4+rWrVqqlevnrmvfv36qlSpkv7++28PRuYag4WgAAAOYqQpAADwGoZhccsGAHBNZGSktm/frm+++cbcN2/ePG3fvt1c4O5aZBtpypymAICCkDQFAAAAANjp2LGjLl68qE6dOqlEiRIqUaKE7r33XmVmZuruu+/2dHiFRnk+AMBRJE0BAIDXMNy0AQBcM3bsWNWsWVOGYejMmTM6c+aMDMNQzZo1NWbMGE+HV2hWa9ZXFoICABSEOU0BAIDXcEd5PeX5AOC6kiVLav369ZozZ47WrVsnSWrYsKEeeugh+fv7ezi6wmOkKQDAUSRNAQAAAAA5+Pv7q3fv3urdu7enQ3Gby0lTsqYAgPxRng8AALwH9fkA4FEzZsxQpUqVNH369BzHpkyZokqVKmnmzJkeiMw9rJd+R5A0BQAUhKQpAADwHpfK813ZRHk+ABTaRx99pL179+qBBx7Icaxr167at2+fZs2aVai+p0yZopiYGAUEBKhx48Zau3Ztvu1TU1M1YMAARUVFyd/fXzfddJMWLlxYqGvbGLaRpjwJAwAKQHk+AAAAAECStGXLFsXExCgkJCTHsZIlSyomJkZbt251ut9PPvlEgwcP1rRp09S4cWNNmjRJCQkJ2rZtm8LDw3O0v3Dhgu644w6Fh4fr888/V7ly5bRnzx6FhoYW5rZMmZeSphZGmgIACkDSFAAAeA3DyNpc7QMAUDipqakqUaJEnscNw1BaWprT/U6YMEGPPvqo+vTpI0maNm2aFixYoJkzZ+rFF1/M0X7mzJk6fvy4Vq5cqaJFi0qSYmJinL7ulazWrK++JE0BAAVwKGk6evRohzscMWJEoYMBAAA3NrPE3sU+AACFExERod27d2vTpk2qVauW3bFNmzZp9+7dKleunFN9XrhwQRs2bNCQIUPMfT4+PmrTpo1WrVqV6znz5s1TfHy8BgwYoP/9738qU6aMunbtqhdeeEG+vr452qenpys9Pd18nVdil4WgAACOcihpmpiY6HD5AklTAAAAALg2NW/eXLNnz9bdd9+tSZMmqXnz5rJYLPrpp5/0zDPPyDAMtWjRwqk+jx49qszMTEVERNjtj4iIyLPUf9euXfr+++/VrVs3LVy4UDt27NATTzyhixcvauTIkTnajx8/XqNGjSowFsNcCMqpWwAA3IAcSppWrFiROV8AAMDV546FnBhpCgCF9uyzz+qTTz7Rnj17dO+999odMwxDRYoU0eDBg696HFarVeHh4Xr33Xfl6+urBg0aaP/+/XrttddyTZoOGTLELq60tDRVqFAhRzvmNAUAOMqhpGlSUtJVDgMAAIA5TQHA0+rVq6epU6fq8ccfV2Zmpt0xX19fTZ06VfXq1XOqz9KlS8vX11eHDh2y23/o0CFFRkbmek5UVJSKFi1qV4ofFxenlJQUXbhwQX5+fnbt/f395e/vX2Asl8vznboFAMANqNALQZ05c0Z//PGHfH191ahRI3fGBAAAAADwkEceeUTNmzfXjBkz9Ndff8kwDNWsWVN9+/ZV9erVne7Pz89PDRo00LJly9SpUydJWSNJly1bpoEDB+Z6TrNmzTR79mxZrVb5+PhIkrZv366oqKgcCVNn2D5Y8yVrCgAogE9hTho7dqwiIiJ06623atCgQfr0009VqVIlzZ49293xAQCAG4nhpg0A4JJq1arp1Vdf1fz587VgwQK9+uqrhUqY2gwePFjvvfeePvjgA23ZskWPP/64zpw5oz59+kiSevbsabdQ1OOPP67jx4/r6aef1vbt27VgwQKNGzdOAwYMcOm+rJTnAwAc5PRI02nTpuVY7On222/X3r17NXfuXHXt2tVtwQEAgBuLYVhkuDgnqavnA8CNateuXapUqZLD7Xfv3q3Y2FiH2nbp0kVHjhzRiBEjlJKSorp162rRokXm4lDJycnmiFJJqlChghYvXqxnnnlGderUUbly5fT000/rhRdecO6mrkB5PgDAUU4nTSdPniwfHx9NmDBBgwYNkiSVKlVK5cqV0++//+7u+AAAAAAA/4Bq1arpnnvuUbdu3dSuXTsFBATkaHPhwgUtWrRI//3vf/W///1PFy5ccLj/gQMH5lmOv2LFihz74uPjtXr1aof7d4TVmvXVh5GmAIACOJ003blzp2rWrKmnnnrKTJpKUlhYmP766y93xgYAAG5ElNcDgEeUK1dOX375pb766isVKVJENWrUUExMjEqUKKHTp09rz5492rx5sy5evCjDMBQdHe3pkJ12eaQpSVMAQP6cTpqGhITowIEDOn/+vLkvNTVV27dvV0hIiFuDAwAANxbK8wHAc/7++2/NmDFD77zzjjZt2qTff/8912rC2rVr64knnlDfvn09EKVrzKRpoVb3AADcSJxOmrZs2VJffvmlGjduLClr5GmjRo107tw53XXXXW4PEAAAAABw9RUtWlT9+/dX//799ddff+nnn3/W33//rZMnTyo4OFhVq1ZV8+bNVaNGDU+HWmjWS9UMjDQFABTE6aTp2LFjtWTJEv3555+yWCw6evSojhw5opCQECUmJl6FEAEAwA3DkOvl+ZT3A4DLatSocU0nR/NiUJ4PAHCQ00UJ1apV0/r169WrVy/FxcUpLi5OvXr10po1a1S9evWrESMAALhhWNy0AQCQU6bVljT1cCAAAK/n9EhTSapSpYref/99d8cCAAAAAMBVYyvPtzDSFABQgEJNf/3777+ra9euql27tmrXrq1u3bpp48aNbg4NAADccAw3bQAA5MK2EJQvQ00BAAVweqTpF198oQcffFBWq9WcD+avv/7Sp59+qrlz56pz585uDxIAANwgmNMUAHAVGeZCUJ6NAwDg/Zweafriiy8qMzNTISEhuvfee3XvvfcqNDRUmZmZGjJkyNWIEQAAAAAAl1lZCAoA4CCnR5ru27dPISEh2rJliyIiIiRJhw8fVrVq1bRv3z63BwgAAG4ghiVrc7UPAIBbLF++XKtXr1bJkiXVtWtXpaamKiIiQv7+/p4OrVBsC0GRMwUAFMTppGnjxo116NAhM2EqSeHh4YqMjFRkZKRbgwMAADcWw7hcOulKHwAA15w7d0533323vv/+e0lZz4Hh4eF64IEHNG7cOL3wwgsejrBwLpfnkzUFAOTPofL85ORkcxsyZIj27dun4cOHa9OmTdq0aZNeeukl7d+/n/J8AAAAALgODB8+XMuWLZNhGOZaFh06dJCfn58WLFjg4egKj4WgAACOcmikaWxsbI5948eP1/jx483XhmGoffv2ysjIcF90AADgxsJCUADgFT799FMFBgZq1apVqlu3riTJ399f0dHR2r59u2eDc4EtacpAUwBAQRxKmhoO1rk52g4AACBXzGkKAF7h8OHDqlGjhurUqWO3v2jRokpNTfVMUG5gpTwfAOAgh5Kmy5cvv9pxAAAAAAC8RFRUlLZv366dO3ea+zZu3KgtW7aoYsWKHoys8KzWy4N8SJoCAAriUNK0ZcuWVzsOAAAAWYyszdU+AACuueeee/TWW2+pVq1aslgs+u2339SoUSMZhqF77rnH0+EVitXInjT1YCAAgGuCQ0nTKx0+fFgLFizQgQMHlJmZaXdsxIgRbgkMAADcgJjTFAC8wpgxY/Tjjz/q999/lySlp6dLkurUqaNRo0Z5MrRCyzbQVD5kTQEABXA6abpu3TrdcccdOnXqVK7HSZoCAAAAwLUtODhYa9eu1Zw5c7R27VpJUsOGDfXQQw/Jz8/Pw9EVjv1IU5KmAID8OZ00femll5SWlpbrMQu/eAAAgCtYCAoAvMKHH36oMmXKqGfPnurZs6e5PykpSWfPnlWNGjU8GF3hZF+3mIGmAICC+Dh7wtq1axUQEKC///5bktSkSROtWrVKERER5ieQAAAAhWK4aQMAuKR3794aM2ZMjv0PPfSQ6tSp44GIXJfJSFMAgBOcTpqePn1a1atXV+XKlWWxWJSRkaHGjRsrPDxcTzzxxNWIEQAAAADgBY4fPy7DuDY/ncpenk/OFABQEKfL80NCQnT+/HlJUmhoqDZv3qxPPvlEO3bsuGZ/eQIAAC/BQlAA4FGVKlUyv//tt9/sXp89e1ZHjhxRqVKlPBGaywzr5e99yZoCAArgdNI0NjZWmzdv1vnz51W/fn0tW7ZMXbt2laRrcl4bAADgRUiaAoBHJSUlScparyI9Pd18nd199933zwblJiwEBQBwhtNJ00GDBmndunXav3+/xo0bp7Zt2+rkyZMqVqyYXn/99asRIwAAAADgHzBy5EhJ0qhRo1S+fHk9/PDD5rGgoCBVr15dd911l6fCcwnl+QAAZzidNO3atas5srRy5crat2+ftm3bpkqVKik0NNTd8QEAgBuJYcnaXO0DAFAotqTp8uXLVbNmTfP19cC2EJTFkjWSFgCA/DidNL1SsWLFVKdOHf3rX/+SxWLRF1984Y64AADADchiZG2u9gEAcM2KFSs8HYLb2QaaUpoPAHCEy0lTScrMzNTXX3/Np3UAAAAAcB3IyMjQsGHDNHfuXB04cEBW6+VVlCwWizIyMjwYXeHYyvNZBAoA4Ai3JE0BAADcgoWgAMArjBkzRq+99pqnw3Ar66XfD+RMAQCO8PF0AAAAAAAA7zJnzhxZLBZ1795dklS+fHm1b99eYWFhGj58uIejKxzrpawp5fkAAEc4PNI0OTk5z2Pp6eluCQYAAAAA4HnJyckqX768PvzwQ3300UcqX7685s2bp+joaJ0/f97T4RWKrTzfh5wpAMABDidNY2JimLMUAABcVRa5YSEot0QCADe2IkWKqHTp0pIkPz8/HTp0SD4+PipatKhmzpyp//u///NwhM6zshAUAMAJTs1pahhMEna9uvem2ipiKerpMACPiFgV7OkQAI+4eOaCdLuno7iCYcnaXO0DAOCS8PBwpaSkSJKio6O1Y8cOxcXFKSkpSSVLlvRwdIVjjjRlqCkAwAEOJ01Hjhx5NeMAAAAAAHiJOnXqaN68edq6das6d+6sV155Rdu2bZMk3XPPPR6OrnAMyvMBAE4gaQoAALyHcWlztQ8AgEvmzp2r9PR0FStWTGPHjlWxYsW0Zs0a1alTR0OHDvV0eIVCeT4AwBk+ng4AAADAZLhpc9KPP/6ojh07qmzZsrJYLPr666/tjvfu3VsWi8Vuu/POO+3aHD9+XN26dVNwcLBCQ0P18MMP6/Tp03Zt/vjjDzVv3lwBAQGqUKGCXn31VeeDBYB/QEBAgEJCQlSkSBH5+Pho2LBhmjdvnsaOHXvNLgSVeSlrylodAABHkDQFAAA3vDNnzujmm2/WlClT8mxz55136uDBg+Y2Z84cu+PdunXT5s2btWTJEs2fP18//vij+vXrZx5PS0tT27ZtFR0drQ0bNui1115TYmKi3n333at2XwDgTgcPHtSzzz6rmJgYT4dSKFbK8wEATnBqISgAAICryWJkba724ax27dqpXbt2+bbx9/dXZGRkrse2bNmiRYsWad26dbrlllskSW+99Zbat2+v119/XWXLltXHH3+sCxcuaObMmfLz81PNmjW1ceNGTZgwwS65CgCedOzYMfXp00c//PCDoqOj9e6776pu3boaMmSIpk2bpgsXLng6xEKzrWvsS9YUAOAARpoCAADv4aHyfEesWLFC4eHhqlatmh5//HEdO3bMPLZq1SqFhoaaCVNJatOmjXx8fLRmzRqzTYsWLeTn52e2SUhI0LZt23TixImrEzQAOOn555/X/PnzderUKW3atEldunRRt27dNHnyZKWnp8swDN1+++2eDrNQLo80JWkKACgYI00BAMB1KS0tze61v7+//P39C9XXnXfeqfvuu0+xsbHauXOnhg4dqnbt2mnVqlXy9fVVSkqKwsPD7c4pUqSIwsLClJKSIklKSUlRbGysXZuIiAjzWMmSJQsVGwC405IlS2SxWHTrrbdKkn766Sft27dPhmHovvvu05AhQ9SgQQMPR1k4toWgyJkCABxRqKRpenq6Zs+erdWrVysyMlIPP/ywkpKSVKtWLYWFhbk7RgAAcKNwx0jRS+dXqFDBbvfIkSOVmJhYqC4ffPBB8/vatWurTp06qly5slasWHHNjrgCgNykpKSoYsWK+uGHHyRJsbGxSk5O1gcffKAePXp4ODrX2BaCYqQpAMARTidNjx07platWumvv/6SJDVu3FhNmzZV+/bt9dJLLxX6YQQAAMCdc5ru3btXwcHB5v7CjjLNTaVKlVS6dGnt2LFDt99+uyIjI3X48GG7NhkZGTp+/Lg5D2pkZKQOHTpk18b2Oq+5UgHgn5aRkaGoqCjzdWRkpJKTk9WtWzcPRuUexqXyfOY0BQA4wuk5TZ9//nlt3rxZAQEB5i+dNm3aKCgoSN9++63bAwQAACiM4OBgu82dSdN9+/bp2LFjZmIhPj5eqamp2rBhg9nm+++/l9VqVePGjc02P/74oy5evGi2WbJkiapVq0ZpPgCv8tdff+m2227TbbfdZg6WadOmjbnvWh1hT3k+AMAZTo80nT9/vkJCQrRlyxaVLVtWkuTr66vo6Gjt2rXL7QECAIAbiGHJ2lztw0mnT5/Wjh07zNe7d+/Wxo0bFRYWprCwMI0aNUqdO3dWZGSkdu7cqeeff15VqlRRQkKCJCkuLk533nmnHn30UU2bNk0XL17UwIED9eCDD5r/X+ratatGjRqlhx9+WC+88II2bdqkN998UxMnTnTtfgHAzU6dOmWW59vYXhuGIcs1mnVkISgAgDOcTpqmpqaqRo0aOcrIMjMzderUKbcFBgAAbkBunNPUGevXr1fr1q3N14MHD5Yk9erVS1OnTtUff/yhDz74QKmpqSpbtqzatm2rMWPG2I1e/fjjjzVw4EDdfvvt8vHxUefOnTV58mTzeEhIiL777jsNGDBADRo0UOnSpTVixAj169ev8PcKAG5WsWLFazYpWpDLSVMPBwIAuCY4nTSNjo7W5s2b9fPPP5v7vvnmG23btk033XSTW4MDAAD4J7Rq1cqcdig3ixcvLrCPsLAwzZ49O982derU0U8//eR0fADwT0lKSvJ0CFeN1Zr1lZGmAABHOD2n6UMPPaSMjAy1bNlSFotFa9asUadOnWSxWPTQQw9djRgBAMANwrYQlKsbAABXojwfAOAMp5Omw4YNU7t27WQYht3Wtm1bDRky5GrECAAAbhSGmzYAAK5gJk2dfgoGANyInC7P9/Pz04IFC/Tjjz9q7dq1kqSGDRuqZcuWbg8OAAAAAAB3sM3CwkhTAIAjnE6a2rRo0UItWrRwZywAAOBG547yekaaAgBykWnN+gVxvS50BQBwL6eTprfddluexywWi5YtW+ZSQAAA4AbmjvJ6kqYAgFxcntPUw4EAAK4JTidNV6xYIYvFYrfCrO01n9gBAAAAwPXjzJkz+uOPP+Tr66tGjRp5OhyXXBpoKl+eWwEADnA6adqzZ0+75OjJkye1YsUKnTp1Sg8++KBbgwMAADcYRpoCgNcYO3asXnnlFZ07d06NGzfWoEGD9OKLL2rs2LHq2rWrp8NzmmGONCVpCgAomNNJ01mzZuXYd/ToUdWpU0fly5d3R0wAAOAGZXHDnKYuz4kKANC0adM0YsQIu32333679u7dq7lz516TSVPbSFNypgAAR/i4o5PSpUurSpUquSZUAQAAAADXlsmTJ8vHx0eTJk0y95UqVUrlypXT77//7rnAXJDJSFMAgBOcHmk6evRou9eZmZnavn27fv75Z5UsWdJtgQEAAAAAPGPnzp2qWbOmnnrqKQ0aNMjcHxYWpr/++stzgbnALM93y9AhAMD1zumkaWJiYp4LPt11110uBwQAAG5gzGkKAF4hJCREBw4c0Pnz5819qamp2r59u0JCQjwYWeFZGWkKAHCC00nTihUr2iVNLRaLwsPDdfvtt2vIkCFuDQ4AAAAA8M9r2bKlvvzySzVu3FhS1sjTRo0a6dy5c9fsYBmrNesrSVMAgCOcTpomJSVdhTAAAABYCAoAvMXYsWO1ZMkS/fnnn7JYLDp69KiOHDmikJAQJSYmejq8Qrk80tTDgQAArglOzeZy8eJFVa5cWfXr1zfngwEAAHArw8UNAOCyatWqad26derVq5fi4uIUFxenXr16ac2aNapevbqnwysUyvMBAM5waqRp0aJFderUKRUvXjzPeU0BAAAAANe27du366abbtL777/v6VDcxnrpgzWeZQEAjnB63cDevXtr27Zt2rRp09WIBwAA3MhcHWXKaFMAcIu4uDg1a9ZM7777rk6ePOnpcNzCNtLU1+mnYADAjcjpOU1TUlIkSQ0bNlTr1q0VERFhflJnsVg0Y8YM90YIAABuGMxpCgDewTAMrVq1SqtXr9agQYN0zz33qFevXkpISLhmR2raRppSng8AcITTSdOPPvpIFotFhmFo0aJF5i9MwzBImgIAAADAdWDp0qX65JNP9OWXX+rYsWP65JNP9OmnnyoyMlI9evTQK6+84ukQnWYwpykAwAkOJ01Hjx6t8uXLq2XLllczHgAAcCNzR3k9I00BwGW33XabbrvtNr3zzjtmAvXrr7/WwYMH9dprr12TSdPMS0NNyZkCABzhcNI0MTFRTZo00cqVK69mPAAA4AZGeT4AeJeLFy/q1KlTOnXqlNLT0z0djksozwcAOIMpsAEAAAAAdr755ht169ZN4eHh6tKli7788kudO3dOlSpV0siRIwvV55QpUxQTE6OAgAA1btxYa9eudei8uXPnymKxqFOnToW6ro1hLgRF0hQAUDCn5jRNT09XcnJyvm0qVqzoUkAAAOAGRnk+AHiFe+65x1zLIjg4WA888IB69eqlW2+9tVD9ffLJJxo8eLCmTZumxo0ba9KkSUpISNC2bdsUHh6e53lJSUn697//rebNmxf2VkxWg/J8AIDjnEqabty4UbGxsXket1gsysjIcDkoAABwgyJpCgBewWKx6I477lCvXr107733KiAgwKX+JkyYoEcffVR9+vSRJE2bNk0LFizQzJkz9eKLL+Z6TmZmprp166ZRo0bpp59+UmpqqksxUJ4PAHCGU0lT6XJJAwAAAADg+rR3716VLVvWLX1duHBBGzZs0JAhQ8x9Pj4+atOmjVatWpXneaNHj1Z4eLgefvhh/fTTT/leIz093W7O1bS0tBxtbAtBUZ0PAHCEU0nTcuXK6eGHH75asQAAgBscC0EBgOd8+OGHKlOmjNq1a6elS5fm27Znz54O93v06FFlZmYqIiLCbn9ERIS2bt2a6zk///yzZsyYoY0bNzp0jfHjx2vUqFH5trENAGKkKQDAEU4lTcuXL1/oSb8BAAAKRHk+AHhM7969FR8fr3bt2ql3796y5JFctFgsTiVNnXXq1Cn16NFD7733nkqXLu3QOUOGDNHgwYPN12lpaapQoYJdG7M8n6GmAAAHOF2eDwAAAAC4PmWfji2vqdmcnbKtdOnS8vX11aFDh+z2Hzp0SJGRkTna79y5U0lJSerYsaO5z2q1SpKKFCmibdu2qXLlynbn+Pv7y9/fP984rAbl+QAAxzmcNK1YsaKioqKuZiwAAOBGx0hTAPAYW2Lyyu9d5efnpwYNGmjZsmXq1KmT2f+yZcs0cODAHO2rV6+uP//8027f8OHDderUKb355ps5RpA6ioWgAADOcDhpmpSUdBXDAAAAYE5TAPAWo0ePVoUKFczV7m1WrVqlEydOqH379k71N3jwYPXq1Uu33HKLGjVqpEmTJunMmTNm/z179lS5cuU0fvx4BQQEqFatWnbnh4aGSlKO/c6wWpnTFADgOMrzAQAAAAB2EhMT1aRJkxxJ08GDB2vt2rXKzMx0qr8uXbroyJEjGjFihFJSUlS3bl0tWrTIXBwqOTlZPj4+bos/N7byfHKmAABHkDQFAADeg/J8APBa586d08GDBwt9/sCBA3Mtx5ekFStW5HvurFmzCn1dG1t5vi9ZUwCAA0iaAgAAr0F5PgB4lq+vryTJYrFozZo15uvsbKNDrzW2Bax8WAkKAOAAkqYAAAAAAEmXE4sWi8X8/kr9+vX7J0NyG8rzAQDOIGkKAAC8B+X5AOBR77//viSpT58+qly5soYPH24eCwoKUvXq1VW7dm1PheeSTGvWVxaCAgA4gqQpAADwHiRNAcCjevXqJUlavny5qlSpYr6+HthGmlKdDwBwBElTAAAAAICSk5Pl7++viIgIjR492tyXm4oVK/6TobmFbboBFoICADiCpCkAAPAalkubq30AAJwXExOj+Ph4/fLLL4qNjc2zncViUUZGxj8YmXtYL1UiWEiaAgAcQNIUAAB4D8rzAcCjbKMx81oE6lp2uTyfpCkAoGAkTQEAAAAAWr58uYKDg83vrzfMaQoAcAZJUwAA4DUsRtbmah8AAOe1bNky1++vF1Zr1lcfsqYAAAf4eDoAAAAAk+GmDQDgkkWLFmn06NHavn27Tp06pY4dOyokJEQtWrTQvn37PB1eoVCeDwBwBklTAAAAAICd1157TaNHj1ZISIj+85//aMGCBTp16pR++eUXvfjii54Or1BsC0Ex0BQA4AiSpgAAwLswyhQAPO6vv/5S+fLlFRERoR9++EHBwcGaM2eOAgICtGLFCk+HVygGI00BAE4gaQoAALyGbU5TVzcAgGtOnDihMmXKSJK2bt2qW265RV26dFFcXJyOHj3q4egKJ/NS0pScKQDAESRNAQAAAAB2wsLCtH37ds2ZM0dJSUmqVauWJOnkyZMKDQ31bHCFZCvP96U+HwDgAJKmAADAe7AQFAB4hdatW+vUqVPq3r27rFarEhISdObMGe3du1dVq1b1dHiFwkJQAABnFPF0AAAAADbuKK+nPB8AXDdhwgSdO3dOO3bsUMeOHdWuXTv98ssvatiwoR588EFPh1col+c09XAgAIBrAklTAAAAAICdiIgIffnll3b7mjVrpp9++slDEbnOas36amGkKQDAASRNAQCA93BHeT0jTQHALY4dO6a3335b69evlyQ1bNhQAwYMUKlSpTwcWeFkUp4PAHACSVMAAOA1KM8HAO+wd+9eNW3aVAcOHDD3LVy4UNOnT9fKlStVvnx5D0ZXOLbyfF9W9gAAOIBfFwAAAAAAO0OHDtX+/ftlsVhUvXp1Va9eXRaLRfv379ewYcM8HV6hWC99qEZ5PgDAESRNAQCA9zDctAEAXLJkyRIFBgZq3bp12rx5szZv3qy1a9fK399fixcv9nR4hWKlPB8A4ASSpgAAwHt4KGn6448/qmPHjipbtqwsFou+/vpr+7AMQyNGjFBUVJQCAwPVpk0b/f3333Ztjh8/rm7duik4OFihoaF6+OGHdfr0abs2f/zxh5o3b66AgABVqFBBr776qvPBAsA/4Pjx46pUqZLq1atn7qtfv74qVaqkEydOeDCywrONNPUhZwoAcABJUwAAcMM7c+aMbr75Zk2ZMiXX46+++qomT56sadOmac2aNSpWrJgSEhJ0/vx5s023bt20efNmLVmyRPPnz9ePP/6ofv36mcfT0tLUtm1bRUdHa8OGDXrttdeUmJiod99996rfHwA4KzIyUtu3b9c333xj7ps3b562b9+uyMhID0ZWeFYrI00BAI5jISgAAOA1PLUQVLt27dSuXbtcjxmGoUmTJmn48OG65557JEkffvihIiIi9PXXX+vBBx/Uli1btGjRIq1bt0633HKLJOmtt95S+/bt9frrr6ts2bL6+OOPdeHCBc2cOVN+fn6qWbOmNm7cqAkTJtglVwHAG3Ts2FFTp05Vp06dFBQUJEk6e/asJOnuu+/2ZGiFZpbnM9QUAOAARpoCAADv4cby/LS0NLstPT29UCHt3r1bKSkpatOmjbkvJCREjRs31qpVqyRJq1atUmhoqJkwlaQ2bdrIx8dHa9asMdu0aNFCfn5+ZpuEhARt27btmi11BXD9Gjt2rGrWrCnDMHTmzBmdOXNGhmGoZs2aGjNmjKfDK5TLc5p6OBAAwDWBkaYAAOC6VKFCBbvXI0eOVGJiotP9pKSkSJIiIiLs9kdERJjHUlJSFB4ebne8SJEiCgsLs2sTGxubow/bsZIlSzodGwBcLSVLltT69es1e/ZsrV+/XpLUsGFDPfTQQ/L39/dwdIVzeU5TsqYAgIKRNAUAAF7DYhiyGK7V59vO37t3r4KDg8391+pDPgB4wsmTJyVJffr0UZ8+fTwcjXtcntPUw4EAAK4JlOcDAADv4cby/ODgYLutsElT24Inhw4dstt/6NAh81hkZKQOHz5sdzwjI0PHjx+3a5NbH9mvAQCedvbsWXXq1ElhYWEKCwvTvffeq3Pnznk6LLewledbGGkKAHAASVMAAIB8xMbGKjIyUsuWLTP3paWlac2aNYqPj5ckxcfHKzU1VRs2bDDbfP/997JarWrcuLHZ5scff9TFixfNNkuWLFG1atUozQfgNSZOnKh58+bJMAwZhqF58+Zp4sSJng7LLWzl+b4kTQEADiBpCgAAvIbFcM/mrNOnT2vjxo3auHGjpKzFnzZu3Kjk5GRZLBYNGjRIY8eO1bx58/Tnn3+qZ8+eKlu2rDp16iRJiouL05133qlHH31Ua9eu1S+//KKBAwfqwQcfVNmyZSVJXbt2lZ+fnx5++GFt3rxZn3zyid58800NHjzYTe8eALhuzpw5slgsaty4sRo3bizDMDRnzhxPh+UWhm0hKJ6CAQAOYE5TAADgPbKV17vUh5PWr1+v1q1bm69ticxevXpp1qxZev7553XmzBn169dPqampuvXWW7Vo0SIFBASY53z88ccaOHCgbr/9dvn4+Khz586aPHmyeTwkJETfffedBgwYoAYNGqh06dIaMWKE+vXrV/h7BQA3S05OVlRUlFauXCmr1aqKFStqz549ng7LLWwjTSnPBwA4gqQpAAC44bVq1cocgZQbi8Wi0aNHa/To0Xm2CQsL0+zZs/O9Tp06dfTTTz8VOk4AuNpOnz6tWrVqyWKxyNfXVxUrVtTatWs9HZZbZJoLQZE0BQAUjKQpAADwGoUtr7+yDwBA4R05ckQffvih+b0k/fe//7X7cKlnz54eic0VtoWgfMiZAgAcQNIUAAB4Dw+V5wMALtu1a5f69Oljt693797m9xaL5ZpMmtpyviwEBQBwBElTAAAAAIApv+lKrmW2kabMaQoAcARJUwAA4DUozwcAz1q+fLmnQ7hqKM8HADiDpCkAAPAelOcDgEe1bNnS0yFcNZfWgZIPWVMAgAN8PB0AAAAAAABXGyNNAQDOYKQpAADwKpTXAwCuhstJU7KmAICCkTQFAADewzAuL2/sSh8AAFzBas36StIUAOAIyvMBAAAAANc9g5GmAAAnMNIUAAB4DYvhenk+5f0AgNxkXkqakjMFADiCkaYAAMB7GG7aAAAu27Ztm3r16qVq1aqpY8eOWr16tUaPHq1NmzZ5OrRCsV76/cBIUwCAIxhpCgAAAACw8/vvv6t58+Y6c+aMDMNQqVKlFBAQoMTERB0+fFhvv/22p0N0mq0839eHpCkAoGCMNAUAAF7DYnXPBgBwzYsvvqjTp0+rQYMG5r66desqLCxMy5cv92BkhXd5pKln4wAAXBtImgIAAO9BeT4AeIVffvlF5cqV06pVq+z2V6hQQXv37vVQVK6xmnOakjUFABSM8nzgKusy8JCatT+pClXSdeG8j/5aH6QZL0dp384As01Rf6v6jTygVnenqqi/oQ0rSuitIeWUerSoByMHCnbmg3Sd/+GiMvdYJX+L/Gr7qvgT/ioS7Wu2SXvlnC6sz1DmEUOWoGxtYrK1mXBeF//IUMYuq4rE+KjUh8VzXCt9dYbOTE9Xxu5Myc8iv7q+KvFUgHyj+PwPAAB3y8zMVPHixeXr62u3/8iRI7Jar80h/ZmXhpoy0hQA4AiPPWlaLJZ8t8TERCUlJeV5fPXq1ZKkWbNmmft8fHwUFRWlLl26KDk52e56rVq1ksVi0SuvvJIjlg4dOpjXzN5+0KBBOc6fO3eu3bmTJk1STExMjj7PnTunsLAwlS5dWunp6TlizWtLSkpSYmJirseqV6+eIx6LxSJ/f3+VK1dOHTt21JdffunsHwWusjrxZ/TNrNIadFdVDXmwknyLGBr3/+3deVwU9f8H8NeysCz3IcihCCIil4AnoplHGJ7lkVepeOeVGmlqKnhkVj/P+pqaqWhZal6ZqaUkpaZ5l4p3qIngLSg3u5/fH7QT6y64yyFIr+fjMQ/dmc985j3Dws6893N88xfMLVRSmREzbqJZu3S8/6YnJnSvA0eXPMSsvFpxQRMZKPdkPix7KOC4wgoOiy0h8oEH4zMhsv5t6mfqJ4ftVAs4rbeGwyJLCPFPGZV2c0CLzgooX9L/RYHqphoPJ2XCrJEcjmsK6lE/FHg4ObNcz4+ePZkom4WIiEonICAAFy9exPvvvw8ASE9Px4QJE3Dz5k0EBQVVcHQlIzgRFBERGaHCkqYpKSnSsmjRItja2mqtmzBhglR27969WttSUlK0xtbR7JucnIzNmzfjwoUL6Nmzp84xPTw8EBcXp7UuOTkZ8fHxcHNze2rMSqUS06ZNQ15e3lPLbt68GYGBgfDz88O2bdsAAL1799Y6h/DwcAwbNkxrnYeHBwAgMDBQ55wPHDigdQzNvleuXMHmzZsREBCAPn36YPjw4U+Nj56dqW94Y89GR1y7qMRfiRaYP74WXGrmoW5wFgDA0kaFyL73sXyGO/44aIPLpy2xINoDgU0y4dcwo4KjJyqewyIrWHRSwNRbDrO6cthNU0KdKpB3/t8vBSy7KqBoYAq5mwnM6slh/aY51LcEVCn/ZrZso5WwfE0BeQ39DzF551WACrB+0xymNQvqsXpdgfxLaoh8ZsiqFCHKZiEiolIZN24chBCIjY2FTCbDuXPnsHDhQshkMowZM6aiwysRNSeCIiIiI1RY93xXV1fp/3Z2dpDJZFrrAODu3bsAgGrVqulsK6zwvm5ubhgyZAjGjh2L9PR02NraSuU6d+6MjRs34uDBg2jRogUAYM2aNXj55Zd1Wqbq07dvX2zfvh0rVqzAqFGjii27cuVK9OvXD0IIrFy5Er1794aFhQUsLCykMgqFApaWlnrPzdTUtNhzBqC1b82aNdGsWTP4+flh8ODB6NWrFyIiIp56TvTsWdkWJJMePSzo6lQ3OBNmCoGT+22kMn9fVuLWDTP4N8rE+RNWFRInUUmoHxf8a2Kr/2FEZAlk78iD3F0GuYvhDyxmfnLABMjekQdlJzOILCBrdx4UTeSQmfLBh4iIqKz169cPN2/exKxZs5CZWdCzw8LCAtOnT0e/fv0qOLqS+XdM0woOhIiIngtVbiC427dvY+vWrZDL5Trj7ygUCrzxxhtYvXq1tC4uLg6DBw82qG5bW1tMnToVs2bNQkZG0S0Ar1y5gkOHDqFXr17o1asX9u/fj2vXrpXshIwUFRUFBweHIrvp5+TkID09XWuhZ0cmExgxMxlnjlji2oWCBLpj9Xzk5siQka79fn14xxSO1Z/eqpmoshBqgUeLsmEWLIdpHe33c+bmXNxum47bbR8h51A+7BdbQWZm+BOL3N0EDoss8XhZDm63eoQ77R5BfVvA7n3Lsj4NqmDsnk9EVHm8++67uHPnDo4cOYIjR47g7t27mDx5ckWHVWJqds8nIiIjPBdJ0+bNm8Pa2lprKSwtLQ3W1tawsrKCi4sL9u3bh9GjR8PKSreF3uDBg7Fx40ZkZGTg119/RVpaGjp37mxwLKNGjYJSqcSCBQuKLLNq1Sp06NABDg4OcHR0RGRkpFai1hCnT5/WOecRI0Y8dT8TExP4+vri6tWrerfPnTsXdnZ20qIZDoCejTEfJMPTLxtzR3pWdChEZe7RvGzk/6WC3WwLnW3KSDM4rrGCw2eWkNcyQdq0TIgcwzNbqntqpH+YDWVHMziuLKgHZkDae5kQ7IpdtYgyWoiIqExYWFigcePGEEJg2bJl2Lt3b0WHVGJqaSIoJk2JiOjpKqx7vjE2bNgAf3//Irfb2NjgxIkTyMvLw65du7Bu3TrMmTNHb9mQkBDUrVsXmzZtwr59+9C/f3+Ymhp+GczNzTFr1iy89dZbGDlypM52lUqFNWvWYPHixdK6fv36YcKECYiJiYGJiWF56nr16mH79u1a6woPNVAcIQRkRdwITJkyBdHR0dLr9PR0Jk6fkdFzbiCsXTre6VYHd1MU0vr7t02hMBewslVptTa1d87H/dv6J8UhqmzS52Uh52A+HJdaQV5d9++cibUMJtZywAMwC5Lj9suPkP1LPixeNuw9nrUpFzJrwGaMUlpnN8MEd199jLyzKiiCnouPMyIioufGgAEDsG7dOvzyyy8QQqBt27ZQq9UAgBUrVhjcW68y0XTP55CmRERkiOfiKdPDwwM+Pj5FbjcxMZG2+/v748qVKxg5ciS+/PJLveUHDx6MJUuWIDExEUeOHDE6nn79+mHevHl4//334eXlpbXtxx9/RHJyMnr37q21XqVSIT4+Hu3atTPoGAqFothzLopKpcKlS5fQpEkTvdvNzc1hbm5udL1UGgKj5ySjefs0THzNB7f+1r7+l/60RF6uDA1eeIQDO+0BADXrZMOlZh7OHWfXY6rchBB4ND8bOb/kF7QidTfgiyFNS8A8w5sDihwATz7gaA6lNrgaeg6URfd6ds8nIiq9Y8eOwdraGi1atMDIkSOhUqng5+eH8+fP43//+99zmjQt+NeEWVMiIjLAc9E931iTJ0/Ghg0bcOLECb3bX3/9dZw+fRpBQUEICAgwun4TExPMnTsXS5cu1ekGv3LlSvTp0wenTp3SWvr06YOVK1eW5HSMsmbNGjx48AA9evQo92ORYcZ8kIy23R/gw9GeyHpsAgfnPDg450GhLMj0ZD6S48dvHDF8xk2ENH8Mn/qZeGfh30g8ZslJoKjSezQvG9k/5sFupgVkljKo7qmhuqeGyC54KslPViNjTQ7yzqugSlUj9898PJyaBZm5DObh/35vl/+3GnkXVVDfExA5QN5FFfIuqiD+SayaNzdF/jk1Hq/MQf7fKuRdUCH9/SyYuMpg5ivXGxs9p4Qom4WIiErlxo0b8PLygkwmw6lTpxAQEIDExETUrl0bV65cqejwjFZ4OB92zyciIkM8Fy1N7927h9TUVK119vb2UCqVest7eHigW7duiImJwY4dO3S2Ozg4ICUlBWZmJe/63KlTJ4SFhWH58uVwcXEBANy5cwfff/89tm/fjqCgIK3yAwYMQLdu3XD//n04Ojo+tf78/Hydc5bJZNKxACAzMxOpqanIz8/HjRs3sHXrVixcuBAjR45EmzZtSnxuVLa6DLwHAJi3Rfvmct54D+zZWPBeWDbDHWoBTF9xFWbmAscSbPC/KTWeeaxExsraUjBZ2YPRmVrrbacpYdFJAZkCyP1DhcwNuVA/EjBxlEERKofj55Ywcfz3e7v0uVnIO6mSXt+PKphsz2mLNeRuMigam8JupgUyvspB5rocQCmDIkgOh4WWkCn54ENERFQecnJyAAAXL15EZGQkgIIhw27dulWRYZWIutD3aWxoSkREhngukqYRERE667755hv06dOnyH3efvtthIeH48iRI2jatKnOdnt7+1LH9dFHH6F58+bS67Vr18LKygovvfSSTtmXXnoJFhYW+OqrrzB27Nin1n327Fm4ublprTM3N0d2drb0esWKFVixYgUUCgWqVauGRo0aYcOGDejWrVspzorKWqR7yFPL5OWYYMl7NbHkvZrPICKisuNyqPixluXOJnBY8PRhJhw/e3qramU7MyjbcZzfqo7d84mIKoc6dergzz//hL+/P9LS0tCoUSMAwM2bN+Hu7l7B0RlPVShrWtT8D0RERIXJBKcd/k9LT0+HnZ0dWuNVmMqYjKD/pqcl/oiqqryMXGx86SukpaUZPNlgedF8HoW3nwVTM/09SQyVn5eNQ7tjKsV5ERE9r9auXYtBgwZBCAFHR0ecPXsWt2/fRkhICPr27Yt169ZVdIjF0nyuaD4LsvNU8Ju+GwBwZmYkrM2fi/ZDRERUAk9+BpQUPymIiIiIiIhIy4ABAxAaGorLly+jRYsWcHFxgVqtxp49e+Dt7V3R4RlNsHs+EREZiUlTIiIiqjTYPZ+IqPIIDg5GcHCw9NrNzU1nCLHnhZoTQRERkZGYNCUiIqLKQy20Z+soaR1ERGS0tm3bGlROJpMhPj6+nKMpW4WTpsyZEhGRIZg0JSIiIiIiIiQkJEAmk+Fp0148jxMpqdX//p8tTYmIyBBMmhIREVHlIf5ZSlsHEREZbcCAAc9lQtQQhVuayqvoORIRUdli0pSIiIiIiIgQFxdX0SGUG3bPJyIiY5lUdABEREREGjL8OxlUiZeKPgkioiokNzcXycnJuH79utZSEkuWLIGXlxeUSiXCwsJw5MiRIsuuWLECLVu2hIODAxwcHBAREVFs+afRDHctkz2fwwsQEdGzx6QpERERVR5ClM1CRESl8ujRI/Tu3Rs2NjaoVasWateuLS3e3t5G17dhwwZER0cjNjYWJ06cQEhICCIjI3H79m295RMSEtC3b1/s27cPhw4dgoeHB15++WUkJyeX6Hw047RyPFMiIjIUk6ZERERERESkZdq0afj222+Rl5cHIYTOYqwFCxZg2LBhGDRoEAICArBs2TJYWlpi1apVesuvW7cOo0aNQmhoKPz8/PDFF19ArVYjPj6+ROejkpKmJdqdiIj+g5g0JSIiokqj1F3z/1mIiKh0vvvuO8hkMkydOhUAUKdOHYwYMQKOjo743//+Z1Rdubm5OH78OCIiIqR1JiYmiIiIwKFDhwyqIzMzE3l5eXB0dNS7PScnB+np6VpLYZru+WxpSkREhmLSlIiIiCoPUUYLERGVSkpKCry9vTF79mwAgJOTEz777DPY2dnhxIkTRtV19+5dqFQquLi4aK13cXFBamqqQXVMmjQJ7u7uWonXwubOnQs7Oztp8fDw0NquVrN7PhERGYdJUyIiIiIiItJibm4OGxsbAIBSqcSNGzeQl5eHnJwcfPvtt880lg8//BDr16/H1q1boVQq9ZaZMmUK0tLSpOXvv//W2i6klqblHS0REVUVphUdABEREZGGTAjISjmRU2n3JyIiwNXVFTdu3ABQ0DU/MTERzs7OSE9Ph7Ozs1F1OTk5QS6X49atW1rrb926BVdX12L3nTdvHj788EPs3bsXwcHBRZYzNzeHubl5kdvVnAiKiIiMxJamREREVHmoy2ghIqJSCQ8PR15eHk6fPo2BAwdCCCGNEzpgwACj6lIoFGjUqJHWJE6aSZ3Cw8OL3O/jjz/G7NmzsXv3bjRu3LhkJ/IPzURQzJkSEZGh2NKUiIiIiIiItKxZs0b6f/369eHm5obDhw8jODgYQ4YMMbq+6OhoREVFoXHjxmjatCkWLVqEjIwMDBo0CEBBIrZGjRqYO3cuAOCjjz5CTEwMvv76a3h5eUljn1pbW8Pa2tro44t/kqZy9s8nIiIDMWlKRERElQa75xMRVazt27fD0dERL7zwgtb6119/Ha+//nqJ6+3duzfu3LmDmJgYpKamIjQ0FLt375Ymh7p+/TpMTP7tCLl06VLk5ubitdde06onNjYWM2bMMPr4amlMUyZNiYjIMEyaEhERUeUh/llKWwcREZVI165dER4ejoMHDwIA5HI5mjVrJr0ujTFjxmDMmDF6tyUkJGi9vnr1aqmPV5ha6p7PpCkRERmGY5oSERERERGRRBRqsS+E0Hr9vFL/M941e+cTEZGh2NKUiIiIKg8hCpbS1kFERFSIpqUpu+cTEZGhmDQlIiKiSkMmCpbS1kFERFSYmhNBERGRkZg0JSIiIiIiIsnJkyfh7e1d5GuZTIYrV65URGglppkIig1NiYjIUEyaEhERUeXB7vlERBUuNzdXayKmnJwcrdfP42RK7J5PRETGYtKUiIiIKg2ZumApbR1ERFQyL7744nOZFH0atVqTNK3gQIiI6LnBpCkREREREREBABISEio6hHKh6Z7PlqZERGQoJk2JiIio8mD3fCIiKgdS93w2NSUiIgOZVHQARERERBJRRosRZsyYAZlMprX4+flJ27OzszF69GhUq1YN1tbW6NGjB27duqVVx/Xr19GpUydYWlqievXqmDhxIvLz80twAYiIqDz8O6ZpBQdCRETPDbY0JSIiov+8wMBA7N27V3ptavrvLdLbb7+NH374Ad9++y3s7OwwZswYdO/eHQcPHgQAqFQqdOrUCa6urvjtt9+QkpKCAQMGwMzMDB988MEzPxciItIl2D2fiIiMxKQpERERVRoyISArZff6kuxvamoKV1dXnfVpaWlYuXIlvv76a7Rt2xYAsHr1avj7++Pw4cNo1qwZfvrpJyQmJmLv3r1wcXFBaGgoZs+ejUmTJmHGjBlQKBSlOh8iIio91T+DmlbFSa6IiKh8sHs+ERERVR6aMU1Luxjp0qVLcHd3h7e3N9544w1cv34dAHD8+HHk5eUhIiJCKuvn54datWrh0KFDAIBDhw6hfv36cHFxkcpERkYiPT0dZ8+eLeUFISKissDu+UREZCy2NCUiIqIqKT09Xeu1ubk5zM3NdcqFhYUhLi4O9erVQ0pKCmbOnImWLVvizJkzSE1NhUKhgL29vdY+Li4uSE1NBQCkpqZqJUw12zXbiIio4mm+T5Mza0pERAZi0pSIiIgqDwFAXQZ1APDw8NBaHRsbixkzZugU79Chg/T/4OBghIWFwdPTExs3boSFhUUpgyEiospA09KU3fOJiMhQTJoSERFRpVGWY5r+/fffsLW1ldbra2Wqj729PXx9fXH58mW0a9cOubm5ePjwoVZr01u3bkljoLq6uuLIkSNaddy6dUvaRkREFU8tTQRVsXEQEdHzg2OaEhERUZVka2urtRiaNH38+DGuXLkCNzc3NGrUCGZmZoiPj5e2X7hwAdevX0d4eDgAIDw8HKdPn8bt27elMnv27IGtrS0CAgLK9qSIiKhENBNBmbClKRERGYgtTYmIiKjyECjRRE46dRhhwoQJ6NKlCzw9PXHz5k3ExsZCLpejb9++sLOzw5AhQxAdHQ1HR0fY2trirbfeQnh4OJo1awYAePnllxEQEID+/fvj448/RmpqKqZNm4bRo0cbnKglIqLyJTgRFBERGYlJUyIiIqo8hCiDpKlx+9+4cQN9+/bFvXv34OzsjBdeeAGHDx+Gs7MzAGDhwoUwMTFBjx49kJOTg8jISHz22WfS/nK5HDt27MDIkSMRHh4OKysrREVFYdasWaU7DyIiKjP/ds9n1pSIiAzDpCkRERH9p61fv77Y7UqlEkuWLMGSJUuKLOPp6YmdO3eWdWhERFRG1ILd84mIyDhMmhIREVHloQZQ2udZdVkEQkREVYmUNOWsHkREZCAmTYmIiKjSkAkBWSm755d2fyIiqnrY0pSIiIzF79mIiIiIiIioSlP/0wtBxqQpEREZiC1NiYiIqPKogImgiIio6tO0NJUzZ0pERAZi0pSIiIgqDyZNiYioHGg+Gtg9n4iIDMXu+URERERERFSlaVqasns+EREZii1NiYiIqPJgS1MiIioHKmkiqAoOhIiInhtMmhIREVHloQZQ2gdadVkEQkREVYn6n+/T5MyaEhGRgdg9n4iIiIiIiKo0IbU0ZdKUiIgMw5amREREVGnIhICslN3rS7s/ERFVPWq1ZkzTCg6EiIieG0yaEhERUeXBMU2JiKgcaLrns6UpEREZit3ziYiIiIiIqEpTcyIoIiIyEluaEhERUeWhFoCslC1F1WxpSkRE2qSkKbOmRERkICZNiYiIqPJg93wiIioH7J5PRETGYvd8IiIiIiIiqtLYPZ+IiIzFlqZERERUiZRBS1OwpSkREWkTbGlKRERGYtKUiIiIKg92zycionKg+qd/voxJUyIiMhC75xMREREREVGVpumeL+cTMBERGYgtTYmIiKjyUAuUunu9mi1NiYhIGyeCIiIiYzFpSkRERJWHUBcspa2DiIioECFNBMWkKRERGYadE4iIiIiIiKhK03TPZ86UiIgMxZamREREVHlwIigiov8kIQTy8/OhUqnKpL7c3Fx4enoiNzcX2dnZMJepUcNGDhtTgezs7DI5BhERVRy5XA5TU9NyneCPSVMiIiKqPDimKRHRf05ubi5SUlKQmZlZZnWq1WosW7YMt27dwp07d9DUKR/+barDRqlGUlJSmR2HiIgqjqWlJdzc3KBQKMqlfiZNiYiIiIiIqEKo1QVJTLlcDnd3dygUijJpNaRSqZCVlQUvLy/I5XLcTs/Gg8xcOFgpUN1GWQaRExFRRRFCIDc3F3fu3EFSUhLq1q0LE5OyH4GUSVMiIiKqPNg9n4joPyU3NxdqtRoeHh6wtLQss3o13fyVSmVBF85sAVkuYKYwh1LJpCkR0fPOwsICZmZmuHbtGnJzc8vlbzuTpkRERFR5CJRB0rRMIiEiomeoPFoI6cN5oIiIqo7y/ux4Np9MRERERERERBXk3+/TmDYlIiLDMGlKRERElYeme35pFyIiosL++Wgox0mWqZzIZDJs27bN4PIJCQmQyWR4+PBhkWVmzJiB0NDQUsf2rFy9ehUymQynTp0q92PFxcXB3t5ea93nn38ODw8PmJiYYNGiReV+/eLj4+Hv7y8Ns1FR+vTpg/nz5xtUtrLEXJU0a9YMmzdvrtAYmDQlIiKiykOtLpuFiIhIS9l/oTZw4EB07dpVa92mTZugVCr1Jlo0ybzAwECdxIq9vT3i4uLKPMay1rp1a4wfP96gcjKZDOvXr9dav2jRInh5eRl1zJSUFHTo0MGofZ43ly9fxqBBg1CzZk2Ym5ujdu3a6Nu3L44dO/bMY+nduzcuXrwovU5PT8eYMWMwadIkJCcnY/jw4ZgwYQLi4+PLLYZ3330X06ZNg1wuB6A/kXvu3Dl4eHigZ8+eyM3NRVxcHGQyGdq3b69V7uHDh5DJZEhISJDWyWQyKJVKXLt2Tats165dMXDgQOn1tGnTMGfOHKSlpRkds0ZWVhYcHR3h5OSEnJwcnf2K+lJA39+XinqfLFmyBF5eXlAqlQgLC8ORI0eKLZ+Xl4dZs2ahTp06UCqVCAkJwe7du7XKPHr0COPHj4enpycsLCzQvHlzHD16VKvMtGnTMHnyZKgr8N6eSVMiIiIiIiKq0p5FH4QvvvgCb7zxBpYuXYp33nmnyHJ//fUX1q5d+wwi0pabm/tMj6dUKjFt2jTk5eWVqh5XV1eYm5uXUVTlqyTneuzYMTRq1AgXL17E8uXLkZiYiK1bt8LPz6/Y91F5sbCwQPXq1aXX169fR15eHjp16gQ3NzdYWlrC2toa1apVK9VxirpWBw4cwJUrV9CjR48i9z169ChatmyJ9u3bY8OGDVAoFAAAU1NT7N27F/v27Xvq8WUyGWJiYootExQUhDp16uCrr74qtlxxMW/evBmBgYHw8/MzqsX0kyrqfbJhwwZER0cjNjYWJ06cQEhICCIjI3H79u0i95k2bRqWL1+OTz/9FImJiRgxYgS6deuGkydPSmWGDh2KPXv24Msvv8Tp06fx8ssvIyIiAsnJyVKZDh064NGjR9i1a1e5nd/TMGlKRERElQe75xMRUTkqr975H3/8Md566y2sX78egwYNKrbsW2+9hdjYWL2tzjQePnyIoUOHwtnZGba2tmjbti3++OMPafuVK1fw6quvwsXFBdbW1mjSpAn27t2rVYeXlxdmz56NAQMGwNbWFsOHDwdQkOBp2bIlLCws4OHhgbFjxyIjI0Pa77PPPkPdunWhVCrh4uKC1157DUBBy7dffvkFixcvhkwmg0wmw9WrV4s8h759++Lhw4dYsWJFsdfju+++Q8OGDaFUKuHt7Y2ZM2ciPz9f2v5kS7zffvsNoaGhUCqVaNy4MbZt26a36/rx48fRuHFjWFpaonnz5rhw4YLOsZcvXw4PDw9YWlqiV69eWi0K1Wo1Zs2aJbXqCw0N1Wotp+kyv2HDBrRq1QpKpRLr1q3DtWvX0KVLFzg4OMDKygqBgYHYuXOn3nMXQmDgwIGoW7cu9u/fj06dOqFOnToIDQ1FbGwsvvvuO737qVQqDBkyBLVr14aFhQXq1auHxYsXa5VJSEhA06ZNYWVlBXt7e7Ro0UJqWfnHH3+gTZs2sLGxga2tLRo1aiS1VizcqjMuLg7169cHAHh7e0s/c33d87/44gv4+/tDqVTCz88Pn3322VOvlT7r169Hu3btipwJ/eeff0bbtm0xZMgQrFixQmsiICsrKwwePBiTJ0/Wu29hY8aMwVdffYUzZ84UW65Lly46LaaNiXnlypXo168f+vXrh5UrVz41Ln1K+j4pCwsWLMCwYcMwaNAgBAQEYNmyZbC0tMSqVauK3OfLL7/Ee++9h44dO8Lb2xsjR45Ex44dpRb4WVlZ2Lx5Mz7++GO8+OKL8PHxwYwZM+Dj44OlS5dK9cjlcnTs2PGp1788MWlKRERElQeTpkRE/3lCCGTm5pd6yc4vVE+OCtl5KmTlqYrdR5TgM2TSpEmYPXs2duzYgW7duj21/Pjx45Gfn49PP/20yDI9e/bE7du3sWvXLhw/fhwNGzbESy+9hPv37wMAHj9+jI4dOyI+Ph4nT55E+/bt0aVLF1y/fl2rnnnz5iEkJAQnT57E9OnTceXKFbRv3x49evTAn3/+iQ0bNuDAgQMYM2YMgILWbGPHjsWsWbNw4cIF7N69Gy+++CIAYPHixQgPD8ewYcOQkpKClJQUeHh4FHkOtra2mDp1KmbNmqWVlC1s//79GDBgAMaNG4fExEQsX74ccXFxmDNnjt7y6enp6NKlC+rXr48TJ05g9uzZmDRpkt6yU6dOxfz583Hs2DGYmppi8ODBWtsvX76MjRs34vvvv8fu3btx8uRJjBo1Stq+ePFizJ8/H/PmzcOff/6JyMhIvPLKK7h06ZJWPZMnT8a4ceNw7tw5REZGYvTo0cjJycGvv/6K06dP46OPPoK1tbXeGE+dOoWzZ8/inXfe0TsL+JNd0jXUajVq1qyJb7/9FomJiYiJicF7772HjRs3AgDy8/PRtWtXtGrVCn/++ScOHTqE4cOHQ/bPoL5vvPEGatasiaNHj+L48eOYPHkyzMzMdI7Tu3dvKRl/5MiRIn/m69atQ0xMDObMmYNz587hgw8+wPTp07FmzZpir5U++/fvR+PGjfVu27p1Kzp16oRp06bho48+0ltmxowZOH36NDZt2qR3u0aLFi3QuXPnpyZYmzZtiiNHjhT7JUdRMV+5cgWHDh1Cr1690KtXL+zfv19nSABDlPR9AgAffPABrK2ti12e/LuhkZubi+PHjyMiIkJaZ2JigoiICBw6dKjIY+bk5OgkkC0sLHDgwAEABe9PlUpVbBmNpk2bYv/+/UUeq7yZVtiRiYiIiIiIiJ6QladCQMyPZVPZtr1PL1NI4qxIWCoMf0zetWsXvvvuO8THx6Nt27YG7WNpaYnY2Fi89957GDZsGOzs7LS2HzhwAEeOHMHt27elbunz5s3Dtm3bsGnTJgwfPhwhISEICQmR9pk9eza2bt2K7du3SwlQAGjbtq1W192hQ4fijTfekMYlrVu3Lj755BO0atUKS5cuxfXr12FlZYXOnTvDxsYGnp6eaNCgAQDAzs4OCoUClpaWcHV1NehcR40ahcWLF2PBggWYPn26zvaZM2di8uTJiIqKAlDQmnH27Nl49913ERsbq1P+66+/hkwmw4oVK6BUKhEQEIDk5GQMGzZMp+ycOXPQqlUrAAXJuk6dOiE7O1tK1GRnZ2Pt2rWoUaMGAODTTz9Fp06dMH/+fLi6umLevHmYNGkS+vTpAwD46KOPsG/fPixatAhLliyRjjN+/Hh0795den39+nX06NFDq4VmUTQJWD8/v2Kuoi4zMzPMnDlTel27dm0cOnQIGzduRK9evZCeno60tDR07twZderUAQD4+/trxThx4kTpuHXr1tV7HAsLC6kbvrOzc5E/99jYWMyfP1+6DrVr15aS4JqfLaB7rfS5du0a3N3dddY/fvwYPXv2xHvvvVdkohwA3N3dMW7cOEydOlVnTNAnzZ07F8HBwdi/fz9atmxZZH25ublITU2Fp6enUTGvWrUKHTp0gIODAwAgMjISq1evxowZM4qN60klfZ8AwIgRI9CrV69iy+iLHQDu3r0LlUoFFxcXrfUuLi44f/58kfVFRkZiwYIFePHFF1GnTh3Ex8djy5Yt0ljONjY2CA8Px+zZs+Hv7w8XFxd88803OHToEHx8fHRi+/vvv6FWq/UmjMsbW5oSERFR5aEWZbMQERE9A8HBwfDy8kJsbCweP34srQ8MDJRacembxGjIkCGoVq2a3tZyf/zxBx4/foxq1apptQZLSkrClStXABQkkCZMmAB/f3/Y29vD2toa586d02kx9mTrtz/++ANxcXFa9UZGRkKtViMpKQnt2rWDp6cnvL290b9/f6xbtw6ZmZklvj7m5uaYNWsW5s2bh7t37+o911mzZmnFo2nJqu+4Fy5cQHBwsFYLtaZNm+o9dnBwsPR/Nzc3ANAah7FWrVpSwhQAwsPDoVarceHCBaSnp+PmzZto0aKFVp0tWrTAuXPntNY9eY3Hjh2L999/Hy1atEBsbCz+/PNPvfEBKFHLZo0lS5agUaNGcHZ2hrW1NT7//HPp5+/o6IiBAwciMjISXbp0weLFi5GSkiLtGx0djaFDhyIiIgIffvih9L4qiYyMDFy5cgVDhgzR+jm+//77OvUW1YK0sKysLL3d3C0sLNCuXTusWLFC52fwpEmTJuHOnTvFdiEHgICAAAwYMKDY1qYWFhYAUOzvgb6YVSoV1qxZg379+knr+vXrh7i4OKMnNirN+8TR0RE+Pj7FLqamZduecvHixahbty78/PygUCgwZswYDBo0SCvp+eWXX0IIgRo1asDc3ByffPIJ+vbtq5MYtbCwgFqtLralb3liS1MiIiKqNIRQQ4jSzZBZ2v2JiKhiWZjJkThLf9ddQ6lUKvzxx58ICQmGXC7H3/ezkJaVC1dbCzjZKIo9tjFq1KiBTZs2oU2bNmjfvj127doFGxsb7Ny5U5roRpN0KczU1BRz5szBwIEDtVqGAgUJUTc3N63ZvjU03XAnTJiAPXv2YN68efDx8YGFhQVee+01ncmerKysdOp+8803MXbsWJ26a9WqBYVCgRMnTiAhIQE//fQTYmJiMGPGDBw9erTYLsDF6devH+bNm4f3338fXl5eOvHMnDlTb+vDosa0NFTh7uaabunlMQv3k9d46NChiIyMxA8//ICffvoJc+fOxfz58/HWW2/p7Ovr6wsAOH/+vNSi1xDr16/HhAkTMH/+fISHh8PGxgb/93//h99//10qs3r1aowdOxa7d+/Ghg0bMG3aNOzZswfNmjXDjBkz8Prrr+OHH37Arl27EBsbi/Xr1xs0vMSTNF8WrFixAmFhYVrbnpxJ/slrpY+TkxMePHigs14ul2Pbtm3o3r072rRpg3379mm1ni3M3t4eU6ZMwcyZM9G5c+dijzdz5kz4+voWOUmTZkgMZ2dno2L+8ccfkZycjN69e2utV6lUiI+PR7t27QAUtLosPJauxsOHD6VW6CV9nwAF3fM/+OCDYsskJiaiVq1aOuudnJwgl8tx69YtrfW3bt0qtrW5s7Mztm3bhuzsbNy7dw/u7u6YPHmyVqvrOnXq4JdffkFGRgbS09Ph5uaG3r1767TMvn//PqysrPT+HX0W2NKUiIiIiIiIKg2ZTAZLhWmpF6Xpv/VYmMmhNJPDUiEvdh9Ncs0Ynp6e+OWXX5Camor27dvj0aNH8PT0lFpxFW7NWFjPnj0RGBio1c0aABo2bIjU1FSYmprqtAhzcnICABw8eBADBw5Et27dUL9+fbi6uhY7KVPhuhMTE/W2Nis8A3lERAQ+/vhj/Pnnn7h69Sp+/vlnAIBCoZC62BrKxMQEc+fOxdKlS3VibNiwIS5cuKA3Hn1dcevVq4fTp09rtTo7evSoUfFoXL9+HTdv3pReHz58GCYmJqhXrx5sbW3h7u6OgwcPau1z8OBBBAQEPLVuDw8PjBgxAlu2bME777xT5GRYoaGhCAgIwPz58/UmdB8+fKh3v4MHD6J58+YYNWoUGjRoAB8fH72tRRs0aIApU6bgt99+Q1BQEL7++mtpm6+vL95++2389NNP6N69O1avXv3U89LHxcUF7u7u+Ouvv3R+hrVr1za6vgYNGiAxMVHvNnNzc2zZsgVNmjRBmzZtiiwHFEy4ZmJiojNB1pM8PDwwZswYvPfee3rf22fOnEHNmjWl3z1DY165ciX69OmDU6dOaS19+vTRmhCqXr16OH78uNa+BV/6/CElS0v6PgEKuuc/GcOTS1Hd8xUKBRo1aoT4+HhpnVqtRnx8PMLDw4s8poZSqUSNGjWQn5+PzZs349VXX9UpY2VlBTc3Nzx48AA//vijTpkzZ84YnSguS2xpSkRERJWHKIPu9ZwIioiIniDwz2eD8TlRg3h4eCAhIQFt2rRBZGQkdu/eDVtb26fu9+GHH+pMiBMREYHw8HB07doVH3/8MXx9fXHz5k388MMP6NatGxo3boy6detiy5Yt6NKlC2QyGaZPn25QK8pJkyahWbNmGDNmDIYOHQorKyskJiZiz549+N///ocdO3bgr7/+wosvvggHBwfs3LkTarUa9erVAwB4eXnh999/x9WrV2FtbQ1HR0eDxhns1KkTwsLCsHz5cq3xEWNiYtC5c2fUqlULr732GkxMTPDHH3/gzJkzeP/993Xqef311zF16lQMHz4ckydPxvXr1zFv3jwAMDrhrVQqERUVhXnz5iE9PR1jx45Fr169pBZ0EydORGxsrDRL+erVq3Hq1KkiZ33XGD9+PDp06ABfX188ePCg2BaRMpkMq1evRkREBFq2bImpU6fCz88Pjx8/xvfff4+ffvoJv/zyi85+devWxdq1a/Hjjz+idu3a+PLLL3H06FEpSZmUlITPP/8cr7zyCtzd3XHhwgVcunQJAwYMQFZWFiZOnIjXXnsNtWvXxo0bN3D06FH06NHDqOtX2MyZMzF27FjY2dmhffv2yMnJwbFjx/DgwQNER0cbVVdkZKTOBFKFmZubY/PmzejZsyfatGmDn3/+GYGBgTrllEolZs6cidGjRz/1mFOmTMGKFSuQlJSk0zJ0//79ePnll42K+c6dO/j++++xfft2BAUFaZUdMGAAunXrhvv378PR0RHR0dEYMmQI/Pz80K5dO2RkZODTTz/FgwcPMHToUAAlf58ABd3zHR0dn3oNihIdHY2oqCg0btwYTZs2xaJFi5CRkYFBgwZpnVONGjUwd+5cAMDvv/+O5ORkhIaGIjk5GTNmzIBarca7774r7fPjjz9CCIF69erh8uXL0hi7hesFDLv+5YktTYmIiKjyEKJsFiIiIj3KKWcKAKhZsyYSEhJw9+5dREZGIj09/an7tG3bFm3btkV+fv6/Mcpk2LlzJ1588UUMGjQIvr6+6NOnD65duyYlHBcsWAAHBwc0b94cXbp0QWRkJBo2bPjU4wUHB+OXX37BxYsX0bJlSzRo0AAxMTFSSzN7e3ts2bIFbdu2hb+/P5YtW4ZvvvlGSkpNmDABcrkcAQEBcHZ2LnLWbX0++ugjZGdna62LjIzEjh078NNPP6FJkyZo1qwZFi5cWOSEO7a2tvj+++9x6tQphIaGYurUqYiJiQFgfHd+Hx8fdO/eHR07dsTLL7+M4OBgfPbZZ9L2sWPHIjo6Gu+88w7q16+P3bt3Y/v27UVOmqShUqkwevRo+Pv7o3379vD19dWq90lNmzbFsWPH4OPjg2HDhsHf3x+vvPIKzp49i0WLFund580330T37t3Ru3dvhIWF4d69exg1apS03dLSEufPn0ePHj3g6+uL4cOHY/To0XjzzTchl8tx7949DBgwAL6+vujVqxc6dOig0+LZGEOHDsUXX3yB1atXo379+mjVqhXi4uJK1NL0jTfewNmzZ3HhwoUiyygUCmzatAnNmzdHmzZtcObMGb3loqKiip2IS8PR0RGTJk3SeX9mZ2dj27ZteicaKy7mtWvXwsrKCi+99JJO2ZdeegkWFhb46quvAAB9+/bFF198gVWrVqFRo0Zo3749UlNT8euvv2p9wVCS90lZ6N27N+bNm4eYmBiEhobi1KlT2L17t1Zs169f1xozNzs7G9OmTUNAQAC6deuGGjVq4MCBA1pDfKSlpWH06NHw8/PDgAED8MILL+DHH3/UGlYjOTkZv/32m04i9VmSidKMKEvPvfT0dNjZ2aE1XoWpzOzpOxBVQS6Hnt4KgKgqysvIxcaXvkJaWppBrWHKk+bz6CW7/jCVFT3WnCHyRS7i076sFOdFRETFy87ORlJSEmrXrl3qMSwLU6lUOHnyJBo0aAC5XI5r9zKQlpWHGvYWqGZtXmbHoYq3bt06DBo0CGlpaRU27iGVrYkTJyI9PR3Lly+v0DiWLl2KrVu34qeffnpq2coSc1UyadIkPHjwAJ9//nmRZYr6DNE8W5T2eYAtTYmIiKjyUKvLZiEiIiqETYWqjrVr1+LAgQNISkrCtm3bMGnSJPTq1YsJ0ypk6tSp8PT0LJeJu4xhZmaGTz/91KCylSXmqqR69eqYPXt2hcbAMU2JiIio8hACAMc0JSKi8lGCeZ6okklNTUVMTAxSU1Ph5uaGnj17Ys6cORUdFpUhe3t7vPfeexUdhjSmqCEqS8xVyTvvvFPRITBpSkRERERERP8VzJo+7959912tCWWIiMoLk6ZERERUaQi1GkJWum5NQrBbFBERaWMfBCIiMhaTpkRERFR5sHs+ERGVI7YzJSIiQ3EiKCIiIiIiIqpQopy/8JLqZ9aUiKjKKO/PDrY0JSIiospDLQAZW5oSEf1XmJmZAQAyMzOfyeznzJkSEVUdmZmZAP79LClrTJoSERFR5SEEgFKOScqkKRFRpbRkyRL83//9H1JTUxESEoJPP/0UTZs2hb29PW7fvg0AsLS0hOyfKe4fPnyI27dvIy8vDwqFAq6urrCxsTHoWCqVCgCQnZ0NuVyO/LwciHwVcnNMkG3Csa+JiJ5nQghkZmbi9u3bsLe3h1wuL5fjMGlKRERERERE5WrDhg2Ijo7GsmXLEBYWhkWLFiEyMhIXLlyAq6srAEiJUwDIyclBamoq7O3tYWlpicePH+P48eNwc3ODQqF46vHUajXu3r2Lq1evwsTEBHce5SAnXw1VmgIWivJ5uCYiomfL3t5e+gwpD0yaEhERUaUh1AKilN3zy3tsIyIiMt6CBQswbNgwDBo0CACwbNky/PDDD1i1ahUmT54MNzc3VK9eHXl5eQCAt99+G1lZWVi2bJlUR+/eveHn54eZM2c+9XiPHz9Gp06dcOzYMVhbW2PR+pM4k5yGGV0C0LJ29fI5SSIiembMzMzKrYWpBpOmREREVHkINUrfPZ/dLomIKpPc3FwcP34cU6ZMkdaZmJggIiIChw4dktbJ5XLpAfiHH35AdHQ0lEqltD00NBTbtm3DRx99pHOMnJwc5OTkSK+zs7Nx7do1KBQKKJVK3M0SSH6kglqu0KqTiIioKCYVHQARERERERFVXXfv3oVKpYKLi4vWehcXF6SmpurdJzU11ajyc+fOhZ2dnbR4eHhobZcBkMkAExmngiIiIsOwpSkRERFVGuyeT0REJTFlyhRER0dLr9PT07USp5tGNq+IsIiI6DnGpCkRERFVHuyeT0RU5Tg5OUEul+PWrVta62/dulXkBB6urq5GlTc3N4e5uXnZBExERAQmTf/zNK1x8pEHsGEO/UflZeRWdAhEFULz3q9MLTPL4vMoH3llEwwREZUJhUKBRo0aIT4+Hl27dgVQMLt9fHw8xowZo3ef8PBwxMfHY/z48dK6PXv2IDw83KBjaj7b0tPTSxU7ERE9fzR/+0v7nMOk6X/co0ePAAAHsLOCIyGqQC9VdABEFevRo0ews7Or0BgUCgVcXV1xILVsPo9cXV2hUCjKpC4iIiq96OhoREVFoXHjxmjatCkWLVqEjIwMDBo0CAAwYMAA1KhRA3PnzgUAjBs3Dq1atcL8+fPRqVMnrF+/HseOHcPnn39u0PE0zzlPjm1KRET/HaV9zmHS9D/O3d0df//9N2xsbCDjoOjPnGaspb///hu2trYVHQ7RM8ffgYolhMCjR4/g7u5e0aFAqVQiKSkJubll0/JbM1syERFVDr1798adO3cQExOD1NRUhIaGYvfu3dJkT9evX4eJyb/zFDdv3hxff/01pk2bhvfeew9169bFtm3bEBQUZNDxnnzO4T2HcXi9DMdrZRxeL8PxWhmn8PWysbEpk+ccmahMffKI/mPS09NhZ2eHtLQ0/hGk/yT+DhAREdGzwHsO4/B6GY7Xyji8XobjtTJOeVwvk6cXISIiIiIiIiIiIvrvYNKUiIiIiIiIiIiIqBAmTYkqkLm5OWJjY2Fubl7RoRBVCP4OEBER0bPAew7j8HoZjtfKOLxehuO1Mk55XC+OaUpERERERERERERUCFuaEhERERERERERERXCpCkRERERERERERFRIUyaEhERERERERERERXCpCkRERERERERERFRIUyaUpWXmpqKt956C97e3jA3N4eHhwe6dOmC+Ph4qcxvv/2Gjh07wsHBAUqlEvXr18eCBQugUqm06pLJZJDJZDh8+LDW+pycHFSrVg0ymQwJCQk65WUyGezs7NCiRQv8/PPP0vaBAweia9euRcbu5eWlVYdm+fDDDzFjxgy92wovmmPo29a+fXu9x7GwsICXlxd69eqlFSs9H572npgxYwauXr1a5HbNezsuLk5aZ2JiAjc3N/Tu3RvXr1/XOl7r1q2l9+STOnXqJB2zcPnx48fr7L9+/XqtfRctWgQvLy+dOrOysuDo6AgnJyfk5OToxFrUcvXq1SJ/Z/z8/HTikclkMDc3R40aNdClSxds2bLF2B8FERERPWNLliyBl5cXlEolwsLCcOTIkWLLf/vtt/Dz85Pu/3fu3PmMIq0cjLleK1asQMuWLeHg4AAHBwdEREQ89fpWJca+tzTWr18PmUxW7DNfVWTs9Xr48CFGjx4NNzc3mJubw9fX9z/z+2jstVq0aBHq1asHCwsLeHh44O2330Z2dvYzirbi/Prrr+jSpQvc3d0hk8mwbdu2p+6TkJCAhg0bwtzcHD4+PoiLizP6uEyaUpV29epVNGrUCD///DP+7//+D6dPn8bu3bvRpk0bjB49GgCwdetWtGrVCjVr1sS+fftw/vx5jBs3Du+//z769OkDIYRWnR4eHli9erXWuq1bt8La2lpvDKtXr0ZKSgoOHjwIJycndO7cGX/99ZfB5zBr1iykpKRoLW+99RYmTJigta5mzZo6ZTXat2+vU8c333yj9zgXLlzA2rVrYW9vj4iICMyZM8fgWKniFf4ZL1q0CLa2tlrrJkyYIJXdu3evzvuiUaNG0nbNvsnJydi8eTMuXLiAnj176hzTw8ND5wMoOTkZ8fHxcHNze2rMSqUS06ZNQ15e3lPLbt68GYGBgfDz85M+KHv37q11DuHh4Rg2bJjWOg8PDwBAYGCgzjkfOHBA6xiafa9cuYLNmzcjICAAffr0wfDhw58aHxEREVWMDRs2IDo6GrGxsThx4gRCQkIQGRmJ27dv6y3/22+/oW/fvhgyZAhOnjyJrl27omvXrjhz5swzjrxiGHu9EhIS0LdvX+zbtw+HDh2Ch4cHXn75ZSQnJz/jyJ89Y6+VxtWrVzFhwgS0bNnyGUVaORh7vXJzc9GuXTtcvXoVmzZtwoULF7BixQrUqFHjGUf+7Bl7rb7++mtMnjwZsbGxOHfuHFauXIkNGzbgvffee8aRP3sZGRkICQnBkiVLDCqflJSETp06oU2bNjh16hTGjx+PoUOH4scffzTuwIKoCuvQoYOoUaOGePz4sc62Bw8eiMePH4tq1aqJ7t2762zfvn27ACDWr18vrQMgpk2bJmxtbUVmZqa0vl27dmL69OkCgNi3b59W+a1bt0qvk5OTBQCxbNkyIYQQUVFR4tVXXy0yfk9PT7Fw4UKDzrWosk87RnH7xsTECBMTE3H+/HmDYqDKZfXq1cLOzk5nfVJSkgAgTp48adS+n3zyiQAg0tLSpHWtWrUSI0eOFNWqVRMHDhyQ1s+ZM0d06dJFhISEiNjYWK3y48aN03o9aNAgUa1aNbFkyRJp/cKFC4Wnp6dOXK1btxbLli0TS5cuFe3atdMb+5PH0IiNjRUhISFFnnNx+65atUoAEHv27Cl2fyIiIqoYTZs2FaNHj5Zeq1Qq4e7uLubOnau3fK9evUSnTp201oWFhYk333yzXOOsLIy9Xk/Kz88XNjY2Ys2aNeUVYqVRkmuVn58vmjdvLr744guDnseqEmOv19KlS4W3t7fIzc19ViFWGsZeq9GjR4u2bdtqrYuOjhYtWrQo1zgrmyfzLPq8++67IjAwUGtd7969RWRkpFHHYktTqrLu37+P3bt3Y/To0bCystLZbm9vj59++gn37t3Tan2n0aVLF/j6+uq0yGzUqBG8vLywefNmAMD169fx66+/on///k+NycLCAkDBt2nPg3HjxkEIge+++66iQ6EKdvv2bWzduhVyuRxyuVxrm0KhwBtvvKHVAjsuLg6DBw82qG5bW1tMnToVs2bNQkZGRpHlrly5gkOHDqFXr17o1asX9u/fj2vXrpXshIwUFRUFBwcHdtMnIiKqhHJzc3H8+HFERERI60xMTBAREYFDhw7p3efQoUNa5QEgMjKyyPJVSUmu15MyMzORl5cHR0fH8gqzUijptZo1axaqV6+OIUOGPIswK42SXK/t27cjPDwco0ePhouLC4KCgvDBBx/oDJVX1ZTkWjVv3hzHjx+XuvD/9ddf2LlzJzp27PhMYn6elNXfeCZNqcq6fPkyhBBa4xU+6eLFiwAAf39/vdv9/PykMoUNHjwYq1atAlCQHOrYsSOcnZ2LjSczMxPTpk2DXC5Hq1atDD0NTJo0CdbW1lrL/v37Dd4fAHbs2KFTxwcffPDU/RwdHVG9enVcvXrVqOPR86F58+Y674vC0tLSYG1tDSsrK7i4uGDfvn1FfgkxePBgbNy4ERkZGfj111+RlpaGzp07GxzLqFGjoFQqsWDBgiLLrFq1Ch06dICDgwMcHR0RGRmpM1TG05w+fVrnnEeMGPHU/UxMTODr68vfBSIiokro7t27UKlUcHFx0Vrv4uKC1NRUvfukpqYaVb4qKcn1etKkSZPg7u6uk5SoakpyrQ4cOICVK1dixYoVzyLESqUk1+uvv/7Cpk2boFKpsHPnTkyfPh3z58/H+++//yxCrjAluVavv/46Zs2ahRdeeAFmZmaoU6cOWrdu/Z/onm+sov7Gp6enIysry+B6TMs6MKLKQjwxFmlZlQWAfv36YfLkyfjrr78QFxeHTz75pMiyffv2hVwuR1ZWFpydnbFy5UoEBwcbfKyJEydi4MCBWuuMHd+lTZs2WLp0qdY6Q78VFkJIk0pR1bJhw4YivzAAABsbG5w4cQJ5eXnYtWsX1q1bV+QYtyEhIahbty42bdqEffv2oX///jA1NfwjxtzcHLNmzcJbb72FkSNH6mxXqVRYs2YNFi9eLK3r168fJkyYgJiYGJiYGPYdYL169bB9+3atdba2tgbty98FIiIiIuDDDz/E+vXrkZCQAKVSWdHhVCqPHj1C//79sWLFCjg5OVV0OM8FtVqN6tWr4/PPP4dcLkejRo2QnJyM//u//0NsbGxFh1epJCQk4IMPPsBnn32GsLAwXL58GePGjcPs2bMxffr0ig6vSmLSlKqsunXrQiaT4fz580WW8fX1BQCcO3cOzZs319l+7tw5BAQE6KyvVq0aOnfujCFDhiA7OxsdOnTAo0eP9B5j4cKFiIiIgJ2d3VNbo+rj5OQEHx8fo/crzMrKqkR13Lt3D3fu3EHt2rVLdXyqnDw8PIp9X5iYmEjb/f39ceXKFYwcORJffvml3vKDBw/GkiVLkJiYWKLZVPv164d58+bh/fffh5eXl9a2H3/8EcnJyejdu7fWepVKhfj4eLRr186gYygUihL9LqhUKly6dAlNmjQxel8iIiIqX05OTpDL5bh165bW+lu3bsHV1VXvPq6urkaVr0pKcr005s2bhw8//BB79+41qiHI88rYa3XlyhVcvXoVXbp0kdap1WoAgKmpKS5cuIA6deqUb9AVqCTvLTc3N5iZmWkNAebv74/U1FTk5uZCoVCUa8wVpSTXavr06ejfvz+GDh0KAKhfvz4yMjIwfPhwTJ061eCGJP8FRf2Nt7W1lYZNNASvKFVZmu67S5Ys0TtO4sOHD/Hyyy/D0dER8+fP19m+fft2XLp0CX379tVb/+DBg5GQkIABAwbojPFYmKurK3x8fEqUMK1oixcvhomJCbp27VrRoVAlMHnyZGzYsAEnTpzQu/3111/H6dOnERQUpPfLhqcxMTHB3LlzsXTpUp1u8CtXrkSfPn1w6tQpraVPnz5YuXJlSU7HKGvWrMGDBw/Qo0ePcj8WERERGUehUKBRo0aIj4+X1qnVasTHxyM8PFzvPuHh4VrlAWDPnj1Flq9KSnK9AODjjz/G7NmzsXv3bjRu3PhZhFrhjL1Wfn5+OH36tNb96iuvvCLN4O3h4fEsw3/mSvLeatGiBS5fviwll4GCYfTc3NyqbMIUKNm1yszM1EmManIRxvaererK6m88W5pSlbZkyRK0aNECTZs2xaxZsxAcHIz8/Hzs2bMHS5cuxblz57B8+XL06dMHw4cPx5gxY2Bra4v4+HhMnDgRr732Gnr16qW37vbt2+POnTsGd+0tSlpaGk6dOqW1rlq1atIH6qNHj3TGNLG0tDTquDk5OTp1mJqaanUZ0RwnLy8PSUlJ+Oqrr/DFF19g7ty5pW7pSpXTvXv3dN4X9vb2RXaz8vDwQLdu3RATE4MdO3bobHdwcEBKSgrMzMxKHFOnTp0QFhaG5cuXS2PQ3LlzB99//z22b9+OoKAgrfIDBgxAt27dcP/+fYOGnMjPz9c5Z5lMpjXeTWZmJlJTU5Gfn48bN25g69atWLhwIUaOHIk2bdqU+NyIiIio/ERHRyMqKgqNGzdG06ZNsWjRImRkZGDQoEEACu4ZatSogblz5wIomPC0VatWmD9/Pjp16oT169fj2LFj+PzzzyvyNJ4ZY6/XRx99hJiYGHz99dfw8vKS7qf0jYtf1RhzrZRKpc79qr29PQDorK+qjH1vjRw5Ev/73/8wbtw4vPXWW7h06RI++OADjB07tiJP45kw9lp16dIFCxYsQIMGDaTu+dOnT0eXLl2KbchVFTx+/BiXL1+WXiclJeHUqVNwdHRErVq1MGXKFCQnJ2Pt2rUAgBEjRuB///sf3n33XQwePBg///wzNm7ciB9++MG4AwuiKu7mzZti9OjRwtPTUygUClGjRg3xyiuviH379kllfv31VxEZGSlsbW2FQqEQgYGBYt68eSI/P1+rLgBi69ateo/z4MEDAUCr3uLKCyFEVFSUAKCzDBkyRAghhKenp97tb775pk5dnp6eYuHChQYfo169elr7atYrFApRq1Yt0atXL/Hzzz8XGTtVfqtXrxZ2dnY665OSkvS+JwCIb775pth9Dx06JACI33//XQghRKtWrcS4ceOKjCEkJETExsZKr58sr2//3377TQAQnp6eQggh5s2bJ+zt7UVubq5O/Tk5OcLe3l4sXry42DqFECI2NlbvOZubm2vtW/h3wc3NTXTu3Fls2bKlyHMkIiKiyuHTTz8VtWrVEgqFQjRt2lQcPnxY2taqVSsRFRWlVX7jxo3C19dXuv//4YcfnnHEFcuY61XUc0nh+7yqzNj3VmFRUVHi1VdfLf8gKxFjr9dvv/0mwsLChLm5ufD29hZz5szReRavqoy5Vnl5eWLGjBmiTp06QqlUCg8PDzFq1Cjx4MGDZx/4M7Zv3z69f4M01ycqKkq0atVKZ5/Q0FChUCiEt7e3WL16tdHHlQnBNrxEREREREREREREGhzTlIiIiIiIiIiIiKgQJk2JiIiIiIiIiIiICmHSlIiIiIiIiIiIiKgQJk2JiIiIiIiIiIiICmHSlIiIiIiIiIiIiKgQJk2JiIiIiIiIiIiICmHSlIiIiIiIiIiIiKgQJk2JqNK4evUqZDIZZDIZ4uLiAABxcXHSuoqUkJAgxZGQkPBMj3f16tVS1+fl5QWZTIYZM2aUui4iIiIioqpkxowZkMlk8PLyemrZsr5Pr0rOnTsHuVwOb29vqFSqig6nRIx5L5Q3fc/Hly9fhlwuR+3atZGbm1uxAf4HMGlKRFpat24t/WGWyWSQy+WoUaMGunTpgt9+++2Zx+Ps7IywsDCEhYUZvE9F3shoPmR5E0VERERElZXmC/Xilor8sr3wPbVmcXJyQnh4OL766qsyP17NmjURFhaGBg0aSOsGDhwImUyG1q1ba5W1tbWVnk/Mzc3LPJYnFU6caRYLCwv4+/tjxowZUKvVRtepeeYbOHBgmcY6c+ZMqNVqjBs3DnK5XGvbli1b0L59ezg7O8Pc3By1atVC9+7dn0mDlGeh8M+pPM/Jx8cHXbt2xdWrV7Fq1apyOw4VMK3oAIioclIoFGjQoAFycnJw5swZ7NixA7t378bBgwfRtGlTvfvk5uZCoVCUaRydOnVCp06dyrROIiIiIqL/sgYNGsDV1RUAcOPGDSQnJwMAQkNDpURgzZo1dfYrj/v9pwkNDYWpqSkuXryIw4cP4/Dhw7h9+zaio6PL7BhDhw7F0KFDDSrbsGFDHD58uMyObYwaNWrA3d0dV65cwfnz5zFz5kxYW1tjwoQJFRJPYbdu3cLmzZshl8vRt29fab0QAoMHD5ZaSioUCvj4+OD+/fvYunUrbG1tdRLTVLzXX38dW7ZswdKlSzFixIiKDqdKY0tTItLLzc0Nhw8fxsmTJ7Ft2zYAQH5+Pr7++msA2t+8fvzxx6hZsyaUSqW0/1dffYUmTZrA0tISNjY2aN++PU6dOqV1jH379iEoKAhKpRIvvPACEhMTdeIoqnv+hg0b0Lx5c1hbW8PS0hIhISHYs2cPZsyYgTZt2kjlateurfUtqlqtxuLFi6XjOjg4oGfPnkhKStKqf+PGjfD29oaFhQU6duwo3UiWhXXr1qFp06ZwcnKCmZkZHBwcEBkZiSNHjugtf/78ebRu3RpKpRI+Pj7YtGmTzvaePXvC2dkZCoUC/v7+WLp0aZnFS0RERERVy9atW6UEZOFkYeH1X331FWQyGfr374+JEyeievXqqFevHgD9Qz/pa5mZk5OD2NhY1K1bFwqFAtWrV8fgwYNx9+5do2I9evQoLl++DEtLSwDA2rVrpe1nzpxB9+7dUa1aNSgUCnh7e2PKlCnIysqSyhw+fBgvvfQSqlWrBqVSCS8vL3Tt2hVXrlwBoNsl28vLC2vWrAEA/PLLL1otCJ/s1bZ+/XrIZDKYmZnh3r170jGnT58OmUyGGjVqSF3Vd+3ahVatWsHGxgYWFhZo2bIl9u3bZ/C1GDp0KI4cOYKkpCRYWVlJ8WmcOnUKL730Etzc3GBubg4rKys0adJEq3WuTCaT9lmzZo1OL7mSPlts2rQJ+fn5aNq0KapXry6t/+KLL6SEabt27ZCcnIyzZ88iJSUFly9fRufOnaWyhvwsNa1kW7dujY8++gjVq1eHk5MT5s6di/T0dPTv3x/W1taoW7eu9BwLaD9XJiQkoEGDBlAqlQgODta6hvo87RkyLi4OtWvXlsq3adNG53ehrJ6PAaBDhw6Qy+X4888/iyxDZUQQERXSqlUrAUB4enpK63bs2CEACABi3LhxQgghoqKiBAChUCiEiYmJ8Pf3F9WqVRNCCPHRRx9J5X19fYW7u7sAIKysrERiYqIQQoiUlBRhZWUlAAhLS0vh5+cnvQYgVq9eLYQQYvXq1dI6jXnz5knrbG1tRVBQkLC0tBQLFy4UK1asEP7+/tL20NBQERYWJmbNmiWEEGLkyJHStsDAQFGtWjUBQLi6uopbt24JIYQ4efKkMDExEQCEnZ2dqFOnjlZs+/btK/L6xcbGSuWSkpL0lhk3bpxQKpXC19dXhISECHNzcwFA2NjYiJSUFCGEEPv27ZPqsbKyEr6+vsLW1lYAECYmJuLEiRNCCCEuXrwo7OzsBADh6OgogoKChEwmEwDEzJkzpWN6enoKACI2Ntag9wERERER/TcUdf+qeS5QKBTCzMxMBAUFieDgYCGE/ntLzfNBq1atpHUdO3YUAIRcLhfBwcHS/WxAQIDIzMw0Kqbbt28LS0tLAUCEhIQIIYRITEwU1tbWAoCwtrYW/v7+0r1wu3bthBBCqFQq6Z7fxcVFhIaGCmdnZ637es3xNM9AXbt2FU5OTtI9elhYmAgLCxPHjx/Xuk9PSkoSWVlZ0v34smXLpHOoW7euACAmTZokhBBi/fr1Umyenp6idu3a0rX5+eefi7wWSUlJ0vE01zstLU16Phk1apRUduvWrcLExER4enqKBg0aCAcHB2nfHTt2CCGECAsLEzY2NgKAcHJyks7t5s2bBj9b6NOnTx8BQIwdO1ZrfePGjQUAYW5uLj3r6GPIz1KIf9+X5ubmwtbWVtSqVUs6R39/f+Hs7CxcXFyk56i7d+8KIbSfKy0tLYW/v7+wsLCQyiUnJ+t9Lwjx9GfIHTt2iNDQUK04wsLCxMiRI4UQZft8rBEcHKzznqOyx6QpEWkpfHMUFhYmQkNDhampqQAgTE1NxeHDh4UQ/94UARA7d+4UQgiRn58vMjIypJsZzQdrXl6e9GHZr18/IYQQ06ZNk24Szpw5o7WuuKRpRkaG9OERHh4u0tLShBBCPHr0SFy6dEkIIXRuZDT++usv6YN3zZo10n41a9YUAMS0adOEEEL069dPSpimpqYKIYTo379/mSVNL168KDIyMqTXly5dkvb54osvdM5h8uTJQoiCD1J7e3sBQPTu3VsIIcTAgQMFABEUFCTVuWjRIgFAWFhYiPT0dCEEk6ZEREREpJ8hSdNTp04JIQru94UwLGmakJAg1fvLL78IIYS4efOmlKjS3Pc+LabQ0FDRpEkTKeEKQMyfP18IIcSAAQOkJNv169eFEEIsXLhQKvfzzz+Lu3fvSq9v3LghHePMmTNSowl9iTJ9SWAh9D9rDBs2TAAQbdq0EUIIceLECamMJinm5eUlAIjBgwcLtVot1Gq16NatmwAgXnjhhSKvReGkaY0aNUSTJk2Eo6Oj9DxUOBGZkpIiPb8IIURWVpbw8fHReg4T4t+fbVRUlNaxDH220KdRo0YCgFiwYIHWes2zYVBQUJH7CmHYz7Jw7GZmZiIpKUk8fvxYKBQKAUA4OzuLBw8eiMuXL0v77dq1Swih/VypSTSeOXNGetbVJLeffC8Y+gxZ+OdU+HmxrJ+PNbp06SIAiAkTJhR7Xal02D2fiPTKzc3F77//jj///BPOzs7o1KkTfvnlF50JmerVq4cOHToAAORyOc6ePYvMzEwAQGxsrNRV5dixYwAgjf9z9uxZaf/AwEAAQK9evZ4a19mzZ5GRkQEAGD16NGxtbQEA1tbW8PHxKXbfY8eOQQgBAIiKioJMJoONjQ1u3LihN7YWLVrAxcUFANCzZ8+nxmaoBw8e4NVXX4WjoyNMTExQt25dadvNmzd1ymvGBHJ1dZWGHjh9+jQASF36z5w5AysrK8hkMowfPx4AkJWVhT///LPM4iYiIiKi/542bdogJCQEAHQm9ylO4aGnWrVqBZlMBnd3d6mrtaHjgp46dQpHjx6FqakpmjVrhrVr10rjmR49ehQA0LJlS3h4eAAoGO9R49ixY6hWrRrCw8MBFEyiU79+ffTt2xcnT56Ek5OTwedTnKioKAAFXeVTU1OxYcMGAEDTpk3h7++PO3fuSN3fV61aBRMTE5iYmGDr1q0AgN9//92g4yQnJ+Po0aO4f/8+TE1N0b59e2lsWqCg6/0777wDd3d3mJqawsLCApcvXwag/znjSaV5tkhLSwMA2NjYaK3XPH89Odzakwz5WRYWFBQELy8vWFlZwdnZGQDwwgsvwN7eHt7e3lK5W7du6RxL83wVGBiI+vXrA/j3+epJhj5DFqW8no81z8Ga607lgxNBEZFenp6eBs3+rkkq6uPv7y/9MdeoVq1aaUMrE4UHudfw9PQs9+M+fvwYkZGRePjwIZRKJRo0aAAzMzPpRkkz3pGxnJycUKdOHZ31xtzYEhERERE9Sd/9viYBVvjetbjkzZMNLwBoJfuKk5SUJI01WlLx8fH4+uuvcfDgQSQmJmLTpk1Yv349UlJSMHHixFLVDRQ0tvDx8cHly5exceNGbNy4EcC/ydTCvL29pSRfYYZMshUbG4uJEydiwoQJWLZsGWJjY1G/fn1069YNANCvXz/s3bsXMpkMAQEBsLa2RmJiIh49emTUc0ZJni00z32PHz/WWh8YGIhjx47h4sWLuHXrVrHPj8Yo/Jxpamqqta5wglaT8CwLpX2GLMvn4/T0dADQqY/KFpOmRFQqT35jGBgYCAsLC2RlZaF9+/aYP3++VObkyZPSN8uBgYHYunUrLly4gHPnzsHf319ngiN9AgMDYWVlhYyMDCxduhSvvPIKbGxskJGRgZSUFPj4+EgDxAOQWqUCQKNGjSCTySCEwMCBAzFu3DgABR+kBw4cgJ2dnXSMkydP4uDBg7h9+zaqV69uUGxPysnJQXZ2tvRaLpfjwoULePjwIYCCb5n79u2Lw4cPS99+67NhwwYEBwfj9u3bSEhIAADpG9EmTZogMTERdnZ22LlzJxwdHQEAd+/eRXx8PJo1a2Z03EREREREGvpaCFavXh1Xr17FxYsXARTce2ruUzWaNGki/X/KlCl49dVXARRMLrt37174+fmVOrYmTZrg3Llz2L9/P27cuIGaNWtKE9cCQOPGjSGEwG+//YaBAwdiyJAhAIARI0Zg+fLl+PXXX4tMmmqeKQo/TxRnwIABiImJwdy5c5Gamgpzc3OpRaOzszM8PT1x7do1NGzYEN98842U6Lt48SKuXbv21ISphpWVFRYuXIjt27fj5s2biImJQdeuXSGTyaRWi8OGDcPy5ctx//59BAUF4dGjRwadW2meLerWrYsTJ07g2rVrWuuHDx+OY8eOIScnB1FRUVi3bp2UKLxw4QJOnTqF3r17G/SzLCsbNmzAsGHDcO7cOamFqeb56kmGPkMW9QxaXs/HmutcuNcilT12zyeiMmVpaYnp06cDABYuXIiaNWsiNDQU1apVQ8OGDfHTTz8BAEaNGgVLS0uoVCo0btwY/v7++Pjjjw2qf+bMmQCAgwcPwsPDA8HBwXBxccGOHTsAAHXq1IGZmRkAICIiAs2aNcOmTZvg7e2NYcOGAQDGjx8Pb29vBAcHw97eHi+++CJOnDgBAIiOjoZMJkNaWhp8fX1Rt25dqYuNMfz8/GBhYSEtPXv2hLe3tzTT5ZAhQxAcHIyuXbsWW8/ixYvh5+cHX19fPHjwACYmJnj33XcBFNyA2tra4sqVK/Dw8ECDBg3g6ekJV1dXTJo0yeiYiYiIiIie5qWXXgIAbNy4ES1btkT9+vWllm8arVu3RmRkJACga9eu8PPzQ2BgIOzt7dGhQweDerU9zeTJk2FtbY3Hjx/D398fAQEBUtf9du3aoU2bNlCpVIiIiICDg4PUHXvFihUAgODg4CLr1iR1jx07hvr166NZs2Zas7g/qX///pDJZEhNTQUAdOnSBQ4ODtL2Dz74AEDBLPPu7u5o0KABXF1dUa9ePaxbt86o81YqlXj77bcBFHSl3759u9b5fPHFFwgMDESdOnW0GnE8eW5btmxBw4YN0b59ewCle7Zo2bIlAN1u9EOHDsXAgQMBAD/++CPc3d0RFBSEGjVqwM/PD7t27QJg2M+yrEyYMAGBgYFo3Lgx8vPzYWlpibfeektvWUOfIZ2dnaVkcP/+/REWFoZPP/20XJ6PMzMzpe78mutO5YNJUyIqc1OmTMGaNWvQpEkTPHjwAJcvX0b16tUxYsQIdO/eHQDg5uaG7du3IyAgAPn5+bCxsTH4ZuGdd97BN998g/DwcOTl5eHy5cvw9vZGQEAAgIIuDp988gk8PDxw69Yt/P7779LNy9KlS7Fw4ULUr18fN2/exLVr1+Dl5YXo6Gi0bt0aANCgQQN8/fXX8PLyQnZ2Njw9PbF06dIyuTYODg749ttvERAQALVaDYVCge+//77YfTZt2gQXFxdkZ2fD29sb33zzDRo2bAigYMybQ4cOoWfPnrC0tMTZs2ehVqvRvn17zJ49u0xiJiIiIiIqbMqUKejXrx/s7e1x8eJFDBgwAH369NEpt23bNsTExKBu3br466+/kJqaCn9/f0ybNg1BQUGljsPf3x+HDh1Ct27doFAocOnSJXh5eWHy5Mn47rvvABT09hoxYgRq166N5ORkXL58GV5eXpgwYQJiYmKKrHvw4MHo0aMH7OzscObMGfz+++/FdnH38vJCq1atpNeaRKHG66+/jh07dqBVq1bIysrChQsXYGNjgwEDBmDo0KFGn/ubb74Je3t7AMCcOXMAAHFxcWjTpg2USiUyMzOxaNEivYnhCRMmICIiApaWljh58qSU6CzNs8Vrr70GU1NTHD58GHfv3pXWy2QyrF69Gps2bcLLL78MGxsbqYXyK6+8Ig1hYMjPsqzs2rULSqUS+fn5CAoKwvfff48aNWoUWd6QZ0iZTIYVK1bAx8cH6enpOHLkiNQatKyfj3ft2gWVSoXg4GDpGZjKh0yU5QAPRERERERERET0n9OnTx9s2LABn3zySZEtNytKXFwcBg0aBKBsxzmtCN27d8fWrVuxbNkyvPnmmxUdTpXGlqZERERERERERFQqsbGxMDExwaJFi0o8wS0V7/Lly/juu+/g5eWFwYMHV3Q4VR4ngiIiIiIiIiIiolLx9/dnsrSc+fj48Bo/Q+yeT0RERERERERERFQIu+cTERERERERERERFcKkKREREREREREREVEhTJoSERERERERERERFcKkKREREREREREREVEhTJoSERERERERERERFcKkKREREREREREREVEhTJoSERERERERERERFcKkKREREREREREREVEhTJoSERERERERERERFfL/KavwnVo0GZYAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "knn = KNeighborsClassifier()\n",
    "\n",
    "# Hyperparameters CV\n",
    "n_neighbors = np.linspace(1, 100, 100, endpoint = True).astype(int) \n",
    "param_grid = {\"n_neighbors\" : n_neighbors} \n",
    "\n",
    "# CV\n",
    "knn_model = GridSearchCV(knn , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "knn_model = knn_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter n_neighbors : {knn_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_knn = knn_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, knn_model, X_test0, y_test0, y_pred_knn, \"K-Nearest Neighbors Classifier (KNN)\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2. SVC - Support Vector Classifier"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter kernel: {'kernel': 'rbf'}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Support Vector Classifier (SVC)\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "93.68%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.98      0.91      0.94      3118\n",
      "  TERMINATED       0.89      0.98      0.93      2338\n",
      "\n",
      "    accuracy                           0.94      5456\n",
      "   macro avg       0.93      0.94      0.94      5456\n",
      "weighted avg       0.94      0.94      0.94      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "svc = SVC(random_state = 42)\n",
    "\n",
    "# Hyperparameters CV\n",
    "kernel = [\"linear\", \"rbf\", \"sigmoid\"] # \"poly\" --> takes too long with degree --> did not check for that.\n",
    "# degree = [2,3] # Only for poly kernel\n",
    "param_grid = {\"kernel\" : kernel} \n",
    "\n",
    "# CV\n",
    "svc_model = GridSearchCV(svc , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "svc_model = svc_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter kernel: {svc_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_svc = svc_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, svc_model, X_test0, y_test0, y_pred_svc, \"Support Vector Classifier (SVC)\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. Tree"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter criterion/max_depth: {'criterion': 'gini', 'max_depth': 30}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Pruned Decision Tree Classifier\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "99.87%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       1.00      1.00      1.00      3118\n",
      "  TERMINATED       1.00      1.00      1.00      2338\n",
      "\n",
      "    accuracy                           1.00      5456\n",
      "   macro avg       1.00      1.00      1.00      5456\n",
      "weighted avg       1.00      1.00      1.00      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "tree = DecisionTreeClassifier(random_state = 42)\n",
    "\n",
    "# Hyperparameters CV\n",
    "criterion = ['gini', 'entropy', 'log_loss']\n",
    "max_depth = np.linspace(1, 100, 100, endpoint = True).astype(int) \n",
    "param_grid = {\"criterion\" : criterion, \"max_depth\" : max_depth} \n",
    "\n",
    "# CV\n",
    "tree_model = GridSearchCV(tree , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "tree_model = tree_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter criterion/max_depth: {tree_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_tree_prune = tree_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, tree_model, X_test0, y_test0, y_pred_tree_prune, \"Pruned Decision Tree Classifier\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4. Random Forest"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter criterion/bootstrap/n_estimators : {'bootstrap': True, 'criterion': 'entropy', 'max_features': None}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Random Forest Classifier\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "99.89%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       1.00      1.00      1.00      3118\n",
      "  TERMINATED       1.00      1.00      1.00      2338\n",
      "\n",
      "    accuracy                           1.00      5456\n",
      "   macro avg       1.00      1.00      1.00      5456\n",
      "weighted avg       1.00      1.00      1.00      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABU0AAAHyCAYAAADfte/mAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8g+/7EAAAACXBIWXMAAA9hAAAPYQGoP6dpAADDcklEQVR4nOzdeVxV1f7/8fdmRhQUlUFFwCFxTDNTMlPLJDVLs67zmPm1tFIbHHJKLbsNat1Mf+VUN8dbWZpdzQw15ykrJ0yUcMJZcEAU2L8/uOw4gQqeg+eor+fjsR6es/baa3/2AYHzOWswTNM0BQAAAAAAAACQJLk5OwAAAAAAAAAAcCUkTQEAAAAAAAAgB5KmAAAAAAAAAJADSVMAAAAAAAAAyIGkKQAAAAAAAADkQNIUAAAAAAAAAHIgaQoAAAAAAAAAOZA0BQAAAAAAAIAcSJoCAAAAAAAAQA4kTQEAgMvp0aOHDMOwKd7e3oqKitLo0aN16dKlPNveag4fPqwePXooODhYPj4+qlatmiZOnKjMzEyHXichISHX6+np6amyZcuqc+fOio+Pd+j1CsIVv34RERG5Xq/sEhER4ezwrumbb77R6NGjNXr06AKdd+rUKY0cOVK1a9dWsWLFVLRoUVWtWlXPP/+8du7cKUlauXKl9TrMmjXL8cHnU5MmTfL8Wnz77beqU6eO/Pz8bI5nx9yjR4+bHisAALh1eTg7AAAAgPy4fPmy4uLi9MYbb2j9+vVatmyZs0Oyy/Hjx3X//fcrMTHRqtu9e7cGDRqkvXv3asqUKYV6/fT0dB05ckRz5sxRbGysdu/erYCAgEK9JgrfN998o88++0yS8p04/eWXX9SqVSsdPXrUpn7Pnj3as2ePvLy8NGnSJAdH6linTp1S+/btlZaW5uxQAADAbYKRpgAAwKXFxsYqMzNT27ZtU1BQkCTphx9+UGxsrJMjs8/o0aOthOn06dN1/PhxPfbYY5KkqVOnatOmTYVy3caNG8s0TR0+fFj16tWTJB09elSLFi0qlOvd6kzTtCkJCQkO6zfniGlnOX/+vB5//HErYdq1a1fFx8crLS1NcXFxGjFihPz8/Jwcpa2VK1fm+lrs2bPHSpiOHTtWmZmZ1vHsr50jR8empqY6rC8AAOCaSJoCAACXZxiG6tSpow4dOlh1W7ZsydVu3759atWqlfz8/FShQoVco+O++OILNW3aVGXKlJG3t7eKFCmiu+++WxMmTFBGRobV7sKFC3r55ZdVsWJF+fr6qnjx4qpZs6Z69+5tkyxJSkrS888/r4iICHl5eal06dLq2LGj9u3bd837yczM1Jw5cyRJVapUUa9evVS6dGkNGzbMajN79uwCvUYFVaZMGXXt2tV6fvDgQevx5s2b9fjjjysiIkJ+fn7y8vJShQoV9MILL+jMmTNWu5zT/keOHKk333xTYWFh8vf3V0xMTK4E46+//qoHHnhAvr6+qlSpkmbMmHHV+OLi4tSpUyeFhITIy8tLZcuWVa9evWxG5ua8/ogRIzRs2DCVKlVKgYGBGjx4sDIyMrRgwQJVqVJF/v7+at68ucOSnpKUnJysV155RRUrVpS3t7cCAwPVsmVLrV271qZd9nT/Jk2aaP78+apWrZq8vLy0dOlSSfn/PlqwYIHq16+vwMBA+fj4qHz58nriiSf0888/S8r6f5I9yjT7efZ1r2batGk6dOiQJKlBgwb6/PPPVaFCBXl5eemuu+7SmDFjNGbMmGu+Dr169VKtWrUUGBgoT09PlSpVKs/XYevWrXrssccUEhIib29vhYSEqGnTppo2bVqB2vx9en6PHj30wAMPWMdHjBghNzc3azr+1abn/+c//1GjRo3k7+8vHx8f3X333ZoyZYpM07TajB492jo/NjZWjz32mIoWLaqOHTte8zUBAAC3ARMAAMDFdO/e3ZRkSjJjY2Ot+hdeeMGqf+edd3K1DQoKsh5nl2XLluXZ79/L66+/brXr27fvVdudOHHCNE3TPHz4sFm2bNk825QoUcKMi4u76v398ccfVtsnnnjCqj99+rRV/8ADDzjo1TTNAwcOWP02btzYqv/ggw+s+k8//dSqnzlz5lXvv2HDhnn2GxAQkKvt/fffb3NvJUuWzNUmJCTEepxt+/btZtGiRfO8funSpc0DBw7kun5efT/++OOmYRhXjelqwsPDc8X0d8nJyWb16tXzjNHd3d389ttvc/VXvHhxm3gWLlyY7++jdevW5bqX7PLuu++apmle9WuW82v+dzExMVa7uXPnXvN1iY2NtdrOnDnTqr/adb29vc3ff//dNE3TPH/+fJ5fI0lmq1at8t3GNE2zcePGpiQzPDzcNM2r/7/u3r27TXzZz03TNEePHn3VuJ9//nmr3ahRo6z6wMDAPP/fAgCA2xMjTQEAwC1h+/btmjdvnvW8bt26udrce++9OnbsmP773/9adf/5z3+sxz169NC2bdt0+vRpXblyRQkJCbrnnnskSZMnT7ZGmK1Zs0aS9PTTT+v8+fM6c+aMNm3apJEjR8rb21uSNHLkSB0+fFgBAQFatWqVLl26pG3btikwMFBnzpzR66+/ftV7OXHihPXY398/z8fHjx/P3wtzg44cOaIvvvhCkuTj46NWrVpZx+rXr6/Y2FgdO3ZMV65c0cmTJ9W7d29J0tq1a7V9+/Zc/aWmpmrRokU6ffq0mjVrJklat26dDh8+LEmaOHGiTp06JUkaNGiQzp49q6+//lrHjh3L1dfAgQN1/vx5SdK///1vJScn67333pOU9drl9dpeunRJa9asUUJCgooVKyZJWrRokZ555hmdOXNGTz/9dK6Y8uPvG0ENGDBAkjRp0iRrg6R+/frpzJkzWrFihXx9fZWRkaF+/frl2tDr7NmzeuaZZ3T8+HEdPXpU0dHR+f4+WrdunUzTVLFixRQfH69Lly5p3759mjZtmmrWrClJMk1T3bt3t65n/m9a+sqVK696f3/++af1OCoqKt+vS06zZ8/WgQMHdPHiRaWmplr//9LS0qwRonv27LG+/l999ZUuX76sQ4cO6dtvv1Xr1q3z3SYvs2bNslmuY+bMmdecjp+QkKCxY8dKknr27Knjx48rJSVF/fr1kyR9/PHH2rFjR67zSpQooS1btujChQv65z//WZCXCAAA3ILYCAoAALi0pk2b5lmXV/27776roKAgPfroowoKCtLx48dtpnOHhIRoxIgRWrNmjU6cOGEzJf/s2bM6fvy4goODFR4erh07dmjt2rUaN26cqlevrnvuuUdvvPGG1f7777+XlDVFu3Hjxrli+emnnwp8r2aOacGFtZv8qlWrbPouV66cpk2bptDQUKuuTJkymjp1qnr37q2DBw/q8uXLNn3ExcWpdu3aNnVPPPGEldh68skn9eOPP0qSEhMTVbZsWWuqtpubm8aMGSM/Pz+1bdtWDzzwgDW9XJIuXryo1atXS8pKgnfp0kVSVqJ10qRJOnTokDWtPac2bdqoYcOGkqSqVataa8IOHTpUxYsXV7NmzawEenZM9shODLq5uWn8+PEqVqyYHnroIT355JOaPXu2Dh06pJ07d1oJTUkqXry4/vWvf8nHx8eqy+/3UXh4uKSsNUjHjBmje++9VzVr1lTnzp1t+isoR3yfpaenq2PHjtq5c6fOnz9v830cFxcnSSpbtqzc3d2VkZGhyZMna9++fapevboaNmyokiVL5ruNI/zwww/W//2ZM2dq5syZudrExsaqRo0aNnXjxo2zPqypUqWKw+IBAACuiZGmAADgluDl5aXKlStr2LBh+u677/JM9lSuXNl6nJ1Iyt4cJiUlRc2bN9eXX36ppKQkm4Rptuz1St977z3VrFlTR44c0dtvv62uXbuqevXquu+++3T27FlJtqNF83L69OmrHitdurT1ODk52Xp87ty5PNv83cqVK3ONgLzRTW5SU1Nz7TjerVs3ffjhh4qPj8+VMM0+5+/yeu2lv17/I0eOSJICAgJsNhb6e/LyzJkz1tcmLCzMqjcMQ+XKlZOU9dr+/euXvb6lJPn6+lqPy5cvLynr++fvMeVH9mjN7JK9Tu7Jkyet+8ke2fr3mP/+PXLXXXflSnDm9/voySefVK9eveTu7q7PPvtML7zwgpo0aaLQ0FAtWbIk3/fzd9mvj/RXgrMgFi5cqO7du2vDhg06d+6cTcJU+ut7JSQkRB9++KECAgL0008/afDgwdbapdkfRuSnjSNc7zWX8v7/e/fddzssBgAA4PpImgIAAJcWGxsr0zSVlpamvXv36s0331SRIkXybOvp6Wk9/ntSdcOGDdZmR127dtXZs2dlmqbatWuXq5+oqCj99ttvio+P1+LFizV69Gi5u7tr8+bNmjx5sqS/kppVqlTJlVgzTTPX1OycKlSooOLFi0uyTVTt2bPHepy9bICjNW7cWOnp6YqNjZW/v79OnTqljh07WhskpaamWkm4GjVqKDExUaZp6l//+tc1+73Way9ljV6VspLEFy5csOr/PlW+RIkScnd3lyRrgyIpK3mZ/Txnm2weHnlPoLpavb1KlSolKet+spcSkGw31Mpuky1nMjdbfr+P3NzcNH36dJ08eVIrV67UJ598oqpVq+rs2bPWkgFSwUeOPvroo9bjDz/8MM82eX3AkC3n8heLFy/W5cuXbZL/OT3//PM6ceKENm3apNmzZ6tVq1ZKT0/XG2+8YX1t89PGXjk/kJg7d26er/moUaNynZfX1w8AANy+SJoCAIA7Qs7Rhb6+vvLy8tLy5cut6dE5vfPOO1q4cKE8PDzUvHlzPf3009YIwexRai1atJCUlfQcPXq0zpw5o4sXL2r9+vXq16/fNdc8dHNzs3bfjouL08yZM3XixAm99dZbVpvOnTtf9fwmTZrkSvT8fWfwa3F3d1eTJk00evRoSVlT4keMGCEpa6p1dpLM09NTfn5+iouLs5LFNyp76nxmZqZGjhyplJQULVy40Fo/NluRIkXUqFEjSdLmzZs1Z84cnTt3zpqaL9km+pwlO4bMzEwNGzZMycnJio2N1cKFCyVlLXvw9+ndecnv91FsbKwmTJigw4cPq27dunr66aet0b05R06WKFHCevz7779f9/q9e/e2RvCuW7dOPXv21IEDB3TlyhXt3btXI0aMsL438pLz/1WxYsV06dIlDRs2LFe7Y8eOaciQIdq2bZsqVKigdu3a6f7775eUlRA/efJkvto4QvPmza2k+6hRo7RlyxZr/dQZM2aoTp06DrkOAAC4xRXqNlMAAAA3IOdu2LGxsflum1P2juXZO4efOnXKZvdrSaZhGGaFChWs59m7smfvzp1X+f77703TNM1Dhw5ddddzSeaoUaOuGfexY8fM8uXL53lu3759b+Rlu6qcu8zn3En90qVLZrly5UxJppubm7lr166r3n/FihVz7Zyes9+c9ztz5sxcX7+8Xn/9bdf7bNu2bTP9/PzyfG1KlSpl7t+//5rXzxn/tWK6muzvnWv9qXz27FkzKioqzxjd3d3NhQsX5uovr13s8/t9lDP+v5f27dtb/c2ZMyfX8ddff/2a97tt2zYzJCTkqv2/9NJLpmmaZmxsbK7vgbziyvm9kn3POb9Wfy9hYWFmWlpavtqY5l9f3/DwcOse8ootW3Z99+7drbrRo0df9Vo5v+6jRo3K9fMBAADcGRhpCgAA7giBgYFavHix6tWrJx8fH1WuXFn//ve/rVGNOfXo0UPNmzdXmTJl5OXlpcDAQEVHR2vevHnWyMCyZctqy5Ytev755xUeHi5PT0+VKlVK9957r4YPH65u3bpdM56goCCtW7dO3bp1U+nSpeXl5aWqVatqwoQJdo/qzC9vb29rFGHOKcmzZ8/WE088oWLFiikoKEhDhgzR0KFD7bpWYGCgVqxYoYYNG8rb21uRkZGaMmWKHnvssVxt69Spo82bN6t9+/YKCgqSh4eHQkND1b17d23evFmRkZF2xeIIAQEBWrdunQYOHKjIyEh5enqqePHiiomJ0U8//aQ2bdrkq5/8fh/Vq1dP3bp1U+XKlVW0aFH5+vqqUqVKeuWVV/Tpp59a/f3jH//QSy+9ZLOx1/XUqVNHv//+u4YPH65atWrJz89PRYoUUZUqVdS3b1/17t37qud2795d48aNU7ly5eTr66tHHnlEP/zwQ652JUuW1Isvvqg6deqoRIkS8vT0VNmyZdWpUyf9+OOP8vLyylcbRxk1apQWLFigRo0aqVixYvLx8bFGt86ePdth1wEAALcuwzT/tlo7AAAAAAAAANzBGGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQA0lTAAAAAAAAAMiBpCkAAAAAAAAA5EDSFAAAAAAAAAByIGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQA0lTAAAAAAAAAMiBpCkAAAAAAAAA5EDSFAAAAAAAAAByIGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAnBZ+/btU7NmzeTv7y/DMNSkSROH9Z2QkCDDMGQYhlauXOmwfm81s2bNsl4HAAAAAACQhaQpcBtavXq1WrZsqdKlS1sJsalTp9rV59mzZzV69GjVrl1bRYsWVdGiRVW9enUNGjRIJ06ccFDktl5++WWtWLFCV65cUb169VStWjWH9e3t7a369eurfv368vf3d1i/15P99TAMQy+++KLNse+//97m+NKlSwvUd48ePQqcXC5durT1OgAAAAB3uvfff19NmjRRaGiovL29FR4eru7du2v//v031F9ERITN3/ienp4KCwtTr169dPLkyVztN2zYoKeeekqhoaHy8vJSqVKl1KJFC/33v//Ns/9t27apS5cuKl++vLy9vRUcHKwmTZpo2rRp143tjz/+0P/93/+pYsWK8vHxUcmSJdWgQQO9/fbbN3SvwO3GME3TdHYQABxr0qRJevXVV1WhQgXt3btXkjRlyhT17dv3hvpLSEhQkyZN9Oeff0qSAgMDVaZMGe3fv18XL15UbGysQ0eBZqtUqZLi4+M1ZMgQjR8/3uH9O0POEZ3+/v46fPiwihYtKklq0aKFTaL0v//9rx599NF8992jRw999tlnaty4cb5Gz16+fFleXl75Dx4AAAC4zUVERCgxMVFVqlRRWlqaDhw4IEkKCQlRXFxcgQdcRERE6M8//1SxYsVUrVo1HT16VImJiZKkVq1a6bvvvrPazpo1S71791ZGRoa8vLxUqVIlJSQk6OLFi5KkMWPGaMSIEVb7adOmqW/fvsrIyJBhGIqMjJSU9f4tLCxMCQkJV43r+++/19NPP231Xa5cOfn5+Sk+Pl7p6elyRKqI9xu41THSFLgNde3aVSkpKVq2bJlD+uvSpYuVMP3ggw908uRJ/f777zp37pwWLVqkkJAQq+3MmTNVt25d+fr6ys/PTw0bNtS3335rHc85LX7WrFl67LHHVKRIEUVGRmr69Ok2beLj4yVJb7/9tgzDUI8ePbRy5Urr/Jx/BOTsU5LOnz+v5557TmFhYfL29lbp0qXVsGFDffbZZ7niyJlgXLNmjWJiYhQQECBvb29VrVpV7777rjIyMqw22Z8WDx48WP3791fJkiUVFBSkl156Senp6fl6TT09PZWSkmLF88cff2jZsmXy9PTM1fbQoUNq2bKlwsLC5OvrK19fX9WoUUOTJk2y/piJiIiw+lq1apXNveV8zf7zn//ovvvuk5eXl+bMmZNrev7WrVvl5eUlwzCs/n755Rd5enrKMAzNmDEjX/cHAAAA3IqeffZZJSQkaPfu3dq/f78GDBggSUpKStKKFStuuN977rlHGzZs0J9//qlGjRpJyvq7PduRI0f03HPPKSMjQ5UqVdK+ffu0c+dOHTp0SA0aNJAkjRw5Ulu3bpUk7dmzx0qYhoeH65dfflF8fLzi4+N18uRJDRs27KqxnDx5Uh07dtTFixdVokQJxcbG6uDBg9qzZ4+Sk5P14YcfWm3//j5Lkpo0aWK9P5Ns31tNmzZNDz/8sHx8fDRy5EgVL15chmHogw8+sM6Pj4/PNbvuyJEj6tWrl8qUKSMvLy9VqFBBY8eOzff7K6AwkDQFbkMlS5aUr6+vQ/rauXOn1q5dK0l6/PHH9eKLL1oJNjc3N7Vu3VpRUVGSpHHjxqlXr17atm2bgoKC5O/vr3Xr1qlNmzb64osvcvXdp08f7dy5U56enkpISFCfPn20Z88ea+p89qeSZcuWVf369VWxYsV8xz1y5EhNnTpVJ06cUPXq1VWsWDFt3LhRsbGxVz1n5cqVatq0qX744Qe5u7srPDxce/bs0WuvvZbnKN2JEydq7ty58vX11YkTJ/Thhx9q5syZ+Yqvbdu2cnNz00cffSTTNK1/n3rqqVxtT548aU3HqVq1qvz9/bVz504NHDhQH3/8sSSpTp06KlWqlCSpWLFiV116oEuXLjp06JAiIyPzXMe0bt26GjVqlCRp0KBBOnTokHr16qX09HS1bdtWvXr1ytf9AQAAALei119/XeXLl7eeZyc4pawlvhwp53X+85//6NKlS5Kk4cOHKywsTJJUokQJm1l32e+rpk+fbg3smDhxou6++26rTYkSJdSnT5+rXnf+/PlKSUmRJI0YMcJm1mCRIkX0wgsv3PA99evXT7/++qsqVqwoPz8/tW/fXpI0b948m+tLUpkyZfTII4/o1KlTatCggWbOnKnz58+ratWqOnjwoEaOHHnN+wAKG0lTANe0a9cu6/GDDz541XYXLlzQW2+9JSkrIXjgwAElJCTovvvuk5T1i//vnnjiCe3fv18///yzJCkzM1MrV65UaGioNmzYoNDQUElS7969tWHDBpupKNfzxx9/SMr6I2Dbtm3av3+/jh8/roEDB171nFGjRik9PV3h4eHav3+/9u7dq5deeklS1h8lf1/HqFy5ctq/f7/27dunMmXKSFK+P32OjIxUq1attGfPHi1cuFCzZs1SiRIl1KVLlzzbHjhwQAcPHtS2bdt09OhR62uR/cfHwoUL1apVK0l/fYq9YcMG3XPPPTZ9PfXUUzp06JDi4uLyvJYkDRkyRPfff79Onz6te++9V9u3b1doaKg+/fTTfN0bAAAAcDvIyMjQJ598IkmqUKGCHn744Rvua9u2bWrQoIEiIiL0888/q1y5clbfkhQXF2c9rl27ts25OZ9nt8vv+7S82HPu9URHR+vQoUPauXOnhg0bpu7du0uSNcpW+itp2qVLF7m7u+ujjz7SwYMHFRwcrPj4eP3666/68ssvJWUtWbBv3z6HxgjkF0lTANeUcy2ba+2wvnPnTqWmpkqSOnToIDc3N3l7e6tdu3aSpD///DPXhlGdO3eWYRg2GzwdO3bMIXG3bt1aUlbSNDw8XDExMfrXv/6l4ODgq56zefNmSVLLli1VvHhxSVKnTp0kZb0O2VNhsj3++OMKCAiQj4+PtX5QQeLP/gS3Z8+eSklJUa9evVSkSJFc7Tw8PPTOO+8oPDxcnp6ecnd31+rVqyVlTWMpiBdeeEFublk/+t3d3fNs4+7urn//+9/y8/Oz7mfGjBkqWbJkga4FAAAA3KouXLigtm3batmyZQoJCdHixYvtGml67tw5bdy40Uoc3nvvvapTp06ebf/+viv77/ec8vs+LS/2nHs9ffv2lY+Pj6Ss9xX333+/KleuLCkrWbpnzx799ttvkmRN79+0aZOkrPdSQUFBMgxDbdq0sWLduHGjQ2ME8oukKYBrql69uvU4e0Soo2QnJj08PKy66y04nvOXevZ0lOTk5Fzt+vTpo1WrVmnQoEGKiorS1q1bNXr0aDVr1swBkWfJjl/66x4KsmB6s2bNFBUVpZSUFLm5ualfv355thswYICmTJmixMRERUZGqn79+tZU/JxrrebHtZLGOR07dsyaHiSJT3cBAABwx0hKSlLjxo21ePFi3XXXXVq7dq3NQI8b0bhxY125csXaN+Cbb77R0KFDreNVqlSxHv/yyy825+Z8nt3OnvdpN3Juzvcdeb3/ypbX+41u3bpJykqaZo8yrVevnqpWrWrTLucyYzlLXgNLgJuBpClwB3v44YcVFRVl88v676pXr677779fUtYv9smTJ1vHTNPUl19+qd27d6t69erWOqrz589XZmam0tLS9PXXX0uSwsPDVbp0abtjDgoKsh7v3btXUtb6P3+3adMmVa9eXe+9956WLVtm7Uq5c+dOnTp1Ks++69WrJylrJ8mzZ89KkubOnSspK1lbt25du+PPyTAM9e/fX1LWzpnZo1X/bsOGDZKk5s2ba+/evVq5cqXKli2bq132HxMXLly45jWv5/z58+ratasyMjKsqUCvvfaazZQhAAAA4Ha0c+dONWjQQFu3blWjRo20fv16VahQIVe7/LyX+jsPDw9169ZNTz75pCRp6tSpOnz4sKSsZbSyR7KOGzdOhw4dkiSdPXtWQ4YMsfrIXmKrV69e1syxgQMH6vfff7fanD59Wh999NFV42jfvr2198GYMWOsWWxS1nuJ9957z3qe/f4r+73Xnj17bK71d3m93+jatasMw9C2bds0depUSX+NMpX+eh/m4eGhefPmWUuNLV++XM8//7zatm171esBhYmkKXAb+vrrr1WpUiWbBb1HjhypSpUqqXPnzlZdfHy84uLidPTo0Wv2N3v2bIWHh0uStVt8rVq1FBAQoKefflrHjh2Tn5+ftUPj119/rcjISEVERFhTKcaNG+eQe6tcubK1YHqnTp3UtGnTPEdofvjhhwoJCVFkZKTq1q2rmJgYSVmbSgUGBubZ9xtvvCEPDw/9+eefqlChgu666y5NmjRJkvTMM8/k+ceSvfr27asTJ05Yn7jmpVatWpKkH374QVWqVFFYWJgOHjyYq132hlxbtmxRzZo11aBBA2vJhIIYMGCA4uPjVbFiRa1Zs0YtWrRQamqqunTpwu6VAAAAuK09+eST1hT6c+fOqWXLlmrQoIEaNGigadOmWe3y+14qL9mJ1suXL1sJyrJly2rKlClyc3PTvn37VLFiRdWoUUNly5a1BlG88cYb1kCOqlWraurUqXJ3d9eBAwdUu3ZtVapUSZUrV1ZwcLBN4vPvSpUqpTlz5qhIkSI6ffq0GjdurPLly6tatWoKDAzUq6++arXNXsf1/fffV9OmTRUdHV2g2XVS1gCa7PemSUlJ8vb2VocOHazj/fr1U9myZXXmzBlVqVJFtWvXVsWKFVWyZElrTVTAGUiaArehlJQUxcfHW7/sJenEiROKj4+3PsksiIiICG3fvl0jR45UrVq1dOnSJcXHxys0NFQvvfSSNb1j+PDhmj59uu655x4dP35cycnJio6O1jfffHPVTYcKysPDQ/Pnz1edOnV06dIlnT59WgsXLszVrlWrVmrUqJFSU1P1+++/y8fHR61bt9b3339/1dGWTZo0UWxsrB555BFlZGQoISFBUVFR+uc//2l9Iupo7u7uKlWqlDVKNy8TJkzQE088oaJFi+rcuXN69dVXrTVbc+rVq5fatWungIAA7dixQxs3bizw9P1vv/1W06dPl2EYmjFjhvz8/PTpp5+qePHi2rJli8aMGVPgewQAAABuFWlpadbj7du3a+PGjVbJHv1pr3vvvddKRn7yySc6efKkpKy9DtasWaMnn3xSJUqUUFxcnHx8fBQTE6MlS5Zo5MiRNv307t1bGzduVKdOnVSmTBklJibqzJkzql+/vl5//fVrxtCqVSv98ssvevbZZxUZGaljx47p6NGjqlmzprXBr5T1XqRVq1by9fVVfHy8hg0bpgceeKDA95wz+dm6dWubgSylS5fWhg0b1LNnT5UsWdLaL6NRo0aaOHFiga8FOIphFvQjAgAAAAAAAAC4jTHSFAAAAAAAAAByIGkKAAAAAAAAADmQNAUAAAAAAACAHEiaAgAAAAAAAEAOJE0BAAAAAAAAIAeSpgAAAAAAAACQg4ezA4BzZWZm6siRIypWrJgMw3B2OACAm8g0TZ07d05lypSRm5vzP0e9dOmSLl++7JC+vLy85OPj45C+AAD2Wb16td59911t3bpVR48e1cKFC9WmTZtrnrNy5UoNGjRIO3fuVFhYmIYPH64ePXrk+5q8zwGAO5ej3ueQNL3DHTlyRGFhYc4OAwDgRAcPHlS5cuWcGsOlS5cUGV5UScczHNJfSEiIDhw4QOIUAFzAhQsXdPfdd6tXr1568sknr9v+wIEDatWqlfr27avZs2drxYoV6t27t0JDQxUTE5Ova/I+BwBg7/scwzRN04Hx4BaTnJys4sWL689tEfIv6vxRRoAztL2rprNDAJwiXVe0Rt/r7NmzCggIcGosKSkpCggI0IGt4fIvZt/vo5RzmYqs+6eSk5Pl7+/voAgBAI5gGMZ1R5oOHjxYS5Ys0Y4dO6y6Dh066OzZs1q6dGm+rpP9PufgwYP8LgCAO0xKSorCwsLsfp/DSNM7XPZUFf+ibna/SQVuVR6Gp7NDAJzjfx+butK0Rf9i/D4CgDvd+vXr1axZM5u6mJgYDRgw4KrnpKWlKS0tzXp+7tw5SZK/v7+VNL10JUNp6ZmOD/h/MjNNnU9L1/m0dJ27lK7zaVd07lK6Vc6nXdHlQrw+ANzpwgKLqFt0hPXc3vc5JE0BAIDLyDAzlWHnHJgMkzekAHArS0pKUnBwsE1dcHCwUlJSlJqaKl9f31znjB8/Xm+88cZV+9yccFpdp2/UpSv8jgCA21W9iBI2SVN7kTQFAAAuI1OmMmVf1tTe8wEAt56hQ4dq0KBB1vPsqZnZtieevSkJU28PNxXz8VAxH08V9fZQMR+P//3rqWI+HvLycJPrzO8AgNtLuRK5P1SzB0lTAAAAAIDLCAkJ0bFjx2zqjh07Jn9//zxHmUqSt7e3vL29r9v3Y7VCNeEftR0RZi6GIXm6s8QMANwuSJoCAACXkalM2TsOyP4eAADOFB0dre+//96mbvny5YqOjra7by93N3l5kNgEAFwfvy0AAIDLyDBNhxQAgOs4f/68tm/fru3bt0uSDhw4oO3btysxMVFS1tT6bt26We379u2r/fv367XXXtOePXv08ccfa8GCBRo4cKAzwgcA3KFImgIAAAAACs2WLVtUp04d1alTR5I0aNAg1alTRyNHjpQkHT161EqgSlJkZKSWLFmi5cuX6+6779b777+vadOmKSYmxinxAwDuTEzPBwAALoONoADg9tOkSROZ15gFMGvWrDzP+eWXXwoxKgAAro2RpgAAwGVkylSGnaWgSdMpU6aoVq1a8vf3l7+/v6Kjo/Xf//7XOn7p0iX169dPJUuWVNGiRdWuXbtcG5QkJiaqVatWKlKkiIKCgvTqq68qPT3dps3KlSt1zz33yNvbW5UqVcozSQAAKBzHz11ydggAgFsMSVMAAHBHK1eunN5++21t3bpVW7Zs0UMPPaQnnnhCO3fulCQNHDhQixcv1n/+8x+tWrVKR44c0ZNPPmmdn5GRoVatWuny5ctat26dPvvsM82aNcuadiplrd/XqlUrNW3aVNu3b9eAAQPUu3dvLVu27KbfLwDciX47lCxJCgss4uRIAAC3CqbnAwAAl+GM6fmtW7e2ef7mm29qypQp2rBhg8qVK6fp06drzpw5euihhyRJM2fOVNWqVbVhwwY1aNBAP/zwg3bt2qUff/xRwcHBql27tsaOHavBgwdr9OjR8vLy0tSpUxUZGan3339fklS1alWtWbNGEydOZI0+ALgJrmRkSpKqlfF3ciQAgFsFI00BAIDLyDBNhxRJSklJsSlpaWnXv35GhubNm6cLFy4oOjpaW7du1ZUrV9SsWTOrTVRUlMqXL6/169dLktavX6+aNWsqODjYahMTE6OUlBRrtOr69ett+shuk90HAODmMJwdAADglkHSFAAA3JbCwsIUEBBglfHjx1+17e+//66iRYvK29tbffv21cKFC1WtWjUlJSXJy8tLxYsXt2kfHByspKQkSVJSUpJNwjT7ePaxa7VJSUlRamqqvbcKAAAAwMGYng8AAFxG5v+KvX1I0sGDB+Xv/9c0TG9v76ueU6VKFW3fvl3Jycn68ssv1b17d61atcrOSAAAAADcqkiaAgAAl5EhUxl2rmmafb6/v79N0vRavLy8VKlSJUlS3bp1tXnzZn3wwQdq3769Ll++rLNnz9qMNj127JhCQkIkSSEhIdq0aZNNf8eOHbOOZf+bXZezjb+/v3x9fQt+kwAAAAAKFdPzAQAA/iYzM1NpaWmqW7euPD09tWLFCutYXFycEhMTFR0dLUmKjo7W77//ruPHj1ttli9fLn9/f1WrVs1qk7OP7DbZfQAAAABwLYw0BQAALiPDzCr29lEQQ4cOVYsWLVS+fHmdO3dOc+bM0cqVK7Vs2TIFBATomWee0aBBgxQYGCh/f3+98MILio6OVoMGDSRJzZs3V7Vq1dS1a1e98847SkpK0vDhw9WvXz9rSYC+ffvqo48+0muvvaZevXrpp59+0oIFC7RkyRL7bhYAAABAoSBpCgAAXIYj1zTNr+PHj6tbt246evSoAgICVKtWLS1btkyPPPKIJGnixIlyc3NTu3btlJaWppiYGH388cfW+e7u7vruu+/03HPPKTo6Wn5+furevbvGjBljtYmMjNSSJUs0cOBAffDBBypXrpymTZummJgYO+8WAAAAQGEgaQoAAO5o06dPv+ZxHx8fTZ48WZMnT75qm/DwcH3//ffX7KdJkyb65ZdfbihGAAAAADcXSVMAAOAyMmUoQ4bdfQAAAACAPUiaAgAAl5FpZhV7+wAAAAAAe7g5OwAAAAAAAAAAcCWMNAUAAC4jwwHT8+09HwAAAABImgIAAJdB0hQAAACAK2B6PgAAAAAAAADkwEhTAADgMjJNQ5mmfSNF7T0fAAAAAEiaAgAAl8H0fAAAAACugOn5AAAAAAAAAJADI00BAIDLyJCbMuz8TDfDQbEAAAAAuHORNAUAAC7DdMCapiZrmgIAAACwE9PzAQAAAAAAACAHRpoCAACXwUZQAAAAAFwBSVMAAOAyMkw3ZZh2rmlqOigYAAAAAHcspucDAAAAAAAAQA6MNAUAAC4jU4Yy7fxMN1MMNQUAAABgH5KmAADAZbCmKQAAAABXwPR8AAAAAAAAAMiBkaYAAMBlOGYjKKbnAwAAALAPSVMAAOAystY0tW96vb3nAwAAAADT8wEAAAAAAAAgB0aaAgAAl5EpN2XY+ZluppieDwAAAMA+JE0BAIDLYE1TAAAAAK6A6fkAAAAAAAAAkAMjTQEAgMvIlJsymZ4PAAAAwMlImgIAAJeRYRrKMA27+wAAAAAAezA9HwAAAAAAAAByYKQpAABwGRlyU4adn+lmMD0fAAAAgJ1ImgIAAJeRabop07RzTVOTpCkAAAAA+zA9HwAAAAAAAAByYKQpAABwGUzPBwAAAOAKSJoCAACXkSkpwzTs7gMAAAAA7MH0fAAAAAAAAADIgZGmAADAZWTKTZl2fqZr7/kAAAAAQNIUAAC4jAzTTRmmnWua2nk+AAAAAPCuAgAAAAAAAAByYKQpAABwGZkylCl7N4Ky73wAAAAAIGkKAABcBtPzAQAAALgC3lUAAAAAAAAAQA6MNAUAAC4jQ27KsPMzXXvPBwAAAACSpgAAwGVkmoYyTTvXNLXzfAAAAABgKAYAAAAAAAAA5MBIUwAA4DIyHTA9P5PPhAEAAADYiaQpAABwGZmmmzJNO5Omdp4PAAAAALyrAAAAAAAAAIAcGGkKAABcRoYMZci+jZzsPR8AAAAASJoCAACXwfR8AAAAAK6AdxUAAAAAAAAAkAMjTQEAgMvIkP3T6zMcEwoA3LFOnjypL7/8Uj///LP27dun5ORk+fv7q3LlymrUqJGeeuoplSpVytlhAgBQqEiaAgAAl8H0fABwnr1792r06NH66quvlJ6eLtM0bY5v2bJF8+bN00svvaSnn35aI0eO1F133eWkaAEAKFy8qwAAAHe08ePHq169eipWrJiCgoLUpk0bxcXF2bRp0qSJDMOwKX379rVpk5iYqFatWqlIkSIKCgrSq6++qvT0dJs2K1eu1D333CNvb29VqlRJs2bNKuzbA4B8q169uubNm6fMzEzVr19fL774ot5//319+umnev/99/Xiiy+qfv36yszM1Jw5c1SjRg1nhwwAQKFhpCkAAHAZGaabMuwcKVrQ81etWqV+/fqpXr16Sk9P17Bhw9S8eXPt2rVLfn5+Vrtnn31WY8aMsZ4XKVLkr2tmZKhVq1YKCQnRunXrdPToUXXr1k2enp566623JEkHDhxQq1at1LdvX82ePVsrVqxQ7969FRoaqpiYGLvuGQAcISwsTIMGDVL79u1VunTpq7Y7ceKE5s6dqw8++OAmRgcAwM1F0hQAALgMU4Yy7VzT1Czg+UuXLrV5PmvWLAUFBWnr1q168MEHrfoiRYooJCQkzz5++OEH7dq1Sz/++KOCg4NVu3ZtjR07VoMHD9bo0aPl5eWlqVOnKjIyUu+//74kqWrVqlqzZo0mTpxI0hSAS9i3b5/c3K7/wVPp0qX14osvqn///jchKgAAnIPp+QAAADkkJydLkgIDA23qZ8+erVKlSqlGjRoaOnSoLl68aB1bv369atasqeDgYKsuJiZGKSkp2rlzp9WmWbNmNn3GxMRo/fr1hXUrAFAg+UmY2tMeAIBbCSNNAQCAy3Dk9PyUlBSbem9vb3l7e1/z3MzMTA0YMEANGza0WauvU6dOCg8PV5kyZfTbb79p8ODBiouL09dffy1JSkpKskmYSrKeJyUlXbNNSkqKUlNT5evrewN3CwCO06tXr3y1MwxD06dPL3D/kydP1rvvvqukpCTdfffd+te//qX77rvvqu0nTZqkKVOmKDExUaVKldJTTz2l8ePHy8fHp8DXBgCgoEiaAgAAl5FpGso07Zuen31+WFiYTf2oUaM0evToa57br18/7dixQ2vWrLGp79Onj/W4Zs2aCg0N1cMPP6z4+HhVrFjRrngBwFXMmjVLhnHtn8Gmad5Q0nT+/PkaNGiQpk6dqvr162vSpEmKiYlRXFycgoKCcrWfM2eOhgwZohkzZuj+++/X3r171aNHDxmGoQkTJhTo2gAA3AiSpgAA4LZ08OBB+fv7W8+vN8q0f//++u6777R69WqVK1fumm3r168vKWv9v4oVKyokJESbNm2yaXPs2DFJstZBDQkJsepytvH392eUKQCXUL58eZukaVJSktLS0qzlSk6fPi1PT0+VLVu2wH1PmDBBzz77rHr27ClJmjp1qpYsWaIZM2ZoyJAhudqvW7dODRs2VKdOnSRJERER6tixozZu3HgjtwYAQIGxCA0AAHAZGXJzSJEkf39/m3K1pKlpmurfv78WLlyon376SZGRkdeNc/v27ZKk0NBQSVJ0dLR+//13HT9+3GqzfPly+fv7q1q1alabFStW2PSzfPlyRUdHF/h1AoDCkJCQoAMHDujAgQOaOHGi3N3d9eOPP+rkyZM6efKkVqxYIXd3d7311lsF6vfy5cvaunWrzbrObm5uatas2VXXdb7//vu1detW6wOp/fv36/vvv1fLli3zbJ+WlqaUlBSbAgCAPUiaAgAAl5E9Pd/eUhD9+vXTF198oTlz5qhYsWJKSkpSUlKSUlNTJUnx8fEaO3astm7dqoSEBC1atEjdunXTgw8+qFq1akmSmjdvrmrVqqlr16769ddftWzZMg0fPlz9+vWzkrV9+/bV/v379dprr2nPnj36+OOPtWDBAg0cONCxLyIAOMDgwYMVERGhhx56yKpr2rSpKlSooBEjRhSor5MnTyojIyPPdZ2z133+u06dOmnMmDF64IEH5OnpqYoVK6pJkyYaNmxYnu3Hjx+vgIAAq/x9iRYAAAqKpCkAALijTZkyRcnJyWrSpIlCQ0OtMn/+fEmSl5eXfvzxRzVv3lxRUVF6+eWX1a5dOy1evNjqw93dXd99953c3d0VHR2tLl26qFu3bhozZozVJjIyUkuWLNHy5ct199136/3339e0adMUExNz0+8ZAK4nMTFRcXFx+vTTT3Xq1CmdOnVK06ZN0549e3To0KFCv/7KlSv11ltv6eOPP9a2bdv09ddfa8mSJRo7dmye7YcOHark5GSrHDx4sNBjBADc3ljTFAAAuIxMuSnTzs90C3q+aZrXPB4WFqZVq1Zdt5/w8HB9//3312zTpEkT/fLLLwWKDwCcoVGjRvrxxx/Vt29f9e3b16o3TVONGjUqUF+lSpWSu7t7nus6Z6/7/HcjRoxQ165d1bt3b0lZm/BduHBBffr00euvvy43N9uf9d7e3tdduxoAgIJgpCkAAHAZGabhkAIAsM+0adN0zz33yDRNm1KnTh1NmzatQH15eXmpbt26Nus6Z2ZmasWKFVdd1/nixYu5EqPu7u6Srv9hFwAAjsBIUwAAAACAjfLly2vLli366aeftHPnTklS9erVbdY4LYhBgwape/fuuvfee3Xfffdp0qRJunDhgnr27ClJ6tatm8qWLavx48dLklq3bq0JEyaoTp06ql+/vvbt26cRI0aodevWVvIUAIDCRNIUAAC4jBvZyCmvPgAAjvHQQw+patWqSk9Pt2tzpfbt2+vEiRMaOXKkkpKSVLt2bS1dutTaHCoxMdFmZOnw4cNlGIaGDx+uw4cPq3Tp0mrdurXefPNNu+8JAID8YHo+AABwGabppkw7i2ny5w0AOMIXX3yh8PBwlStXTu3bt9fixYv10EMPXXf95qvp37+//vzzT6WlpWnjxo2qX7++dWzlypWaNWuW9dzDw0OjRo3Svn37lJqaqsTERE2ePFnFixe3864AAMgfRpoCAAAAAGx89dVX6tatm03dPffco1WrVikoKEgtW7Z0UmQAANwcDMUAAAAuI0OGQwoAwD5vvfWWDMPQgAEDrLqyZcuqTJky2rx5s/MCAwDgJiFpCgAAXEam+de6pjdenH0XAHDr27Vrl6pUqaIJEybY1JcuXVpHjhxxUlQAANw8JE0BAAAAADZ8fHyUkpKizMxMqy4tLU0HDhxQkSJFnBgZAAA3B0lTwE6LPyupvg9XUdu7aqrtXTU1oHVlbf6pmHX8+y9K6tV2ldT2rpqKKVNb55Pdc/Ux54NgDWhdWY9XqKUno2pe83opp93VuW61q/YF3Gr+0f+Ylh35VX3fOOzsUOAC7N0EKrsAAOwTHR2to0ePWmuXHjp0SM2aNVNKSoqio6OdHB0AAIWPdxWAnUqHXlGvYUf00dI4/eu/e3V3w3Ma3TNSCXE+kqRLqW66t0mKOrxw7Kp9pF829GDrs2rV/eR1rzfh5fKKrHrJYfEDznTX3RfVqstp7d/p4+xQ4CIyZTikAADsM2rUKHl4eGj58uUyDEOHDx/W2rVr5eHhoREjRjg7PAAACp3LJU2TkpL0wgsvqEKFCvL29lZYWJhat26tFStWWG3WrVunli1bqkSJEvLx8VHNmjU1YcIEZWRk2PRlGIYMw9CGDRts6tPS0lSyZEkZhqGVK1fmam8YhgICAtSwYUP99NNP1vEePXqoTZs2V409IiLCpo/s8vbbb2v06NF5HstZsq+R17FHH300z+v4+voqIiJC//jHP2xixc3ToHmK7nv4nMpWuKxyFdPUc0iSfPwytWdr1rSlJ589ofYvHFdU3YtX7aPbq0l6ss8JRUZdOxm6+LOSupDirqf6HnfoPQDO4FMkQ4M/+lOTXi2nc4yaBgDApdSvX18//fSTHnzwQfn6+srX11eNGzfWjz/+qPr16zs7PAAACp1LJU0TEhJUt25d/fTTT3r33Xf1+++/a+nSpWratKn69esnSVq4cKEaN26scuXKKTY2Vnv27NFLL72kcePGqUOHDjJN290fwsLCNHPmTJu6hQsXqmjRonnGMHPmTB09elRr165VqVKl9Nhjj2n//v35vocxY8bo6NGjNuWFF17QK6+8YlNXrly5XG2zPfroo7n6mDt3bp7XiYuL0+eff67ixYurWbNmevPNN/MdKxwvI0Na+U1xpV10U9V7Lzi07z/3emvOxBC9+sGfMlzqfy5wY/q/dVibVvjrl5+LXb8x7hgZpuGQAgCwX8OGDRUbG6vz58/r/Pnzio2NVaNGjZwdFgAAN4WHswPI6fnnn5dhGNq0aZP8/Pys+urVq6tXr166cOGCnn32WT3++OP65JNPrOO9e/dWcHCwHn/8cS1YsEDt27e3jnXv3l0ffvihJk2aJF9fX0nSjBkz1L17d40dOzZXDMWLF1dISIhCQkI0ZcoUlS1bVsuXL9f//d//5eseihUrppCQkDyP5UzUuru7X7Wtt7f3VfvI6zrly5fXgw8+qNDQUI0cOVJPPfWUqlSpkq944RgHdvtoQOvKupzmJl+/TI2cfkDhd6U5rP/LaYbGPx+h3iOOKKjcFR1N9HZY34AzNH7ijCrVTNULLSs7OxS4GEesScqapgBgP3d3dzVo0EBr1661qe/Vq5d27typjRs3OikyAABuDpd5V3H69GktXbpU/fr1s0mYZitevLh++OEHnTp1Sq+88kqu461bt9Zdd92Va0Rm3bp1FRERoa+++kqSlJiYqNWrV6tr167XjSk7yXr58uUbuaWb7qWXXpJpmvr222+v2iYtLU0pKSk2BfYrVzFNHy+P04dL9uqxbif13kvh+nOv4xKbM8eHqnylS3q43RmH9Qk4S+kyl/XcmCP6Z//yupLmMr+GAABADqZp5prFJ0k7duzQli1bnBARAAA3l8uMNN23b59M01RUVNRV2+zdu1eSVLVq1TyPR0VFWW1y6tWrl2bMmKEuXbpo1qxZatmypUqXLn3NeC5evKjhw4fL3d1djRs3zvd9DB48WMOHD7ep++9//1ugaSzfffddruUDhg0bpmHDhl3zvMDAQAUFBSkhIeGqbcaPH6833ngj37Egfzy9TJWNzEquV66VqrjtRfTNtNJ66Z1DDul/+5piStjjoxZhxbMq/vf369M1aqjji8fU7dUkh1wHuBkq1UpVidLpmrzsr5/X7h5SzQYX9HjPk3osopYyM5lefafKlKFMO6fXsxEUANy4MWPGWI8PHTpk8/zChQv67bff5OPDBo4AgNufyyRN8/oU0xFtJalLly4aMmSI9u/fr1mzZunDDz+8atuOHTvK3d1dqampKl26tKZPn65atWrl+1qvvvqqevToYVNXtmzZAsXbtGlTTZkyxaYuMDAwX+eapmltKpWXoUOHatCgQdbzlJQUhYWFFSg+XJ9pSlcuO24E3YhpB3T50l/9xW0vogmDyuv9hX+oTMStMRIayLb956Lq0/Qum7qXJx7UwX0+WjC5NAnTO5wpw+6kp0nSFABuWPYGtpJ0+PDhXAMuTNNUdHS0M0IDAOCmcpmkaeXKlWUYhvbs2XPVNnfdlfUme/fu3br//vtzHd+9e7eqVauWq75kyZJ67LHH9Mwzz+jSpUtq0aKFzp07l+c1Jk6cqGbNmikgIOC6o1HzUqpUKVWqVKnA5+Xk5+d3Q32cOnVKJ06cUGRk5FXbeHt7y9ub9TAdacZboar3UIpKl72i1PNuil1YQr+tK6o358RLkk4f99CZ4546csBLknRgj4+K+GWqdNnL8i+RIUk6fshT58566PhhT2VmSPE7spaGKBOZJl+/zFyJ0eTTWf91y1dOU9GAjJt1q4BDpF5w159xvjZ1ly666dyZ3PUAAODmKl++vAzDUGJiory8vGz2WihSpIiioqI0btw4J0YIAMDN4TJJ08DAQMXExGjy5Ml68cUXc61revbsWTVv3lyBgYF6//33cyVNFy1apD/++CPPzZ2krCn6LVu21ODBg+Xu7n7VOEJCQuxOejrLBx98IDc3N7Vp08bZodxRzp700Lsvhuv0cQ8VKZahyKqX9OaceNVtfF6StOTzUvpiwl9/bL7SNmvjm5cnJqp5+9OSpM/fC9XyBX+NJn6+edZGXu98uU9333/+Zt0KADhdpumA6fl2ng8Ad7Lspb7c3NxUp04drVu3zrkBAQDgJC6TNJWkyZMnq2HDhrrvvvs0ZswY1apVS+np6Vq+fLmmTJmi3bt36//9v/+nDh06qE+fPurfv7/8/f21YsUKvfrqq3rqqaf0j3/8I8++H330UZ04cUL+/v52xZicnKzt27fb1JUsWdKa4n7u3DklJdmuL1mkSJECXTctLS1XHx4eHipVqpT1PPs6V65c0YEDB/TFF19o2rRpGj9+/C2b9L1VDZpw8JrHu76SpK6vXHvN0VcmJeqVSYn5vubd95/XsiPb890ecHWvPcXPLWTJNN2Uadq3vIm95wMApAMHDtjMUEtPT5eHh0u9fQQAoFC51LuKChUqaNu2bWratKlefvll1ahRQ4888ohWrFhhrfH51FNPKTY2VomJiWrUqJGqVKmiiRMn6vXXX9e8efOuup6nYRgqVaqUvLy87Ipx5cqVqlOnjk3Juc7PyJEjFRoaalNee+21Al1j6dKlufp44IEHbNpkX6dSpUrq2rWrkpOTtWLFCg0ePNiu+wMAAACA8PBwxcXFqXHjxvLx8VHjxo21YsUK9erVi9GnAIA7gst9VBgaGqqPPvpIH3300VXbNGrUSEuXLr1uX9faMKp48eK5jl9vg6lZs2Zp1qxZVz1+rV3r89v2etco6HUAALiVMD0fAFzDypUr1bx5c6Wnp0vKeq9Uvnx5671KXntMAABwO3GpkaYAAODOlinDIQUAYJ+RI0cqIyNDbdu2teoqV66s4OBgrV271omRAQBwc5A0BQAAAADY2LJliyIjI/XVV1/Z1IeGhurw4cNOigoAgJvH5abnAwCAOxfT8wHANXh4eORaviwzM1OHDx+Wu7u7k6ICAODmYaQpAABwGdlJU3sLAMA+derUUUJCgp599llJ0okTJ9SxY0edOHFCdevWdXJ0AAAUPpKmAAAAAAAbQ4YMkSTNmDFDhmFo//79+vLLL2UYhl599VUnRwcAQOEjaQoAAFwGI00BwDW0aNFCc+bMUfny5WWapkzTVPny5fXFF1+oRYsWzg4PAIBCx5qmAAAAAIBc2rdvr/bt2+vkyZOSpFKlSjk5IgAAbh6SpgAAwGWwERQAOE9iYmK+j5cvX76wwwEAwKlImgIAAJdhSsqUfUlP8/pNAAB5iIyMzFc7wzCUnp5eyNEAAOBcJE0BAAAAADJNPnYCACAbSVMAAOAymJ4PAM4TGxvr7BAAAHAZJE0BAIDLIGkKAM7TuHFjZ4cAAIDLcHN2AAAAAAAA1/Pdd9/p/vvvl7+/v/z9/dWwYUMtXrzY2WEBAHBTkDQFAAAuI3ukqb0FAGCfjz/+WE888YQ2btyo8+fP6/z581q/fr3atGmjyZMnOzs8AAAKHUlTAADgMkiaAoBrGD9+vEzTVKVKlTRw4EANHDhQd911l0zT1Ntvv+3s8AAAKHSsaQoAAAAAsHHq1CmVLl1a27Ztk5+fnyRpzJgxqlChgs6cOePk6AAAKHyMNAUAAC7DNA2HFACAfZo2bapixYpZCVNJ8vPzU9GiRdWsWTMnRgYAwM3BSFMAAOAyMmUoU/YlPe09HwAgdejQQX369FHXrl3Vvn17SdKCBQt04sQJdejQQatXr7baPvjgg84KEwCAQkPSFAAAAABgo3v37jIMQ3PmzNGcOXNsjnXu3Nl6bBiG0tPTb3Z4AAAUOpKmAADAZThiIyc2ggIAxzBN09khAADgNCRNAQCAy3DEmqSsaQoA9jtw4ICzQwAAwKlImgIAAAAAbISHhzs7BAAAnIqkKQAAcBlMzwcA17F8+XLFxsbq2LFjNlP1DcPQ9OnTnRgZAACFj6QpAABwGUzPBwDXMHr0aI0dOzZXvWmaJE0BAHcEkqYAAAAAABuffPKJTNNUeHi4wsPDZRh8IAUAuLOQNAUAAC7DdMD0fEaaAoD90tPTVbFiRf3xxx/ODgUAAKdwc3YAAAAA2UxJpmlncfZNAMBt4MUXX9TRo0e1YcMGZ4cCAIBTMNIUAAAAAGBj0KBBmjt3rho2bKgSJUrI39/fOmYYhuLj450YHQAAhY+kKQAAcBmZMmTIvun1mXaeDwCQ/u///k979uyRaZo6ffq0Tp8+bR1jfVMAwJ2ApCkAAHAZpmnYvSYpa5oCgP0WLlwoSWrYsKEiIiLk4cFbRwDAnYU1TQEAwB1t/PjxqlevnooVK6agoCC1adNGcXFxNm0uXbqkfv36qWTJkipatKjatWunY8eO2bRJTExUq1atVKRIEQUFBenVV19Venq6TZuVK1fqnnvukbe3typVqqRZs2YV9u0BwA0pU6aMqlSpop9//ln//ve/NXPmTJsCAMDtjqQpAABwGZmm4ZBSEKtWrVK/fv20YcMGLV++XFeuXFHz5s114cIFq83AgQO1ePFi/ec//9GqVat05MgRPfnkk9bxjIwMtWrVSpcvX9a6dev02WefadasWRo5cqTV5sCBA2rVqpWaNm2q7du3a8CAAerdu7eWLVtm/wsHAA724Ycf6vDhw5o3b57Onz/v7HAAALjpmGMBAABchmlmFXv7KIilS5faPJ81a5aCgoK0detWPfjgg0pOTtb06dM1Z84cPfTQQ5KkmTNnqmrVqtqwYYMaNGigH374Qbt27dKPP/6o4OBg1a5dW2PHjtXgwYM1evRoeXl5aerUqYqMjNT7778vSapatarWrFmjiRMnKiYmxr6bBgAHa9WqlSSpc+fOuY4ZhpFrJD0AALcbRpoCAADkkJycLEkKDAyUJG3dulVXrlxRs2bNrDZRUVEqX7681q9fL0lav369atasqeDgYKtNTEyMUlJStHPnTqtNzj6y22T3AQCuxDTNaxYAAG53jDQFAAAuw5EbQaWkpNjUe3t7y9vb+5rnZmZmasCAAWrYsKFq1KghSUpKSpKXl5eKFy9u0zY4OFhJSUlWm5wJ0+zj2ceu1SYlJUWpqany9fUtwF0CQOEaNWqUs0MAAMCpSJoCAACX4cikaVhYmE39qFGjNHr06Gue269fP+3YsUNr1qyxKwYAuNWRNAUA3OlImgIAgNvSwYMH5e/vbz2/3ijT/v3767vvvtPq1atVrlw5qz4kJESXL1/W2bNnbUabHjt2TCEhIVabTZs22fR37Ngx61j2v9l1Odv4+/szyhSASzp16pQ++ugjbdmyRZJUr1499evXTyVLlnRyZAAAFD6SpgAAwGVkmoYMO0eaZv7vfH9/f5uk6dWYpqkXXnhBCxcu1MqVKxUZGWlzvG7duvL09NSKFSvUrl07SVJcXJwSExMVHR0tSYqOjtabb76p48ePKygoSJK0fPly+fv7q1q1alab77//3qbv5cuXW30AgCs5ePCg7r//fh05csSq+/777zVt2jStW7fO5sMlAABuR2wEBQAAXIZpOqYURL9+/fTFF19ozpw5KlasmJKSkpSUlKTU1FRJUkBAgJ555hkNGjRIsbGx2rp1q3r27Kno6Gg1aNBAktS8eXNVq1ZNXbt21a+//qply5Zp+PDh6tevnzXCtW/fvtq/f79ee+017dmzRx9//LEWLFiggQMHOvQ1BABHGDZsmA4fPizDMBQVFaWoqCgZhqHDhw/r9ddfd3Z4AAAUOpKmAADgjjZlyhQlJyerSZMmCg0Ntcr8+fOtNhMnTtRjjz2mdu3a6cEHH1RISIi+/vpr67i7u7u+++47ubu7Kzo6Wl26dFG3bt00ZswYq01kZKSWLFmi5cuX6+6779b777+vadOmKSYm5qbeLwDkx/Lly+Xr66vNmzdr586d2rlzpzZt2iRvb28tW7bM2eEBAFDomJ4PAABcRtZIUXs3gipo++uf4OPjo8mTJ2vy5MlXbRMeHp5r+v3fNWnSRL/88kvBAgQAJzh9+rSqVKmiOnXqWHX33HOPKlSooD/++MOJkQEAcHMw0hQAALgM0zQcUgAA9gkJCdHevXu1ePFiq27RokXau3evtcEdAAC3M5KmAAAAAAAbrVu31pUrV9SmTRsVK1ZMxYoVU9u2bZWRkaHHH3/c2eEBAFDoSJoCAACXYTqoAADsM27cOFWvXl2maerChQu6cOGCTNNU9erVNXbsWGeHBwBAoWNNUwAA4DIcMb2e6fkAYL8SJUpoy5Ytmjt3rjZv3ixJqlevnjp27Chvb28nRwcAQOEjaQoAAAAAyMXb21s9evRQjx49nB0KAAA3HdPzAQCA62B+PgA41fTp01WhQgVNmzYt17HJkyerQoUKmjFjhhMiAwDg5iJpCgAAXMf/pufbU8T0fAC4YV988YUOHjyop59+OtexTp066dChQ5o1a9YN9T158mRFRETIx8dH9evX16ZNm67Z/uzZs+rXr59CQ0Pl7e2tu+66S99///0NXRsAgIJiej4AAAAAQJK0e/duRUREKCAgINexEiVKKCIiQnv27Clwv/Pnz9egQYM0depU1a9fX5MmTVJMTIzi4uIUFBSUq/3ly5f1yCOPKCgoSF9++aXKli2rP//8U8WLF7+R2wIAoMBImgIAAJdhmlnF3j4AADfm7NmzKlas2FWPm6aplJSUAvc7YcIEPfvss+rZs6ckaerUqVqyZIlmzJihIUOG5Go/Y8YMnT59WuvWrZOnp6ckKSIiosDXBQDgRuUraTpmzJh8dzhy5MgbDgYAANzZrCn2dvYBALgxwcHBOnDggHbs2KEaNWrYHNuxY4cOHDigsmXLFqjPy5cva+vWrRo6dKhV5+bmpmbNmmn9+vV5nrNo0SJFR0erX79++vbbb1W6dGl16tRJgwcPlru7e672aWlpSktLs57fSGIXAICc8pU0HT16tAwjf29ASJoCAAAAwK2pUaNGmjNnjh5//HFNmjRJjRo1kmEY+vnnnzVw4ECZpqkHH3ywQH2ePHlSGRkZCg4OtqkPDg6+6lT//fv366efflLnzp31/fffa9++fXr++ed15coVjRo1Klf78ePH64033ihQXAAAXEu+kqbly5fPd9IUAADghjliIydGmgLADXv55Zc1f/58/fnnn2rbtq3NMdM05eHhoUGDBhV6HJmZmQoKCtInn3wid3d31a1bV4cPH9a7776bZ9J06NChNnGlpKQoLCys0OMEANy+8pU0TUhIKOQwAAAAWNMUAJytTp06mjJlip577jllZGTYHHN3d9eUKVNUp06dAvVZqlQpubu769ixYzb1x44dU0hISJ7nhIaGytPT02YqftWqVZWUlKTLly/Ly8vLpr23t7e8vb0LFBcAANdywxtBXbhwQb/99pvc3d113333OTImAAAAAICT9O7dW40aNdL06dO1a9cumaap6tWrq1evXoqKiipwf15eXqpbt65WrFihNm3aSMoaSbpixQr1798/z3MaNmyoOXPmKDMzU25ubpKkvXv3KjQ0NFfCFACAwuB2IyeNGzdOwcHBeuCBBzRgwAAtWLBAFSpU0Jw5cxwdHwAAuJOYDioAALtUqVJF77zzjr777jstWbJE77zzzg0lTLMNGjRIn376qT777DPt3r1bzz33nC5cuKCePXtKkrp162azUdRzzz2n06dP66WXXtLevXu1ZMkSvfXWW+rXr5/d9wYAQH4UeKTp1KlTc2329PDDD+vgwYOaN2+eOnXq5LDgAADAncU0DZl2rklq7/kAcKfav3+/KlSokO/2Bw4cUGRkZL7atm/fXidOnNDIkSOVlJSk2rVra+nSpdbmUImJidaIUkkKCwvTsmXLNHDgQNWqVUtly5bVSy+9pMGDBxfspgAAuEEFTpp++OGHcnNz04QJEzRgwABJUsmSJVW2bFn9+uuvjo4PAAAAAHATVKlSRU888YQ6d+6sFi1ayMfHJ1eby5cva+nSpfr3v/+tb7/9VpcvX853//3797/qdPyVK1fmqouOjtaGDRvy3T8AAI5U4KRpfHy8qlevrhdffNFKmkpSYGCgdu3a5cjYAADAnYjp9QDgFGXLltXXX3+thQsXysPDQ9WqVVNERISKFSum8+fP688//9TOnTt15coVmaap8PBwZ4cMAEChKXDSNCAgQEeOHNGlS5esurNnz2rv3r0KCAhwaHAAAODOwvR8AHCeP/74Q9OnT9fHH3+sHTt26Ndff81zNmHNmjX1/PPPq1evXk6IEgCAm6PASdPGjRvr66+/Vv369SVljTy97777lJqaqscee8zhAQIAAAAACp+np6f69u2rvn37ateuXVqzZo3++OMPJScny9/fX5UrV1ajRo1UrVo1Z4cKAEChK3DSdNy4cVq+fLl+//13GYahkydP6sSJEwoICNDo0aMLIUQAAHDHMGX/9Hym9wOA3apVq0ZyFABwR3O7fhNbVapU0ZYtW9S9e3dVrVpVVatWVffu3bVx40ZFRUUVRowAAOCOYTioAAAAAMCNK/BIU0mqVKmSZs6c6ehYAAAAAAAAAMDpCjzSVJJ+/fVXderUSTVr1lTNmjXVuXNnbd++3cGhAQCAO47poAIAAAAAdijwSNOvvvpKHTp0UGZmpkwz613Jrl27tGDBAs2bN0/t2rVzeJAAAOAOwZqmAAAAAFxAgUeaDhkyRBkZGQoICFDbtm3Vtm1bFS9eXBkZGRo6dGhhxAgAAAAAAAAAN02BR5oeOnRIAQEB2r17t4KDgyVJx48fV5UqVXTo0CGHBwgAAO4gppFV7O0DAOAQsbGx2rBhg0qUKKFOnTrp7NmzCg4Olre3t7NDAwCgUBU4aVq/fn0dO3bMSphKUlBQkEJCQhQSEuLQ4AAAwJ3FNLOKvX0AAOyTmpqqxx9/XD/99JOkrPeBQUFBevrpp/XWW29p8ODBTo4QAIDCla/p+YmJiVYZOnSoDh06pOHDh2vHjh3asWOHRowYocOHDzM9HwAAAABuA8OHD9eKFStkmqa1l0WrVq3k5eWlJUuWODk6AAAKX75GmkZGRuaqGz9+vMaPH289N01TLVu2VHp6uuOiAwAAdxY2ggIAl7BgwQL5+vpq/fr1ql27tiTJ29tb4eHh2rt3r3ODAwDgJshX0tTM5zy3/LYDAADIE2uaAoBLOH78uKpVq6ZatWrZ1Ht6eurs2bPOCQoAgJsoX0nT2NjYwo4DAAAAAOAiQkNDtXfvXsXHx1t127dv1+7du1W+fHknRgYAwM2Rr6Rp48aNCzsOAAAAGWZWsbcPAIB9nnjiCf3rX/9SjRo1ZBiGfvnlF913330yTVNPPPGEs8MDAKDQ5Stp+nfHjx/XkiVLdOTIEWVkZNgcGzlypEMCAwAAdyDWNAUAlzB27FitXr1av/76qyQpLS1NklSrVi298cYbzgwNAICbosBJ082bN+uRRx7RuXPn8jxO0hQAAAAAbm3+/v7atGmT5s6dq02bNkmS6tWrp44dO8rLy8vJ0QEAUPgKnDQdMWKEUlJS8jxmGGy8AAAA7MBGUADgEj7//HOVLl1a3bp1U7du3az6hIQEXbx4UdWqVXNidAAAFD63gp6wadMm+fj46I8//pAkNWjQQOvXr1dwcLD1CSQAAMANMR1UAAB26dGjh8aOHZurvmPHjqpVq5YTIgIA4OYqcNL0/PnzioqKUsWKFWUYhtLT01W/fn0FBQXp+eefL4wYAQAAAAAu4PTp0zJNPp0CANz+Cjw9PyAgQJcuXZIkFS9eXDt37tT8+fO1b98+fnkCAAD7sBEUADhVhQoVrMe//PKLzfOLFy/qxIkTKlmypDNCAwDgpipw0jQyMlI7d+7UpUuXdM8992jFihXq1KmTJLGuDQAAsA9JUwBwqoSEBElZ+1WkpaVZz3N68sknb25QAAA4QYGTpgMGDNDmzZt1+PBhvfXWW2revLmSk5Pl5+en9957rzBiBAAAAADcBKNGjZIkvfHGGypXrpyeeeYZ61iRIkUUFRWlxx57zFnhAQBw0xQ4adqpUydrZGnFihV16NAhxcXFqUKFCipevLij4wMAAHcS08gq9vYBALgh2UnT2NhYVa9e3XoOAMCdpsBJ07/z8/NTrVq19I9//EOGYeirr75yRFwAAOAOZJhZxd4+AAD2WblypbNDAADAqexOmkpSRkaGvvnmGxkGIzsAAAAA4FaXnp6u119/XfPmzdORI0eUmZlpHTMMQ+np6U6MDgCAwueQpCkAAIBDsBEUALiEsWPH6t1333V2GAAAOI2bswMAAAAAALiWuXPnyjAMdenSRZJUrlw5tWzZUoGBgRo+fLiTowMAoPDle6RpYmLiVY+lpaU5JBgAAAAAgPMlJiaqXLly+vzzz/XFF1+oXLlyWrRokcLDw3Xp0iVnhwcAQKHLd9I0IiKCNUsBAEChMuSAjaAcEgkA3Nk8PDxUqlQpSZKXl5eOHTsmNzc3eXp6asaMGfrnP//p5AgBAChcBVrT1DRZJOx21faumvIwPJ0dBuAUZTYUc3YIgFNcPn9ZetjZUfyNaWQVe/sAANglKChISUlJkqTw8HDt27dPVatWVUJCgkqUKOHk6AAAKHz5TpqOGjWqMOMAAAAAALiIWrVqadGiRdqzZ4/atWunt99+W3FxcZKkJ554wsnRAQBQ+EiaAgAA12H+r9jbBwDALvPmzVNaWpr8/Pw0btw4+fn5aePGjapVq5aGDRvm7PAAACh0bs4OAAAAwGI6qBTQ6tWr1bp1a5UpU0aGYeibb76xOd6jRw8ZhmFTHn30UZs2p0+fVufOneXv76/ixYvrmWee0fnz523a/Pbbb2rUqJF8fHwUFhamd955p+DBAsBN4OPjo4CAAHl4eMjNzU2vv/66Fi1apHHjxrERFADgjkDSFAAA3PEuXLigu+++W5MnT75qm0cffVRHjx61yty5c22Od+7cWTt37tTy5cv13XffafXq1erTp491PCUlRc2bN1d4eLi2bt2qd999V6NHj9Ynn3xSaPcFAI509OhRvfzyy4qIiHB2KAAAFLoCbQQFAABQmAwzq9jbR0G1aNFCLVq0uGYbb29vhYSE5Hls9+7dWrp0qTZv3qx7771XkvSvf/1LLVu21HvvvacyZcpo9uzZunz5smbMmCEvLy9Vr15d27dv14QJE2ySqwDgTKdOnVLPnj21atUqhYeH65NPPlHt2rU1dOhQTZ06VZcvX3Z2iAAA3BSMNAUAAK7DgdPzU1JSbEpaWppdoa1cuVJBQUGqUqWKnnvuOZ06dco6tn79ehUvXtxKmEpSs2bN5Obmpo0bN1ptHnzwQXl5eVltYmJiFBcXpzNnztgVGwA4ymuvvabvvvtO586d044dO9S+fXt17txZH374odLS0mSaph5++GFnhwkAQKEjaQoAAG5LYWFhCggIsMr48eNvuK9HH31Un3/+uVasWKF//vOfWrVqlVq0aKGMjAxJUlJSkoKCgmzO8fDwUGBgoJKSkqw2wcHBNm2yn2e3AQBnW758uQzDUKNGjdSoUSMdPHhQ33zzjUzT1JNPPqnNmzfrhx9+cHaYAAAUuhuanp+WlqY5c+Zow4YNCgkJ0TPPPKOEhATVqFFDgYGBjo4RAADcKW5wI6dcfUg6ePCg/P39rWpvb+8b7rJDhw7W45o1a6pWrVqqWLGiVq5cyYgrALeVpKQklS9fXqtWrZIkRUZGKjExUZ999pm6du3q5OgAALh5CjzS9NSpU7r33nvVu3dvTZs2TcuXL9fu3bvVtGlTffjhh4URIwAAuENkr2lqb5Ekf39/m2JP0vTvKlSooFKlSmnfvn2SpJCQEB0/ftymTXp6uk6fPm2tgxoSEqJjx47ZtMl+frW1UgHgZktPT1doaKj1PPvnU+fOnZ0VEgAATlHgpOlrr72mnTt3ysfHR6aZ9a6kWbNmKlKkiP773/86PEAAAABXc+jQIZ06dcpKLERHR+vs2bPaunWr1eann35SZmam6tevb7VZvXq1rly5YrVZvny5qlSpohIlStzcGwCAa9i1a5ceeughPfTQQ9q1a5ekrPd82XWMsAcA3AkKPD3/u+++U0BAgHbv3q0yZcpIktzd3RUeHq79+/c7PEAAAHAHMY2sYm8fBXT+/Hlr1KgkHThwQNu3b1dgYKACAwP1xhtvqF27dgoJCVF8fLxee+01VapUSTExMZKkqlWr6tFHH9Wzzz6rqVOn6sqVK+rfv786dOhg/b3UqVMnvfHGG3rmmWc0ePBg7dixQx988IEmTpxo3/0CgIOdO3fOmp6fLfu5aZoyDDt/TgMAcAsocNL07NmzqlatWq5pZBkZGTp37pzDAgMAAHcgB65pWhBbtmxR06ZNreeDBg2SJHXv3l1TpkzRb7/9ps8++0xnz55VmTJl1Lx5c40dO9Zmyv/s2bPVv39/Pfzww3Jzc1O7du1sli4KCAjQDz/8oH79+qlu3boqVaqURo4cqT59+tz4vQKAg5UvX56kKAAAuoGkaXh4uHbu3Kk1a9ZYdYsXL1ZcXJzuuusuhwYHAABwMzRp0sRadigvy5Ytu24fgYGBmjNnzjXb1KpVSz///HOB4wOAmyUhIcHZIQAA4BIKvKZpx44dlZ6ersaNG8swDG3cuFFt2rSRYRjq2LFjYcQIAADuEI7cCAoAAAAAblSBk6avv/66WrRoIdM0bUrz5s01dOjQwogRAADcKUwHFQAAAACwQ4Gn53t5eWnJkiVavXq1Nm3aJEmqV6+eGjdu7PDgAAAAAAAAAOBmK3DSNNuDDz6oBx980JGxAACAO50jptcz0hQAAACAnQqcNH3ooYeueswwDK1YscKugAAAwB3MEdPrSZoCAAAAsFOBk6YrV66UYRg2O8xmPzcMw6HBAQAAAACc58KFC/rtt9/k7u6u++67z9nhAABw0xQ4adqtWzeb5GhycrJWrlypc+fOqUOHDg4NDgAA3GEYaQoALmPcuHF6++23lZqaqvr162vAgAEaMmSIxo0bp06dOjk7PAAAClWBk6azZs3KVXfy5EnVqlVL5cqVc0RMAADgDmU4YE1Tu9dEBQBo6tSpGjlypE3dww8/rIMHD2revHkkTQEAtz03R3RSqlQpVapUKc+EKgAAAADg1vLhhx/Kzc1NkyZNsupKliypsmXL6tdff3VeYAAA3CQFHmk6ZswYm+cZGRnau3ev1qxZoxIlSjgsMAAAAACAc8THx6t69ep68cUXNWDAAKs+MDBQu3btcl5gAADcJAVOmo4ePfqqGz499thjdgcEAADuYKxpCgAuISAgQEeOHNGlS5esurNnz2rv3r0KCAhwYmQAANwcBU6ali9f3iZpahiGgoKC9PDDD2vo0KEODQ4AAAAAcPM1btxYX3/9terXry8pa+Tpfffdp9TUVAbLAADuCAVOmiYkJBRCGAAAAGwEBQCuYty4cVq+fLl+//13GYahkydP6sSJEwoICNDo0aOdHR4AAIWuQBtBXblyRRUrVtQ999wj0+QdCQAAKASmnQUAYLcqVapo8+bN6t69u6pWraqqVauqe/fu2rhxo6KiopwdHgAAha5AI009PT117tw5FS1a9KrrmgIAAAAAbm179+7VXXfdpZkzZzo7FAAAnKJAI00lqUePHoqLi9OOHTsKIx4AAHAns3eUKaNNAcAhqlatqoYNG+qTTz5RcnKys8MBAOCmK/CapklJSZKkevXqqWnTpgoODrZGnRqGoenTpzs2QgAAcMdgTVMAcA2maWr9+vXasGGDBgwYoCeeeELdu3dXTEwMsw4BAHeEAidNv/jiCxmGIdM0tXTpUusXpmmaJE0BAAAA4Dbw448/av78+fr666916tQpzZ8/XwsWLFBISIi6du2qt99+29khAgBQqPKdNB0zZozKlSunxo0bF2Y8AADgTuaI6fWMNAUAuz300EN66KGH9PHHH1sJ1G+++UZHjx7Vu+++S9IUAHDby3fSdPTo0WrQoIHWrVtXmPEAAIA7GNPzAcC1XLlyRefOndO5c+eUlpbm7HAAALhpCrwRFAAAAADg9rZ48WJ17txZQUFBat++vb7++mulpqaqQoUKGjVq1A31OXnyZEVERMjHx0f169fXpk2b8nXevHnzZBiG2rRpc0PXBQDgRhRoTdO0tDQlJiZes0358uXtCggAANzBmJ4PAC7hiSeesPay8Pf319NPP63u3bvrgQceuKH+5s+fr0GDBmnq1KmqX7++Jk2apJiYGMXFxSkoKOiq5yUkJOiVV15Ro0aNbvRWAAC4IQVKmm7fvl2RkZFXPW4YhtLT0+0OCgAA3KFImgKASzAMQ4888oi6d++utm3bysfHx67+JkyYoGeffVY9e/aUJE2dOlVLlizRjBkzNGTIkDzPycjIUOfOnfXGG2/o559/1tmzZ+2KAQCAgihQ0lSSTJN3IgAAAABwOzt48KDKlCnjkL4uX76srVu3aujQoVadm5ubmjVrpvXr11/1vDFjxigoKEjPPPOMfv7552teIy0tzWbN1ZSUFPsDBwDc0QqUNC1btqyeeeaZwooFAADc4dgICgCc5/PPP1fp0qXVokUL/fjjj9ds261bt3z3e/LkSWVkZCg4ONimPjg4WHv27MnznDVr1mj69Onavn17vq4xfvx4vfHGG/mOCQCA6ylQ0rRcuXI3vOg3AADAdTE9HwCcpkePHoqOjlaLFi3Uo0cPGYaRZzvDMAqUNC2oc+fOqWvXrvr0009VqlSpfJ0zdOhQDRo0yHqekpKisLCwwgoRAHAHKPD0fAAAAADA7SnncmxXW5qtoEu2lSpVSu7u7jp27JhN/bFjxxQSEpKrfXx8vBISEtS6dWurLjMzU5Lk4eGhuLg4VaxY0eYcb29veXt7FyguAACuJd9J0/Llyys0NLQwYwEAAHc6RpoCgNNkJyb//theXl5eqlu3rlasWKE2bdpY/a9YsUL9+/fP1T4qKkq///67Td3w4cN17tw5ffDBB4wgBQDcFPlOmiYkJBRiGAAAAKxpCgCuYsyYMQoLC7N2u8+2fv16nTlzRi1btixQf4MGDVL37t1177336r777tOkSZN04cIFq/9u3bqpbNmyGj9+vHx8fFSjRg2b84sXLy5JueoBACgsTM8HAAAAANgYPXq0GjRokCtpOmjQIG3atEkZGRkF6q99+/Y6ceKERo4cqaSkJNWuXVtLly61NodKTEyUm5ubw+IHAMBeJE0BAIDrYHo+ALis1NRUHT169IbP79+/f57T8SVp5cqV1zx31qxZN3xdAABuBElTAADgMpieDwDO5e7uLkkyDEMbN260nueUPToUAIDbGUlTAAAAAIAkyTSzPnkyDMN6/Hd9+vS5mSEBAOAUJE0BAIDrYHo+ADjVzJkzJUk9e/ZUxYoVNXz4cOtYkSJFFBUVpZo1azorPAAAbhqSpgAAwHWQNAUAp+revbskKTY2VpUqVbKeAwBwpyFpCgAAAABQYmKivL29FRwcrDFjxlh1eSlfvvzNDA0AgJuOpCkAAHAZxv+KvX0AAAouIiJC0dHRWrt2rSIjI6/azjAMpaen38TIAAC4+UiaAgAA18H0fABwquzNn662CRQAAHcKkqYAAAAAAMXGxsrf3996DADAnYykKQAAcBmGmVXs7QMAUHCNGzfO8zEAAHciN2cHAAAAYDEdVAAAdlm6dKnGjBmjvXv36ty5c2rdurUCAgL04IMP6tChQ84ODwCAQkfSFAAAAABg491339WYMWMUEBCg//f//p+WLFmic+fOae3atRoyZIizwwMAoNCRNAUAAK6FUaYA4HS7du1SuXLlFBwcrFWrVsnf319z586Vj4+PVq5c6ezwAAAodCRNAQCAy8he09TeAgCwz5kzZ1S6dGlJ0p49e3Tvvfeqffv2qlq1qk6ePOnk6AAAKHwkTQEAAAAANgIDA7V3717NnTtXCQkJqlGjhiQpOTlZxYsXd25wAADcBCRNAQCA62AjKABwCU2bNtW5c+fUpUsXZWZmKiYmRhcuXNDBgwdVuXJlZ4cHAECh83B2AAAAANkcMb2e6fkAYL8JEyYoNTVV+/btU+vWrdWiRQutXbtW9erVU4cOHZwdHgAAhY6kKQAAAADARnBwsL7++mubuoYNG+rnn392UkQAANxcJE0BAIDrcMT0ekaaAoBDnDp1Sh999JG2bNkiSapXr5769eunkiVLOjkyAAAKH0lTAADgMpieDwCu4eDBg7r//vt15MgRq+7777/XtGnTtG7dOpUrV86J0QEAUPjYCAoAAAAAYGPYsGE6fPiwDMNQVFSUoqKiZBiGDh8+rNdff93Z4QEAUOhImgIAANdhOqgU0OrVq9W6dWuVKVNGhmHom2++sQ3LNDVy5EiFhobK19dXzZo10x9//GHT5vTp0+rcubP8/f1VvHhxPfPMMzp//rxNm99++02NGjWSj4+PwsLC9M477xQ8WAC4CZYvXy5fX19t3rxZO3fu1M6dO7Vp0yZ5e3tr2bJlzg4PAIBCR9IUAAC4DiclTS9cuKC7775bkydPzvP4O++8ow8//FBTp07Vxo0b5efnp5iYGF26dMlq07lzZ+3cuVPLly/Xd999p9WrV6tPnz7W8ZSUFDVv3lzh4eHaunWr3n33XY0ePVqffPJJwQMGgEJ2+vRpVahQQXXq1LHq7rnnHlWoUEFnzpxxYmQAANwcrGkKAADueC1atFCLFi3yPGaapiZNmqThw4friSeekCR9/vnnCg4O1jfffKMOHTpo9+7dWrp0qTZv3qx7771XkvSvf/1LLVu21HvvvacyZcpo9uzZunz5smbMmCEvLy9Vr15d27dv14QJE2ySqwDgCkJCQrR3714tXrxYrVu3liQtWrRIe/fuVWhoqJOjAwCg8DHSFAAAuIzsjaDsLVLWyM6cJS0t7YZiOnDggJKSktSsWTOrLiAgQPXr19f69eslSevXr1fx4sWthKkkNWvWTG5ubtq4caPV5sEHH5SXl5fVJiYmRnFxcYzaAuByWrdurStXrqhNmzYqVqyYihUrprZt2yojI0OPP/64s8MDAKDQkTQFAACuw4HT88PCwhQQEGCV8ePH31BISUlJkqTg4GCb+uDgYOtYUlKSgoKCbI57eHgoMDDQpk1efeS8BgC4inHjxql69eoyTVMXLlzQhQsXZJqmqlevrrFjxzo7PAAACh3T8wEAwG3p4MGD8vf3t557e3s7MRoAuLWUKFFCW7Zs0Zw5c7RlyxZJUr169dSxY0d+ngIA7ggkTQEAgMswTFOGeQM7Of2tD0ny9/e3SZreqJCQEEnSsWPHbNbxO3bsmGrXrm21OX78uM156enpOn36tHV+SEiIjh07ZtMm+3l2GwBwFcnJyZKknj17qmfPnk6OBgCAm4/p+QAAwHU4cHq+o0RGRiokJEQrVqyw6lJSUrRx40ZFR0dLkqKjo3X27Flt3brVavPTTz8pMzNT9evXt9qsXr1aV65csdosX75cVapUUYkSJRwbNADcoIsXL6pNmzYKDAxUYGCg2rZtq9TUVGeHBQDATUfSFAAA3PHOnz+v7du3a/v27ZKyNn/avn27EhMTZRiGBgwYoHHjxmnRokX6/fff1a1bN5UpU0Zt2rSRJFWtWlWPPvqonn32WW3atElr165V//791aFDB5UpU0aS1KlTJ3l5eemZZ57Rzp07NX/+fH3wwQcaNGiQk+4aAHKbOHGiFi1aJNM0ZZqmFi1apIkTJzo7LAAAbjqSpgAAwGUYpmNKQW3ZskV16tRRnTp1JEmDBg1SnTp1NHLkSEnSa6+9phdeeEF9+vRRvXr1dP78eS1dulQ+Pj5WH7Nnz1ZUVJQefvhhtWzZUg888IA++eQT63hAQIB++OEHHThwQHXr1tXLL7+skSNHqk+fPva9aADgQHPnzpVhGKpfv77q168v0zQ1d+5cZ4cFAMBNx5qmAADAdThiev0NnN+kSROZ11hL1TAMjRkzRmPGjLlqm8DAQM2ZM+ea16lVq5Z+/vnnggcIADdJYmKiQkNDtW7dOmVmZqp8+fL6888/nR0WAAA3HSNNAQAAAACSspYrKV++vAzDkLu7u8qXL68LFy44OywAAG46RpoCAACXcaPT6//eBwDgxp04cUKff/659ViS/v3vf9uMyO/WrZtTYgMA4GYhaQoAAFyHk6bnAwD+sn//fvXs2dOmrkePHtZjwzBImgIAbnskTQEAAAAAlmut8QwAwJ2CpCkAAHAZTM8HAOeKjY11dggAALgEkqYAAMB1MD0fAJyqcePGzg4BAACX4ObsAAAAAAAAAADAlTDSFAAAuBSm1wMAAABwNpKmAADAdZhmVrG3DwAAAACwA9PzAQAAAAAAACAHRpoCAACXYZj2T89nej8AAAAAezHSFAAAuA7TQQUAYLe4uDh1795dVapUUevWrbVhwwaNGTNGO3bscHZoAAAUOkaaAgAAAABs/Prrr2rUqJEuXLgg0zRVsmRJ+fj4aPTo0Tp+/Lg++ugjZ4cIAEChYqQpAABwGUamYwoAwD5DhgzR+fPnVbduXauudu3aCgwMVGxsrBMjAwDg5iBpCgAAXAfT8wHAJaxdu1Zly5bV+vXrberDwsJ08OBBJ0UFAMDNw/R8wAna9z+mhi2TFVYpTZcvuWnXliKa/maoDsX7ODs0oEDOfZamSyvTlf5npgxvQ1413eXfz1se4X99Jnf27UtK25yujJOm3Hyz2hTr5yXPCHdJUmayqTOjUnVlX6Yyk025lTDk86CH/J/zlpufYfVjXjZ1bvplpS67ooxTptxLGir2jLeKtPa86fcNAMDtLiMjQ0WLFpW7u7tN/YkTJ5SZyZB+AMDtz2kjTQ3DuGYZPXq0EhISrnp8w4YNkqRZs2ZZdW5ubgoNDVX79u2VmJhoc70mTZrIMAy9/fbbuWJp1aqVdc2c7QcMGJDr/Hnz5tmcO2nSJEVEROTqMzU1VYGBgSpVqpTS0tJyxXq1kpCQoNGjR+d5LCoqKlc8hmHI29tbZcuWVevWrfX1118X9EsBJ6gVfUGLZ5XSgMcqa2iHCnL3MPXW3P3y9s1wdmhAgVz+JUN+7bxUaloRlfzQV2a6qVMvXVRm6l9D/Tyj3FR8uI+C5vopcJKvTNPU6ZdSZWb8r40h+TTyUOC7vgpa4KcSI3x0eXOGkv95yeZaZ16/pLQt6So+zEdB8/1UYqyv3Msbwu3FMB1TAAD2qVatmvbu3atx48ZJklJSUvTKK6/oyJEjqlGjhpOjAwCg8DktaXr06FGrTJo0Sf7+/jZ1r7zyitX2xx9/tDl29OhRm7V1ss89fPiwvvrqK8XFxenpp5/Odc2wsDDNmjXLpu7w4cNasWKFQkNDrxuzj4+Phg8fritXrly37VdffaXq1asrKipK33zzjSSpffv2NvcQHR2tZ5991qYuLCxMklS9evVc97xmzRqba2SfGx8fr6+++krVqlVThw4d1KdPn+vGB+d6vXMFLV8QqD/3+mj/Ll+9P6C8gstdUeVaqc4ODSiQkpOKqMhjnvKs4C7Pyu4qPsJHGUmmruz56wMAvzZe8q7jIY8ybvKKcpf//3kr45ipjKNZmS03f0N+7bzkVdVdHqFu8q7noSJPeipt+199XFqfrrRf0lVyQhF53/e/vmq6y/tuJkzcdkzTMQUAYJeXXnpJpmlq1KhRMgxDu3fv1sSJE2UYhvr37+/s8AAAKHROe7cZEhJiPQ4ICJBhGDZ1knTy5ElJUsmSJXMdyynnuaGhoXrmmWf04osvKiUlRf7+/la7xx57TAsWLNDatWvVsGFDSdJnn32m5s2b5xqZmpeOHTtq0aJF+vTTT/X8889fs+306dPVpUsXmaap6dOnq3379vL19ZWvr6/VxsvLS0WKFMnz3jw8PK55z5Jszi1XrpwaNGigqKgo9erVS//4xz/UrFmz694TXIOff1Zy6NxZ9+u0BFybeT7rXzf/vEeAZqaaurjkitzLGHIPzrtNxolMXVqZLu86f/1/uPRzujyj3HX+i8u6uPSKDJ+s0an+fbxl+DDaFAAAR+vSpYuOHDmiMWPG6OLFi5IkX19fjRgxQl26dHFydAAAFL7bbiOo48ePa+HChXJ3d8+1/o6Xl5c6d+6smTNnWnWzZs1Sr1698tW3v7+/Xn/9dY0ZM0YXLly4arv4+HitX79e//jHP/SPf/xDP//8s/78888bu6EC6t69u0qUKHHVafppaWlKSUmxKXAuwzDV943D2rGpiP6M873+CYCLMjNNJU+6JK9a7vKsaPvz98KXl3W06TklNT2vtPUZKvlhERmetsnOMyNSdbTxOR1rfUGGn1R82F9r/GYcydTl3zJ0ZX+GAt/2VcBAH136KV1n37Wdwo9bH9PzAcB1vPbaazpx4oQ2bdqkTZs26eTJkxoyZIizwwIA4Ka4JZKm999/v4oWLWpTckpOTlbRokXl5+en4OBgxcbGql+/fvLz88vVV69evbRgwQJduHBBq1evVnJysh577LF8x/L888/Lx8dHEyZMuGqbGTNmqEWLFipRooQCAwMVExNjk6jNj99//z3XPfft2/e657m5uemuu+5SQkJCnsfHjx+vgIAAq2QvBwDn6f/WYYVHXdL458KdHQpgl+R305Qen6kS43JvaOb7qKdKf+anklN85R5m6MzrqTLTbDNb/gO8VeqzIgp8x1cZh00lf5D218FMSYZU4g1feVV3l8/9HvJ/yVup36fLvESG7LZiOqgAABzC19dX9957r0zT1NSpU/Xjjz86OyQAAG6KW2IxuPnz56tq1apXPV6sWDFt27ZNV65c0X//+1/Nnj1bb775Zp5t7777blWuXFlffvmlYmNj1bVrV3l45P9l8Pb21pgxY/TCCy/oueeey3U8IyNDn332mT744AOrrkuXLnrllVc0cuRIubnlL09dpUoVLVq0yKYu51ID12Kapgwj7+mqQ4cO1aBBg6znKSkpJE6dqN+bh1T/kRS93LaiTh71cnY4wA07+94lXVqbrlJTi8g9KPfPObeihtyKGvIo7yavGu5KeuS8Ulelq0hzT6uNe0k3uZeUPCMkw1861TdVxXp5yb2Um9xKGXIvndVHNo8IN8mUMo6b8mBDKAAAHKpbt26aPXu2Vq1aJdM09dBDDykzM1OS9Omnn+Z7th4AALeqWyJpGhYWpkqVKl31uJubm3W8atWqio+P13PPPad///vfebbv1auXJk+erF27dmnTpk0FjqdLly567733NG7cOEVERNgcW7ZsmQ4fPqz27dvb1GdkZGjFihV65JFH8nUNLy+va97z1WRkZOiPP/5QvXr18jzu7e0tb2/vAvcLRzPV783Duv/RZL36VCUdO8jXBLcm0zSV/H6aLq1KV6nJReRRJh8fDGWPBLx8nTaSzP+18arlrksr0pV50ZRbkawEafrBTMlNcg8iYXo7ccT0eqbnA4D9tmzZoqJFi6phw4Z67rnnlJGRoaioKO3Zs0cfffQRSVMAwG3vlpieX1BDhgzR/PnztW3btjyPd+rUSb///rtq1KihatWqFbh/Nzc3jR8/XlOmTMk1DX769Onq0KGDtm/fblM6dOig6dOn38jtFMhnn32mM2fOqF27doV+Ldy4/m8d1kNPntHb/cKVet5NJUpfUYnSV+Tlk+ns0IACSX43TalLr6jEGz4y/KSMU5nKOJVpTZlPP5ypc5+l6fKeDKUnZa1LenpYquQted+fte7ppXXpuvjdFV2Jz1D6kUxdWpuu5H+myauWu5WE9W3uKSPA0Nlxl3TlQIbSfklXyr/SVOQxTzaCut2YpmMKAMAuhw4dUkREhAzD0Pbt21WtWjXt2rVLkZGRio+Pd3Z4AAAUultipOmpU6eUlJRkU1e8eHH5+OReN0/KGpnatm1bjRw5Ut99912u4yVKlNDRo0fl6emZx9n506pVK9WvX1//7//9PwUHB0uSTpw4ocWLF2vRokWqUaOGTftu3bqpbdu2On36tAIDA6/bf3p6eq57NgzDupYkXbx4UUlJSUpPT9ehQ4e0cOFCTZw4Uc8995yaNm16w/eGwte6xylJ0ntf2/7B+d6AMC1fcP3vD8BVXPz6iiTp1POpNvXFh/tkJTS9pMvbM3Rh3hVlnjPlFmjIu7a7Sn/qJ/fArISo4S1d+Pay0idlyrySNXLUt4mninb7a8kKtyKGSn7oq+T303Syx0UZAYZ8H/aQ//8xShsAgMKSlpa1vvjevXsVExMjKWvJsGPHjjkzLAAAbopbImnarFmzXHVz585Vhw4drnrOwIEDFR0drU2bNum+++7Ldbx48eJ2x/XPf/5T999/v/X8888/l5+fnx5++OFcbR9++GH5+vrqiy++0Isvvnjdvnfu3KnQ0FCbOm9vb1269NdO0Z9++qk+/fRTeXl5qWTJkqpbt67mz5+vtm3b2nFXuBliytzt7BAAhyizodg1j7uXdlPJiUWu2ca7rodKf3r9X0eeEe4q9a9r94VbH9PzAcA1VKxYUb/99puqVq2q5ORk1a1bV5J05MgRlSlTxsnRAQBQ+AzTZA7bnSwlJUUBAQFqoifkYdz4yFvgVna9xB9wu7p8/rLmPTxbycnJ+d5ssLBk/z6KfnSMPDzznkmSX+lXLmn90pEucV8AcKv6/PPP1bNnT5mmqcDAQO3cuVPHjx/X3XffrY4dO2r27NnODvGasn+vZP8uePLjtdqWeFafdK2r5tVDnB0eAKAQ/f13wI26JUaaAgAAAABunm7duql27drat2+fGjZsqODgYGVmZmr58uWqUKGCs8MDAKDQkTQFAAAug+n5AOA6atWqpVq1alnPQ0NDcy0hBgDA7YqkKQAAcB2ZZlaxtw8AQIE99NBD+WpnGIZWrFhRyNEAAOBcJE0BAAAAAFq5cqUMw9D1tr0wDOMmRQQAgPOQNAWA/9/enYdFVf1/AH8PA8Ow77KJIAKCbOICoplaKC5RpLlgKq6pqWnkWiqopWaZS5qWufUtwy3Nr7mkCGmIllu54ILihuC+ICjr+f3hb+6XkUWGddT363nu8zDnnnvv5x4G5t7PnHMuEWkP8f9LZfdBREQa69evHxOiRERE/49JUyIiIiIiIsKqVatqOwQiIiKtoVPbARARERGpyPC/h0FVeKntkyAieoHk5uYiLS0Nly9fVlsqYvHixXBxcYFSqURQUBD++uuvUusuW7YMrVu3hoWFBSwsLBASElJmfSIioqrGpCkRERFpDyGqZiEiokrJzMxEz549YWJignr16qF+/frS4urqqvH+1q5di6ioKERHR+PIkSPw9/dHaGgobty4UWL9hIQEREREID4+HklJSXByckKHDh2QlpZW2VMjIiIqFyZNiYiIiIiISM3kyZOxfv165OXlQQhRbNHUV199hSFDhmDAgAFo1KgRli5dCkNDQ6xYsaLE+j/99BPef/99NG7cGJ6envj+++9RWFiIuLi4yp4aERFRuTBpSkRERFqj0kPz/38hIqLK+fXXXyGTyfDJJ58AABo0aIBhw4bB0tISixYt0mhfubm5OHz4MEJCQqQyHR0dhISEICkpqVz7yM7ORl5eHiwtLUtcn5OTgwcPHqgtRERElcGkKREREWkPUUULERFVSnp6OlxdXTFjxgwAgLW1Nb755huYmZnhyJEjGu3r1q1bKCgogK2trVq5ra0tMjIyyrWPCRMmwMHBQS3xWtSsWbNgZmYmLU5OThrFSERE9DQmTYmIiIiIiEiNvr4+TExMAABKpRJXr15FXl4ecnJysH79+hqNZfbs2YiNjcWmTZugVCpLrDNp0iTcv39fWq5cuVKjMRIR0YtHt7YDICIiIlKRCQFZJR/kVNntiYgIsLOzw9WrVwE8GZp/6tQp2NjY4MGDB7CxsdFoX9bW1pDL5bh+/bpa+fXr12FnZ1fmtl9++SVmz56N3bt3w8/Pr9R6+vr60NfX1yguIiKisrCnKREREWmPwipaiIioUoKDg5GXl4fjx4+jf//+EEJI84T269dPo30pFAo0bdpU7SFOqoc6BQcHl7rdnDlzMGPGDOzYsQPNmjWr2IkQERFVEHuaEhERERERkZrVq1dLP/v6+sLe3h4HDhyAn58fBg0apPH+oqKiEBkZiWbNmiEwMBDz589HVlYWBgwYAOBJItbR0RGzZs0CAHz++eeYOnUq1qxZAxcXF2nuU2NjYxgbG1fBGRIREZWNSVMiIiLSGhyeT0RUu7Zs2QJLS0u88sorauW9e/dG7969K7zfnj174ubNm5g6dSoyMjLQuHFj7NixQ3o41OXLl6Gj87+BkEuWLEFubi7eeecdtf1ER0cjJiamwnEQERGVF5OmREREpD3E/y+V3QcREVVIeHg4goODkZiYCACQy+Vo0aKF9LoyRo4ciZEjR5a4LiEhQe31xYsXK308IiKiyuCcpkRERERERCQRRXrsCyHUXhMREb0s2NOUiIiItIcQT5bK7oOIiIiIiKgSmDQlIiIirSETT5bK7oOIiIiIiKgymDQlIiIiIiIiydGjR+Hq6lrqa5lMhvPnz9dGaERERDWGSVMiIiLSHhyeT0RU63Jzc9UexJSTk6P2WiaT1XxQRERENYxJUyIiItIassInS2X3QUREFfPqq68yKUpERAQmTYmIiIiIiOj/JSQk1HYIREREWkGntgMgIiIikqiG51d20UBMTAxkMpna4unpKa1//PgxRowYASsrKxgbG6Nbt264fv262j4uX76MLl26wNDQEHXq1MG4ceOQn59fJU1CREREREQ1jz1NiYiISHuI/18quw8NeXt7Y/fu3dJrXd3/XSJ9+OGH+O2337B+/XqYmZlh5MiR6Nq1KxITEwEABQUF6NKlC+zs7LB//36kp6ejX79+0NPTw8yZMyt5MkREREREVBuYNCUiIqKXnq6uLuzs7IqV379/H8uXL8eaNWvw2muvAQBWrlwJLy8vHDhwAC1atMDvv/+OU6dOYffu3bC1tUXjxo0xY8YMTJgwATExMVAoFDV9OkREREREVEkcnk9ERERaQyZElSwA8ODBA7UlJyen1OOeO3cODg4OcHV1xbvvvovLly8DAA4fPoy8vDyEhIRIdT09PVGvXj0kJSUBAJKSkuDr6wtbW1upTmhoKB48eICTJ09WRzMREREREVE1Y9KUiIiItEcVzmnq5OQEMzMzaZk1a1aJhwwKCsKqVauwY8cOLFmyBKmpqWjdujUyMzORkZEBhUIBc3NztW1sbW2RkZEBAMjIyFBLmKrWq9YREREREdHzh8PziYiI6IV05coVmJqaSq/19fVLrNepUyfpZz8/PwQFBcHZ2Rnr1q2DgYFBtcdJRERERETahz1NiYiISHsIAIWVXP7/QVCmpqZqS2lJ06eZm5vDw8MDKSkpsLOzQ25uLu7du6dW5/r169IcqHZ2drh+/Xqx9ap1RERERET0/GHSlIiIiLRGVc5pWlEPHz7E+fPnYW9vj6ZNm0JPTw9xcXHS+jNnzuDy5csIDg4GAAQHB+P48eO4ceOGVGfXrl0wNTVFo0aNKhULERERERHVDg7PJyIiopfa2LFjERYWBmdnZ1y7dg3R0dGQy+WIiIiAmZkZBg0ahKioKFhaWsLU1BSjRo1CcHAwWrRoAQDo0KEDGjVqhL59+2LOnDnIyMjA5MmTMWLEiHL3biUiIiIiIu3CpCkRERFpDwHpQU6V2ocGrl69ioiICNy+fRs2NjZ45ZVXcODAAdjY2AAA5s2bBx0dHXTr1g05OTkIDQ3FN998I20vl8uxdetWDB8+HMHBwTAyMkJkZCSmT59eufMgIiIiIqJaw6QpERERaQ8hqiBpqtn2sbGxZa5XKpVYvHgxFi9eXGodZ2dnbNu2TaPjEhERERGR9uKcpkRERERERERERERFsKcpERERaY9CALIq2AcREREREVElMGlKREREWkMmBGSVHJ5f2e2JiIiIiIg4PJ+IiIiIiIiIiIioCPY0JSIiIu1RCw+CIiIiIiIiehqTpkRERKQ9mDQlIiIiIiItwOH5REREREREREREREWwpykRERFpD/Y0JSIiIiIiLcCkKREREWmPQgCyKtgHERERERFRJXB4PhEREREREREREVER7GlKREREWkMmBGSVHF5f2e2JiIiIiIiYNCUiIiLtwTlNiYiIiIhIC3B4PhEREREREREREVER7GlKRERE2qNQALJK9hQtZE9TIiIiIiKqHCZNiYiISHtweD4REREREWkBDs8nIiIiIiIiIiIiKoI9TYmIiEiLVEFPU7CnKRERERERVQ6TpkRERKQ9ODyfiIiIiIi0AIfnExERERERERERERXBnqZERESkPQoFKj28vpA9TYmIiIiIqHKYNCUiIiLtIQqfLJXdBxERERERUSVweD4RERERERERERFREexpSkRERNqDD4IiIiKqMCEE8vPzUVBQUNuhEBFVK7lcDl1dXchksmo7BpOmREREpD04pykREVGF5ObmIj09HdnZ2bUdChFRjTA0NIS9vT0UCkW17J9JUyIiIiIiIqLnWGFhIVJTUyGXy+Hg4ACFQlGtva+IiGqTEAK5ubm4efMmUlNT4e7uDh2dqp+BlElTIiIi0h4cnk9ERKSx3NxcFBYWwsnJCYaGhrUdDhFRtTMwMICenh4uXbqE3NxcKJXKKj8Gk6ZERESkPQSqIGlaJZEQERE9d6qjpxURkbaq7v95/I9KREREREREREREVAR7mhIREZH24PB8IiIiIiLSAuxpSkRERNqjsLBqFiIiIqJykMlk2Lx5c22H8UKqqbZNSEiATCbDvXv3pLLNmzfDzc0NcrkcY8aMwapVq2Bubl5tMZw5cwZ2dnbIzMystmO8bFq0aIGNGzfWagxMmhIRERERERFRrejfvz9kMhlkMhn09PRQv359jB8/Ho8fP67t0KpV0fMuuqSkpNRqTOHh4eWqm5GRgVGjRsHV1RX6+vpwcnJCWFgY4uLiqjfIErRs2RLp6ekwMzOTyoYOHYp33nkHV65cwYwZM9CzZ0+cPXu22mKYNGkSRo0aBRMTk2LrPD09oa+vj4yMjGLrXFxcMH/+/GLlMTExaNy4sVpZbbT5yZMn0a1bN7i4uEAmk5UYa0n+/fdftG7dGkqlEk5OTpgzZ06xOuvXr4enpyeUSiV8fX2xbds2tfWTJ0/GxIkTUViLHSKYNCUiIiLtoRqeX9mFiIiInhsdO3ZEeno6Lly4gHnz5uHbb79FdHR0bYdV7VTnXXSpX79+hfaVm5tbxdGV7uLFi2jatCn27NmDL774AsePH8eOHTvQrl07jBgxosbiUFEoFLCzs4NMJgMAPHz4EDdu3EBoaCgcHBxgYmICAwMD1KlTp1LHycvLK7H88uXL2Lp1K/r3719s3Z9//olHjx7hnXfewerVqyt87Npq8+zsbLi6umL27Nmws7Mr1zYPHjxAhw4d4OzsjMOHD+OLL75ATEwMvvvuO6nO/v37ERERgUGDBuHo0aMIDw9HeHg4Tpw4IdXp1KkTMjMzsX379io/r/Ji0pSIiIi0B5OmREREVUIIgezc/FpZhIafxfr6+rCzs4OTkxPCw8MREhKCXbt2Setv376NiIgIODo6wtDQEL6+vvj555/V9tG2bVt88MEHGD9+PCwtLWFnZ4eYmBi1OufOncOrr74KpVKJRo0aqR1D5fjx43jttddgYGAAKysrvPfee3j48KG0XtUbc+bMmbC1tYW5uTmmT5+O/Px8jBs3DpaWlqhbty5WrlxZ7vMuusjlcgDAH3/8gcDAQOjr68Pe3h4TJ05Efn6+2vmOHDkSY8aMgbW1NUJDQwEAJ06cQKdOnWBsbAxbW1v07dsXt27dkrbbsGEDfH19pfMLCQlBVlYWYmJisHr1avz6669Sr9eEhIQS437//fchk8nw119/oVu3bvDw8IC3tzeioqJw4MCBUs93woQJ8PDwgKGhIVxdXTFlyhS1ROQ///yDdu3awcTEBKampmjatCkOHToEALh06RLCwsJgYWEBIyMjeHt7Sz0Tiw7PT0hIkHp7vvbaa9J5lDQ8/9dff0WTJk2gVCrh6uqKadOmqbWxTCbDkiVL8Oabb8LIyAifffZZiee1bt06+Pv7w9HRsdi65cuXo3fv3ujbty9WrFhRats8S0XbvLKaN2+OL774Ar169YK+vn65tvnpp5+Qm5uLFStWwNvbG7169cIHH3yAr776SqqzYMECdOzYEePGjYOXlxdmzJiBJk2aYNGiRVIduVyOzp07IzY2tsrPq7z4ICgiIiIiIiKiF8yjvAI0mrqzVo59anooDBUVSzecOHEC+/fvh7Ozs1T2+PFjNG3aFBMmTICpqSl+++039O3bFw0aNEBgYKBUb/Xq1YiKisLBgweRlJSE/v37o1WrVmjfvj0KCwvRtWtX2Nra4uDBg7h//z7GjBmjduysrCyEhoYiODgYf//9N27cuIHBgwdj5MiRWLVqlVRvz549qFu3Lvbu3YvExEQMGjQI+/fvx6uvvoqDBw9i7dq1GDp0KNq3b4+6detq3AZpaWno3Lkz+vfvjx9++AGnT5/GkCFDoFQq1RLBq1evxvDhw5GYmAgAuHfvHl577TUMHjwY8+bNw6NHjzBhwgT06NEDe/bsQXp6OiIiIjBnzhy8/fbbyMzMxL59+yCEwNixY5GcnIwHDx5ICV9LS8tisd25cwc7duzAZ599BiMjo2Lry5o31MTEBKtWrYKDgwOOHz+OIUOGwMTEBOPHjwcAvPvuuwgICMCSJUsgl8tx7Ngx6OnpAQBGjBiB3Nxc7N27F0ZGRjh16hSMjY2LHaNly5Y4c+YMGjZsiI0bN6Jly5awtLTExYsX1ert27cP/fr1w8KFC9G6dWucP38e7733HgCo9XKOiYnB7NmzMX/+fOjqlvye3rdvH5o1a1asPDMzE+vXr8fBgwfh6emJ+/fvY9++fWjdunWpbVSSyrT5Tz/9hKFDh5a5/+3bt2scU1mSkpLw6quvQqFQSGWhoaH4/PPPcffuXVhYWCApKQlRUVFq24WGhhabAzcwMBCzZ8+ustg0xaQpERERaY9CAaCSPUUL2dOUiIjoebJ161YYGxsjPz8fOTk50NHRUetx5ujoiLFjx0qvR40ahZ07d2LdunVqSVM/Pz8p4eXu7o5FixYhLi4O7du3x+7du3H69Gns3LkTDg4OAICZM2eiU6dO0vZr1qzB48eP8cMPP0jJqUWLFiEsLAyff/45bG1tATxJJi5cuBA6Ojpo2LAh5syZg+zsbHz88ccAnsxvOXv2bPz555/o1avXM89bpVOnTli/fj2++eYbODk5YdGiRZDJZPD09MS1a9cwYcIETJ06FTo6OtI5Fp0r8tNPP0VAQABmzpwpla1YsQJOTk44e/YsHj58iPz8fHTt2lVKSvv6+kp1DQwMkJOTU+Yw7JSUFAgh4OnpWWqd0kyePFn62cXFBWPHjkVsbKyUNL18+TLGjRsn7dvd3V2qf/nyZXTr1k2K19XVtcRjKBQKaRi+qsdxSaZNm4aJEyciMjJS2t+MGTMwfvx4taRp7969MWDAgDLP69KlSyUmTWNjY+Hu7g5vb28AQK9evbB8+XKNE5SVafM333wTQUFBZdYpqYdsZWRkZBSbZkL1t5ORkQELCwtkZGRIZUXrPD3vq4ODA65cuYLCwkLpfV+TmDQlIiIirSFEIYSo3GTvld2eiIjoRWCgJ8ep6aG1dmxNtGvXDkuWLEFWVhbmzZsHXV1ddOvWTVpfUFCAmTNnYt26dUhLS0Nubi5ycnJgaGioth8/Pz+11/b29rhx4wYAIDk5GU5OTlLCFACCg4PV6icnJ8Pf31+tN1+rVq1QWFiIM2fOSEkeb29vtQSOra0tfHx8pNdyuRxWVlbSsZ913iqq4yYnJyM4OFiao1MVx8OHD3H16lXUq1cPANC0aVO1/f3zzz+Ij48vsQfm+fPn0aFDB7z++uvw9fVFaGgoOnTogHfeeQcWFhZlxlmUplMvFLV27VosXLgQ58+flxK4pqam0vqoqCgMHjwY//nPfxASEoLu3bujQYMGAIAPPvgAw4cPx++//46QkBB069at2O9bE//88w8SExPVhtwXFBTg8ePHyM7Olt5bJSVDn/bo0SMolcpi5StWrECfPn2k13369EGbNm3w9ddfl/jAqNJUps1NTEw0Opa2MTAwQGFhIXJycmBgYFDjx+ecpkREREREREQvGJlMBkOFbq0sRZN95WFkZAQ3Nzf4+/tjxYoVOHjwIJYvXy6t/+KLL7BgwQJMmDAB8fHxOHbsGEJDQ4s9/Eg1lLtoG1THk7dLOk5Fjq06b9Vib2+vURxPD9V++PAhwsLCcOzYMbVFNZerXC7Hrl27sH37djRq1Ahff/01GjZsiNTU1HIf093dHTKZDKdPn9Yo1qSkJLz77rvo3Lkztm7diqNHj+KTTz5R+x3GxMTg5MmT6NKlC/bs2YNGjRph06ZNAIDBgwfjwoUL6Nu3L44fP45mzZrh66+/1iiGoh4+fIhp06aptdPx48dx7tw5tQRoScPhn2ZtbY27d++qlZ06dQoHDhzA+PHjoaurC11dXbRo0QLZ2dlqc3Sampri/v37xfZ57949mJmZAah4mwNPhucbGxuXuezbt0/j/ZbFzs4O169fVytTvVb1/C2tztM9g+/cuQMjI6NaSZgCTJoSERGRNhHiyfD6yix8EBQREdFzS0dHBx9//DEmT56MR48eAQASExPx1ltvoU+fPvD394erqyvOnj2r0X69vLxw5coVpKenS2VPP0DHy8sL//zzD7KysqSyxMREaRh+TfHy8kJSUpJaD8PExESYmJiUOUdqkyZNcPLkSbi4uKglY93c3KTkn0wmQ6tWrTBt2jQcPXoUCoVCSkwqFAoUFBSUGZulpSVCQ0OxePFitXZSuXfvXonbqeap/eSTT9CsWTO4u7vj0qVLxep5eHjgww8/xO+//46uXbuqPVDLyckJw4YNwy+//IKPPvoIy5YtKzPWsjRp0gRnzpwp1k5ubm4aDwMPCAjAqVOn1MqWL1+OV199Ff/8849aYjYqKkrtC4GGDRvi8OHDxfZ55MgReHh4AKh4mwNPhuc/nUR/eilPb1pNBAcHY+/evWoP+dq1axcaNmwo9WoODg5GXFyc2na7du0q1vv7xIkTCAgIqNL4NMGkKREREWkPIapmISIioudW9+7dIZfLsXjxYgBPetrt2rUL+/fvR3JyMoYOHVqsl9qzhISEwMPDA5GRkfjnn3+wb98+fPLJJ2p13n33XSiVSkRGRuLEiROIj4/HqFGj0Ldv32LzL1an999/H1euXMGoUaNw+vRp/Prrr4iOjkZUVFSZCb0RI0bgzp07iIiIwN9//43z589j586dGDBgAAoKCnDw4EHMnDkThw4dwuXLl/HLL7/g5s2b8PLyAvBkntF///0XZ86cwa1bt9SSXkUtXrwYBQUFCAwMxMaNG3Hu3DkkJydj4cKFxZJeKu7u7rh8+TJiY2Nx/vx5LFy4UErWAk+GuI8cORIJCQm4dOkSEhMT8ffff0uxjRkzBjt37kRqaiqOHDmC+Ph4aV1FTJ06FT/88AOmTZuGkydPIjk5GbGxsWrzrpZXaGgokpKSpIRzXl4e/vOf/yAiIgI+Pj5qy+DBg3Hw4EGcPHkSAPDhhx/it99+w2effYbk5GScOHECn3zyCZKSkjB69GjpGBVpc+DJ8PySEsNFl7J6cebm5krJ1dzcXKSlpeHYsWNISUmR6ixatAivv/669Lp3795QKBQYNGgQTp48ibVr12LBggVqD34aPXo0duzYgblz5+L06dOIiYnBoUOHMHLkSLXj79u3Dx06dCjnb6LqMWlKRERERERERFpDV1cXI0eOxJw5c5CVlYXJkyejSZMmCA0NRdu2bWFnZ4fw8HCN9qmjo4NNmzbh0aNHCAwMxODBg9XmswQAQ0ND7Ny5E3fu3EHz5s3xzjvv4PXXX1d7KFVNcHR0xLZt2/DXX3/B398fw4YNw6BBg56Z0HNwcEBiYiIKCgrQoUMH+Pr6YsyYMTA3N4eOjg5MTU2xd+9edO7cGR4eHpg8eTLmzp0rPQxryJAhaNiwIZo1awYbGxskJiaWeBxXV1ccOXIE7dq1w0cffQQfHx+0b98ecXFxanO0FvXmm2/iww8/xMiRI9G4cWPs378fU6ZMkdbL5XLcvn0b/fr1g4eHB3r06IFOnTph2rRpAJ7MNzpixAh4eXmhY8eO8PDwwDfffFOR5gXwJNG5detW/P7772jevDlatGiBefPmSQ/I0kSnTp2gq6uL3bt3AwC2bNmC27dv4+233y5W18vLC15eXlJv05YtW2L79u3Yvn07WrVqhbZt22L//v2Ii4tTmye3Im1eFa5du4aAgAAEBAQgPT0dX375JQICAjB48GCpzq1bt3D+/HnptZmZGX7//XekpqaiadOm+OijjzB16lS89957Up2WLVtizZo1+O677+Dv748NGzZg8+bNaueclpaG/fv3P/NBXNVJJiozoyw99x48eAAzMzO0xVvQlek9ewOiF5DDged3Ymyiysh9mIvY13/C/fv31Sbhrw2qz6PXTd6FrkxRqX3li1zEZWrHeRERUe1Qfa6oPgu6fpOII5fv4bu+TdHBu/Qngz+vHj9+jNTUVNSvX7/EB9IQUfVavHgxtmzZgp07d9Z2KC+MCRMm4O7du/juu+9KrVPa/76nPwMqSrfCWxIRERFVNSEAVPL7XH4fTEREREQ1aOjQobh37x4yMzOf66fVa5M6deqoDemvDUyaEhERERERERERVZCurm6xOXKpcj766KPaDoFJUyIiItIeorAQQlZYuX2Iym1PRERERETEpCkRERFpDw7PJyIiIiIiLaBT2wEQERERERERUeXxOc9E9DKp7v957GlKRERE2qNQADL2NCUiItKEnp4eACA7OxsGBga1HA0RUc3Izs4G8L//gVWNSVMiIiLSHkIAqOScpEyaEhFppcWLF+OLL75ARkYG/P398fXXXyMwMLDU+uvXr8eUKVNw8eJFuLu74/PPP0fnzp1rMOLnh1wuh7m5OW7cuAEAMDQ0hEwmq+WoiIiqhxAC2dnZuHHjBszNzSGXy6vlOEyaEhERERERUbVau3YtoqKisHTpUgQFBWH+/PkIDQ3FmTNnUKdOnWL19+/fj4iICMyaNQtvvPEG1qxZg/DwcBw5cgQ+Pj61cAbaz87ODgCkxCkR0YvO3Nxc+t9XHZg0JSIiIq0hCgVEJYfncz43IiLt89VXX2HIkCEYMGAAAGDp0qX47bffsGLFCkycOLFY/QULFqBjx44YN24cAGDGjBnYtWsXFi1ahKVLl9Zo7M8LmUwGe3t71KlTB3l5ebUdDhFRtdLT06u2HqYqTJoSERGR9hCFqPzw/EpuT0REVSo3NxeHDx/GpEmTpDIdHR2EhIQgKSmpxG2SkpIQFRWlVhYaGorNmzeXWD8nJwc5OTnS6wcPHlQ+8OeUXC6v9kQCEdHLQKe2AyAiIiIiIqIX161bt1BQUABbW1u1cltbW2RkZJS4TUZGhkb1Z82aBTMzM2lxcnJSW68jk0GHU3wSEZEG2NOUiIiItAaH5xMRUUVMmjRJrWfqgwcP1BKnG4a3rI2wiIjoOcakKREREWkPDs8nInrhWFtbQy6X4/r162rl169fL/UBHnZ2dhrV19fXh76+ftUETEREBCZNX3qq3jj5yAPYMYdeUrkPc2s7BKJakZf15CER2tQzsyo+j/LBh18QEWkThUKBpk2bIi4uDuHh4QCAwsJCxMXFYeTIkSVuExwcjLi4OIwZM0Yq27VrF4KDg8t1TNVn28s8tykR0ctK9b+/svc5TJq+5DIzMwEAf2JbLUdCVIter+0AiGpXZmYmzMzMajUGhUIBOzs7/JlRNZ9HdnZ2UCgUVbIvIiKqvKioKERGRqJZs2YIDAzE/PnzkZWVhQEDBgAA+vXrB0dHR8yaNQsAMHr0aLRp0wZz585Fly5dEBsbi0OHDuG7774r1/FU9zlPz21KREQvj8re5zBp+pJzcHDAlStXYGJiApmMM6PXNNVcS1euXIGpqWlth0NU4/g3ULuEEMjMzISDg0NthwKlUonU1FTk5lZNz2+FQgGlUlkl+yIiosrr2bMnbt68ialTpyIjIwONGzfGjh07pIc9Xb58GTo6/3tOccuWLbFmzRpMnjwZH3/8Mdzd3bF582b4+PiU63hP3+fwmkMzbK/yY1tphu1VfmwrzRRtLxMTkyq5z5EJbRqTR/SSefDgAczMzHD//n3+E6SXEv8GiIiIqCbwmkMzbK/yY1tphu1VfmwrzVRHe+k8uwoRERERERERERHRy4NJUyIiIiIiIiIiIqIimDQlqkX6+vqIjo6Gvr5+bYdCVCv4N0BEREQ1gdccmmF7lR/bSjNsr/JjW2mmOtqLc5oSERERERERERERFcGepkRERERERERERERFMGlKREREREREREREVASTpkRERERERERERERFMGlKREREREREREREVASTpvTCy8jIwKhRo+Dq6gp9fX04OTkhLCwMcXFxUp39+/ejc+fOsLCwgFKphK+vL7766isUFBSo7Usmk0Emk+HAgQNq5Tk5ObCysoJMJkNCQkKx+jKZDGZmZmjVqhX27Nkjre/fvz/Cw8NLjd3FxUVtH6pl9uzZiImJKXFd0UV1jJLWdezYscTjGBgYwMXFBT169FCLlZ4Pz3pPxMTE4OLFi6WuV723V61aJZXp6OjA3t4ePXv2xOXLl9WO17ZtW+k9+bQuXbpIxyxaf8yYMcW2j42NVdt2/vz5cHFxKbbPR48ewdLSEtbW1sjJySkWa2nLxYsXS/2b8fT0LBaPTCaDvr4+HB0dERYWhl9++UXTXwURERHVsMWLF8PFxQVKpRJBQUH466+/yqy/fv16eHp6Stf/27Ztq6FItYMm7bVs2TK0bt0aFhYWsLCwQEhIyDPb90Wi6XtLJTY2FjKZrMx7vheRpu117949jBgxAvb29tDX14eHh8dL8/eoaVvNnz8fDRs2hIGBAZycnPDhhx/i8ePHNRRt7dm7dy/CwsLg4OAAmUyGzZs3P3ObhIQENGnSBPr6+nBzc8OqVas0Pi6TpvRCu3jxIpo2bYo9e/bgiy++wPHjx7Fjxw60a9cOI0aMAABs2rQJbdq0Qd26dREfH4/Tp09j9OjR+PTTT9GrVy8IIdT26eTkhJUrV6qVbdq0CcbGxiXGsHLlSqSnpyMxMRHW1tZ44403cOHChXKfw/Tp05Genq62jBo1CmPHjlUrq1u3brG6Kh07diy2j59//rnE45w5cwY//PADzM3NERISgs8++6zcsVLtK/o7nj9/PkxNTdXKxo4dK9XdvXt3sfdF06ZNpfWqbdPS0rBx40acOXMG3bt3L3ZMJyenYh9AaWlpiIuLg729/TNjViqVmDx5MvLy8p5Zd+PGjfD29oanp6f0QdmzZ0+1cwgODsaQIUPUypycnAAA3t7exc75zz//VDuGatvz589j48aNaNSoEXr16oX33nvvmfERERFR7Vi7di2ioqIQHR2NI0eOwN/fH6Ghobhx40aJ9ffv34+IiAgMGjQIR48eRXh4OMLDw3HixIkajrx2aNpeCQkJiIiIQHx8PJKSkuDk5IQOHTogLS2thiOveZq2lcrFixcxduxYtG7duoYi1Q6atldubi7at2+PixcvYsOGDThz5gyWLVsGR0fHGo685mnaVmvWrMHEiRMRHR2N5ORkLF++HGvXrsXHH39cw5HXvKysLPj7+2Px4sXlqp+amoouXbqgXbt2OHbsGMaMGYPBgwdj586dmh1YEL3AOnXqJBwdHcXDhw+Lrbt79654+PChsLKyEl27di22fsuWLQKAiI2NlcoAiMmTJwtTU1ORnZ0tlbdv315MmTJFABDx8fFq9Tdt2iS9TktLEwDE0qVLhRBCREZGirfeeqvU+J2dncW8efPKda6l1X3WMcradurUqUJHR0ecPn26XDGQdlm5cqUwMzMrVp6amioAiKNHj2q07cKFCwUAcf/+famsTZs2Yvjw4cLKykr8+eefUvlnn30mwsLChL+/v4iOjlarP3r0aLXXAwYMEFZWVmLx4sVS+bx584Szs3OxuNq2bSuWLl0qlixZItq3b19i7E8fQyU6Olr4+/uXes5lbbtixQoBQOzatavM7YmIiKh2BAYGihEjRkivCwoKhIODg5g1a1aJ9Xv06CG6dOmiVhYUFCSGDh1arXFqC03b62n5+fnCxMRErF69urpC1BoVaav8/HzRsmVL8f3335frfuxFoml7LVmyRLi6uorc3NyaClFraNpWI0aMEK+99ppaWVRUlGjVqlW1xqltns6zlGT8+PHC29tbraxnz54iNDRUo2Oxpym9sO7cuYMdO3ZgxIgRMDIyKrbe3Nwcv//+O27fvq3W+04lLCwMHh4exXpkNm3aFC4uLti4cSMA4PLly9i7dy/69u37zJgMDAwAPPk27XkwevRoCCHw66+/1nYoVMtu3LiBTZs2QS6XQy6Xq61TKBR499131Xpgr1q1CgMHDizXvk1NTfHJJ59g+vTpyMrKKrXe+fPnkZSUhB49eqBHjx7Yt28fLl26VLET0lBkZCQsLCw4TJ+IiEgL5ebm4vDhwwgJCZHKdHR0EBISgqSkpBK3SUpKUqsPAKGhoaXWf5FUpL2elp2djby8PFhaWlZXmFqhom01ffp01KlTB4MGDaqJMLVGRdpry5YtCA4OxogRI2BrawsfHx/MnDmz2FR5L5qKtFXLli1x+PBhaQj/hQsXsG3bNnTu3LlGYn6eVNX/eCZN6YWVkpICIYTafIVPO3v2LADAy8urxPWenp5SnaIGDhyIFStWAHiSHOrcuTNsbGzKjCc7OxuTJ0+GXC5HmzZtynsamDBhAoyNjdWWffv2lXt7ANi6dWuxfcycOfOZ21laWqJOnTq4ePGiRsej50PLli2LvS+Kun//PoyNjWFkZARbW1vEx8eX+iXEwIEDsW7dOmRlZWHv3r24f/8+3njjjXLH8v7770OpVOKrr74qtc6KFSvQqVMnWFhYwNLSEqGhocWmyniW48ePFzvnYcOGPXM7HR0deHh48G+BiIhIC926dQsFBQWwtbVVK7e1tUVGRkaJ22RkZGhU/0VSkfZ62oQJE+Dg4FAsKfGiqUhb/fnnn1i+fDmWLVtWEyFqlYq014ULF7BhwwYUFBRg27ZtmDJlCubOnYtPP/20JkKuNRVpq969e2P69Ol45ZVXoKenhwYNGqBt27YvxfB8TZX2P/7Bgwd49OhRufejW9WBEWkL8dRcpFVVFwD69OmDiRMn4sKFC1i1ahUWLlxYat2IiAjI5XI8evQINjY2WL58Ofz8/Mp9rHHjxqF///5qZZrO79KuXTssWbJEray83woLIaSHStGLZe3ataV+YQAAJiYmOHLkCPLy8rB9+3b89NNPpc5x6+/vD3d3d2zYsAHx8fHo27cvdHXL/xGjr6+P6dOnY9SoURg+fHix9QUFBVi9ejUWLFgglfXp0wdjx47F1KlToaNTvu8AGzZsiC1btqiVmZqalmtb/i0QERERAbNnz0ZsbCwSEhKgVCprOxytkpmZib59+2LZsmWwtrau7XCeC4WFhahTpw6+++47yOVyNG3aFGlpafjiiy8QHR1d2+FplYSEBMycORPffPMNgoKCkJKSgtGjR2PGjBmYMmVKbYf3QmLSlF5Y7u7ukMlkOH36dKl1PDw8AADJyclo2bJlsfXJyclo1KhRsXIrKyu88cYbGDRoEB4/foxOnTohMzOzxGPMmzcPISEhMDMze2Zv1JJYW1vDzc1N4+2KMjIyqtA+bt++jZs3b6J+/fqVOj5pJycnpzLfFzo6OtJ6Ly8vnD9/HsOHD8d//vOfEusPHDgQixcvxqlTpyr0NNU+ffrgyy+/xKeffgoXFxe1dTt37kRaWhp69uypVl5QUIC4uDi0b9++XMdQKBQV+lsoKCjAuXPn0Lx5c423JSIiouplbW0NuVyO69evq5Vfv34ddnZ2JW5jZ2enUf0XSUXaS+XLL7/E7NmzsXv3bo06gjyvNG2r8+fP4+LFiwgLC5PKCgsLAQC6uro4c+YMGjRoUL1B16KKvLfs7e2hp6enNgWYl5cXMjIykJubC4VCUa0x15aKtNWUKVPQt29fDB48GADg6+uLrKwsvPfee/jkk0/K3ZHkZVDa/3hTU1Np2sTyYIvSC0s1fHfx4sUlzpN47949dOjQAZaWlpg7d26x9Vu2bMG5c+cQERFR4v4HDhyIhIQE9OvXr9gcj0XZ2dnBzc2tQgnT2rZgwQLo6OggPDy8tkMhLTBx4kSsXbsWR44cKXF97969cfz4cfj4+JT4ZcOz6OjoYNasWViyZEmxYfDLly9Hr169cOzYMbWlV69eWL58eUVORyOrV6/G3bt30a1bt2o/FhEREWlGoVCgadOmiIuLk8oKCwsRFxeH4ODgErcJDg5Wqw8Au3btKrX+i6Qi7QUAc+bMwYwZM7Bjxw40a9asJkKtdZq2laenJ44fP652vfrmm29KT/B2cnKqyfBrXEXeW61atUJKSoqUXAaeTKNnb2//wiZMgYq1VXZ2drHEqCoXoeno2RddVf2PZ09TeqEtXrwYrVq1QmBgIKZPnw4/Pz/k5+dj165dWLJkCZKTk/Htt9+iV69eeO+99zBy5EiYmpoiLi4O48aNwzvvvIMePXqUuO+OHTvi5s2b5R7aW5r79+/j2LFjamVWVlbSB2pmZmaxOU0MDQ01Om5OTk6xfejq6qoNGVEdJy8vD6mpqfjxxx/x/fffY9asWZXu6Ura6fbt28XeF+bm5qUOs3JycsLbb7+NqVOnYuvWrcXWW1hYID09HXp6ehWOqUuXLggKCsK3334rzUFz8+ZN/Pe//8WWLVvg4+OjVr9fv354++23cefOnXJNOZGfn1/snGUymdp8N9nZ2cjIyEB+fj6uXr2KTZs2Yd68eRg+fDjatWtX4XMjIiKi6hMVFYXIyEg0a9YMgYGBmD9/PrKysjBgwAAAT64ZHB0dMWvWLABPHnjapk0bzJ07F126dEFsbCwOHTqE7777rjZPo8Zo2l6ff/45pk6dijVr1sDFxUW6nippXvwXjSZtpVQqi12vmpubA0Cx8heVpu+t4cOHY9GiRRg9ejRGjRqFc+fOYebMmfjggw9q8zRqhKZtFRYWhq+++goBAQHS8PwpU6YgLCyszI5cL4KHDx8iJSVFep2amopjx47B0tIS9erVw6RJk5CWloYffvgBADBs2DAsWrQI48ePx8CBA7Fnzx6sW7cOv/32m2YHFkQvuGvXrokRI0YIZ2dnoVAohKOjo3jzzTdFfHy8VGfv3r0iNDRUmJqaCoVCIby9vcWXX34p8vPz1fYFQGzatKnE49y9e1cAUNtvWfWFECIyMlIAKLYMGjRICCGEs7NzieuHDh1abF/Ozs5i3rx55T5Gw4YN1bZVlSsUClGvXj3Ro0cPsWfPnlJjJ+23cuVKYWZmVqw8NTW1xPcEAPHzzz+XuW1SUpIAIA4ePCiEEKJNmzZi9OjRpcbg7+8voqOjpddP1y9p+/379wsAwtnZWQghxJdffinMzc1Fbm5usf3n5OQIc3NzsWDBgjL3KYQQ0dHRJZ6zvr6+2rZF/xbs7e3FG2+8IX755ZdSz5GIiIi0w9dffy3q1asnFAqFCAwMFAcOHJDWtWnTRkRGRqrVX7dunfDw8JCu/3/77bcajrh2adJepd2XFL3Oe5Fp+t4qKjIyUrz11lvVH6QW0bS99u/fL4KCgoS+vr5wdXUVn332WbF78ReVJm2Vl5cnYmJiRIMGDYRSqRROTk7i/fffF3fv3q35wGtYfHx8if+DVO0TGRkp2rRpU2ybxo0bC4VCIVxdXcXKlSs1Pq5MCPbhJSIiIiIiIiIiIlLhnKZERERERERERERERTBpSkRERERERERERFQEk6ZERERERERERERERTBpSkRERERERERERFQEk6ZERERERERERERERTBpSkRERERERERERFQEk6ZERERERERERERERTBpSkRa4+LFi5DJZJDJZFi1ahUAYNWqVVJZbUpISJDiSEhIqNHjXbx4sdL7c3FxgUwmQ0xMTKX3RURERET0IomJiYFMJoOLi8sz61b1dfqLJDk5GXK5HK6urigoKKjtcCpEk/dCdSvp/jglJQVyuRz169dHbm5u7Qb4EmDSlIjUtG3bVvrHLJPJIJfL4ejoiLCwMOzfv7/G47GxsUFQUBCCgoLKvU1tXsioPmR5EUVERERE2kr1hXpZS21+2V70mlq1WFtbIzg4GD/++GOVH69u3boICgpCQECAVNa/f3/IZDK0bdtWra6pqal0f6Kvr1/lsTytaOJMtRgYGMDLywsxMTEoLCzUeJ+qe77+/ftXaazTpk1DYWEhRo8eDblcrrbul19+QceOHWFjYwN9fX3Uq1cPXbt2rZEOKTWh6O+pOs/Jzc0N4eHhuHjxIlasWFFtx6EndGs7ACLSTgqFAgEBAcjJycGJEyewdetW7NixA4mJiQgMDCxxm9zcXCgUiiqNo0uXLujSpUuV7pOIiIiI6GUWEBAAOzs7AMDVq1eRlpYGAGjcuLGUCKxbt26x7arjev9ZGjduDF1dXZw9exYHDhzAgQMHcOPGDURFRVXZMQYPHozBgweXq26TJk1w4MCBKju2JhwdHeHg4IDz58/j9OnTmDZtGoyNjTF27Nhaiaeo69evY+PGjZDL5YiIiJDKhRAYOHCg1FNSoVDAzc0Nd+7cwaZNm2BqalosMU1l6927N3755RcsWbIEw4YNq+1wXmjsaUpEJbK3t8eBAwdw9OhRbN68GQCQn5+PNWvWAFD/5nXOnDmoW7culEqltP2PP/6I5s2bw9DQECYmJujYsSOOHTumdoz4+Hj4+PhAqVTilVdewalTp4rFUdrw/LVr16Jly5YwNjaGoaEh/P39sWvXLsTExKBdu3ZSvfr166t9i1pYWIgFCxZIx7WwsED37t2Rmpqqtv9169bB1dUVBgYG6Ny5s3QhWRV++uknBAYGwtraGnp6erCwsEBoaCj++uuvEuufPn0abdu2hVKphJubGzZs2FBsfffu3WFjYwOFQgEvLy8sWbKkyuIlIiIiohfLpk2bpARk0WRh0fIff/wRMpkMffv2xbhx41CnTh00bNgQQMlTP5XUMzMnJwfR0dFwd3eHQqFAnTp1MHDgQNy6dUujWP/++2+kpKTA0NAQAPDDDz9I60+cOIGuXbvCysoKCoUCrq6umDRpEh49eiTVOXDgAF5//XVYWVlBqVTCxcUF4eHhOH/+PIDiQ7JdXFywevVqAMAff/yh1oPw6VFtsbGxkMlk0NPTw+3bt6VjTpkyBTKZDI6OjtJQ9e3bt6NNmzYwMTGBgYEBWrdujfj4+HK3xeDBg/HXX38hNTUVRkZGUnwqx44dw+uvvw57e3vo6+vDyMgIzZs3V+udK5PJpG1Wr15dbJRcRe8tNmzYgPz8fAQGBqJOnTpS+ffffy8lTNu3b4+0tDScPHkS6enpSElJwRtvvCHVLc/vUtVLtm3btvj8889Rp04dWFtbY9asWXjw4AH69u0LY2NjuLu7S/exgPp9ZUJCAgICAqBUKuHn56fWhiV51j3kqlWrUL9+fal+u3btiv0tVNX9MQB06tQJcrkc//77b6l1qIoIIqIi2rRpIwAIZ2dnqWzr1q0CgAAgRo8eLYQQIjIyUgAQCoVC6OjoCC8vL2FlZSWEEOLzzz+X6nt4eAgHBwcBQBgZGYlTp04JIYRIT08XRkZGAoAwNDQUnp6e0msAYuXKlUIIIVauXCmVqXz55ZdSmampqfDx8RGGhoZi3rx5YtmyZcLLy0ta37hxYxEUFCSmT58uhBBi+PDh0jpvb29hZWUlAAg7Oztx/fp1IYQQR48eFTo6OgKAMDMzEw0aNFCLLT4+vtT2i46OluqlpqaWWGf06NFCqVQKDw8P4e/vL/T19QUAYWJiItLT04UQQsTHx0v7MTIyEh4eHsLU1FQAEDo6OuLIkSNCCCHOnj0rzMzMBABhaWkpfHx8hEwmEwDEtGnTpGM6OzsLACI6Orpc7wMiIiIiejmUdv2qui9QKBRCT09P+Pj4CD8/PyFEydeWqvuDNm3aSGWdO3cWAIRcLhd+fn7S9WyjRo1Edna2RjHduHFDGBoaCgDC399fCCHEqVOnhLGxsQAgjI2NhZeXl3Qt3L59eyGEEAUFBdI1v62trWjcuLGwsbFRu65XHU91DxQeHi6sra2la/SgoCARFBQkDh8+rHadnpqaKh49eiRdjy9dulQ6B3d3dwFATJgwQQghRGxsrBSbs7OzqF+/vtQ2e/bsKbUtUlNTpeOp2vv+/fvS/cn7778v1d20aZPQ0dERzs7OIiAgQFhYWEjbbt26VQghRFBQkDAxMREAhLW1tXRu165dK/e9RUl69eolAIgPPvhArbxZs2YCgNDX15fudUpSnt+lEP97X+rr6wtTU1NRr1496Ry9vLyEjY2NsLW1le6jbt26JYRQv680NDQUXl5ewsDAQKqXlpZW4ntBiGffQ27dulU0btxYLY6goCAxfPhwIUTV3h+r+Pn5FXvPUdVj0pSI1BS9OAoKChKNGzcWurq6AoDQ1dUVBw4cEEL876IIgNi2bZsQQoj8/HyRlZUlXcyoPljz8vKkD8s+ffoIIYSYPHmydJFw4sQJtbKykqZZWVnSh0dwcLC4f/++EEKIzMxMce7cOSGEKHYho3LhwgXpg3f16tXSdnXr1hUAxOTJk4UQQvTp00dKmGZkZAghhOjbt2+VJU3Pnj0rsrKypNfnzp2Ttvn++++LncPEiROFEE8+SM3NzQUA0bNnTyGEEP379xcAhI+Pj7TP+fPnCwDCwMBAPHjwQAjBpCkRERERlaw8SdNjx44JIZ5c7wtRvqRpQkKCtN8//vhDCCHEtWvXpESV6rr3WTE1btxYNG/eXEq4AhBz584VQgjRr18/Kcl2+fJlIYQQ8+bNk+rt2bNH3Lp1S3p99epV6RgnTpyQOk2UlCgrKQksRMn3GkOGDBEARLt27YQQQhw5ckSqo0qKubi4CABi4MCBorCwUBQWFoq3335bABCvvPJKqW1RNGnq6OgomjdvLiwtLaX7oaKJyPT0dOn+RQghHj16JNzc3NTuw4T43+82MjJS7VjlvbcoSdOmTQUA8dVXX6mVq+4NfXx8St1WiPL9LovGrqenJ1JTU8XDhw+FQqEQAISNjY24e/euSElJkbbbvn27EEL9vlKVaDxx4oR0r6tKbj/9XijvPWTR31PR+8Wqvj9WCQsLEwDE2LFjy2xXqhwOzyeiEuXm5uLgwYP4999/YWNjgy5duuCPP/4o9kCmhg0bolOnTgAAuVyOkydPIjs7GwAQHR0tDVU5dOgQAEjz/5w8eVLa3tvbGwDQo0ePZ8Z18uRJZGVlAQBGjBgBU1NTAICxsTHc3NzK3PbQoUMQQgAAIiMjIZPJYGJigqtXr5YYW6tWrWBrawsA6N69+zNjK6+7d+/irbfegqWlJXR0dODu7i6tu3btWrH6qjmB7OzspKkHjh8/DgDSkP4TJ07AyMgIMpkMY8aMAQA8evQI//77b5XFTUREREQvn3bt2sHf3x8Aij3cpyxFp55q06YNZDIZHBwcpKHW5Z0X9NixY/j777+hq6uLFi1a4IcffpDmM/37778BAK1bt4aTkxOAJ/M9qhw6dAhWVlYIDg4G8OQhOr6+voiIiMDRo0dhbW1d7vMpS2RkJIAnQ+UzMjKwdu1aAEBgYCC8vLxw8+ZNafj7ihUroKOjAx0dHWzatAkAcPDgwXIdJy0tDX///Tfu3LkDXV1ddOzYUZqbFngy9P6jjz6Cg4MDdHV1YWBggJSUFAAl32c8rTL3Fvfv3wcAmJiYqJWr7r+enm7taeX5XRbl4+MDFxcXGBkZwcbGBgDwyiuvwNzcHK6urlK969evFzuW6v7K29sbvr6+AP53f/W08t5Dlqa67o9V98GqdqfqwQdBEVGJnJ2dy/X0d1VSsSReXl7SP3MVKyuryoZWJYpOcq/i7Oxc7cd9+PAhQkNDce/ePSiVSgQEBEBPT0+6UFLNd6Qpa2trNGjQoFi5Jhe2RERERERPK+l6X5UAK3rtWlby5umOFwDUkn1lSU1NleYarai4uDisWbMGiYmJOHXqFDZs2IDY2Fikp6dj3Lhxldo38KSzhZubG1JSUrBu3TqsW7cOwP+SqUW5urpKSb6iyvOQrejoaIwbNw5jx47F0qVLER0dDV9fX7z99tsAgD59+mD37t2QyWRo1KgRjI2NcerUKWRmZmp0n1GRewvVfd/Dhw/Vyr29vXHo0CGcPXsW169fL/P+URNF7zN1dXXVyoomaFUJz6pQ2XvIqrw/fvDgAQAU2x9VLSZNiahSnv7G0NvbGwYGBnj06BE6duyIuXPnSnWOHj0qfbPs7e2NTZs24cyZM0hOToaXl1exBxyVxNvbG0ZGRsjKysKSJUvw5ptvwsTEBFlZWUhPT4ebm5s0QTwAqVcqADRt2hQymQxCCPTv3x+jR48G8OSD9M8//4SZmZl0jKNHjyIxMRE3btxAnTp1yhXb03JycvD48WPptVwux5kzZ3Dv3j0AT75ljoiIwIEDB6Rvv0uydu1a+Pn54caNG0hISAAA6RvR5s2b49SpUzAzM8O2bdtgaWkJALh16xbi4uLQokULjeMmIiIiIlIpqYdgnTp1cPHiRZw9exbAk2tP1XWqSvPmzaWfJ02ahLfeegvAk4fL7t69G56enpWOrXnz5khOTsa+fftw9epV1K1bV3pwLQA0a9YMQgjs378f/fv3x6BBgwAAw4YNw7fffou9e/eWmjRV3VMUvZ8oS79+/TB16lTMmjULGRkZ0NfXl3o02tjYwNnZGZcuXUKTJk3w888/S4m+s2fP4tKlS89MmKoYGRlh3rx52LJlC65du4apU6ciPDwcMplM6rU4ZMgQfPvtt7hz5w58fHyQmZlZrnOrzL2Fu7s7jhw5gkuXLqmVv/feezh06BBycnIQGRmJn376SUoUnjlzBseOHUPPnj3L9busKmvXrsWQIUOQnJws9TBV3V89rbz3kKXdg1bX/bGqnYuOWqSqx+H5RFSlDA0NMWXKFADAvHnzULduXTRu3BhWVlZo0qQJfv/9dwDA+++/D0NDQxQUFKBZs2bw8vLCnDlzyrX/adOmAQASExPh5OQEPz8/2NraYuvWrQCABg0aQE9PDwAQEhKCFi1aYMOGDXB1dcWQIUMAAGPGjIGrqyv8/Pxgbm6OV199FUeOHAEAREVFQSaT4f79+/Dw8IC7u7s0xEYTnp6eMDAwkJbu3bvD1dVVetLloEGD4Ofnh/Dw8DL3s2DBAnh6esLDwwN3796Fjo4Oxo8fD+DJBaipqSnOnz8PJycnBAQEwNnZGXZ2dpgwYYLGMRMRERERPcvrr78OAFi3bh1at24NX19fqeebStu2bREaGgoACA8Ph6enJ7y9vWFubo5OnTqVa1Tbs0ycOBHGxsZ4+PAhvLy80KhRI2nofvv27dGuXTsUFBQgJCQEFhYW0nDsZcuWAQD8/PxK3bcqqXvo0CH4+vqiRYsWak9xf1rfvn0hk8mQkZEBAAgLC4OFhYW0fubMmQCePGXewcEBAQEBsLOzQ8OGDfHTTz9pdN5KpRIffvghgCdD6bds2aJ2Pt9//z28vb3RoEEDtU4cT5/bL7/8giZNmqBjx44AKndv0bp1awDFh9EPHjwY/fv3BwDs3LkTDg4O8PHxgaOjIzw9PbF9+3YA5ftdVpWxY8fC29sbzZo1Q35+PgwNDTFq1KgS65b3HtLGxkZKBvft2xdBQUH4+uuvq+X+ODs7WxrOr2p3qh5MmhJRlZs0aRJWr16N5s2b4+7du0hJSUGdOnUwbNgwdO3aFQBgb2+PLVu2oFGjRsjPz4eJiUm5LxY++ugj/PzzzwgODkZeXh5SUlLg6uqKRo0aAXgyxGHhwoVwcnLC9evXcfDgQeniZcmSJZg3bx58fX1x7do1XLp0CS4uLoiKikLbtm0BAAEBAVizZg1cXFzw+PFjODs7Y8mSJVXSNhYWFli/fj0aNWqEwsJCKBQK/Pe//y1zmw0bNsDW1haPHz+Gq6srfv75ZzRp0gTAkzlvkpKS0L17dxgaGuLkyZMoLCxEx44dMWPGjCqJmYiIiIioqEmTJqFPnz4wNzfH2bNn0a9fP/Tq1atYvc2bN2Pq1Klwd3fHhQsXkJGRAS8vL0yePBk+Pj6VjsPLywtJSUl4++23oVAocO7cObi4uGDixIn49ddfATwZ7TVs2DDUr18faWlpSElJgYuLC8aOHYupU6eWuu+BAweiW7duMDMzw4kTJ3Dw4MEyh7i7uLigTZs20mtVolCld+/e2Lp1K9q0aYNHjx7hzJkzMDExQb9+/TB48GCNz33o0KEwNzcHAHz22WcAgFWrVqFdu3ZQKpXIzs7G/PnzS0wMjx07FiEhITA0NMTRo0elRGdl7i3eeecd6Orq4sCBA7h165ZULpPJsHLlSmzYsAEdOnSAiYmJ1EP5zTfflKYwKM/vsqps374dSqUS+fn58PHxwX//+184OjqWWr8895AymQzLli2Dm5sbHjx4gL/++kvqDVrV98fbt29HQUEB/Pz8pHtgqh4yUZUTPBARERERERER0UunV69eWLt2LRYuXFhqz83asmrVKgwYMABA1c5zWhu6du2KTZs2YenSpRg6dGhth/NCY09TIiIiIiIiIiKqlOjoaOjo6GD+/PkVfsAtlS0lJQW//vorXFxcMHDgwNoO54XHB0EREREREREREVGleHl5MVlazdzc3NjGNYjD84mIiIiIiIiIiIiK4PB8IiIiIiIiIiIioiKYNCUiIiIiIiIiIiIqgklTIiIiIiIiIiIioiKYNCUiIiIiIiIiIiIqgklTIiIiIiIiIiIioiKYNCUiIiIiIiIiIiIqgklTIiIiIiIiIiIioiKYNCUiIiIiIiIiIiIqgklTIiIiIiIiIiIioiL+D09x+uiEWpBcAAAAAElFTkSuQmCC",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "forest = RandomForestClassifier(random_state = 42)\n",
    "\n",
    "# Hyperparameters\n",
    "criterion = ['gini', 'entropy', 'log_loss']\n",
    "bootstrap = [True, False] # Bootstrap samples when building trees. If False, the whole dataset is used to build each tree.\n",
    "max_features = [\"sqrt\", \"log2\", None]  # None = m = p = Bagging Random Forest. / sqrt = m = sqrt(p) = Classic Random Forest. / log2 = m = log2(p) = Other Random Forest.\n",
    "param_grid = {\"criterion\" : criterion, \"bootstrap\" : bootstrap, \"max_features\" : max_features} \n",
    "\n",
    "# CV\n",
    "forest_model = GridSearchCV(forest , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "forest_model = forest_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter criterion/bootstrap/n_estimators : {forest_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_forest = forest_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, forest_model, X_test0, y_test0, y_pred_forest, \"Random Forest Classifier\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 5. Gradient Boosting Classifier"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Best Parameter learning_rate : {'learning_rate': 1.12}\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model : Phase 0 - Gradient Boosting Classifier\n",
      "\n",
      "a).\n",
      "Accuracy Score : (True P + True N) / N total :\n",
      "98.08%\n",
      "\n",
      "b).\n",
      "Classification Report :\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "   COMPLETED       0.99      0.98      0.98      3118\n",
      "  TERMINATED       0.97      0.98      0.98      2338\n",
      "\n",
      "    accuracy                           0.98      5456\n",
      "   macro avg       0.98      0.98      0.98      5456\n",
      "weighted avg       0.98      0.98      0.98      5456\n",
      "\n",
      "\n",
      "c).\n",
      "Plots :\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Model\n",
    "gra_boost = GradientBoostingClassifier(random_state = 42)  \n",
    "\n",
    "# Hyperparameters\n",
    "learning_rate = np.linspace(0.01, 10, 10, endpoint = True) \n",
    "# n_estimators = np.linspace(1000, 10000, 10, endpoint = True).astype(int) # Number of boosting stages to be run. Default = 100.\n",
    "param_grid = {\"learning_rate\" : learning_rate} # , \"n_estimators\" : n_estimators}\n",
    "\n",
    "# CV\n",
    "gra_boost_model = GridSearchCV(gra_boost , param_grid = param_grid)\n",
    "\n",
    "# Final Model\n",
    "gra_boost_model = gra_boost_model.fit(X_train0, y_train0)\n",
    "display(f'Best Parameter learning_rate : {gra_boost_model.best_params_}')\n",
    "\n",
    "# y_pred\n",
    "y_pred_gra_boost = gra_boost_model.predict(X_test0)\n",
    "\n",
    "# Accuracy Score\n",
    "accuracy(df0, 0, gra_boost_model, X_test0, y_test0, y_pred_gra_boost, \"Gradient Boosting Classifier\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 4) ROC Curve"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x15bb9cbda60>"
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "models = [\n",
    "    (\"1. Logistic L2\", log_model),\n",
    "    (\"2. Logistic Elastic Net\", log_el_model),\n",
    "    (\"3. LDA\", lda_model),\n",
    "    (\"4. QDA\", qda_model),\n",
    "    (\"5. Naive Bayes\", nb_model),\n",
    "    (\"6. KNN\", knn_model),\n",
    "    (\"7. SVC\", knn_model),\n",
    "    (\"8. Tree\", tree_model),\n",
    "    (\"9. Random Forest\", forest_model),\n",
    "    (\"10. Grand. Boosting\", gra_boost_model)\n",
    "]\n",
    "\n",
    "fig = plt.figure(figsize=(20, 5))\n",
    "\n",
    "for name, model in models:\n",
    "    RocCurveDisplay.from_estimator(model, X_test0, y_test0, ax = plt.gca(), name = name, pos_label=\"COMPLETED\")\n",
    "    \n",
    "plt.gca().set_xlabel(\"True Positive Rate (Completed)\", fontsize = 10, fontweight = 'bold')\n",
    "plt.gca().set_ylabel(\"False Positive Rate (Completed)\", fontsize = 10, fontweight = 'bold')\n",
    "plt.legend(loc = [1.05, 0.25])\n",
    "plt.title(\"ROC Curve - All Models - Phase 0\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
